ANNUAL REPORT

FY 2020 — Form 10-K

FY 2020PDF · 409 pages2.3 MB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-K
(MARK ONE)
☒ 	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
☐ 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020 	Commission file number 1-2189
Abbott Laboratories
An Illinois Corporation 	36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(I.R.S. employer identification number)
(224) 667-6100
(telephone number)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class 	Trading Symbol(s) 	Name of Each Exchange on Which Registered
Common Shares, Without Par Value 	ABT 	New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ⌧ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.
Yes ☐ No ⌧
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes ⌧ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ⌧ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in
Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ⌧ 	Accelerated Filer ☐ 	Non-Accelerated Filer ☐ 	Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over
financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit
report. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes ☐ No ☒
The aggregate market value of the 1,727,625,764 shares of voting stock held by nonaffiliates of the registrant, computed by reference to the closing price as
reported on the New York Stock Exchange, as of the last business day of Abbott Laboratories’ most recently completed second fiscal quarter (June 30, 2020), was
$157,956,823,602. Abbott has no non-voting common equity. Number of common shares outstanding as of January 31, 2021: 1,771,529,358
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the 2021 Abbott Laboratories Proxy Statement are incorporated by reference into Part III. The Definitive Proxy Statement will be filed on or about
March 12, 2021.

-- 1 of 409 --

1
PART I
ITEM 1. BUSINESS
GENERAL DEVELOPMENT OF BUSINESS
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott’s* principal business is the discovery,
development, manufacture, and sale of a broad and diversified line of health care products.
NARRATIVE DESCRIPTION OF BUSINESS
Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products,
and Medical Devices.
Established Pharmaceutical Products
These products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and
sold outside the United States in emerging markets. These products are generally sold directly to wholesalers, distributors,
government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers
and public warehouses, depending on the market served. Certain products are co-marketed or co-promoted with, or licensed
from, other companies.
The principal products included in the broad therapeutic area portfolios of the Established Pharmaceutical Products
segment are:
● gastroenterology products, including Creon™, for the treatment of pancreatic exocrine insufficiency associated
with several underlying conditions, including cystic fibrosis and chronic pancreatitis; Duspatal™ and Dicetel™,
for the treatment of irritable bowel syndrome or biliary spasm; Heptral™, Transmetil™, and Samyr™, for the
treatment of intrahepatic cholestasis (associated with liver disease) or depressive symptoms; and Duphalac™, for
regulation of the physiological rhythm of the colon;
● women’s health products, including Duphaston™, for the treatment of many different gynecological disorders;
and Femoston™, a hormone replacement therapy for postmenopausal women;
● cardiovascular and metabolic products, including Lipanthyl™ and TriCor™, for the treatment of dyslipidemia;
Teveten™ and Teveten™ Plus, for the treatment of essential hypertension, and Physiotens™, for the treatment of
hypertension; and Synthroid™, for the treatment of hypothyroidism;
● pain and central nervous system products, including Serc™, for the treatment of Ménière’s disease and vestibular
vertigo; Brufen™, for the treatment of pain, fever, and inflammation; and Sevedol™, for the treatment of severe
migraines; and
● respiratory drugs and vaccines, including the anti-infective clarithromycin (sold under the trademarks Biaxin™,
Klacid™, and Klaricid™); and Influvac™, an influenza vaccine.
The Established Pharmaceutical Products segment directs its primary marketing efforts toward building strong brands
with key stakeholders, including consumers, pharmacists, physicians, and other healthcare providers. Government agencies
are also important customers.
Competition in the Established Pharmaceutical Products segment is generally from other health care and
pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of
additional forms of already marketed established products by generic or branded competitors may increase competitive
pressures.
* As used throughout the text of this report on Form 10-K, the term “Abbott” refers to Abbott Laboratories, an Illinois
corporation, or Abbott Laboratories and its consolidated subsidiaries, as the context requires.

-- 2 of 409 --

2
Diagnostic Products
These products include a broad line of diagnostic systems and tests manufactured, marketed, and sold worldwide.
These products are generally marketed and sold directly to blood banks, hospitals, commercial laboratories, clinics,
physicians’ offices, retailers, government agencies, alternate care testing sites, and plasma protein therapeutic companies
from Abbott owned distribution centers, public warehouses or third party distributors.
The principal products included in the Diagnostic Products segment are:
● core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine,
including the Alinity® family of instruments, ARCHITECT®, ABBOTT PRISM®, and Cell-Dyn®, with assays
used for screening and/or diagnosis for cancer, cardiac, metabolics, drugs of abuse, fertility, general chemistries,
infectious diseases such as hepatitis and HIV, therapeutic drug monitoring, and a suite of SARS-CoV-2 serology
assays;
● molecular diagnostics polymerase chain reaction (PCR) instrument systems, including Alinity® m and m2000™
that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and
measure infectious agents including HIV, hepatitis, HPV, sexually transmitted infections, and SARS-CoV-2; and
products for oncology with the Vysis® FISH product line of genomic-based tests;
● point of care systems, including the i-STAT® and next-generation i-STAT® Alinity® and cartridges for testing
blood gas, chemistry, electrolytes, coagulation and immunoassay;
● rapid diagnostics lateral flow testing products in the area of infectious diseases, including respiratory viruses such
as SARS-CoV-2 and influenza, HIV, hepatitis, and tropical diseases such as malaria and dengue fever; molecular
point-of-care testing for HIV, including the m-PIMA® HIV-1/2 Viral Load Test, and for SARS-CoV-2 and
influenza A & B, RSV and strep A, including the ID NOW® rapid molecular system; cardiometabolic testing,
including Afinion® and Cholestech™ platforms and tests; a toxicology business for drug and alcohol testing; and
remote patient monitoring and consumer self-testing; and
● informatics and automation solutions for use in laboratories, including laboratory automation systems, the RALS®
point of care solution, and AlinIQ®, a suite of informatics tools and professional services.
The Diagnostic Products segment’s products are subject to competition in technological innovation, price, convenience
of use, service, instrument warranty provisions, product performance, laboratory efficiency, long-term supply contracts, and
product potential for overall cost-effectiveness and productivity gains. Some products in this segment can be subject to
rapid product obsolescence or regulatory changes. Although Abbott has benefited from technological advantages of certain
of its current products, these advantages may be reduced or eliminated as competitors introduce new products.
Nutritional Products
These products include a broad line of pediatric and adult nutritional products manufactured, marketed, and sold
worldwide. These products are generally marketed and sold directly to consumers and to institutions, wholesalers, retailers,
health care facilities, government agencies, and third-party distributors from Abbott-owned distribution centers or third-
party distributors.
The principal products included in the Nutritional Products segment are:
● various forms of prepared infant formula and follow-on formula, including Similac®*, Similac Pro-Advance®*,
Similac® Advance®, Similac® Advance® Non-GMO, Similac Pro-Sensitive®*, Similac Sensitive®, Similac
Sensitive® Non-GMO, Go&Grow by Similac®*, Similac® NeoSure®, Similac® Organic, Similac® Special Care®,
Similac Total Comfort®*, Similac® For Supplementation, Isomil® Advance®, Isomil®, Alimentum®, Gain™,
Grow™, Similac En Mei Li™, and Eleva™;
● adult and other pediatric nutritional products, including Ensure®, Ensure Plus®, Ensure® Enlive®, Ensure® (with
NutriVigor®), Ensure® Max Protein, Ensure® High Protein, Glucerna®, Glucerna Hunger Smart®, ProSure™,
PediaSure®, PediaSure SideKicks®, PediaSure® Peptide, EleCare®, Juven®, Abound™, Pedialyte® and Zone
Perfect®; and

-- 3 of 409 --

3
● nutritional products used in enteral feeding in health care institutions, including Jevity®, Glucerna® 1.2 Cal,
Glucerna® 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump) and Freego™ sets, Nepro®, and Vital®.
* These products are available with 2'‐FL HMO (Human Milk Oligosaccharide) in several markets.
Primary marketing efforts for nutritional products are directed toward consumers or to securing the recommendation of
Abbott’s brand of products by physicians or other health care professionals. In addition, certain nutritional products sold as
Similac®, Gain™, Grow™, Eleva™, PediaSure®, PediaSure SideKicks®, Pedialyte®, Ensure®, Zone Perfect®, and
Glucerna® are also promoted directly to the public by consumer marketing efforts in select markets where appropriate.
Competition for nutritional products in the segment is generally from other diversified consumer and health care
manufacturers. Competitive factors include consumer advertising, formulation, packaging, scientific innovation, price,
retail distribution, and availability of product forms. A significant aspect of competition is the search for ingredient
innovations. The introduction of new products by competitors, changes in medical practices and procedures, and regulatory
changes can result in product obsolescence. In addition, private label and local manufacturers’ products may increase
competitive pressure.
Medical Devices
These products include a broad line of rhythm management, electrophysiology, heart failure, vascular and structural
heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as
neuromodulation devices for the management of chronic pain and movement disorders. Medical devices are manufactured,
marketed and sold worldwide. In the United States, depending upon the product, medical devices are generally marketed
and sold directly to wholesalers, hospitals, ambulatory surgery centers, physicians’ offices, and distributors from Abbott-
owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or
through distributors, depending on the market served.
The principal products included in the Medical Devices segment are:
● rhythm management products, including Assurity MRI® and Endurity MRI® pacemaker systems; Ellipse®,
Fortify Assura®, and Gallant™ implantable cardioverter defibrillators and Gallant and Quadra Assura MP®
implantable cardioverter defibrillator with cardiac resynchronization therapy and MultiPoint® Pacing technology;
and Confirm Rx® implantable cardiac monitor;
● electrophysiology products, including the TactiCath® family of ablation catheters and FlexAbility® irrigated
ablation catheters; Ampere® RF ablation generator; EnSite® family of cardiac mapping systems; and the
Advisor® HD Grid mapping catheter;
● heart failure related products, including the HeartMate™ left ventricular device family and the CardioMEMS®
HF System pulmonary artery sensor, a heart failure monitoring system;
● vascular products, including the XIENCE™ family of drug-eluting coronary stent systems developed on the
Multi-Link Vision® platform; StarClose SE® and Perclose ProGlide® vessel closure devices, TREK® coronary
balloon dilatation products, Hi-Torque Balance Middleweight Universal II® guidewires, Supera® Peripheral Stent
System, a peripheral vascular stent system; Acculink®/Accunet® and Xact®/Emboshield NAV6®, carotid stent
systems; and the OPTIS® integrated system with the Dragonfly OPTIS® imaging catheter and PressureWire®
fractional flow reserve measurement systems;
● structural heart products, including MitraClip®, a percutaneous mitral valve repair system; Trifecta® Valve with
Glide™ Technology, a surgical tissue heart valve; Portico® transcatheter aortic heart valve; Regent™ mechanical
heart valve; Amplatzer® PFO occluders; Amplatzer Amulet® occluder devices; the Tendyne® Transcatheter
Mitral Valve Implantation (TMVI) system; and the TriClip® Transcatheter Tricuspid Valve Repair System;
● continuous glucose and blood glucose monitoring systems, including test strips, sensors, data management
decision software, and accessories for people with diabetes, under the FreeStyle® brand such as the FreeStyle
Libre® system; and

-- 4 of 409 --

4
● neuromodulation products, including spinal cord stimulators Proclaim® Elite and Proclaim® XR Recharge-free
implantable pulse generators (IPG) and Prodigy MRI® IPG, each with BurstDR® stimulation, and Proclaim®
DRG IPG, a neurostimulation device designed for dorsal root ganglion therapy, for the treatment of chronic pain
disorders; and the Infinity® Deep Brain Stimulation System with directional lead technology for the treatment of
movement disorders.
These products are subject to competition in technological innovation, price, convenience of use, service, product
performance, long-term supply contracts, and product potential for overall cost-effectiveness and productivity gains. Some
products in this segment can be subject to rapid product obsolescence or regulatory changes. Although Abbott has
benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated
as competitors introduce new products.
INFORMATION WITH RESPECT TO ABBOTT’S BUSINESS IN GENERAL
Sources and Availability of Raw Materials
Abbott purchases, in the ordinary course of business, raw materials and supplies essential to Abbott’s operations from
numerous suppliers in the United States and around the world. There have been no recent significant availability problems
or supply shortages for raw materials or supplies.
Patents, Trademarks, and Licenses
Abbott is aware of the desirability for patent and trademark protection for its products. Accordingly, where possible,
patents and trademarks are sought and obtained for Abbott’s products in the United States and countries of interest to
Abbott. Abbott owns or has licenses under a substantial number of patents and patent applications. Principal trademarks
and the products they cover are discussed in the Narrative Description of Business on pages 1 through 4. These, and
various patents which expire during the period 2021 to 2041, in the aggregate, are believed to be of material importance in
the operation of Abbott’s business. Abbott believes that no single patent, license, or trademark is material in relation to
Abbott’s business as a whole.
Seasonal Aspects, Customers, and Renegotiation
There are no significant seasonal aspects to Abbott’s business. Abbott has no single customer that, if the customer were
lost, would have a material adverse effect on Abbott. No material portion of Abbott’s business is subject to renegotiation of
profits or termination of contracts at the election of a government.
Environmental Matters
Abbott believes that its operations comply in all material respects with applicable laws and regulations concerning
environmental protection. Regulations under federal and state environmental laws impose stringent limitations on
emissions and discharges to the environment from various manufacturing operations. Abbott’s capital and operating
expenditures for pollution control in 2020 were not material and are not expected to be material in 2021.
Abbott has been identified as one of many potentially responsible parties in investigations and/or remediations at
several locations in the United States, including Puerto Rico, under the Comprehensive Environmental Response,
Compensation, and Liability Act, commonly known as Superfund. Abbott is also engaged in remediation at several other
sites, some of which are owned by Abbott, in cooperation with the Environmental Protection Agency or similar agencies.
While it is not feasible to predict with certainty the final costs related to those investigations and remediation activities,
Abbott believes that such costs, together with other expenditures to maintain compliance with applicable laws and
regulations concerning environmental protection, should not have a material adverse effect on Abbott’s financial position,
cash flows, or results of operations.
Human Capital
The sustainability of Abbott’s business depends on attracting, engaging and developing talented people with diverse
backgrounds who share Abbott’s mission to help people live their healthiest possible lives. Abbott provides its employees
opportunities to grow and develop their careers, market competitive compensation and benefit programs, and the
satisfaction of being part of a global company dedicated to improving health in more than 160 countries.

-- 5 of 409 --

5
As of December 31, 2020, Abbott employed approximately 109,000 people, 70% of whom were employed outside of
the U.S. Women represented 47% of Abbott’s U.S. workforce, 45% of its global workforce, and 39% of its managers.
Health and Safety
The health, safety and wellness of its employees is an Abbott priority embedded at every level of its business. Abbott’s
integrated Environmental, Health and Safety organization governs health, safety and wellness at Abbott’s facilities. Abbott
also maintains global policies and standards for managing employee health and safety.
Abbott takes a holistic approach to employee well-being. Abbott’s global wellness programs are designed to meet the
unique needs of employees across businesses and geographies and offer a wide range of programs, including supporting the
mental, financial and physical health of employees and their families. For example, for over 20 years, Abbott has annually
offered Exercise Across Abbott, which is a four-week physical wellness program that encourages employees to team up
with colleagues and track how many minutes they exercise each day. Over 22,000 Abbott employees across 72 countries
took part in 2020.
During the COVID-19 pandemic, Abbott has taken aggressive steps to limit exposure and enhance the safety of
facilities for its employees, including implementing mandatory temperature screening and social distancing, providing and
requiring the use of personal protective equipment, and at most U.S. facilities, onsite COVID-19 testing.
Talent Management
Abbott has an integrated global talent management process that is designed to identify and assess talent across the
organization and provide equal and consistent opportunities for employees to develop their skills. All levels of employees
participate in Abbott’s annual performance management process to create development plans that support their particular
career objectives, and Abbott provides a broad range of training, mentoring and other development opportunities to help its
employees meet these objectives. The board of directors conducts an annual Talent Management Review, focusing on
development of talent, diversity, and succession planning for critical positions. Similar reviews take place at every level of
Abbott to develop talent and diversity across the organization.
Diversity and Inclusion
Abbott is committed to developing a workplace that is inclusive for all. Abbott ties executive compensation to human
capital management, including diversity outcomes, to sustain an inclusive culture and the fair and balanced treatment of
Abbott’s employees.
Abbott’s employee networks play an important role in building an inclusive culture across all Abbott operations. A
member of Abbott’s senior management serves as a sponsor for each of these networks, helping to align their objectives
with Abbott’s business strategies. Abbott has ten such networks, which are: Advancing Professionals Network (supporting
early career employees), Asian Leadership and Cultural Network, Black Business Network, Flex Network (employees with
part-time and flexible schedules), LA VOICE Network (supporting Hispanic and Latino employees), People with
Disabilities Network, PRIDE (supporting LGBTQ employees), Veterans Network, Women Leaders of Abbott, and Women
in STEM.
Abbott offers professional development programs, which provide recent college graduates the opportunity to rotate
through different areas of Abbott, often with the chance to work outside their home country. In 2020, 52% of the
participants were women. Also, Abbott hosts hundreds of college students for paid internships. In 2020, 55% of the U.S.
interns were women and 39% were minorities. Further, Abbott has operated a STEM internship program for high school
students in the U.S. since 2012. The program’s objective is to increase the number of students pursuing STEM-related
careers and contribute to a more diverse talent pipeline for Abbott. In 2020, 58% of the STEM interns were women and
71% were minorities.

-- 6 of 409 --

6
Compensation and Benefits
Abbott is committed to building, retaining, and motivating a diverse talent pipeline that can meet the current and future
needs of its businesses. To that end, Abbott provides market competitive compensation, healthcare benefits, pension and/or
retirement savings plans, and several programs to facilitate employees building an ownership stake in Abbott, including a
global long-term incentive program for employees generally beginning at the manager level. Abbott also has procedures
and processes focused on providing employees equitable compensation, regardless of race or gender or other personal
characteristics.
Regulation
The development, manufacture, marketing, sale, promotion, and distribution of Abbott’s products are subject to
comprehensive government regulation by the U.S. Food and Drug Administration (FDA) and similar international
regulatory agencies. Government regulation by various international, supranational, federal and state agencies addresses
(among other matters) the development and approval to market Abbott’s products, as well as the inspection of, and controls
over, research and laboratory procedures, clinical investigations, product approvals and manufacturing, labeling, packaging,
supply chains, marketing and promotion, pricing and reimbursement, sampling, distribution, quality control, post-market
surveillance, record keeping, storage, and disposal practices. In addition, Abbott’s clinical laboratories and associated
testing services are subject to comprehensive government regulation, including registration, certification, and licensure, by
federal, state, and local agencies, such as the Centers for Medicare & Medicaid Services, the Drug Enforcement
Administration, the Substance Abuse and Mental Health Services Administration, and their respective foreign counterparts.
Certain of these agencies require our clinical laboratories to meet quality assurance, quality control, and personnel
standards and undergo inspections.
During the COVID-19 public health emergency, many pandemic-related products (including diagnostic tests) were
authorized by regulators for emergency use solely during the pandemic. In addition, many governments enacted policies to
expedite or promote access to health care in order to slow or stop the spread of the virus. Examples include expansion of
telehealth coverages and increased reimbursements for diagnostic testing. It is uncertain when the public health emergency
will end and to what extent these policies will continue or revert back to previous policies.
Abbott’s international operations are also affected by trade and investment regulations in many countries. These may
require local investment, restrict Abbott’s investments, or limit the import of raw materials and finished products.
Abbott’s laboratory facilities and home monitoring services, which provide services, related products and medical
devices to consumers, are subject to additional laws and regulations applicable to health care providers and suppliers that
submit claims for reimbursement to third-party payors. In the United States, Medicare, Medicaid, and other third-party
payors may from time to time conduct inquiries, claims audits, investigations, and enforcement actions relating to the
claims or enrollment criteria.
Abbott is subject to laws and regulations pertaining to health care fraud and abuse, including state and federal anti-
kickback, anti-self-referral, and false claims laws in the United States. Prescription drug, nutrition, and medical device
manufacturers such as Abbott are also subject to taxes, as well as application, product, user, establishment, and other fees.
Governmental agencies can also invalidate intellectual property rights.
Compliance with these laws and regulations is costly and materially affects Abbott’s business. Among other effects,
health care regulations and significant changes thereto (such as the introduction of the Medical Device Regulation and the
In Vitro Diagnostic Medical Device Regulation in the European Union) substantially increase the time, difficulty, and costs
incurred in developing, obtaining and maintaining approval to market, and marketing newly developed and existing
products. Abbott expects this regulatory environment will continue to require significant technical expertise and investment
to ensure compliance. Failure to comply can delay the release of a new product or result in regulatory and enforcement
actions, the seizure or recall of a product, the suspension or revocation of the authority necessary for a product’s production
and sale, suspension or revocation of billing privileges, and other civil or criminal sanctions, including fines and penalties.
Similarly, compliance with the laws and regulations governing clinical laboratories and testing services requires specialized
expertise. Failure to comply with these regulatory requirements can result in sanctions, including suspension, revocation, or
limitation of a laboratory’s certification, which is necessary to conduct business, as well as significant fines or criminal
penalties.

-- 7 of 409 --

7
Abbott’s business can also be affected by ongoing studies of the utilization, safety, efficacy, and outcomes of health
care products and their components that are regularly conducted by industry participants, government agencies, and others.
These studies can call into question the utilization, safety, and efficacy of previously marketed products. In some cases,
these studies have resulted, and may in the future result, in the discontinuation of marketing of such products in one or
more countries, and may give rise to claims for damages from persons who believe they have been injured as a result of
their use.
Access to human health care products continues to be a subject of investigation and action by governmental agencies,
legislative bodies, and private organizations in many countries. A major focus is cost containment. Efforts to reduce health
care costs are also being made in the private sector, notably by health care payors and providers, which have instituted
various cost reduction and containment measures. Abbott expects insurers and providers will continue attempts to reduce
the cost or utilization of health care products. Many countries control the price of health care products directly or indirectly,
through reimbursement, payment, pricing, or coverage limitations. Budgetary pressures on health care payors may also
heighten the scope and severity of pricing pressures on Abbott’s products for the foreseeable future. In the United States,
the federal government regularly evaluates reimbursement for medical devices, diagnostics, supplies, and other products, as
well as the procedures in which these products may be used. The government follows a diagnosis-related group (DRG)
payment system for certain institutional services provided under Medicare or Medicaid and has implemented a prospective
payment system (PPS) for services delivered in hospital outpatient, nursing home, and home health settings. DRG and PPS
entitle a health care facility to a fixed reimbursement based on the diagnosis and/or procedure rather than actual costs
incurred in patient treatment, thereby increasing the incentive for the facility to limit or control expenditures for many
health care products. Other payment methodology changes have been proposed and implemented from time to time. For
example, Medicare implemented a competitive bidding system for certain durable medical equipment (including diabetes
products), enteral nutrition products, and supplies. Additionally, the Protecting Access to Medicare Act established a new
payment system for clinical laboratory tests in 2018.
The Patient Protection and Affordable Care Act (the Affordable Care Act) includes provisions known as the Physician
Payments Sunshine Act, which requires manufacturers of drugs, devices, and medical supplies covered under Medicare and
Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data to the Centers for
Medicare & Medicaid Services for subsequent public disclosure. In October 2018, the Substance Use Disorder Prevention
that Promotes Opioid Recovery and Treatment for Patients and Communities Act significantly expanded the types of
healthcare providers for which reporting is required, beginning with reports filed in 2022. Similar reporting requirements
have also been enacted on the state level domestically, and an increasing number of governments worldwide either have
adopted or are considering similar laws requiring transparency of interactions with health care professionals. Failure to
report appropriate data may result in civil or criminal fines and/or penalties.
Policy changes or implementation of new health care legislation could result in significant changes to health care
systems. In the United States, this could include potential modification, including expansion or repeal of all or parts of the
Affordable Care Act.
The regulation of data privacy and security, and the protection of the confidentiality of certain personal information
(including patient health information, financial information and other sensitive personal information), is increasing. For
example, the European Union, various other countries, and various U.S. states (e.g., California) have enacted stricter data
protection laws that contain enhanced financial penalties for noncompliance. Similarly, the U.S. Department of Health and
Human Services has issued rules governing the use, disclosure, and security of protected health information, and the FDA
has issued further guidance concerning cybersecurity for medical devices. In addition, certain countries have issued or are
considering “data localization” laws, which limit companies’ ability to transfer protected data across country borders.
Failure to comply with data privacy and security laws and regulations can result in business disruption and enforcement
actions, which could include civil or criminal penalties. Transferring and managing protected information will become
more challenging as laws and regulations are enacted or amended, and Abbott expects there will be increasing complexity
in this area.
Governmental cost containment efforts also affect Abbott’s nutritional products business. In the United States, for
example, under regulations governing the federally funded Special Supplemental Nutrition Program for Women, Infants,
and Children, all states must have a cost containment program for infant formula. As a result, through competitive bidding
states obtain rebates from manufacturers of infant formula whose products are used in the program.

-- 8 of 409 --

8
Abbott expects debate to continue at all government levels worldwide over the manufacture, quality assurance
requirements, marketing authorization processes, post-market surveillance requirements, availability, method of delivery,
and payment for health care products and services, as well as data privacy and security. Abbott believes that future
legislation and regulation in the markets it serves could affect the timing and expense associated with bringing health care
products or services to market, access to health care products and services, increase rebates, reduce prices or
reimbursements or the rate of price increases for health care products and services, change health care delivery systems,
create new fees and obligations for the pharmaceutical, nutrition, diagnostic, and medical device industries, or require
additional reporting and disclosure. It is not possible to predict the extent to which Abbott or the health care industry in
general might be affected by the matters discussed above.
INTERNET INFORMATION
Copies of Abbott’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and
amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934
are available free of charge through Abbott’s investor relations website (www.abbottinvestor.com) as soon as reasonably
practicable after Abbott electronically files the material with, or furnishes it to, the Securities and Exchange Commission
(the Commission). These reports and other information are also available, free of charge, at www.sec.gov.
Abbott’s corporate governance guidelines, outline of directorship qualifications, code of business conduct and the
charters of Abbott’s audit committee, compensation committee, nominations and governance committee, and public policy
committee are all available on Abbott’s investor relations website (www.abbottinvestor.com).

-- 9 of 409 --

9
ITEM 1A. RISK FACTORS
In addition to the other information in this report, the following risk factors should be considered before deciding to
invest in any of Abbott’s securities. Additional risks and uncertainties not presently known to Abbott, or risks Abbott
currently considers immaterial, could also affect Abbott’s actual results. Abbott’s business, financial condition, results of
operations, or prospects could be materially adversely affected by any of these risks.
Business and Operational Risks
Abbott may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off
businesses, which could cause it to incur significant expenses and could negatively affect profitability.
Abbott may pursue acquisitions, licensing arrangements, and strategic alliances, or dispose of or spin-off some of its
businesses, as part of its business strategy. Abbott may not complete these transactions in a timely manner, on a cost-
effective basis, or at all, and may not realize the expected benefits. If Abbott is successful in making an acquisition, the
products and technologies that are acquired may not be successful or may require significantly greater resources and
investments than originally anticipated. Abbott may not be able to integrate acquisitions successfully into its existing
business or transition disposed businesses efficiently, and could incur or assume significant debt and unknown or
contingent liabilities. Abbott could also experience negative effects on its reported results of operations from acquisition or
disposition-related charges, amortization of expenses related to intangibles and charges for impairment of long-term assets.
These effects could cause a deterioration of Abbott’s credit rating, result in increased borrowing costs and interest expense,
and decrease liquidity.
Abbott depends on sophisticated information technology systems and maintains protected personal data, and a cyber
attack or other breach affecting these information technology systems or protected data could have a material adverse
effect on Abbott’s results of operations.
Similar to other large multi-national companies, the size and complexity of the information technology systems on
which Abbott relies for both its infrastructure and products makes them susceptible to a cyber attack, malicious intrusion,
breakdown, destruction, loss of data privacy, or other significant disruption. These systems have been and are expected to
continue to be the target of malware and other cyber attacks. In addition, third party hacking attempts may cause Abbott’s
information technology systems and related products, protected data, or proprietary information to be compromised or
stolen. A significant attack or other disruption could result in adverse consequences, including increased costs and
expenses, manufacturing challenges or disruption, problems with product functionality, damage to customer relations, lost
revenue, and legal or regulatory penalties.
Abbott also collects, manages and processes protected personal data, including protected health information, in
connection with certain medical products and service offerings. Abbott is subject to certain regional and local data
protection laws that prohibit or restrict the transfer of protected data across country borders. For additional information
concerning data privacy and security regulation, see the discussion in “Regulation” under Item 1, “Business.” A breach of
protected personal information could result in adverse consequences, including regulatory inquiries or litigation, increased
costs and expenses, reputational damage, lost revenue, and fines or penalties.
Abbott invests in its systems and technology and in the protection of its products and data to reduce the risk of an
attack or other significant disruption, and monitors its systems on an ongoing basis for any current or potential threats and
for changes in technology and the regulatory environment. There can be no assurance that these measures and efforts will
prevent future attacks or other significant disruptions to any of the systems on which Abbott relies or that related product
issues will not arise in the future. Similarly, there can be no assurance that third party information technology providers
with whom Abbott contracts will not suffer a significant attack or disruption that impacts customers like Abbott. Any
significant breach, attack or other disruption involving Abbott’s systems or products could have a material adverse effect on
Abbott’s business.

-- 10 of 409 --

10
Abbott’s research and development efforts may not succeed in developing commercially successful products and
technologies, which may cause Abbott’s revenue and profitability to decline.
To remain competitive, Abbott must continue to launch new products and technologies. To accomplish this, Abbott
commits substantial efforts, funds, and other resources to research and development. A risk of failure is inherent in the
research and development of new products and technologies. Abbott must make ongoing substantial expenditures without
any assurance that its efforts will be commercially successful. Failure can occur at any point in the process, including after
significant funds have been invested.
Promising new products and technologies may fail to reach the market or may only have limited commercial success
because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory
approvals, limited scope of approved uses, excessive costs to manufacture, failure to establish or maintain intellectual
property rights, or infringement of the intellectual property rights of others. Even if Abbott successfully develops new
products or enhancements or new generations of Abbott’s existing products, they may be quickly rendered obsolete by
changing customer preferences, changing industry or regulatory standards, or competitors’ innovations. Innovations may
not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or
uncertainty over third-party reimbursement. Abbott cannot state with certainty when or whether any of its products under
development will be launched, whether it will be able to develop, license, or otherwise acquire compounds or products, or
whether any products will be commercially successful. Failure to launch successful new products or technologies, or new
indications or uses for existing products, may cause Abbott’s products or technologies to become obsolete, causing
Abbott’s revenues and operating results to suffer.
The manufacture of many of Abbott’s products is a highly exacting and complex process, and if Abbott or one of its
suppliers encounters problems manufacturing products, Abbott’s business could suffer.
The manufacture of many of Abbott’s products is a highly exacting and complex process, due in part to strict
regulatory requirements. Problems may arise during manufacturing for a variety of reasons, including equipment
malfunction, failure to follow specific protocols and procedures, problems with raw materials, natural disasters, and
environmental factors. In addition, single suppliers are currently used for certain products and materials. If problems arise
during the production of a lot or batch of product, those products may have to be discarded. If problems are not discovered
before the product is released to the market, recall and product liability costs may also be incurred. Any of these events
could, among other things, lead to increased costs, lost revenue, damage to customer relations, time and expense spent
investigating the cause and, depending on the cause, similar losses with respect to other lots, batches or products. To the
extent Abbott or one of its suppliers experiences significant manufacturing problems, this could have a material adverse
effect on Abbott’s revenues and profitability.
Abbott has significant indebtedness, which could adversely affect its business, including decreasing its business
flexibility.
As of December 31, 2020, Abbott's consolidated indebtedness was approximately $18.7 billion. This consolidated
indebtedness could have the effect, among other things, of reducing Abbott's flexibility to respond to changing business and
economic conditions, and reducing funds available for working capital, capital expenditures, acquisitions, and other general
corporate purposes.
Further, Abbott may be required to raise additional financing for working capital, capital expenditures, future
acquisitions or other general corporate purposes. Abbott's ability to arrange additional financing or refinancing will depend
on, among other factors, Abbott's financial position and performance, as well as prevailing market conditions and other
factors beyond Abbott's control. Consequently, Abbott cannot assure that it will be able to obtain additional financing or
refinancing on terms acceptable to Abbott or at all, which could adversely impact Abbott's ability to make scheduled
payments with respect to its consolidated indebtedness and its profitability and financial condition.
Additionally, further borrowing could cause a deterioration of Abbott's credit ratings. Abbott's credit ratings reflect
each credit rating agency's then opinion of Abbott's financial strength, operating performance, and ability to meet its debt
obligations. Adverse changes in Abbott's credit ratings may result in increased borrowing costs for future long-term debt or
short-term borrowing facilities and may limit financing options, including access to the unsecured borrowing market.
Abbott may also be subject to additional restrictive covenants that would reduce flexibility.

-- 11 of 409 --

11
Legal and Regulatory Risks
Abbott is subject to numerous governmental regulations and it can be costly to comply with these regulations and to
develop compliant products and processes.
Abbott’s products are subject to rigorous regulation by the FDA and numerous international, supranational, federal,
and state authorities. The process of obtaining regulatory approvals to market a drug, medical device, or diagnostic product
can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses
of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain, approvals for future products,
or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and substantial
additional costs.
In addition, no assurance can be given that Abbott will remain in compliance with applicable FDA and other
regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements
include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and
postmarketing reporting, including adverse event reports and field alerts. Many of Abbott’s facilities and procedures and
those of Abbott’s suppliers are subject to ongoing regulation, including periodic inspection by the FDA and other
regulatory authorities. Abbott must incur expense and spend time and effort to ensure compliance with these complex
regulations. Possible regulatory actions for non-compliance could include warning letters, fines, damages, injunctions, civil
penalties, recalls, seizures of Abbott’s products, and criminal prosecution.
These actions could result in, among other things, substantial modifications to Abbott’s business practices and
operations; refunds, recalls, or seizures of Abbott’s products; a total or partial shutdown of production in one or more
facilities while Abbott or Abbott’s suppliers remedy the alleged violation; the inability to obtain future pre-market
approvals or marketing authorizations; and withdrawals or suspensions of current products from the market. Any of these
events could disrupt Abbott’s business and have a material adverse effect on Abbott’s revenues, profitability and financial
condition.
Laws and regulations affecting government benefit programs could impose new obligations on Abbott, require Abbott to
change its business practices, and restrict its operations in the future.
Abbott’s industry is subject to various international, supranational, federal, and state laws and regulations pertaining to
government benefit program reimbursement, price reporting and regulation, and health care fraud and abuse, including
anti-kickback and false claims laws, and international and individual state laws relating to pricing and sales and marketing
practices. Violations of these laws may be punishable by criminal and/or civil sanctions, including, in some instances,
substantial fines, imprisonment, and exclusion from participation in government health care programs, including Medicare,
Medicaid, and Veterans Administration health programs in the U.S. These laws and regulations are broad in scope and they
are subject to evolving interpretations, which could require Abbott to incur substantial costs associated with compliance or
to alter one or more of its sales or marketing practices. In addition, violations of these laws, or allegations of such
violations, could disrupt Abbott’s business and result in a material adverse effect on Abbott’s revenues, profitability, and
financial condition.
Changes in the health care regulatory environment may adversely affect Abbott’s business.
Both in the U.S. and internationally, government authorities may enact changes in regulatory requirements, make
legislative or administrative reforms to existing reimbursement programs, make adverse decisions relating to Abbott’s
products’ coverage or reimbursement, or make changes to patient access to health care, all of which could adversely impact
the demand for and usage of Abbott’s products or the prices that Abbott’s customers are willing to pay for them.
Further, in the U.S., a number of the provisions of the Affordable Care Act and the Health Care and Education
Reconciliation Act of 2010 address access to health care products and services. These provisions may be modified,
expanded, repealed, or otherwise invalidated, in whole or in part. Future rulemaking could affect rebates, prices or the rate
of price increases for health care products and services, or required reporting and disclosure. Abbott cannot predict the
timing or impact of any future rulemaking or changes in the law.
For additional information concerning health care regulation, see the discussion in “Regulation” under Item 1,
“Business.”

-- 12 of 409 --

12
The expiration or loss of patent protection and licenses may affect Abbott’s future revenues and operating income.
Many of Abbott’s businesses rely on patent and trademark and other intellectual property protection. Although most of
the challenges to Abbott’s intellectual property have come from other companies, governments may also challenge
intellectual property protections. To the extent Abbott’s intellectual property is successfully challenged, invalidated, or
circumvented or to the extent it does not allow Abbott to compete effectively, Abbott’s businesses could suffer. To the
extent that countries do not enforce Abbott’s intellectual property rights, Abbott’s future revenues and operating income
could be reduced. Any material litigation regarding Abbott’s patents and trademarks is described in the section captioned
“Legal Proceedings.”
Significant safety concerns could arise for Abbott’s products, which could have a material adverse effect on Abbott’s
revenues and financial condition.
Health care products typically receive regulatory approval based on data obtained in controlled clinical trials of limited
duration. Following regulatory approval, these products will be used over longer periods of time in many patients.
Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, Abbott
may be required to amend the conditions of use for a product. For example, Abbott may be required to provide additional
warnings on a product’s label or narrow its approved intended use, either of which could reduce the product’s market
acceptance. If serious safety issues arise with an Abbott product, sales of the product could be halted by Abbott or by
regulatory authorities. Safety issues affecting suppliers’ or competitors’ products also may reduce the market acceptance of
Abbott’s products.
In addition, in the ordinary course of business, Abbott is the subject of product liability claims and lawsuits alleging
that its products or the products of other companies that Abbott promotes have resulted or could result in an unsafe
condition for, or injury to, patients. Product liability claims and lawsuits, safety alerts or product recalls, and other
allegations of product safety or quality issues, regardless of their validity or ultimate outcome, may have a material adverse
effect on Abbott’s business and reputation and on Abbott’s ability to attract and retain customers. Consequences may also
include additional costs, a decrease in market share for the products, lower income or exposure to other claims. Product
liability losses are self-insured. Product liability claims could have a material adverse effect on Abbott’s profitability and
financial condition.
Economic and Industry Risks
Abbott is subject to risks related to public health crises, such as widespread outbreaks of infectious diseases like the
COVID-19 pandemic.
As a global healthcare company, public health crises, such as the widespread outbreaks of infectious diseases like the
COVID-19 pandemic, may negatively impact Abbott's operations. Health concerns and significant changes in political or
economic conditions caused by such outbreaks can cause significant reductions in demand for routine diagnostic testing
and medical device procedures or increased difficulty in serving customers, disrupt manufacturing and supply chains, and
negatively affect our operations as well as the operations of our suppliers, distributors and other third-party partners.
Furthermore, such widespread outbreaks may impact the broader economies of affected countries, including negatively
impacting economic growth, the proper functioning of financial and capital markets, foreign currency exchange rates, and
interest rates.
With regard to the COVID-19 pandemic, the FDA issued Emergency Use Authorizations (EUAs) for several COVID-
19 related products in 2020, including Abbott diagnostic tests. EUAs are authorized for the duration of the COVID-19
public health emergency unless sooner terminated or revoked. Abbott is actively pursuing the FDA’s customary regulatory
approval process for these diagnostic tests which has uncertainty as discussed in “Abbott is subject to numerous
governmental regulations and it can be costly to comply with these regulations and to develop compliant products and
processes.” in “Legal and Regulatory Risks” under “Item 1A. Risk Factors.”
Due to the unpredictability of the duration and impact of the current COVID-19 pandemic, the extent to which the
COVID-19 pandemic will have a material effect on Abbott’s business, financial condition or results of operations is
uncertain. A more detailed discussion on the impact of the COVID-19 pandemic on Abbott’s business is contained in the
“Financial Review” section in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of
Operations of this report.

-- 13 of 409 --

13
Abbott is subject to cost containment efforts that could cause a reduction in future revenues and operating income.
In the United States and other countries, Abbott’s businesses have experienced downward pressure on product pricing.
Cost containment efforts by governments and private organizations are described in greater detail in the section captioned
“Regulation.” To the extent these cost containment efforts are not offset by greater patient access to health care or other
factors, Abbott’s future revenues and operating income will be reduced.
Competitors’ intellectual property may prevent Abbott from selling its products or have a material adverse effect on
Abbott’s future profitability and financial condition.
Competitors may claim that an Abbott product infringes their intellectual property. Resolving an intellectual property
infringement claim can be costly and time consuming and may require Abbott to enter into license agreements. Abbott
cannot guarantee that it would be able to obtain license agreements on commercially reasonable terms. A successful claim
of patent or other intellectual property infringement could subject Abbott to significant damages or an injunction
preventing the manufacture, sale or use of affected Abbott products. Any of these events could have a material adverse
effect on Abbott’s profitability and financial condition.
New products and technological advances by Abbott’s competitors may negatively affect Abbott’s results of operations.
Abbott’s products face intense competition from competitive products. Competitors’ products may be safer, more
effective, more effectively marketed or sold, or have lower prices or superior performance features than Abbott’s products.
Abbott cannot predict with certainty the timing or impact of the introduction of competitors’ products.
Fluctuation in foreign currency exchange rates may adversely affect our financial statements and Abbott’s ability to
realize projected sales and earnings.
Although Abbott’s financial statements are denominated in U.S. dollars, a significant portion of Abbott’s revenues and
costs are realized in other currencies. Sales outside of the United States in 2020 made up approximately 62 percent of
Abbott’s net sales. Abbott’s profitability is affected by movement of the U.S. dollar against other currencies. Fluctuations in
exchange rates between the U.S. dollar and other currencies may also affect the reported value of Abbott’s assets and
liabilities, as well as its cash flows. Some foreign currencies are subject to government exchange controls. While Abbott
enters into hedging arrangements to mitigate some of its foreign currency exposure, Abbott cannot predict with any
certainty changes in foreign currency exchange rates or its ability to mitigate these risks.
Information on the impact of foreign exchange rates on Abbott’s financial results is contained in the “Financial Review
— Results of Operations” section in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of
Operations of this report. A discussion of the steps taken to mitigate the impact of foreign exchange is contained in Item
7A, Quantitative and Qualitative Disclosures about Market Risk in Abbott’s 2020 Form 10-K. Information on Abbott’s
hedging arrangements is contained in Note 12 to the consolidated financial statements in this report.
Deterioration in the economic condition and credit quality of certain countries may negatively affect Abbott’s results of
operations.
Unfavorable economic conditions in certain countries may increase the time it takes to collect outstanding trade
receivables. Financial instability and fiscal deficits in these countries may result in additional austerity measures to reduce
costs, including health care. Deterioration in the quality of sovereign debt, including credit downgrades, could increase
Abbott’s collection risk where a significant amount of Abbott’s receivables in these countries are with governmental health
care systems or where Abbott’s customers depend on payment by government health care systems.
The international nature of Abbott’s business subjects it to additional business risks that may cause its revenue and
profitability to decline.
Abbott’s business is subject to risks associated with managing a global supply chain and doing business internationally.
Sales outside of the United States in 2020 made up approximately 62 percent of Abbott’s net sales. Additional risks
associated with Abbott’s international operations include:
● differing local product preferences and product requirements;

-- 14 of 409 --

14
● trade protection measures, including tariffs, import or export licensing requirements, and changes to international
trade agreements;
● difficulty in establishing, staffing, and managing operations;
● differing labor regulations;
● potentially negative consequences from changes in or interpretations of tax laws;
● political and economic instability, including sovereign debt issues;
● restrictions on local currency conversion and/or cash extraction;
● price controls, limitations on participation in local enterprises, expropriation, nationalization, and other
governmental action;
● inflation, recession, and fluctuations in interest rates;
● diminished protection of intellectual property; and
● potential penalties or other adverse consequences for violations of anti-corruption, anti-bribery, and other similar
laws and regulations, including the Foreign Corrupt Practices Act and the U.K. Bribery Act.
Events contemplated by these risks may, individually or in the aggregate, have a material adverse effect on Abbott’s
revenues and profitability.
Other factors can have a material adverse effect on Abbott’s future profitability and financial condition.
Many other factors can affect Abbott’s profitability and its financial condition, including:
● changes in or interpretations of laws and regulations, including changes in accounting standards, taxation
requirements, product marketing application standards, product labeling standards, source and use laws, and
environmental laws;
● differences between the fair value measurement of assets and liabilities and their actual value, particularly for
pensions, retiree health care, stock compensation, intangibles, goodwill, and contingent consideration; and for
contingent liabilities such as litigation, the absence of a recorded amount, or an amount recorded at the minimum,
compared to the actual amount;
● changes in the rate of inflation (including the cost of raw materials, commodities, and supplies), interest rates,
market value of Abbott’s equity investments, and the performance of investments held by Abbott or Abbott’s
employee benefit trusts;
● changes in the creditworthiness of counterparties that transact business with or provide services to Abbott or
Abbott’s employee benefit trusts;
● changes in business, economic, and political conditions, including: war, political instability, terrorist attacks, the
threat of future terrorist activity and related military action; global climate, extreme weather and natural disasters;
the cost and availability of insurance due to any of the foregoing events; labor disputes, strikes, slow-downs, or
other forms of labor or union activity; and pressure from third-party interest groups;
● changes in Abbott’s business units and investments and changes in the relative and absolute contribution of each
to earnings and cash flow resulting from evolving business strategies, changing product mix, changes in tax laws
or tax rates both in the U.S. and abroad and opportunities existing now or in the future;
● changes in the buying patterns of a major distributor, retailer, or wholesale customer resulting from buyer
purchasing decisions, pricing, seasonality, or other factors, or other problems with licensors, suppliers,
distributors, and business partners; and
● legal difficulties, any of which could preclude or delay commercialization of products or adversely affect
profitability, including claims asserting statutory or regulatory violations, and adverse litigation decisions.

-- 15 of 409 --

15
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Form 10-K contains forward-looking statements that are based on management’s current expectations, estimates,
and projections. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “forecasts,”
variations of these words, and similar expressions are intended to identify these forward-looking statements. Certain
factors, including but not limited to those identified under “Item 1A. Risk Factors” of this Form 10-K, may cause actual
results to differ materially from current expectations, estimates, projections, forecasts, and from past results. No assurance
can be made that any expectation, estimate, or projection contained in a forward-looking statement will be achieved or will
not be affected by the factors cited above or other unknown or future events. Abbott undertakes no obligation to release
publicly any revisions to forward-looking statements as the result of subsequent events or developments, except as required
by law.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
As of December 31, 2020, Abbott owned or leased properties totaling approximately 43 million square feet, of which
approximately 65% is owned by Abbott. Abbott’s principal corporate offices are located in Illinois and are owned by
Abbott.
Abbott operates 93 manufacturing facilities globally. Abbott’s facilities are deemed suitable and provide adequate
productive capacity. The manufacturing facilities are used by Abbott’s reportable segments as follows:
Manufacturing
Reportable Segments 	Sites
Medical Devices 	27
Diagnostic Products 	24
Established Pharmaceutical Products 	28
Nutritional Products 	14
Worldwide Total 	93
Abbott’s research and development facilities in the United States are primarily located in California, Illinois,
Minnesota, New Jersey, and Ohio. Abbott also has research and development facilities in various other countries, including
China, Colombia, India, Singapore, Spain, and the United Kingdom.
There are no material encumbrances on the properties.
ITEM 3. LEGAL PROCEEDINGS
Abbott is involved in various claims, legal proceedings and investigations. While it is not feasible to predict the
outcome of such pending claims, proceedings and investigations with certainty, management is of the opinion that their
ultimate resolution should not have a material adverse effect on Abbott’s financial position, cash flows, or results of
operations.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.

-- 16 of 409 --

16
INFORMATION ABOUT OUR EXECUTIVE OFFICERS
Executive officers of Abbott are elected annually by the board of directors. Each executive officer holds office until a
successor has been duly elected or appointed and qualified or until the officer’s death, resignation, or removal. Vacancies
may be filled at any time by the board. Any executive officer may be removed by the board of directors when, in its
judgment, removal would serve the best interests of Abbott.
Abbott’s executive officers, their ages as of February 19, 2021, and the dates of their first election as officers of Abbott
are listed below. The executive officers’ principal occupations and employment for the past five years and the year of
appointment to the earliest reported office are also shown. Unless otherwise stated, employment was by Abbott. There are
no family relationships between any executive officers or directors.
Miles D. White, 65
2020 to present — Executive Chairman and Director.
1999 to 2020 — Chairman of the Board and Chief Executive Officer, and Director.
Elected Corporate Officer — 1993.
Robert B. Ford, 47
2020 to present — President and Chief Executive Officer, and Director.
2018 to 2020 — President and Chief Operating Officer, and Director since 2019.
2015 to 2018 — Executive Vice President, Medical Devices.
Elected Corporate Officer — 2008.
Hubert L. Allen, 55
2013 to present — Executive Vice President, General Counsel and Secretary.
Elected Corporate Officer — 2012.
John M. Capek, 59
2015 to present — Executive Vice President, Ventures.
Elected Corporate Officer — 2006.
Lisa D. Earnhardt, 51
2019 to present — Executive Vice President, Medical Devices.
2008 to 2019 — President, CEO, and Director, Intersect ENT (a medical technology company focused on developing
treatments for ear, nose and throat conditions).
Elected Corporate Officer — 2019.
Robert E. Funck, Jr., 59
2020 to present — Executive Vice President, Finance and Chief Financial Officer.
2018 to 2020 — Senior Vice President, Finance and Controller.
2013 to 2018 — Vice President, Controller.
Elected Corporate Officer — 2005.

-- 17 of 409 --

17
John F. Ginascol, 62
2019 to present — Executive Vice President, Core Diagnostics.
2008 to 2019 — Vice President, Nutrition, Supply Chain.
Elected Corporate Officer — 2008.
Andrew H. Lane, 50
2017 to present — Executive Vice President, Established Pharmaceuticals.
2015 to 2017 — Senior Vice President, Established Pharmaceuticals, Emerging Markets.
Elected Corporate Officer — 2015.
Mary K. Moreland, 54
2019 to present — Executive Vice President, Human Resources.
2013 to 2019 — Divisional Vice President, Compensation, Benefits and HR M&A.
Elected Corporate Officer — 2019.
Daniel Salvadori, 42
2017 to present — Executive Vice President, Nutritional Products.
2014 to 2017 — Senior Vice President, Established Pharmaceuticals, Latin America.
Elected Corporate Officer — 2014.
Andrea Wainer, 52
2019 to present — Executive Vice President, Rapid and Molecular Diagnostics.
2015 to 2019 — Vice President, Molecular Diagnostics.
Elected Corporate Officer — 2015.
Gregory A. Ahlberg, 54
2020 to present — Senior Vice President, Core Laboratory Diagnostics, Commercial Operations.
2017 to 2020 —Vice President, Diagnostics, Commercial Operations, Europe, Middle East and Africa.
2012 to 2017 — Divisional Vice President, USA, Abbott Diagnostics Division.
Elected Corporate Officer — 2017.
Roger M. Bird, 64
2015 to present — Senior Vice President, U.S. Nutrition.
Elected Corporate Officer — 2015.
Charles R. Brynelsen, 64
2017 to present — Senior Vice President, Abbott Vascular.
2016 to 2017 — Managing Director, CB Business Advisors, Inc. (a medical device consulting firm).
2015 to 2016 — Senior Vice President and President, Medtronic Early Technologies, Medtronic plc (a global medical
device company).
Elected Corporate Officer — 2017.

-- 18 of 409 --

18
Michael D. Dale, 61
2019 to present — Senior Vice President, Structural Heart.
2017 to 2019 — Vice President, Structural Heart.
2016 to 2017 — Divisional Vice President and General Manager, Structural Heart.
2014 to 2016 — President and Chief Executive Officer, GI Dynamics, Inc. (a medical device company focused on
developing gastrointestinal therapies).
Elected Corporate Officer — 2017.
Sammy Karam, 59
2019 to present — Senior Vice President, Established Pharmaceuticals, Emerging Markets.
2014 to 2019 — Divisional Vice President, Global Marketing Commercial Execution, Established Pharmaceuticals.
Elected Corporate Officer — 2019.
Joseph Manning, 52
2017 to present — Senior Vice President, International Nutrition.
2015 to 2017 — Vice President, Nutrition, Asia Pacific.
Elected Corporate Officer — 2015.
Michael J. Pederson, 59
2019 to present — Senior Vice President, Electrophysiology and Heart Failure.
2017 to 2019 — Senior Vice President, Cardiac Arrhythmias and Heart Failure.
2015 to 2017 — Divisional Vice President and General Manager, Abbott Electrophysiology.
Elected Corporate Officer — 2017.
Christopher J. Scoggins, 51
2019 to present — Senior Vice President, Rapid Diagnostics.
2015 to 2019 — Vice President, Diabetes Care, Commercial Operations.
Elected Corporate Officer — 2015.
Jared L. Watkin, 53
2015 to present — Senior Vice President, Diabetes Care.
Elected Corporate Officer — 2015.
Alejandro D. Wellisch, 46
2017 to present — Senior Vice President, Established Pharmaceuticals, Latin America.
2014 to 2017 — General Manager, Argentina, Bolivia, Paraguay and Uruguay, Established Pharmaceuticals.
Elected Corporate Officer — 2017.

-- 19 of 409 --

19
Randel W. Woodgrift, 59
2019 to present — Senior Vice President, CRM.
2017 to 2019 — Vice President, Global Operations, Cardiovascular and Neuromodulation.
2015 to 2017 — Vice President, Operations and R&D, Abbott Vascular.
Elected Corporate Officer — 2015.
Philip P. Boudreau, 48
2020 to present — Vice President, Finance and Controller.
2017 to 2020 — Divisional Vice President, Controller, Medical Devices.
2012 to 2017 — Divisional Vice President, Controller and Commercial Support, Point of Care.
Elected Corporate Officer — 2020.

-- 20 of 409 --

20
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES
Principal Market
The principal market for Abbott’s common shares is the New York Stock Exchange under the symbol “ABT.” Shares
are also listed on the Chicago Stock Exchange and traded on various regional and electronic exchanges. Outside the United
States, Abbott’s shares are listed on the SIX Swiss Exchange.
Shareholders
There were 37,450 shareholders of record of Abbott common shares as of December 31, 2020.
Tax Information for Shareholders
In 2001, the Illinois Department of Commerce and Economic Opportunity (DCEO) designated Abbott as an Illinois
High Impact Business (HIB) for a period not to exceed twenty years. In 2020, the DCEO granted a two year extension for
Abbott's HIB designation. Dividends paid by a corporation that is designated as a HIB and conducts business in a foreign
trade zone may be eligible for a subtraction from base income for Illinois income tax purposes. Abbott certified that the
HIB requirements were met for the calendar year ending December 31, 2020.
If you have any questions, please contact your tax advisor.
Issuer Purchases of Equity Securities
(c) Total Number of (d) Maximum Number (or
(a) Total Number 	Shares (or Units) Approximate Dollar Value) of
of Shares 	(b) Average Price Purchased as Part of Shares (or Units) that May
(or Units) 	Paid per Share Publicly Announced Yet Be Purchased Under the
Period 	Purchased 	(or Unit) 	Plans or Programs 	Plans or Programs
October 1, 2020 — October 31, 2020 	0 (1) $ 	0 	0 $ 	3,270,234,923 (2)
November 1, 2020 — November 30, 2020 	0 (1) $ 	0 	0 $ 	3,270,234,923 (2)
December 1, 2020 — December 31, 2020 	1,600,411 (1) $ 107.999 	1,600,411 $ 	3,097,391,913 (2)
Total 	1,600,411 (1) $ 107.999 	1,600,411 $ 	3,097,391,913 (2)
(1) These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with
the vesting of restricted stock or restricted stock units.
(2) On September 11, 2014, the board of directors authorized the repurchase of up to $3 billion of its common shares,
from time to time (the “2014 Plan”). On October 11, 2019, the board of directors authorized the repurchase of up to $3
billion of Abbott common shares, from time to time (the “2019 Plan”). The 2019 Plan is in addition to the unused
portion of the 2014 Plan.

-- 21 of 409 --

21
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Financial Review
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term
receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s
products under a contract most impact which products are sold; price controls, competition and rebates most impact the net
selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s
primary products are medical devices, diagnostic testing products, nutritional products and branded generic
pharmaceuticals. Sales in international markets comprise approximately 62 percent of consolidated net sales.
In 2020, the coronavirus (COVID-19) pandemic affected Abbott’s diversified health care businesses in various ways.
As is further described below, some businesses have performed at the levels required to successfully meet new demands,
others have faced challenges, and still others have been relatively less impacted by the pandemic.
Abbott’s Diagnostics business experienced the most significant change in sales from 2019 to 2020 as sales from new
tests and other related products to detect COVID-19 more than outweighed the negative impact of COVID-19 on routine
diagnostic testing volumes. Abbott mobilized its teams across multiple fronts to develop and launch the following new
diagnostic tests for COVID-19 in 2020:
● In March, Abbott launched a molecular test using polymerase chain reaction (PCR) methods on its m2000™
RealTime lab-based platform to detect COVID-19 pursuant to an Emergency Use Authorization (EUA) in the
U.S. and CE Mark.
● In March, Abbott also launched a molecular test to detect COVID-19 on its ID NOW™ rapid point-of-care
platform in the U.S. pursuant to an EUA.
● In April, Abbott launched an IgG (Immunoglobulin G) lab-based serology blood test on its ARCHITECT®
i1000SR and i2000SR® laboratory instruments for the detection of an antibody to determine if someone was
previously infected with the virus. The serology test was granted an EUA in the U.S. and CE Mark in April.
● In May, Abbott launched a lab-based serology blood test on its Alinity® i system pursuant to an EUA in the U.S.
and CE Mark.
● In May, Abbott also launched a molecular PCR test on its Alinity m system to detect COVID-19 pursuant to an
EUA in the U.S. Abbott received CE Mark for this test in June.
● In June, Abbott launched a lateral flow COVID-19 rapid antibody test on its Panbio™ system in select countries
pursuant to a CE Mark. This serology test detects an antibody to determine if someone was previously infected
with the virus.
● In August, Abbott launched its AdviseDx SARS-CoV-2 IgM (Immunoglobulin M) lab-based serology test for use
on its ARCHITECT and Alinity platforms pursuant to a CE Mark. Abbott was granted an EUA in the U.S. for this
test in October.
● In August, Abbott launched its BinaxNOW™ COVID-19 Ag Card test, a portable, lateral flow rapid test to detect
COVID-19 pursuant to an EUA in the U.S.
● In September, Abbott launched its Panbio rapid antigen test to detect COVID-19 pursuant to a CE Mark. In
October, Abbott received approval by the World Health Organization for emergency use listing for the Panbio
antigen test.
● In December, Abbott received CE Mark and launched its SARS-CoV-2-IgG II quantitative lab-based serology
blood test for use on its ARCHITECT and Alinity i platforms.
● In December, Abbott received an EUA in the U.S. for virtually guided at-home use of its BinaxNOW COVID-19
Ag Card rapid test to detect COVID-19 and launched the product for at-home use.
● In December, Abbott launched its multiplex molecular test on its Alinity m system to detect COVID-19, flu A, flu
B, and respiratory syncytial virus (RSV) pursuant to a CE Mark.

-- 22 of 409 --

22
In 2020, Abbott’s COVID-19 testing related sales totaled approximately $3.884 billion, led by sales related to Abbott’s
BinaxNOW, Panbio and ID NOW rapid testing platforms.
In addition to negatively impacting routine core diagnostic testing volumes, the pandemic negatively affected the
number of cardiovascular and neuromodulation procedures performed by health care providers globally, thereby reducing
the demand for Abbott’s cardiovascular and neuromodulation devices and routine diagnostic tests in 2020. The decrease
began in February in China as that country implemented quarantine restrictions and postponed non-emergency health care
activities. The negative impact on cardiovascular and neuromodulation procedures and routine diagnostic tests expanded to
other countries and geographic regions as COVID-19 spread geographically in the first half of 2020 and health care
systems in these countries shifted their focus to fighting COVID-19.
The extent of the impact and the timing of a recovery in the number of procedures and routine testing in a particular
country or geographic region depended upon the progression of COVID-19 cases in the country or region. The recovery in
procedures and routine testing volumes in China began in March. In other parts of the world, such as the U.S. and Europe,
volumes improved across Abbott’s hospital-based businesses as the second quarter progressed and the improvement
continued in the third quarter. However, in the fourth quarter, the improving trends in the demand for procedures and
routine testing flattened or were negatively impacted depending upon the business and the region as many countries
experienced an increase in the number of COVID-19 cases and hospitalizations.
Abbott’s branded generic pharmaceuticals business was also negatively affected by the pandemic in 2020 as COVID-
19 spread across emerging market countries in the second and third quarters of 2020. Abbott’s nutritional and diabetes care
businesses were the least affected by the pandemic as is further discussed below.
Abbott is continually implementing business continuity plans in the face of the pandemic. Due to the critical nature of
its products and services, Abbott was generally exempt from governmental orders issued during the first quarter of 2020 in
the U.S. and other countries requiring businesses to cease operations. The majority of its office-based work was conducted
remotely during the period of such governmental orders and the company implemented strict travel restrictions. As some
governmental orders were lifted in May and June 2020, Abbott entered a new phase in its operations whereby some office-
based employees started working at Abbott’s offices on a rotational basis. As various governmental orders and guidelines
were modified in the fourth quarter to put in place new restrictions, Abbott continued to ensure that its guidance was
aligned with such restrictions. Abbott has taken aggressive steps to limit exposure and enhance the safety of facilities for
its employees.
Due to the unpredictability of the duration and impact of the current COVID-19 pandemic, the extent to which the
COVID-19 pandemic will have a material effect on its business, financial condition or results of operations is uncertain.
While Abbott’s 2020 sales were most significantly affected by the COVID-19 pandemic, the increase in total sales
over the last three years also reflects volume growth due to the introduction of new products across various businesses as
well as higher sales of various existing products. Sales in emerging markets, which represent approximately 37 percent of
total company sales, increased 2.0 percent in 2020 and 8.2 percent in 2019, excluding the impact of foreign exchange.
(Emerging markets include all countries except the United States, Western Europe, Japan, Canada, Australia and New
Zealand.)
Over the last three years, Abbott’s operating margin as a percentage of sales increased from 11.9 percent in 2018 to
14.2 percent in 2019 and 15.5 percent in 2020. The increase in 2020 reflects the sales volume increases in the rapid and
molecular diagnostics businesses, partially offset by lower Medical Devices sales due to the impact of the pandemic and the
unfavorable effect of foreign exchange. In addition, a reduction in the costs associated with business acquisitions and
restructuring activities drove an improvement in operating margins from 2018 to 2020. In 2019, the increase in Abbott’s
operating margin also reflects margin improvement in various businesses and lower intangible amortization expense
compared to 2018.
With respect to the performance of each reportable segment over the last three years, sales in the Medical Devices
segment excluding the impact of foreign exchange decreased 3.8 percent in 2020 and increased 10.5 percent in 2019. The
sales decrease in 2020 was driven by Abbott’s cardiovascular and neuromodulation businesses due primarily to reduced
procedure volumes as a result of the COVID-19 pandemic. These decreases were partially offset by double-digit growth in
Diabetes Care. The sales increase in 2019 was driven primarily by higher Diabetes Care, Structural Heart,
Electrophysiology and Heart Failure sales.

-- 23 of 409 --

23
In 2020, operating earnings for the Medical Devices segment decreased 19.4 percent. The operating margin profile
decreased from 30.8 percent of sales in 2019 to 25.8 percent in 2020 primarily due to lower sales and manufacturing
volumes as a result of the pandemic and pricing pressures on drug eluting stents (DES) as a result of market competition in
the U.S. and other major markets.
In 2020, key product approvals in the Medical Devices segment included:
● CE Mark for Abbott’s Tendyne™ Transcatheter Mitral Valve Implantation system for the treatment of significant
mitral regurgitation (MR) in patients requiring a heart valve replacement who are not candidates for open-heart
surgery or transcatheter mitral valve repair,
● CE Mark for Abbott’s TriClip® heart valve repair system, the world’s first minimally invasive, clip-based device
for repair of a leaky tricuspid heart valve,
● U.S. Food and Drug Administration (FDA) clearance of FreeStyle® Libre 2 as an integrated continuous glucose
monitoring (iCGM) system for adults and children ages 4 and older with diabetes,
● CE Mark for Abbott’s FreeStyle Libre 3 system, which automatically delivers real time, up-to-the-minute glucose
readings, 14-day accuracy and real-time glucose alarms,
● CE Mark for the Libre Sense™ Glucose Sport Biosensor that provides continuous glucose monitoring to help
athletes better understand the efficacy of their nutrition choices on training and athletic performance,
● U.S. FDA approval of the next-generation Gallant™ implantable cardioverter defibrillator and cardiac
resynchronization therapy defibrillator devices which help manage heart rhythm disorders and offer Bluetooth
technology and a new patient smartphone app for improved remote monitoring and enhanced patient-physician
engagement,
● CE Mark for MitraClip® G4, Abbott’s next-generation MitraClip mitral valve repair device,
● CE Mark of EnSite™ X EP System, a next-generation 3D cardiac mapping platform used for ablation therapy to
treat abnormal heart rhythms,
● U.S. FDA clearance and CE Mark of the IonicRF™ Generator, a non-surgical, minimally invasive device that
uses heat to target specific nerves for the management of chronic pain, and
● U.S. FDA approval of updated labeling to allow Abbott’s HeartMate 3™ heart pump to be used in pediatric
patients with advanced refractory left ventricular heart failure.
In Abbott’s worldwide diagnostics business, sales increased 40.6 percent in 2020 and 5.9 percent in 2019, excluding
the impact of foreign exchange. As was discussed above, sales growth in 2020 was driven by demand for Abbott's
portfolio of COVID-19 diagnostics tests across its rapid and lab-based platforms, partially offset by lower volumes of
routine laboratory testing due to the pandemic. Growth in 2019 reflected continued market penetration by the core
laboratory business in the U.S. and internationally. The 2019 growth included the continued adoption by customers of
Alinity, which is Abbott’s integrated family of next-generation diagnostic systems and solutions that are designed to
increase efficiency by running more tests in less space, generating test results faster and minimizing human errors while
continuing to provide quality results.
Abbott has regulatory approvals in the U.S., Europe, China, and other markets for the “Alinity c” and “Alinity i”
instruments and has continued to build out its test menu for clinical chemistry and immunoassay diagnostics. Abbott has
obtained regulatory approval for the “Alinity h” instrument for hematology in Europe and Japan. Abbott has also obtained
regulatory approvals in the U.S. and Europe for the “Alinity s” (blood screening) and “Alinity m” (molecular) instruments
and several testing assays.
In 2020, operating earnings for the Diagnostics segment increased 94.8 percent. The operating margin profile increased
from 24.9 percent of sales in 2018 to 34.5 percent in 2020 primarily due to higher sales in 2020 in Rapid Diagnostics and
Molecular Diagnostics, partially offset by lower volumes of routine testing in Core Laboratory.

-- 24 of 409 --

24
In Abbott’s worldwide nutritional products business, sales over the last three years were positively impacted by
numerous new product introductions, including the roll-outs of human milk oligosaccharide, or HMO, in infant formula
and of high-protein Ensure®, that leveraged Abbott’s strong brands. Sales were also positively affected by demographics
such as an aging population and an increasing rate of chronic disease in developed markets and the rise of a middle class in
many emerging markets. Excluding the impact of foreign exchange, total adult nutrition sales increased 10.3 percent in
2020 and 6.6 percent in 2019 led by the continued growth of Ensure, Abbott’s market-leading complete and balanced
nutrition brand, and Glucerna®, Abbott’s market-leading diabetes-specific nutrition brand, across several countries. The
2019 sales growth was partially offset by the unfavorable impact of the discontinuation of a non-core product line in the
U.S. Excluding the impact of foreign exchange, total pediatric nutrition sales increased 0.3 percent in 2020 and 3.4 percent
in 2019 driven by the PediaSure® and Pedialyte® brands in the U.S. as well as infant and toddler product growth across
several markets in Asia and Latin America, partially offset by challenging market dynamics in the infant category in
Greater China. The 2020 increase was also driven by higher Similac® sales in the U.S.
The Established Pharmaceutical Products segment focuses on the sale of its products in emerging markets. Excluding
the impact of foreign exchange, Established Pharmaceutical sales increased 1.9 percent in 2020 and 7.3 percent in 2019.
The sales increases in 2020 and 2019 reflect higher sales in several geographies including India, China, Brazil and Russia.
Operating margins decreased from 20.2 percent of sales in 2018 to 18.5 percent in 2020 primarily due to the unfavorable
impact of foreign exchange, product mix and lower gross margins.
With respect to Abbott’s financial position, at December 31, 2020, Abbott’s cash and cash equivalents and short-term
investments total approximately $7.1 billion compared to $4.1 billion at December 31, 2019. Abbott’s long-term debt and
short-term borrowings total $18.7 billion and $18.1 billion at December 31, 2020 and 2019, respectively.
Abbott declared dividends of $1.53 per share in 2020 compared to $1.32 per share in 2019, an increase of
approximately 16 percent. Dividends paid totaled $2.560 billion in 2020 compared to $2.270 billion in 2019. The year-
over-year change in the amount of dividends paid primarily reflects the increase in the dividend rate. In December 2020,
Abbott increased the company’s quarterly dividend by 25 percent to $0.45 per share from $0.36 per share, effective with
the dividend paid in February 2021.
In 2021, Abbott will focus on continuing to meet the demand for COVID-19 tests and will continue to invest in
product development areas that provide the opportunity for strong sustainable growth over the next several years. In its
diagnostics business, Abbott will continue to focus on driving market adoption and geographic expansion of its Alinity
suite of diagnostics instruments. In the medical devices business, Abbott will continue to focus on expanding its market
position in various areas including diabetes care, structural heart, electrophysiology, and heart failure. In its nutritionals
business, Abbott will continue to focus on driving growth globally and further enhancing its portfolio with the introduction
of line extensions of its science-based products. In the established pharmaceuticals business, Abbott will continue to focus
on growing its business with the depth and breadth of its portfolio in emerging markets.

-- 25 of 409 --

25
Critical Accounting Policies
Sales Rebates — In 2020, approximately 41 percent of Abbott’s consolidated gross revenues were subject to various
forms of rebates and allowances that Abbott recorded as reductions of revenues at the time of sale. Most of these rebates
and allowances in 2020 are in the Nutritional Products and Diabetes Care businesses. Abbott provides rebates to state
agencies that administer the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC),
wholesalers, group purchasing organizations, and other government agencies and private entities. Rebate amounts are
usually based upon the volume of purchases using contractual or statutory prices for a product. Factors used in the rebate
calculations include the identification of which products have been sold subject to a rebate, which customer or government
agency price terms apply, and the estimated lag time between sale and payment of a rebate. Using historical trends,
adjusted for current changes, Abbott estimates the amount of the rebate that will be paid, and records the liability as a
reduction of gross sales when Abbott records its sale of the product. Settlement of the rebate generally occurs from one to
six months after sale. Abbott regularly analyzes the historical rebate trends and makes adjustments to reserves for changes
in trends and terms of rebate programs. Rebates and chargebacks charged against gross sales in 2020, 2019 and 2018
amounted to approximately $3.3 billion, $3.1 billion and $3.0 billion, respectively, or 20.1 percent, 19.1 percent and 19.0
percent of gross sales, respectively, based on gross sales of approximately $16.6 billion, $16.3 billion and $16.0 billion,
respectively, subject to rebate. A one-percentage point increase in the percentage of rebates to related gross sales would
decrease net sales by approximately $166 million in 2020. Abbott considers a one-percentage point increase to be a
reasonably likely increase in the percentage of rebates to related gross sales. Other allowances charged against gross sales
were approximately $207 million, $169 million and $175 million for cash discounts in 2020, 2019 and 2018, respectively,
and $232 million, $192 million and $191 million for returns in 2020, 2019 and 2018, respectively. Cash discounts are
known within 15 to 30 days of sale, and therefore can be reliably estimated. Returns can be reliably estimated because
Abbott’s historical returns are low, and because sales returns terms and other sales terms have remained relatively
unchanged for several periods.
Management analyzes the adequacy of ending rebate accrual balances each quarter. In the domestic nutritional
business, management uses both internal and external data available to estimate the accruals. In the WIC business,
estimates are required for the amount of WIC sales within each state where Abbott holds the WIC contract. The state where
the sale is made, which is the determining factor for the applicable rebated price, is reliably determinable. Rebated prices
are based on contractually obligated agreements generally lasting a period of two to four years. Except for a change in
contract price or a transition period before or after a change in the supplier for the WIC business in a state, accruals are
based on historical redemption rates and data from the U.S. Department of Agriculture (USDA) and the states submitting
rebate claims. The USDA, which administers the WIC program, has been making its data available for many years.
Management also estimates the states' processing lag time based on sales and claims data. Inventory in the retail
distribution channel does not vary substantially. Management has access to several large customers' inventory management
data, which allows management to make reliable estimates of inventory in the retail distribution channel. At December 31,
2020, Abbott had WIC business in 27 states.
Historically, adjustments to prior years’ rebate accruals have not been material to net income. Abbott employs various
techniques to verify the accuracy of claims submitted to it, and where possible, works with the organizations submitting
claims to gain insight into changes that might affect the rebate amounts. For government agency programs, the calculation
of a rebate involves interpretations of relevant regulations, which are subject to challenge or change in interpretation.
Income Taxes — Abbott operates in numerous countries where its income tax returns are subject to audits and
adjustments. Because Abbott operates globally, the nature of the audit items is often very complex, and the objectives of
the government auditors can result in a tax on the same income in more than one country. Abbott employs internal and
external tax professionals to minimize audit adjustment amounts where possible. In accordance with the accounting rules
relating to the measurement of tax contingencies, in order to recognize an uncertain tax benefit, the taxpayer must be more
likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more
than 50 percent likely to be realized upon resolution of the benefit. Application of these rules requires a significant amount
of judgment. In the U.S., Abbott’s federal income tax returns through 2016 are settled. Undistributed foreign earnings
remain indefinitely reinvested in foreign operations. Determining the amount of unrecognized deferred tax liability related
to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in its
foreign entities is not practicable.

-- 26 of 409 --

26
Pension and Post-Employment Benefits — Abbott offers pension benefits and post-employment health care to many of
its employees. Abbott engages outside actuaries to assist in the determination of the obligations and costs under these
programs. Abbott must develop long-term assumptions, the most significant of which are the health care cost trend rates,
discount rates and the expected return on plan assets. The discount rates used to measure liabilities were determined based
on high-quality fixed income securities that match the duration of the expected retiree benefits. The health care cost trend
rates represent Abbott’s expected annual rates of change in the cost of health care benefits and are a forward projection of
health care costs as of the measurement date. A difference between the assumed rates and the actual rates, which will not
be known for years, can be significant in relation to the obligations and the annual cost recorded for these programs. Low
interest rates have significantly increased actuarial losses for these plans. At December 31, 2020, pretax net actuarial losses
and prior service costs and (credits) recognized in Accumulated other comprehensive income (loss) were net losses of $4.6
billion for Abbott’s defined benefit plans and net losses of $419 million for Abbott’s medical and dental plans. Actuarial
losses and gains are amortized over the remaining service attribution periods of the employees under the corridor method,
in accordance with the rules for accounting for post-employment benefits. Differences between the expected long-term
return on plan assets and the actual annual return are amortized over a five-year period.
Valuation of Intangible Assets — Abbott has acquired and continues to acquire significant intangible assets that Abbott
records at fair value at the acquisition date. Transactions involving the purchase or sale of intangible assets occur with
some frequency between companies in the health care field and valuations are usually based on a discounted cash flow
analysis. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk,
cost of capital, terminal values and market participants. Each of these factors can significantly affect the value of the
intangible asset. Abbott engages independent valuation experts who review Abbott’s critical assumptions and calculations
for acquisitions of significant intangibles. Abbott reviews definite-lived intangible assets for impairment each quarter using
an undiscounted net cash flows approach. If the undiscounted cash flows of an intangible asset are less than the carrying
value of an intangible asset, the intangible asset is written down to its fair value, which is usually the discounted cash flow
amount. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest group level for
which cash flows are identifiable. Goodwill and indefinite-lived intangible assets, which relate to in-process research and
development acquired in a business combination, are reviewed for impairment annually or when an event that could result
in impairment occurs. At December 31, 2020, goodwill amounted to $23.7 billion and net intangibles amounted to $14.8
billion. Amortization expense in continuing operations for intangible assets amounted to $2.1 billion in 2020, $1.9 billion
in 2019 and $2.2 billion in 2018. There was no reduction of goodwill relating to impairments in 2020, 2019 and 2018.
Litigation — Abbott accounts for litigation losses in accordance with Financial Accounting Standards Board (FASB)
Accounting Standards Codification (ASC) No. 450, “Contingencies.” Under ASC No. 450, loss contingency provisions are
recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum
loss contingency amount is recorded. These estimates are often initially developed substantially earlier than the ultimate
loss is known, and the estimates are refined each accounting period as additional information becomes known.
Accordingly, Abbott is often initially unable to develop a best estimate of loss, and therefore the minimum amount, which
could be zero, is recorded. As information becomes known, either the minimum loss amount is increased, resulting in
additional loss provisions, or a best estimate can be made, also resulting in additional loss provisions. Occasionally, a best
estimate amount is changed to a lower amount when events result in an expectation of a more favorable outcome than
previously expected. Abbott estimates the range of possible loss to be from approximately $90 million to $120 million for
its legal proceedings and environmental exposures. Accruals of approximately $105 million have been recorded at
December 31, 2020 for these proceedings and exposures. These accruals represent management’s best estimate of probable
loss, as defined by FASB ASC No. 450, “Contingencies.”

-- 27 of 409 --

27
Results of Operations
Sales
The following table details the components of sales growth by reportable segment for the last two years:
Components of % Change
Total
% Change 	Price 	Volume Exchange
Total Net Sales
2020 vs. 2019 	8.5 	(0.4) 	10.2 	(1.3)
2019 vs. 2018 	4.3 	0.2 	7.3 	(3.2)
Total U.S.
2020 vs. 2019 	14.2 	(1.1) 	15.3 	—
2019 vs. 2018 	5.2 	(0.4) 	5.6 	—
Total International
2020 vs. 2019 	5.3 	0.1 	7.2 	(2.0)
2019 vs. 2018 	3.9 	0.5 	8.3 	(4.9)
Established Pharmaceutical Products Segment
2020 vs. 2019 	(4.1) 	2.7 	(0.8) 	(6.0)
2019 vs. 2018 	1.4 	3.0 	4.3 	(5.9)
Nutritional Products Segment
2020 vs. 2019 	3.2 	0.8 	3.9 	(1.5)
2019 vs. 2018 	2.5 	0.9 	3.9 	(2.3)
Diagnostic Products Segment
2020 vs. 2019 	40.1 	(0.8) 	41.4 	(0.5)
2019 vs. 2018 	2.9 	(0.5) 	6.4 	(3.0)
Medical Devices Segment
2020 vs. 2019 	(3.7) 	(1.9) 	(1.9) 	0.1
2019 vs. 2018 	7.6 	(0.9) 	11.4 	(2.9)
The increase in Total Net Sales in 2020 reflects volume growth in the Diagnostics and Nutritional Products segments.
In Medical Devices, the impact of COVID-19 on Abbott’s cardiovascular and neuromodulation businesses was partially
offset by double-digit volume growth in Diabetes Care. The increase in Total Net Sales in 2019 reflects volume growth
across all of Abbott’s segments. The price declines related to the Medical Devices segment in 2020 and 2019 primarily
reflect DES pricing pressures as a result of market competition in the U.S. and other major markets.

-- 28 of 409 --

28
A comparison of significant product and product group sales is as follows. Percent changes are versus the prior year
and are based on unrounded numbers.
Total 	Impact of 	Total Change
2020 	2019 	Change 	Exchange Excl. Exchange
(dollars in millions)
Total Established Pharmaceuticals —
Key Emerging Markets 	$ 3,209 $ 3,392 	(5)% 	(8)% 	3 %
Other 	1,094 	1,094 	— 	1 	(1)
Nutritionals —
International Pediatric Nutritionals 	2,140 	2,282 	(6) 	(2) 	(4)
U.S. Pediatric Nutritionals 	1,987 	1,879 	6 	— 	6
International Adult Nutritionals 	2,228 	2,017 	11 	(3) 	14
U.S. Adult Nutritionals 	1,292 	1,231 	5 	— 	5
Diagnostics —
Core Laboratory 	4,475 	4,656 	(4) 	(1) 	(3)
Molecular 	1,438 	442 	225 	(1) 	226
Point of Care 	516 	561 	(8) 	— 	(8)
Rapid Diagnostics 	4,376 	2,054 	113 	1 	112
Medical Devices —
Rhythm Management 	1,914 	2,144 	(11) 	— 	(11)
Electrophysiology 	1,578 	1,721 	(8) 	1 	(9)
Heart Failure 	740 	769 	(4) 	— 	(4)
Vascular (a) 	2,339 	2,850 	(18) 	— 	(18)
Structural Heart 	1,247 	1,400 	(11) 	— 	(11)
Neuromodulation 	702 	831 	(16) 	— 	(16)
Diabetes Care 	3,267 	2,524 	29 	— 	29
(a) Vascular Product Lines:
Coronary and Endovascular 	2,263 	2,740 	(17) 	— 	(17)

-- 29 of 409 --

29
Total 	Impact of 	Total Change
2019 	2018 	Change 	Exchange Excl. Exchange
(dollars in millions)
Total Established Pharmaceuticals —
Key Emerging Markets 	$ 3,392 $ 3,363 	1 % 	(7)% 	8 %
Other 	1,094 	1,059 	3 	(3) 	6
Nutritionals —
International Pediatric Nutritionals 	2,282 	2,254 	1 	(4) 	5
U.S. Pediatric Nutritionals 	1,879 	1,843 	2 	— 	2
International Adult Nutritionals 	2,017 	1,900 	6 	(5) 	11
U.S. Adult Nutritionals 	1,231 	1,232 	— 	— 	—
Diagnostics —
Core Laboratory 	4,656 	4,386 	6 	(4) 	10
Molecular 	442 	484 	(9) 	(3) 	(6)
Point of Care 	561 	553 	2 	— 	2
Rapid Diagnostics 	2,054 	2,072 	(1) 	(2) 	1
Medical Devices —
Rhythm Management 	2,144 	2,198 	(3) 	(3) 	—
Electrophysiology 	1,721 	1,561 	10 	(3) 	13
Heart Failure 	769 	646 	19 	(1) 	20
Vascular (a) 	2,850 	2,929 	(3) 	(3) 	—
Structural Heart 	1,400 	1,239 	13 	(3) 	16
Neuromodulation 	831 	864 	(4) 	(2) 	(2)
Diabetes Care 	2,524 	1,933 	31 	(5) 	36
(a) Vascular Product Lines:
Coronary and Endovascular 	2,740 	2,778 	(1) 	(2) 	1
In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or
divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or
divided, as appropriate, by the prior year average foreign exchange rates.
Total Established Pharmaceutical Products sales increased 1.9 percent in 2020 and 7.3 percent in 2019, excluding the
unfavorable impact of foreign exchange. The Established Pharmaceutical Products segment is focused on several key
emerging markets including India, Russia, China and Brazil. Excluding the impact of foreign exchange, total sales in these
key emerging markets increased 2.6 percent in 2020 and 7.9 percent in 2019 due to higher sales in several geographies
including China, Brazil, India and Russia. Excluding the impact of foreign exchange, sales in Established Pharmaceuticals’
other emerging markets decreased 0.5 percent in 2020 and increased 5.6 percent in 2019.
Total Nutritional Products sales increased 4.7 percent in 2020 and 4.8 percent in 2019, excluding the impact of foreign
exchange. In 2020, International Pediatric Nutritional sales, excluding the effect of foreign exchange, decreased 4.1
percent as growth across Abbott’s pediatric products in various countries in Southeast Asia was more than offset by
challenging market dynamics in the infant category in Greater China. The 4.6 percent increase in 2019 International
Pediatric Nutritional sales, excluding the effect of foreign exchange, was driven by growth across Abbott’s portfolio,
including Similac and PediaSure in various countries in Asia and Latin America and Pedialyte in Latin America. This
growth was partially offset by challenging market dynamics in the infant category in Greater China. In the U.S. Pediatric
Nutritional business, sales increased 5.8 percent in 2020 and 1.9 percent in 2019, reflecting growth in Similac in 2020 and
growth in PediaSure and Pedialyte in both years.

-- 30 of 409 --

30
In the International Adult Nutritional business, sales increased 13.6 percent and 10.9 percent in 2020 and 2019,
respectively, excluding the effect of foreign exchange, due to continued growth of Ensure and Glucerna in several
countries. In 2020 U.S. Adult Nutritional sales increased 4.9 percent, primarily due to growth of Ensure. In 2019, U.S.
Adult Nutritional sales were unchanged from 2018 due to the impact of Abbott’s discontinuation of a non-core product line
during the third quarter of 2018 that was offset by growth in other areas of the business.
In the Diagnostics segment, Core Laboratory sales decreased 2.8 percent in 2020, excluding the effect of foreign
exchange, as the lower volume of routine testing performed in hospital and other laboratories due to COVID-19 was
partially offset by sales of Abbott’s COVID-19 laboratory-based tests for the detection of the IgG and IgM antibodies,
which determine if someone was previously infected with the virus. Core Laboratory antibody testing-related sales on
Abbott’s ARCHITECT and Alinity i platforms were $268 million in 2020. The 225.7 percent increase in Molecular
Diagnostics sales in 2020, excluding the effect of foreign exchange, reflects higher volumes due to demand for Abbott’s
laboratory-based molecular tests for COVID-19 on its m2000 and Alinity m platforms. Abbott received U.S. FDA
approval in March 2020 for its Alinity m molecular diagnostics system. Molecular Diagnostics COVID-19 testing-related
sales were $1.023 billion in 2020.
In Rapid Diagnostics, sales increased 112.3 percent in 2020, excluding the effect of foreign exchange, due to strong
demand for Abbott’s point-of-care COVID-19 molecular test on its ID NOW platform and its BinaxNOW COVID-19 Ag
Card test in the U.S. as well as international demand for COVID-19 rapid tests on its Panbio system and increased testing
in the first quarter for the flu in the U.S. These increases were partially offset by the unfavorable impact of COVID-19 on
routine diagnostic testing. Rapid Diagnostics COVID-19 testing-related sales were $2.593 billion in 2020.
In the Diagnostics segment, the sales increase in 2019 was driven by above-market growth in Core Laboratory in the
U.S. and internationally, where Abbott achieved continued adoption of its Alinity family of diagnostic instruments. The 6.3
percent decrease in 2019 Molecular sales, excluding the effect of foreign exchange, reflects the negative impact of lower
non-governmental organization purchases in Africa. In Rapid Diagnostics, sales growth in 2019 in various areas, including
infectious disease testing in developed markets and cardio-metabolic testing, was mostly offset by lower than expected
infectious disease testing sales in Africa.
Excluding the effect of foreign exchange, total Medical Devices sales decreased 3.8 percent and increased 10.5 percent
in 2020 and 2019, respectively. In 2020, double-digit growth in Diabetes Care was more than offset by decreases in
Abbott’s cardiovascular and neuromodulation businesses due to the impact of COVID-19 and lower vascular sales in China
in the fourth quarter of 2020 as a result of a new national tender program. The 2019 sales increase was driven by double-
digit growth in Diabetes Care, Structural Heart, Electrophysiology and Heart Failure.
The 2020 and 2019 growth in Diabetes Care revenue was driven by continued growth of FreeStyle Libre, Abbott’s
continuous glucose monitoring system, internationally and in the U.S. In 2020, FreeStyle Libre sales totaled $2.635 billion,
which reflected a 42.6 percent increase over 2019, excluding the effect of foreign exchange. FreeStyle Libre sales in 2019
were $1.842 billion, which reflected a 69.8 percent increase, excluding the effect of foreign exchange, over 2018 when
sales totaled $1.128 billion.
In 2019, growth in Structural Heart revenue was broad-based across several areas of the business, including MitraClip,
Abbott's market-leading device for the minimally invasive treatment of mitral regurgitation (MR), a leaky heart valve.
2019 growth in Electrophysiology revenue reflects higher sales of cardiac diagnostic and ablation catheters in both the
U.S. and internationally. The growth in Heart Failure revenue in 2019 was driven by rapid market adoption in the U.S. of
Abbott's HeartMate 3® Left Ventricular Assist Device (LVAD) following FDA approval in October 2018 as a destination
(long-term use) therapy for people living with advanced heart failure as well as higher sales of Abbott’s CardioMEMS®
heart failure monitoring system. In Vascular, excluding the effect of foreign exchange, sales in 2019 were flat as the 1.3
percent increase in coronary and endovascular product sales, which includes drug-eluting stents, balloon catheters,
guidewires, vascular imaging/diagnostics products, vessel closure, carotid and other coronary and peripheral products, was
offset by reductions in royalty and contract manufacturing revenue. In Rhythm Management, higher 2019 international
sales, excluding the effect of foreign exchange, were offset by a 4.4 percent decrease in U.S. revenue. In 2019, the 2.4
percent decline in Neuromodulation sales, excluding the effect of foreign exchange, reflects a 4.2 percent decline in U.S.
sales.
Abbott has periodically sold product rights to non-strategic products and has recorded the related gains in net sales in
accordance with Abbott’s revenue recognition policies as discussed in Note 1 to the consolidated financial statements.
Related net sales were not significant in 2020, 2019 and 2018.

-- 31 of 409 --

31
The expiration of licenses and patent protection can affect the future revenues and operating income of Abbott. There
are no significant patent or license expirations in the next three years that are expected to materially affect Abbott.
In April 2017, Abbott received a warning letter from the U.S. FDA related to its manufacturing facility in Sylmar, CA
which was acquired by Abbott on January 4, 2017 as part of the acquisition of St. Jude Medical, Inc. (St. Jude Medical).
This facility manufactures implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and
monitors. Abbott prepared and executed a comprehensive plan of corrective actions. On April 28, 2020, Abbott received a
letter from the FDA indicating that, based on the FDA’s evaluation, it appeared that Abbott had addressed the items in the
warning letter. As a result, the warning letter is considered closed.
Operating Earnings
Gross profit margins were 50.5 percent of net sales in 2020, 52.5 percent in 2019 and 51.3 percent in 2018. In 2020,
the decrease primarily reflects the mix of sales across Abbott’s various businesses and operational inefficiencies due to the
impact of COVID-19, as well as the increase in intangible asset amortization, the impairment of intangible assets and the
unfavorable effect of foreign exchange on gross margin in 2020. In 2019, the increase primarily reflects lower intangible
amortization expense and lower integration and restructuring costs.
Research and development (R&D) expenses were $2.4 billion in 2020 and 2019, and $2.3 billion in 2018. R&D
spending in 2020 was relatively flat compared to 2019 as the impact of the immediate expensing in 2019 of an R&D asset
valued at $102 million that was acquired in conjunction with the acquisition of Cephea Valve Technologies, Inc. (Cephea)
was partially offset by the $55 million impairment of an in-process R&D intangible asset in 2020. R&D expense in 2020
also reflects lower integration and restructuring costs in 2020 related to R&D, partially offset by higher spending on
various projects. R&D expenses in 2019 increased 6.1 percent, primarily reflecting the immediate expensing of the Cephea
R&D asset as well as higher R&D spending in various businesses, primarily in Medical Devices, partially offset by the
favorable effect of foreign exchange. In 2020, R&D expenditures totaled $1.3 billion for the Medical Devices segment,
$608 million for the Diagnostic Products segment, $189 million for the Nutritional Products segment and $177 million for
the Established Pharmaceutical Products segment.
Selling, general and administrative (SG&A) expenses were basically flat in 2020 and 2019 versus the respective prior
years. In 2020, the favorable effect of foreign exchange, income of approximately $100 million from a litigation settlement
in 2020, lower spending due to COVID-19 travel restrictions, and the impact of various cost saving initiatives were offset
by higher spending to drive growth in various businesses. In 2019, the favorable effect of foreign exchange and lower
acquisition-related integration costs offset higher selling and marketing costs to drive continued growth across various
businesses.
Restructurings
From 2017 to 2020, Abbott management approved restructuring plans as part of the integration of the acquisitions of
St. Jude Medical into the Medical Devices segment, and Alere Inc. (Alere) into the Diagnostic Products segment, in order
to leverage economies of scale and reduce costs. As of December 31, 2017, the accrued balance associated with these
actions was $68 million. From 2018 to 2020, Abbott recorded employee related severance and other charges totaling
approximately $137 million, comprised of $13 million in 2020, $72 million in 2019 and $52 million in 2018.
Approximately $30 million was recorded in Cost of products sold, approximately $15 million was recorded in Research
and development, and approximately $92 million was recorded in Selling, general and administrative expense over the last
three years. As of December 31, 2020, the accrued liabilities remaining in the Consolidated Balance Sheet related to these
actions total $25 million and primarily represent severance obligations.
From 2016 to 2020, Abbott management approved plans to streamline operations in order to reduce costs and improve
efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses.
Abbott recorded employee related severance and other charges of approximately $36 million in 2020, $66 million in 2019
and $28 million in 2018. Approximately $6 million in 2020, $16 million in 2019 and $10 million in 2018 are recorded in
Cost of products sold, approximately $2 million in 2020, $28 million in 2019 and $2 million in 2018 are recorded in
Research and development, and approximately $28 million in 2020, $22 million in 2019 and $16 million in 2018 are
recorded in Selling, general and administrative expense.

-- 32 of 409 --

32
Interest Expense and Interest (Income)
Interest expense, net decreased $76 million in 2020 due to a reduction in interest expense resulting from the favorable
impact of the euro debt financing in November 2019, the repayment of debt in December 2019 and a lower interest rate
environment in 2020. In 2019, interest expense, net decreased $145 million due to the favorable impact of the euro debt
financing in September 2018, as well as the repayment of debt in 2018 and the first quarter of 2019.
Debt Extinguishment Costs
On December 19, 2019, Abbott redeemed the $2.850 billion principal amount of its 2.9% Notes due 2021. Abbott
incurred a charge of $63 million related to the early repayment of this debt.
On October 28, 2018, Abbott redeemed approximately $4 billion of debt, which included $750 million principal
amount of its 2.00% Notes due 2020; $597 million principal amount of its 4.125% Notes due 2020; $900 million principal
amount of its 3.25% Notes due 2023; $450 million principal amount of its 3.4% Notes due 2023; and $1.300 billion
principal amount of its 3.75% Notes due 2026. Abbott incurred a net charge of $153 million related to the early repayment
of this debt and the unwinding of related interest rate swaps.
On March 22, 2018, Abbott redeemed all of the $947 million principal amount of its 5.125% Notes due 2019, as well
as $1.055 billion of the $2.850 billion principal amount of its 2.35% Notes due 2019. Abbott incurred a net charge of $14
million related to the early repayment of this debt.
Other (Income) Expense, net
Other (income) expense, net, for 2020, 2019 and 2018 includes approximately $205 million, $225 million, and $160
million of income in each year, respectively, related to the non-service cost components of the net periodic benefit costs
associated with the pension and post-retirement medical plans. Other (income) expense, net for 2020 also includes equity
investment impairments that totaled approximately $115 million.
Taxes on Earnings
The income tax rates on earnings from continuing operations were 10.0 percent in 2020, 9.6 percent in 2019 and 18.8
percent in 2018.
In 2020, taxes on earnings from continuing operations include the recognition of approximately $170 million of tax
benefits associated with the impairment of certain assets, approximately $140 million of net tax benefits as a result of the
resolution of various tax positions related to prior years, and approximately $100 million in excess tax benefits associated
with share-based compensation. In 2020, taxes on earnings from continuing operations also include a $26 million increase
to the transition tax associated with the 2017 Tax Cuts and Jobs Act (TCJA). The $26 million increase to the transition tax
liability was the result of the resolution of various tax positions related to prior years. This adjustment increased the
cumulative net tax expense related to the TCJA to $1.53 billion.
In 2019, taxes on earnings from continuing operations included approximately $100 million in excess tax benefits
associated with share-based compensation, an $86 million reduction of the transition tax and $68 million of tax expense
resulting from tax legislation enacted in the fourth quarter of 2019 in India. The $86 million reduction to the transition tax
liability was the result of the issuance of final transition tax regulations by the U.S. Department of Treasury in 2019. In
2018, taxes on earnings from continuing operations included $98 million of net tax expense related to the settlement of
Abbott’s 2014-2016 federal income tax audit in the U.S., partial settlement of the former St. Jude Medical consolidated
group’s 2014 and 2015 federal income tax returns in the U.S. and audit settlements in various countries as well as
approximately $90 million in excess tax benefits associated with share-based compensation. In 2018, Abbott also recorded
$130 million of additional tax expense related to the TCJA; the $130 million reflected a $120 million increase in the
transition tax from $2.89 billion to $3.01 billion and a $10 million reduction in the net benefit related to the remeasurement
of deferred tax assets and liabilities.

-- 33 of 409 --

33
Exclusive of these discrete items, tax expense was favorably impacted by lower tax rates and tax exemptions on
foreign income primarily derived from operations in Puerto Rico, Switzerland, Ireland, the Netherlands, Costa Rica,
Singapore, and Malta. Abbott benefits from a combination of favorable statutory tax rules, tax rulings, grants, and
exemptions in these tax jurisdictions. See Note 15 to the consolidated financial statements for a full reconciliation of the
effective tax rate to the U.S. federal statutory rate.
Discontinued Operations
The net earnings of discontinued operations include income tax benefits of $24 million in 2020 and $39 million in
2018. The 2020 tax benefits primarily relate to the resolution of various tax positions related to Abbott’s developed
markets branded generic pharmaceuticals business which was sold to Mylan Inc. (Mylan) in 2015. The tax positions relate
to years prior to the sale to Mylan. The 2018 tax benefits primarily relate to the resolution of various tax positions related
to the operations of AbbVie Inc. (AbbVie) for years prior to the separation. Abbott completed the separation of AbbVie,
which was formed to hold Abbott’s research-based proprietary pharmaceuticals business, in January 2013. Abbott retained
all liabilities for all U.S. federal and foreign income taxes on income prior to the separation.
Research and Development Programs
Abbott currently has numerous pharmaceutical, medical devices, diagnostic and nutritional products in development.
Research and Development Process
In the Established Pharmaceuticals segment, the development process focuses on the geographic expansion and
continuous improvement of the segment’s existing products to provide benefits to patients and customers. As Established
Pharmaceuticals does not actively pursue primary research, development usually begins with work on existing products or
after the acquisition of an advanced stage licensing opportunity.
Depending upon the product, the phases of development may include:
● Drug product development.
● Phase I bioequivalence studies to compare a future Established Pharmaceutical’s brand with an already marketed
compound with the same active pharmaceutical ingredient (API).
● Phase II studies to test the efficacy of benefits in a small group of patients.
● Phase III studies to broaden the testing to a wider population that reflects the actual medical use.
● Phase IV and other post-marketing studies to obtain new clinical use data on existing products within approved
indications.
The specific requirements (e.g., scope of clinical trials) for obtaining regulatory approval vary across different
countries and geographic regions. The process may range from one year for a bioequivalence study project to 6 or more
years for complex formulations, new indications, or geographic expansion in specific countries, such as China.
In the Diagnostics segment, the phases of the research and development process include:
● Discovery which focuses on identification of a product that will address a specific therapeutic area, platform, or
unmet clinical need.
● Concept/Feasibility during which the materials and manufacturing processes are evaluated, testing may include
product characterization and analysis is performed to confirm clinical utility.
● Development during which extensive testing is performed to demonstrate that the product meets specified design
requirements and that the design specifications conform to user needs and intended uses.

-- 34 of 409 --

34
The regulatory requirements for diagnostic products vary across different countries and geographic regions. In the
U.S., the FDA classifies diagnostic products into classes (I, II, or III) and the classification determines the regulatory
process for approval. While the Diagnostics segment has products in all three classes, the vast majority of its products are
categorized as Class I or Class II. Submission of a separate regulatory filing is not required for Class I products. Class II
devices typically require pre-market notification to the FDA through a regulatory filing known as a 510(k) submission.
Most Class III products are subject to the FDA’s Premarket Approval (PMA) requirements. Other Class III products, such
as those used to screen blood, require the submission and approval of a Biological License Application (BLA).
In the European Union (EU), diagnostic products are also categorized into different categories and the regulatory
process, which has been governed by the European In Vitro Diagnostic Medical Device Directive, depends upon the
category, with certain product categories requiring review and approval by an independent company, known as a Notified
Body, before the manufacturer can affix a CE mark to the product to declare conformity to the Directive. Other products
only require a self-certification process. In the second quarter of 2017, the EU adopted the new In Vitro Diagnostic
Regulation (IVDR) which replaces the existing directive in the EU for in vitro diagnostic products. The IVDR will apply
after a five-year transition period and imposes additional premarket and postmarket regulatory requirements on
manufacturers of such products.
In the Medical Devices segment, the research and development process begins with research on a specific technology
that is evaluated for feasibility and commercial viability. If the research program passes that hurdle, it moves forward into
development. The development process includes evaluation, selection and qualification of a product design, completion of
applicable clinical trials to test the product’s safety and efficacy, and validation of the manufacturing process to
demonstrate its repeatability and ability to consistently meet pre-determined specifications.
Similar to the diagnostic products discussed above, in the U.S., medical devices are classified as Class I, II, or III.
Most of Abbott’s medical device products are classified as Class II devices that follow the 510(k) regulatory process or
Class III devices that are subject to the PMA process.
In the EU, medical devices are also categorized into different classes and the regulatory process, which has been
governed by the European Medical Device Directive and the Active Implantable Medical Device Directive, varies by class.
Each product must bear a CE mark to show compliance with the Directive. In the second quarter of 2017, the EU adopted
the new Medical Devices Regulation (MDR) which replaces the existing directives in the EU for medical devices and
imposes additional premarket and postmarket regulatory requirements on manufacturers of such products. While the MDR
was previously adopted to apply after a three year transition period, in 2020 the European Parliament postponed the date of
application by one year.
Some products require submission of a design dossier to the appropriate regulatory authority for review and approval
prior to CE marking of the device. For other products, the company is required to prepare a technical file which includes
testing results and clinical evaluations but can self-certify its ability to apply the CE mark to the product. Outside the U.S.
and the EU, the regulatory requirements vary across different countries and regions.
After approval and commercial launch of some medical devices, post-market trials may be conducted either due to a
conditional requirement of the regulatory market approval or with the objective of proving product superiority.
In the Nutritional segment, the research and development process generally focuses on identifying and developing
ingredients and products that address the nutritional needs of particular populations (e.g., infants and adults) or patients
(e.g., people with diabetes). Depending upon the country and/or region, if claims regarding a product’s efficacy will be
made, clinical studies typically must be conducted.
In the U.S., the FDA requires that it be notified of proposed new formulations and formulation or packaging changes
related to infant formula products. Prior to the launch of an infant formula or product packaging change, the company is
required to obtain the FDA’s confirmation that it has no objections to the proposed product or packaging. For other
nutritional products, notification or pre-approval from the FDA is not required unless the product includes a new food
additive. In some countries, regulatory approval may be required for certain nutritional products, including infant formula
and medical nutritional products.

-- 35 of 409 --

35
Areas of Focus
In 2021 and beyond, Abbott’s significant areas of therapeutic focus will include the following:
Established Pharmaceuticals — Abbott focuses on building country-specific portfolios made up of high-quality medicines
that meet the needs of people in emerging markets. Over the next several years, Abbott plans to expand its product
portfolio in key therapeutic areas with the aim of being among the first to launch new off-patent and differentiated
medicines. In addition, Abbott continues to expand existing brands into new markets, implement product enhancements
that provide value to patients and acquire strategic products and technology through licensing activities. Abbott is also
actively working on the further development of several key brands such as Creon™, Duphaston™, Duphalac™ and
Influvac™. Depending on the product, the activities focus on development of new data, markets, formulations, delivery
systems, or indications. One example includes the launch of Abbott’s quadrivalent influenza vaccination Influvac® Tetra
in 12 markets and an expanded indication in 16 markets to cover children, adolescents and young adults from 3 to 17 years
old.
Medical Devices — Abbott’s research and development programs focus on:
● Cardiac Rhythm Management – Development of next-generation rhythm management technologies, including
advanced communication capabilities and leadless pacing therapies.
● Heart Failure – Continued enhancements to Abbott’s mechanical circulatory support and pulmonary artery
pressure systems, including enhanced clinical performance and usability.
● Electrophysiology – Development of next-generation technologies in the areas of ablation, diagnostic, mapping,
and visualization and recording.
● Vascular – Development of next-generation technologies for use in coronary and peripheral vascular procedures.
● Structural Heart – Development of minimally-invasive transcatheter and surgical devices for the repair and
replacement of heart valves and other structural heart conditions.
● Neuromodulation – Development of additional clinical evidence and next-generation technologies leveraging
digital health to improve patient and physician engagement to treat chronic pain, movement disorders and other
indications.
● Diabetes Care – Develop enhancements and additional indications for the FreeStyle Libre platform of continuous
glucose monitoring products to help patients improve their ability to manage diabetes and for use beyond
diabetes.
Nutritionals — Abbott is focusing its research and development spend on platforms that span the pediatric and adult
nutrition areas: gastro intestinal/immunity health, brain health, mobility and metabolism, and user experience platforms.
Numerous new products that build on advances in these platforms are currently under development, including clinical
outcome testing, and are expected to be launched over the coming years.
Core Laboratory Diagnostics — Abbott continues to commercialize its next-generation blood screening, immunoassay,
clinical chemistry and hematology systems, along with assays, including a focus on unmet medical need, in various areas
including infectious disease, cardiac care, metabolics, and oncology, as well as informatics solutions to help optimize
diagnostics laboratory performance and automation solutions to increase efficiency in laboratories.
Molecular Diagnostics — Several new molecular in vitro diagnostic (IVD) tests are in various stages of development and
launch.
Rapid Diagnostics — Abbott’s research and development programs focus on the development of diagnostic products for
infectious disease, cardiometabolic disease and toxicology.
In addition, the Diagnostics Divisions are pursuing the FDA’s customary regulatory process for various COVID-19 tests for
which an EUA was obtained in 2020.

-- 36 of 409 --

36
Given the diversity of Abbott’s business, its intention to remain a broad-based health care company and the numerous
sources for potential future growth, no individual project is expected to be material to cash flows or results of operations
over the next five years. Factors considered included research and development expenses projected to be incurred for the
project over the next year relative to Abbott’s total research and development expenses, as well as qualitative factors, such
as marketplace perceptions and impact of a new product on Abbott’s overall market position. There were no delays in
Abbott’s 2020 research and development activities that are expected to have a material impact on operations.
While the aggregate cost to complete the numerous projects currently in development is expected to be material, the
total cost to complete will depend upon Abbott’s ability to successfully finish each project, the rate at which each project
advances, and the ultimate timing for completion. Given the potential for significant delays and the risk of failure inherent
in the development of medical device, diagnostic and pharmaceutical products and technologies, it is not possible to
accurately estimate the total cost to complete all projects currently in development. Abbott plans to manage its portfolio of
projects to achieve research and development spending that will be competitive in each of the businesses in which it
participates, and such spending is expected to approximate 7.0 percent of total Abbott sales in 2021. Abbott does not
regularly accumulate or make management decisions based on the total expenses incurred for a particular development
phase in a given period.
Goodwill
At December 31, 2020, goodwill recorded as a result of business combinations totaled $23.7 billion. Goodwill is
reviewed for impairment annually in the third quarter or when an event that could result in an impairment occurs, using a
quantitative assessment to determine whether it is more likely than not that the fair value of any reporting unit is less than
its carrying amount. The income and market approaches are used to calculate the fair value of each reporting unit. The
results of the last impairment test indicated that the fair value of each reporting unit was substantially in excess of its
carrying value.
Financial Condition
Cash Flow
Net cash from operating activities amounted to $7.9 billion, $6.1 billion and $6.3 billion in 2020, 2019 and 2018,
respectively. The increase in Net cash from operating activities in 2020 was primarily due to the favorable cash flow
impact of higher segment operating earnings, lower payments related to interest, integration expenses, and restructuring
actions, and the proceeds from a litigation settlement partially offset by an increased investment in working capital and
higher income tax payments. The decrease in Net cash from operating activities in 2019 was primarily due to an increased
investment in working capital, timing of pension contributions relative to 2018 and higher income tax payments, partially
offset by the favorable cash flow impact of improved segment operating earnings and lower interest and acquisition-related
expenses.
While a significant portion of Abbott’s cash and cash equivalents at December 31, 2020, are reinvested in foreign
subsidiaries, Abbott does not expect such reinvestment to affect its liquidity and capital resources. Due to the enactment of
the TCJA, if these funds were needed for operations in the U.S., Abbott does not expect to incur significant additional
income taxes in the future to repatriate these funds.
Abbott funded $400 million in 2020, $382 million in 2019 and $114 million in 2018 to defined benefit pension plans.
Abbott expects pension funding of approximately $410 million in 2021 for its pension plans. Abbott expects annual cash
flow from operating activities to continue to exceed Abbott’s capital expenditures and cash dividends.
Debt and Capital
At December 31, 2020, Abbott’s long-term debt rating was A by Standard & Poor’s Corporation and A3 by Moody’s.
Abbott expects to maintain an investment grade rating.

-- 37 of 409 --

37
Abbott has readily available financial resources, including unused lines of credit that support commercial paper
borrowing arrangements and provide Abbott with the ability to borrow up to $5 billion on an unsecured basis. The lines of
credit are part of a Five Year Credit Agreement (Revolving Credit Agreement) that Abbott entered into on November 12,
2020. At that time, Abbott also terminated its 2018 revolving credit agreement. There were no outstanding borrowings
under the 2018 revolving credit agreement at the time of its termination. Any borrowings under the Revolving Credit
Agreement will mature and be payable on November 12, 2025. Any borrowings under the Revolving Credit Agreement
will bear interest, at Abbott’s option, based on either a base rate or Eurodollar rate, plus an applicable margin based on
Abbott’s credit ratings.
In 2020, financing activities related to the issuance and repayment of long-term debt included the following:
● On June 24, 2020, Abbott completed the issuance of $1.3 billion aggregate principal amount of senior notes,
consisting of $650 million of its 1.15% Notes due 2028 and $650 million of its 1.40% Notes due 2030.
● On September 28, 2020, Abbott repaid the €1.140 billion outstanding principal amount of its 0.00% Notes due
2020 upon maturity. The repayment equated to approximately $1.3 billion.
As of December 31, 2020, Abbott’s total debt is $18.7 billion.
In 2018 and 2019, Abbott committed to reducing its debt levels which had increased as part of the acquisitions of St.
Jude Medical and Alere in 2017. In 2018, net repayments totaled approximately $8.3 billion of debt.
On February 24, 2019, Abbott redeemed the $500 million outstanding principal amount of its 2.80% Notes due 2020.
In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term
notes. This bond redemption authorization superseded the board’s previous authorization under which $700 million had
not yet been redeemed. On December 19, 2019, Abbott redeemed the $2.850 billion outstanding principal amount of its
2.90% Notes due 2021. $2.15 billion of the 2019 $5 billion redemption authorization remains available as of December 31,
2020.
On November 19, 2019, Abbott’s wholly owned subsidiary, Abbott Ireland Financing DAC, completed a euro debt
offering of €1.180 billion of long-term debt. The proceeds equated to approximately $1.3 billion. The Notes are
guaranteed by Abbott.
On November 21, 2019, Abbott borrowed ¥59.8 billion under a 5-year term loan and designated the yen-denominated
loan as a hedge of its net investment in certain foreign subsidiaries. The term loan bears interest at TIBOR plus a fixed
spread, and the interest rate is reset quarterly. The proceeds equated to approximately $550 million.
In total, these 2019 transactions resulted in the repayment of approximately of $1.6 billion of debt, net of borrowings.
In September 2014, the board of directors authorized the repurchase of up to $3.0 billion of Abbott’s common shares
from time to time. Under the program authorized in 2014, Abbott repurchased 36.2 million shares at a cost of $1.666
billion in 2015, 10.4 million shares at a cost of $408 million in 2016, 1.9 million shares at a cost of $130 million in 2018,
6.3 million shares at a cost of $525 million in 2019, and 1.6 million shares at a cost of $173 million in 2020 for a total of
approximately $2.9 billion. In October 2019, the board of directors authorized the repurchase of up to $3 billion of
Abbott’s common shares from time to time. The 2019 authorization is in addition to the approximately $100 million
unused portion of the share repurchase program authorized in 2014.
On April 27, 2016, the board of directors authorized the issuance and sale for general corporate purposes of up to 75
million common shares that would result in proceeds of up to $3 billion. No shares have been issued under this
authorization.
Abbott declared dividends of $1.53 per share in 2020 compared to $1.32 per share in 2019, an increase of
approximately 16 percent. Dividends paid were $2.560 billion in 2020 compared to $2.270 billion in 2019. The year-over-
year change in dividends paid primarily reflects the impact of the increase in the dividend rate.

-- 38 of 409 --

38
Working Capital
Working capital was $8.5 billion at December 31, 2020 and $4.8 billion at December 31, 2019. The increase was due
in large part to the higher level of cash and cash equivalents, which was due primarily to the increase in cash generated
from operating activities, and the repayment of the current portion of long term debt after the issuance of new long term
notes in 2020. Working capital also increased due to the higher levels of accounts receivable and inventory partially offset
by an increase in accounts payable associated with the growth of the business.
Abbott monitors the credit worthiness of customers and establishes an allowance that reflects the current estimate of
credit losses expected to be incurred over the life of the financial asset. Abbott considers various factors in establishing,
monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the
historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk
factors and forward-looking information, such as country risk, when determining credit limits for customers and
establishing adequate allowances.
Capital Expenditures
Capital expenditures of $2.2 billion in 2020, $1.6 billion in 2019 and $1.4 billion in 2018 were principally for
upgrading and expanding manufacturing and research and development facilities and equipment in various segments,
investments in information technology, and laboratory instruments placed with customers. The 2020 increase in capital
expenditures primarily reflects the building of capacity for the manufacture of COVID-19 diagnostics tests.
Contractual Obligations
The table below summarizes Abbott’s estimated contractual obligations as of December 31, 2020.
Payments Due By Period
2026 and
(in millions) 	Total 	2021 	2022‑2023 2024‑2025 Thereafter
Long‑term debt, including current maturities 	$ 18,490 $ 	7 $ 3,203 $ 2,802 $ 12,478
Interest on debt obligations 	9,011 	596 	1,152 	1,024 	6,239
Operating lease obligations 	1,315 	272 	405 	231 	407
Purchase commitments (a) 	4,757 	4,192 	478 	77 	10
Other long‑term liabilities (b) 	3,845 	— 	1,959 	1,266 	620
Total (c) 	$ 37,418 $ 5,067 $ 7,197 $ 5,400 $ 19,754
(a) Purchase commitments are for purchases made in the normal course of business to meet operational and capital
expenditure requirements.
(b) Other long-term liabilities include estimated payments for the transition tax under the TCJA, net of applicable credits.
(c) Net unrecognized tax benefits totaling approximately $740 million are excluded from the table above as Abbott is
unable to reasonably estimate the period of cash settlement with the respective taxing authorities on such items. See
Note 15 — Taxes on Earnings from Continuing Operations for further details. The company has employee benefit
obligations consisting of pensions and other post-employment benefits, including medical and life, which have been
excluded from the table. A discussion of the company’s pension and post-retirement plans, including funding matters
is included in Note 14 — Post-employment Benefits.

-- 39 of 409 --

39
Contingent Obligations
Abbott periodically acquires a business or product rights in which Abbott agrees to pay contingent consideration based
on attaining certain thresholds or based on the occurrence of certain events.
Legislative Issues
Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the
world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products
and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be
adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1,
Business, and Item 1A, Risk Factors.
Recently Issued Accounting Standards
In December 2019, the FASB issued Accounting Standards Update (ASU) 2019-12, Income Taxes (Topic 740):
Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules
regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim
period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard
becomes effective for Abbott in the first quarter of 2021. Adoption of this new standard will not have a material impact on
Abbott’s consolidated financial statements.
In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other
Comprehensive Income, which allows companies to reclassify stranded tax effects resulting from the 2017 Tax Cuts and
Jobs Act, from Accumulated other comprehensive income (loss) to retained earnings (Earnings employed in the business).
Abbott adopted the new standard at the beginning of the fourth quarter of 2018. As a result of the adoption of the new
standard, approximately $337 million of stranded tax effects were reclassified from Accumulated other comprehensive
income (loss) to Earnings employed in the business.
In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other
Than Inventory, which requires the recognition of the income tax effects of intercompany sales and transfers of assets, other
than inventory, in the period in which the transfer occurs. Abbott adopted the standard on January 1, 2018, using a modified
retrospective approach and recorded a cumulative catch-up adjustment to Earnings employed in the business in the
Consolidated Balance Sheet that was not significant.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, which changes the methodology
to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The
new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be
incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative
adjustment that was not significant to Earnings employed in the business in the Consolidated Balance Sheet.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions investors
that any forward-looking statements or projections made by Abbott, including those made in this document, are subject to
risks and uncertainties that may cause actual results to differ materially from those projected. Economic, competitive,
governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, Risk Factors.

-- 40 of 409 --

40
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Financial Instruments and Risk Management
Market Price Sensitive Investments
The fair value of equity securities held by Abbott with a readily determinable fair value was approximately $20 million
and $11 million as of December 31, 2020 and 2019, respectively. These equity securities are subject to potential changes in
fair value. A hypothetical 20 percent decrease in the share prices of these investments would decrease their fair value at
December 31, 2020 by approximately $4 million. Changes in the fair value of these securities are recorded in earnings.
The fair value of investments in mutual funds that are held in a rabbi trust for the purpose of paying benefits under a
deferred compensation plan was approximately $366 million and $346 million as of December 31, 2020 and 2019,
respectively. Changes in the fair value of these investments, as well as an offsetting change in the benefit obligation, are
recorded in earnings.
Non-Publicly Traded Equity Securities
Abbott holds equity securities that are not traded on public stock exchanges. The carrying value of these investments
was $113 million and $158 million as of December 31, 2020 and 2019, respectively. No individual investment is recorded
at a value in excess of $15 million. Abbott measures these investments at cost minus impairment, if any, plus or minus
changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same
issuer.
Interest Rate Sensitive Financial Instruments
At December 31, 2020 and 2019, Abbott had interest rate hedge contracts totaling $2.9 billion to manage its exposure
to changes in the fair value of debt. The effect of these hedges is to change the fixed interest rate to a variable rate for the
portion of the debt that is hedged. Abbott does not use derivative financial instruments, such as interest rate swaps, to
manage its exposure to changes in interest rates for its investment securities. The fair value of long-term debt at December
31, 2020 and 2019 amounted to $22.8 billion and $20.8 billion, respectively (average interest rates of 3.3% as of December
31, 2020 and 2019) with maturities through 2046. At December 31, 2020 and 2019, the fair value of current and long-term
investment securities amounted to approximately $1.1 billion and $1.2 billion, respectively. A hypothetical 100-basis point
change in the interest rates would not have a material effect on cash flows, income or fair values.
Foreign Currency Sensitive Financial Instruments
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to
changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional
currencies are not the U.S. dollar. These contracts are designated as cash flow hedges of the variability of the cash flows
due to changes in foreign currency exchange rates and are marked-to-market with the resulting gains or losses reflected in
Accumulated other comprehensive income (loss). Gains or losses will be included in Cost of products sold at the time the
products are sold, generally within the next twelve to eighteen months. At December 31, 2020 and 2019, Abbott held $8.1
billion and $6.8 billion, respectively, of such contracts. Contracts held at December 31, 2020 will mature in 2021 or 2022
depending upon the contract. Contracts held at December 31, 2019 matured in 2020 or will mature in 2021 depending
upon the contract.
Abbott enters into foreign currency forward exchange contracts to manage its exposure to foreign currency
denominated intercompany loans and trade payables and third-party trade payables and receivables. The contracts are
marked-to-market, and resulting gains or losses are reflected in income and are generally offset by losses or gains on the
foreign currency exposure being managed. At December 31, 2020 and 2019, Abbott held $11.0 billion and $9.1 billion,
respectively, of such contracts, which mature in the next 13 months.

-- 41 of 409 --

41
In November 2019, Abbott borrowed ¥59.8 billion under a 5-year term loan and designated the yen-denominated loan
as a hedge of the net investment in certain foreign subsidiaries. The proceeds equated to approximately $550 million. The
value of this long-term debt was approximately $577 million and $546 million as of December 31, 2020 and December 31,
2019, respectively. The change in the value of the debt, which is due to changes in foreign exchange rates, was recorded in
Accumulated other comprehensive income (loss), net of tax.
The following table reflects the total foreign currency forward exchange contracts outstanding at December 31, 2020
and 2019:
2020 	2019
Weighted 	Fair and 	Weighted 	Fair and
Average 	Carrying Value 	Average 	Carrying Value
Contract 	Exchange 	Receivable/ 	Contract 	Exchange 	Receivable/
(dollars in millions) 	Amount 	Rate 	(Payable) 	Amount 	Rate 	(Payable)
Primarily U.S. Dollars to be exchanged for
the following currencies:
Euro 	$ 7,781 	1.1821 $ 	(91) $ 7,085 	1.1189 $ 	65
Chinese Yuan 	2,401 	6.4900 	(99) 	2,177 	7.0216 	4
Japanese Yen 	1,589 105.3861 	(20) 	1,092 106.8530 	13
All other currencies 	7,369 	n/a 	(198) 	5,532 	n/a 	(23)
Total 	$ 19,140 	$ 	(408) $ 15,886 	$ 	59

-- 42 of 409 --

42
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Page
Consolidated Statement of Earnings 	43
Consolidated Statement of Comprehensive Income 	44
Consolidated Statement of Cash Flows 	45
Consolidated Balance Sheet 	46
Consolidated Statement of Shareholders’ Investment 	48
Notes to Consolidated Financial Statements 	49
Management Report on Internal Control Over Financial Reporting 	81
Report of Independent Registered Public Accounting Firm 	82
Report of Independent Registered Public Accounting Firm 	84

-- 43 of 409 --

43
Abbott Laboratories and Subsidiaries
Consolidated Statement of Earnings
(in millions except per share data)
Year Ended December 31
2020 	2019 	2018
Net Sales 	$ 34,608 $ 31,904 $ 30,578
Cost of products sold, excluding amortization of intangible assets 	15,003 	13,231 	12,706
Amortization of intangible assets 	2,132 	1,936 	2,178
Research and development 	2,420 	2,440 	2,300
Selling, general and administrative 	9,696 	9,765 	9,744
Total Operating Cost and Expenses 	29,251 	27,372 	26,928
Operating Earnings 	5,357 	4,532 	3,650
Interest expense 	546 	670 	826
Interest income 	(46) 	(94) 	(105)
Net foreign exchange (gain) loss 	(8) 	7 	28
Debt extinguishment costs 	— 	63 	167
Other (income) expense, net 	(103) 	(191) 	(139)
Earnings from Continuing Operations Before Taxes 	4,968 	4,077 	2,873
Taxes on Earnings from Continuing Operations 	497 	390 	539
Earnings from Continuing Operations 	4,471 	3,687 	2,334
Net Earnings from Discontinued Operations, net of taxes 	24 	— 	34
Net Earnings 	$ 4,495 $ 3,687 $ 2,368
Basic Earnings Per Common Share --
Continuing Operations 	$ 	2.51 $ 	2.07 $ 	1.32
Discontinued Operations 	0.01 	— 	0.02
Net Earnings 	$ 	2.52 $ 	2.07 $ 	1.34
Diluted Earnings Per Common Share --
Continuing Operations 	$ 	2.49 $ 	2.06 $ 	1.31
Discontinued Operations 	0.01 	— 	0.02
Net Earnings 	$ 	2.50 $ 	2.06 $ 	1.33
Average Number of Common Shares Outstanding Used for Basic Earnings Per
Common Share 	1,773 	1,768 	1,758
Dilutive Common Stock Options 	13 	13 	12
Average Number of Common Shares Outstanding Plus Dilutive Common Stock
Options 	1,786 	1,781 	1,770
Outstanding Common Stock Options Having No Dilutive Effect 	9 	61 	—
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 44 of 409 --

44
Abbott Laboratories and Subsidiaries
Consolidated Statement of Comprehensive Income
(in millions)
Year Ended December 31
2020 	2019 	2018
Net Earnings 	$ 4,495 $ 3,687 $ 2,368
Foreign currency translation gain (loss) adjustments 	65 	(12) 	(1,460)
Net actuarial gains (losses) and prior service cost and credits and amortization of
net actuarial losses and prior service cost and credits, net of taxes of $(79) in
2020, $(238) in 2019 and $47 in 2018 	(331) 	(814) 	132
Net (losses) gains on derivative instruments designated as cash flow hedges, net of
taxes of $(87) in 2020, $(17) in 2019 and $50 in 2018 	(215) 	(53) 	136
Other Comprehensive Income (Loss) 	(481) 	(879) 	(1,192)
Comprehensive Income 	$ 4,014 $ 2,808 $ 1,176
Supplemental Accumulated Other Comprehensive Income (Loss) Information,
net of tax as of December 31:
Cumulative foreign currency translation (loss) adjustments 	$ (4,859) $ (4,924) $ (4,912)
Net actuarial (losses) and prior service (cost) and credits 	(3,871) 	(3,540) 	(2,726)
Cumulative (losses) gains on derivative instruments designated as cash flow
hedges 	(216) 	(1) 	52
Accumulated other comprehensive income (loss) 	$ (8,946) $ (8,465) $ (7,586)
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 45 of 409 --

45
Abbott Laboratories and Subsidiaries
Consolidated Statement of Cash Flows
(in millions)
Year Ended December 31
2020 	2019 	2018
Cash Flow From (Used in) Operating Activities:
Net earnings 	$ 4,495 $ 3,687 $ 2,368
Adjustments to reconcile earnings to net cash from operating activities -
Depreciation 	1,195 	1,078 	1,100
Amortization of intangible assets 	2,132 	1,936 	2,178
Share-based compensation 	546 	519 	477
Amortization of inventory step-up 	— 	— 	32
Investing and financing losses, net 	425 	184 	126
Loss on extinguishment of debt 	— 	63 	167
Trade receivables 	(924) 	(275) 	(190)
Inventories 	(493) 	(593) 	(514)
Prepaid expenses and other assets 	(627) 	(138) 	23
Trade accounts payable and other liabilities 	1,766 	220 	747
Income taxes 	(614) 	(545) 	(214)
Net Cash From Operating Activities 	7,901 	6,136 	6,300
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment 	(2,177) 	(1,638) 	(1,394)
Acquisitions of businesses and technologies, net of cash acquired 	(42) 	(170) 	(54)
Proceeds from business dispositions 	58 	48 	48
Purchases of investment securities 	(83) 	(103) 	(131)
Proceeds from sales of investment securities 	10 	21 	73
Other 	19 	27 	102
Net Cash From (Used in) Investing Activities 	(2,215) 	(1,815) 	(1,356)
Cash Flow From (Used in) Financing Activities:
Proceeds from issuance of (repayments of) short-term debt, net and other 	2 	— 	(26)
Proceeds from issuance of long-term debt and debt with maturities over 3 months 	1,281 	1,842 	4,009
Repayments of long-term debt and debt with maturities over 3 months 	(1,333) 	(3,441) 	(12,433)
Purchases of common shares 	(403) 	(718) 	(238)
Proceeds from stock options exercised 	245 	298 	271
Dividends paid 	(2,560) 	(2,270) 	(1,974)
Other 	(11) 	— 	—
Net Cash From (Used in) Financing Activities 	(2,779) 	(4,289) 	(10,391)
Effect of exchange rate changes on cash and cash equivalents 	71 	(16) 	(116)
Net Increase (Decrease) in Cash and Cash Equivalents 	2,978 	16 	(5,563)
Cash and Cash Equivalents, Beginning of Year 	3,860 	3,844 	9,407
Cash and Cash Equivalents, End of Year 	$ 6,838 $ 3,860 $ 3,844
Supplemental Cash Flow Information:
Income taxes paid 	$ 	970 $ 	930 $ 	740
Interest paid 	549 	677 	845
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 46 of 409 --

46
Abbott Laboratories and Subsidiaries
Consolidated Balance Sheet
(dollars in millions)
December 31
2020 	2019
Assets
Current assets:
Cash and cash equivalents 	$ 	6,838 $ 	3,860
Investments, primarily bank time deposits and U.S. treasury bills 	310 	280
Trade receivables, less allowances of — 2020: $460; 2019: $384 	6,414 	5,425
Inventories:
Finished products 	3,030 	2,784
Work in process 	712 	560
Materials 	1,270 	972
Total inventories 	5,012 	4,316
Other prepaid expenses and receivables 	1,867 	1,786
Total current assets 	20,441 	15,667
Investments 	821 	883
Property and equipment, at cost:
Land 	538 	519
Buildings 	4,014 	3,702
Equipment 	12,884 	11,468
Construction in progress 	1,357 	1,110
18,793 	16,799
Less: accumulated depreciation and amortization 	9,764 	8,761
Net property and equipment 	9,029 	8,038
Intangible assets, net of amortization 	14,784 	17,025
Goodwill 	23,744 	23,195
Deferred income taxes and other assets 	3,729 	3,079
$ 72,548 $ 67,887

-- 47 of 409 --

47
Abbott Laboratories and Subsidiaries
Consolidated Balance Sheet
(dollars in millions)
December 31
2020 	2019
Liabilities and Shareholders’ Investment
Current liabilities:
Short-term borrowings 	$ 	213 $ 	201
Trade accounts payable 	3,946 	3,252
Salaries, wages and commissions 	1,416 	1,237
Other accrued liabilities 	5,165 	4,035
Dividends payable 	798 	635
Income taxes payable 	362 	226
Current portion of long-term debt 	7 	1,277
Total current liabilities 	11,907 	10,863
Long-term debt 	18,527 	16,661
Post-employment obligations and other long-term liabilities 	9,111 	9,062
Commitments and contingencies
Shareholders’ investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 	— 	—
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2020: 1,981,156,896; 2019: 1,976,855,085 	24,145 	23,853
Common shares held in treasury, at cost — Shares: 2020: 209,926,622; 2019: 214,351,838 	(10,042) 	(10,147)
Earnings employed in the business 	27,627 	25,847
Accumulated other comprehensive income (loss) 	(8,946) 	(8,465)
Total Abbott Shareholders’ Investment 	32,784 	31,088
Noncontrolling interests in subsidiaries 	219 	213
Total Shareholders’ Investment 	33,003 	31,301
$ 72,548 $ 67,887
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 48 of 409 --

48
Abbott Laboratories and Subsidiaries
Consolidated Statement of Shareholders’ Investment
(in millions except shares and per share data)
Year Ended December 31
2020 	2019 	2018
Common Shares:
Beginning of Year
Shares: 2020: 1,976,855,085; 2019: 1,971,189,465; 2018: 1,965,908,188 	$ 23,853 $ 23,512 $ 23,206
Issued under incentive stock programs
Shares: 2020: 4,301,811; 2019: 5,665,620; 2018: 5,281,277 	181 	209 	163
Share-based compensation 	548 	521 	479
Issuance of restricted stock awards 	(437) 	(389) 	(336)
End of Year
Shares: 2020: 1,981,156,896; 2019: 1,976,855,085; 2018: 1,971,189,465 	$ 24,145 $ 23,853 $ 23,512
Common Shares Held in Treasury:
Beginning of Year
Shares: 2020: 214,351,838; 2019: 215,570,043; 2018: 222,305,719 	$ (10,147) $ (9,962) $ (10,225)
Issued under incentive stock programs
Shares: 2020: 6,290,757; 2019: 7,796,030; 2018: 8,870,735 	298 	361 	408
Purchased
Shares: 2020: 1,865,541; 2019: 6,577,825; 2018: 2,135,059 	(193) 	(546) 	(145)
End of Year
Shares: 2020: 209,926,622; 2019: 214,351,838; 2018: 215,570,043 	$ (10,042) $ (10,147) $ (9,962)
Earnings Employed in the Business:
Beginning of Year 	$ 25,847 $ 24,560 $ 23,978
Impact of adoption of new accounting standards 	(5) 	— 	351
Net earnings 	4,495 	3,687 	2,368
Cash dividends declared on common shares (per share — 2020: $1.53; 2019: $1.32;
2018: $1.16) 	(2,722) 	(2,343) 	(2,047)
Effect of common and treasury share transactions 	12 	(57) 	(90)
End of Year 	$ 27,627 $ 25,847 $ 24,560
Accumulated Other Comprehensive Income (Loss):
Beginning of Year 	$ (8,465) $ (7,586) $ (6,062)
Impact of adoption of new accounting standards 	— 	— 	(332)
Other comprehensive income (loss) 	(481) 	(879) 	(1,192)
End of Year 	$ (8,946) $ (8,465) $ (7,586)
Noncontrolling Interests in Subsidiaries:
Beginning of Year 	$ 	213 $ 	198 $ 	201
Noncontrolling Interests’ share of income, business combinations, net of distributions
and share repurchases 	6 	15 	(3)
End of Year 	$ 	219 $ 	213 $ 	198
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 49 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements
49
Note 1 — Summary of Significant Accounting Policies
NATURE OF BUSINESS — Abbott’s principal business is the discovery, development, manufacture and sale of a
broad line of health care products.
BASIS OF CONSOLIDATION — The consolidated financial statements include the accounts of the parent company
and subsidiaries, after elimination of intercompany transactions.
USE OF ESTIMATES — The consolidated financial statements have been prepared in accordance with generally
accepted accounting principles in the United States and necessarily include amounts based on estimates and assumptions by
management. Actual results could differ from those amounts. Significant estimates include amounts for sales rebates,
income taxes, pension and other post-employment benefits, valuation of intangible assets, litigation, derivative financial
instruments, and inventory and accounts receivable exposures.
FOREIGN CURRENCY TRANSLATION — The statements of earnings of foreign subsidiaries whose functional
currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period. The net
assets of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars
using exchange rates as of the balance sheet date. The U.S. dollar effects that arise from translating the net assets of these
subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in
equity as a component of Accumulated other comprehensive income (loss). Transaction gains and losses are recorded on
the Net foreign exchange (gain) loss line of the Consolidated Statement of Earnings.
REVENUE RECOGNITION — Revenue from product sales is recognized upon the transfer of control, which is
generally upon shipment or delivery, depending on the delivery terms set forth in the customer contract. Provisions for
discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the
related sales are recorded. Sales incentives to customers are not material. Historical data is readily available and reliable,
and is used for estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an
improved version of an existing product, or for shipments in excess of a customer’s normal requirements are recorded when
the conditions noted above are met. In those situations, management records a returns reserve for such revenue, if
necessary. In certain of Abbott’s businesses, primarily within diagnostics, Abbott participates in selling arrangements that
include multiple performance obligations (e.g., instruments, reagents, procedures, and service agreements). The total
transaction price of the contract is allocated to each performance obligation in an amount based on the estimated relative
standalone selling prices of the promised goods or services underlying each performance obligation. Sales of product
rights for marketable products are recorded as revenue upon disposition of the rights.
INCOME TAXES — Deferred income taxes are provided for the tax effect of differences between the tax bases of
assets and liabilities and their reported amounts in the financial statements at the enacted statutory rate to be in effect when
the taxes are paid. No additional income taxes have been provided for any remaining undistributed foreign earnings not
subject to the transition tax related to the U.S. Tax Cuts and Jobs Act (TCJA), or any additional outside basis differences
that exist, as these amounts continue to be indefinitely reinvested in foreign operations. Effective for fiscal years beginning
after December 31, 2017, the TCJA subjects taxpayers to tax on global intangible low-taxed income (GILTI) earned by
certain foreign subsidiaries. Abbott treats the GILTI tax as a period expense and provides for the tax in the year that the tax
is incurred. Interest and penalties on income tax obligations are included in taxes on earnings.
EARNINGS PER SHARE — Unvested restricted stock units and awards that contain non-forfeitable rights to
dividends are treated as participating securities and are included in the computation of earnings per share under the two-
class method. Under the two-class method, net earnings are allocated between common shares and participating securities.
Earnings from Continuing Operations allocated to common shares in 2020, 2019 and 2018 were $4.449 billion,
$3.666 billion and $2.320 billion, respectively. Net earnings allocated to common shares in 2020, 2019 and 2018 were
$4.473 billion, $3.666 billion and $2.353 billion, respectively.

-- 50 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
50
Note 1 — Summary of Significant Accounting Policies (Continued)
PENSION AND POST-EMPLOYMENT BENEFITS — Abbott accrues for the actuarially determined cost of pension
and post-employment benefits over the service attribution periods of the employees. Abbott must develop long-term
assumptions, the most significant of which are the health care cost trend rates, discount rates and the expected return on
plan assets. Differences between the expected long-term return on plan assets and the actual return are amortized over a
five-year period. Actuarial losses and gains are amortized over the remaining service attribution periods of the employees
under the corridor method.
FAIR VALUE MEASUREMENTS — For assets and liabilities that are measured using quoted prices in active
markets, total fair value is the published market price per unit multiplied by the number of units held without consideration
of transaction costs. Assets and liabilities that are measured using significant other observable inputs are valued by
reference to similar assets or liabilities, adjusted for contract restrictions and other terms specific to that asset or liability.
For these items, a significant portion of fair value is derived by reference to quoted prices of similar assets or liabilities in
active markets. For all remaining assets and liabilities, fair value is derived using a fair value model, such as a discounted
cash flow model or Black-Scholes model. Purchased intangible assets are recorded at fair value. The fair value of
significant purchased intangible assets is based on independent appraisals. Abbott uses a discounted cash flow model to
value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net
cash flows, risk, the cost of capital, terminal values and market participants. Intangible assets are reviewed for impairment
on a quarterly basis. Goodwill and indefinite-lived intangible assets are tested for impairment at least annually.
SHARE-BASED COMPENSATION — The fair value of stock options and restricted stock awards and units are
amortized over their requisite service period, which could be shorter than the vesting period if an employee is retirement
eligible, with a charge to compensation expense.
LITIGATION — Abbott accounts for litigation losses in accordance with Financial Accounting Standards Board
(FASB) Accounting Standards Codification (ASC) No. 450, “Contingencies.” Under ASC No. 450, loss contingency
provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be
made, a minimum loss contingency amount is recorded. Legal fees are recorded as incurred.
CASH, CASH EQUIVALENTS AND INVESTMENTS — Cash equivalents consist of bank time deposits, U.S.
government securities money market funds and U.S. treasury bills with original maturities of three months or less. Abbott
holds certain investments with a carrying value of $277 million that are accounted for under the equity method of
accounting. Investments held in a rabbi trust and investments in publicly traded equity securities are recorded at fair value
and changes in fair value are recorded in earnings. Investments in equity securities that are not traded on public stock
exchanges are recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in
orderly transactions for identical or similar investments of the same issuer. Investments in debt securities are classified as
held-to-maturity, as management has both the intent and ability to hold these securities to maturity, and are reported at cost,
net of any unamortized premium or discount. Income relating to these securities is reported as interest income.
TRADE RECEIVABLE VALUATIONS — Accounts receivable are stated at the net amount expected to be collected.
The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of
the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for
doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific
exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as
country risk, when determining credit limits for customers and establishing adequate allowances. Accounts receivable are
charged off after all reasonable means to collect the full amount (including litigation, where appropriate) have been
exhausted.
INVENTORIES — Inventories are stated at the lower of cost (first-in, first-out basis) or net realizable value. Cost
includes material and conversion costs.

-- 51 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
51
Note 1 — Summary of Significant Accounting Policies (Continued)
PROPERTY AND EQUIPMENT — Depreciation and amortization are provided on a straight-line basis over the
estimated useful lives of the assets. The following table shows estimated useful lives of property and equipment:
Classification 	Estimated Useful Lives
Buildings 	10 to 50 years
Equipment 	2 to 20 years
PRODUCT LIABILITY — Abbott accrues for product liability claims when it is probable that a liability has been
incurred and the amount of the liability can be reasonably estimated based on existing information. The liabilities are
adjusted quarterly as additional information becomes available. Product liability losses are self-insured.
RESEARCH AND DEVELOPMENT COSTS — Internal research and development costs are expensed as incurred.
Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone
payments are due to third parties under research and development arrangements, the milestone payment obligations are
expensed when the milestone results are achieved.
ACQUIRED IN-PROCESS AND COLLABORATIONS RESEARCH AND DEVELOPMENT (IPR&D) — The
initial costs of rights to IPR&D projects obtained in an asset acquisition are expensed as IPR&D unless the project has an
alternative future use. These costs include initial payments incurred prior to regulatory approval in connection with
research and development collaboration agreements that provide rights to develop, manufacture, market and/or sell
pharmaceutical or medical device products. The fair value of IPR&D projects acquired in a business combination are
capitalized and accounted for as indefinite-lived intangible assets until completed and are then amortized over the
remaining useful life. Collaborations are not significant.
CONCENTRATION OF RISK AND GUARANTEES — Due to the nature of its operations, Abbott is not subject to
significant concentration risks relating to customers, products or geographic locations. Product warranties are not
significant.
Abbott has no material exposures to off-balance sheet arrangements; no special purpose entities; nor activities that
include non-exchange-traded contracts accounted for at fair value. Abbott periodically acquires a business or product rights
in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or based on the occurrence of
certain events.
Note 2 – New Accounting Standards
Recently Adopted Accounting Standards
In February 2018, the FASB issued Accounting Standards Update (ASU) 2018-02, Reclassification of Certain Tax
Effects from Accumulated Other Comprehensive Income, which allows companies to reclassify stranded tax effects
resulting from the 2017 Tax Cuts and Jobs Act, from Accumulated other comprehensive income (loss) to retained earnings
(Earnings employed in the business). Abbott adopted the new standard at the beginning of the fourth quarter of 2018. As a
result of the adoption of the new standard, approximately $337 million of stranded tax effects were reclassified from
Accumulated other comprehensive income (loss) to Earnings employed in the business.

-- 52 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
52
Note 2 — New Accounting Standards (Continued)
In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other
Than Inventory, which requires the recognition of the income tax effects of intercompany sales and transfers of assets, other
than inventory, in the period in which the transfer occurs. Abbott adopted the standard on January 1, 2018, using a
modified retrospective approach and recorded a cumulative catch-up adjustment to Earnings employed in the business in
the Consolidated Balance Sheet that was not significant.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, which changes the methodology
to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The
new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be
incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative
adjustment that was not significant to Earnings employed in the business in the Consolidated Balance Sheet.
Recent Accounting Standards Not Yet Adopted
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income
Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod
tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for
transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first
quarter of 2021. Adoption of this new standard will not have a material impact on Abbott’s consolidated financial
statements.
Note 3 — Revenue
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term
receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s
products under a contract most impact which products are sold; price controls, competition and rebates most impact the net
selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott's
products are generally sold directly to retailers, wholesalers, distributors, hospitals, health care facilities, laboratories,
physicians' offices and government agencies throughout the world. Abbott has four reportable segments: Established
Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

-- 53 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
53
Note 3 — Revenue (Continued)
The following tables provide detail by sales category:
2020 	2019 	2018
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical
Products —
Key Emerging Markets 	$ 	— $ 3,209 $ 3,209 $ 	— $ 3,392 $ 3,392 $ 	— $ 3,363 $ 3,363
Other 	— 	1,094 	1,094 	— 	1,094 	1,094 	— 	1,059 	1,059
Total 	— 	4,303 	4,303 	— 	4,486 	4,486 	— 	4,422 	4,422
Nutritionals —
Pediatric Nutritionals 	1,987 	2,140 	4,127 	1,879 	2,282 	4,161 	1,843 	2,254 	4,097
Adult Nutritionals 	1,292 	2,228 	3,520 	1,231 	2,017 	3,248 	1,232 	1,900 	3,132
Total 	3,279 	4,368 	7,647 	3,110 	4,299 	7,409 	3,075 	4,154 	7,229
Diagnostics —
Core Laboratory 	1,166 	3,309 	4,475 	1,086 	3,570 	4,656 	985 	3,401 	4,386
Molecular 	621 	817 	1,438 	149 	293 	442 	152 	332 	484
Point of Care 	369 	147 	516 	438 	123 	561 	432 	121 	553
Rapid Diagnostics 	2,618 	1,758 	4,376 	1,214 	840 	2,054 	1,148 	924 	2,072
Total 	4,774 	6,031 	10,805 	2,887 	4,826 	7,713 	2,717 	4,778 	7,495
Medical Devices —
Rhythm Management 	903 	1,011 	1,914 	1,057 	1,087 	2,144 	1,105 	1,093 	2,198
Electrophysiology 	660 	918 	1,578 	742 	979 	1,721 	678 	883 	1,561
Heart Failure 	547 	193 	740 	574 	195 	769 	467 	179 	646
Vascular 	853 	1,486 	2,339 	1,047 	1,803 	2,850 	1,126 	1,803 	2,929
Structural Heart 	540 	707 	1,247 	616 	784 	1,400 	488 	751 	1,239
Neuromodulation 	564 	138 	702 	660 	171 	831 	690 	174 	864
Diabetes Care 	864 	2,403 	3,267 	678 	1,846 	2,524 	457 	1,476 	1,933
Total 	4,931 	6,856 	11,787 	5,374 	6,865 	12,239 	5,011 	6,359 	11,370
Other 	38 	28 	66 	27 	30 	57 	36 	26 	62
Total 	$ 13,022 $ 21,586 $ 34,608 $ 11,398 $ 20,506 $ 31,904 $ 10,839 $ 19,739 $ 30,578
Abbott recognizes revenue from product sales upon the transfer of control, which is generally upon shipment or
delivery, depending on the delivery terms set forth in the customer contract. For maintenance agreements that provide
service beyond Abbott’s standard warranty and other service agreements, revenue is recognized ratably over the contract
term. A time-based measure of progress appropriately reflects the transfer of services to the customer. Payment terms
between Abbott and its customers vary by the type of customer, country of sale, and the products or services offered. The
term between invoicing and the payment due date is not significant.

-- 54 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
54
Note 3 — Revenue (Continued)
Management exercises judgment in estimating variable consideration. Provisions for discounts, rebates and sales
incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded.
Sales incentives to customers are not material. Historical data is readily available and reliable, and is used for estimating
the amount of the reduction in gross sales. Abbott provides rebates to government agencies, wholesalers, group purchasing
organizations and other private entities.
Rebate amounts are usually based upon the volume of purchases using contractual or statutory prices for a product.
Factors used in the rebate calculations include the identification of which products have been sold subject to a rebate,
which customer or government agency price terms apply, and the estimated lag time between sale and payment of a rebate.
Using historical trends, adjusted for current changes, Abbott estimates the amount of the rebate that will be paid, and
records the liability as a reduction of gross sales when Abbott records its sale of the product. Settlement of the rebate
generally occurs from one to six months after sale. Abbott regularly analyzes the historical rebate trends and makes
adjustments to reserves for changes in trends and terms of rebate programs. Historically, adjustments to prior years' rebate
accruals have not been material to net income.
Other allowances charged against gross sales include cash discounts and returns, which are not significant. Cash
discounts are known within 15 to 30 days of sale, and therefore can be reliably estimated. Returns can be reliably
estimated because Abbott's historical returns are low, and because sales return terms and other sales terms have remained
relatively unchanged for several periods. Product warranties are also not significant.
Abbott also applies judgment in determining the timing of revenue recognition related to contracts that include
multiple performance obligations. The total transaction price of the contract is allocated to each performance obligation in
an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each
performance obligation. For goods or services for which observable standalone selling prices are not available, Abbott uses
an expected cost plus a margin approach to estimate the standalone selling price of each performance obligation.
Remaining Performance Obligations
As of December 31, 2020, the estimated revenue expected to be recognized in the future related to performance
obligations that are unsatisfied (or partially unsatisfied) was approximately $3.8 billion in the Diagnostic Products segment
and approximately $430 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60
percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent
12 months and the remainder thereafter.
These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum
purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring
services related to previously implanted devices. Abbott has applied the practical expedient described in ASC 606-10-50-
14 and has not included remaining performance obligations related to contracts with original expected durations of one year
or less in the amounts above.
Assets Recognized for Costs to Obtain a Contract with a Customer
Abbott has applied the practical expedient in ASC 340-40-25-4 and records as an expense the incremental costs of
obtaining contracts with customers in the period of occurrence when the amortization period of the asset that Abbott
otherwise would have recognized is one year or less. Upfront commission fees paid to sales personnel as a result of
obtaining or renewing contracts with customers are incremental to obtaining the contract. Abbott capitalizes these amounts
as contract costs. Capitalized commission fees are amortized based on the contract duration to which the assets relate
which ranges from two to ten years. The amounts as of December 31, 2020 and 2019 were not significant.

-- 55 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
55
Note 3 — Revenue (Continued)
Additionally, the cost of transmitters provided to customers that use Abbott’s remote monitoring service with respect to
certain medical devices are capitalized as contract costs. Capitalized transmitter costs are amortized based on the timing of
the transfer of services to which the assets relate, which typically ranges from eight to ten years. The amounts as of
December 31, 2020 and 2019 were not significant.
Other Contract Assets and Liabilities
Abbott discloses Trade receivables separately in the Consolidated Balance Sheet at the net amount expected to be
collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed
at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not
significant.
Contract liabilities primarily relate to payments received from customers in advance of performance under the contract.
Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront
for various multi-period extended service arrangements. Changes in the contract liabilities during the period are as follows:
(in millions)
Contract Liabilities
Balance at December 31, 2018 	$ 	259
Unearned revenue from cash received during the period 	411
Revenue recognized related to contract liability balance 	(376)
Balance at December 31, 2019 	294
Unearned revenue from cash received during the period 	505
Revenue recognized related to contract liability balance 	(394)
Balance at December 31, 2020 	$ 	405
Note 4 — Discontinued Operations and Business Dispositions
The net earnings of discontinued operations include income tax benefits of $24 million in 2020 and $39 million in
2018. The 2020 tax benefits primarily relate to the resolution of various tax positions related to Abbott’s developed markets
branded generic pharmaceuticals business which was sold to Mylan Inc. (Mylan) in 2015. The tax positions relate to years
prior to the sale to Mylan. The 2018 tax benefits primarily relate to the resolution of various tax positions related to the
operations of AbbVie Inc. (AbbVie) for years prior to the separation. Abbott completed the separation of AbbVie, which
was formed to hold Abbott’s research-based proprietary pharmaceuticals business, in January 2013. Abbott retained all
liabilities for all U.S. federal and foreign income taxes on income prior to the separation.
Note 5 — Supplemental Financial Information
Other (income) expense, net, for 2020, 2019 and 2018 includes approximately $205 million, $225 million and $160
million of income, respectively, related to the non-service cost components of the net periodic benefit costs associated with
the pension and post-retirement medical plans.

-- 56 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
56
Note 5 — Supplemental Financial Information (Continued)
The following summarizes the activity for 2020 related to the allowance for doubtful accounts as of December 31,
2020:
(in millions)
Allowance for Doubtful Accounts
Balance at December 31, 2019 	$ 	228
Impact of adopting ASU 2016-13 	7
Provisions/charges to income 	88
Amounts charged off and other deductions 	(35)
Balance at December 31, 2020 	$ 	288
The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life
of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for
doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific
exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as
country risk, when determining credit limits for customers and establishing adequate allowances.
The detail of various balance sheet components is as follows:
December 31, December 31,
(in millions) 	2020 	2019
Long-term Investments:
Equity securities 	$ 	776 $ 	836
Other 	45 	47
Total 	$ 	821 $ 	883
Abbott’s long-term investments as of December 31, 2020 declined versus the balance as of December 31, 2019 due
primarily to investment impairments totaling approximately $115 million, recorded in Other (income) expense, net within
the Consolidated Statement of Earnings, which was partially offset by approximately $35 million of additional investments
during 2020.
Abbott’s equity securities as of December 31, 2020 and December 31, 2019, include $366 million and $346 million,
respectively, of investments in mutual funds that are held in a rabbi trust acquired as part of the St. Jude Medical, Inc. (St.
Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of
paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to
creditor claims in the event of insolvency.
Abbott also holds certain investments as of December 31, 2020 with a carrying value of $277 million that are
accounted for under the equity method of accounting and other equity investments with a carrying value of $113 million
that do not have a readily determinable fair value. The $113 million carrying value is net of an approximately $60 million
impairment of an investment in 2020 for which Abbott had previously recorded an unrealized gain of approximately $50
million in 2018.

-- 57 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
57
Note 5 — Supplemental Financial Information (Continued)
In 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired a research &
development (R&D) asset valued at $102 million, which was immediately expensed. The $102 million of expense was
recorded in the R&D line of Abbott's Consolidated Statement of Earnings.
December 31, December 31,
(in millions) 	2020 	2019
Other Accrued Liabilities:
Accrued rebates payable to government agencies 	$ 	316 $ 	212
Accrued other rebates (a) 	805 	655
All other 	4,044 	3,168
Total 	$ 	5,165 $ 	4,035
(a) Accrued wholesaler chargeback rebates of $178 million and $175 million at December 31, 2020 and 2019,
respectively, are netted in trade receivables because Abbott’s customers are invoiced at a higher catalog
price but only remit to Abbott their contract price for the products.
December 31, December 31,
(in millions) 	2020 	2019
Post-employment Obligations and Other Long-term Liabilities:
Defined benefit pension plans and post-employment medical and
dental plans for significant plans 	$ 	3,119 $ 	2,817
Deferred income taxes 	1,406 	1,546
Operating lease liabilities 	902 	755
All other (b) 	3,684 	3,944
Total 	$ 	9,111 $ 	9,062
(b) Includes approximately $740 million and $580 million of net unrecognized tax benefits in 2020 and 2019,
respectively.

-- 58 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
58
Note 6 — Accumulated Other Comprehensive Income (Loss)
The components of the changes in accumulated other comprehensive income (loss) from continuing operations, net of
income taxes, are as follows:
Cumulative
Gains (Losses)
Cumulative 	Net Actuarial 	on Derivative
Foreign 	(Losses) and 	Instruments
Currency 	Prior Service 	Designated as
Translation 	(Costs) and 	Cash Flow
(in millions) 	Adjustments 	Credits 	Hedges 	Total
Balance at December 31, 2018 	$ 	(4,912) $ 	(2,726) $ 	52 $ 	(7,586)
Other comprehensive income (loss) before reclassifications 	(12) 	(719) 	2 	(729)
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	— 	(95) 	(55) 	(150)
Net current period other comprehensive income (loss) 	(12) 	(814) 	(53) 	(879)
Balance at December 31, 2019 	(4,924) 	(3,540) 	(1) 	(8,465)
Other comprehensive income (loss) before reclassifications 	65 	(523) 	(140) 	(598)
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	— 	192 	(75) 	117
Net current period other comprehensive income (loss) 	65 	(331) 	(215) 	(481)
Balance at December 31, 2020 	$ 	(4,859) $ 	(3,871) $ 	(216) $ 	(8,946)
(a) (Income) loss amounts reclassified from accumulated other comprehensive income related to cash flow hedges are
recorded as Cost of products sold. Net actuarial losses and prior service cost is included as a component of net periodic
benefit cost – see Note 14 for additional information.
Note 7 — Goodwill and Intangible Assets
The total amount of goodwill reported was $23.7 billion at December 31, 2020 and $23.2 billion at December 31,
2019. Foreign currency translation adjustments increased goodwill by approximately $550 million in 2020 and decreased
goodwill $103 million in 2019. The amount of goodwill related to reportable segments at December 31, 2020 was $3.0
billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.8
billion for the Diagnostic Products segment, and $16.6 billion for the Medical Devices segment. There was no reduction of
goodwill relating to impairments in 2020 and 2019.
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.8 billion and
$27.6 billion as of December 31, 2020 and 2019, respectively, and accumulated amortization was $14.2 billion and
$11.9 billion as of December 31, 2020 and 2019, respectively. Foreign currency translation adjustments increased
intangible assets by approximately $67 million in 2020 and decreased intangible assets by $71 million in 2019. In 2020,
asset impairments related to the Medical Devices segment decreased intangible assets by $148 million. The impairment
was recorded in the Cost of products sold, excluding amortization of intangible assets line of Abbott’s Consolidated
Statement of Earnings. The estimated annual amortization expense for intangible assets recorded at December 31, 2020 is
approximately $2.0 billion in 2021, $2.0 billion in 2022, $1.9 billion in 2023, $1.9 billion in 2024 and $1.9 billion in 2025.
Amortizable intangible assets are amortized over 2 to 20 years.

-- 59 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
59
Note 7 — Goodwill and Intangible Assets (Continued)
Indefinite-lived intangible assets, which relate to IPR&D acquired in a business combination, were approximately $1.2
billion and $1.3 billion at December 31, 2020 and 2019, respectively. The decrease is due to an IPR&D intangible asset
related to the Medical Devices segment that became amortizable in 2020 and a $55 million impairment of an IPR&D
intangible asset related to the Medical Devices segment that was recorded in the Research and development line of
Abbott’s Consolidated Statement of Earnings in 2020.
Note 8 — Restructuring Plans
From 2017 to 2020, Abbott management approved restructuring plans as part of the integration of the acquisitions of
St. Jude Medical into the Medical Devices segment, and Alere Inc. (Alere) into the Diagnostic Products segment, in order
to leverage economies of scale and reduce costs. As of December 31, 2017, the accrued balance associated with these
actions was $68 million. From 2018 to 2020, Abbott recorded employee related severance and other charges totaling
approximately $137 million, comprised of $13 million in 2020, $72 million in 2019 and $52 million in 2018.
Approximately $30 million was recorded in Cost of products sold, approximately $15 million was recorded in Research
and development, and approximately $92 million was recorded in Selling, general and administrative expense over the last
three years. As of December 31, 2020, the accrued liabilities remaining in the Consolidated Balance Sheet related to these
actions total $25 million and primarily represent severance obligations.
From 2016 to 2020, Abbott management approved plans to streamline operations in order to reduce costs and improve
efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses.
Abbott recorded employee related severance and other charges of approximately $36 million in 2020, $66 million in 2019
and $28 million in 2018. Approximately $6 million in 2020, $16 million in 2019 and $10 million in 2018 are recorded in
Cost of products sold, approximately $2 million in 2020, $28 million in 2019 and $2 million in 2018 are recorded in
Research and development, and approximately $28 million in 2020, $22 million in 2019 and $16 million in 2018 are
recorded in Selling, general and administrative expense.
The following summarizes the activity for these restructurings:
(in millions)
Accrued balance at December 31, 2017 	$ 	119
Restructuring charges 	28
Payments and other adjustments 	(77)
Accrued balance at December 31, 2018 	70
Restructuring charges 	66
Payments and other adjustments 	(57)
Accrued balance at December 31, 2019 	79
Restructuring charges 	36
Payments and other adjustments 	(45)
Accrued balance at December 31, 2020 	$ 	70
Note 9 — Incentive Stock Program
The 2017 Incentive Stock Program authorizes the granting of nonqualified stock options, restricted stock awards,
restricted stock units, performance awards, foreign benefits and other share-based awards. Stock options and restricted
stock awards and units comprise the majority of benefits that have been granted and are currently outstanding under this
program and a prior program. In 2020, Abbott granted 4,015,420 stock options, 569,961 restricted stock awards and
5,239,575 restricted stock units under this program.

-- 60 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
60
Note 9 — Incentive Stock Program (Continued)
Under Abbott’s stock incentive programs, the purchase price of shares under option must be at least equal to the fair
market value of the common stock on the date of grant, and the maximum term of an option is 10 years. Options generally
vest equally over three years. Restricted stock awards generally vest over 3 years, with no more than one-third of the award
vesting in any one year upon Abbott reaching a minimum return on equity target. Restricted stock units vest over three
years and upon vesting, the recipient receives one share of Abbott stock for each vested restricted stock unit. The aggregate
fair market value of options and restricted stock awards and units is recognized as expense over the requisite service period,
which may be shorter than the vesting period if an employee is retirement eligible. Forfeitures are estimated at the time of
grant. Restricted stock awards and settlement of vested restricted stock units are issued out of treasury shares. Abbott
generally issues new shares for exercises of stock options. As a policy, Abbott does not purchase its shares relating to its
share-based programs.
In April 2017, Abbott’s shareholders authorized the 2017 Incentive Stock Program under which a maximum of 170
million shares were available for issuance. At December 31, 2020, approximately 113 million shares remained available for
future issuance.
The following table summarizes stock option activity for the year ended December 31, 2020 and the outstanding stock
options as of December 31, 2020.
Weighted
Weighted 	Average
Average 	Remaining 	Aggregate
(intrinsic values in millions) 	Options 	Exercise Price Life (Years) Intrinsic Value
Outstanding at December 31, 2019 	29,877,915 $ 	48.78 	6.2 $ 	1,138
Granted 	4,015,420 	87.84
Exercised 	(4,872,830) 	39.62
Lapsed 	(100,619) 	75.22
Outstanding at December 31, 2020 	28,919,886 $ 	55.65 	6.0 $ 	1,557
Exercisable at December 31, 2020 	20,390,745 $ 	46.16 	5.0 $ 	1,291
The following table summarizes restricted stock awards and units activity for the year ended December 31, 2020.
Weighted
Average
Grant-Date
Share Units Fair Value
Outstanding at December 31, 2019 	14,463,314 $ 65.51
Granted 	5,809,536 	87.83
Vested 	(7,167,631) 	60.67
Forfeited 	(612,351) 	75.16
Outstanding at December 31, 2020 	12,492,868 $ 78.19
The fair market value of restricted stock awards and units vested in 2020, 2019 and 2018 was $631 million,
$588 million and $458 million, respectively.
The total intrinsic value of options exercised in 2020, 2019 and 2018 was $279 million, $315 million and $249 million,
respectively. The total unrecognized compensation cost related to all share-based compensation plans at December 31,
2020 amounted to approximately $407 million, which is expected to be recognized over the next three years.

-- 61 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
61
Note 9 — Incentive Stock Program (Continued)
Total non-cash stock compensation expense charged against income from continuing operations in 2020, 2019 and
2018 for share-based plans totaled approximately $546 million, $519 million and $477 million, respectively, and the tax
benefit recognized was approximately $200 million, $197 million and $185 million, respectively. Stock compensation cost
capitalized as part of inventory is not significant.
The table below summarizes the fair value of an option granted in 2020, 2019 and 2018 and the assumptions included
in the Black-Scholes option-pricing model used to estimate the fair value:
2020 	2019 	2018
Fair value 	$ 14.39 	$ 14.50 	$ 10.93
Risk-free interest rate 	1.3 % 	2.5 % 	2.7 %
Average life of options (years) 	6.0 	6.0 	6.0
Volatility 	19.4 % 	19.8 % 	19.0 %
Dividend yield 	1.6 % 	1.7 % 	1.9 %
The risk-free interest rate is based on the rates available at the time of the grant for zero-coupon U.S. government
issues with a remaining term equal to the option’s expected life. The average life of an option is based on both historical
and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on Abbott’s
stock and historical volatility of Abbott’s stock over the expected life of the option. Dividend yield is based on the option’s
exercise price and annual dividend rate at the time of grant.

-- 62 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
62
Note 10 — Debt and Lines of Credit
The following is a summary of long-term debt at December 31:
(in millions) 	2020 	2019
0.00% Notes, due 2020 	$ 	— $ 1,272
2.55% Notes, due 2022 	750 	750
0.875% Notes, due 2023 	1,398 	1,272
3.40% Notes, due 2023 	1,050 	1,050
5-year term loan due 2024 	577 	546
0.10% Notes, due 2024 	724 	658
3.875% Notes, due 2025 	500 	500
2.95% Notes, due 2025 	1,000 	1,000
1.50% Notes, due 2026 	1,398 	1,272
3.75% Notes, due 2026 	1,700 	1,700
0.375% Notes, due 2027 	724 	658
1.15% Notes, due 2028 	650 	—
1.40% Notes, due 2030 	650 	—
4.75% Notes, due 2036 	1,650 	1,650
6.15% Notes, due 2037 	547 	547
6.00% Notes, due 2039 	515 	515
5.30% Notes, due 2040 	694 	694
4.75% Notes, due 2043 	700 	700
4.90% Notes, due 2046 	3,250 	3,250
Unamortized debt issuance costs 	(87) 	(90)
Other, including fair value adjustments relating to interest rate hedge
contracts designated as fair value hedges 	144 	(6)
Total carrying amount of long-term debt 	18,534 	17,938
Less: Current portion 	7 	1,277
Total long-term portion 	$ 18,527 $ 16,661
On June 24, 2020, Abbott completed the issuance of $1.3 billion aggregate principal amount of senior notes, consisting
of $650 million of its 1.15% Notes due 2028 and $650 million of its 1.40% Notes due 2030.
On September 28, 2020, Abbott repaid the €1.140 billion outstanding principal amount of its 0.00% Notes due 2020
upon maturity. The repayment equated to approximately $1.3 billion.
Abbott has readily available financial resources, including unused lines of credit that support commercial paper
borrowing arrangements and provide Abbott with the ability to borrow up to $5 billion on an unsecured basis. The lines of
credit are part of a Five Year Credit Agreement (Revolving Credit Agreement) that Abbott entered into on November 12,
2020. At that time, Abbott also terminated its 2018 revolving credit agreement. There were no outstanding borrowings
under the 2018 revolving credit agreement at the time of its termination. Any borrowings under the Revolving Credit
Agreement will mature and be payable on November 12, 2025. Any borrowings under the Revolving Credit Agreement
will bear interest, at Abbott’s option, based on either a base rate or Eurodollar rate, plus an applicable margin based on
Abbott’s credit ratings.

-- 63 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
63
Note 10 — Debt and Lines of Credit (Continued)
In 2019, Abbott’s long-term borrowings and debt issuance included the following:
● On November 19, 2019, Abbott’s wholly owned subsidiary, Abbott Ireland Financing DAC, completed an
offering of €1.180 billion of long-term debt consisting of €590 million of 0.10% Notes due 2024 and €590 million
of 0.375% Notes due 2027. The proceeds equated to approximately $1.3 billion. The Notes are guaranteed by
Abbott.
● On November 21, 2019, Abbott borrowed ¥59.8 billion under a 5-year term loan and designated the yen-
denominated loan as a hedge of its net investment in certain foreign subsidiaries. The term loan bears interest at
TIBOR plus a fixed spread, and the interest rate is reset quarterly. The proceeds equated to approximately $550
million.
In 2019, Abbott’s repayment of long-term debt included the following:
● $0.500 billion outstanding principal amount of its 2.80% Notes due 2020 – redeemed on February 24, 2019
● $2.850 billion principal amount of its 2.9% Notes due 2021 – redeemed on December 19, 2019. Abbott incurred a
charge of $63 million related to the early repayment of this debt.
The 2.80% Notes were redeemed under the board of directors’ 2018 bond redemption authorization discussed below.
The 2.9% Notes were redeemed under a bond redemption authorization approved by the board of directors in September
2019 for the early redemption of up to $5 billion of outstanding long-term notes. The 2019 bond redemption authorization
superseded the board’s 2018 authorization. $2.15 billion of the $5 billion authorization remans available as of December
31, 2020.
On January 5, 2018, Abbott repaid $2.8 billion under a 5-year term loan agreement and $1.15 billion of borrowings
under its lines of credit.
On February 16, 2018, the board of directors authorized the early redemption of up to $5 billion of outstanding long-
term notes. 2018 redemptions under this authorization include the following:
● $0.947 billion principal amount of its 5.125% Notes due 2019 – redeemed on March 22, 2018
● $1.055 billion of the $2.850 billion principal amount of its 2.35% Notes due 2019 – redeemed on March 22, 2018
● $1.300 billion of the $1.795 billion outstanding principal amount of its 2.35% Notes due 2019 – redeemed on
June 22, 2018
● $0.495 billion outstanding principal amount of its 2.35% Notes due 2019 – redeemed on September 28, 2018
Abbott incurred a net charge of $14 million related to the March 22, 2018 early repayment of debt.
On September 17, 2018, Abbott repaid upon maturity the $500 million aggregate principal amount outstanding of the
2.00% Senior Notes due 2018.
On September 27, 2018, Abbott’s wholly owned subsidiary, Abbott Ireland Financing DAC, completed a euro debt
offering of €3.420 billion of long-term debt consisting of €1.140 billion of non-interest bearing Senior Notes due 2020 at
99.727% of par value; €1.140 billion of 0.875% Senior Notes due 2023 at 99.912% of par value; and €1.140 billion of
1.50% Senior Notes due 2026 at 99.723% of par value. The proceeds equated to approximately $4 billion. The notes are
guaranteed by Abbott.

-- 64 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
64
Note 10 — Debt and Lines of Credit (Continued)
On October 28, 2018, Abbott redeemed approximately $4 billion of debt, which included $750 million principal
amount of its 2.00% Notes due 2020; $597 million principal amount of its 4.125% Notes due 2020; $900 million principal
amount of its 3.25% Notes due 2023; $450 million principal amount of its 3.4% Notes due 2023; and $1.300 billion
principal amount of its 3.75% Notes due 2026. These amounts were in addition to the $5 billion authorization in 2018
discussed above. In conjunction with the redemption, Abbott unwound approximately $1.1 billion in interest rate swaps
relating to the 3.40% Note due in 2023 and the 3.75% Note due in 2026. Abbott incurred a net charge of $153 million
related to the early repayment of this debt and the unwinding of related interest rate swaps.
Principal payments required on long-term debt outstanding at December 31, 2020 are $7 million in 2021, $753 million
in 2022, $2.4 billion in 2023, $1.3 billion in 2024, $1.5 billion in 2025 and $12.5 billion in 2026 and thereafter.
At December 31, 2020, Abbott’s long-term debt rating was A by Standard & Poor’s Corporation and A3 by Moody’s.
Abbott’s weighted-average interest rate on short-term borrowings was 0.4%at December 31, 2020, 2019 and 2018.
Note 11 — Leases
Leases where Abbott is the Lessee
Abbott has entered into operating leases as the lessee for office space, manufacturing facilities, R&D laboratories,
warehouses, vehicles and equipment. Finance leases are not significant. Abbott’s operating leases generally have
remaining lease terms of 1 to 10 years. Some leases include options to extend beyond the original lease term, generally up
to 10 years and some include options to terminate early. These options have been included in the determination of the lease
liability when it is reasonably certain that the option will be exercised.
For all of its asset classes, Abbott elected the practical expedient allowed under FASB ASC No. 842, “Leases” to
account for each lease component (e.g., the right to use office space) and the associated non-lease components (e.g.,
maintenance services) as a single lease component. Abbott also elected the short-term lease accounting policy for all asset
classes; therefore, Abbott is not recognizing a lease liability or right of use (ROU) asset for any lease that, at the
commencement date, has a lease term of 12 months or less and does not include an option to purchase the underlying asset
that Abbott is reasonably certain to exercise.
As Abbott’s leases typically do not provide an implicit rate, the interest rate used to determine the present value of the
payments under each lease typically reflects Abbott’s incremental borrowing rate based on information available at the
lease commencement date. Abbott’s incremental borrowing rates at January 1, 2019 were used for operating leases that
commenced prior to January 1, 2019 when ASC 842 was adopted.

-- 65 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
65
Note 11 — Leases (Continued)
The following table provides information related to Abbott’s operating leases:
(in millions, except weighted averages) 	2020 	2019
Operating lease cost (a) 	$ 329 $ 314
Cash paid for amounts included in the measurement of operating lease
liabilities 	264 	253
ROU assets arising from entering into new operating lease obligations 	396 	310
Weighted average remaining lease term at December 31 (in years) 	8 	8
Weighted average discount rate at December 31 	3.2 % 3.9 %
(a) Includes short-term lease expense and variable lease costs, which were immaterial in the years ended
December 31, 2020 and 2019.
Future minimum lease payments under non-cancellable operating leases as of December 31, 2020 were as follows:
(in millions)
2021 	$ 	272
2022 	228
2023 	177
2024 	131
2025 	100
Thereafter 	407
Total future minimum lease payments – undiscounted 	1,315
Less: imputed interest 	(172)
Present value of lease liabilities 	$ 	1,143
The following table summarizes the amounts and location of operating lease ROU assets and lease liabilities:
(in millions) 	December 31, 2020 December 31, 2019 	Balance Sheet Caption
Operating Lease - ROU Asset 	$ 	1,101 $ 	934 Deferred income taxes and other assets
Operating Lease Liability:
Current 	$ 	241 $ 	205 Other accrued liabilities
Non-current 	902 	755 Post-employment obligations and other
long-term liabilities
Total Liability 	$ 	1,143 $ 	960

-- 66 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
66
Note 11 — Leases (Continued)
Leases where Abbott is the Lessor
Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically
include an operating or sales-type lease as well as performance obligations for reagents and other consumables. Sales-type
leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to
extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease
revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue
between the lease and non-lease components is based on stand-alone selling prices. Operating lease revenue represented
less than 3 percent of Abbott’s total net sales in the years ended December 31, 2020 and 2019.
Assets related to operating leases are reported within Net property and equipment on the Consolidated Balance Sheet.
The original cost and the net book value of such assets were $3.3 billion and $1.4 billion, respectively, as of December 31,
2020 and $2.8 billion and $1.2 billion, respectively, as of December 31, 2019.
Note 12 — Financial Instruments, Derivatives and Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to
changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional
currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $8.1 billion at December 31, 2020,
and $6.8 billion at December 31, 2019, are designated as cash flow hedges of the variability of the cash flows due to
changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of December 31, 2020
will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen
months.
Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency
denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the
receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans,
the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S.
dollars and European currencies. For intercompany and trade payables and receivables, the currency exposures are
primarily the U.S. dollar and European currencies. At December 31, 2020 and 2019, Abbott held gross notional amounts of
$11.0 billion and $9.1 billion, respectively, of such foreign currency forward exchange contracts.
In November 2019, Abbott borrowed ¥59.8 billion under a 5-year term loan and designated the yen-denominated loan
as a hedge of the net investment in certain foreign subsidiaries. The proceeds equated to approximately $550 million. The
value of this long-term debt was approximately $577 million and $546 million as of December 31, 2020 and December 31,
2019, respectively. The change in the value of the debt, which is due to changes in foreign exchange rates, was recorded in
Accumulated other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts totaling approximately $2.9 billion at December 31, 2020 and 2019, to
manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of
the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the
hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts
at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
In October 2018, Abbott unwound approximately $1.1 billion in interest rate swaps relating to the 3.40% Note due in
2023 and the 3.75% Note due in 2026. As a part of the unwinding, Abbott paid approximately $90 million in cash, which
was included in the Financing Activities section of the Consolidated Statement of Cash Flows in 2018.

-- 67 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
67
Note 12 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative financial instruments as of
December 31:
Fair Value — Assets 	Fair Value — Liabilities
(in millions) 	2020 	2019 	Balance Sheet Caption 	2020 	2019 	Balance Sheet Caption
Interest rate swaps designated
as fair value hedges
$ 210 $ 48 Deferred income taxes and
other assets
$ — $ — Post-employment
obligations and other
long-term liabilities
Foreign currency forward
exchange contracts:
Hedging instruments 	30 	110 Other prepaid expenses
and receivables
433 	56 Other accrued liabilities
Others not designated as
hedges
60 	38 Other prepaid expenses
and receivables
65 	33 Other accrued liabilities
Debt designated as a hedge of
net investment in a foreign
subsidiary
— 	— n/a 	577 	546 Long-term debt
$ 300 $ 196 	$1,075 $ 635
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow
hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial
instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income.
Gain (loss) Recognized in 	Income (expense) and
Other Comprehensive 	Gain (loss) Reclassified
Income (loss) 	into Income
(in millions) 	2020 	2019 2018 	2020 	2019 	2018 	Income Statement Caption
Foreign currency forward exchange contracts
designated as cash flow hedges
$ (207) $ 9 $ 73 $ 102 $ 79 $ (114) Cost of products sold
Debt designated as a hedge of net investment
in a foreign subsidiary
(31) 	4 	— 	n/a 	n/a 	n/a n/a
Interest rate swaps designated as fair value
hedges
n/a 	n/a 	n/a 	162 	148 	(97) Interest expense
A loss of $171 million, a gain of $75 million and a loss of $100 million were recognized in 2020, 2019 and 2018,
respectively, related to foreign currency forward exchange contracts not designated as hedges. These amounts are reported
in the Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.
The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to
changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking
the interest rate swaps to market.

-- 68 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
68
Note 12 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The carrying values and fair values of certain financial instruments as of December 31 are shown in the table below.
The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to
financial instruments consist of select major international financial institutions. Abbott does not expect any losses from
nonperformance by these counterparties.
2020 	2019
Carrying 	Fair 	Carrying 	Fair
(in millions) 	Value 	Value 	Value 	Value
Long-term Investment Securities:
Equity securities 	$ 	776 $ 	776 $ 	836 $ 	836
Other 	45 	45 	47 	47
Total Long-term debt 	(18,534) (22,809) (17,938) 	(20,772)
Foreign Currency Forward Exchange Contracts:
Receivable position 	90 	90 	148 	148
(Payable) position 	(498) 	(498) 	(89) 	(89)
Interest Rate Hedge Contracts:
Receivable position 	210 	210 	48 	48
(Payable) position 	— 	— 	— 	—
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

-- 69 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
69
Note 12 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring
basis in the balance sheet:
Basis of Fair Value Measurement
Quoted 	Significant
Prices in 	Other 	Significant
Outstanding Active 	Observable Unobservable
(in millions) 	Balances 	Markets 	Inputs 	Inputs
December 31, 2020:
Equity securities 	$ 	386 $ 386 $ 	— $ 	—
Interest rate swap derivative financial instruments 	210 	— 	210 	—
Foreign currency forward exchange contracts 	90 	— 	90 	—
Total Assets 	$ 	686 $ 386 $ 	300 $ 	—
Fair value of hedged long-term debt 	$ 3,049 $ 	— $ 	3,049 $ 	—
Foreign currency forward exchange contracts 	498 	— 	498 	—
Contingent consideration related to business combinations 	68 	— 	— 	68
Total Liabilities 	$ 3,615 $ 	— $ 	3,547 $ 	68
December 31, 2019:
Equity securities 	$ 	357 $ 357 $ 	— $ 	—
Interest rate swap derivative financial instruments 	48 	— 	48 	—
Foreign currency forward exchange contracts 	148 	— 	148 	—
Total Assets 	$ 	553 $ 357 $ 	196 $ 	—
Fair value of hedged long-term debt 	$ 2,890 $ 	— $ 	2,890 $ 	—
Foreign currency forward exchange contracts 	89 	— 	89 	—
Contingent consideration related to business combinations 	68 	— 	— 	68
Total Liabilities 	$ 3,047 $ 	— $ 	2,979 $ 	68
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes
values for comparable derivative instruments. The fair value of the debt was determined based on the face value of the debt
adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant
other observable inputs.
Contingent consideration relates to businesses acquired by Abbott. The fair value of the contingent consideration was
determined based on an independent appraisal adjusted for the time value of money and other changes in fair value. The
maximum amount for certain contingent consideration is not determinable as it is based on a percent of certain sales.
Excluding such contingent consideration, the maximum amount estimated to be due is approximately $200 million, which
is dependent upon attaining certain sales thresholds or based on the occurrence of certain events, such as regulatory
approvals.

-- 70 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
70
Note 13 — Litigation and Environmental Matters
Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of
locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential
contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for
which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to
exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.
Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal
proceedings and environmental exposures to be from approximately $90 million to $120 million. The recorded accrual
balance at December 31, 2020 for these proceedings and exposures was approximately $105 million. This accrual
represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the
next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not
feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their
ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of
operations.
Note 14 — Post-Employment Benefits
Retirement plans consist of defined benefit, defined contribution and medical and dental plans. Information for
Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:
Medical and Dental
Defined Benefit Plans 	Plans
(in millions) 	2020 	2019 	2020 	2019
Projected benefit obligations, January 1 	$ 11,238 $ 9,093 $ 1,556 $ 1,292
Service cost — benefits earned during the year 	336 	250 	46 	23
Interest cost on projected benefit obligations 	300 	337 	42 	52
(Gains) losses, primarily changes in discount rates, plan design changes, law
changes and differences between actual and estimated health care costs 	1,305 	1,856 	(5) 	228
Benefits paid 	(327) 	(302) 	(73) 	(76)
Other, including foreign currency translation 	277 	4 	1 	37
Projected benefit obligations, December 31 	$ 13,129 $ 11,238 $ 1,567 $ 1,556
Plan assets at fair value, January 1 	$ 10,277 $ 8,553 $ 360 $ 351
Actual return (loss) on plan assets 	1,463 	1,622 	46 	65
Company contributions 	400 	382 	12 	12
Benefits paid 	(327) 	(302) 	(65) 	(68)
Other, including foreign currency translation 	205 	22 	— 	—
Plan assets at fair value, December 31 	$ 12,018 $ 10,277 $ 353 $ 360
Projected benefit obligations greater than plan assets, December 31 	$ (1,111) $ (961) $ (1,214) $ (1,196)
Long-term assets 	$ 824 $ 687 $ 	— $ 	—
Short-term liabilities 	(29) 	(26) 	(1) 	(1)
Long-term liabilities 	(1,906) 	(1,622) 	(1,213) 	(1,195)
Net liability 	$ (1,111) $ (961) $ (1,214) $ (1,196)
Amounts Recognized in Accumulated Other Comprehensive Income (loss):
Actuarial losses, net 	$ 4,559 $ 4,131 $ 486 $ 529
Prior service cost (credits) 	(5) 	(2) 	(67) 	(95)
Total 	$ 4,554 $ 4,129 $ 419 $ 434

-- 71 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
71
Note 14 — Post-Employment Benefits (Continued)
The $1.3 billion and $1.9 billion of defined benefit plan losses in 2020 and 2019, respectively, that increased the
projected benefit obligations in those years, primarily reflect the year-over-year decline in the discount rates used to
measure the obligations. The projected benefit obligations for non-U.S. defined benefit plans were $4.1 billion and
$3.3 billion at December 31, 2020 and 2019, respectively. The accumulated benefit obligations for all defined benefit plans
were $11.9 billion and $10.2 billion at December 31, 2020 and 2019, respectively.
For plans where the projected benefit obligations exceeded plan assets at December 31, 2020 and 2019, the projected
benefit obligations and the aggregate plan assets were as follows:
(in millions) 	2020 	2019
Projected benefit obligation 	$ 8,946 $ 7,585
Fair value of plan assets 	7,010 	5,936
For plans where the accumulated benefit obligations exceeded plan assets at December 31, 2020 and 2019, the
aggregate accumulated benefit obligations, the projected benefit obligations and the aggregate plan assets were as follows:
(in millions) 	2020 	2019
Accumulated benefit obligation 	$ 2,459 $ 1,985
Projected benefit obligation 	2,773 	2,266
Fair value of plan assets 	965 	821
The components of the net periodic benefit cost were as follows:
Medical and
Defined Benefit Plans 	Dental Plans
(in millions) 	2020 	2019 	2018 	2020 	2019 	2018
Service cost — benefits earned during the year 	$ 336 $ 250 $ 293 $ 	46 $ 	23 $ 	26
Interest cost on projected benefit obligations 	300 	337 	308 	42 	52 	48
Expected return on plans' assets 	(770) 	(710) 	(680) 	(28) 	(27) 	(33)
Amortization of actuarial losses 	255 	132 	205 	21 	22 	33
Amortization of prior service cost (credits) 	1 	1 	1 	(28) 	(32) 	(45)
Total net cost 	$ 122 $ 	10 $ 127 $ 	53 $ 	38 $ 	29
Other comprehensive income (loss) for each respective year includes the amortization of actuarial losses and prior
service costs (credits) as noted in the previous table. Other comprehensive income (loss) for each respective year also
includes: net actuarial losses of $611 million for defined benefit plans and a gain of $23 million for medical and dental
plans in 2020, net actuarial losses of $944 million for defined benefit plans and a loss of $190 million for medical and
dental plans in 2019; net actuarial losses of $86 million for defined benefit plans and a gain of $53 million for medical and
dental plans in 2018. The net actuarial losses in 2020 and 2019 are primarily due to the year-over-year decline in discount
rates partially offset by the impact of actual asset returns in excess of expected returns in each of the period.

-- 72 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
72
Note 14 — Post-Employment Benefits (Continued)
The weighted average assumptions used to determine benefit obligations for defined benefit plans and medical and
dental plans are as follows:
2020 	2019 	2018
Discount rate 	2.3 % 3.0 % 4.0 %
Expected aggregate average long-term change in compensation 	4.3 % 4.3 % 4.3 %
The weighted average assumptions used to determine the net cost for defined benefit plans and medical and dental
plans are as follows:
2020 	2019 	2018
Discount rate 	3.0 % 4.0 % 3.4 %
Expected return on plan assets 	7.5 % 7.5 % 7.7 %
Expected aggregate average long-term change in compensation 	4.3 % 4.3 % 4.4 %
The assumed health care cost trend rates for medical and dental plans at December 31 were as follows:
2020 	2019 	2018
Health care cost trend rate assumed for the next year 	8 % 	9 % 	9 %
Rate that the cost trend rate gradually declines to 	5 % 	5 % 	5 %
Year that rate reaches the assumed ultimate rate 	2025 	2025 	2025
The discount rates used to measure liabilities were determined based on high-quality fixed income securities that
match the duration of the expected retiree benefits. The health care cost trend rates represent Abbott’s expected annual rates
of change in the cost of health care benefits and are forward projections of health care costs as of the measurement date.

-- 73 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
73
Note 14 — Post-Employment Benefits (Continued)
The following table summarizes the bases used to measure the defined benefit and medical and dental plan assets at
fair value:
Basis of Fair Value Measurement
Quoted Significant
Prices in 	Other 	Significant
Outstanding Active Observable Unobservable Measured at
(in millions) 	Balances 	Markets 	Inputs 	Inputs 	NAV (j)
December 31, 2020:
Equities:
U.S. large cap (a) 	$ 	3,410 $ 2,202 $ 	— $ 	— $ 	1,208
U.S. mid and small cap (b) 	775 	721 	— 	3 	51
International (c) 	2,654 	542 	— 	— 	2,112
Fixed income securities:
U.S. government securities (d) 	475 	23 	289 	— 	163
Corporate debt instruments (e) 	1,408 	425 	908 	— 	75
Non-U.S. government securities (f) 	523 	16 	— 	— 	507
Other (g) 	503 	159 	72 	— 	272
Absolute return funds (h) 	1,618 	462 	— 	— 	1,156
Cash and Cash Equivalents 	281 	77 	— 	— 	204
Other (i) 	724 	9 	— 	— 	715
$ 12,371 $ 4,636 $ 1,269 $ 	3 $ 	6,463
December 31, 2019:
Equities:
U.S. large cap (a) 	$ 	2,873 $ 1,647 $ 	— $ 	— $ 	1,226
U.S. mid and small cap (b) 	648 	548 	4 	2 	94
International (c) 	2,202 	464 	— 	— 	1,738
Fixed income securities:
U.S. government securities (d) 	562 	52 	357 	— 	153
Corporate debt instruments (e) 	1,266 	362 	724 	— 	180
Non-U.S. government securities (f) 	445 	3 	2 	— 	440
Other (g) 	320 	69 	27 	— 	224
Absolute return funds (h) 	1,557 	424 	— 	— 	1,133
Cash and Cash Equivalents 	182 	84 	— 	— 	98
Other (i) 	582 	8 	— 	1 	573
$ 10,637 $ 3,661 $ 1,114 $ 	3 $ 	5,859
(a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices.
(b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid and small cap
indices.
(c) A mix of index funds and actively managed pooled investment funds that are benchmarked to various non-U.S. equity
indices in both developed and emerging markets.
(d) A mix of index funds and actively managed accounts that are benchmarked to various U.S. government bond indices.
(e) A mix of index funds and actively managed accounts that are benchmarked to various corporate bond indices.
(f) Primarily United Kingdom, Japan and Eurozone government bonds.
(g) Primarily asset backed securities and an actively managed, diversified fixed income vehicle benchmarked to the one-
month Libor / Euribor.
(h) Primarily funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across
a wide range of asset classes and strategies including, but not limited to equities, fixed income, commodities, interest
rate futures, currencies and other securities to outperform an agreed upon benchmark with specific return and volatility
targets.

-- 74 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
74
Note 14 — Post-Employment Benefits (Continued)
(i) Primarily investments in private funds, such as private equity, private credit, private real estate and private energy
funds.
(j) Investments measured at fair value using the net asset value (NAV) practical expedient have not been classified in the
fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair
value hierarchy to the amounts presented in the consolidated balance sheet.
Equities that are valued using quoted prices are valued at the published market prices. Equities in a common collective
trust or a registered investment company are valued at the NAV provided by the fund administrator. The NAV is based on
the value of the underlying assets owned by the fund minus its liabilities. For approximately half of these funds,
investments may be redeemed once per month, with a required 7 to 30 day notice period. For the remaining funds, daily
redemption of an investment is allowed. Fixed income securities that are valued using significant other observable inputs
are valued at prices obtained from independent financial service industry recognized vendors. Abbott did not have any
unfunded commitments related to fixed income funds at December 31, 2020 and 2019. Fixed income securities in a
common collective trust or a registered investment company are valued at the NAV provided by the fund administrator. For
the majority of these funds, investments may be redeemed either weekly or monthly, with a required 2 to 14 day notice
period. For the remaining funds, investments may be generally redeemed daily.
Absolute return funds are valued at the NAV provided by the fund administrator. All private funds are valued at the
NAV provided by the fund on a one-quarter lag adjusted for known cash flows and significant events through the reporting
date. Abbott did not have any unfunded commitments related to absolute return funds at December 31, 2020 and 2019.
Investments in these funds may be generally redeemed monthly or quarterly with required notice periods ranging from 5 to
90 days. For approximately $245 million and $110 million of the absolute return funds, redemptions are subject to a 33
percent gate and a 25 percent gate, respectively, and $60 million is subject to a lock until 2022. Investments in the private
funds cannot be redeemed but the funds will make distributions through liquidation. The estimate of the liquidation period
for each fund ranges from 2021 to 2030. Abbott’s unfunded commitment in these funds was $523 million and $579 million
as of December 31, 2020 and 2019, respectively.
The investment mix of equity securities, fixed income and other asset allocation strategies is based upon achieving a
desired return, as well as balancing higher return, more volatile equity securities with lower return, less volatile fixed
income securities. Investment allocations are made across a range of markets, industry sectors, capitalization sizes, and in
the case of fixed income securities, maturities and credit quality. The plans do not directly hold any securities of Abbott.
There are no known significant concentrations of risk in the plans’ assets. Abbott’s medical and dental plans’ assets are
invested in a similar mix as the pension plan assets. The actual asset allocation percentages at year end are consistent with
the company’s targeted asset allocation percentages.
The plans’ expected return on assets, as shown above is based on management’s expectations of long-term average
rates of return to be achieved by the underlying investment portfolios. In establishing this assumption, management
considers historical and expected returns for the asset classes in which the plans are invested, as well as current economic
and capital market conditions.
Abbott funds its domestic pension plans according to IRS funding limitations. International pension plans are funded
according to similar regulations. Abbott funded $400 million in 2020 and $382 million in 2019 to defined pension plans.
Abbott expects to contribute approximately $410 million to its pension plans in 2021.

-- 75 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
75
Note 14 — Post-Employment Benefits (Continued)
Total benefit payments expected to be paid to participants, which includes payments funded from company assets, as
well as paid from the plans, are as follows:
Defined 	Medical and
(in millions) 	Benefit Plans Dental Plans
2021 	$ 	340 $ 	72
2022 	355 	73
2023 	373 	74
2024 	395 	75
2025 	415 	76
2026 to 2030 	2,410 	394
The Abbott Stock Retirement Plan is the principal defined contribution plan. Abbott’s contributions to this plan were
$164 million in 2020, $158 million in 2019 and $146 million in 2018. The 2018 contributions include amounts related to
participants of the St. Jude Medical Retirement Plan which was terminated in January 2018.
Note 15 — Taxes on Earnings from Continuing Operations
Taxes on earnings from continuing operations reflect the annual effective rates, including charges for interest and
penalties. Deferred income taxes reflect the tax consequences on future years of differences between the tax bases of assets
and liabilities and their financial reporting amounts.
In 2020, taxes on earnings from continuing operations include the recognition of approximately $170 million of tax
benefits associated with the impairment of certain assets, approximately $140 million of net tax benefits as a result of the
resolution of various tax positions related to prior years, and approximately $100 million in excess tax benefits associated
with share-based compensation. In 2020, taxes on earnings from continuing operations also include a $26 million increase
to the transition tax associated with the 2017 TCJA. The $26 million increase to the transition tax liability was the result of
the resolution of various tax positions related to prior years. This adjustment increased the cumulative net tax expense
related to the TCJA to $1.53 billion. The one-time transition tax is based on Abbott’s total post-1986 earnings and profits
(E&P) that were previously deferred from U.S. income taxes. The tax computation also requires the determination of the
amount of post-1986 E&P considered held in cash and other specified assets. As of December 31, 2020, the remaining
balance of Abbott’s transition tax obligation is approximately $805 million, which will be paid over the next six years as
allowed by the TCJA.
In 2019, taxes on earnings from continuing operations included an $86 million reduction of the transition tax and $68
million of tax expense resulting from tax legislation enacted in the fourth quarter of 2019 in India. The $86 million
reduction to the transition tax liability was the result of the issuance of final transition tax regulations by the U.S.
Department of Treasury in 2019. In 2018, taxes on earnings from continuing operations included $98 million of net tax
expense related to the settlement of Abbott’s 2014-2016 federal income tax audit in the U.S., partial settlement of the
former St. Jude Medical consolidated group’s 2014 and 2015 federal income tax returns in the U.S. and audit settlements in
various countries. In 2018, Abbott also recorded $130 million of additional tax expense related to the TCJA; the $130
million reflected a $120 million increase in the transition tax from $2.89 billion to $3.01 billion and a $10 million reduction
in the net benefit related to the remeasurement of deferred tax assets and liabilities.
Undistributed foreign earnings remain indefinitely reinvested in foreign operations. Determining the amount of
unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax
and additional outside basis difference in its foreign entities is not practicable. In the U.S., Abbott’s federal income tax
returns through 2016 are settled. There are numerous other income tax jurisdictions for which tax returns are not yet
settled, none of which are individually significant. Reserves for interest and penalties are not significant.

-- 76 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
76
Note 15 — Taxes on Earnings from Continuing Operations (Continued)
Earnings from continuing operations before taxes, and the related provisions for taxes on earnings from continuing
operations, were as follows:
(in millions) 	2020 	2019 	2018
Earnings From Continuing Operations Before Taxes:
Domestic 	$ 1,588 $ 889 $ (430)
Foreign 	3,380 	3,188 	3,303
Total 	$ 4,968 $ 4,077 $ 2,873
(in millions) 	2020 	2019 	2018
Taxes on Earnings From Continuing Operations:
Current:
Domestic 	$ 39 $ 291 $ (812)
Foreign 	566 	590 	606
Total current 	605 	881 	(206)
Deferred:
Domestic 	(18) 	(305) 	832
Foreign 	(90) 	(186) 	(87)
Total deferred 	(108) 	(491) 	745
Total 	$ 497 $ 390 $ 539
Differences between the effective income tax rate and the U.S. statutory tax rate were as follows:
2020 	2019 	2018
Statutory tax rate on earnings from continuing operations 	21.0 % 21.0 % 21.0 %
Impact of foreign operations 	(3.3) 	(5.0) 	(5.4)
Impact of TCJA and other related items 	0.5 	(2.1) 	6.3
Foreign-derived intangible income benefit 	(1.0) 	(2.0) 	(1.9)
Domestic impairment loss 	(2.7) 	— 	(2.1)
Excess tax benefits related to stock compensation 	(1.9) 	(2.5) 	(3.1)
Research tax credit 	(1.0) 	(1.2) 	(1.8)
Resolution of certain tax positions pertaining to prior years 	(2.8) 	— 	3.4
Intercompany restructurings and integration 	0.5 	— 	—
State taxes, net of federal benefit 	0.5 	0.8 	0.4
All other, net 	0.2 	0.6 	2.0
Effective tax rate on earnings from continuing operations 	10.0 % 9.6 % 18.8 %
Impact of foreign operations is primarily derived from operations in Puerto Rico, Switzerland, Ireland, the
Netherlands, Costa Rica, Singapore, and Malta.

-- 77 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
77
Note 15 — Taxes on Earnings from Continuing Operations (Continued)
The tax effect of the differences that give rise to deferred tax assets and liabilities were as follows:
(in millions) 	2020 	2019
Deferred tax assets:
Compensation and employee benefits 	$ 1,003 $ 982
Other, primarily reserves not currently deductible, and NOL’s and credit
carryforwards 	2,383 	2,378
Trade receivable reserves 	196 	190
Inventory reserves 	146 	110
Lease liabilities 	259 	209
Deferred intercompany profit 	254 	259
Total deferred tax assets before valuation allowance 	4,241 	4,128
Valuation allowance 	(1,060) 	(978)
Total deferred tax assets 	3,181 	3,150
Deferred tax liabilities:
Depreciation 	(297) 	(219)
Right of Use lease assets 	(251) 	(209)
Other, primarily the excess of book basis over tax basis of intangible
assets (2,876) 	(3,258)
Total deferred tax liabilities 	(3,424) 	(3,686)
Total net deferred tax assets (liabilities) 	$ (243) $ (536)
Abbott has incurred losses in a foreign jurisdiction where realization of the future economic benefit is so remote that
the benefit is not reflected as a deferred tax asset.
The following table summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax
liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled:
(in millions) 	2020 	2019
January 1 	$ 1,175 $ 1,120
Increase due to current year tax positions 	190 	137
Increase due to prior year tax positions 	97 	75
Decrease due to prior year tax positions 	(144) 	(117)
Settlements 	(27) 	(32)
Lapse of statute 	(81) 	(8)
December 31 	$ 1,210 $ 1,175
The total amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate is approximately
$1.08 billion. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits
may decrease within a range of $70 million to $430 million, including cash adjustments, within the next twelve months as a
result of concluding various domestic and international tax matters.

-- 78 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
78
Note 16 — Segment and Geographic Area Information
Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products.
Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories,
physicians’ offices and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products—International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products—Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products—Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial
laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Rapid
Diagnostics, Molecular Diagnostics and Point of Care divisions are aggregated and reported as the Diagnostic Products
segment.
Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural
heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management,
Electrophysiology and Heart Failure, Vascular, Neuromodulation, Structural Heart and Diabetes Care divisions are
aggregated and reported as the Medical Devices segment.
Abbott's underlying accounting records are maintained on a legal entity basis for government and public reporting
requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The cost of
some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that
approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not
allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s
assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as
described above, and are not presented in accordance with generally accepted accounting principles applied to the
consolidated financial statements.
Net Sales to External Customers (a) 	Operating Earnings (a)
(in millions) 	2020 	2019 	2018 	2020 	2019 	2018
Established Pharmaceutical Products 	$ 4,303 $ 4,486 $ 4,422 $ 794 $ 	904 $ 894
Nutritional Products 	7,647 	7,409 	7,229 	1,751 	1,705 	1,652
Diagnostic Products 	10,805 	7,713 	7,495 	3,725 	1,912 	1,868
Medical Devices 	11,787 	12,239 	11,370 	3,038 	3,769 	3,500
Total Reportable Segments 	34,542 	31,847 	30,516 $ 9,308 $ 8,290 $ 7,914
Other 	66 	57 	62
Total 	$ 34,608 $ 31,904 $ 30,578
(a) Net sales and operating earnings were unfavorably affected by the impact of foreign exchange in 2020, 2019 and 2018.

-- 79 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
79
Note 16 — Segment and Geographic Area Information (Continued)
(in millions) 	2020 	2019 	2018
Total Reportable Segment Operating Earnings 	$ 9,308 $ 8,290 $ 7,914
Corporate functions and benefit plan costs 	(518) 	(468) 	(618)
Net interest expense 	(500) 	(576) 	(721)
Loss on extinguishment of debt 	— 	(63) 	(167)
Share-based compensation 	(546) 	(519) 	(477)
Amortization of intangible assets 	(2,132) 	(1,936) 	(2,178)
Other, net (b) 	(644) 	(651) 	(880)
Earnings from Continuing Operations Before Taxes 	$ 4,968 $ 4,077 $ 2,873
(b) Other, net includes integration costs associated with the acquisition of St. Jude Medical and Alere and restructuring
charges in 2020, 2019 and 2018. Other, net in 2020 also includes costs related to asset impairments, partially offset by
income from the settlement of litigation. Other, net in 2018 also includes inventory step-up amortization associated
with the acquisition of Alere. Charges for restructuring actions and other cost reduction initiatives were approximately
$125 million in 2020, $215 million in 2019 and $153 million in 2018.
Additions to
Depreciation 	Property and Equipment 	Total Assets
(in millions) 	2020 	2019 	2018 	2020 	2019 	2018 	2020 	2019 	2018
Established
Pharmaceuticals 	$ 88 $ 98 $ 92 $ 109 $ 109 $ 131 $ 2,888 $ 2,858 $ 2,664
Nutritionals 	143 	139 	150 	201 	141 	86 	3,478 	3,274 	3,071
Diagnostics 	488 	403 	397 	1,263 	726 	609 	7,696 	5,235 	4,464
Medical Devices 	281 	266 	294 	402 	532 	408 	6,893 	6,640 	5,886
Total Reportable
Segments 	1,000 	906 	933 	1,975 	1,508 	1,234 $ 20,955 $ 18,007 $ 16,085
Other 	195 	172 	167 	218 	160 	160
Total 	$ 1,195 $ 1,078 $ 1,100 $ 2,193 $ 1,668 $ 1,394
(in millions) 	2020 	2019 	2018
Total Reportable Segment Assets 	$ 20,955 $ 18,007 $ 16,085
Cash and investments 	7,969 	5,023 	4,983
Goodwill and intangible assets 	38,528 	40,220 	42,196
All other 	5,096 	4,637 	3,909
Total Assets 	$ 72,548 $ 67,887 $ 67,173

-- 80 of 409 --

Abbott Laboratories and Subsidiaries
Notes to Consolidated Financial Statements (Continued)
80
Note 16 — Segment and Geographic Area Information (Continued)
Net Sales to External
Customers (c)
(in millions) 	2020 	2019 	2018
United States 	$ 13,022 $ 11,398 $ 10,839
Germany 	2,108 	1,751 	1,619
China 	1,965 	2,346 	2,311
Japan 	1,386 	1,435 	1,326
India 	1,323 	1,397 	1,333
Switzerland 	1,140 	1,068 	1,005
The Netherlands 	1,084 	975 	930
All Other Countries 	12,580 	11,534 	11,215
Consolidated 	$ 34,608 $ 31,904 $ 30,578
(c) Sales by country are based on the country that sold the product.
Long-lived assets on a geographic basis primarily include property and equipment. It excludes goodwill, intangible
assets, deferred tax assets, and financial instruments. At December 31, 2020 and 2019, long-lived assets totaled $11.7
billion and $10.2 billion, respectively, and in the United States such assets totaled $6.1 billion and $5.1 billion, respectively.
Long-lived asset balances associated with other countries were not material on an individual country basis in either of the
two years.

-- 81 of 409 --

81
Management Report on Internal Control Over Financial Reporting
The management of Abbott Laboratories is responsible for establishing and maintaining adequate internal control over
financial reporting. Abbott’s internal control system was designed to provide reasonable assurance to the company’s
management and board of directors regarding the preparation and fair presentation of published financial statements.
All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems
determined to be effective can provide only reasonable assurance with respect to financial statement preparation and
presentation.
Abbott’s management assessed the effectiveness of the company’s internal control over financial reporting as of
December 31, 2020. In making this assessment, it used the criteria set forth in Internal Control — Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our assessment, we
believe that, as of December 31, 2020, the company’s internal control over financial reporting was effective based on those
criteria.
Abbott’s independent registered public accounting firm has issued an audit report on their assessment of the effectiveness
of the company’s internal control over financial reporting. This report appears on page 84.
Robert B. Ford
President and Chief Executive Officer
Robert E. Funck, Jr.
Executive Vice President, Finance and Chief Financial Officer
Philip P. Boudreau
Vice President, Finance and Controller
February 19, 2021

-- 82 of 409 --

82
Report of Independent Registered Public Accounting Firm
To the Shareholders and Board of Directors of Abbott Laboratories
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Abbott Laboratories and subsidiaries (the Company) as
of December 31, 2020 and 2019, the related consolidated statements of earnings, comprehensive income, shareholders’
investment and cash flows for each of the three years in the period ended December 31, 2020, and the related notes
(collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the
results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity
with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2020, based on criteria
established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission (2013 framework), and our report dated February 19, 2021 expressed an unqualified opinion
thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion
on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement,
whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits
also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our
opinion.

-- 83 of 409 --

83
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements
that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or
disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex
judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated
financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a
separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Income taxes – Unrecognized tax benefits
Description of the
Matter
As described in Note 15 to the consolidated financial statements, unrecognized tax benefits
were approximately $1.2 billion at December 31, 2020. Unrecognized tax benefits are assessed
by management quarterly for identification and measurement, or more frequently if there are
any indicators suggesting change in unrecognized tax benefits. Assessing tax positions
involves judgement including interpreting tax laws of multiple jurisdictions and assumptions
relevant to the measurement of an unrecognized tax benefit, including the estimated amount of
tax liability that may be incurred should the tax position not be sustained upon inspection by a
tax authority. These judgements and assumptions can significantly affect unrecognized tax
benefits.
How We Addressed
the Matter in our
Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of
controls over the Company’s identification and measurement of unrecognized tax benefits, as
well as its process for the assessment of events that may indicate a change in unrecognized tax
benefits is warranted. For example, we tested controls over management’s review of the
completeness of identified unrecognized tax benefits, as well as controls over management’s
review of significant assumptions used within the measurement of unrecognized tax benefits.
With the support of our tax professionals, among other audit procedures performed, we
evaluated the reasonableness of management’s judgement with respect to the interpretation of
tax laws of multiple jurisdictions by reading and evaluating management’s documentation,
including relevant accounting policies, and by considering how tax law, including statutes,
regulations and case law, affected management’s judgments. We tested the completeness of
management’s assessment of the identification of unrecognized tax benefits and possible
outcomes related to it including evaluation of technical merits of the unrecognized tax benefits.
We also tested, with the support of our valuation specialists, appropriateness and consistency
of management’s methods and significant assumptions associated with the measurement of
unrecognized tax benefits, including assessing the estimated amount of tax liability that may
be incurred should the tax position not be sustained upon inspection by a tax authority.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2013.
Chicago, Illinois
February 19, 2021

-- 84 of 409 --

84
Report of Independent Registered Public Accounting Firm
To the Shareholders and Board of Directors of Abbott Laboratories
Opinion on Internal Control over Financial Reporting
We have audited Abbott Laboratories and subsidiaries’ internal control over financial reporting as of December 31, 2020,
based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Abbott Laboratories
and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of
December 31, 2020, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related
consolidated statements of earnings, comprehensive income, shareholders' investment and cash flows for each of the three
years in the period ended December 31, 2020, and the related notes and our report dated February 19, 2021 expressed an
unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting included in the accompanying Management
Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal
control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in
all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material
weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk,
and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides
a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and
procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and
that receipts and expenditures of the company are being made only in accordance with authorizations of management and
directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Chicago, Illinois
February 19, 2021

-- 85 of 409 --

85
ITEM 9. 	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and the Chief
Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and
procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls
and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits
with the Commission under the Securities Exchange Act of 1934 (the Exchange Act) is recorded, processed, summarized
and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information
required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and
communicated to Abbott’s management, including its principal executive officer and principal financial officer, as
appropriate to allow timely decisions regarding required disclosure.
Internal Control Over Financial Reporting
Management’s annual report on internal control over financial reporting. Management’s report on Abbott’s internal
control over financial reporting is included on page 81 hereof. The report of Abbott’s independent registered public
accounting firm related to their assessment of the effectiveness of internal control over financial reporting is included on
page 84 hereof.
Changes in internal control over financial reporting. During the quarter ended December 31, 2020, there were no
changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that
have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.
ITEM 9B. OTHER INFORMATION
None.

-- 86 of 409 --

86
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Incorporated herein by reference are “Nominees for Election as Directors,” “Committees of the Board of Directors,”
and “Procedure for Recommendation and Nomination of Directors and Transaction of Business at Annual Meeting” to be
included in the 2021 Abbott Laboratories Proxy Statement. The 2021 Definitive Proxy Statement will be filed on or about
March 12, 2021. Also incorporated herein by reference is the text found under the caption, “Information About Our
Executive Officers” on pages 16 through 19 hereof.
Abbott has adopted a code of ethics that applies to its principal executive officer, principal financial officer, and
principal accounting officer and controller. That code is part of Abbott’s code of business conduct which is available free of
charge through Abbott’s investor relations website (www.abbottinvestor.com). Abbott intends to include on its website any
amendment to, or waiver from, a provision of its code of ethics that applies to Abbott’s principal executive officer,
principal financial officer, and principal accounting officer and controller that relates to any element of the code of ethics
definition enumerated in Item 406(b) of Regulation S-K.
ITEM 11. EXECUTIVE COMPENSATION
The material to be included in the 2021 Proxy Statement under the headings “2020 Director Compensation” and
“Executive Compensation” is incorporated herein by reference. The 2021 Definitive Proxy Statement will be filed on or
about March 12, 2021.
ITEM 12. 	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
(a) Equity Compensation Plan Information.
The following table presents information as of December 31, 2020 about our compensation plans under which Abbott
common shares have been authorized for issuance.
(c)
Number of
(a) 	securities remaining
Number of 	available for
securities to be 	(b) 	future issuance
issued upon 	Weighted average 	under equity
exercise of 	exercise price 	compensation
outstanding 	of outstanding 	plans (excluding
options, warrants options, warrants securities reflected
Plan Category 	and rights 	and rights 	in column (a))
Equity compensation plans approved by security holders (1) 	28,034,365 $ 	56.45 	124,762,755
Equity compensation plans not approved by security holders 	0 	— 	0
Total (1)(2) 	28,034,365 $ 	56.45 	124,762,755
(1) 	(i) 	Abbott Laboratories 2009 Incentive Stock Program. Benefits under the Abbott Laboratories 2009
Incentive Stock Program (the “2009 Program”) include non-qualified stock options, restricted stock,
restricted stock units, performance awards, other share-based awards (including stock appreciation rights,
dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits.
The shares that remain available for issuance under the 2009 Program may be issued in connection with
any one of these benefits and may be either authorized but unissued shares or treasury shares (except that
restricted stock awards are satisfied from treasury shares).

-- 87 of 409 --

87
If there is a lapse, expiration, termination, forfeiture or cancellation of any benefit granted under the 2009
Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved
for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type
authorized under the Abbott Laboratories 2017 Incentive Stock Program (the “2017 Program”). If shares
are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to
rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock
options by delivery of other common shares of Abbott, the shares subject to or reserved for that benefit,
or so reacquired, may not again be used for new stock options, rights, or awards of any type authorized
under the 2009 Program.
In April 2017, the 2009 Program was replaced by the 2017 Program. No further awards will be granted
under the 2009 Program.
(ii) 	Abbott Laboratories 2017 Incentive Stock Program. Benefits under the 2017 Program include non-
qualified stock options, restricted stock, restricted stock units, performance awards, other share-based
awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-
employee directors, and foreign benefits. The shares that remain available for issuance under the 2017
Program may be issued in connection with any one of these benefits and may be either authorized but
unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).
If there is a lapse, expiration, termination, forfeiture or cancellation of any benefit granted under the 2017
Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved
for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type
authorized under the 2017 Program. If shares are issued under any benefit under the 2017 Program and
thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the
payment of the purchase price of shares under stock options by delivery of other common shares of
Abbott, the shares subject to or reserved for that benefit, or so reacquired, may not again be used for new
stock options, rights, or awards of any type authorized under the 2017 Program.
(iii) 	Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees. Eligible employees of
participating non-U.S. affiliates of Abbott may participate in this plan. An eligible employee may
authorize payroll deductions at the rate of 1% to 10% of eligible compensation (in multiples of one
percent) subject to a limit of US $12,500 during any purchase cycle.
Purchase cycles are generally six months long and usually begin on August 1 and February 1. On the last
day of each purchase cycle, Abbott uses participant contributions to acquire Abbott common shares. The
shares may be either authorized but unissued shares, treasury shares, or shares acquired on the open
market. The purchase price is typically 85% of the lower of the fair market value of the shares on the
purchase date or on the first day of that purchase cycle. As the number of shares subject to outstanding
options is indeterminable, columns (a) and (b) of the above table do not include information on the
Employee Stock Purchase Plan. As of December 31, 2020, an aggregate of 11,611,818 common shares
were available for future issuance under the Employee Stock Purchase Plan, including shares subject to
purchase during the current purchase cycle.
In April 2017, the 2009 Employee Stock Purchase Plan for Non-U.S. Employees was amended and
restated as the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees.
(2) 	Not included in the table: St. Jude Medical, Inc. Plans. In 2017, in connection with the acquisition of St.
Jude Medical, Inc., options outstanding under the St. Jude Medical, Inc. 2007 Stock Incentive Plan, as
Amended and Restated (2014) were assumed by Abbott and converted into Abbott options of
substantially equivalent value. As of December 31, 2020, 885,521 options remained outstanding under
these plans. These options have a weighted average purchase price of $30.46. No further awards will be
granted under these plans.

-- 88 of 409 --

88
For additional information concerning the Abbott Laboratories 2009 Incentive Stock Program, the Abbott Laboratories
2017 Incentive Stock Program, and the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees,
see the discussion in Note 9 entitled “Incentive Stock Program” of the Notes to Consolidated Financial Statements included
under Item 8, “Financial Statements and Supplementary Data.”
(b) Information Concerning Security Ownership. Incorporated herein by reference is the material under the heading
“Security Ownership of Executive Officers and Directors” and “Information Concerning Security Ownership” in the
2021 Proxy Statement. The 2021 Definitive Proxy Statement will be filed on or about March 12, 2021.
ITEM 13. 	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
The material to be included in the 2021 Proxy Statement under the headings “The Board of Directors,” “Committees of
the Board of Directors,” and “Approval Process for Related Person Transactions” is incorporated herein by reference. The
2021 Definitive Proxy Statement will be filed on or about March 12, 2021.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The material to be included in the 2021 Proxy Statement under the headings “Audit Fees and Non-Audit Fees” and
“Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of the Independent Auditor” is
incorporated herein by reference. The 2021 Definitive Proxy Statement will be filed on or about March 12, 2021.

-- 89 of 409 --

89
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a) Documents filed as part of this Form 10-K.
(1) Financial Statements: See Item 8, “Financial Statements and Supplementary Data,” on page 42 hereof, for a list
of financial statements.
(2) Financial Statement Schedules: The required financial statement schedules are found on the pages indicated
below. These schedules should be read in conjunction with the Consolidated Financial Statements of Abbott
Laboratories:
Abbott Laboratories Financial Statement Schedules 	Page No.
Valuation and Qualifying Accounts (Schedule II) 	101
Schedules I, III, IV, and V are not submitted because they are not applicable
or not required
Report of Independent Registered Public Accounting Firm 	102
Individual Financial Statements of businesses acquired by the registrant have
been omitted pursuant to Rule 3.05 of Regulation S-X
(3) Exhibits Required by Item 601 of Regulation S-K: The information called for by this paragraph is set forth in
Item 15(b) below.
(b) Exhibits filed.
10-K
Exhibit
Table
Item No.
3.1 	* Articles of Incorporation, Abbott Laboratories, filed as Exhibit 3.1 to the Abbott Laboratories Quarterly Report
on Form 10-Q for the quarter ended March 31, 1998.
3.2 	* By-Laws of Abbott Laboratories, as amended and restated effective April 24, 2020, filed as Exhibit 3.1 to the
Abbott Laboratories Current Report on Form 8-K dated February 21, 2020.
4.1 	* Indenture dated as of February 9, 2001, between Abbott Laboratories and The Bank of New York Mellon Trust
Company, N.A. (as successor to J.P. Morgan Trust Company, National Association, successor to Bank One
Trust Company, N.A.) (including form of Security), filed as Exhibit 4.1 to the Abbott Laboratories Registration
Statement on Form S-3 dated February 12, 2001.
4.2 	* Supplemental Indenture dated as of February 27, 2006, between Abbott Laboratories and The Bank of New
York Mellon Trust Company, N.A. (as successor to J.P. Morgan Trust Company, National Association), filed as
Exhibit 4.2 to the Abbott Laboratories Registration Statement on Form S-3 dated February 28, 2006.
4.3 	* Form of $1,000,000,000 6.150% Note due 2037, filed as Exhibit 99.6 to the Abbott Laboratories Current
Report on Form 8-K dated November 6, 2007.
4.4 	* Actions of the Authorized Officers with respect to Abbott’s 5.150% Notes due 2012, 5.600% Notes due 2017
and 6.150% Notes due 2037, filed as Exhibit 99.3 to the Abbott Laboratories Current Report on Form 8-K
dated November 6, 2007.
4.5 	* Form of $1,000,000,000 6.000% Note due 2039, filed as Exhibit 99.5 to the Abbott Laboratories Current
Report on Form 8-K dated February 26, 2009.
4.6 	* Actions of the Authorized Officers with respect to Abbott’s 5.125% Note due 2019 and 6.000% Note due 2039,
filed as Exhibit 99.3 to the Abbott Laboratories Current Report on Form 8-K dated February 26, 2009.

-- 90 of 409 --

90
10-K
Exhibit
Table
Item No.
4.7 	* Form of 2040 Note, filed as Exhibit 99.6 to the Abbott Laboratories Current Report on Form 8-K dated
May 27, 2010.
4.8 	* Actions of the Authorized Officers with respect to Abbott’s 2.70% Notes, 4.125% Notes and 5.30% Notes,
filed as Exhibit 99.3 to the Abbott Laboratories Current Report on Form 8-K dated May 27, 2010.
4.9 	* Indenture, dated as of March 10, 2015, between Abbott Laboratories and U.S. Bank National Association
(including form of Security), filed as Exhibit 4.1 to the Abbott Laboratories Current Report on Form 8-K dated
March 5, 2015.
4.10 	* Form of 2.550% Note due 2022, filed as Exhibit 99.5 to the Abbott Laboratories Current Report on Form 8-K
dated March 5, 2015.
4.11 	* Form of 2.950% Note due 2025, filed as Exhibit 99.6 to the Abbott Laboratories Current Report on Form 8-K
dated March 5, 2015.
4.12 	* Actions of the Authorized Officers with respect to Abbott’s 2.000% Notes, 2.550% Notes and 2.950% Notes,
filed as Exhibit 99.3 to the Abbott Laboratories Current Report on Form 8-K dated March 5, 2015.
4.13 	* Form of 3.400% Notes due 2023, filed as Exhibit 4.4 to the Abbott Laboratories Current Report on Form 8-K
dated November 22, 2016.
4.14 	* Form of 3.750% Notes due 2026, filed as Exhibit 4.5 to the Abbott Laboratories Current Report on Form 8-K
dated November 22, 2016.
4.15 	* Form of 4.750% Notes due 2036, filed as Exhibit 4.6 to the Abbott Laboratories Current Report on Form 8-K
dated November 22, 2016.
4.16 	* Form of 4.900% Notes due 2046, filed as Exhibit 4.7 to the Abbott Laboratories Current Report on Form 8-K
dated November 22, 2016.
4.17 	* Officers’ Certificate Pursuant to Sections 3.1 and 3.3 of the Indenture with respect to 2.350% Notes due 2019,
2.900% Notes due 2021, 3.400% Notes due 2023, 3.750% Notes due 2026, 4.750% Notes due 2036 and
4.900% Notes due 2046 (including forms of notes), filed as Exhibit 4.22 to the Abbott Laboratories 2016
Annual Report on Form 10-K.
4.18 	* Form of 3.875% Notes due 2025, filed as Exhibit 4.5 to the Abbott Laboratories Current Report on Form 8-K
dated March 22, 2017.
4.19 	* Form of 4.75% Notes due 2043, filed as Exhibit 4.6 to the Abbott Laboratories Current Report on Form 8-K
dated March 22, 2017.
4.20 	* Officers’ Certificate Pursuant to Sections 3.1 and 3.3 of the Indenture with respect to 2.000% Notes due 2018,
2.800% Notes due 2020, 3.25% Notes due 2023, 3.875% Notes due 2025, and 4.75% Notes due 2043
(including form of notes), filed as Exhibit 4.7 to the Abbott Laboratories Quarterly Report on Form 10-Q for
the period ended March 31, 2017.

-- 91 of 409 --

91
10-K
Exhibit
Table
Item No.
4.21 	† Indenture, dated as of July 28, 2009, between St. Jude Medical, LLC (successor to St. Jude Medical, Inc.) and
U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the St. Jude Medical, Inc. Current Report on
Form 8-K dated July 28, 2009.
4.22 	† Fourth Supplemental Indenture, dated as of April 2, 2013, between St. Jude Medical, LLC (successor to
St. Jude Medical, Inc.) and U.S. Bank National Association, as trustee, relating to St. Jude Medical, LLC’s
3.25% Senior Notes due 2023 and 4.75% Senior Notes due 2043 (including forms of notes), filed as
Exhibit 4.1 to the St. Jude Medical, Inc. Current Report on Form 8-K dated April 2, 2013.
4.23 	† Fifth Supplemental Indenture, dated as of September 23, 2015, between St. Jude Medical, LLC (successor to
St. Jude Medical, Inc.) and U.S. Bank National Association, as trustee, relating to St. Jude Medical, LLC’s
2.000% Senior Notes due 2018, 2.800% Senior Notes due 2020 and 3.875% Senior Notes due 2025, filed as
Exhibit 4.1 to the St. Jude Medical, Inc. Current Report on Form 8-K dated September 23, 2015.
4.24 	† Sixth Supplemental Indenture, dated as of January 4, 2017, among St. Jude Medical, Inc., St. Jude
Medical, LLC and U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the St. Jude Medical, LLC
Current Report on Form 8-K dated January 4, 2017.
4.25 	* Form of Seventh Supplemental Indenture between St. Jude Medical, LLC and U.S. Bank National Association,
as trustee, filed as Exhibit 4.3 to the Abbott Laboratories Registration Statement on Form S-4 dated
February 21, 2017.
4.26 	* Indenture dated September 27, 2018, among Abbott Ireland Financing DAC, as issuer, Abbott Laboratories, as
guarantor and U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the Abbott Laboratories
Current Report on Form 8-K dated September 27, 2018.
4.27 	* First Supplemental Indenture dated September 27, 2018, among Abbott Ireland Financing DAC, as issuer,
Abbott Laboratories, as guarantor, U.S. Bank National Association, as trustee, Elavon Financial Services DAC,
U.K. Branch, as paying agent and transfer agent, and Elavon Financial Services DAC, as registrar, filed as
Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-K dated September 27, 2018.
4.28 	* Second Supplemental Indenture dated November 19, 2019, among Abbott Ireland Financing DAC, as issuer,
Abbott Laboratories, as guarantor, U.S. Bank National Association, as trustee, and Elavon Financial Services
DAC, as paying agent, transfer agent and registrar, filed as Exhibit 4.2 to the Abbott Laboratories Current
Report on Form 8-K dated November 19, 2019.
4.29 	* Form of 0.875% Note due 2023 (included in Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-
K dated September 27, 2018).
4.30 	* Form of 1.500% Note due 2026 (included in Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-
K dated September 27, 2018).
4.31 	* Form of 0.100% Note due 2024 (included in Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-
K dated November 19, 2019).
4.32 	* Form of 0.375% Note due 2027 (included in Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-
K dated November 19, 2019).

-- 92 of 409 --

92
10-K
Exhibit
Table
Item No.
4.33 	* Officers’ Certificate Pursuant to Sections 3.1 and 3.3 of the Indenture with respect to 1.150% Notes due 2028
and 1.400% Notes due 2030, filed as Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-K dated
June 22, 2020.
4.34 	* Form of 1.150% Notes due 2028, filed as Exhibit 4.3 to the Abbott Laboratories Current Report on Form 8-K
filed on June 24, 2020 (included in Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-K dated
June 22, 2020).
4.35 	* Form of 1.400% Notes due 2030, filed as Exhibit 4.4 to the Abbott Laboratories Current Report on Form 8-K
filed on June 24, 2020 (included in Exhibit 4.2 to the Abbott Laboratories Current Report on Form 8-K dated
June 22, 2020).
Other debt instruments are omitted in accordance with Item 601(b)(4)(iii)(A) of Regulation S-K. Copies of
such agreements will be furnished to the Securities and Exchange Commission upon request.
4.36 	* Description of Registrant's Securities, filed as Exhibit 4.34 to the 2019 Abbott Laboratories Annual Report on
Form 10-K).
10.1 	* Supplemental Plan Abbott Laboratories Extended Disability Plan, filed as an exhibit (pages 50-51) to the 1992
Abbott Laboratories Annual Report on Form 10-K.**
10.2 	Abbott Laboratories Deferred Compensation Plan, as amended.**
10.3 	* Abbott Laboratories 401(k) Supplemental Plan, as amended and restated, filed as Exhibit 10.3 to the 2012
Abbott Laboratories Annual Report on Form 10-K.**
10.4 	* Abbott Laboratories Supplemental Pension Plan, as amended and restated, filed as Exhibit 10.4 to the 2014
Abbott Laboratories Annual Report on Form 10-K.**
10.5 	* 1986 Abbott Laboratories Management Incentive Plan, as amended and restated, filed as Exhibit 10.5 to the
2014 Abbott Laboratories Annual Report on Form 10-K.**
10.6 	* 1998 Abbott Laboratories Performance Incentive Plan, as amended, filed as Exhibit 10.6 to the 2014 Abbott
Laboratories Annual Report on Form 10-K.**
10.7 	* Rules for the 1998 Abbott Laboratories Performance Incentive Plan, as amended and restated, filed as
Exhibit 10.7 to the 2012 Abbott Laboratories Annual Report on Form 10-K.**
10.8 	* Abbott Laboratories 2009 Incentive Stock Program, as amended and restated, filed as Exhibit 10.9 to the 2014
Abbott Laboratories Annual Report on Form 10-K.**
10.9 	* Abbott Laboratories 2017 Incentive Stock Program (incorporated by reference to Exhibit B of Abbott’s
Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on
March 17, 2017).**
10.10 * Abbott Laboratories Non-Employee Directors’ Fee Plan, as amended and restated, filed as Exhibit 10.10 to the
2016 Abbott Laboratories Annual Report on Form 10-K.**

-- 93 of 409 --

93
10-K
Exhibit
Table
Item No.
10.11 * Form of Non-Employee Director Restricted Stock Unit Agreement under Abbott Laboratories 1996 Incentive
Stock Program, filed as Exhibit 10.2 to the Abbott Laboratories Current Report on Form 8-K dated
December 10, 2004.**
10.12 * Form of Non-Employee Director Non-Qualified Stock Option Agreement, filed as Exhibit 10.2 to the Abbott
Laboratories Current Report on Form 8-K dated April 24, 2009.**
10.13 * Form of Non-Employee Director Restricted Stock Unit Agreement, filed as Exhibit 10.3 to the Abbott
Laboratories Current Report on Form 8-K dated April 24, 2009.**
10.14 * Form of Non-Qualified Stock Option Agreement (ratably vested), filed as Exhibit 10.5 to the Abbott
Laboratories Current Report on Form 8-K dated April 24, 2009.**
10.15 * Form of Performance Restricted Stock Unit Agreement for foreign executive officers (annual performance
based), filed as Exhibit 10.40 to the 2013 Abbott Laboratories Annual Report on Form 10-K.**
10.16 * Form of Performance Restricted Stock Unit Agreement for foreign executive officers (interim performance
based), filed as Exhibit 10.42 to the 2013 Abbott Laboratories Annual Report on Form 10-K.**
10.17 * Form of Restricted Stock Unit Agreement for executive officers (cliff vested), filed as Exhibit 10.44 to the
2013 Abbott Laboratories Annual Report on Form 10-K.**
10.18 * Form of Restricted Stock Unit Agreement for foreign executive officers (cliff vested), filed as Exhibit 10.46 to
the 2013 Abbott Laboratories Annual Report on Form 10-K.**
10.19 * Form of Non-Employee Director Restricted Stock Unit Agreement, filed as Exhibit 10.47 to the 2013 Abbott
Laboratories Annual Report on Form 10-K.**
10.20 * Form of Non-Employee Director Restricted Stock Unit Agreement for foreign non-employee directors, filed as
Exhibit 10.48 to the 2013 Abbott Laboratories Annual Report on Form 10-K.**
10.21 * Form of Performance Restricted Stock Agreement for executive officers (annual performance based), filed as
Exhibit 10.53 to the 2013 Abbott Laboratories Annual Report on Form 10-K.**
10.22 * Form of Performance Restricted Stock Agreement for executive officers (interim performance based), filed as
Exhibit 10.55 to the 2013 Abbott Laboratories Annual Report on Form 10-K.**
10.23 * Form of Restricted Stock Agreement for executive officers (cliff vested), filed as Exhibit 10.57 to the 2013
Abbott Laboratories Annual Report on Form 10-K.**
10.24 * Form of Non-Qualified Stock Option Agreement, filed as Exhibit 10.58 to the 2013 Abbott Laboratories
Annual Report on Form 10-K.**
10.25 * Form of Non-Qualified Stock Option Agreement for executive officers, filed as Exhibit 10.59 to the 2013
Abbott Laboratories Annual Report on Form 10-K.**
10.26 * Form of Non-Qualified Stock Option Agreement for foreign employees, filed as Exhibit 10.60 to the 2013
Abbott Laboratories Annual Report on Form 10-K.**

-- 94 of 409 --

94
10-K
Exhibit
Table
Item No.
10.27 * Form of Non-Qualified Stock Option Agreement for foreign executive officers, filed as Exhibit 10.61 to the
2013 Abbott Laboratories Annual Report on Form 10-K.**
10.28 * Form of Non-Employee Director Non-Qualified Stock Option Agreement, filed as Exhibit 10.64 to the 2013
Abbott Laboratories Annual Report on Form 10-K.**
10.29 * Form of Non-Employee Director Non-Qualified Stock Option Agreement for foreign non-employee directors,
filed as Exhibit 10.65 to the 2013 Abbott Laboratories Annual Report on Form 10-K.**
10.30 * Form of Restricted Stock Unit Agreement (ratably vested) under the Abbott Laboratories 2017 Incentive Stock
Program, filed as Exhibit 10.2 to the Abbott Laboratories Current Report on Form 8-K dated April 28, 2017.**
10.31 * Form of Restricted Stock Unit Agreement for foreign employees (ratably vested) under the Abbott
Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.3 to the Abbott Laboratories Current Report on
Form 8-K dated April 28, 2017.**
10.32 * Form of Restricted Stock Unit Agreement (cliff vested) under the Abbott Laboratories 2017 Incentive Stock
Program, filed as Exhibit 10.4 to the Abbott Laboratories Current Report on Form 8-K dated April 28, 2017.**
10.33 * Form of Restricted Stock Unit Agreement for foreign employees (cliff vested) under the Abbott Laboratories
2017 Incentive Stock Program, filed as Exhibit 10.5 to the Abbott Laboratories Current Report on Form 8-K
dated April 28, 2017.**
10.34 * Form of Performance Restricted Stock Unit Agreement for foreign employees (annual performance based)
under the Abbott Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.6 to the Abbott Laboratories
Current Report on Form 8-K dated April 28, 2017.**
10.35 * Form of Performance Restricted Stock Unit Agreement for foreign employees (interim performance based)
under the Abbott Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.7 to the Abbott Laboratories
Current Report on Form 8-K dated April 28, 2017.**
10.36 * Form of Restricted Stock Agreement (ratably vested) under the Abbott Laboratories 2017 Incentive Stock
Program, filed as Exhibit 10.8 to the Abbott Laboratories Current Report on Form 8-K dated April 28, 2017.**
10.37 * Form of Restricted Stock Agreement (cliff vested) under the Abbott Laboratories 2017 Incentive Stock
Program, filed as Exhibit 10.9 to the Abbott Laboratories Current Report on Form 8-K dated April 28, 2017.**
10.38 * Form of Performance Restricted Stock Agreement (annual performance based) under the Abbott Laboratories
2017 Incentive Stock Program, filed as Exhibit 10.10 to the Abbott Laboratories Current Report on Form 8-K
dated April 28, 2017.**
10.39 * Form of Performance Restricted Stock Agreement (interim performance based) under the Abbott Laboratories
2017 Incentive Stock Program, filed as Exhibit 10.11 to the Abbott Laboratories Current Report on Form 8-K
dated April 28, 2017.**
10.40 * Form of Non-Qualified Stock Option Agreement under the Abbott Laboratories 2017 Incentive Stock Program,
filed as Exhibit 10.12 to the Abbott Laboratories Current Report on Form 8-K dated April 28, 2017.**

-- 95 of 409 --

95
10-K
Exhibit
Table
Item No.
10.41 * Form of Non-Qualified Stock Option Agreement for foreign employees under the Abbott Laboratories 2017
Incentive Stock Program, filed as Exhibit 10.13 to the Abbott Laboratories Current Report on Form 8-K dated
April 28, 2017.**
10.42 * Form of Restricted Stock Unit Agreement for executive officers (cliff vested) under the Abbott Laboratories
2017 Incentive Stock Program, filed as Exhibit 10.14 to the Abbott Laboratories Current Report on Form 8-K
dated April 28, 2017.**
10.43 * Form of Restricted Stock Unit Agreement for foreign executive officers (cliff vested) under the Abbott
Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.15 to the Abbott Laboratories Current Report
on Form 8-K dated April 28, 2017.**
10.44 * Form of Performance Restricted Stock Unit Agreement for foreign executive officers (annual performance
based) under the Abbott Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.16 to the Abbott
Laboratories Current Report on Form 8-K dated April 28, 2017.**
10.45 * Form of Performance Restricted Stock Unit Agreement for foreign executive officers (interim performance
based) under the Abbott Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.17 to the Abbott
Laboratories Current Report on Form 8-K dated April 28, 2017.**
10.46 * Form of Restricted Stock Agreement for executive officers (ratably vested) under the Abbott Laboratories 2017
Incentive Stock Program, filed as Exhibit 10.18 to the Abbott Laboratories Current Report on Form 8-K dated
April 28, 2017.**
10.47 * Form of Restricted Stock Agreement for executive officers (cliff vested) under the Abbott Laboratories 2017
Incentive Stock Program, filed as Exhibit 10.19 to the Abbott Laboratories Current Report on Form 8-K dated
April 28, 2017.**
10.48 * Form of Performance Restricted Stock Agreement for executive officers (annual performance based) under the
Abbott Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.20 to the Abbott Laboratories Current
Report on Form 8-K dated April 28, 2017.**
10.49 * Form of Performance Restricted Stock Agreement for executive officers (interim performance based) under the
Abbott Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.21 to the Abbott Laboratories Current
Report on Form 8-K dated April 28, 2017.**
10.50 * Form of Non-Qualified Stock Option Agreement for executive officers under the Abbott Laboratories 2017
Incentive Stock Program, filed as Exhibit 10.22 to the Abbott Laboratories Current Report on Form 8-K dated
April 28, 2017.**
10.51 * Form of Non-Qualified Stock Option Agreement for foreign executive officers under the Abbott Laboratories
2017 Incentive Stock Program, filed as Exhibit 10.23 to the Abbott Laboratories Current Report on Form 8-K
dated April 28, 2017.**
10.52 * Form of Non-Employee Director Restricted Stock Unit Agreement under the Abbott Laboratories 2017
Incentive Stock Program, filed as Exhibit 10.24 to the Abbott Laboratories Current Report on Form 8-K dated
April 28, 2017.**

-- 96 of 409 --

96
10-K
Exhibit
Table
Item No.
10.53 * Form of Non-Employee Director Restricted Stock Unit Agreement for foreign non-employee directors under
the Abbott Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.25 to the Abbott Laboratories
Current Report on Form 8-K dated April 28, 2017.**
10.54 * Form of Non-Employee Director Non-Qualified Stock Option Agreement under the Abbott Laboratories 2017
Incentive Stock Program, filed as Exhibit 10.26 to the Abbott Laboratories Current Report on Form 8-K dated
April 28, 2017.**
10.55 * Form of Non-Employee Director Non-Qualified Stock Option Agreement for foreign non-employee directors
under the Abbott Laboratories 2017 Incentive Stock Program, filed as Exhibit 10.27 to the Abbott Laboratories
Current Report on Form 8-K dated April 28, 2017.**
10.56 	Form of Performance Restricted Stock Unit Agreement for foreign employees (annual performance based)
under the Abbott Laboratories 2017 Incentive Stock Program.**
10.57 	Form of Performance Restricted Stock Unit Agreement for foreign employees (interim performance based)
under the Abbott Laboratories 2017 Incentive Stock Program.**
10.58 	Form of Performance Restricted Stock Agreement (annual performance based) under the Abbott Laboratories
2017 Incentive Stock Program.**
10.59 	Form of Performance Restricted Stock Agreement (interim performance based) under the Abbott Laboratories
2017 Incentive Stock Program.**
10.60 	Form of Performance Restricted Stock Unit Agreement for foreign executive officers (annual performance
based) under the Abbott Laboratories 2017 Incentive Stock Program.**
10.61 	Form of Performance Restricted Stock Unit Agreement for foreign executive officers (interim performance
based) under the Abbott Laboratories 2017 Incentive Stock Program.**
10.62 	Form of Performance Restricted Stock Agreement for executive officers (annual performance based) under the
Abbott Laboratories 2017 Incentive Stock Program.**
10.63 	Form of Performance Restricted Stock Agreement for executive officers (interim performance based) under the
Abbott Laboratories 2017 Incentive Stock Program.**
10.64 * Form of Agreement Regarding Change in Control by and between Abbott Laboratories and its named
executive officers (other than Mr. White), filed as Exhibit 10.1 to the Abbott Laboratories Current Report on
Form 8-K dated November 30, 2012.**
10.65 * Form of Extension of Agreement Regarding Change in Control by and between Abbott Laboratories and its
named executive officers (other than Mr. White), extending the agreement term to December 31, 2020, filed as
Exhibit 10.74 to the 2018 Abbott Laboratories Annual Report on Form 10-K.**
10.66 	Form of Extension of Agreement Regarding Change in Control by and between Abbott Laboratories and its
named executive officers (other than Mr. White), extending the agreement term to December 31, 2022.**
10.67 * Form of Time Sharing Agreement between Abbott Laboratories Inc. and M.D. White, filed as Exhibit 10.6 to
the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended June 30, 2006.**

-- 97 of 409 --

97
10-K
Exhibit
Table
Item No.
10.68 	Form of Time Sharing Agreement between Abbott Laboratories Inc. and Robert B. Ford.**
10.69 † St. Jude Medical, Inc. 2007 Stock Incentive Plan, as amended and restated (2014), filed as Exhibit 10.22 to
St. Jude Medical, Inc. Annual Report on Form 10-K for the year ended January 3, 2015 dated February 26,
2015.**
10.70 † Form of Non-Qualified Stock Option Agreement (Global) and related Notice of Non-Qualified Stock Option
Grant for stock options granted on or after December 10, 2012 under the St. Jude Medical, Inc. 2007 Stock
Incentive Plan, filed as Exhibit 10.24 to the St. Jude Medical, Inc. Annual Report on Form 10-K for the year
ended December 29, 2012 dated February 26, 2013.**
10.71 † Form of Non-Qualified Stock Option Agreement for Non-Employee Directors and related Notice of Non-
Qualified Stock Option Grant for stock options granted on or after December 10, 2012 under the St. Jude
Medical, Inc. 2007 Stock Incentive Plan, filed as Exhibit 10.25 to the St. Jude Medical, Inc. Annual Report on
Form 10-K for the year ended December 29, 2012, dated February 26, 2013.**
10.72 † Form of Restricted Stock Units Award Agreement (Global) and related Restricted Stock Units Award
Certificate for restricted stock units granted on or after December 10, 2012 under the St. Jude Medical, Inc.
2007 Stock Incentive Plan, filed as Exhibit 10.27 to the St. Jude Medical, Inc. Annual Report on Form 10-K
for the year ended December 29, 2012, dated February 26, 2013.**
10.73 * Management Savings Plan, as amended and restated, filed as Exhibit 10.75 to the 2019 Abbott Laboratories
Annual Report on Form 10-K).**
10.74 	Abbott Overseas Managers Pension Plan, as amended and restated.**
10.75 	Five Year Credit Agreement, dated as of November 12, 2020, among Abbott Laboratories, as borrower, various
financial institutions, as lenders, and JPMorgan Chase Bank, N.A., as administrative agent.
21 	Subsidiaries of Abbott Laboratories.
23.1 	Consent of Independent Registered Public Accounting Firm.
31.1 	Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
31.2 	Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities
Exchange Act of 1934.
32.1 	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.

-- 98 of 409 --

98
10-K
Exhibit
Table
Item No.
101 	The following financial statements and notes from the Abbott Laboratories Annual Report on Form 10-K for
the year ended December 31, 2020 filed on February 19, 2021, formatted in Inline XBRL: (i) Consolidated
Statement of Earnings; (ii) Consolidated Statement of Comprehensive Income; (iii) Consolidated Statement of
Cash Flows; (iv) Consolidated Balance Sheet; (v) Consolidated Statement of Shareholders’ Investment; and
(vi) the notes to the consolidated financial statements.
104 	Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and
included in Exhibit 101).
* Incorporated herein by reference. Commission file number 1-2189.
** Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
† Incorporated herein by reference. Commission file number 1-12441.
Abbott will furnish copies of any of the above exhibits to a shareholder upon written request to the Secretary, Abbott
Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.
(c) Financial Statement Schedule filed (page 101).
ITEM 16. FORM 10-K SUMMARY
None.

-- 99 of 409 --

99
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Abbott Laboratories has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ABBOTT LABORATORIES
By /s/ ROBERT B. FORD
Robert B. Ford
President and Chief Executive Officer
Date:February 19, 2021
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of Abbott Laboratories on February 19, 2021 in the capacities indicated below.
/s/ ROBERT B. FORD 	/s/ ROBERT E. FUNCK, JR.
Robert B. Ford 	Robert E. Funck, Jr.
President and Chief Executive Officer,
and Director of Abbott Laboratories
(principal executive officer)
Executive Vice President, Finance
and Chief Financial Officer
(principal financial officer)
/s/ PHILIP P. BOUDREAU 	/s/ MILES D. WHITE
Philip P. Boudreau 	Miles D. White
Vice President, Finance and Controller
(principal accounting officer)
Executive Chairman of the Board
/s/ ROBERT J. ALPERN 	/s/ ROXANNE S. AUSTIN
Robert J. Alpern, M.D. 	Roxanne S. Austin
Director of Abbott Laboratories 	Director of Abbott Laboratories
/s/ SALLY E. BLOUNT 	/s/ MICHELLE A. KUMBIER
Sally E. Blount, Ph.D. 	Michelle A. Kumbier
Director of Abbott Laboratories 	Director of Abbott Laboratories
/s/ EDWARD M. LIDDY 	/s/ DARREN W. MCDEW
Edward M. Liddy
Director of Abbott Laboratories
Darren W. McDew
Director of Abbott Laboratories
/s/ NANCY MCKINSTRY 	/s/ PHEBE N. NOVAKOVIC
Nancy McKinstry 	Phebe N. Novakovic
Director of Abbott Laboratories 	Director of Abbott Laboratories
/s/ WILLIAM A. OSBORN 	/s/ DANIEL J. STARKS
William A. Osborn 	Daniel J. Starks
Director of Abbott Laboratories 	Director of Abbott Laboratories

-- 100 of 409 --

100
/s/ JOHN G. STRATTON 	/s/ GLENN F. TILTON
John G. Stratton 	Glenn F. Tilton
Director of Abbott Laboratories 	Director of Abbott Laboratories

-- 101 of 409 --

101
ABBOTT LABORATORIES AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
FOR THE YEARS ENDED DECEMBER 31, 2020, 2019 AND 2018
(in millions of dollars)
Amounts
Balance 	Provisions/ Charged Off
Allowances for Doubtful 	at Beginning Charges 	and Other 	Balance at
Accounts and Product Returns 	of Year 	to Income Deductions End of Year
2020 	$ 	384 $ 187 $ 	(111) $ 	460
2019 	314 	137 	(68) 	384
2018 	294 	110 	(90) 	314

-- 102 of 409 --

102
Report of Independent Registered Public Accounting Firm
To the Shareholders and Board of Directors of Abbott Laboratories
Opinion on the Financial Statement Schedule
We have audited the consolidated financial statements of Abbott Laboratories and subsidiaries (the Company) as of
December 31, 2020 and 2019, for each of the three years in the period ended December 31, 2020, and have issued our
report thereon dated February 19, 2021 (included elsewhere in this Annual Report on Form 10-K). Our audits of the
consolidated financial statements included the financial statement schedule listed in Item 15(a)(2) of this Annual Report on
Form 10-K (the “schedule”). This schedule is the responsibility of the Company’s management. Our responsibility is to
express an opinion on the Company’s schedule, based on our audits.
In our opinion, the schedule presents fairly, in all material respects, the information set forth therein when considered in
conjunction with the consolidated financial statements.
/s/ Ernst & Young LLP
Chicago, Illinois
February 19, 2021

-- 103 of 409 --

1
Exhibit 10.2
ABBOTT LABORATORIES
DEFERRED COMPENSATION PLAN
ARTICLE I
Introduction
Section 1.1 	Purpose. The Plan is designed to assist the Employers in attracting and retaining key employees by providing
those employees with the opportunity to defer the receipt of a portion of their compensation and to have that deferred compensation
treated as if it were invested pending its distribution by the Plan.
Section 1.2 	ERISA. The Plan is intended to be exempt from Parts 2, 3, and 4 of Title I of ERISA and, therefore,
participation in the Plan is limited to a select group of management and highly compensated employees, within the meaning of Sections
201(2), 301(a)3 and 401(a)(1) of ERISA.
Section 1.3 	Employers.
(a) 	After the Effective Date, any Subsidiary of the Company that is not then an Employer may adopt the Plan with the
Company’s consent as described in Section 13.12.
(b) 	Each Employer shall be liable to the Company for an amount equal to the Plan benefits earned by its Eligible
Employees. Where an Eligible Employee has been employed by more than one Employer, the Plan Administrator shall allocate the
liability to the Company associated with that Eligible Employee’s Plan benefits among his or her Employers. The Plan Administrator
shall establish procedures for determining the time at which and manner in which the Employers shall pay this liability to the Company.
Section 1.4 	Grandfathered Amounts. Notwithstanding anything in this Plan to the contrary, any amounts under this Plan
that were earned and vested before January 1, 2005 (as determined in accordance with Code Section 409A) (“Grandfathered Amounts”)
shall be subject to the terms and conditions of the Plan as administered and as in effect on October 3, 2004. Amendments made to the
Plan pursuant to this amendment and restatement or otherwise shall not affect the Grandfathered Amounts unless expressly provided for
in the amendment. The terms and conditions applicable to the Grandfathered Amounts are set forth in Appendix A attached hereto.
Section 1.5 	Effective Date. The Plan has been amended and restated, effective as of January 1, 2021.
ARTICLE II
Definitions
When used in this Plan, unless the context clearly requires a different meaning, the following words and terms shall have the meanings
set forth below. Whenever appropriate, words used in the singular shall be deemed to include the plural, and vice versa, and the
masculine gender shall be deemed to include the feminine gender.
Section 2.1 	Account. “Account(s)” means the account(s) established for record keeping purposes for each Participant
pursuant to Article VI.
Section 2.2 	Base Compensation. “Base Compensation” means the Participant’s total compensation earned in a Plan Year
for personal service actually rendered to an Employer, including sales bonuses, sales incentives and sales commissions (excluding
Eligible Bonuses, all other bonuses, commissions, relocation expenses, reimbursements, expense allowances, fringe benefits (cash or
noncash), welfare benefits (whether or not those amounts are includible in gross income) and other non-regular forms of compensation)
before deductions for (i) Deferral Elections made pursuant to Section 4.1 or (ii) contributions made on the Participant’s behalf to any
Employer 401(k) Plan or to any cafeteria plan under Section 125 of the Internal Revenue Code of 1986, as amended (the “Code”)
maintained by an Employer. Notwithstanding the foregoing, the Plan Administrator or its delegate may designate amounts to be included
in or excluded from Base Compensation.

-- 104 of 409 --

2
Section 2.3 	Beneficiary. “Beneficiary” means the person, persons or entity designated by the Participant to receive any
benefits payable under the Plan pursuant to Article IX.
Section 2.4 	Board of Review. “Board of Review” means the Abbott Laboratories Employee Benefit Board of Review
appointed and acting under the Abbott Laboratories Annuity Retirement Plan and having the powers and duties described in this Plan.
Section 2.5 	Company. “Company” means Abbott Laboratories, its successors, any organization into which or with which
Abbott Laboratories may merge or consolidate or to which all or substantially all of its assets may be transferred.
Section 2.6 	Deferral Election. “Deferral Election” means an election under the Plan by a Participant to defer the receipt
of a portion of his or her Eligible Compensation made on a Deferral Election Form.
Section 2.7 	Deferral Election Form. “Deferral Election Form” means the form provided to the Participant by the Plan
pursuant to Section 4.1 on which the Participant makes his or her Deferral Election.
Section 2.8 	Deferral Account. “Deferral Account(s)” means the account(s) established for record keeping purposes for
each Participant’s Deferral Election pursuant to Section 6.1.
Section 2.9 	Disability. The date of “Disability” of a Participant means that, the date on which the Participant is, by reason
of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a
continuous period of not less than twelve months, eligible to receive income replacement benefits under the terms of the Abbott
Laboratories Extended Disability Plan (“EDP”) or, for a Participant whose Employer does not participate in the EDP, such similar
accident and health plan, providing income replacement benefits, in which his or her Employer participates, for a period of six months.
Section 2.10 	Distribution Election. “Distribution Election” is defined in Section 4.3(a).
Section 2.11 	Distribution Election Form. “Distribution Election Form” means the form provided to the Participant by the
Plan pursuant to Section 4.3 on which the Participant specifies the time at which the amounts credited to one of the Participant’s
Account(s) are to be distributed and their method of payment.
Section 2.12 	Effective Date. “Effective Date” is defined in Section 1.5.
Section 2.13 	Eligibility Date. “Eligibility Date” is defined in Section 3.1(b).
Section 2.14 	Eligible Bonus. “Eligible Bonus” means an annual cash incentive bonus for a Plan Year that the Plan
Administrator, or its delegate, has designated as being eligible for deferral under the Plan. As of the Effective Date, cash bonuses paid
under the Abbott Laboratories Cash Profit Sharing Plan or any Employer’s annual incentive bonus plan with a performance period
commencing on January 1 and ending on December 31 of the applicable Plan Year are eligible for deferral under the Plan.
Section 2.15 	Eligible Compensation. “Eligible Compensation” means the Participant’s Base Compensation and Eligible
Bonuses.
Section 2.16 	Eligible Employee. “Eligible Employee” means any person employed by an Employer who is both
(i) 	a United States employee or an expatriate who is based and paid in the United States, and
(ii) 	shown as having a grade level of 20 (or equivalent level of compensation if on a different pay grade system) or higher
on his or her Employer’s Human Resource System

-- 105 of 409 --

3
and who is not (a) both an officer of the Company and eligible to participate in the Abbott Laboratories 401(k) Supplemental Plan,
except as contemplated by Section 3.1 hereof for the Plan Year in which the person is first named an officer, (b) an individual who
provides services to an Employer under a contract, arrangement or understanding with either the individual directly or with an agency or
leasing organization that treats the individual as either an independent contractor or an employee of such agency or leasing organization,
even if such individual is subsequently determined (by an Employer, the Internal Revenue Service, any other governmental agency,
judicial action, or otherwise) to have been a common law employee of an Employer rather than an independent contractor or employee of
such agency or leasing organization, or (c) any Employee who is employed by an Employer located in Puerto Rico, other than any person
designated as a “U.S. Expatriate” on the records of an Employer.
For all Plan purposes, an individual shall be an “Eligible Employee” for any Plan Year only if during that Plan Year an Employer treats
that individual as its employee for purposes of employment taxes and wage withholding for Federal income taxes, even if such individual
is subsequently determined (by an Employer, the Internal Revenue Service, any other governmental agency, judicial action, or otherwise)
to have been a common law employee of an Employer in that Plan Year.
Section 2.17 	Employer. “Employer” shall mean the Company, the participating Employers on the Effective Date, and any
Subsidiary of the Company that subsequently adopts the Plan in the manner provided in Section 13.12.
Section 2.18 	Employer Contribution. “Employer Contribution” means the contribution deemed to have been made by an
Employer pursuant to Section 5.1.
Section 2.19 	Employer Contribution Account. “Employer Contribution Account(s)” means the account(s) established for
record keeping purposes for each Participant’s Employer Contributions pursuant to Section 6.1.
Section 2.20 	Employer 401(k) Plan. “Employer 401(k) Plan” means any defined contribution retirement plan that is
maintained by an Employer, qualified under Code Section 401(a), and includes a cash or deferred arrangement under Code
Section 401(k). The term shall specifically include, but not be limited to, the Abbott Laboratories 401(k) Plan and the Abbott
Laboratories Stock Retirement Plan.
Section 2.21 	ERISA. “ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
Section 2.22 	Hardship Distribution. “Hardship Distribution” is defined in Section 8.5(a).
Section 2.23 	In-Service Distribution. “In-Service Distribution” is defined in Section 4.3.
Section 2.24 	Initial Election. “Initial Election” is defined in Section 4.3(a).
Section 2.25 	Investment Election. “Investment Election” is defined in Section 4.2(a).
Section 2.26 	Investment Election Form. “Investment Election Form” means the form provided to the Participant by the
Plan pursuant to Section 4.2 on which the Participant specifies the Investment Funds in which the Participant’s Account(s) are to be
deemed to be invested.
Section 2.27 	Investment Fund(s). “Investment Fund(s)” means one or more of the funds selected by the Plan
Administrator pursuant to Section 4.2.
Section 2.28 	Investment Fund Subaccounts. “Investment Fund Subaccounts” is defined in Section 6.1(b).
Section 2.29 	Matching DCP Deferral. “Matching DCP Deferral” for a Participant for a Plan Year is an amount equal to the
total dollar amount of the Participant’s deferrals for the Plan Year pursuant to Employee Deferral Elections under Section 4.1(b), but in
no event shall a Participant’s Matching DCP Deferral for a Plan Year

-- 106 of 409 --

4
exceed the amount by which (a) the Participant’s Base Compensation for the Plan Year up to the limit on compensation as defined in
Code Section 401(a)(17) exceeds (b) the Participant’s Base Compensation for the Plan Year less the total dollar amount deferred pursuant
to Employee Deferral Elections under Section 4.1(b) for the Plan Year.
Section 2.30 	Participant. “Participant” means any Eligible Employee who elects to participate in this Plan by filing a
Deferral Election, Investment Fund Election, and Distribution Election as provided in Article IV.
Section 2.31 	Plan. “Plan” means the Abbott Laboratories Deferred Compensation Plan.
Section 2.32 	Plan Administrator. “Plan Administrator” means the Board of Review.
Section 2.33 	Plan Year. “Plan Year” means a twelve-month period beginning January 1 and ending the following
December 31.
Section 2.34 	Rate of Return. “Rate of Return” means, for each Investment Fund, an amount equal to the net gain or net
loss (expressed as a percentage) on the assets of that Investment Fund.
Section 2.35 	Retirement. “Retirement” means a Termination of Employment after having satisfied the age and service
requirements of (a), (b), or (c) below, as applicable:
(a) 	for the Participant hired before 2004, the date on which the Participant attains age 50 and completes 10 years of vesting
service; or
(b) 	for the Participant hired after 2003, the date on which the Participant attains age 55 and completes 10 years of vesting
service; or age 65; or
(c) 	with respect to a Participant covered by Supplement I of the Abbott Laboratories Annuity Retirement Plan (“ARP”) as
Abbott Retained Employees (as such term is defined in the ARP), the date on which the Participant attains age 55 and completes 5 years
of vesting service (as such term is described in the AbbVie Pension Plan for Former BASF and Former Solvay Employees).
For purposes of this Section 2.35, “vesting service” shall have the meaning set forth in the ARP for a Participant who is covered
by the ARP, and shall have the meaning set forth in the Employer 401(k) Plan in which the Participant is eligible to participate for a
Participant who is not covered by the ARP. Except as otherwise provided by the Administrator, for purposes of this Section 2.35, the
hire date of any employee of a business entity, part or all of which is or was acquired by or becomes a part of, a participating employer,
will be considered the date that the business entity was acquired by or became a part of the participating employer, and vesting service
prior to such date shall be credited only to the extent provided by the Administrator.
Section 2.36 	Subsequent Election. “Subsequent Election” is defined in Section 4.2(a).
Section 2.37 	Subsidiary. “Subsidiary” shall mean any corporation, limited liability company, partnership, joint venture, or
business trust organized in the United States 50 percent or more of the voting stock of which is owned, directly or indirectly, by the
Company.
Section 2.38 	Termination of Employment. “Termination of Employment” means the cessation of a Participant’s services as
an employee, whether voluntary or involuntary, for any reason other than death; provided, that the Participant shall not be considered to
have terminated employment for purposes of the Plan until he or she would be considered to have incurred a “separation from service”
from the Employer within the meaning of Code Section 409A.
Section 2.39 	Unforeseeable Emergency. “Unforeseeable Emergency” means a severe financial hardship to the Participant
resulting from an illness or accident of the Participant, the Participant’s spouse or a dependent of the Participant, loss of the Participant’s
property due to casualty (including the need to rebuild a home

-- 107 of 409 --

5
following damage to a home not otherwise covered by insurance, for example, not as a result of a natural disaster), or other similar
extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant as determined by the
Plan Administrator.
ARTICLE III
Participation
Section 3.1 	Participation.
(a) 	Except as provided in Sections 3.1(b) and (c), an Eligible Employee may become a Participant by making a Deferral
Election, Investment Fund Election, and Distribution Election pursuant to Article IV on or before the deadline set by the Plan
Administrator pursuant to Section 4.4.
(b) 	A newly hired individual who is an Eligible Employee shall become eligible to participate in the Plan on the first day
of the month next following the month after the individual’s date of hire (the “Eligibility Date”); provided, that in no event shall such
individual begin to participate in the plan later than 90 days following his or her date of hire. Notwithstanding the election requirements
of Section 3.1(a), a newly Eligible Employee who was not eligible to participate in any other plan that would be aggregated with the Plan
under Treasury Regulation §1.409A-1(c) may make a Deferral Election, Investment Fund Election and Distribution Election pursuant
to Article IV within the thirty (30) day period immediately following the Eligibility Date and in accordance with applicable law and the
rules and procedures set by the Plan Administrator. Any such election shall become irrevocable for the remainder of the Plan Year as of
the end of the thirty (30) day period immediately following the Eligibility Date, and shall be effective as of the first payroll period
commencing after the end of such 30-day period.
(c) 	An individual who becomes an Eligible Employee as a result of a job promotion or transfer may only make a Deferral
Election, Investment Fund Election and Distribution Election pursuant to Article IV with respect to Eligible Compensation to be earned
in the Plan Year next following the year of such promotion or transfer. Any such election shall be made in accordance
with Article IV and shall become effective for Eligible Compensation earned in the Plan Year following the year in which the election is
made.
(d) 	An Eligible Employee of the Rapid Diagnostics division on the Effective Date may make a Deferral Election,
Investment Fund Election and Distribution Election pursuant to Article IV within the thirty (30) day period immediately following the
Effective Date. Any such election shall become irrevocable as of the end of such thirty (30) day period for the rest of the Plan Year, and
shall become effective for Base Compensation as of the first payroll period commencing after the end of such thirty (30) day period, and
shall be effective for the Eligible Employee’s Eligible Bonus earned for such Plan Year.
Section 3.2 	Termination of Participation. A Participant who ceases to be an Eligible Employee due to a Termination of
Employment will remain a Participant but (i) may no longer make Deferral Elections with respect to any Plan Year following the year of
such termination and (ii) all deferrals under the Plan shall cease as of the date of the Participant’s Termination of Employment. A
Participant who ceases to be an Eligible Employee due to a job promotion (or demotion) may no longer make Deferral Elections with
respect to any Plan Year following the year of such promotion or demotion but the Participant’s Deferral Elections for the Plan Year in
which such promotion or demotion occurs shall remain irrevocable. A Participant shall remain a Participant until (i) his or her death or
(ii) his or her Accounts have been distributed.

-- 108 of 409 --

6
ARTICLE IV
Election Forms
Section 4.1 	Deferral Elections.
(a) 	Participants shall make their Deferral Elections annually on a form provided by the Plan Administrator (a “Deferral
Election Form”). Each Deferral Election shall apply to only a single Plan Year.
(b) 	On his or her Deferral Election Form, the Participant shall specify the amount (expressed as a percentage) of his or her
Base Compensation and the amount (also expressed as a percentage) of his or her Eligible Bonuses that the Participant elects to defer for
that Plan Year together with such other information as the Plan Administrator may, in its sole and absolute discretion, require.
(c) 	For any Plan Year, a Participant may elect to defer:
(i) 	between five percent (5%) and seventy-five percent (75%) of his or her Base Compensation (in whole
percentage increments), and
(ii) 	between five percent (5%) and one hundred percent (100%) of his or her Eligible Bonus (in whole percentage
increments);
provided, however, that in no event may a Participant elect to defer his or her Eligible Compensation to the extent that his or her
remaining compensation would be insufficient to satisfy all applicable withholding taxes and contributions required under Employer
sponsored benefit plans in which the Participant participates.
(d) 	A Participant may revoke his or her Deferral Election and file a subsequent Deferral Election at any time prior to the
deadline for the receipt of election forms set by the Plan Administrator pursuant to Section 4.4. The latest Deferral Election filed prior to
such deadline shall take effect for the applicable Plan Year, and all prior Deferral Elections shall be considered null and void. A
Participant may not revoke his or her Deferral Election at any time after the deadline for making such Deferral Election set by the Plan
Administrator pursuant to Section 4.4. Notwithstanding the foregoing, an Eligible Employee who submits a deferral election for the
same Plan Year under any other nonqualified deferred compensation plan maintained by the Company or any Subsidiary shall be deemed
to have revoked any Deferral Election previously filed under the Plan, and all prior Deferral Elections shall be considered null and void;
provided, that such other deferral election must be submitted in accordance with the rules of such other plan and in any event no later
than December 31 immediately preceding the Plan Year for which it is to be effective, and any Deferral Election filed under the Plan
subsequent to such other plan deferral election shall render such other plan deferral election null and void.
Section 4.2 	Investment Elections. The Plan Administrator shall, from time to time, make available investment options
(the “Investment Funds”) that serve as benchmark funds for the amounts a Participant defers under the Plan. A Participant’s Plan
deferrals shall not actually be invested in the Investment Funds and the Participant shall not be considered a shareholder of any of the
Investment Funds he or she selects by virtue of participation in the Plan. Instead, the Participant’s Plan deferrals shall be considered
invested in, and his or her Plan Account shall reflect such Investment Fund’s Rate of Return. A Participant’s election of investments shall
be subject to the following rules:
(a) 	Participants shall make their investment elections on an Investment Election Form provided by the Plan Administrator
(an “Investment Election”).
(b) 	The Investment Election Form completed by the Participant shall apply only to the Eligible Compensation being
deferred in a single Plan Year and shall specify the Investment Funds in which the deferrals for each such Plan Year are to be deemed to
be invested, and the portion (expressed in whole percentage increments) of the deferrals for such Plan Year that are to be deemed to be
invested in each such Investment Fund, and shall continue in effect until revoked or changed as permitted by the Plan Administrator.

-- 109 of 409 --

7
Section 4.3 	Distribution Elections.
(a) 	Participants shall make their distribution elections in accordance with the Distribution Election Form provided by the
Plan Administrator (a “Distribution Election”) as permitted or required by such form. Each Distribution Election (the “Initial Election”)
shall apply only to the Eligible Compensation being deferred in a single Plan Year and must be made by the deadline set by the Plan
Administrator pursuant to Section 4.4, at which time the Initial Election shall be irrevocable, subject to Section 4.3(c).
(b) 	On the Distribution Election Form:
(i) 	Mandatory Retirement Election. In all cases, the Participant shall select the method of payment from among
the methods of payment described in Section 8.3(a) to apply in the event payment is made upon Retirement
pursuant to this Distribution Election in accordance with Sections 8.3 or 8.4 or upon Disability in accordance
with Section 8.7.
(ii) 	Optional In-Service Distribution Election. The Participant shall also have the option to elect that the Eligible
Compensation being deferred for that Plan Year shall be paid to the Participant while he or she is still
employed by an Employer (an “In-Service Distribution”). If the Participant elects to receive an In-Service
Distribution of the Eligible Compensation being deferred, then the Participant shall also select the year in
which the payments are to be made. A Participant may not elect to receive an In-Service Distribution in a
Plan Year that is less than two (2) years after the end of the Plan Year in which the Eligible Compensation is
earned.
(c) 	Notwithstanding anything to the contrary in Section 4.3, a Participant may change the form of distribution or his or her
Distribution Election (a “Subsequent Election”) to the extent permitted by the Plan Administrator and Code Section 409A(a)(4)(C),
including the requirements that such Subsequent Election:
(i) 	shall not take effect until at least 12 months after the date on which the Subsequent Election is filed with the
Plan Administrator;
(ii) 	shall result in the first distribution subject to such Subsequent Election being made at least five years after the
date such distribution would otherwise have been paid pursuant to the previous election; and
(iii) 	shall be filed with the Plan Administrator at least 12 months before the date the first scheduled distribution is
to be paid pursuant to the previous election.
Section 4.4 	Deadline for Submitting Election Forms. The Plan Administrator may set a deadline or deadlines for the
receipt of the election forms required under the Plan; provided, however, that, except as provided in Section 3.1(b) or (d), such forms
must be filed on or before the end of the year immediately preceding the Plan Year for which it is to be effective.
ARTICLE V
Employer Contributions
Section 5.1 	Employer Contributions. Each Participant who makes a Deferral Election will be credited with an Employer
Contribution equal to 5% of the Participant’s Matching DCP Deferral. The Plan Administrator may, however, in his or her discretion,
otherwise set the amount of the Employer Contribution, subject to and not in excess of applicable limits imposed by the Internal Revenue
Service.
Section 5.2 	Allocation of Employer Contributions. A Participant’s Employer Contribution for a Plan Year shall be
allocated among the same Investment Funds and in the same proportion as the Participant has elected for his or her deferrals for that Plan
Year.

-- 110 of 409 --

8
Section 5.3 	Distribution of Employer Contributions. An Employer Contribution for a Plan Year shall be distributed to the
Participant according to the election made by the Participant governing his or her deferrals for that same Plan Year.
ARTICLE VI
Maintenance and Crediting of Accounts
Section 6.1 	Maintenance of Accounts.
(a) 	The Plan shall maintain a separate Account for each Deferral Election (a “Deferral Account”) made by and each
Employer Contribution (an “Employer Contribution Account”) made for a Participant. A Participant’s Accounts shall reflect the
Participant’s Investment Fund Elections and Distribution Elections made pursuant to Article IV, any Employer Contributions made on
behalf of the Participant pursuant to Article V, adjustments to the Account made pursuant to this Article VI, and distributions made with
respect to the Account pursuant to Article VIII. The Accounts shall be used solely as a device for the measurement and determination of
the amounts to be paid to the Participants pursuant to this Plan and shall not constitute or be treated as a trust fund of any kind.
(b) 	Each Account shall be divided into separate subaccounts (“Investment Fund Subaccounts”), each of which corresponds
to the Investment Fund selected by the Participant pursuant to Section 4.2(b).
Section 6.2 	Crediting of Accounts.
(a) 	No later than five (5) business days following the end of each pay period, the Plan shall credit each Participant’s
Investment Fund Subaccounts to reflect amounts deferred from the Participant’s Eligible Compensation during that pay period and the
Investment Fund Election made by the Participant with respect to that Eligible Compensation.
(b) 	At the end of each Plan Year, the Plan shall credit each Participant’s Investment Fund Subaccounts to reflect any
Employer Contribution deemed to have been made on behalf of the Participant for that Plan Year and the allocation of that contribution
among the Investment Funds pursuant to Section 4.2.
(c) 	The Plan Administrator shall adjust each Investment Fund Subaccount to reflect any transfers under the Plan to or from
that Investment Fund Subaccount, as of the end of each business day to reflect any distributions under the Plan made with respect to that
Investment Fund Subaccount, and the Rate of Return on the related Investment Fund.
Section 6.3 	Statement of Accounts. Each Participant shall be issued quarterly statements of his or her Account(s) in such
form as the Plan Administrator deems desirable, setting forth the balance to the credit of such Participant in his or her Account(s) as of
the end of the most recently completed quarter.
ARTICLE VII
Vesting and Forfeitures
Section 7.1 	Deferral Accounts. A Participant’s Deferral Accounts shall be one hundred percent (100%) vested and non-
forfeitable at all times.
Section 7.2 	Employer Contribution Account.
(a) 	A Participant’s Employer Contribution Account shall become vested according to the same vesting schedule that
applies to the matching contributions made by the Participant’s Employer on behalf of the Participant under the Employer 401(k) Plan in
which the Participant participates.

-- 111 of 409 --

9
(b) 	If a Participant’s employment with the Employers terminates (whether voluntarily or involuntarily) before the
Participant’s Employer Contribution Account becomes one hundred percent (100%) vested and non-forfeitable, then the Participant shall
forfeit that portion of his or her Employer Contribution Account that is not fully vested and non-forfeitable.
ARTICLE VIII
Distribution of Benefits
Section 8.1 	Distribution of Benefits in the Event of a Termination of Employment. If a Participant elects to receive his or
her Plan benefits as an In-Service Distribution, then in the event of that Participant’s Termination of Employment (other than due to
Retirement) prior to receiving that In-Service Distribution, the Company shall pay that Participant’s Plan benefits in a lump-sum to the
Participant within 90 days following his or her Termination of Employment. If a Participant elects to receive his or her Plan benefits
upon Retirement, then in the event of that Participant’s Termination of Employment prior to the date the Participant attains eligibility for
Retirement, the Company shall pay that Participant’s Plan benefits in a lump-sum to the Participant within 90 days following his or her
Termination of Employment.
Section 8.2 	In-Service Distributions. Subject to the provisions of Section 8.6, the Company shall pay In-Service
Distributions in a lump-sum to the Participant on the first business day in February of the year designated by the Participant on his or her
Distribution Election Form.
Section 8.3 	Distribution of Benefits in the Event of Retirement.
(a) 	If, pursuant to Section 4.3, a Participant has elected to receive his or her Plan benefits for a Plan Year upon his or her
Retirement, then the Company shall pay the Participant his or her Plan benefits commencing on the first business day in February next
following the date of the Participant’s Retirement in any of the following forms pursuant to the Participant’s Initial Election or
Subsequent Election, as applicable:
(i) 	in substantially equal quarterly or annual installments to the Participant over fifteen (15) years; or
(ii) 	in substantially equal quarterly or annual installments to the Participant over ten (10) years; or
(iii) 	in substantially equal quarterly or annual installments to the Participant over five (5) years; or
(iv) 	in a lump-sum; or
(v) 	if no such election is on file with the Plan Administrator, in substantially equal quarterly installments to the
Participant over ten (10) years.
Quarterly installments shall be paid on the first business day of each calendar quarter and annual installments shall be
paid on the first business day of each calendar year.
(b) 	Notwithstanding the foregoing, if the total sum of (i) a Participant’s Deferral Accounts (as adjusted for amounts
accrued but not yet credited) in this Plan and (ii) deferrals of compensation under any other agreement, method, program or arrangement
which must be aggregated with this Plan under Treasury Regulations section 1.409A-1(c)(2), is less than the applicable dollar amount
under Code Section 402(g)(1)(B) in effect for the Plan Year in which such date occurs ($19,500 for the 2021 Plan Year), the balance of
such Participant’s Deferral Accounts in this Plan shall be paid in a single lump sum as soon as administratively practicable following
such date. Payment shall terminate and liquidate the Participant’s interest in the Plan and any other aggregated agreement, method,
program or arrangement.

-- 112 of 409 --

10
Section 8.4 	Distribution of Benefits on the Earlier to Occur of a Participant’s Retirement or a Specified Date.
If a Participant has elected to receive his or her Plan benefits on a specified date pursuant to Section 4.3(b)(ii), if the
Participant’s Retirement occurs prior to such specified date,
(a) 	For amounts deferred with respect to Plan Years beginning prior to January 1, 2008, the Company shall pay the
Participant his or her Plan benefits in a lump sum on the first business day in February next following the Participant’s Retirement; and
(b) 	For amounts deferred with respect to Plan Years beginning on or after January 1, 2008, the Company shall pay the
Participant his or her Plan benefits in accordance with Section 8.3(a), subject to Section 8.3(b).
Section 8.5 	Distributions Due to Unforeseeable Emergency.
(a) 	A Participant may receive the early payment of all or part of the balance in his or her Account(s) in the event of an
Unforeseeable Emergency (a “Hardship Distribution”) subject to the following restrictions:
(i) 	The Participant has requested the Hardship Distribution from the Plan Administrator on a form provided by or
in the format requested by the Plan Administrator;
(ii) 	The Plan Administrator has determined that an Unforeseeable Emergency has occurred;
(iii) 	The Plan Administrator determines the amount of the Hardship Distribution, which amount will be limited to
the amount reasonably necessary to satisfy the emergency need (including any amounts necessary to pay any
Federal, state, local or foreign income taxes or penalties reasonably anticipated to result from the Hardship
Distribution); and
(iv) 	The Hardship Distribution shall be distributed in a lump-sum within 30 days following determination by the
Plan Administrator of the amount of the Hardship Distribution.
(b) 	The circumstances that would constitute a Unforeseeable Emergency will depend on the facts and circumstances of
each case, but, in any case, a Hardship Distribution may not be made to the extent that such hardship may be relieved through
(i) reimbursement or compensation by insurance or otherwise, (ii) liquidation of the Participant’s assets, to the extent that liquidation of
the Participant’s assets would not itself cause severe financial hardship, or (iii) by cessation of deferrals under this Plan in compliance
with Code Section 409A.
Section 8.6 	Distribution of Benefits in the Event of Death. In the event of a Participant’s death prior to the complete
distribution of his or her Accounts, the Company shall distribute his or her total Plan benefits to his or her Beneficiary in a lump sum
within 90 days after the date of the Participant’s death.
Section 8.7 	Distribution of Benefits in the Event of Disability.
In the event of a Participant’s Disability, the Company shall pay the Participant his or her Plan benefits commencing on the first
business day in February next following the date of the Participant’s Disability in the form set forth below:
(a) 	For any Participant who has elected to receive his or her Plan benefits upon Retirement, pursuant to the Participant’s
Distribution Election to receive his or her Plan benefits in one of the Retirement forms permitted under Section 8.3(a), subject
to Section 8.3(b).
(b) 	For a Participant who has elected to receive his or her Plan benefits as an In-Service Distribution, if the Participant’s
Disability occurs prior to the date specified in such Distribution Election:

-- 113 of 409 --

11
(i) 	For amounts deferred with respect to Plan Years beginning on or subsequent to January 1, 2008, pursuant to
the Participant’s Distribution Election to receive his or her Plan benefits in one of the Retirement forms
permitted under Section 8.3(a), subject to Section 8.3(b).
(ii) 	For amounts deferred with respect to all Plan Years beginning prior to January 1, 2008, pursuant to the
Participant’s Distribution Election to receive his or her Plan benefits in a lump sum under Section 4.3(b)(ii).
Section 8.8 	Postponing or Amending Distributions. A Participant may postpone a scheduled distribution or amend the
form of distribution specified in Section 8.2, Section 8.3(a) or Section 8.4 only by making a Subsequent Election pursuant to the terms
of Section 4.3(c).
Section 8.9 	Distribution of Benefits Pursuant to a Domestic Relations Order. The Company shall pay all or a portion of a
Participant’s Plan benefits in a lump sum to any person other than the Participant pursuant to the terms of a domestic relations order. For
this purpose, a domestic relations order means a judgment, decree or order (including approval of a property settlement agreement)
which relates to the provision of child support, alimony payments, or marital property rights to a spouse, former spouse, child or other
dependent of the Participant and which is made pursuant to a state domestic relations law (including a community property law).
ARTICLE IX
Beneficiary Designation
Section 9.1 	Beneficiary Designation. Each Participant shall have the right, at any time, to designate any person, persons
or entity as his or her Beneficiary or Beneficiaries. A Beneficiary designation shall be made, and may be amended, by the Participant by
filing a designation with the Plan Administrator, on such form and in accordance with such procedures as the Plan Administrator may
establish from time to time.
Section 9.2 	Failure to Designate a Beneficiary. If a Participant or Beneficiary fails to designate a Beneficiary as provided
above, or if all designated Beneficiaries predecease the Participant or his or her Beneficiary, then the Participant’s Beneficiary shall be
deemed to be, in the following order:
(i) 	to the spouse of such person, if any; or
(ii) 	to the deceased person’s estate.
Section 9.3 	Facility of Payment. When, in the Plan Administrator’s opinion, a Participant or Beneficiary is under a legal
disability or is incapacitated in any way so as to be unable to manage his or her financial affairs, the Plan Administrator may make any
benefit payments to the Participant or Beneficiary’s legal representative, or spouse, or the Plan Administrator may apply the payment for
the benefit of the Participant or Beneficiary in any way the Plan Administrator considers advisable, in each case, without subjecting the
Participant or Beneficiary to accelerated taxation and/or tax penalties under Code Section 409A.
ARTICLE X
Administration of Plan
Section 10.1 	Plan Administrator. The Board of Review, or such person as the Board of Review shall designate pursuant
to Section 10.3, shall serve as the Plan Administrator of the Plan. The administration of the Plan shall be under the supervision of the
Plan Administrator. It shall be a principal duty of the Plan Administrator to see that the Plan is carried out, in accordance with its terms,
for the exclusive benefit of persons entitled to participate in the Plan without discrimination among them. Benefits under the Plan shall
be paid only if the Plan Administrator decides, in his or her discretion, that the applicant is entitled to them. The Plan Administrator will
have full power to administer the Plan in all of its details, subject to applicable requirements of law. For this purpose, the Plan

-- 114 of 409 --

12
Administrator’s powers will include but will not be limited to, the following authority, in addition to all other powers provided by this
Plan:
(i) 	To make and enforce such rules and regulations as it deems necessary or proper for the efficient
administration of the Plan, including the establishment of any claims procedures that may be required by
applicable provisions of law;
(ii) 	To exercise discretion in interpreting the Plan, any interpretation to be reviewed under the arbitrary and
capricious standard;
(iii) 	To exercise discretion in deciding all questions concerning the Plan and the eligibility of any person to
participate in the Plan; such decision to be reviewed under the arbitrary and capricious standard;
(iv) 	To appoint such agents, counsel, accountants, consultants and other persons as may be required to assist in
administering the Plan;
(v) 	To allocate and delegate its responsibilities under the Plan and to designate other persons to carry out any of
its responsibilities under the Plan, any such allocations, delegation or designation to be in writing;
(vi) 	To determine the amount and type of benefits to which any Participant or Beneficiary shall be entitled
hereunder, including the method and date for all valuations under the Plan;
(vii) 	To receive from the Employers and from Participants such information as shall be necessary for the proper
administration of the Plan or any of its programs;
(viii) 	To maintain or cause to be maintained all the necessary records for the administration of the Plan;
(ix) 	To receive, review and keep on file (as it deems convenient and proper) reports of benefit payments made by
the Plan;
(x) 	To determine and allocate among the Employers the liability to the Company associated with Plan benefits in
accordance with Section 1.3 and to determine the time at which and manner in which that liability shall be
paid to the Company;
(xi) 	To make, or cause to be made, equitable adjustments for any mistakes or errors made in the administration of
the Plan; and
(xii) 	To do all other acts which the Plan Administrator deems necessary or proper to accomplish and implement its
responsibilities under the Plan.
Section 10.2 	Reliance on Tables, etc. In administering the Plan, the Plan Administrator will be entitled to the extent
permitted by law to rely conclusively on all tables, valuations, certificates, opinions and reports which are furnished by, or in accordance
with the instructions of accountants, counsel, or other experts employed or engaged by the Plan Administrator.
Section 10.3 	Delegation. The Board of Review shall have the authority to appoint another corporation or one or more
other persons to serve as the Plan Administrator hereunder, in which event such corporation or person (or persons) shall exercise all of
the powers, duties, responsibilities, and obligations of the Plan Administrator hereunder.
Section 10.4 	Operations. The day to day operation of the Plan will be handled by the person or persons designated by the
Plan Administrator.

-- 115 of 409 --

13
Section 10.5 	Uniform Rules. The Plan Administrator shall administer the Plan on a reasonable and nondiscriminatory
basis and shall apply uniform rules to all similarly situated Participants.
Section 10.6 	Plan Administrator’s Decisions Final. Any interpretation of the provisions of the Plan (including but not
limited to the provisions of any of its Programs) and any decision on any matter within the discretion of the Plan Administrator made by
the Plan Administrator in good faith shall be binding on all persons. A misstatement or other mistake of fact shall be corrected when it
becomes known and the Plan Administrator shall make such adjustment on account thereof as it considers equitable and practicable.
Neither the Plan Administrator nor any Employer shall be liable in any manner for any determination of fact made in good faith.
ARTICLE XI
Claims for Benefits
Section 11.1 	Claims and Review Procedures. The Plan Administrator shall adopt procedures for the filing and review of
claims in accordance with Section 503 of ERISA.
ARTICLE XII
Amendment and Termination of Plan
Section 12.1 	Amendment. The Company may amend this Plan, in whole or in part, at any time provided, however, that no
amendment shall be effective to decrease the balance in any Account as accrued at the time of such amendment. Any amendment which
would allow officers of the Company to participate in the Plan shall require the approval of the Abbott Laboratories Board of Directors.
Any amendment which increases the total cost of the Plan to the Employers in excess of $250,000 in each of the three full calendar years
next following the date of the amendment shall be approved by the Board of Review. The Executive Vice President, Human Resources
of the Company shall approve all other amendments to the Plan and the extension of the Plan to any division or Subsidiary of the
Company.
Section 12.2 	Termination. The Board of Review may at any time terminate the Plan with respect to future Deferral
Elections. The Board of Review may also terminate and liquidate the Plan in its entirety; provided that such termination and liquidation
are consistent with the provisions of Code Section 409A. Upon any such termination, the Company shall pay to the Participant the
benefits the Participant is entitled to receive under the Plan, determined as of the termination date, in compliance with Code
Section 409A.
ARTICLE XIII
Miscellaneous
Section 13.1 	Unfunded Plan. This Plan is intended to be an unfunded plan maintained primarily for the purpose of
providing deferred compensation for a select group of management or highly compensated employees, within the meaning of Sections
201, 301 and 401 of ERISA and therefore meant to be exempt from Parts 2, 3 and 4 of Title I of ERISA. All payments pursuant to the
Plan shall be made from the general funds of the Company and no special or separate fund shall be established or other segregation of
assets made to assure payment. No Participant or other person shall have under any circumstances any interest in any particular property
or assets of the Company as a result of participating in the Plan.
Section 13.2 	Nonassignability. Except as specifically set forth in the Plan with respect to the designation of Beneficiaries,
neither a Participant nor any other person shall have any right to commute, sell, assign, transfer, pledge, anticipate, mortgage or
otherwise encumber, transfer, hypothecate or convey in advance of actual receipt the amounts, if any, payable hereunder, or any part
thereof, which are, and all rights to which are, expressly declared to be unassignable and non-transferable. No part of the amounts
payable shall, prior to actual payment, be subject to seizure or sequestration for the payment of any debts, judgments, alimony or separate
maintenance owed

-- 116 of 409 --

14
by a Participant or any other person, nor be transferable by operation of law in the event of a Participant’s or any other person’s
bankruptcy or insolvency.
Section 13.3 	Validity and Severability. The invalidity or unenforceability of any provision of this Plan shall not affect the
validity or enforceability of any other provision of this Plan, which shall remain in full force and effect, and any prohibition or
unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
Section 13.4 Governing Law. The validity, interpretation, construction and performance of this Plan shall in all respects be
governed by the laws of the State of Illinois, without reference to principles of conflict of law, except to the extent preempted by federal
law.
Section 13.5 	Employment Status. This Plan does not constitute a contract of employment or impose on the Participant or
the Company any obligation for the Participant to remain an employee of the Company or change the status of the Participant’s
employment or the policies of the Company and its affiliates regarding termination of employment.
Section 13.6 	Underlying Incentive Plans and Programs. Nothing in this Plan shall prevent the Company from modifying,
amending or terminating the compensation or the incentive plans and programs pursuant to which Eligible Bonuses or Eligible
Compensation are earned and which are deferred under this Plan.
Section 13.7 	Successors of the Company. The rights and obligations of the Company under the Plan shall inure to the
benefit of, and shall be binding upon, the successors and assigns of the Company.
Section 13.8 	Waiver of Breach. The waiver by the Company of any breach of any provision of the Plan by the Participant
shall not operate or be construed as a waiver of any subsequent breach by the Participant.
Section 13.9 	Notice. Any notice or filing required or permitted to be given to the Company under the Plan shall be
sufficient if in writing and hand-delivered, or sent by first class mail to the principal office of the Company, directed to the attention of
the Plan Administrator. Such notice shall be deemed given as of the date of delivery, or, if delivery is made by mail, as of the date shown
on the postmark.
Section 13.10 	Waiver of Notice. Any notice required under the Plan may be waived by the person entitled to such notice.
Section 13.11 	Evidence. Evidence required of anyone under the Plan may be by certificate, affidavit, document or other
information which the person acting on it considers pertinent and reliable, and signed, made or presented by the proper party or parties.
Section 13.12 	Additional Employers. Subject to the consent of the Board of Review, any Subsidiary of the Company may
adopt the Plan by filing a written instrument to that effect with the Company.
Section 13.13 	Separation and Distribution Agreement of 2004. The provisions of this Section 13.13 shall apply to an
Eligible Employee who is a Participant in the Plan and who transfers from employment with the Company or an Employer to
Hospira, Inc. or to a subsidiary of Hospira, Inc. (collectively, the “Hospira Companies”) as a result of the transactions contemplated by
that certain Separation and Distribution Agreement by and between Abbott Laboratories and Hospira, Inc., dated as of April 12, 2004
(the “Distribution Agreement”), and such transfer of employment is made in accordance with and subject to the terms of the Employee
Benefits Agreement as described in the Distribution Agreement (each such transferred Participant referred to herein as a “Transferred
Hospira Participant”).
(a) 	A Transferred Hospira Participant’s transfer of employment to the Hospira Companies will not be considered as a
termination of employment as a result of Termination of Employment, Retirement or Disability for purposes of determining eligibility for
distributions under Article VII of the Plan. Such Transferred Hospira Participant’s termination of employment resulting from
Termination of Employment, Retirement or Disability shall occur only upon his or her subsequent termination of employment from the
Hospira Companies (and Termination of

-- 117 of 409 --

15
Employment, Retirement and Disability with respect to such Transferred Hospira Participants shall mean such events in relation to the
Hospira Companies rather than in relation to the Company and the Employers);
(b) 	Following his or her transfer to employment with the Hospira Companies, a Transferred Hospira Participant will
remain a participant but will not be eligible to make Deferral Elections. A Transferred Hospira Participant shall remain a Participant
until (i) his or her death or (ii) his or her Accounts have been distributed in accordance with the Plan and in accordance with the
Transferred Hospira Participant’s elections regarding the manner of distribution of such Accounts.
Section 13.14 	Section 409A. To the extent applicable, it is intended that the Plan comply with the provisions of Code
Section 409A. The Plan will be administered and interpreted in a manner consistent with this intent, and any provision that would cause
the Plan to fail to satisfy Code Section 409A will have no force and effect until amended to comply therewith (which amendment may be
retroactive to the extent permitted by Code Section 409A). Notwithstanding anything contained herein to the contrary, to the extent
required to avoid accelerated taxation and/or tax penalties under Code Section 409A and applicable guidance issued thereunder, amounts
that would otherwise be payable pursuant to the Plan during the six-month period immediately following the Participant’s Termination of
Employment or Retirement shall instead be paid on the first business day after the date that is six months following the Participant’s
Termination of Employment or Retirement (or upon the Participant’s death, if earlier), plus, to the extent subject to a six-month delay, a
return equal to the Rate of Return that would be achieved if such amounts were invested in accordance with the Participant’s Investment
Elections under Section 4.2 from the respective dates on which such amounts would otherwise have been paid until the actual date of
payment.
SUPPLEMENT B
TRANSFER OF LIABILITIES FROM THE
ABBOTT DEFERRED COMPENSATION PLAN FOR FORMER EMPLOYEES OF SOLVAY
B-1. 	Purpose and Effect. The purpose of this Supplement B is to provide for the transfer of liabilities from the Abbott
Deferred Compensation Plan for Former Employees of Solvay, as it may be amended (the “Solvay DCP”), to this Plan with respect to
certain Abbott Retained Employees and Abbott LTD Participants as set forth in the EMA (the “Solvay DCP Participants”). The Solvay
DCP is not open to new contributions, so the purpose of this Supplement B is to facilitate the administration of any Abbott Retained
Employee and Abbott LTD Participant accounts that are transferred into the Plan (the “Deferred Compensation Accounts”) from the
Solvay DCP until such time as they are fully distributed. Except as specifically provided in this Supplement B to document certain
benefits, rights and features of the Solvay DCP Plan, the Plan terms shall apply to the Deferred Compensation Accounts.
B-2. 	Transfer of Liabilities from Solvay DCP. As soon as practicable on or after January 1, 2013, and subject to such terms
and conditions as the Plan Administrator may establish, all liabilities attributable to the Solvay DCP Participants shall be transferred
from the Solvay DCP to this Plan. The Plan shall credit each such Solvay DCP Participant’s account with (a) the amount deferred by
such individual into the Solvay DCP as of the applicable transfer date, plus (b) any employer contributions, whether vested or unvested,
deemed to have been made in relation to the amount described in (a), including, in each case, any earnings thereon.
B-3. 	Distribution Elections. Distribution elections made under the Solvay DCP with respect to transferred amounts
described in Section B-2 above shall be recognized, implemented and honored by the Plan and such amounts shall be distributable to the
applicable Solvay DCP Participant in accordance with such elections. Elections with respect to amounts deferred under this Plan on or
after January 1, 2013 shall be in accordance with Article IV and other applicable provisions of this Plan.
B-4. 	Earnings Equivalents. Earnings equivalents shall be credited to each Deferred Compensation Account on the basis
determined by the Plan Administrator from time to time. A Solvay DCP Participant’s election

-- 118 of 409 --

16
for the deemed investment of the amounts in his or her Deferred Compensation Account shall be made in accordance with such rules and
procedures as the Plan Administrator may adopt from time to time.
B-5. 	Vesting and Forfeiture.
(a) 	A Solvay DCP Participant’s right to future payment of his or her Deferred Compensation Account attributable to
deferral contributions, together with the earnings equivalents thereon, shall always be 100% vested and nonforfeitable. Subject to
paragraph (b) below, a Solvay DCP Participant’s right to future payment of his or her Deferred Compensation Account attributable to
employer contributions, together with the earnings equivalents thereon, shall be vested and nonforfeitable based on his or her service
with Abbott Laboratories.
(b) 	If a Solvay DCP Participant is terminated for cause, including but not limited to conviction of a felony, acts involving
moral turpitude, offensive personal conduct, dishonesty, disloyalty, disorderly conduct, vandalism, violation of the rules of the Company,
revealing trade secrets, insubordination, interference with production, or any other act or course of action deemed detrimental to the
Company by the Plan Administrator, then the only amount which the Solvay DCP Participant will receive will be that amount
attributable to his or her deferral contributions and the earnings equivalents attributable thereto. This amount, valued as of the most
recent valuation date administratively practicable before the distribution, will be distributed in accordance with the provisions of the
Plan. The balance of his or her Deferred Compensation Account will be forfeited concurrent with the distribution.
B-6. 	Distributions.
(a) 	Unless otherwise provided in the Plan or in paragraph (b) below, in the event that a Solvay DCP Participant has a
Termination of Employment, he or she shall receive, in the form of a lump sum distribution 75 days after the date of Termination of
Employment, an amount equal to the value of his or her vested Deferred Compensation Account as of the most recent valuation date
administratively practicable before the distribution. Notwithstanding the foregoing, but subject to the Plan terms and paragraph
(b) below, the Solvay DCP Participant may elect to receive the value of his or her vested Deferred Compensation Account in any one of
the following alternative forms:
(1) 	a lump sum distribution 75 days after the date of Termination of Employment or, if later, January 1 of the
calendar year following the calendar year in which he or she has a Termination of Employment;
(2) 	annual installments over a five year period beginning 75 days after the date of Termination of Employment; or
(3) 	annual installments over a ten year period beginning 75 days after the date of Termination of Employment.
Any election (or any change or revocation of an election) shall not be effective unless it is accepted by the Plan Administrator at least 12
months prior to the date of Termination of Employment and results in a further deferral of payment (or the commencement of payment)
of the Solvay DCP Participant’s Deferred Compensation Account of at least five years (unless payment is on account of death). In the
event the value of a Deferred Compensation Account is not distributed in a lump sum within 75 days after a Solvay DCP Participant’s
Termination of Employment, the amounts credited to such Deferred Compensation Account shall continue to be credited for earnings
equivalents in accordance with Section B-4 until the latest valuation date administratively practicable before such amounts are
distributed;
(b) 	In the event that there is a change of control of the Company, as defined under Code Section 409A, then each Solvay
DCP Participant shall receive, in the form of a lump sum distribution made 75 days after the change of control occurs, an amount equal
to the value of his or her vested Deferred Compensation Account as of the most recent valuation date administratively practicable before
distribution. Notwithstanding the foregoing, accelerated distributions under this paragraph (b) shall be limited to the extent necessary to
prevent the Solvay DCP Participant from receiving any “excess parachute payment” as described in Code Section 280 or any successor
section thereto, provided that the determination of what shall constitute an “excess parachute payment”

-- 119 of 409 --

17
shall be made by the Plan Administrator, and provided further that such limitation may be applied by the Plan Administrator only if and
to the extent such limitation of acceleration does not cause a violation of Code Section 409A. In the event that a portion of the benefit
otherwise payable under this paragraph (b) may not be accelerated pursuant to the limitations of the immediately preceding sentence, the
payments which would be due latest in time shall be accelerated first, to the extent required to comply with Code Section 409A.
B-7. 	Use of Terms. Terms used in this Supplement B have the meanings of those terms as set forth in the Plan, unless they
are defined in this Supplement B. All of the terms and provisions of the Plan shall apply to this Supplement B except that where the
terms of the Plan and this Supplement B conflict, the terms of this Supplement B shall govern.
1. 	The Plan shall otherwise remain unchanged and in full force and effect.

-- 120 of 409 --

Exhibit 10.56
ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT
On «Grant_Date» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the
“Employee”) a Performance Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the
“Units”).
The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the
Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement. In the
event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus,
and the Program administrative rules, the Program shall control. This Award is intended to conform with the qualified
performance-based compensation requirements of Section 162(m) of the Code and the regulations thereunder, to the extent
applicable, and shall be construed accordingly.
The terms and conditions of the Award are as follows:
1. 	Definitions. To the extent not defined herein, capitalized terms shall have the same meaning as in the
Program.
(a) 	Agreement: This Performance Restricted Stock Unit Agreement.
(b) 	Cause: Cause shall mean the following, as determined by the Company in its sole discretion:
(i) 	material breach by the Employee of the terms and conditions of the Employee’s
employment, including, but not limited to:
(A) 	material breach by the Employee of the Code of Business Conduct;
(B) 	material breach by the Employee of the Employee’s employment contract, if any;
(C) 	commission by the Employee of an act of fraud, embezzlement or theft in
connection with the Employee’s duties or in the course of the Employee’s
employment;
(D) 	wrongful disclosure by the Employee of secret processes or confidential
information of the Company or any of its Subsidiaries; or
(E) 	failure by the Employee to substantially perform the duties of the Employee’s
employment (other than any such failure resulting from the Employee’s Disability);
or
(ii) 	to the extent permitted by applicable law, engagement by the Employee, directly or
indirectly, for the benefit of the Employee or others, in any activity, employment or business
which is competitive with the Company or any of its Subsidiaries.

-- 121 of 409 --

2
(c) 	Code of Business Conduct: The Company’s Code of Business Conduct, as amended from time to
time.
(d) 	Controlled Group:
(i) 	Abbott and any corporation, partnership and proprietorship under common control (as
defined under the aggregation rules of subsections 414 (b), (c), or (m) of the Code) with
Abbott; and
(ii) 	during the period of the TAP Pharmaceutical Products Inc. (“TAP”) joint venture between
Takeda Pharmaceutical Company Limited and Abbott ending April 30, 2008, TAP and any
corporation, partnership and proprietorship under common control (as defined above) with
TAP.
(e) 	Data: Certain personal information about the Employee held by the Company and the Subsidiary
that employs the Employee (if applicable), including (but not limited to) the Employee’s name,
home address and telephone number, date of birth, social security number or other employee
identification number, salary, nationality, job title, any Shares held in the Company, details of all
Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or
outstanding in the Employee’s favor, for the purpose of managing and administering the Program.
(f) 	Disability: As of a particular date, the Employee is, by reason of any medically determinable
physical or mental impairment that can be expected to result in death or can be expected to last for a
continuous period of not less than 12 months, receiving income replacement benefits for a period of
at least six (6) months under (i) the terms of the Abbott Laboratories Long-Term Disability Plan
(formerly known as the Extended Disability Plan) (the “LTD Plan”), or (ii) if the Employee’s
employer does not participate in the LTD Plan, such similar accident and health plan providing
replacement benefits in which the Employee’s employer participates.
(g) 	Employee’s Representative: The Employee’s legal guardian or other legal representative.
(h) 	Program: The Abbott Laboratories 2017 Incentive Stock Program.
(i) 	Retirement:
(i) 	Except as provided under (iii) below, for employees hired by the Controlled Group prior to
January 1, 2004, Retirement means any of the following:
· 	age 50 with 10 years of service;
· 	age 65 with at least three (3) years of service; or
· 	age 55 with an age and service combination of 70 points, where each year of age is
one (1) point and each year of service is one (1) point.

-- 122 of 409 --

3
(ii) 	Except as provided under (iii) below, for employees hired by the Controlled Group after
December 31, 2003, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iii) 	For participants in the Abbott Laboratories Pension Plan for Former BASF and Former
Solvay Employees, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iv) 	For purposes of calculating service under this Section 1(i), except as otherwise provided by
the Committee or its delegate, service is earned only if performed for a member of the
Controlled Group while that Controlled Group member is a part of the Controlled Group.
Program administrative rules apply in determining Retirement eligibility and credited
service.
(v) 	If an Employee has a Termination and (A) as of the date of that Termination met the
definition of Retirement, and (B) is subsequently rehired by a member of the Controlled
Group, then for purposes of this Agreement that Employee will continue to be treated as
meeting the definition of Retirement.
(j) 	Termination: A severance of employment for any reason (including Retirement) from the Company
and all Subsidiaries. Any Termination shall be effective on the last day the Employee performs
services for or on behalf of the Company or its Subsidiary, and employment shall not be extended
by any statutory or common law notice of termination period.
2. 	Delivery Dates and Shareholder Rights. The Delivery Dates for Shares underlying the Units are the
respective dates on which the Shares are payable to the Employee pursuant to Section 4 below. Prior to the
Delivery Date(s):
(a) 	the Employee shall not be treated as a shareholder as to those Shares underlying the Units, and shall
have only a contractual right to receive Shares, unsecured by any assets of the Company or its
Subsidiaries;
(b) 	the Employee shall not be permitted to vote the Shares underlying the Units; and
(c) 	the Employee’s right to receive such Shares will be subject to the adjustment provisions relating to
mergers, reorganizations, and similar events set forth in the Program.
Subject to the requirements of local law, the Employee shall receive cash payments equal to the dividends
and distributions paid on Shares underlying the Units (the “Dividend

-- 123 of 409 --

4
Equivalents”) (other than dividends or distributions of securities of the Company which may be issued with
respect to its Shares by virtue of any stock split, combination, stock dividend or recapitalization) to the same
extent and on the same date (or as soon as practicable thereafter) as if each Unit were a Share; provided,
however, that no Dividend Equivalents shall be payable to or for the benefit of the Employee with respect to
dividends or distributions the record date for which occurs on or after the date the Employee has forfeited
the Units, or the date the Units are settled. For purposes of compliance with the requirements of Code
Section 409A, to the extent applicable, the specified date for payment of any Dividend Equivalents to which
the Employee is entitled under this Section 2 is the calendar year during the term of this Agreement in which
the associated dividends or distributions are paid on Shares underlying the Units. The Employee shall have
no right to determine the year in which Dividend Equivalents will be paid.
3. 	Restrictions. The Units are subject to the forfeiture provisions in Sections 5 and 6 below. The Units are not
earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of
(collectively, the “Restrictions”) until the Units are settled.
4. 	Lapse of Restrictions. Subject to Sections 5 and 6 below:
(a) 	During Employment. While the Employee is employed with the Company or its Subsidiaries:
(i) 	the Restrictions on one-third of the total number of Units will lapse on the last business day
of February 202__, provided the Company’s prior year return on equity is a minimum of [•]
percent;
(ii) 	the Restrictions on an additional one-third of the total number of Units will lapse on the last
business day of February 202__, provided the Company’s prior year return on equity is a
minimum of [•] percent; and
(iii) 	the Restrictions on an additional one-third of the total number of Units will lapse on the last
business day of February 202__, provided the Company’s prior year return on equity is a
minimum of [•] percent.
If the Restrictions do not lapse on the respective date set forth in subsection 4(a)(i), (ii), and (iii)
above, such Restrictions shall not lapse at a later date.
Units for which Restrictions have lapsed, as described in this subsection 4(a), shall be settled in the
form of Shares on the date(s) on which such Restrictions lapse (each, a “Delivery Date”). Unless
indicated otherwise, Shares shall be delivered in an equal number (subject to rounding) as of each
Delivery Date.
(b) 	Retirement. The Restrictions shall continue to apply in the event of the Employee’s Termination
due to Retirement, but may lapse thereafter in accordance with the provisions of subsection 4(a), in
which case any Units not previously settled shall be settled in the form of Shares on the Delivery
Date(s) set forth in subsection 4(a) above occurring after the date of such Retirement as if the
Employee had remained employed. Notwithstanding the foregoing, in the event of the Employee’s
death after his or her Termination due to Retirement, for

-- 124 of 409 --

5
any Units not previously settled on a Delivery Date, the restrictions shall lapse on the Employee’s
date of death and the Units will be settled in the form of Shares as soon as administratively possible
after, and effective as of, the date of death.
(c) 	Death. The Restrictions shall lapse on the date of the Employee’s Termination due to death, and
any Units not previously settled on a Delivery Date shall be settled (for the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution) in the form
of Shares as soon as administratively possible after, and effective as of, the date of death.
(d) 	Disability. The Restrictions shall lapse on the date of the Employee’s Disability, and any Units not
previously settled on a Delivery Date shall be settled in the form of Shares as soon as
administratively possible after, and effective as of, the date of Disability.
5. 	Effect of Certain Bad Acts. Any Units not previously settled shall be cancelled and forfeited immediately
if, in the sole opinion and discretion of the Committee or its delegate, the Employee engages in activity that
constitutes Cause, whether or not the Employee experiences a Termination or remains employed with the
Company or a Subsidiary.
6. 	Forfeiture of Units. In the event of the Employee’s Termination for any reason other than Retirement,
death or Disability, any Units with respect to which Restrictions have not lapsed as of the date of
Termination shall be forfeited without consideration to the Employee or the Employee’s Representative. In
the event that the Employee is terminated by the Company other than for Cause, the Company may, in its
sole discretion, cause some or all of the Units not previously settled on a Delivery Date to continue to be
subject to the Restrictions, provided such Restrictions may lapse thereafter in accordance with the
provisions of subsection 4(a), in which case such Units shall be settled in the form of Shares on the Delivery
Date(s) set forth in subsection 4(a) above occurring after the date of such Termination. In accepting this
Award, the Employee acknowledges that in the event of Termination (whether or not in breach of local labor
laws), the Employee’s right to vest in the Units, if any, will terminate effective as of the date that the
Employee is no longer actively employed and will not be extended by any notice period mandated under
local law (e.g., active employment would not include a period of “garden leave” or similar period pursuant
to local law) and that the Committee shall have the exclusive discretion to determine when the Employee is
no longer actively employed for purposes of this Award.
7. 	Withholding Taxes. The Company shall be entitled to withhold, or require the Employee to remit, any
federal, state, local, and other applicable taxes (in U.S. or non U.S. jurisdictions), including income, social
security and Medicare withholding taxes arising from the grant of the Award, the lapse of Restrictions or the
delivery of Shares pursuant to this Agreement by, without limitation:
(a) 	having the Company withhold Shares;
(b) 	tendering Shares received in connection with the Units back to the Company;
(c) 	delivering other previously acquired Shares having a Fair Market Value approximately equal to the
amount to be withheld;

-- 125 of 409 --

6
(d) 	selling Shares issued pursuant to the Units and having the Company withhold from proceeds of the
sale of such Shares;
(e) 	having the Company or a Subsidiary, as applicable, withhold from any cash compensation payable
to the Employee; or
(f) 	requiring the Employee to repay the Company or Subsidiary, in cash or in Shares for taxes paid on
the Employee's behalf.
Notwithstanding the foregoing, if the Employee is subject to Section 16 of the Exchange Act pursuant to
Rule 16a-2 promulgated thereunder, any tax withholding obligations shall be satisfied by having the
Company withhold a number of Shares otherwise issuable upon settlement of the Units that is sufficient to
satisfy such obligations consistent with the Company's withholding practices.
If, to satisfy tax withholding obligations, the Company withholds Shares otherwise issuable to the
Employee, the Employee shall be deemed to have been issued the full number of Shares underlying the
Units, subject to the Restrictions set forth in this Agreement.
8. 	No Right to Continued Employment. This Agreement and the Employee’s participation in the Program is
not and shall not be interpreted to:
(a) 	form an employment contract or relationship with the Company or its Subsidiaries;
(b) 	confer upon the Employee any right to continue in the employ of the Company or any of its
Subsidiaries; or
(c) 	interfere with the ability of the Company or its Subsidiaries to terminate the Employee’s
employment at any time.
9. 	Nature of Grant. In accepting this grant of Units, the Employee acknowledges that:
(a) 	The Program is established voluntarily by the Company, it is discretionary in nature and it may be
modified, amended, suspended or terminated by the Company at any time;
(b) 	This Award is a one-time benefit and does not create any contractual or other right to receive future
grants of Units, benefits in lieu of Units, or other Program Benefits in the future, even if Units have
been granted repeatedly in the past;
(c) 	All decisions with respect to future Unit grants, if any, and their terms and conditions, will be made
by the Committee, in its sole discretion;
(d) 	Nothing contained in this Agreement is intended to create or enlarge any other contractual
obligations between the Company and the Employee;
(e) 	The Employee is voluntarily participating in the Program;
(f) 	The Units and Shares subject to the Units are:

-- 126 of 409 --

7
(i) 	extraordinary items that do not constitute compensation of any kind for services of any kind
rendered to the Company or its Subsidiaries, and are outside the scope of the Employee’s
employment contract, if any;
(ii) 	not intended to replace any pension rights or compensation;
(iii) 	not part of the Employee’s normal or expected compensation or salary for any purposes,
including, but not limited to, calculating any severance, resignation, termination,
redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or
retirement or welfare benefits, or similar payments and in no event should be considered as
compensation for, or relating in any way to, past services for the Company or its
Subsidiaries;
(g) 	The future value of the Shares underlying the Units is unknown and cannot be predicted with
certainty;
(h) 	In consideration of the Award, no claim or entitlement to compensation or damages shall arise from
the Units resulting from Termination (for any reason whatsoever) and the Employee irrevocably
releases the Company and its Subsidiaries from any such claim that may arise; if any such claim is
found by a court of competent jurisdiction to have arisen, then, by signing or electronically
accepting this Agreement, the Employee shall be deemed irrevocably to have waived the
Employee’s entitlement to pursue such claim;
(i) 	The Units and the Benefits under the Program, if any, will not automatically transfer to another
company in the case of a merger, take-over or transfer of liability; and
(j) 	Neither the Company nor any of its Subsidiaries shall be liable for any change in value of the Units,
the amount realized upon settlement of the Units or the amount realized upon a subsequent sale of
any Shares acquired upon settlement of the Units, resulting from any fluctuation of the United States
Dollar/local currency foreign exchange rate.
10. 	Data Privacy.
(a) 	Pursuant to applicable personal data protection laws, the collection, processing and transfer of the
Employee’s personal Data is necessary for the Company’s administration of the Program and the
Employee’s participation in the Program. The Employee’s denial and/or objection to the collection,
processing and transfer of personal Data may affect his or her ability to participate in the Program.
As such (where required under applicable law), the Employee:
(i) 	voluntarily acknowledges, consents and agrees to the collection, use, processing and
transfer of personal Data as described herein; and
(ii) 	authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic
or other form, for purposes of implementing, administering and managing the Employee’s
participation in the Program, including any requisite transfer of such Data as may be
required for the

-- 127 of 409 --

8
administration of the Program and/or the subsequent holding of Shares on the Employee’s
behalf to a broker or other third party with whom the Employee may elect to deposit any
Shares acquired pursuant to the Program.
(b) 	Data may be provided by the Employee or collected, where lawful, from third parties, and the
Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the
exclusive purpose of implementing, administering and managing the Employee’s participation in the
Program. Data processing will take place through electronic and non-electronic means according to
logics and procedures strictly correlated to the purposes for which the Data is collected and with
confidentiality and security provisions as set forth by applicable laws and regulations in the
Employee’s country of residence. Data processing operations will be performed minimizing the use
of personal and identification data when such operations are unnecessary for the processing
purposes sought. The Data will be accessible within the Company’s organization only by those
persons requiring access for purposes of the implementation, administration and operation of the
Program and for the Employee’s participation in the Program.
(c) 	The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as
necessary for the purpose of implementation, administration and management of the Employee’s
participation in the Program, and the Company and the Subsidiary that employs the Employee (if
applicable) may further transfer Data to any third parties assisting the Company in the
implementation, administration and management of the Program. These recipients may be located
throughout the world.
(d) 	The Employee may, at any time, exercise his or her rights provided under applicable personal data
protection laws, which may include the right to:
(i) 	obtain confirmation as to the existence of the Data;
(ii) 	verify the content, origin and accuracy of the Data;
(iii) 	request the integration, update, amendment, deletion or blockage (for breach of applicable
laws) of the Data; and
(iv) 	oppose, for legal reasons, the collection, processing or transfer of the Data which is not
necessary or required for the implementation, administration and/or operation of the
Program and the Employee’s participation in the Program.
The Employee may seek to exercise these rights by contacting his or her local human resources
manager.
(e) 	Upon request of the Company or the Subsidiary that employs the Employee (if applicable), the
Employee agrees to provide an executed data privacy consent form (or any other agreements or
consents that may be required), as deemed necessary by the Company or the Subsidiary that
employs the Employee (if applicable) for the purpose of administering the Employee’s participation
in the

-- 128 of 409 --

9
Program in compliance with the data privacy laws in the Employee’s country, either now or in the
future. If the Employee fails to provide any such consent or agreement requested by the Company
and/or the Subsidiary that employs the Employee (if applicable) and the Committee or its delegate
determines that the collection, processing and/or transfer of Data without such consent or agreement
would violate the laws in the Employee’s country, the Employee understands and agrees that the
Employee will not be able to participate in the Program and the Award will be null and void.
11. 	Form of Payment. The Company may, in its sole discretion, settle the Employee’s Units in the form of a
cash payment to the extent settlement in Shares: (i) is prohibited under local law; (ii) would require the
Employee, the Company and/or its Subsidiaries to obtain the approval of any governmental and/or
regulatory body in the Employee’s country; (iii) would result in adverse tax consequences for the Employee
or the Company; or (iv) is administratively burdensome. Alternatively, the Company may, in its sole
discretion, settle the Employee’s Units in the form of Shares but require the Employee to sell such Shares
immediately or within a specified period of time following the Employee’s Termination (in which case, this
Agreement shall give the Company the authority to issue sales instructions on the Employee’s behalf).
12. 	Private Placement. The grant of this Unit is not intended to be a public offering of securities in the
Employee’s country. The Company has not submitted any registration statement, prospectus or other filings
with the local securities authorities (unless otherwise required under local law), and this grant of Units is not
subject to the supervision of the local securities authorities.
13. 	Exchange Controls. As a condition to this grant of Units, the Employee agrees to comply with any
applicable foreign exchange rules and regulations.
14. 	Compliance with Applicable Laws and Regulations.
(a) 	The Company shall not be required to issue or deliver any Shares pursuant to this Agreement
pending compliance with all applicable federal and state securities and other laws (including any
registration requirements or tax withholding requirements) and compliance with the rules and
practices of any stock exchange upon which the Company’s Shares are listed.
(b) 	Regardless of any action the Company or its Subsidiaries take with respect to any or all income tax,
social insurance, payroll tax, payment on account or other tax-related items related to the
Employee’s participation in the Program and legally applicable to the Employee or deemed by the
Company or its Subsidiaries to be an appropriate charge to the Employee even if technically due by
the Company or its Subsidiaries (“Tax-Related Items”), the Employee acknowledges that the
ultimate liability for all Tax-Related Items is and remains the Employee’s responsibility and may
exceed the amount actually withheld by the Company or its Subsidiaries. The Employee further
acknowledges that the Company and/or its Subsidiaries: (i) make no representations or undertakings
regarding the treatment of any Tax-Related Items in connection with any aspect of the Units,
including, but not limited to, the grant, lapse of Restrictions or settlement of the Units, the issuance
of Shares upon payment of the Units, the subsequent sale of Shares acquired pursuant to such
issuance and the receipt of any dividends and/or

-- 129 of 409 --

10
any Dividend Equivalents; and (ii) do not commit to and are under no obligation to structure the
terms of the grant or any aspect of the Units to reduce or eliminate the Employee’s liability for Tax-
Related Items or achieve any particular tax result. Further, if the Employee has become subject to
tax in more than one (1) jurisdiction between the date of grant and the date of any relevant taxable
event, the Employee acknowledges that the Company and/or its Subsidiaries may be required to
withhold or account for Tax-Related Items in more than one (1) jurisdiction.
15. 	Code Section 409A. Payments made pursuant to this Agreement are intended to be exempt from or to
otherwise comply with the provisions of Code Section 409A to the extent applicable. The Program and this
Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company
determines that any payments under this Agreement are subject to Code Section 409A and this Agreement
fails to comply with that section’s requirements, the Company may, at the Company’s sole discretion, and
without the Employee’s consent, amend this Agreement to cause it to comply with Code Section 409A or
otherwise be exempt from Code Section 409A.
To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A and
applicable guidance issued thereunder, the Employee shall not be deemed to have had a Termination unless
the Employee has incurred a “separation from service” as defined in Treasury Regulation §1.409A-1(h), and
amounts that would otherwise be payable pursuant to this Agreement during the six-month period
immediately following the Employee’s Termination (including Retirement) shall instead be paid on the first
business day after the date that is six (6) months following the Employee’s Termination (or upon the
Employee’s death, if earlier). For purposes of Code Section 409A, to the extent applicable: (i) all payments
provided hereunder shall be treated as a right to a series of separate payments and each separately identified
amount to which the Employee is entitled under this Agreement shall be treated as a separate payment; (ii)
the term “as soon as administratively possible” means a period of time that is within 60 days after the
Termination due to death or Disability (as applicable); and (iii) the date of the Employee’s Disability shall
be determined by the Company in its sole discretion.
Although this Agreement and the payments provided hereunder are intended to be exempt from or to
otherwise comply with the requirements of Code Section 409A, the Company does not represent or warrant
that this Agreement or the payments provided hereunder will comply with Code Section 409A or any other
provision of federal, state, local, or non-United States law. None of the Company, its Subsidiaries, or their
respective directors, officers, employees or advisers shall be liable to the Employee (or any other individual
claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a
result of compensation paid under this Agreement, and the Company and its Subsidiaries shall have no
obligation to indemnify or otherwise protect the Employee from the obligation to pay any taxes pursuant to
Code Section 409A.
16. 	No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the
Company making any recommendations regarding the Units, the Employee’s participation in the Program or
the Employee’s acquisition or sale of the underlying Shares. The Employee is hereby advised to consult
with the Employee’s own

-- 130 of 409 --

11
personal tax, legal and financial advisors regarding participation in the Program before taking any action
related to the Program.
17. 	Imposition of Other Requirements. The Company reserves the right to impose other requirements on the
Employee’s participation in the Program, on the Units and on any Shares acquired under the Program, to the
extent the Company or its Subsidiaries determines it is necessary or advisable in order to comply with local
law or facilitate the administration of the Program, and to require the Employee to sign any additional
agreements or undertakings that may be necessary to accomplish the foregoing. The Employee agrees to
take any and all actions, and consents to any and all actions taken by the Company and its Subsidiaries, as
may be required to allow the Company and its Subsidiaries to comply with local laws, rules and regulations
in the Employee’s country. In addition, the Employee agrees to take any and all actions as may be required
to comply with the Employee’s personal obligations under local laws, rules and regulations in the
Employee’s country.
18. 	Determinations. Each decision, determination, interpretation or other action made or taken pursuant to the
provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be
final, conclusive and binding for all purposes and upon all persons, including, without limitation, the
Company, the Employee, the Employee’s Representative, and the person or persons to whom rights under
the Award have passed by will or the laws of descent or distribution.
19. 	Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to
current or future participation in the Program by electronic means. The Employee hereby consents to
receive such documents by electronic delivery and agrees to participate in the Program through an on-line or
electronic system established and maintained by the Company or a third party designated by the Company.
20. 	Addendum. This grant of Units shall be subject to any special terms and conditions set forth in any
Addendum to this Agreement for the Employee’s country. Moreover, if the Employee relocates to one of
the countries included in the Addendum, the special terms and conditions for such country will apply to the
Employee, to the extent the Company determines that the application of such terms and conditions is
necessary or advisable in order to comply with local law or facilitate the administration of the Program (or
the Company may establish alternative terms and conditions as may be necessary or advisable to
accommodate the Employee’s relocation). The Addendum constitutes part of this Agreement.
21. 	Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, and each other provision of this
Agreement shall be severable and enforceable to the extent permitted by law. To the extent a court or
tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or
unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to
revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full
extent permitted under local law.
22. 	Entire Agreement. This Agreement and the Program constitute the entire agreement between the
Employee and the Company regarding the Award and supersede all prior and contemporaneous agreements
and understandings, oral or written, between the parties

-- 131 of 409 --

12
regarding the Award. Except as expressly set forth herein, this Agreement (and any provision of this
Agreement) may not be modified, changed, clarified, or interpreted by the parties, except in a writing
specifying the modification, change, clarification, or interpretation, and signed by a duly authorized
Company officer.
23. 	Succession. This Agreement shall be binding upon and operate for the benefit of the Company and its
successors and assigns, and the Employee, the Employee’s Representative, and the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution.
24. 	Language. If the Employee has received this Agreement or any other document related to the Program
translated into a language other than English and if the meaning of the translated version is different than the
English version, the English version will control.
25. 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
U.S. State of Illinois without giving effect to any state’s conflict of laws principles.
26. 	Venue. For any legal action relating to this Agreement, the parties to this Agreement consent to the
exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there
is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County,
Illinois, USA.
* 	* 	*
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer as of the
grant date above set forth.
ABBOTT LABORATORIES
By
Robert B. Ford
President and Chief Executive Officer

-- 132 of 409 --

13
ADDENDUM TO THE ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT
In addition to the terms and conditions set forth in the Agreement, the Award is subject to the following terms and
conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Program. If the
Employee is employed in a country identified in the Addendum, the additional terms and conditions for such country shall
apply. If the Employee transfers residence and/or employment to a country identified in the Addendum, the additional terms
and conditions for such country shall apply to the extent the Company determines, in its sole discretion, that the application
of such terms and conditions is necessary or advisable to comply with local law or to facilitate administration of the Program
(or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the
Employee’s transfer).
EUROPEAN UNION / EUROPEAN ECONOMIC AREA, SWITZERLAND AND THE UNITED KINGDOM
Data Privacy. The following provision replaces Section 10 of the Agreement in its entirety:
Pursuant to applicable personal data protection laws, Abbott and the Subsidiary that employs the Employee (the
“Employer”) hereby notifies the Employee of the following in relation to the Employee’s Personal Data (defined below) and
the collection, processing and transfer in electronic or other form of such Personal Data in relation to the administration of
the Units and the Employee’s participation in the Program. The collection, processing and transfer of the Employee’s
Personal Data is necessary for the legitimate purpose of Abbott and the Employer’s administration of the Units and the
Employee’s participation in the Program, and the Employee’s denial and/or objection to the collection, processing and
transfer of Personal Data may affect the Employee’s participation in the Program. As such, by accepting the Units, the
Employee acknowledges the collection, use, processing and transfer of Personal Data as described herein.
Abbott and the Employer hold certain personally identifiable information about the Employee, specifically, the Employee’s
name, home address and telephone number, date of birth, social security number or other employee identification number,
salary, nationality, job title, any Shares or directorships held in Abbott, details of all Units or any other entitlement to Shares
awarded, canceled, purchased, vested, unvested or outstanding in the Employee’s favor, for the purpose of managing and
administering the Program (“Personal Data”). The Personal Data may be provided by the Employee or collected, where
lawful, from third parties. Abbott or the Employer each act as controllers of the Personal Data and will process the Personal
Data in this context for the exclusive legitimate purpose of implementing, administering and managing the Employee’s
participation in the Program and meeting related legal obligations associated with these actions.
The processing will take place through electronic and non-electronic means according to logics and procedures correlated to
the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by
applicable laws and regulations. Personal Data will be accessible within Abbott’s organization only by those persons
requiring access for purposes of the implementation, administration and operation of the Program and other aspects of the
employment relationship and for the Employee’s participation in the Program.
Abbott and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation,
administration and management of the Employee’s participation in the Program, and Abbott and the Employer may each
further transfer Personal Data to third parties assisting Abbott or the

-- 133 of 409 --

14
Employer in the implementation, administration and management of the Program, including UBS Financial Services Inc. or
any successor or other third party that Abbott, the Employer or UBS Financial Services Inc. (or its successor) may engage to
assist with the administration of the Program from time to time. These recipients may be located in the European Economic
Area, Switzerland, the United Kingdom, or elsewhere throughout the world, such as the United States. By participating in
the Program, the Employee understands that these recipients may receive, possess, use, retain and transfer the Personal Data,
in electronic or other form, for purposes of implementing, administering and managing the Employee’s participation in the
Program, including any requisite transfer of such Personal Data as may be required for the administration of the Program
and/or the subsequent holding of Shares on the Employee’s behalf to a broker or other third party with whom the Employee
may elect to deposit any Shares acquired pursuant to the Program. The Employee further understands that he or she may
request a list with the names and addresses of any potential recipients of the Employee’s Personal Data by contacting the
Employee’s local human resources manager or Abbott's human resources Department. When transferring Personal Data to
these potential recipients, Abbott and the Employer provide appropriate safeguards in accordance with EU Standard
Contractual Clauses, the EU-U.S. Privacy Shield Framework, or other legally binding and permissible arrangements. The
Employee may request a copy of such safeguards from the Employee’s local human resources manager or Abbott's human
resources department.
To the extent provided by law, the Employee may, at any time, have the right to request: access to Personal Data,
rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of
Personal Data. The Employee may also have the right to object, on grounds related to a particular situation, to the processing
of Personal Data, as well as opt-out of the Program herein, in any case without cost, by contacting in writing the Employee’s
human resources manager. The Employee’s provision of Personal Data is a contractual requirement. The Employee
understands, however, that the only consequence of refusing to provide Personal Data is that Abbott and the Employer may
not be able to let the Employee participate in the Program, or grant other equity awards or administer or maintain such
awards. For more information on the consequences of the Employee’s refusal to provide Personal Data, the Employee
understands that the Employee may contact his or her local human resources manager or Abbott's human resources
department.
When Abbott and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for
compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems
and/or records containing the Personal Data and/or take steps to properly anonymize it so that the Employee can no longer
be identified from it.
ALGERIA
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
AUSTRALIA
1. 	Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Program, the Employee will not
be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Program if the provision
of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act,
or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.
2. 	Australian Offer Document. In addition to the Agreement and the Program, the Employee must review the
Australian Offer Document and the Australian Addendum to the Program for additional

-- 134 of 409 --

15
important information pertaining to the Award. Both of these documents can be accessed in the library section of the UBS
website at www.ubs.com/onesource/abt. By accepting the Award, the Employee acknowledges and confirms that the
Employee has reviewed these documents.
BRAZIL
Labor Law Acknowledgment. The Employee agrees, for all legal purposes, (i) the benefits provided under the Agreement
and the Program are the result of commercial transactions unrelated to the Employee’s employment; (ii) the Agreement and
the Program are not a part of the terms and conditions of the Employee’s employment; and (iii) the income from the Units, if
any, is not part of the Employee’s remuneration from employment.
CANADA
1. 	Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the
Award shall be settled only in Shares (and may not be settled in cash).
2. 	Resale Restriction. The Employee understands that the Employee is permitted to sell Shares acquired under the
Program through the designated broker appointed under the Program, provided the resale of Shares takes place outside of
Canada through the facilities of the stock exchange on which the Shares are traded. The principal market for the Shares is the
New York Stock Exchange under the symbol "ABT". Shares are also listed on the Chicago Stock Exchange and traded on
various regional and electronic exchanges. Outside the United States, the Shares are listed on the SIX Swiss Exchange.
3. 	English Language. The parties to the Agreement acknowledge that it is their express wish that the Agreement, as
well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or
indirectly hereto, be drawn up in English. Les parties reconnaissent avoir exigé la rédaction en anglais de la présente
convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou
indirectement, relativement à ou suite à la présente convention.
4. 	Data Privacy. The following provision supplements Section 10 of the Agreement:
The Employee hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant
information from all personnel involved in the administration and operation of the Program. The Employee further
authorizes the Company and any of its Subsidiaries to disclose and discuss the Program with their advisors. The Employee
further authorizes the Company and any of its Subsidiaries to record such information and to keep such information in the
Employee’s employee file.
CHILE
Private Placement. The following provision shall replace Section 12 of the Agreement:
The grant of the Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be
a private placement.
a) The starting date of the offer will be the Grant Date (as defined in the Agreement), and this offer conforms to
General Ruling no. 336 of the Chilean Commission for the Financial Market;

-- 135 of 409 --

16
b) The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the
Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight;
c) The issuer is not obligated to provide public information in Chile regarding the foreign securities, as such securities
are not registered with the Chilean Commission for the Financial Market; and
d) The foreign securities shall not be subject to public offering as long as they are not registered with the
corresponding registry of securities in Chile.
a) La fecha de inicio de la oferta será el de la fecha de otorgamiento (o “Grant Date”, según este término se define en
el documento denominado “Agreement”) y esta oferta se acoge a la norma de Carácter General n° 336 de la
Comisión para el Mercado Financiero de Chile;
b) La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva
la Comisión para el Mercado Financiero de Chile, por lo que tales valores no están sujetos a la fiscalización de
ésta;
c) Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información
pública respecto de esos valores; y
d) Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores
correspondiente.
CHINA
The following provisions shall apply to individuals who are subject to the People’s Republic of China (“China”) exchange
control requirements, as determined by the Company in its sole discretion:
1. 	Treatment of Units upon Retirement. Provided that the Employee is not subject to Section 16 of the Exchange Act
pursuant to Rule 16a-2 promulgated thereunder, if the Employee experiences a Termination due to Retirement, Restrictions
on the Units shall lapse on the date of the Termination, and any Units not previously settled on a Delivery Date shall be
settled in the form of Shares as soon as administratively possible after, and effective as of, the date of Termination.
2. 	Foreign Exchange Control Laws. The Employee agrees to hold the Shares received upon settlement of the Units
with the Company’s designated broker. Upon a Termination, the Employee shall be required to sell all Shares issued
pursuant to the Units within 90 days (or such shorter period as may be required by the State Administration of Foreign
Exchange) of the Termination date and repatriate the sales proceeds to China in the manner designated by the Company. For
purposes of the foregoing, the Company shall establish procedures for effectuating the forced sale of the Shares (including
procedures whereby the Company may issue sell instructions on behalf of the Employee), and the Employee hereby agrees
to comply with such procedures and take any and all actions as the Company determines, in its sole discretion, are necessary
or advisable for purposes of complying with local laws, rules and regulations in China.
The Employee understands and agrees that the repatriation of dividends and sales proceeds may need to be effected through
a special exchange control account established by the Company or its Subsidiaries, and the Employee hereby consents and
agrees that sales proceeds from the sale of Shares acquired under the Program may be transferred to such account by the
Company on the Employee’s behalf prior to being delivered to the Employee. The sales proceeds may be paid to the
Employee in U.S. dollars or local

-- 136 of 409 --

17
currency at the Company’s discretion. If the sales proceeds are paid to the Employee in U.S. dollars, the Employee
understands that the Employee will be required to set up a U.S. dollar bank account in China so that the proceeds may be
deposited into this account. If the sales proceeds are paid to the Employee in local currency, the Employee acknowledges
that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face
delays in converting the dividends and proceeds to local currency due to exchange control restrictions. The Employee
agrees to bear any currency fluctuation risk between the time the Shares are sold and the net proceeds are converted into
local currency and distributed to the Employee. The Employee further agrees to comply with any other requirements that
may be imposed by the Company or its Subsidiaries in China in the future in order to facilitate compliance with exchange
control requirements in China. The Employee agrees to be subject to these restrictions even after Termination.
Neither the Company nor any of its Subsidiaries shall be liable for any costs, fees, lost interest or dividends or other losses
the Employee may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the
Company’s operation and enforcement of the Program, the Agreement and the Units in accordance with Chinese law
including, without limitation, any applicable State Administration of Foreign Exchange rules, regulations and requirements.
CROATIA
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
DENMARK
Treatment of Units upon Termination. Notwithstanding any provisions in the Agreement to the contrary, if the Employee is
determined to be an “Employee,” as defined in Section 2 of the Danish Act on the Use of Rights to Purchase or Subscribe
for Shares etc. in Employment Relationships, as in effect prior to January 1, 2019 (the “Stock Option Act”), the treatment of
the Units upon a Termination shall be governed by Sections 4 and 5 of the Stock Option Act. However, if the provisions in
the Agreement or the Program governing the treatment of the Units upon a Termination are more favorable, the provisions of
the Agreement or the Program will govern.
FINLAND
Withholding of Tax-Related Items. Notwithstanding Section 7 of the Agreement, if the Employee is a local national of
Finland, any Tax-Related Items shall be withheld only in cash from the Employee’s regular salary/wages or other amounts
payable to the Employee in cash, or such other withholding methods as may be permitted under the Program and allowed
under local law.
FRANCE
1. 	Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1
and seq. of the French commercial code.
2. 	English Language. The parties to the Agreement acknowledge that it is their express wish that the Agreement, as
well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or
indirectly hereto, be drawn up in English. Les parties reconnaissent avoir exigé la rédaction en anglais de la présente
convention, ainsi que de tous

-- 137 of 409 --

18
documents exécutés, avis donnés et procédures judiciaires intentées, directement ou indirectement, relativement à ou
suite à la présente convention.
HONG KONG
1. 	Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the
Award shall be settled only in Shares (and may not be settled in cash).
2. 	Lapse of Restrictions. If, for any reason, Shares are issued to the Employee within six (6) months of the Grant Date,
the Employee agrees that he or she will not sell or otherwise dispose of any such Shares prior to the six-month anniversary
of the Grant Date.
3. 	IMPORTANT NOTICE. WARNING: The contents of the Agreement, the Addendum, the Program, and all other
materials pertaining to the Units and/or the Program have not been reviewed by any regulatory authority in Hong Kong. The
Employee is hereby advised to exercise caution in relation to the offer thereunder. If the Employee has any doubts about any
of the contents of the aforesaid materials, the Employee should obtain independent professional advice.
4. 	Wages. The Units and Shares subject to the Units do not form part of the Employee’s wages for the purposes of
calculating any statutory or contractual payments under Hong Kong law.
5. 	Nature of the Program. The Company specifically intends that the Program will not be treated as an occupational
retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court,
tribunal or legal/regulatory body in Hong Kong determines that the Program constitutes an occupational retirement scheme
for the purposes of ORSO, the grant of the Units shall be null and void.
INDIA
Repatriation Requirements. As a condition of this Award, the Employee agrees to repatriate all sales proceeds and dividends
attributable to Shares acquired under the Program in accordance with local foreign exchange rules and regulations. Neither
the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to
comply with applicable laws.
ISRAEL
1. 	Securities Law Notice. The Israeli Securities Authority granted to the Company an exemption from the requirement
to file a prospectus with respect to the Program. A copy of the Program and the Form S-8 registration statement for the
Program filed with the United States Securities and Exchange Commission can be accessed in the library section of the UBS
website at www.ubs.com/onesource/abt or are available free of charge upon request from the Employee’s local human
resources department.
2. 	Holding and Sale of Shares. In consideration for the grant of the Award, the Employee agrees to hold the Shares
received upon settlement of the Units subject to the Award and any ad all previously granted restricted stock units with the
Company’s designated broker. The Employee understands and agrees that upon the Employee’s sale of Shares, unless
otherwise determined by the Company, (a) the repatriation of sales proceeds shall be effected through the Subsidiary that
employs the Employee, (b) the Subsidiary that employs the Employee will withhold the requisite tax and other mandatory
withholding (e.g., National Insurance payments) from the sales proceeds and (c) the Subsidiary that employs the Employee
will transfer the remaining sale proceeds (net of the requisite tax and other mandatory

-- 138 of 409 --

19
withholding) to the Employee. The Employee acknowledges and agrees that the process and requirements set forth herein
shall continue to apply following the Employee’s Termination.
3. 	Indemnification for Tax Liabilities. As a condition of the grant of Units, the Employee expressly consents and
agrees to indemnify the Company and/or its Subsidiaries and hold them harmless from any and all liability attributable to
taxes, interest or penalties thereon, including without limitation, liabilities relating to the necessity to withhold any taxes.
MEXICO
1. 	Commercial Relationship. The Employee expressly acknowledges that the Employee’s participation in the Program
and the Company’s grant of the Award does not constitute an employment relationship between the Employee and the
Company. The Employee has been granted the Award as a consequence of the commercial relationship between the
Company and the Company’s Subsidiary in Mexico that employs the Employee, and the Company’s Subsidiary in Mexico is
the Employee’s sole employer. Based on the foregoing: (a) the Employee expressly acknowledges that the Program and the
benefits derived from participation in the Program do not establish any rights between the Employee and the Subsidiary in
Mexico that employs the Employee; (b) the Program and the benefits derived from participation in the Program are not part
of the employment conditions and/or benefits provided by the Subsidiary in Mexico that employs the Employee; and (c) any
modifications or amendments of the Program or benefits granted thereunder by the Company, or a termination of the
Program by the Company, shall not constitute a change or impairment of the terms and conditions of the Employee’s
employment with the Subsidiary in Mexico.
2. 	Extraordinary Item of Compensation. The Employee expressly recognizes and acknowledges that the Employee’s
participation in the Program is a result of the discretionary and unilateral decision of the Company, as well as the
Employee’s free and voluntary decision to participate in the Program in accord with the terms and conditions of the
Program, the Employee’s Agreement and this Addendum. As such, the Employee acknowledges and agrees that the
Company may, in its sole discretion, amend and/or discontinue the Employee’s participation in the Program at any time and
without any liability. The value of the Units is an extraordinary item of compensation outside the scope of the Employee’s
employment contract, if any. The Units are not part of the Employee’s regular or expected compensation for purposes of
calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or
retirement benefits, or any similar payments, which are the exclusive obligations of the Company’s Subsidiary in Mexico
that employs the Employee.
MOROCCO
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
NETHERLANDS
Waiver of Termination Rights. The Employee waives any and all rights to compensation or damages as a result of a
Termination, insofar as those rights result or may result from: (a) the loss or diminution in value of such rights or
entitlements under the Program; or (b) the Employee ceasing to have rights, or ceasing to be entitled to any Awards under
the Program as a result of such Termination.

-- 139 of 409 --

20
NEW ZEALAND
Securities Law Notice.
Warning
This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Program and the Agreement,
will be converted into Shares. Shares give you a stake in the ownership of Abbott Laboratories. You may receive a return if
dividends are paid.
If Abbott Laboratories runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of
preference shares have been paid. You may lose some or all of your investment.
New Zealand law normally requires people who offer financial products to give information to investors before they invest.
This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer
because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually
required. You will also have fewer other legal protections for this investment.
Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting rights) with respect to
the underlying Shares.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The Shares are quoted on the New York Stock Exchange. This means that if you acquire Shares under the Program, you
may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you
invested. The price will depend on the demand for the Shares.
You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed
below:
1. Abbott Laboratories’ most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-
edgar?CIK=abt&owner=exclude&action=getcompany&Find=Search
2. Abbott Laboratories’ most recent published financial statements (Form 10-Q or 10-K) and the auditor’s
report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?
CIK=abt&owner=exclude&action=getcompany&Find=Search
3. The Abbott Laboratories 2017 Incentive Stock Program: This document can be accessed in the library
section of the UBS website at www.ubs.com/onesource/abt.
4. Abbott Laboratories 2017 Incentive Stock Program Prospectus: This document can be accessed in the
library section of the UBS website at www.ubs.com/onesource/abt.
A copy of the above documents will be sent to you free of charge on written request being mailed to: Senior Manager,
Equity Programs, Abbott Laboratories, D058G, AP6B-2, Abbott Park, IL 60064, USA.
PAKISTAN
1. 	Repatriation Requirements. As a condition of this Award, the Employee agrees to repatriate all Dividend
Equivalents and all sales proceeds and dividends attributable to Shares acquired under the Program in accordance with local
foreign exchange rules and regulations. Neither the Company nor any

-- 140 of 409 --

21
of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to comply with applicable
laws.
2. 	Exchange Control Obligations. To the extent applicable, the Employee is required to comply with certain consent
and reporting requirements to the State Bank of Pakistan (Pakistan’s central bank) under the exchange control laws of
Pakistan. As the exchange control regulations can change frequently and at times, without notice, the Employee should
consult his or her legal advisor prior to acquiring or selling Shares under the Program to ensure compliance with current
regulations. Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the
Employee’s failure to comply with applicable laws.
PHILIPPINES
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
ROMANIA
1. 	Termination. A Termination shall include the situation where the Employee’s employment contract is terminated by
operation of law on the date the Employee reaches the standard retirement age and has completed the minimum contribution
record for receipt of state retirement pension or the relevant authorities award the Employee an early-retirement pension of
any type.
2. 	English Language. The Employee hereby expressly agrees that this Agreement, the Program as well as all
documents, notices and proceedings entered into, relating directly or indirectly hereto, be drawn up or communicated only in
the English language. Angajatul consimte în mod expres prin prezentul ca acest Contract, Programul precum şi orice alte
documente, notificări, înştiinţări legate direct sau indirect de acest Contract să fie redactate sau efectuate doar în limba
engleză.
RUSSIA
1. 	Sale or Transfer of Shares. Notwithstanding anything to the contrary in the Program or the Agreement, the
Employee shall not be permitted to sell or otherwise dispose of the Shares acquired pursuant to the Award in Russia. The
Employee may sell the Shares only through a broker established and operating outside Russia.
2. 	Cash Payments to a Russian Bank Account. The Employee agrees to promptly repatriate proceeds resulting from
the sale of Shares acquired under the Program to a foreign currency account at an authorized bank in Russia if legally
required at the time Shares are sold and to comply with all applicable local foreign exchange rules and regulations. Neither
the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to
comply with applicable laws.
SINGAPORE
Qualifying Person Exemption. The grant of the Award under the Program is being made pursuant to the “Qualifying
Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the “SFA”). The
Program has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is
not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability
under the SFA in relation to the content of prospectuses would not apply. The Employee should note that, as a result,
the Award is subject

-- 141 of 409 --

22
to section 257 of the SFA and the Employee will not be able to make: (a) any subsequent sale of the Shares underlying the
Award in Singapore; or (b) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such
sale or offer is made pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the
SFA.
SOUTH AFRICA
1. 	Exchange Control Obligations. The Employee is solely responsible for complying with applicable exchange control
regulations and rulings (the “Exchange Control Regulations”) in South Africa. As the Exchange Control Regulations change
frequently and without notice, the Employee should consult the Employee’s legal advisor prior to the acquisition or sale of
Shares under the Program to ensure compliance with current Exchange Control Regulations. Neither the Company nor any
of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to comply with applicable
laws.
2. 	Securities Law Information and Deemed Acceptance of Units. Neither the Units nor the underlying Shares shall be
publicly offered or listed on any stock exchange in South Africa. The offer is intended to be private pursuant to Section
96(1)(g)(ii) of the Companies Act, 71 of 2008 (the “Companies Act”) and is not subject to the supervision of any South
African governmental authority.
Pursuant to Section 96(1)(g)(ii) of the Companies Act, the Units offer must be finalized within six (6) months following the
date the offer is communicated to the Employee. If the Employee does not want to accept the Units, the Employee is
required to decline the Units no later than the six (6) months following the date the offer is communicated to the Employee.
If the Employee does not reject the Units within six (6) months following the date the offer is communicated to the
Employee, the Employee will be deemed to accept the Units.
SPAIN
1. 	Acknowledgement of Discretionary Nature of the Program; No Vested Rights
By accepting the Award, the Employee consents to participation in the Program and acknowledges receipt of a copy of the
Program.
The Employee understands that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the
Program to individuals who may be employees of the Company or its Subsidiaries throughout the world. The decision is a
limited decision that is entered into upon the express assumption and condition that any grant will not economically or
otherwise bind the Company or any of its Subsidiaries on an ongoing basis. Consequently, the Employee understands that
the Units are granted on the assumption and condition that the Units and the Shares acquired upon settlement of the Units
shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be
considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.
In addition, the Employee understands that this grant would not be made to the Employee but for the assumptions and
conditions referenced above; thus, the Employee acknowledges and freely accepts that should any or all of the assumptions
be mistaken or should any of the conditions not be met for any reason the Award shall be null and void.
The Employee understands and agrees that, as a condition of the Award, unless otherwise provided in Section 4 of the
Agreement, any unvested Units as of the date the Employee ceases active employment will be forfeited without entitlement
to the underlying Shares or to any amount of indemnification in the

-- 142 of 409 --

23
event of Termination. The Employee acknowledges that the Employee has read and specifically accepts the conditions
referred to in the Agreement regarding the impact of a Termination on the Units.
2. 	Termination for Cause. Notwithstanding anything to the contrary in the Program or the Agreement, “Cause” shall be
as defined as set forth in the Agreement, regardless of whether the Termination is considered a fair termination (i.e.,
“despido procedente”) under Spanish legislation.
TUNISIA
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
UKRAINE
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
UNITED KINGDOM
1. 	Withholding Taxes. The following provision supplements Section 7 of the Agreement.
The Employee agrees that he or she is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related
Items as and when requested by the Company or the Subsidiary in the United Kingdom that employs the Employee (the
“Employer”) or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant
authority). The Employee also agrees to indemnify and keep indemnified the Company and the Employer against any Tax-
Related Items that they are required to pay or withhold or have paid or will pay on the Employee’s behalf to HMRC (or any
other tax authority or any other relevant authority).
Notwithstanding the foregoing, if the Employee is a director or executive officer of the Company (within the meaning of
Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), he or she would not be eligible to have the
Company or the Employer cover any income tax liability on his or her behalf. In this case, any income tax not collected
from or paid by the Employee within 90 days after the end of the U.K. tax year in which the event giving rise to the income
tax liability occurred (or such other period specified in U.K. law) will constitute a benefit to the Employee on which
additional income tax and national insurance contributions (“NICs”) will be payable. The Employee will be responsible for
paying and reporting any income tax due on this additional benefit directly to HMRC under the self-assessment regime and
for reimbursing the Company or the Employer (as applicable) the value of any employee NICs due on this additional benefit,
which the Company or the Employer may recover from the Employee by any of the means referred to in Section 7 of the
Agreement.
2. 	Exclusion of Claim. The Employee acknowledges and agrees that the Employee will have no entitlement to
compensation or damages insofar as such entitlement arises or may arise from the Employee’s ceasing to have rights under
or to be entitled to the Units, whether or not as a result of Termination (whether the Termination is in breach of contract or
otherwise), or from the loss or diminution in value of the Units. Upon the grant of the Award, the Employee shall be deemed
to have waived irrevocably any such entitlement.

-- 143 of 409 --

24
UZBEKISTAN
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
VIETNAM
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.

-- 144 of 409 --

Exhibit 10.57
ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT
On «Grant_Date» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the
“Employee”) a Performance Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the
“Units”).
The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the
Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement. In the
event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus,
and the Program administrative rules, the Program shall control. This Award is intended to conform with the qualified
performance-based compensation requirements of Section 162(m) of the Code and the regulations thereunder, to the extent
applicable, and shall be construed accordingly.
The terms and conditions of the Award are as follows:
1. 	Definitions. To the extent not defined herein, capitalized terms shall have the same meaning as in the
Program.
(a) 	Agreement: This Performance Restricted Stock Unit Agreement.
(b) 	Cause: Cause shall mean the following, as determined by the Company in its sole discretion:
(i) 	material breach by the Employee of the terms and conditions of the Employee’s
employment, including, but not limited to:
(A) 	material breach by the Employee of the Code of Business Conduct;
(B) 	material breach by the Employee of the Employee’s employment contract, if any;
(C) 	commission by the Employee of an act of fraud, embezzlement or theft in
connection with the Employee’s duties or in the course of the Employee’s
employment;
(D) 	wrongful disclosure by the Employee of secret processes or confidential
information of the Company or any of its Subsidiaries; or
(E) 	failure by the Employee to substantially perform the duties of the Employee’s
employment (other than any such failure resulting from the Employee’s Disability);
or
(ii) 	to the extent permitted by applicable law, engagement by the Employee, directly or
indirectly, for the benefit of the Employee or others, in any activity, employment or business
which is competitive with the Company or any of its Subsidiaries.

-- 145 of 409 --

2
(c) 	Code of Business Conduct: The Company’s Code of Business Conduct, as amended from time to
time.
(d) 	Controlled Group:
(i) 	Abbott and any corporation, partnership and proprietorship under common control (as
defined under the aggregation rules of subsections 414 (b), (c), or (m) of the Code) with
Abbott; and
(ii) 	during the period of the TAP Pharmaceutical Products Inc. (“TAP”) joint venture between
Takeda Pharmaceutical Company Limited and Abbott ending April 30, 2008, TAP and any
corporation, partnership and proprietorship under common control (as defined above) with
TAP.
(e) 	Data: Certain personal information about the Employee held by the Company and the Subsidiary
that employs the Employee (if applicable), including (but not limited to) the Employee’s name,
home address and telephone number, date of birth, social security number or other employee
identification number, salary, nationality, job title, any Shares held in the Company, details of all
Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or
outstanding in the Employee’s favor, for the purpose of managing and administering the Program.
(f) 	Disability: As of a particular date, the Employee is, by reason of any medically determinable
physical or mental impairment that can be expected to result in death or can be expected to last for a
continuous period of not less than 12 months, receiving income replacement benefits for a period of
at least six (6) months under (i) the terms of the Abbott Laboratories Long-Term Disability Plan
(formerly known as the Extended Disability Plan) (the “LTD Plan”), or (ii) if the Employee’s
employer does not participate in the LTD Plan, such similar accident and health plan providing
replacement benefits in which the Employee’s employer participates.
(g) 	Employee’s Representative: The Employee’s legal guardian or other legal representative.
(h) 	Program: The Abbott Laboratories 2017 Incentive Stock Program.
(i) 	Retirement:
(i) 	Except as provided under (iii) below, for employees hired by the Controlled Group prior to
January 1, 2004, Retirement means any of the following:
· 	age 50 with 10 years of service;
· 	age 65 with at least three (3) years of service; or
· 	age 55 with an age and service combination of 70 points, where each year of age is
one (1) point and each year of service is one (1) point.

-- 146 of 409 --

3
(ii) 	Except as provided under (iii) below, for employees hired by the Controlled Group after
December 31, 2003, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iii) 	For participants in the Abbott Laboratories Pension Plan for Former BASF and Former
Solvay Employees, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iv) 	For purposes of calculating service under this Section 1(i), except as otherwise provided by
the Committee or its delegate, service is earned only if performed for a member of the
Controlled Group while that Controlled Group member is a part of the Controlled Group.
Program administrative rules apply in determining Retirement eligibility and credited
service.
(v) 	If an Employee has a Termination and (A) as of the date of that Termination met the
definition of Retirement, and (B) is subsequently rehired by a member of the Controlled
Group, then for purposes of this Agreement that Employee will continue to be treated as
meeting the definition of Retirement.
(j) 	Termination: A severance of employment for any reason (including Retirement) from the Company
and all Subsidiaries. Any Termination shall be effective on the last day the Employee performs
services for or on behalf of the Company or its Subsidiary, and employment shall not be extended
by any statutory or common law notice of termination period.
2. 	Delivery Dates and Shareholder Rights. The Delivery Dates for Shares underlying the Units are the
respective dates on which the Shares are payable to the Employee pursuant to Section 4 below. Prior to the
Delivery Date(s):
(a) 	the Employee shall not be treated as a shareholder as to those Shares underlying the Units, and shall
have only a contractual right to receive Shares, unsecured by any assets of the Company or its
Subsidiaries;
(b) 	the Employee shall not be permitted to vote the Shares underlying the Units; and
(c) 	the Employee’s right to receive such Shares will be subject to the adjustment provisions relating to
mergers, reorganizations, and similar events set forth in the Program.
Subject to the requirements of local law, the Employee shall receive cash payments equal to the dividends
and distributions paid on Shares underlying the Units (the “Dividend

-- 147 of 409 --

4
Equivalents”) (other than dividends or distributions of securities of the Company which may be issued with
respect to its Shares by virtue of any stock split, combination, stock dividend or recapitalization) to the same
extent and on the same date (or as soon as practicable thereafter) as if each Unit were a Share; provided,
however, that no Dividend Equivalents shall be payable to or for the benefit of the Employee with respect to
dividends or distributions the record date for which occurs on or after the date the Employee has forfeited
the Units, or the date the Units are settled. For purposes of compliance with the requirements of Code
Section 409A, to the extent applicable, the specified date for payment of any Dividend Equivalents to which
the Employee is entitled under this Section 2 is the calendar year during the term of this Agreement in which
the associated dividends or distributions are paid on Shares underlying the Units. The Employee shall have
no right to determine the year in which Dividend Equivalents will be paid.
3. 	Restrictions. The Units are subject to the forfeiture provisions in Sections 5 and 6 below. The Units are not
earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of
(collectively, the “Restrictions”) until the Units are settled.
4. 	Lapse of Restrictions. Subject to Sections 5 and 6 below:
(a) 	During Employment. While the Employee is employed with the Company or its Subsidiaries:
(i) 	the Restrictions on one-third of the total number of Units will lapse on «M_1st_yr_vest»,
provided the Company’s prior year return on equity is a minimum of [•] percent;
(ii) 	the Restrictions on an additional one-third of the total number of Units will lapse on
«M_2nd_yr_vest», provided the Company’s prior year return on equity is a minimum of [•]
percent; and
(iii) 	the Restrictions on an additional one-third of the total number of Units will lapse on
«M_3rd_yr_vest», provided the Company’s prior year return on equity is a minimum of [•]
percent.
If the Restrictions do not lapse on the respective date set forth in subsection 4(a)(i), (ii), and (iii)
above, such Restrictions shall not lapse at a later date.
Units for which Restrictions have lapsed, as described in this subsection 4(a), shall be settled in the
form of Shares on the date(s) on which such Restrictions lapse (each, a “Delivery Date”). Unless
indicated otherwise, Shares shall be delivered in an equal number (subject to rounding) as of each
Delivery Date.
(b) 	Retirement. The Restrictions shall continue to apply in the event of the Employee’s Termination
due to Retirement, but may lapse thereafter in accordance with the provisions of subsection 4(a), in
which case any Units not previously settled shall be settled in the form of Shares on the Delivery
Date(s) set forth in subsection 4(a) above occurring after the date of such Retirement as if the
Employee had remained employed. Notwithstanding the foregoing, in the event of the Employee’s
death after his or her Termination due to Retirement, for

-- 148 of 409 --

5
any Units not previously settled on a Delivery Date, the restrictions shall lapse on the Employee’s
date of death and the Units will be settled in the form of Shares as soon as administratively possible
after, and effective as of, the date of death.
(c) 	Death. The Restrictions shall lapse on the date of the Employee’s Termination due to death, and
any Units not previously settled on a Delivery Date shall be settled (for the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution) in the form
of Shares as soon as administratively possible after, and effective as of, the date of death.
(d) 	Disability. The Restrictions shall lapse on the date of the Employee’s Disability, and any Units not
previously settled on a Delivery Date shall be settled in the form of Shares as soon as
administratively possible after, and effective as of, the date of Disability.
5. 	Effect of Certain Bad Acts. Any Units not previously settled shall be cancelled and forfeited immediately
if, in the sole opinion and discretion of the Committee or its delegate, the Employee engages in activity that
constitutes Cause, whether or not the Employee experiences a Termination or remains employed with the
Company or a Subsidiary.
6. 	Forfeiture of Units. In the event of the Employee’s Termination for any reason other than Retirement,
death or Disability, any Units with respect to which Restrictions have not lapsed as of the date of
Termination shall be forfeited without consideration to the Employee or the Employee’s Representative. In
the event that the Employee is terminated by the Company other than for Cause, the Company may, in its
sole discretion, cause some or all of the Units not previously settled on a Delivery Date to continue to be
subject to the Restrictions, provided such Restrictions may lapse thereafter in accordance with the
provisions of subsection 4(a), in which case such Units shall be settled in the form of Shares on the Delivery
Date(s) set forth in subsection 4(a) above occurring after the date of such Termination. In accepting this
Award, the Employee acknowledges that in the event of Termination (whether or not in breach of local labor
laws), the Employee’s right to vest in the Units, if any, will terminate effective as of the date that the
Employee is no longer actively employed and will not be extended by any notice period mandated under
local law (e.g., active employment would not include a period of “garden leave” or similar period pursuant
to local law) and that the Committee shall have the exclusive discretion to determine when the Employee is
no longer actively employed for purposes of this Award.
7. 	Withholding Taxes. The Company shall be entitled to withhold, or require the Employee to remit, any
federal, state, local, and other applicable taxes (in U.S. or non-U.S. jurisdictions), including income, social
security and Medicare withholding taxes arising from the grant of the Award, the lapse of Restrictions or the
delivery of Shares pursuant to this Agreement by, without limitation:
(a) 	having the Company withhold Shares;
(b) 	tendering Shares received in connection with the Units back to the Company;
(c) 	delivering other previously acquired Shares having a Fair Market Value approximately equal to the
amount to be withheld;

-- 149 of 409 --

6
(d) 	selling Shares issued pursuant to the Units and having the Company withhold from proceeds of the
sale of such Shares;
(e) 	having the Company or a Subsidiary, as applicable, withhold from any cash compensation payable
to the Employee; or
(f) 	requiring the Employee to repay the Company or Subsidiary, in cash or in Shares, for taxes paid on
the Employee's behalf.
Notwithstanding the foregoing, if the Employee is subject to Section 16 of the Exchange Act pursuant to
Rule 16a-2 promulgated thereunder, any tax withholding obligations shall be satisfied by having the
Company withhold a number of Shares otherwise issuable upon settlement of the Units that is sufficient to
satisfy such obligations consistent with the Company's withholding practices.
If, to satisfy tax withholding obligations, the Company withholds Shares otherwise issuable to the
Employee, the Employee shall be deemed to have been issued the full number of Shares underlying the
Units, subject to the Restrictions set forth in this Agreement.
8. 	No Right to Continued Employment. This Agreement and the Employee’s participation in the Program is
not and shall not be interpreted to:
(a) 	form an employment contract or relationship with the Company or its Subsidiaries;
(b) 	confer upon the Employee any right to continue in the employ of the Company or any of its
Subsidiaries; or
(c) 	interfere with the ability of the Company or its Subsidiaries to terminate the Employee’s
employment at any time.
9. 	Nature of Grant. In accepting this grant of Units, the Employee acknowledges that:
(a) 	The Program is established voluntarily by the Company, it is discretionary in nature and it may be
modified, amended, suspended or terminated by the Company at any time;
(b) 	This Award is a one-time benefit and does not create any contractual or other right to receive future
grants of Units, benefits in lieu of Units, or other Program Benefits in the future, even if Units have
been granted repeatedly in the past;
(c) 	All decisions with respect to future Unit grants, if any, and their terms and conditions, will be made
by the Committee, in its sole discretion;
(d) 	Nothing contained in this Agreement is intended to create or enlarge any other contractual
obligations between the Company and the Employee;
(e) 	The Employee is voluntarily participating in the Program;
(f) 	The Units and Shares subject to the Units are:

-- 150 of 409 --

7
(i) 	extraordinary items that do not constitute compensation of any kind for services of any kind
rendered to the Company or its Subsidiaries, and are outside the scope of the Employee’s
employment contract, if any;
(ii) 	not intended to replace any pension rights or compensation;
(iii) 	not part of the Employee’s normal or expected compensation or salary for any purposes,
including, but not limited to, calculating any severance, resignation, termination,
redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or
retirement or welfare benefits, or similar payments and in no event should be considered as
compensation for, or relating in any way to, past services for the Company or its
Subsidiaries;
(g) 	The future value of the Shares underlying the Units is unknown and cannot be predicted with
certainty;
(h) 	In consideration of the Award, no claim or entitlement to compensation or damages shall arise from
the Units resulting from Termination (for any reason whatsoever) and the Employee irrevocably
releases the Company and its Subsidiaries from any such claim that may arise; if any such claim is
found by a court of competent jurisdiction to have arisen, then, by signing or electronically
accepting this Agreement, the Employee shall be deemed irrevocably to have waived the
Employee’s entitlement to pursue such claim;
(i) 	The Units and the Benefits under the Program, if any, will not automatically transfer to another
company in the case of a merger, take-over or transfer of liability; and
(j) 	Neither the Company nor any of its Subsidiaries shall be liable for any change in value of the Units,
the amount realized upon settlement of the Units or the amount realized upon a subsequent sale of
any Shares acquired upon settlement of the Units, resulting from any fluctuation of the United States
Dollar/local currency foreign exchange rate.
10. 	Data Privacy.
(a) 	Pursuant to applicable personal data protection laws, the collection, processing and transfer of the
Employee’s personal Data is necessary for the Company’s administration of the Program and the
Employee’s participation in the Program. The Employee’s denial and/or objection to the collection,
processing and transfer of personal Data may affect his or her ability to participate in the Program.
As such (where required under applicable law), the Employee:
(i) 	voluntarily acknowledges, consents and agrees to the collection, use, processing and
transfer of personal Data as described herein; and
(ii) 	authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic
or other form, for purposes of implementing, administering and managing the Employee’s
participation in the Program, including any requisite transfer of such Data as may be

-- 151 of 409 --

8
required for the administration of the Program and/or the subsequent holding of Shares on
the Employee’s behalf to a broker or other third party with whom the Employee may elect
to deposit any Shares acquired pursuant to the Program.
(b) 	Data may be provided by the Employee or collected, where lawful, from third parties, and the
Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the
exclusive purpose of implementing, administering and managing the Employee’s participation in the
Program. Data processing will take place through electronic and non-electronic means according to
logics and procedures strictly correlated to the purposes for which the Data is collected and with
confidentiality and security provisions as set forth by applicable laws and regulations in the
Employee’s country of residence. Data processing operations will be performed minimizing the use
of personal and identification data when such operations are unnecessary for the processing
purposes sought. The Data will be accessible within the Company’s organization only by those
persons requiring access for purposes of the implementation, administration and operation of the
Program and for the Employee’s participation in the Program.
(c) 	The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as
necessary for the purpose of implementation, administration and management of the Employee’s
participation in the Program, and the Company and the Subsidiary that employs the Employee (if
applicable) may further transfer Data to any third parties assisting the Company in the
implementation, administration and management of the Program. These recipients may be located
throughout the world.
(d) 	The Employee may, at any time, exercise his or her rights provided under applicable personal data
protection laws, which may include the right to:
(i) 	obtain confirmation as to the existence of the Data;
(ii) 	verify the content, origin and accuracy of the Data;
(iii) 	request the integration, update, amendment, deletion or blockage (for breach of applicable
laws) of the Data; and
(iv) 	oppose, for legal reasons, the collection, processing or transfer of the Data which is not
necessary or required for the implementation, administration and/or operation of the
Program and the Employee’s participation in the Program.
The Employee may seek to exercise these rights by contacting his or her local human resources
manager.
(e) 	Upon request of the Company or the Subsidiary that employs the Employee (if applicable), the
Employee agrees to provide an executed data privacy consent form (or any other agreements or
consents that may be required), as deemed necessary by the Company or the Subsidiary that
employs the Employee (if applicable) for the purpose of administering the Employee’s participation
in the

-- 152 of 409 --

9
Program in compliance with the data privacy laws in the Employee’s country, either now or in the
future. If the Employee fails to provide any such consent or agreement requested by the Company
and/or the Subsidiary that employs the Employee (if applicable) and the Committee or its delegate
determines that the collection, processing and/or transfer of Data without such consent or agreement
would violate the laws in the Employee’s country, the Employee understands and agrees that the
Employee will not be able to participate in the Program and the Award will be null and void.
11. 	Form of Payment. The Company may, in its sole discretion, settle the Employee’s Units in the form of a
cash payment to the extent settlement in Shares: (i) is prohibited under local law; (ii) would require the
Employee, the Company and/or its Subsidiaries to obtain the approval of any governmental and/or
regulatory body in the Employee’s country; (iii) would result in adverse tax consequences for the Employee
or the Company; or (iv) is administratively burdensome. Alternatively, the Company may, in its sole
discretion, settle the Employee’s Units in the form of Shares but require the Employee to sell such Shares
immediately or within a specified period of time following the Employee’s Termination (in which case, this
Agreement shall give the Company the authority to issue sales instructions on the Employee’s behalf).
12. 	Private Placement. The grant of this Unit is not intended to be a public offering of securities in the
Employee’s country. The Company has not submitted any registration statement, prospectus or other filings
with the local securities authorities (unless otherwise required under local law), and this grant of Units is not
subject to the supervision of the local securities authorities.
13. 	Exchange Controls. As a condition to this grant of Units, the Employee agrees to comply with any
applicable foreign exchange rules and regulations.
14. 	Compliance with Applicable Laws and Regulations.
(a) 	The Company shall not be required to issue or deliver any Shares pursuant to this Agreement
pending compliance with all applicable federal and state securities and other laws (including any
registration requirements or tax withholding requirements) and compliance with the rules and
practices of any stock exchange upon which the Company’s Shares are listed.
(b) 	Regardless of any action the Company or its Subsidiaries take with respect to any or all income tax,
social insurance, payroll tax, payment on account or other tax-related items related to the
Employee’s participation in the Program and legally applicable to the Employee or deemed by the
Company or its Subsidiaries to be an appropriate charge to the Employee even if technically due by
the Company or its Subsidiaries (“Tax-Related Items”), the Employee acknowledges that the
ultimate liability for all Tax-Related Items is and remains the Employee’s responsibility and may
exceed the amount actually withheld by the Company or its Subsidiaries. The Employee further
acknowledges that the Company and/or its Subsidiaries: (i) make no representations or undertakings
regarding the treatment of any Tax-Related Items in connection with any aspect of the Units,
including, but not limited to, the grant, lapse of Restrictions or settlement of the Units, the issuance
of Shares upon payment of the Units, the subsequent sale of Shares acquired pursuant to such
issuance and the receipt of any dividends and/or

-- 153 of 409 --

10
any Dividend Equivalents; and (ii) do not commit to and are under no obligation to structure the
terms of the grant or any aspect of the Units to reduce or eliminate the Employee’s liability for Tax-
Related Items or achieve any particular tax result. Further, if the Employee has become subject to
tax in more than one (1) jurisdiction between the date of grant and the date of any relevant taxable
event, the Employee acknowledges that the Company and/or its Subsidiaries may be required to
withhold or account for Tax-Related Items in more than one (1) jurisdiction.
15. 	Code Section 409A. Payments made pursuant to this Agreement are intended to be exempt from or to
otherwise comply with the provisions of Code Section 409A to the extent applicable. The Program and this
Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company
determines that any payments under this Agreement are subject to Code Section 409A and this Agreement
fails to comply with that section’s requirements, the Company may, at the Company’s sole discretion, and
without the Employee’s consent, amend this Agreement to cause it to comply with Code Section 409A or
otherwise be exempt from Code Section 409A.
To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A and
applicable guidance issued thereunder, the Employee shall not be deemed to have had a Termination unless
the Employee has incurred a “separation from service” as defined in Treasury Regulation §1.409A-1(h), and
amounts that would otherwise be payable pursuant to this Agreement during the six-month period
immediately following the Employee’s Termination (including Retirement) shall instead be paid on the first
business day after the date that is six (6) months following the Employee’s Termination (or upon the
Employee’s death, if earlier). For purposes of Code Section 409A, to the extent applicable: (i) all payments
provided hereunder shall be treated as a right to a series of separate payments and each separately identified
amount to which the Employee is entitled under this Agreement shall be treated as a separate payment; (ii)
the term “as soon as administratively possible” means a period of time that is within 60 days after the
Termination due to death or Disability (as applicable); and (iii) the date of the Employee’s Disability shall
be determined by the Company in its sole discretion.
Although this Agreement and the payments provided hereunder are intended to be exempt from or to
otherwise comply with the requirements of Code Section 409A, the Company does not represent or warrant
that this Agreement or the payments provided hereunder will comply with Code Section 409A or any other
provision of federal, state, local, or non-United States law. None of the Company, its Subsidiaries, or their
respective directors, officers, employees or advisers shall be liable to the Employee (or any other individual
claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a
result of compensation paid under this Agreement, and the Company and its Subsidiaries shall have no
obligation to indemnify or otherwise protect the Employee from the obligation to pay any taxes pursuant to
Code Section 409A.
16. 	No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the
Company making any recommendations regarding the Units, the Employee’s participation in the Program or
the Employee’s acquisition or sale of the underlying Shares. The Employee is hereby advised to consult
with the Employee’s own

-- 154 of 409 --

11
personal tax, legal and financial advisors regarding participation in the Program before taking any action
related to the Program.
17. 	Imposition of Other Requirements. The Company reserves the right to impose other requirements on the
Employee’s participation in the Program, on the Units and on any Shares acquired under the Program, to the
extent the Company or its Subsidiaries determines it is necessary or advisable in order to comply with local
law or facilitate the administration of the Program, and to require the Employee to sign any additional
agreements or undertakings that may be necessary to accomplish the foregoing. The Employee agrees to
take any and all actions, and consents to any and all actions taken by the Company and its Subsidiaries, as
may be required to allow the Company and its Subsidiaries to comply with local laws, rules and regulations
in the Employee’s country. In addition, the Employee agrees to take any and all actions as may be required
to comply with the Employee’s personal obligations under local laws, rules and regulations in the
Employee’s country.
18. 	Determinations. Each decision, determination, interpretation or other action made or taken pursuant to the
provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be
final, conclusive and binding for all purposes and upon all persons, including, without limitation, the
Company, the Employee, the Employee’s Representative, and the person or persons to whom rights under
the Award have passed by will or the laws of descent or distribution.
19. 	Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to
current or future participation in the Program by electronic means. The Employee hereby consents to
receive such documents by electronic delivery and agrees to participate in the Program through an on-line or
electronic system established and maintained by the Company or a third party designated by the Company.
20. 	Addendum. This grant of Units shall be subject to any special terms and conditions set forth in any
Addendum to this Agreement for the Employee’s country. Moreover, if the Employee relocates to one of
the countries included in the Addendum, the special terms and conditions for such country will apply to the
Employee, to the extent the Company determines that the application of such terms and conditions is
necessary or advisable in order to comply with local law or facilitate the administration of the Program (or
the Company may establish alternative terms and conditions as may be necessary or advisable to
accommodate the Employee’s relocation). The Addendum constitutes part of this Agreement.
21. 	Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, and each other provision of this
Agreement shall be severable and enforceable to the extent permitted by law. To the extent a court or
tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or
unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to
revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full
extent permitted under local law.
22. 	Entire Agreement. This Agreement and the Program constitute the entire agreement between the
Employee and the Company regarding the Award and supersede all prior and contemporaneous agreements
and understandings, oral or written, between the parties

-- 155 of 409 --

12
regarding the Award. Except as expressly set forth herein, this Agreement (and any provision of this
Agreement) may not be modified, changed, clarified, or interpreted by the parties, except in a writing
specifying the modification, change, clarification, or interpretation, and signed by a duly authorized
Company officer.
23. 	Succession. This Agreement shall be binding upon and operate for the benefit of the Company and its
successors and assigns, and the Employee, the Employee’s Representative, and the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution.
24. 	Language. If the Employee has received this Agreement or any other document related to the Program
translated into a language other than English and if the meaning of the translated version is different than the
English version, the English version will control.
25. 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
U.S. State of Illinois without giving effect to any state’s conflict of laws principles.
26. 	Venue. For any legal action relating to this Agreement, the parties to this Agreement consent to the
exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there
is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County,
Illinois, USA.
* 	* 	*
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer as of the
grant date above set forth.
ABBOTT LABORATORIES
By
Robert B. Ford
President and Chief Executive Officer

-- 156 of 409 --

13
ADDENDUM TO THE ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT
In addition to the terms and conditions set forth in the Agreement, the Award is subject to the following terms and
conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Program. If the
Employee is employed in a country identified in the Addendum, the additional terms and conditions for such country shall
apply. If the Employee transfers residence and/or employment to a country identified in the Addendum, the additional terms
and conditions for such country shall apply to the extent the Company determines, in its sole discretion, that the application
of such terms and conditions is necessary or advisable to comply with local law or to facilitate administration of the Program
(or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the
Employee’s transfer).
EUROPEAN UNION / EUROPEAN ECONOMIC AREA, SWITZERLAND AND THE UNITED KINGDOM
Data Privacy. The following provision replaces Section 10 of the Agreement in its entirety:
Pursuant to applicable personal data protection laws, Abbott and the Subsidiary that employs the Employee (the
“Employer”) hereby notifies the Employee of the following in relation to the Employee’s Personal Data (defined below) and
the collection, processing and transfer in electronic or other form of such Personal Data in relation to the administration of
the Units and the Employee’s participation in the Program. The collection, processing and transfer of the Employee’s
Personal Data is necessary for the legitimate purpose of Abbott and the Employer’s administration of the Units and the
Employee’s participation in the Program, and the Employee’s denial and/or objection to the collection, processing and
transfer of Personal Data may affect the Employee’s participation in the Program. As such, by accepting the Units, the
Employee acknowledges the collection, use, processing and transfer of Personal Data as described herein.
Abbott and the Employer hold certain personally identifiable information about the Employee, specifically, the Employee’s
name, home address and telephone number, date of birth, social security number or other employee identification number,
salary, nationality, job title, any Shares or directorships held in Abbott, details of all Units or any other entitlement to Shares
awarded, canceled, purchased, vested, unvested or outstanding in the Employee’s favor, for the purpose of managing and
administering the Program (“Personal Data”). The Personal Data may be provided by the Employee or collected, where
lawful, from third parties. Abbott or the Employer each act as controllers of the Personal Data and will process the Personal
Data in this context for the exclusive legitimate purpose of implementing, administering and managing the Employee’s
participation in the Program and meeting related legal obligations associated with these actions.
The processing will take place through electronic and non-electronic means according to logics and procedures correlated to
the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by
applicable laws and regulations. Personal Data will be accessible within Abbott’s organization only by those persons
requiring access for purposes of the implementation, administration and operation of the Program and other aspects of the
employment relationship and for the Employee’s participation in the Program.
Abbott and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation,
administration and management of the Employee’s participation in the Program, and Abbott and the Employer may each
further transfer Personal Data to third parties assisting Abbott or the Employer in the implementation, administration and
management of the Program, including UBS

-- 157 of 409 --

14
Financial Services Inc. or any successor or other third party that Abbott, the Employer or UBS Financial Services Inc. (or its
successor) may engage to assist with the administration of the Program from time to time. These recipients may be located in
the European Economic Area, Switzerland, the United Kingdom, or elsewhere throughout the world, such as the United
States. By participating in the Program, the Employee understands that these recipients may receive, possess, use, retain and
transfer the Personal Data, in electronic or other form, for purposes of implementing, administering and managing the
Employee’s participation in the Program, including any requisite transfer of such Personal Data as may be required for the
administration of the Program and/or the subsequent holding of Shares on the Employee’s behalf to a broker or other third
party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program. The Employee further
understands that he or she may request a list with the names and addresses of any potential recipients of the Employee’s
Personal Data by contacting the Employee’s local human resources manager or Abbott's human resources Department.
When transferring Personal Data to these potential recipients, Abbott and the Employer provide appropriate safeguards in
accordance with EU Standard Contractual Clauses, the EU-U.S. Privacy Shield Framework, or other legally binding and
permissible arrangements. The Employee may request a copy of such safeguards from the Employee’s local human
resources manager or Abbott's human resources department.
To the extent provided by law, the Employee may, at any time, have the right to request: access to Personal Data,
rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of
Personal Data. The Employee may also have the right to object, on grounds related to a particular situation, to the processing
of Personal Data, as well as opt-out of the Program herein, in any case without cost, by contacting in writing the Employee’s
human resources manager. The Employee’s provision of Personal Data is a contractual requirement. The Employee
understands, however, that the only consequence of refusing to provide Personal Data is that Abbott and the Employer may
not be able to let the Employee participate in the Program, or grant other equity awards or administer or maintain such
awards. For more information on the consequences of the Employee’s refusal to provide Personal Data, the Employee
understands that the Employee may contact his or her local human resources manager or Abbott's human resources
department.
When Abbott and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for
compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems
and/or records containing the Personal Data and/or take steps to properly anonymize it so that the Employee can no longer
be identified from it.
ALGERIA
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
AUSTRALIA
1. 	Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Program, the Employee will not
be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Program if the provision
of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act,
or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.
2. 	Australian Offer Document. In addition to the Agreement and the Program, the Employee must review the
Australian Offer Document and the Australian Addendum to the Program for additional important information pertaining to
the Award. Both of these documents can be accessed in the library

-- 158 of 409 --

15
section of the UBS website at www.ubs.com/onesource/abt. By accepting the Award, the Employee acknowledges and
confirms that the Employee has reviewed these documents.
BRAZIL
Labor Law Acknowledgment. The Employee agrees, for all legal purposes, (i) the benefits provided under the Agreement
and the Program are the result of commercial transactions unrelated to the Employee’s employment; (ii) the Agreement and
the Program are not a part of the terms and conditions of the Employee’s employment; and (iii) the income from the Units, if
any, is not part of the Employee’s remuneration from employment.
CANADA
1. 	Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the
Award shall be settled only in Shares (and may not be settled in cash).
2. 	Resale Restriction. The Employee understands that the Employee is permitted to sell Shares acquired under the
Program through the designated broker appointed under the Program, provided the resale of Shares takes place outside of
Canada through the facilities of the stock exchange on which the Shares are traded. The principal market for the Shares is the
New York Stock Exchange under the symbol "ABT". Shares are also listed on the Chicago Stock Exchange and traded on
various regional and electronic exchanges. Outside the United States, the Shares are listed on the SIX Swiss Exchange.
3. 	English Language. The parties to the Agreement acknowledge that it is their express wish that the Agreement, as
well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or
indirectly hereto, be drawn up in English. Les parties reconnaissent avoir exigé la rédaction en anglais de la présente
convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou
indirectement, relativement à ou suite à la présente convention.
4. 	Data Privacy. The following provision supplements Section 10 of the Agreement:
The Employee hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant
information from all personnel involved in the administration and operation of the Program. The Employee further
authorizes the Company and any of its Subsidiaries to disclose and discuss the Program with their advisors. The Employee
further authorizes the Company and any of its Subsidiaries to record such information and to keep such information in the
Employee’s employee file.
CHILE
Private Placement. The following provision shall replace Section 12 of the Agreement:
The grant of the Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be
a private placement.
a) The starting date of the offer will be the Grant Date (as defined in the Agreement), and this offer conforms to
General Ruling no. 336 of the Chilean Commission for the Financial Market;
b) The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the
Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight;

-- 159 of 409 --

16
c) The issuer is not obligated to provide public information in Chile regarding the foreign securities, as such securities
are not registered with the Chilean Commission for the Financial Market; and
d) The foreign securities shall not be subject to public offering as long as they are not registered with the
corresponding registry of securities in Chile.
a) La fecha de inicio de la oferta será el de la fecha de otorgamiento (o “Grant Date”, según este término se define en
el documento denominado “Agreement”) y esta oferta se acoge a la norma de Carácter General n° 336 de la
Comisión para el Mercado Financiero de Chile;
b) La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva
la Comisión para el Mercado Financiero de Chile, por lo que tales valores no están sujetos a la fiscalización de
ésta;
c) Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información
pública respecto de esos valores; y
d) Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores
correspondiente.
CHINA
The following provisions shall apply to individuals who are subject to the People’s Republic of China (“China”) exchange
control requirements, as determined by the Company in its sole discretion:
1. 	Treatment of Units upon Retirement. Provided that the Employee is not subject to Section 16 of the Exchange Act
pursuant to Rule 16a-2 promulgated thereunder, if the Employee experiences a Termination due to Retirement, Restrictions
on the Units shall lapse on the date of the Termination, and any Units not previously settled on a Delivery Date shall be
settled in the form of Shares as soon as administratively possible after, and effective as of, the date of Termination.
2. 	Foreign Exchange Control Laws. The Employee agrees to hold the Shares received upon settlement of the Units
with the Company’s designated broker. Upon a Termination, the Employee shall be required to sell all Shares issued
pursuant to the Units within 90 days (or such shorter period as may be required by the State Administration of Foreign
Exchange) of the Termination date and repatriate the sales proceeds to China in the manner designated by the Company. For
purposes of the foregoing, the Company shall establish procedures for effectuating the forced sale of the Shares (including
procedures whereby the Company may issue sell instructions on behalf of the Employee), and the Employee hereby agrees
to comply with such procedures and take any and all actions as the Company determines, in its sole discretion, are necessary
or advisable for purposes of complying with local laws, rules and regulations in China.
The Employee understands and agrees that the repatriation of dividends and sales proceeds may need to be effected through
a special exchange control account established by the Company or its Subsidiaries, and the Employee hereby consents and
agrees that sales proceeds from the sale of Shares acquired under the Program may be transferred to such account by the
Company on the Employee’s behalf prior to being delivered to the Employee. The sales proceeds may be paid to the
Employee in U.S. dollars or local currency at the Company’s discretion. If the sales proceeds are paid to the Employee in
U.S. dollars, the Employee understands that the Employee will be required to set up a U.S. dollar bank account in China so
that the proceeds may be deposited into this account. If the sales proceeds are paid to the Employee in local currency, the
Employee acknowledges that the Company is under no obligation to secure any

-- 160 of 409 --

17
particular exchange conversion rate and that the Company may face delays in converting the dividends and proceeds to local
currency due to exchange control restrictions. The Employee agrees to bear any currency fluctuation risk between the time
the Shares are sold and the net proceeds are converted into local currency and distributed to the Employee. The Employee
further agrees to comply with any other requirements that may be imposed by the Company or its Subsidiaries in China in
the future in order to facilitate compliance with exchange control requirements in China. The Employee agrees to be subject
to these restrictions even after Termination.
Neither the Company nor any of its Subsidiaries shall be liable for any costs, fees, lost interest or dividends or other losses
the Employee may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the
Company’s operation and enforcement of the Program, the Agreement and the Units in accordance with Chinese law
including, without limitation, any applicable State Administration of Foreign Exchange rules, regulations and requirements.
CROATIA
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
DENMARK
Treatment of Units upon Termination. Notwithstanding any provisions in the Agreement to the contrary, if the Employee is
determined to be an “Employee,” as defined in Section 2 of the Danish Act on the Use of Rights to Purchase or Subscribe
for Shares etc. in Employment Relationships, as in effect prior to January 1, 2019 (the “Stock Option Act”), the treatment of
the Units upon a Termination shall be governed by Sections 4 and 5 of the Stock Option Act. However, if the provisions in
the Agreement or the Program governing the treatment of the Units upon a Termination are more favorable, the provisions of
the Agreement or the Program will govern.
FINLAND
Withholding of Tax-Related Items. Notwithstanding Section 7 of the Agreement, if the Employee is a local national of
Finland, any Tax-Related Items shall be withheld only in cash from the Employee’s regular salary/wages or other amounts
payable to the Employee in cash, or such other withholding methods as may be permitted under the Program and allowed
under local law.
FRANCE
1. 	Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1
and seq. of the French commercial code.
2. 	English Language. The parties to the Agreement acknowledge that it is their express wish that the Agreement, as
well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or
indirectly hereto, be drawn up in English. Les parties reconnaissent avoir exigé la rédaction en anglais de la présente
convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou
indirectement, relativement à ou suite à la présente convention.

-- 161 of 409 --

18
HONG KONG
1. 	Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the
Award shall be settled only in Shares (and may not be settled in cash).
2. 	Lapse of Restrictions. If, for any reason, Shares are issued to the Employee within six (6) months of the Grant Date,
the Employee agrees that he or she will not sell or otherwise dispose of any such Shares prior to the six-month anniversary
of the Grant Date.
3. 	IMPORTANT NOTICE. WARNING: The contents of the Agreement, the Addendum, the Program, and all other
materials pertaining to the Units and/or the Program have not been reviewed by any regulatory authority in Hong Kong. The
Employee is hereby advised to exercise caution in relation to the offer thereunder. If the Employee has any doubts about any
of the contents of the aforesaid materials, the Employee should obtain independent professional advice.
4. 	Wages. The Units and Shares subject to the Units do not form part of the Employee’s wages for the purposes of
calculating any statutory or contractual payments under Hong Kong law.
5. 	Nature of the Program. The Company specifically intends that the Program will not be treated as an occupational
retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court,
tribunal or legal/regulatory body in Hong Kong determines that the Program constitutes an occupational retirement scheme
for the purposes of ORSO, the grant of the Units shall be null and void.
INDIA
Repatriation Requirements. As a condition of this Award, the Employee agrees to repatriate all sales proceeds and dividends
attributable to Shares acquired under the Program in accordance with local foreign exchange rules and regulations. Neither
the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to
comply with applicable laws.
ISRAEL
1. 	Securities Law Notice. The Israeli Securities Authority granted to the Company an exemption from the requirement
to file a prospectus with respect to the Program. A copy of the Program and the Form S-8 registration statement for the
Program filed with the United States Securities and Exchange Commission can be accessed in the library section of the UBS
website at www.ubs.com/onesource/abt or are available free of charge upon request from the Employee’s local human
resources department.
2. 	Holding and Sale of Shares. In consideration for the grant of the Award, the Employee agrees to hold the Shares
received upon settlement of the Units subject to the Award and any and all previously granted restricted stock units with the
Company’s designated broker. The Employee understands and agrees that upon the Employee’s sale of Shares, unless
otherwise determined by the Company, (a) the repatriation of sales proceeds shall be effected through the Subsidiary that
employs the Employee, (b) the Subsidiary that employs the Employee will withhold the requisite tax and other mandatory
withholding (e.g., National Insurance payments) from the sales proceeds and (c) the Subsidiary that employs the Employee
will transfer the remaining sale proceeds (net of the requisite tax and other mandatory withholding) to the Employee. The
Employee acknowledges and agrees that the process and requirements set forth herein shall continue to apply following the
Employee’s Termination.

-- 162 of 409 --

19
3. 	Indemnification for Tax Liabilities. As a condition of the grant of Units, the Employee expressly consents and
agrees to indemnify the Company and/or its Subsidiaries and hold them harmless from any and all liability attributable to
taxes, interest or penalties thereon, including without limitation, liabilities relating to the necessity to withhold any taxes.
MEXICO
1. 	Commercial Relationship. The Employee expressly acknowledges that the Employee’s participation in the Program
and the Company’s grant of the Award does not constitute an employment relationship between the Employee and the
Company. The Employee has been granted the Award as a consequence of the commercial relationship between the
Company and the Company’s Subsidiary in Mexico that employs the Employee, and the Company’s Subsidiary in Mexico is
the Employee’s sole employer. Based on the foregoing: (a) the Employee expressly acknowledges that the Program and the
benefits derived from participation in the Program do not establish any rights between the Employee and the Subsidiary in
Mexico that employs the Employee; (b) the Program and the benefits derived from participation in the Program are not part
of the employment conditions and/or benefits provided by the Subsidiary in Mexico that employs the Employee; and (c) any
modifications or amendments of the Program or benefits granted thereunder by the Company, or a termination of the
Program by the Company, shall not constitute a change or impairment of the terms and conditions of the Employee’s
employment with the Subsidiary in Mexico.
2. 	Extraordinary Item of Compensation. The Employee expressly recognizes and acknowledges that the Employee’s
participation in the Program is a result of the discretionary and unilateral decision of the Company, as well as the
Employee’s free and voluntary decision to participate in the Program in accord with the terms and conditions of the
Program, the Employee’s Agreement and this Addendum. As such, the Employee acknowledges and agrees that the
Company may, in its sole discretion, amend and/or discontinue the Employee’s participation in the Program at any time and
without any liability. The value of the Units is an extraordinary item of compensation outside the scope of the Employee’s
employment contract, if any. The Units are not part of the Employee’s regular or expected compensation for purposes of
calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or
retirement benefits, or any similar payments, which are the exclusive obligations of the Company’s Subsidiary in Mexico
that employs the Employee.
MOROCCO
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
NETHERLANDS
Waiver of Termination Rights. The Employee waives any and all rights to compensation or damages as a result of a
Termination, insofar as those rights result or may result from: (a) the loss or diminution in value of such rights or
entitlements under the Program; or (b) the Employee ceasing to have rights, or ceasing to be entitled to any Awards under
the Program as a result of such Termination.

-- 163 of 409 --

20
NEW ZEALAND
Securities Law Notice.
Warning
This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Program and the Agreement,
will be converted into Shares. Shares give you a stake in the ownership of Abbott Laboratories. You may receive a return if
dividends are paid.
If Abbott Laboratories runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of
preference shares have been paid. You may lose some or all of your investment.
New Zealand law normally requires people who offer financial products to give information to investors before they invest.
This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer
because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually
required. You will also have fewer other legal protections for this investment.
Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting rights) with respect to
the underlying Shares.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The Shares are quoted on the New York Stock Exchange. This means that if you acquire Shares under the Program, you
may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you
invested. The price will depend on the demand for the Shares.
You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed
below:
1. Abbott Laboratories’ most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-
edgar?CIK=abt&owner=exclude&action=getcompany&Find=Search
2. Abbott Laboratories’ most recent published financial statements (Form 10-Q or 10-K) and the auditor’s
report on those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?
CIK=abt&owner=exclude&action=getcompany&Find=Search
3. The Abbott Laboratories 2017 Incentive Stock Program: This document can be accessed in the library
section of the UBS website at www.ubs.com/onesource/abt.
4. Abbott Laboratories 2017 Incentive Stock Program Prospectus: This document can be accessed in the
library section of the UBS website at www.ubs.com/onesource/abt.
A copy of the above documents will be sent to you free of charge on written request being mailed to: Senior Manager,
Equity Programs, Abbott Laboratories, D058G, AP6B-2, Abbott Park, IL 60064, USA.]
PAKISTAN
1. 	Repatriation Requirements. As a condition of this Award, the Employee agrees to repatriate all Dividend
Equivalents and all sales proceeds and dividends attributable to Shares acquired under the Program in accordance with local
foreign exchange rules and regulations. Neither the Company nor any

-- 164 of 409 --

21
of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to comply with applicable
laws.
2. 	Exchange Control Obligations. To the extent applicable, the Employee is required to comply with certain consent
and reporting requirements to the State Bank of Pakistan (Pakistan’s central bank) under the exchange control laws of
Pakistan. As the exchange control regulations can change frequently and at times, without notice, the Employee should
consult his or her legal advisor prior to acquiring or selling Shares under the Program to ensure compliance with current
regulations. Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the
Employee’s failure to comply with applicable laws.
PHILIPPINES
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
ROMANIA
1. 	Termination. A Termination shall include the situation where the Employee’s employment contract is terminated by
operation of law on the date the Employee reaches the standard retirement age and has completed the minimum contribution
record for receipt of state retirement pension or the relevant authorities award the Employee an early-retirement pension of
any type.
2. 	English Language. The Employee hereby expressly agrees that this Agreement, the Program as well as all
documents, notices and proceedings entered into, relating directly or indirectly hereto, be drawn up or communicated only in
the English language. Angajatul consimte în mod expres prin prezentul ca acest Contract, Programul precum şi orice alte
documente, notificări, înştiinţări legate direct sau indirect de acest Contract să fie redactate sau efectuate doar în limba
engleză.
RUSSIA
1. 	Sale or Transfer of Shares. Notwithstanding anything to the contrary in the Program or the Agreement, the
Employee shall not be permitted to sell or otherwise dispose of the Shares acquired pursuant to the Award in Russia. The
Employee may sell the Shares only through a broker established and operating outside Russia.
2. 	Cash Payments to a Russian Bank Account. The Employee agrees to promptly repatriate proceeds resulting from
the sale of Shares acquired under the Program to a foreign currency account at an authorized bank in Russia if legally
required at the time Shares are sold and to comply with all applicable local foreign exchange rules and regulations. Neither
the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to
comply with applicable laws.
SINGAPORE
Qualifying Person Exemption. The grant of the Award under the Program is being made pursuant to the “Qualifying
Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the “SFA”). The
Program has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is
not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability
under the SFA in relation to the content of prospectuses would not apply. The Employee should note that, as a result,
the Award is subject

-- 165 of 409 --

22
to section 257 of the SFA and the Employee will not be able to make: (a) any subsequent sale of the Shares underlying the
Award in Singapore; or (b) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such
sale or offer is made pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the
SFA.
SOUTH AFRICA
1. 	Exchange Control Obligations. The Employee is solely responsible for complying with applicable exchange control
regulations and rulings (the “Exchange Control Regulations”) in South Africa. As the Exchange Control Regulations change
frequently and without notice, the Employee should consult the Employee’s legal advisor prior to the acquisition or sale of
Shares under the Program to ensure compliance with current Exchange Control Regulations. Neither the Company nor any
of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to comply with applicable
laws.
2. 	Securities Law Information and Deemed Acceptance of Units. Neither the Units nor the underlying Shares shall be
publicly offered or listed on any stock exchange in South Africa. The offer is intended to be private pursuant to Section
96(1)(g)(ii) of the Companies Act, 71 of 2008 (the “Companies Act”) and is not subject to the supervision of any South
African governmental authority.
Pursuant to Section 96(1)(g)(ii) of the Companies Act, the Units offer must be finalized within six (6) months following the
date the offer is communicated to the Employee. If the Employee does not want to accept the Units, the Employee is
required to decline the Units no later than the six (6) months following the date the offer is communicated to the Employee.
If the Employee does not reject the Units within six (6) months following the date the offer is communicated to the
Employee, the Employee will be deemed to accept the Units.
SPAIN
1. 	Acknowledgement of Discretionary Nature of the Program; No Vested Rights
By accepting the Award, the Employee consents to participation in the Program and acknowledges receipt of a copy of the
Program.
The Employee understands that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the
Program to individuals who may be employees of the Company or its Subsidiaries throughout the world. The decision is a
limited decision that is entered into upon the express assumption and condition that any grant will not economically or
otherwise bind the Company or any of its Subsidiaries on an ongoing basis. Consequently, the Employee understands that
the Units are granted on the assumption and condition that the Units and the Shares acquired upon settlement of the Units
shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be
considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.
In addition, the Employee understands that this grant would not be made to the Employee but for the assumptions and
conditions referenced above; thus, the Employee acknowledges and freely accepts that should any or all of the assumptions
be mistaken or should any of the conditions not be met for any reason the Award shall be null and void.
The Employee understands and agrees that, as a condition of the Award, unless otherwise provided in Section 4 of the
Agreement, any unvested Units as of the date the Employee ceases active employment will be forfeited without entitlement
to the underlying Shares or to any amount of indemnification in the

-- 166 of 409 --

23
event of Termination. The Employee acknowledges that the Employee has read and specifically accepts the conditions
referred to in the Agreement regarding the impact of a Termination on the Units.
2. 	Termination for Cause. Notwithstanding anything to the contrary in the Program or the Agreement, “Cause” shall be
as defined as set forth in the Agreement, regardless of whether the Termination is considered a fair termination (i.e.,
“despido procedente”) under Spanish legislation.
TUNISIA
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
UKRAINE
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
UNITED KINGDOM
1. 	Withholding Taxes. The following provision supplements Section 7 of the Agreement.
The Employee agrees that he or she is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related
Items as and when requested by the Company or the Subsidiary in the United Kingdom that employs the Employee (the
“Employer”) or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant
authority). The Employee also agrees to indemnify and keep indemnified the Company and the Employer against any Tax-
Related Items that they are required to pay or withhold or have paid or will pay on the Employee’s behalf to HMRC (or any
other tax authority or any other relevant authority).
Notwithstanding the foregoing, if the Employee is a director or executive officer of the Company (within the meaning of
Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), he or she would not be eligible to have the
Company or the Employer cover any income tax liability on his or her behalf. In this case, any income tax not collected
from or paid by the Employee within 90 days after the end of the U.K. tax year in which the event giving rise to the income
tax liability occurred (or such other period specified in U.K. law) will constitute a benefit to the Employee on which
additional income tax and national insurance contributions (“NICs”) will be payable. The Employee will be responsible for
paying and reporting any income tax due on this additional benefit directly to HMRC under the self-assessment regime and
for reimbursing the Company or the Employer (as applicable) the value of any employee NICs due on this additional benefit,
which the Company or the Employer may recover from the Employee by any of the means referred to in Section 7 of the
Agreement.
2. 	Exclusion of Claim. The Employee acknowledges and agrees that the Employee will have no entitlement to
compensation or damages insofar as such entitlement arises or may arise from the Employee’s ceasing to have rights under
or to be entitled to the Units, whether or not as a result of Termination (whether the Termination is in breach of contract or
otherwise), or from the loss or diminution in value of the Units. Upon the grant of the Award, the Employee shall be deemed
to have waived irrevocably any such entitlement.

-- 167 of 409 --

24
UZBEKISTAN
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.
VIETNAM
Settlement in Cash. Notwithstanding Section 4 of the Agreement or any other provision in the Agreement to the contrary,
pursuant to Section 11 of the Agreement, the Units will be settled in the form of a cash payment, except as otherwise
determined by the Company.

-- 168 of 409 --

Exhibit 10.58
ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK AGREEMENT
On «Grant_Date» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the
“Employee”) a Performance Restricted Stock Award (the “Award”) of « NoShares12345» Shares.
The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the
Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement. In the
event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus,
and the Program administrative rules, the Program shall control. This Award is intended to conform with the qualified
performance-based compensation requirements of Section 162(m) of the Code and the regulations thereunder, to the extent
applicable, and shall be construed accordingly.
The terms and conditions of the Award are as follows:
1. 	Definitions. To the extent not defined herein, capitalized terms shall have the same meaning as in the
Program.
(a) 	Agreement: This Performance Restricted Stock Agreement.
(b) 	Cause: Cause shall mean the following, as determined by the Company in its sole discretion:
(i) 	material breach by the Employee of the terms and conditions of the Employee’s
employment, including, but not limited to:
(A) 	material breach by the Employee of the Code of Business Conduct;
(B) 	material breach by the Employee of the Employee’s Employee Agreement;
(C) 	commission by the Employee of an act of fraud, embezzlement or theft in
connection with the Employee’s duties or in the course of the Employee’s
employment;
(D) 	wrongful disclosure by the Employee of secret processes or confidential
information of the Company or any of its Subsidiaries; or
(E) 	failure by the Employee to substantially perform the duties of the Employee’s
employment (other than any such failure resulting from the Employee’s Disability);
or
(ii) 	to the extent permitted by applicable law, engagement by the Employee, directly or
indirectly, for the benefit of the Employee or others, in any activity, employment or business
which is competitive with the Company or any of its Subsidiaries.

-- 169 of 409 --

2
(c) 	Code of Business Conduct: The Company’s Code of Business Conduct, as amended from time to
time.
(d) 	Controlled Group:
(i) 	Abbott and any corporation, partnership and proprietorship under common control (as
defined under the aggregation rules of subsections 414 (b), (c), or (m) of the Code) with
Abbott; and
(ii) 	during the period of the TAP Pharmaceutical Products Inc. (“TAP”) joint venture between
Takeda Pharmaceutical Company Limited and Abbott ending April 30, 2008, TAP and any
corporation, partnership and proprietorship under common control (as defined above) with
TAP.
(e) 	Data: Certain personal information about the Employee held by the Company and the Subsidiary
that employs the Employee (if applicable), including (but not limited to) the Employee’s name,
home address and telephone number, date of birth, social security number or other employee
identification number, salary, nationality, job title, any Shares held in the Company, details of all
Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or
outstanding in the Employee’s favor, for the purpose of managing and administering the Program.
(f) 	Disability: Sickness or accidental bodily injury, directly and independently of all other causes, that
disables the Employee so that the Employee is completely prevented from performing all the duties
of his or her occupation or employment.
(g) 	Employee Agreement: The Employee Agreement entered into by and between the Company and the
Employee as it may be amended from time to time.
(h) 	Employee’s Representative: The Employee’s legal guardian or other legal representative.
(i) 	Program: The Abbott Laboratories 2017 Incentive Stock Program.
(j) 	Retirement:
(i) 	Except as provided under (iii) below, for employees hired by the Controlled Group prior to
January 1, 2004, Retirement means any of the following:
· 	age 50 with 10 years of service;
· 	age 65 with at least three (3) years of service; or
· 	age 55 with an age and service combination of 70 points, where each year of age is
one (1) point and each year of service is one (1) point.

-- 170 of 409 --

3
(ii) 	Except as provided under (iii) below, for employees hired by the Controlled Group after
December 31, 2003, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iii) 	For participants in the Abbott Laboratories Pension Plan for Former BASF and Former
Solvay Employees, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iv) 	For purposes of calculating service under this Section 1(j), except as otherwise provided by
the Committee or its delegate, service is earned only if performed for a member of the
Controlled Group while that Controlled Group member is a part of the Controlled Group.
Program administrative rules apply in determining Retirement eligibility and credited
service.
(v) 	If an Employee has a Termination and (A) as of the date of that Termination met the
definition of Retirement, and (B) is subsequently rehired by a member of the Controlled
Group, then for purposes of this Agreement that Employee will continue to be treated as
meeting the definition of Retirement.
(k) 	Termination: A severance of employment for any reason (including Retirement) from the Company
and all Subsidiaries.
2. 	Shareholder Rights. Subject to the conditions below, the Employee shall have all the rights of a
shareholder with respect to the Shares (and any securities of the Company which may be issued with respect
to the Shares by virtue of any stock split, combination, stock dividend or recapitalization, which securities
shall be deemed to be “Shares” hereunder) including the right to vote and to receive all cash dividends or
other cash distributions paid or made with respect to the Shares regardless of whether the Restrictions
described below are in effect.
3. 	Restrictions. The Shares are subject to the forfeiture provisions in Sections 5 and 6 below. The Shares are
not earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of
(collectively, the “Restrictions”) until an event or combination of events described in subsections 4(a), (b),
(c) or (d) occurs.
4. 	Lapse of Restrictions. Subject to the provisions of Sections 5 and 6 below:
(a) 	During Employment. While the Employee is employed with the Company or its Subsidiaries:

-- 171 of 409 --

4
(i) 	the Restrictions on one-third of the Shares will lapse on the last business day of February
202_, provided the Company’s prior year return on equity is a minimum of [•] percent;
(ii) 	the Restrictions on an additional one-third of the total number of Shares will lapse on the
last business day of February 202_, provided the Company’s prior year return on equity is a
minimum of [•] percent; and
(iii) 	the Restrictions on an additional one-third of the total number of Shares will lapse on the
last business day of February 202_, provided the Company’s prior year return on equity is a
minimum of [•] percent.
If the Restrictions do not lapse on the respective date set forth in subsection 4(a)(i), (ii), and (iii)
above, such Restrictions shall not lapse at a later date.
(b) 	Retirement. The Restrictions shall continue to apply in the event of the Employee’s Termination
due to Retirement, but may lapse thereafter in accordance with the provisions of subsection 4(a)
above as if the Employee had remained employed. Notwithstanding the foregoing, in the event of
the Employee’s death after his or her Termination due to Retirement, the restrictions shall lapse on
the date of the Employee’s death.
(c) 	Death. The Restrictions shall lapse on the date of the Employee’s Termination due to death.
(d) 	Disability. The Restrictions shall lapse on the date the Employee incurs 12 consecutive months of
Disability.
5. 	Effect of Certain Bad Acts. Any Shares with respect to which Restrictions have not lapsed shall be
cancelled and forfeited immediately if, in the sole opinion and discretion of the Committee or its delegate,
the Employee engages in activity that constitutes Cause, whether or not the Employee experiences a
Termination or remains employed with the Company or a Subsidiary.
6. 	Forfeiture of Shares. In the event of the Employee’s Termination for any reason other than Retirement,
death or Disability, any Shares with respect to which Restrictions have not lapsed as of the date of
Termination shall be forfeited without consideration to the Employee or the Employee’s Representative. In
the event that the Employee is terminated by the Company other than for Cause, the Company may, in its
sole discretion, cause Restrictions on some or all of the Shares to lapse on the dates set forth in subsection
4(a) above as if the Employee had remained employed on such dates.
7. 	Withholding Taxes. The Company shall be entitled to withhold, or require the Employee to remit, any
federal, state, local, and other applicable taxes (in U.S. or non-U.S. jurisdictions), including income, social
security and Medicare withholding taxes arising from the grant of the Award, the lapse of Restrictions or the
delivery of Shares pursuant to this Agreement by, without limitation:
(a) 	having the Company withhold Shares;
(b) 	tendering Shares received in connection with the Award back to the Company;

-- 172 of 409 --

5
(c) 	delivering other previously acquired Shares having a Fair Market Value approximately equal to the
amount to be withheld;
(d) 	selling Shares issued pursuant to the Award and having the Company withhold from proceeds of the
sale of such Shares;
(e) 	having the Company or a Subsidiary, as applicable, withhold from any cash compensation payable
to the Employee; or
(f) 	requiring the Employee to repay the Company or Subsidiary, in cash or in Shares, for taxes paid on
the Employee’s behalf.
Notwithstanding the foregoing, if the Employee is subject to Section 16 of the Exchange Act pursuant to
Rule 16a-2 promulgated thereunder, any tax withholding obligations shall be satisfied by having the
Company withhold a number of Shares otherwise issuable pursuant to the Award that is sufficient to satisfy
such obligations consistent with the Company’s withholding practices.
If, to satisfy tax withholding obligations, the Company withholds Shares otherwise issuable to the
Employee, the Employee shall be deemed to have been issued the full number of Shares underlying the
Award, subject to the Restrictions set forth in this Agreement.
8. 	No Right to Continued Employment. This Agreement and the Employee’s participation in the Program is
not and shall not be interpreted to:
(a) 	form an employment contract or relationship with the Company or its Subsidiaries;
(b) 	confer upon the Employee any right to continue in the employ of the Company or any of its
Subsidiaries; or
(c) 	interfere with the ability of the Company or its Subsidiaries to terminate the Employee’s
employment at any time.
9. 	No Contract as of Right. The Award does not create any contractual or other right to receive additional
Awards or other Program Benefits. Nothing contained in this Agreement is intended to create or enlarge any
other contractual obligations between the Company and the Employee. Future Awards, if any, and their
terms and conditions, will be at the sole discretion of the Committee.
10. 	No Right to Compensation. Unless expressly provided by the Company in writing, any value associated
with the Award is an item of compensation outside the scope of the Employee’s employment contract, if any,
and shall not be deemed part of the Employee’s normal or expected compensation for purposes of
calculating any severance, resignation, redundancy, or end-of-service payments, bonuses, long-service
awards, insurance plan, investment or stock purchase plan, pension, retirement, or any other employee
benefits, or similar payments under plans of the Company or any of its Subsidiaries.

-- 173 of 409 --

6
11. 	Data Privacy.
(a) 	Pursuant to applicable personal data protection laws, the collection, processing and transfer of the
Employee’s personal Data is necessary for the Company’s administration of the Program and the
Employee’s participation in the Program. The Employee’s denial and/or objection to the collection,
processing and transfer of personal Data may affect his or her ability to participate in the Program.
As such (where required under applicable law), the Employee:
(i) 	voluntarily acknowledges, consents and agrees to the collection, use, processing and
transfer of personal Data as described herein; and
(ii) 	authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic
or other form, for purposes of implementing, administering and managing the Employee’s
participation in the Program, including any requisite transfer of such Data as may be
required for the administration of the Program and/or the subsequent holding of Shares on
the Employee’s behalf to a broker or other third party with whom the Employee may elect
to deposit any Shares acquired pursuant to the Program.
(b) 	Data may be provided by the Employee or collected, where lawful, from third parties, and the
Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the
exclusive purpose of implementing, administering and managing the Employee’s participation in the
Program. Data processing will take place through electronic and non-electronic means according to
logics and procedures strictly correlated to the purposes for which the Data is collected and with
confidentiality and security provisions as set forth by applicable laws and regulations in the
Employee’s country of residence. Data processing operations will be performed minimizing the use
of personal and identification data when such operations are unnecessary for the processing
purposes sought. The Data will be accessible within the Company’s organization only by those
persons requiring access for purposes of the implementation, administration and operation of the
Program and for the Employee’s participation in the Program.
(c) 	The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as
necessary for the purpose of implementation, administration and management of the Employee’s
participation in the Program, and the Company and the Subsidiary that employs the Employee (if
applicable) may further transfer Data to any third parties assisting the Company in the
implementation, administration and management of the Program. These recipients may be located
throughout the world.
(d) 	The Employee may, at any time, exercise his or her rights provided under applicable personal data
protection laws, which may include the right to:
(i) 	obtain confirmation as to the existence of the Data;
(ii) 	verify the content, origin and accuracy of the Data;

-- 174 of 409 --

7
(iii) 	request the integration, update, amendment, deletion or blockage (for breach of applicable
laws) of the Data; and
(iv) 	oppose, for legal reasons, the collection, processing or transfer of the Data which is not
necessary or required for the implementation, administration and/or operation of the
Program and the Employee’s participation in the Program.
The Employee may seek to exercise these rights by contacting his or her local human resources
manager.
12. 	No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the
Company making any recommendations regarding the Award, the Employee’s participation in the Program
or the Employee’s acquisition or sale of the underlying Shares. The Employee is hereby advised to consult
with the Employee’s own personal tax, legal and financial advisors regarding participation in the Program
before taking any action related to the Program.
13. 	Entire Agreement. This Agreement and the Program constitute the entire agreement between the
Employee and the Company regarding the Award and supersede all prior and contemporaneous agreements
and understandings, oral or written, between the parties regarding the Award. Except as expressly set forth
herein, this Agreement (and any provision of this Agreement) may not be modified, changed, clarified, or
interpreted by the parties, except in a writing specifying the modification, change, clarification, or
interpretation, and signed by a duly authorized Company officer.
14. 	Succession. This Agreement shall be binding upon and operate for the benefit of the Company and its
successors and assigns, and the Employee, the Employee’s Representative, and the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution.
15. 	Compliance with Applicable Laws and Regulations. The Company shall not be required to issue or
deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state
securities and other laws (including any registration requirements or tax withholding requirements) and
compliance with the rules and practices of any stock exchange upon which the Company’s Shares are listed.
Furthermore, if the Employee relocates to another country, the Company may establish special or alternative
terms and conditions as necessary or advisable to comply with local law, facilitate the administration of the
Program and/or accommodate the Employee’s relocation.
16. 	Code Section 409A. The Award is intended to be exempt from the requirements of Code Section 409A.
The Program and this Agreement shall be administered and interpreted in a manner consistent with this
intent. If the Company determines that the Award is subject to Code Section 409A and this Agreement fails
to comply with that section’s requirements, the Company may, at the Company’s sole discretion, and
without the Employee’s consent, amend this Agreement to cause it to comply with Code Section 409A or
otherwise be exempt from Code Section 409A.
Although this Agreement and the Benefits provided hereunder are intended to be exempt from the
requirements of Code Section 409A, the Company does not represent or warrant

-- 175 of 409 --

8
that this Agreement or the Benefits provided hereunder will comply with Code Section 409A or any other
provision of federal, state, local, or non-United States law. None of the Company, its Subsidiaries, or their
respective directors, officers, employees or advisers shall be liable to the Employee (or any other individual
claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a
result of compensation paid under this Agreement, and the Company and its Subsidiaries shall have no
obligation to indemnify or otherwise protect the Employee from the obligation to pay any taxes pursuant to
Code Section 409A.
17. 	Determinations. Each decision, determination, interpretation or other action made or taken pursuant to the
provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be
final, conclusive and binding for all purposes and upon all persons, including, without limitation, the
Company, the Employee, the Employee’s Representative, and the person or persons to whom rights under
the Award have passed by will or the laws of descent or distribution.
18. 	Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, and each other provision of this
Agreement shall be severable and enforceable to the extent permitted by law. To the extent a court or
tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or
unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to
revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full
extent permitted under local law.
19. 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
U.S. State of Illinois without giving effect to any state’s conflict of laws principles.
20. 	Venue. For any legal action relating to this Agreement, the parties to this Agreement consent to the
exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there
is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County,
Illinois, USA.
* 	* 	*
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer as of the
grant date above set forth.
ABBOTT LABORATORIES
By
Robert B. Ford
President and Chief Executive Officer

-- 176 of 409 --

Exhibit 10.59
ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK AGREEMENT
On «Grant_Date» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the
“Employee”) a Performance Restricted Stock Award (the “Award”) of « NoShares12345» Shares.
The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the
Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement. In the
event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus,
and the Program administrative rules, the Program shall control. This Award is intended to conform with the qualified
performance-based compensation requirements of Section 162(m) of the Code and the regulations thereunder, to the extent
applicable, and shall be construed accordingly.
The terms and conditions of the Award are as follows:
1. 	Definitions. To the extent not defined herein, capitalized terms shall have the same meaning as in the
Program.
(a) 	Agreement: This Performance Restricted Stock Agreement.
(b) 	Cause: Cause shall mean the following, as determined by the Company in its sole discretion:
(i) 	material breach by the Employee of the terms and conditions of the Employee’s
employment, including, but not limited to:
(A) 	material breach by the Employee of the Code of Business Conduct;
(B) 	material breach by the Employee of the Employee’s Employee Agreement;
(C) 	commission by the Employee of an act of fraud, embezzlement or theft in
connection with the Employee’s duties or in the course of the Employee’s
employment;
(D) 	wrongful disclosure by the Employee of secret processes or confidential
information of the Company or any of its Subsidiaries; or
(E) 	failure by the Employee to substantially perform the duties of the Employee’s
employment (other than any such failure resulting from the Employee’s Disability);
or
(ii) 	to the extent permitted by applicable law, engagement by the Employee, directly or
indirectly, for the benefit of the Employee or others, in any activity, employment or business
which is competitive with the Company or any of its Subsidiaries.

-- 177 of 409 --

2
(c) 	Code of Business Conduct: The Company’s Code of Business Conduct, as amended from time to
time.
(d) 	Controlled Group:
(i) 	Abbott and any corporation, partnership and proprietorship under common control (as
defined under the aggregation rules of subsections 414 (b), (c), or (m) of the Code) with
Abbott; and
(ii) 	during the period of the TAP Pharmaceutical Products Inc. (“TAP”) joint venture between
Takeda Pharmaceutical Company Limited and Abbott ending April 30, 2008, TAP and any
corporation, partnership and proprietorship under common control (as defined above) with
TAP.
(e) 	Data: Certain personal information about the Employee held by the Company and the Subsidiary
that employs the Employee (if applicable), including (but not limited to) the Employee’s name,
home address and telephone number, date of birth, social security number or other employee
identification number, salary, nationality, job title, any Shares held in the Company, details of all
Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or
outstanding in the Employee’s favor, for the purpose of managing and administering the Program.
(f) 	Disability: Sickness or accidental bodily injury, directly and independently of all other causes, that
disables the Employee so that the Employee is completely prevented from performing all the duties
of his or her occupation or employment.
(g) 	Employee Agreement: The Employee Agreement entered into by and between the Company and the
Employee as it may be amended from time to time.
(h) 	Employee’s Representative: The Employee’s legal guardian or other legal representative.
(i) 	Program: The Abbott Laboratories 2017 Incentive Stock Program.
(j) 	Retirement:
(i) 	Except as provided under (iii) below, for employees hired by the Controlled Group prior to
January 1, 2004, Retirement means any of the following:
· 	age 50 with 10 years of service;
· 	age 65 with at least three (3) years of service; or
· 	age 55 with an age and service combination of 70 points, where each year of age is
one (1) point and each year of service is one (1) point.

-- 178 of 409 --

3
(ii) 	Except as provided under (iii) below, for employees hired by the Controlled Group after
December 31, 2003, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iii) 	For participants in the Abbott Laboratories Pension Plan for Former BASF and Former
Solvay Employees, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iv) 	For purposes of calculating service under this Section 1(j), except as otherwise provided by
the Committee or its delegate, service is earned only if performed for a member of the
Controlled Group while that Controlled Group member is a part of the Controlled Group.
Program administrative rules apply in determining Retirement eligibility and credited
service.
(v) 	If an Employee has a Termination and (A) as of the date of that Termination met the
definition of Retirement, and (B) is subsequently rehired by a member of the Controlled
Group, then for purposes of this Agreement that Employee will continue to be treated as
meeting the definition of Retirement.
(k) 	Termination: A severance of employment for any reason (including Retirement) from the Company
and all Subsidiaries.
2. 	Shareholder Rights. Subject to the conditions below, the Employee shall have all the rights of a
shareholder with respect to the Shares (and any securities of the Company which may be issued with respect
to the Shares by virtue of any stock split, combination, stock dividend or recapitalization, which securities
shall be deemed to be “Shares” hereunder) including the right to vote and to receive all cash dividends or
other cash distributions paid or made with respect to the Shares regardless of whether the Restrictions
described below are in effect.
3. 	Restrictions. The Shares are subject to the forfeiture provisions in Sections 5 and 6 below. The Shares are
not earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of
(collectively, the “Restrictions”) until an event or combination of events described in subsections 4(a), (b),
(c) or (d) occurs.
4. 	Lapse of Restrictions. Subject to the provisions of Sections 5 and 6 below:
(a) 	During Employment. While the Employee is employed with the Company or its Subsidiaries:

-- 179 of 409 --

4
(i) 	the Restrictions on one-third of the Shares will lapse on «M_1st_yr_vest», provided the
Company’s prior year return on equity is a minimum of [•] percent;
(ii) 	the Restrictions on an additional one-third of the total number of Shares will lapse on
«M_2nd_yr_vest», provided the Company’s prior year return on equity is a minimum of [•]
percent; and
(iii) 	the Restrictions on an additional one-third of the total number of Shares will lapse on
«M_3rd_yr_vest», provided the Company’s prior year return on equity is a minimum of [•]
percent.
If the Restrictions do not lapse on the respective date set forth in subsection 4(a)(i), (ii), and (iii)
above, such Restrictions shall not lapse at a later date.
(b) 	Retirement. The Restrictions shall continue to apply in the event of the Employee’s Termination
due to Retirement, but may lapse thereafter in accordance with the provisions of subsection 4(a)
above as if the Employee had remained employed. Notwithstanding the foregoing, in the event of
the Employee’s death after his or her Termination due to Retirement, the restrictions shall lapse on
the date of the Employee’s death.
(c) 	Death. The Restrictions shall lapse on the date of the Employee’s Termination due to death.
(d) 	Disability. The Restrictions shall lapse on the date the Employee incurs 12 consecutive months of
Disability.
5. 	Effect of Certain Bad Acts. Any Shares with respect to which Restrictions have not lapsed shall be
cancelled and forfeited immediately if, in the sole opinion and discretion of the Committee or its delegate,
the Employee engages in activity that constitutes Cause, whether or not the Employee experiences a
Termination or remains employed with the Company or a Subsidiary.
6. 	Forfeiture of Shares. In the event of the Employee’s Termination for any reason other than Retirement,
death, or Disability, any Shares with respect to which Restrictions have not lapsed as of the date of
Termination shall be forfeited without consideration to the Employee or the Employee’s Representative. In
the event that the Employee is terminated by the Company other than for Cause, the Company may, in its
sole discretion, cause Restrictions on some or all of the Shares to lapse on the dates set forth in subsection
4(a) above as if the Employee had remained employed on such dates.
7. 	Withholding Taxes. The Company shall be entitled to withhold, or require the Employee to remit, any
federal, state, local, and other applicable taxes (in U.S. or non-U.S. jurisdictions), including income, social
security and Medicare withholding taxes arising from the grant of the Award, the lapse of Restrictions or the
delivery of Shares pursuant to this Agreement by, without limitation:
(a) 	having the Company withhold Shares;
(b) 	tendering Shares received in connection with the Award back to the Company;

-- 180 of 409 --

5
(c) 	delivering other previously acquired Shares having a Fair Market Value approximately equal to the
amount to be withheld;
(d) 	selling Shares issued pursuant to the Award and having the Company withhold from proceeds of the
sale of such Shares;
(e) 	having the Company or a Subsidiary, as applicable, withhold from any cash compensation payable
to the Employee; or
(f) 	requiring the Employee to repay the Company or Subsidiary, in cash or in Shares, for taxes paid on
the Employee’s behalf.
Notwithstanding the foregoing, if the Employee is subject to Section 16 of the Exchange Act pursuant to
Rule 16a-2 promulgated thereunder, any tax withholding obligations shall be satisfied by having the
Company withhold a number of Shares otherwise issuable pursuant to the Award that is sufficient to satisfy
such obligations consistent with the Company’s withholding practices.
If, to satisfy tax withholding obligations, the Company withholds Shares otherwise issuable to the
Employee, the Employee shall be deemed to have been issued the full number of Shares underlying the
Award, subject to the Restrictions set forth in this Agreement.
8. 	No Right to Continued Employment. This Agreement and the Employee’s participation in the Program is
not and shall not be interpreted to:
(a) 	form an employment contract or relationship with the Company or its Subsidiaries;
(b) 	confer upon the Employee any right to continue in the employ of the Company or any of its
Subsidiaries; or
(c) 	interfere with the ability of the Company or its Subsidiaries to terminate the Employee’s
employment at any time.
9. 	No Contract as of Right. The Award does not create any contractual or other right to receive additional
Awards or other Program Benefits. Nothing contained in this Agreement is intended to create or enlarge any
other contractual obligations between the Company and the Employee. Future Awards, if any, and their
terms and conditions, will be at the sole discretion of the Committee.
10. 	No Right to Compensation. Unless expressly provided by the Company in writing, any value associated
with the Award is an item of compensation outside the scope of the Employee’s employment contract, if any,
and shall not be deemed part of the Employee’s normal or expected compensation for purposes of
calculating any severance, resignation, redundancy, or end-of-service payments, bonuses, long-service
awards, insurance plan, investment or stock purchase plan, pension, retirement, or any other employee
benefits, or similar payments under plans of the Company or any of its Subsidiaries.

-- 181 of 409 --

6
11. 	Data Privacy.
(a) 	Pursuant to applicable personal data protection laws, the collection, processing and transfer of the
Employee’s personal Data is necessary for the Company’s administration of the Program and the
Employee’s participation in the Program. The Employee’s denial and/or objection to the collection,
processing and transfer of personal Data may affect his or her ability to participate in the Program.
As such (where required under applicable law), the Employee:
(i) 	voluntarily acknowledges, consents and agrees to the collection, use, processing and
transfer of personal Data as described herein; and
(ii) 	authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic
or other form, for purposes of implementing, administering and managing the Employee’s
participation in the Program, including any requisite transfer of such Data as may be
required for the administration of the Program and/or the subsequent holding of Shares on
the Employee’s behalf to a broker or other third party with whom the Employee may elect
to deposit any Shares acquired pursuant to the Program.
(b) 	Data may be provided by the Employee or collected, where lawful, from third parties, and the
Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the
exclusive purpose of implementing, administering and managing the Employee’s participation in the
Program. Data processing will take place through electronic and non-electronic means according to
logics and procedures strictly correlated to the purposes for which the Data is collected and with
confidentiality and security provisions as set forth by applicable laws and regulations in the
Employee’s country of residence. Data processing operations will be performed minimizing the use
of personal and identification data when such operations are unnecessary for the processing
purposes sought. The Data will be accessible within the Company’s organization only by those
persons requiring access for purposes of the implementation, administration and operation of the
Program and for the Employee’s participation in the Program.
(c) 	The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as
necessary for the purpose of implementation, administration and management of the Employee’s
participation in the Program, and the Company and the Subsidiary that employs the Employee (if
applicable) may further transfer Data to any third parties assisting the Company in the
implementation, administration and management of the Program. These recipients may be located
throughout the world.
(d) 	The Employee may, at any time, exercise his or her rights provided under applicable personal data
protection laws, which may include the right to:
(i) 	obtain confirmation as to the existence of the Data;
(ii) 	verify the content, origin and accuracy of the Data;

-- 182 of 409 --

7
(iii) 	request the integration, update, amendment, deletion or blockage (for breach of applicable
laws) of the Data; and
(iv) 	oppose, for legal reasons, the collection, processing or transfer of the Data which is not
necessary or required for the implementation, administration and/or operation of the
Program and the Employee’s participation in the Program.
The Employee may seek to exercise these rights by contacting his or her local human resources
manager.
12. 	No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the
Company making any recommendations regarding the Award, the Employee’s participation in the Program
or the Employee’s acquisition or sale of the underlying Shares. The Employee is hereby advised to consult
with the Employee’s own personal tax, legal and financial advisors regarding participation in the Program
before taking any action related to the Program.
13. 	Entire Agreement. This Agreement and the Program constitute the entire agreement between the
Employee and the Company regarding the Award and supersede all prior and contemporaneous agreements
and understandings, oral or written, between the parties regarding the Award. Except as expressly set forth
herein, this Agreement (and any provision of this Agreement) may not be modified, changed, clarified, or
interpreted by the parties, except in a writing specifying the modification, change, clarification, or
interpretation, and signed by a duly authorized Company officer.
14. 	Succession. This Agreement shall be binding upon and operate for the benefit of the Company and its
successors and assigns, and the Employee, the Employee’s Representative, and the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution.
15. 	Compliance with Applicable Laws and Regulations. The Company shall not be required to issue or
deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state
securities and other laws (including any registration requirements or tax withholding requirements) and
compliance with the rules and practices of any stock exchange upon which the Company’s Shares are listed.
Furthermore, if the Employee relocates to another country, the Company may establish special or alternative
terms and conditions as necessary or advisable to comply with local law, facilitate the administration of the
Program, and/or accommodate the Employee’s relocation.
16. 	Code Section 409A. The Award is intended to be exempt from the requirements of Code Section 409A.
The Program and this Agreement shall be administered and interpreted in a manner consistent with this
intent. If the Company determines that the Award is subject to Code Section 409A and this Agreement fails
to comply with that section’s requirements, the Company may, at the Company’s sole discretion, and
without the Employee’s consent, amend this Agreement to cause it to comply with Code Section 409A or
otherwise be exempt from Code Section 409A.
Although this Agreement and the Benefits provided hereunder are intended to be exempt from the
requirements of Code Section 409A, the Company does not represent or warrant

-- 183 of 409 --

8
that this Agreement or the Benefits provided hereunder will comply with Code Section 409A or any other
provision of federal, state, local, or non-United States law. None of the Company, its Subsidiaries, or their
respective directors, officers, employees or advisers shall be liable to the Employee (or any other individual
claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a
result of compensation paid under this Agreement, and the Company and its Subsidiaries shall have no
obligation to indemnify or otherwise protect the Employee from the obligation to pay any taxes pursuant to
Code Section 409A.
17. 	Determinations. Each decision, determination, interpretation or other action made or taken pursuant to the
provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be
final, conclusive and binding for all purposes and upon all persons, including, without limitation, the
Company, the Employee, the Employee’s Representative, and the person or persons to whom rights under
the Award have passed by will or the laws of descent or distribution.
18. 	Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, and each other provision of this
Agreement shall be severable and enforceable to the extent permitted by law. To the extent a court or
tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or
unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to
revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full
extent permitted under local law.
19. 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
U.S. State of Illinois without giving effect to any state’s conflict of laws principles.
20. 	Venue. For any legal action relating to this Agreement, the parties to this Agreement consent to the
exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there
is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County,
Illinois, USA.
* 	* 	*
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer as of the
grant date above set forth.
ABBOTT LABORATORIES
By
Robert B. Ford
President and Chief Executive Officer

-- 184 of 409 --

Exhibit 10.60
ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT
On «Grant_Date» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the
“Employee”) a Performance Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the
“Units”).
The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the
Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement. In the
event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus,
and the Program administrative rules, the Program shall control. This Award is intended to conform with the qualified
performance-based compensation requirements of Section 162(m) of the Code and the regulations thereunder, to the extent
applicable, and shall be construed accordingly.
The terms and conditions of the Award are as follows:
1. 	Definitions. To the extent not defined herein, capitalized terms shall have the same meaning as in the
Program.
(a) 	Agreement: This Performance Restricted Stock Unit Agreement.
(b) 	Cause: Cause shall mean the following, as determined by the Company in its sole discretion:
(i) 	material breach by the Employee of the terms and conditions of the Employee’s
employment, including, but not limited to:
(A) 	material breach by the Employee of the Code of Business Conduct;
(B) 	material breach by the Employee of the Employee’s employment contract,
if any;
(C) 	commission by the Employee of an act of fraud, embezzlement or theft in
connection with the Employee’s duties or in the course of the Employee’s
employment;
(D) 	wrongful disclosure by the Employee of secret processes or confidential
information of the Company or any of its Subsidiaries; or
(E) 	failure by the Employee to substantially perform the duties of the
Employee’s employment (other than any such failure resulting from the
Employee’s Disability); or
(ii) 	to the extent permitted by applicable law, engagement by the Employee, directly or
indirectly, for the benefit of the Employee or others, in any

-- 185 of 409 --

2
activity, employment or business which is competitive with the Company or any of its
Subsidiaries.
(c) 	Change in Control Agreement: An Agreement Regarding Change in Control in effect between the
Company (or the Surviving Entity) and the Employee, if any.
(d) 	Change in Control Cause: shall mean the occurrence of any of the following circumstances during
the period that begins six (6) months immediately before a Change in Control and ends two (2)
years immediately following such Change in Control: the willful engaging by the Employee in
illegal conduct or gross misconduct which is demonstrably and materially injurious to the Company.
For purposes of this definition, no act, or failure to act, on the Employee’s part shall be deemed
“willful” unless done, or omitted to be done, by the Employee not in good faith and without
reasonable belief that the Employee’s action or omission was in the best interest of the Company.
Notwithstanding the foregoing, the Employee shall not be deemed to have been terminated for
Change in Control Cause unless and until the Company delivers to the Employee a copy of a
resolution duly adopted by the affirmative vote of not less than three-quarters of the entire
membership of the Board at a meeting of the Board called and held for such purpose (after
reasonable notice to the Employee and an opportunity for the Employee, together with counsel, to
be heard before the Board) finding that, in the good faith opinion of the Board, the Employee was
guilty of conduct set forth above and specifying the particulars thereof in detail.
(e) 	Change in Control Good Reason: shall mean the occurrence of any of the following circumstances
without the Employee’s express written consent during the period that begins six (6) months
immediately before a Change in Control and ends two (2) years immediately following such Change
in Control:
(i) 	a significant adverse change in the nature, scope or status of the Employee’s position,
authorities or duties from those in effect immediately prior to the Change in Control,
including, without limitation, if the Employee was, immediately prior to the Change in
Control, an Employee officer of a public company, the Employee ceasing to be an
Employee officer of a public company;
(ii) 	the failure by the Company to pay the Employee any portion of the Employee’s current
compensation, or to pay the Employee any portion of any installment of deferred
compensation under any deferred compensation program of the Company, within seven
(7) days of the date such compensation is due;
(iii) 	a reduction in the Employee’s annual base salary (or a material change in the frequency of
payment) as in effect immediately prior to the Change in Control as the same may be
increased from time to time;
(iv) 	the failure by the Company to award the Employee an annual bonus in any year which is at
least equal to the annual bonus, awarded to the Employee under the annual bonus plan of
the Company for the year immediately preceding the year of the Change in Control;

-- 186 of 409 --

3
(v) 	the failure by the Company to award the Employee equity-based incentive compensation
(such as stock options, shares of restricted stock, restricted stock units, or other equity-based
compensation) on a periodic basis consistent with the Company’s practices with respect to
timing, value and terms prior to the Change in Control;
(vi) 	the failure by the Company to continue to provide the Employee with the welfare benefits,
fringe benefits and perquisites enjoyed by the Employee immediately prior to the Change in
Control under any of the Company’s plans or policies, including, but not limited to, those
plans and policies providing pension, life insurance, medical, health and accident, disability,
vacation, Employee automobile, Employee tax or financial advice benefits or club dues;
(vii) 	the relocation of the Company’s principal Employee offices to a location more than 35
miles from the location of such offices immediately prior to the Change in Control or the
Company requiring the Employee to be based anywhere other than the location where the
Employee primarily performs services for the Company immediately prior to the Change in
Control except for required travel for the Company’s business to an extent substantially
consistent with the Employee’s business travel obligations immediately prior to the Change
in Control; or
(viii) the failure of the Company to obtain a satisfactory agreement from any successor to the
Company to assume and agree to perform any Change in Control Agreement.
For purposes of any determination regarding the existence of Change in Control Good Reason, any
good faith determination by the Employee that Change in Control Good Reason exists shall be
conclusive.
(f) 	Code of Business Conduct: The Company’s Code of Business Conduct, as amended from time to
time.
(g) 	Controlled Group:
(i) 	Abbott and any corporation, partnership and proprietorship under common control (as
defined under the aggregation rules of subsections 414(b), (c), or (m) of the Code) with
Abbott; and
(ii) 	during the period of the TAP Pharmaceutical Products Inc. (“TAP”) joint venture between
Takeda Pharmaceutical Company Limited and Abbott ending April 30, 2008, TAP and any
corporation, partnership and proprietorship under common control (as defined above) with
TAP.
(h) 	Data: Certain personal information about the Employee held by the Company and the Subsidiary
that employs the Employee (if applicable), including (but not limited to) the Employee’s name,
home address and telephone number, date of birth, social security number or other employee
identification number, salary, nationality, job title, any Shares held in the Company, details of all
Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested

-- 187 of 409 --

4
or outstanding in the Employee’s favor, for the purpose of managing and administering the Program.
(i) 	Disability: As of a particular date, the Employee is, by reason of any medically determinable
physical or mental impairment that can be expected to result in death or can be expected to last for a
continuous period of not less than 12 months, receiving income replacement benefits for a period of
at least six (6) months under (i) the terms of the Abbott Laboratories Long-Term Disability Plan
(formerly known as the Extended Disability Plan) (the “LTD Plan”), or (ii) if the Employee’s
employer does not participate in the LTD Plan, such similar accident and health plan providing
replacement benefits in which the Employee’s employer participates.
(j) 	Employee’s Representative: The Employee’s legal guardian or other legal representative.
(k) 	Program: The Abbott Laboratories 2017 Incentive Stock Program.
(l) 	Retirement:
(i) 	Except as provided under (iii) below, for employees hired by the Controlled Group prior to
January 1, 2004, Retirement means any of the following:
· 	age 50 with 10 years of service;
· 	age 65 with at least three (3) years of service; or
· 	age 55 with an age and service combination of 70 points, where each year of age is
one (1) point and each year of service is one (1) point.
(ii) 	Except as provided under (iii) below, for employees hired by the Controlled Group after
December 31, 2003, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iii) 	For participants in the Abbott Laboratories Pension Plan for Former BASF and Former
Solvay Employees, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iv) 	For purposes of calculating service under this Section 1(l), except as otherwise provided by
the Committee or its delegate, service is earned only if performed for a member of the
Controlled Group while that

-- 188 of 409 --

5
Controlled Group member is a part of the Controlled Group. Program administrative rules
apply in determining Retirement eligibility and credited service.
(v) 	If an Employee has a Termination and (A) as of the date of that Termination met the
definition of Retirement, and (B) is subsequently rehired by a member of the Controlled
Group, then for purposes of this Agreement that Employee will continue to be treated as
meeting the definition of Retirement.
(m) 	Termination: A severance of employment for any reason (including Retirement) from the Company
and all Subsidiaries. Any Termination shall be effective on the last day the Employee performs
services for or on behalf of the Company or its Subsidiary, and employment shall not be extended
by any statutory or common law notice of termination period.
2. 	Delivery Dates and Shareholder Rights. The Delivery Dates for Shares underlying the Units are the
respective dates on which the Shares are payable to the Employee pursuant to Section 4 below. Prior to the
Delivery Date(s):
(a) 	the Employee shall not be treated as a shareholder as to those Shares underlying the Units, and shall
have only a contractual right to receive Shares, unsecured by any assets of the Company or its
Subsidiaries;
(b) 	the Employee shall not be permitted to vote the Shares underlying the Units; and
(c) 	the Employee’s right to receive such Shares will be subject to the adjustment provisions relating to
mergers, reorganizations, and similar events set forth in the Program.
Subject to the requirements of local law, the Employee shall receive cash payments equal to the dividends
and distributions paid on Shares underlying the Units (the “Dividend Equivalents”) (other than dividends or
distributions of securities of the Company which may be issued with respect to its Shares by virtue of any
stock split, combination, stock dividend or recapitalization) to the same extent and on the same date (or as
soon as practicable thereafter) as if each Unit were a Share; provided, however, that no Dividend
Equivalents shall be payable to or for the benefit of the Employee with respect to dividends or distributions
the record date for which occurs on or after the date the Employee has forfeited the Units, or the date the
Units are settled. For purposes of compliance with the requirements of Code Section 409A, to the extent
applicable, the specified date for payment of any Dividend Equivalents to which the Employee is entitled
under this Section 2 is the calendar year during the term of this Agreement in which the associated dividends
or distributions are paid on Shares underlying the Units. The Employee shall have no right to determine the
year in which Dividend Equivalents will be paid.
3. 	Restrictions. The Units are subject to the forfeiture provisions in Sections 6 and 7 below. The Units are not
earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of
(collectively, the “Restrictions”) until the Units are settled.

-- 189 of 409 --

6
4. 	Lapse of Restrictions. Subject to Sections 5, 6 and 7 below:
(a) 	During Employment. While the Employee is employed with the Company or its Subsidiaries:
(i) 	the Restrictions on one-third of the total number of Units will lapse on the last business day
of February 202_, provided the Company’s prior year return on equity is a minimum of [•]
percent;
(ii) 	the Restrictions on an additional one-third of the total number of Units will lapse on the last
business day of February 202_, provided the Company’s prior year return on equity is a
minimum of [•] percent; and
(iii) 	the Restrictions on an additional one-third of the total number of Units will lapse on the last
business day of February 202_, provided the Company’s prior year return on equity is a
minimum of [•] percent.
If the Restrictions do not lapse on the respective date set forth in subsection 4(a)(i), (ii), and (iii)
above, such Restrictions shall not lapse at a later date.
Units for which Restrictions have lapsed, as described in this subsection 4(a), shall be settled in the
form of Shares on the date(s) on which such Restrictions lapse (each, a “Delivery Date”). Unless
indicated otherwise, Shares shall be delivered in an equal number (subject to rounding) as of each
Delivery Date.
(b) 	Retirement. The Restrictions shall continue to apply in the event of the Employee’s Termination
due to Retirement, but may lapse thereafter in accordance with the provisions of subsection 4(a), in
which case any Units not previously settled shall be settled in the form of Shares on the Delivery
Date(s) set forth in subsection 4(a) above occurring after the date of such Retirement as if the
Employee had remained employed. Notwithstanding the foregoing, in the event of the Employee’s
death after his or her Termination due to Retirement, for any Units not previously settled on a
Delivery Date, the restrictions shall lapse on the Employee’s date of death and the Units will be
settled in the form of Shares as soon as administratively possible after, and effective as of, the date
of death.
(c) 	Death. The Restrictions shall lapse on the date of the Employee’s Termination due to death, and
any Units not previously settled on a Delivery Date shall be settled (for the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution) in the form
of Shares as soon as administratively possible after, and effective as of, the date of death.
(d) 	Disability. The Restrictions shall lapse on the date of the Employee’s Disability, and any Units not
previously settled on a Delivery Date shall be settled in the form of Shares as soon as
administratively possible after, and effective as of, the date of Disability.
5. 	Change in Control. In the event of a Change in Control, the entity surviving such Change in Control or the
ultimate parent thereof (referred to herein as the “Surviving Entity”) may assume, convert or replace this
Award with an award of at least equal value (determined using the same value for purchasing Company
shares as used for purchasing

-- 190 of 409 --

7
Company shares not subject to this Agreement on the date of the Change in Control) with terms and
conditions not less favorable than the terms and conditions provided in this Agreement, in which case the
new award will vest according to the terms of the applicable award agreement. If the Surviving Entity does
not assume, convert or replace this Award, the Restrictions shall lapse on the date of the Change in Control.
If the Surviving Entity does assume, convert or replace this Award, then in the event the Employee’s
Termination (i) occurs within the time period beginning six (6) months immediately before a Change in
Control and ending two (2) years immediately following such Change in Control, and (ii) was initiated by
the Company (or the Surviving Entity) for a reason other than Change in Control Cause or was initiated by
the Employee for Change in Control Good Reason, the Restrictions shall lapse on the later of the date of the
Change in Control and the date of the Employee’s Termination. The provisions of this Section 5 shall
supersede Section 13(a)(iv) and (v) of the Program.
6. 	Effect of Certain Bad Acts. If Section 5 does not apply, any Units not previously settled shall be cancelled
and forfeited immediately if, in the sole opinion and discretion of the Committee or its delegate, the
Employee engages in activity that constitutes Cause, whether or not the Employee experiences a
Termination or remains employed with the Company or a Subsidiary. If Section 5 does apply, any Units not
previously settled shall be cancelled and forfeited immediately if, in the sole opinion and discretion of the
Board, the Employee engages in an activity that constitutes Change in Control Cause.
7. 	Forfeiture of Units. In the event of the Employee’s Termination for any reason other than those set forth in
subsections 4(b), (c), (d) or Section 5, any Units with respect to which Restrictions have not lapsed as of the
date of Termination shall be forfeited without consideration to the Employee or the Employee’s
Representative. If the Company terminates the Employee other than for Cause and such termination is not
covered by Section 5, the Company may, in its sole discretion, cause some or all of the Units not previously
settled on a Delivery Date to continue to be subject to the Restrictions, provided such Restrictions may lapse
thereafter in accordance with the provisions of subsection 4(a), in which case such Units shall be settled in
the form of Shares on the Delivery Date(s) set forth in subsection 4(a) above occurring after the date of such
Termination. In accepting this Award, the Employee acknowledges that in the event of Termination
(whether or not in breach of local labor laws), the Employee’s right to vest in the Units, if any, will
terminate effective as of the date that the Employee is no longer actively employed and will not be extended
by any notice period mandated under local law (e.g., active employment would not include a period of
“garden leave” or similar period pursuant to local law) and that the Committee shall have the exclusive
discretion to determine when the Employee is no longer actively employed for purposes of this Award.
8. 	Withholding Taxes. The Company shall be entitled to withhold, or require the Employee to remit, any
federal, state, local, and other applicable taxes (in U.S. or non-U.S. jurisdictions), including income, social
security and Medicare withholding taxes arising from the grant of the Award, the lapse of Restrictions or the
delivery of Shares pursuant to this Agreement by, without limitation:
(a) 	having the Company withhold Shares;
(b) 	tendering Shares received in connection with the Units back to the Company;

-- 191 of 409 --

8
(c) 	delivering other previously acquired Shares having a Fair Market Value approximately equal to the
amount to be withheld;
(d) 	selling Shares issued pursuant to the Units and having the Company withhold from proceeds of the
sale of such Shares;
(e) 	having the Company or a Subsidiary, as applicable, withhold from any cash compensation payable
to the Employee; or
(f) 	requiring the Employee to repay the Company or Subsidiary, in cash or in Shares, for taxes paid on
the Employee’s behalf.
Notwithstanding the foregoing, if the Employee is subject to Section 16 of the Exchange Act pursuant to
Rule 16a-2 promulgated thereunder, any tax withholding obligations shall be satisfied by having the
Company withhold a number of Shares otherwise issuable upon settlement of the Units that is sufficient to
satisfy such obligations consistent with the Company’s withholding practices.
If, to satisfy tax withholding obligations, the Company withholds Shares otherwise issuable to the
Employee, the Employee shall be deemed to have been issued the full number of Shares underlying the
Units, subject to the Restrictions set forth in this Agreement.
9. 	No Right to Continued Employment. This Agreement and the Employee’s participation in the Program is
not and shall not be interpreted to:
(a) 	form an employment contract or relationship with the Company or its Subsidiaries;
(b) 	confer upon the Employee any right to continue in the employ of the Company or any of its
Subsidiaries; or
(c) 	interfere with the ability of the Company or its Subsidiaries to terminate the Employee’s
employment at any time.
10. 	Nature of Grant. In accepting this grant of Units, the Employee acknowledges that:
(a) 	The Program is established voluntarily by the Company, it is discretionary in nature and it may be
modified, amended, suspended or terminated by the Company at any time;
(b) 	This Award is a one-time benefit and does not create any contractual or other right to receive future
grants of Units, benefits in lieu of Units, or other Program Benefits in the future, even if Units have
been granted repeatedly in the past;
(c) 	All decisions with respect to future Unit grants, if any, and their terms and conditions, will be made
by the Committee, in its sole discretion;
(d) 	Nothing contained in this Agreement is intended to create or enlarge any other contractual
obligations between the Company and the Employee;

-- 192 of 409 --

9
(e) 	The Employee is voluntarily participating in the Program;
(f) 	The Units and Shares subject to the Units are:
(i) 	extraordinary items that do not constitute compensation of any kind for services of any kind
rendered to the Company or its Subsidiaries, and are outside the scope of the Employee’s
employment contract, if any;
(ii) 	not intended to replace any pension rights or compensation;
(iii) 	not part of the Employee’s normal or expected compensation or salary for any purposes,
including, but not limited to, calculating any severance, resignation, termination,
redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or
retirement or welfare benefits, or similar payments and in no event should be considered as
compensation for, or relating in any way to, past services for the Company or its
Subsidiaries;
(g) 	The future value of the Shares underlying the Units is unknown and cannot be predicted with
certainty;
(h) 	In consideration of the Award, no claim or entitlement to compensation or damages shall arise from
the Units resulting from Termination (for any reason whatsoever) and the Employee irrevocably
releases the Company and its Subsidiaries from any such claim that may arise; if any such claim is
found by a court of competent jurisdiction to have arisen, then, by signing or electronically
accepting this Agreement, the Employee shall be deemed irrevocably to have waived the
Employee’s entitlement to pursue such claim;
(i) 	The Units and the Benefits under the Program, if any, will not automatically transfer to another
company in the case of a merger, take-over or transfer of liability; and
(j) 	Neither the Company nor any of its Subsidiaries shall be liable for any change in value of the Units,
the amount realized upon settlement of the Units or the amount realized upon a subsequent sale of
any Shares acquired upon settlement of the Units, resulting from any fluctuation of the United States
Dollar/local currency foreign exchange rate.
11. 	Data Privacy.
(a) 	Pursuant to applicable personal data protection laws, the collection, processing and transfer of the
Employee’s personal Data is necessary for the Company’s administration of the Program and the
Employee’s participation in the Program. The Employee’s denial and/or objection to the collection,
processing and transfer of personal Data may affect his or her ability to participate in the Program.
As such (where required under applicable law), the Employee:
(i) 	voluntarily acknowledges, consents and agrees to the collection, use, processing and
transfer of personal Data as described herein; and

-- 193 of 409 --

10
(ii) 	authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic
or other form, for purposes of implementing, administering and managing the Employee’s
participation in the Program, including any requisite transfer of such Data as may be
required for the administration of the Program and/or the subsequent holding of Shares on
the Employee’s behalf to a broker or other third party with whom the Employee may elect
to deposit any Shares acquired pursuant to the Program.
(b) 	Data may be provided by the Employee or collected, where lawful, from third parties, and the
Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the
exclusive purpose of implementing, administering and managing the Employee’s participation in the
Program. Data processing will take place through electronic and non-electronic means according to
logics and procedures strictly correlated to the purposes for which the Data is collected and with
confidentiality and security provisions as set forth by applicable laws and regulations in the
Employee’s country of residence. Data processing operations will be performed minimizing the use
of personal and identification data when such operations are unnecessary for the processing
purposes sought. The Data will be accessible within the Company’s organization only by those
persons requiring access for purposes of the implementation, administration and operation of the
Program and for the Employee’s participation in the Program.
(c) 	The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as
necessary for the purpose of implementation, administration and management of the Employee’s
participation in the Program, and the Company and the Subsidiary that employs the Employee (if
applicable) may further transfer Data to any third parties assisting the Company in the
implementation, administration and management of the Program. These recipients may be located
throughout the world.
(d) 	The Employee may, at any time, exercise his or her rights provided under applicable personal data
protection laws, which may include the right to:
(i) 	obtain confirmation as to the existence of the Data;
(ii) 	verify the content, origin and accuracy of the Data;
(iii) 	request the integration, update, amendment, deletion or blockage (for breach of applicable
laws) of the Data; and
(iv) 	oppose, for legal reasons, the collection, processing or transfer of the Data which is not
necessary or required for the implementation, administration and/or operation of the
Program and the Employee’s participation in the Program.
The Employee may seek to exercise these rights by contacting his or her local human resources
manager.

-- 194 of 409 --

11
(e) 	Upon request of the Company or the Subsidiary that employs the Employee (if applicable), the
Employee agrees to provide an executed data privacy consent form (or any other agreements or
consents that may be required), as deemed necessary by the Company or the Subsidiary that
employs the Employee (if applicable) for the purpose of administering the Employee’s participation
in the Program in compliance with the data privacy laws in the Employee’s country, either now or in
the future. If the Employee fails to provide any such consent or agreement requested by the
Company and/or the Subsidiary that employs the Employee (if applicable) and the Committee or its
delegate determines that the collection, processing and/or transfer of Data without such consent or
agreement would violate the laws in the Employee’s country, the Employee understands and agrees
that the Employee will not be able to participate in the Program and the Award will be null and void.
12. 	Form of Payment. The Company may, in its sole discretion, settle the Employee’s Units in the form of a
cash payment to the extent settlement in Shares: (i) is prohibited under local law; (ii) would require the
Employee, the Company and/or its Subsidiaries to obtain the approval of any governmental and/or
regulatory body in the Employee’s country; (iii) would result in adverse tax consequences for the Employee
or the Company; or (iv) is administratively burdensome. Alternatively, the Company may, in its sole
discretion, settle the Employee’s Units in the form of Shares but require the Employee to sell such Shares
immediately or within a specified period of time following the Employee’s Termination (in which case, this
Agreement shall give the Company the authority to issue sales instructions on the Employee’s behalf).
13. 	Private Placement. The grant of this Unit is not intended to be a public offering of securities in the
Employee’s country. The Company has not submitted any registration statement, prospectus or other filings
with the local securities authorities (unless otherwise required under local law), and this grant of Units is not
subject to the supervision of the local securities authorities.
14. 	Exchange Controls. As a condition to this grant of Units, the Employee agrees to comply with any
applicable foreign exchange rules and regulations.
15. 	Compliance with Applicable Laws and Regulations.
(a) 	The Company shall not be required to issue or deliver any Shares pursuant to this Agreement
pending compliance with all applicable federal and state securities and other laws (including any
registration requirements or tax withholding requirements) and compliance with the rules and
practices of any stock exchange upon which the Company’s Shares are listed.
(b) 	Regardless of any action the Company or its Subsidiaries take with respect to any or all income tax,
social insurance, payroll tax, payment on account or other tax-related items related to the
Employee’s participation in the Program and legally applicable to the Employee or deemed by the
Company or its Subsidiaries to be an appropriate charge to the Employee even if technically due by
the Company or its Subsidiaries (“Tax-Related Items”), the Employee acknowledges that the
ultimate liability for all Tax-Related Items is and remains the Employee’s responsibility and may
exceed the amount actually withheld by the Company or its Subsidiaries. The Employee further
acknowledges that the Company and/or

-- 195 of 409 --

12
its Subsidiaries: (i) make no representations or undertakings regarding the treatment of any Tax-
Related Items in connection with any aspect of the Units, including, but not limited to, the grant,
lapse of Restrictions or settlement of the Units, the issuance of Shares upon payment of the Units,
the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends
and/or any Dividend Equivalents; and (ii) do not commit to and are under no obligation to structure
the terms of the grant or any aspect of the Units to reduce or eliminate the Employee’s liability for
Tax-Related Items or achieve any particular tax result. Further, if the Employee has become subject
to tax in more than one (1) jurisdiction between the date of grant and the date of any relevant
taxable event, the Employee acknowledges that the Company and/or its Subsidiaries may be
required to withhold or account for Tax-Related Items in more than one (1) jurisdiction.
16. 	Code Section 409A. Payments made pursuant to this Agreement are intended to be exempt from or to
otherwise comply with the provisions of Code Section 409A to the extent applicable. The Program and this
Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company
determines that any payments under this Agreement are subject to Code Section 409A and this Agreement
fails to comply with that section’s requirements, the Company may, at the Company’s sole discretion, and
without the Employee’s consent, amend this Agreement to cause it to comply with Code Section 409A or
otherwise be exempt from Code Section 409A.
To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A and
applicable guidance issued thereunder, the Employee shall not be deemed to have had a Termination unless
the Employee has incurred a “separation from service” as defined in Treasury Regulation §1.409A-1(h), and
amounts that would otherwise be payable pursuant to this Agreement during the six-month period
immediately following the Employee’s Termination (including Retirement) shall instead be paid on the first
business day after the date that is six (6) months following the Employee’s Termination (or upon the
Employee’s death, if earlier). For purposes of Code Section 409A, to the extent applicable: (i) all payments
provided hereunder shall be treated as a right to a series of separate payments and each separately identified
amount to which the Employee is entitled under this Agreement shall be treated as a separate payment; (ii)
except as otherwise provided in Section 13(a) of the Program, upon the lapse of Restrictions pursuant to
Section 5 of this Agreement, any Units not previously settled on a Delivery Date shall be settled as soon as
administratively possible after, and effective as of, the date of the Change in Control or the date of the
Employee’s Termination (as applicable); (iii) the term “as soon as administratively possible” means a period
of time that is within 60 days after the Termination, Disability or Change in Control (as applicable); and (iv)
the date of the Employee’s Disability shall be determined by the Company in its sole discretion.
Although this Agreement and the payments provided hereunder are intended to be exempt from or to
otherwise comply with the requirements of Code Section 409A, the Company does not represent or warrant
that this Agreement or the payments provided hereunder will comply with Code Section 409A or any other
provision of federal, state, local, or non-United States law. None of the Company, its Subsidiaries, or their
respective directors, officers, employees or advisers shall be liable to the Employee (or any other individual
claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a
result of compensation paid under this Agreement,

-- 196 of 409 --

13
and the Company and its Subsidiaries shall have no obligation to indemnify or otherwise protect the
Employee from the obligation to pay any taxes pursuant to Code Section 409A.
17. 	No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the
Company making any recommendations regarding the Units, the Employee’s participation in the Program or
the Employee’s acquisition or sale of the underlying Shares. The Employee is hereby advised to consult
with the Employee’s own personal tax, legal and financial advisors regarding participation in the Program
before taking any action related to the Program.
18. 	Imposition of Other Requirements. The Company reserves the right to impose other requirements on the
Employee’s participation in the Program, on the Units and on any Shares acquired under the Program, to the
extent the Company or its Subsidiaries determines it is necessary or advisable in order to comply with local
law or facilitate the administration of the Program, and to require the Employee to sign any additional
agreements or undertakings that may be necessary to accomplish the foregoing. The Employee agrees to
take any and all actions, and consents to any and all actions taken by the Company and its Subsidiaries, as
may be required to allow the Company and its Subsidiaries to comply with local laws, rules and regulations
in the Employee’s country. In addition, the Employee agrees to take any and all actions as may be required
to comply with the Employee’s personal obligations under local laws, rules and regulations in the
Employee’s country.
19. 	Determinations. Each decision, determination, interpretation or other action made or taken pursuant to the
provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be
final, conclusive and binding for all purposes and upon all persons, including, without limitation, the
Company, the Employee, the Employee’s Representative, and the person or persons to whom rights under
the Award have passed by will or the laws of descent or distribution.
20. 	Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to
current or future participation in the Program by electronic means. The Employee hereby consents to
receive such documents by electronic delivery and agrees to participate in the Program through an on-line or
electronic system established and maintained by the Company or a third party designated by the Company.
21. 	Addendum. This grant of Units shall be subject to any special terms and conditions set forth in any
Addendum to this Agreement for the Employee’s country. Moreover, if the Employee relocates to one of
the countries included in the Addendum, the special terms and conditions for such country will apply to the
Employee, to the extent the Company determines that the application of such terms and conditions is
necessary or advisable in order to comply with local law or facilitate the administration of the Program (or
the Company may establish alternative terms and conditions as may be necessary or advisable to
accommodate the Employee’s relocation). The Addendum constitutes part of this Agreement.
22. 	Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, and each other provision of this
Agreement shall be severable and enforceable to the extent permitted by law. To the extent a court or
tribunal of competent jurisdiction determines

-- 197 of 409 --

14
that any provision of this Agreement is invalid or unenforceable, in whole or in part, the Company, in its
sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent
necessary to make it valid and enforceable to the full extent permitted under local law.
23. 	Entire Agreement. This Agreement, the Program, the Program prospectus, the Program administrative
rules, and any applicable Company policies constitute the entire agreement between the Employee and the
Company regarding the Award and supersede all prior and contemporaneous agreements and
understandings, oral or written, between the parties regarding the Award. Except as expressly set forth
herein, this Agreement (and any provision of this Agreement) may not be modified, changed, clarified, or
interpreted by the parties, except in a writing specifying the modification, change, clarification, or
interpretation, and signed by a duly authorized Company officer.
24. 	Succession. This Agreement shall be binding upon and operate for the benefit of the Company and its
successors and assigns, and the Employee, the Employee’s Representative, and the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution.
25. 	Language. If the Employee has received this Agreement or any other document related to the Program
translated into a language other than English and if the meaning of the translated version is different than the
English version, the English version will control.
26. 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
U.S. State of Illinois without giving effect to any state’s conflict of laws principles.
27. 	Venue. For any legal action relating to this Agreement, the parties to this Agreement consent to the
exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there
is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County,
Illinois, USA.
* 	* 	*
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer as of the
grant date above set forth.
ABBOTT LABORATORIES
By
Robert B. Ford
President and Chief Executive Officer

-- 198 of 409 --

15
ADDENDUM TO THE ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT
In addition to the terms and conditions set forth in the Agreement, the Award is subject to the following terms and
conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Program. If the
Employee is employed in a country identified in the Addendum, the additional terms and conditions for such country shall
apply. If the Employee transfers residence and/or employment to a country identified in the Addendum, the additional terms
and conditions for such country shall apply to the extent the Company determines, in its sole discretion, that the application
of such terms and conditions is necessary or advisable to comply with local law or to facilitate administration of the Program
(or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the
Employee’s transfer).
EUROPEAN UNION / EUROPEAN ECONOMIC AREA, SWITZERLAND AND THE UNITED KINGDOM
Data Privacy. The following provision replaces Section 11 of the Agreement in its entirety:
Pursuant to applicable personal data protection laws, Abbott and the Subsidiary that employs the Employee (the
“Employer”) hereby notifies the Employee of the following in relation to the Employee’s Personal Data (defined below) and
the collection, processing and transfer in electronic or other form of such Personal Data in relation to the administration of
the Units and the Employee’s participation in the Program. The collection, processing and transfer of the Employee’s
Personal Data is necessary for the legitimate purpose of Abbott and the Employer’s administration of the Units and the
Employee’s participation in the Program, and the Employee’s denial and/or objection to the collection, processing and
transfer of Personal Data may affect the Employee’s participation in the Program. As such, by accepting the Units, the
Employee acknowledges the collection, use, processing and transfer of Personal Data as described herein.
Abbott and the Employer hold certain personally identifiable information about the Employee, specifically, the Employee’s
name, home address and telephone number, date of birth, social security number or other employee identification number,
salary, nationality, job title, any Shares or directorships held in Abbott, details of all Units or any other entitlement to Shares
awarded, canceled, purchased, vested, unvested or outstanding in the Employee’s favor, for the purpose of managing and
administering the Program (“Personal Data”). The Personal Data may be provided by the Employee or collected, where
lawful, from third parties. Abbott or the Employer each act as controllers of the Personal Data and will process the Personal
Data in this context for the exclusive legitimate purpose of implementing, administering and managing the Employee’s
participation in the Program and meeting related legal obligations associated with these actions.
The processing will take place through electronic and non-electronic means according to logics and procedures correlated to
the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by
applicable laws and regulations. Personal Data will be accessible within Abbott’s organization only by those persons
requiring access for purposes of the implementation, administration and operation of the Program and other aspects of the
employment relationship and for the Employee’s participation in the Program.
Abbott and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation,
administration and management of the Employee’s participation in the Program, and Abbott and the Employer may each
further transfer Personal Data to third parties assisting Abbott or the Employer in the implementation, administration and
management of the Program, including UBS

-- 199 of 409 --

16
Financial Services Inc. or any successor or other third party that Abbott, the Employer or UBS Financial Services Inc. (or its
successor) may engage to assist with the administration of the Program from time to time. These recipients may be located in
the European Economic Area, Switzerland, the United Kingdom, or elsewhere throughout the world, such as the United
States. By participating in the Program, the Employee understands that these recipients may receive, possess, use, retain and
transfer the Personal Data, in electronic or other form, for purposes of implementing, administering and managing the
Employee’s participation in the Program, including any requisite transfer of such Personal Data as may be required for the
administration of the Program and/or the subsequent holding of Shares on the Employee’s behalf to a broker or other third
party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program. The Employee further
understands that he or she may request a list with the names and addresses of any potential recipients of the Employee’s
Personal Data by contacting the Employee’s local human resources manager or Abbott's human resources Department.
When transferring Personal Data to these potential recipients, Abbott and the Employer provide appropriate safeguards in
accordance with EU Standard Contractual Clauses, the EU-U.S. Privacy Shield Framework, or other legally binding and
permissible arrangements. The Employee may request a copy of such safeguards from the Employee’s local human
resources manager or Abbott's human resources department.
To the extent provided by law, the Employee may, at any time, have the right to request: access to Personal Data,
rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of
Personal Data. The Employee may also have the right to object, on grounds related to a particular situation, to the processing
of Personal Data, as well as opt-out of the Program herein, in any case without cost, by contacting in writing the Employee’s
human resources manager. The Employee’s provision of Personal Data is a contractual requirement. The Employee
understands, however, that the only consequence of refusing to provide Personal Data is that Abbott and the Employer may
not be able to let the Employee participate in the Program, or grant other equity awards or administer or maintain such
awards. For more information on the consequences of the Employee’s refusal to provide Personal Data, the Employee
understands that the Employee may contact his or her local human resources manager or Abbott's human resources
department.
When Abbott and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for
compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems
and/or records containing the Personal Data and/or take steps to properly anonymize it so that the Employee can no longer
be identified from it.
ALGERIA
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
AUSTRALIA
1. 	Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Program, the Employee will not
be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Program if the provision
of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act,
or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.
2. 	Australian Offer Document. In addition to the Agreement and the Program, the Employee must review the
Australian Offer Document and the Australian Addendum to the Program for additional important information pertaining to
the Award. Both of these documents can be accessed in the library

-- 200 of 409 --

17
section of the UBS website at www.ubs.com/onesource/abt. By accepting the Award, the Employee acknowledges and
confirms that the Employee has reviewed these documents.
BRAZIL
Labor Law Acknowledgment. The Employee agrees, for all legal purposes, (i) the benefits provided under the Agreement
and the Program are the result of commercial transactions unrelated to the Employee’s employment; (ii) the Agreement and
the Program are not a part of the terms and conditions of the Employee’s employment; and (iii) the income from the Units, if
any, is not part of the Employee’s remuneration from employment.
CANADA
1. 	Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the
Award shall be settled only in Shares (and may not be settled in cash).
2. 	Resale Restriction. The Employee understands that the Employee is permitted to sell Shares acquired under the
Program through the designated broker appointed under the Program, provided the resale of Shares takes place outside of
Canada through the facilities of the stock exchange on which the Shares are traded. The principal market for the Shares is the
New York Stock Exchange under the symbol "ABT". Shares are also listed on the Chicago Stock Exchange and traded on
various regional and electronic exchanges. Outside the United States, the Shares are listed on the SIX Swiss Exchange.
3. 	English Language. The parties to the Agreement acknowledge that it is their express wish that the Agreement, as
well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or
indirectly hereto, be drawn up in English. Les parties reconnaissent avoir exigé la rédaction en anglais de la présente
convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou
indirectement, relativement à ou suite à la présente convention.
4. 	Data Privacy. The following provision supplements Section 11 of the Agreement:
The Employee hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant
information from all personnel involved in the administration and operation of the Program. The Employee further
authorizes the Company and any of its Subsidiaries to disclose and discuss the Program with their advisors. The Employee
further authorizes the Company and any of its Subsidiaries to record such information and to keep such information in the
Employee’s employee file.
CHILE
Private Placement. The following provision shall replace Section 13 of the Agreement:
The grant of the Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be
a private placement.
a) The starting date of the offer will be the Grant Date (as defined in the Agreement), and this offer conforms to
General Ruling no. 336 of the Chilean Commission for the Financial Market;
b) The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the
Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight;

-- 201 of 409 --

18
c) The issuer is not obligated to provide public information in Chile regarding the foreign securities, as such securities
are not registered with the Chilean Commission for the Financial Market; and
d) The foreign securities shall not be subject to public offering as long as they are not registered with the
corresponding registry of securities in Chile.
a) La fecha de inicio de la oferta será el de la fecha de otorgamiento (o “Grant Date”, según este término se define en
el documento denominado “Agreement”) y esta oferta se acoge a la norma de Carácter General n° 336 de la
Comisión para el Mercado Financiero de Chile;
b) La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva
la Comisión para el Mercado Financiero de Chile, por lo que tales valores no están sujetos a la fiscalización de
ésta;
c) Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información
pública respecto de esos valores; y
d) Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores
correspondiente.
CHINA
The following provisions shall apply to individuals who are subject to the People’s Republic of China (“China”) exchange
control requirements, as determined by the Company in its sole discretion:
1. 	Treatment of Units upon Retirement. Provided that the Employee is not subject to Section 16 of the Exchange Act
pursuant to Rule 16a-2 promulgated thereunder, if the Employee experiences a Termination due to Retirement, Restrictions
on the Units shall lapse on the date of the Termination, and any Units not previously settled on a Delivery Date shall be
settled in the form of Shares as soon as administratively possible after, and effective as of, the date of Termination.
2. 	Foreign Exchange Control Laws. The Employee agrees to hold the Shares received upon settlement of the Units
with the Company’s designated broker. Upon a Termination, the Employee shall be required to sell all Shares issued
pursuant to the Units within 90 days (or such shorter period as may be required by the State Administration of Foreign
Exchange) of the Termination date and repatriate the sales proceeds to China in the manner designated by the Company. For
purposes of the foregoing, the Company shall establish procedures for effectuating the forced sale of the Shares (including
procedures whereby the Company may issue sell instructions on behalf of the Employee), and the Employee hereby agrees
to comply with such procedures and take any and all actions as the Company determines, in its sole discretion, are necessary
or advisable for purposes of complying with local laws, rules and regulations in China.
The Employee understands and agrees that the repatriation of dividends and sales proceeds may need to be effected through
a special exchange control account established by the Company or its Subsidiaries, and the Employee hereby consents and
agrees that sales proceeds from the sale of Shares acquired under the Program may be transferred to such account by the
Company on the Employee’s behalf prior to being delivered to the Employee. The sales proceeds may be paid to the
Employee in U.S. dollars or local currency at the Company’s discretion. If the sales proceeds are paid to the Employee in
U.S. dollars, the Employee understands that the Employee will be required to set up a U.S. dollar bank account in China so
that the proceeds may be deposited into this account. If the sales proceeds are paid to the Employee in local currency, the
Employee acknowledges that the Company is under no obligation to secure any

-- 202 of 409 --

19
particular exchange conversion rate and that the Company may face delays in converting the dividends and proceeds to local
currency due to exchange control restrictions. The Employee agrees to bear any currency fluctuation risk between the time
the Shares are sold and the net proceeds are converted into local currency and distributed to the Employee. The Employee
further agrees to comply with any other requirements that may be imposed by the Company or its Subsidiaries in China in
the future in order to facilitate compliance with exchange control requirements in China. The Employee agrees to be subject
to these restrictions even after Termination.
Neither the Company nor any of its Subsidiaries shall be liable for any costs, fees, lost interest or dividends or other losses
the Employee may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the
Company’s operation and enforcement of the Program, the Agreement and the Units in accordance with Chinese law
including, without limitation, any applicable State Administration of Foreign Exchange rules, regulations and requirements.
CROATIA
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
DENMARK
Treatment of Units upon Termination. Notwithstanding any provisions in the Agreement to the contrary, if the Employee is
determined to be an “Employee,” as defined in Section 2 of the Danish Act on the Use of Rights to Purchase or Subscribe
for Shares etc. in Employment Relationships, as in effect prior to January 1, 2019 (the “Stock Option Act”), the treatment of
the Units upon a Termination shall be governed by Sections 4 and 5 of the Stock Option Act. However, if the provisions in
the Agreement or the Program governing the treatment of the Units upon a Termination are more favorable, the provisions of
the Agreement or the Program will govern.
FINLAND
Withholding of Tax-Related Items. Notwithstanding Section 8 of the Agreement, if the Employee is a local national of
Finland, any Tax-Related Items shall be withheld only in cash from the Employee’s regular salary/wages or other amounts
payable to the Employee in cash, or such other withholding methods as may be permitted under the Program and allowed
under local law.
FRANCE
1. 	Nature of the Award. The Units are not granted under the French specific regime provided by Articles L.225-197-1
and seq. of the French commercial code.
2. 	English Language. The parties to the Agreement acknowledge that it is their express wish that the Agreement, as
well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or
indirectly hereto, be drawn up in English. Les parties reconnaissent avoir exigé la rédaction en anglais de la présente
convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou
indirectement, relativement à ou suite à la présente convention.

-- 203 of 409 --

20
HONG KONG
1. 	Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the
Award shall be settled only in Shares (and may not be settled in cash).
2. 	Lapse of Restrictions. If, for any reason, Shares are issued to the Employee within six (6) months of the Grant Date,
the Employee agrees that he or she will not sell or otherwise dispose of any such Shares prior to the six-month anniversary
of the Grant Date.
3. 	IMPORTANT NOTICE. WARNING: The contents of the Agreement, the Addendum, the Program, and all other
materials pertaining to the Units and/or the Program have not been reviewed by any regulatory authority in Hong Kong. The
Employee is hereby advised to exercise caution in relation to the offer thereunder. If the Employee has any doubts about any
of the contents of the aforesaid materials, the Employee should obtain independent professional advice.
4. 	Wages. The Units and Shares subject to the Units do not form part of the Employee’s wages for the purposes of
calculating any statutory or contractual payments under Hong Kong law.
5. 	Nature of the Program. The Company specifically intends that the Program will not be treated as an occupational
retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court,
tribunal or legal/regulatory body in Hong Kong determines that the Program constitutes an occupational retirement scheme
for the purposes of ORSO, the grant of the Units shall be null and void.
INDIA
Repatriation Requirements. As a condition of this Award, the Employee agrees to repatriate all sales proceeds and dividends
attributable to Shares acquired under the Program in accordance with local foreign exchange rules and regulations. Neither
the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to
comply with applicable laws.
ISRAEL
1. 	Securities Law Notice. The Israeli Securities Authority granted to the Company an exemption from the requirement
to file a prospectus with respect to the Program. A copy of the Program and the Form S-8 registration statement for the
Program filed with the United States Securities and Exchange Commission can be accessed in the library section of the UBS
website at www.ubs.com/onesource/abt or are available free of charge upon request from the Employee’s local human
resources department.
2. 	Holding and Sale of Shares. In consideration for the grant of the Award, the Employee agrees to hold the Shares
received upon settlement of the Units subject to the Award and any and all previously granted restricted stock units with the
Company’s designated broker. The Employee understands and agrees that upon the Employee’s sale of Shares, unless
otherwise determined by the Company, (a) the repatriation of sales proceeds shall be effected through the Subsidiary that
employs the Employee, (b) the Subsidiary that employs the Employee will withhold the requisite tax and other mandatory
withholding (e.g., National Insurance payments) from the sales proceeds and (c) the Subsidiary that employs the Employee
will transfer the remaining sale proceeds (net of the requisite tax and other mandatory withholding) to the Employee. The
Employee acknowledges and agrees that the process and requirements set forth herein shall continue to apply following the
Employee’s Termination.

-- 204 of 409 --

21
3. 	Indemnification for Tax Liabilities. As a condition of the grant of Units, the Employee expressly consents and
agrees to indemnify the Company and/or its Subsidiaries and hold them harmless from any and all liability attributable to
taxes, interest or penalties thereon, including without limitation, liabilities relating to the necessity to withhold any taxes.
MEXICO
1. 	Commercial Relationship. The Employee expressly acknowledges that the Employee’s participation in the Program
and the Company’s grant of the Award does not constitute an employment relationship between the Employee and the
Company. The Employee has been granted the Award as a consequence of the commercial relationship between the
Company and the Company’s Subsidiary in Mexico that employs the Employee, and the Company’s Subsidiary in Mexico is
the Employee’s sole employer. Based on the foregoing: (a) the Employee expressly acknowledges that the Program and the
benefits derived from participation in the Program do not establish any rights between the Employee and the Subsidiary in
Mexico that employs the Employee; (b) the Program and the benefits derived from participation in the Program are not part
of the employment conditions and/or benefits provided by the Subsidiary in Mexico that employs the Employee; and (c) any
modifications or amendments of the Program or benefits granted thereunder by the Company, or a termination of the
Program by the Company, shall not constitute a change or impairment of the terms and conditions of the Employee’s
employment with the Subsidiary in Mexico.
2. 	Extraordinary Item of Compensation. The Employee expressly recognizes and acknowledges that the Employee’s
participation in the Program is a result of the discretionary and unilateral decision of the Company, as well as the
Employee’s free and voluntary decision to participate in the Program in accord with the terms and conditions of the
Program, the Employee’s Agreement and this Addendum. As such, the Employee acknowledges and agrees that the
Company may, in its sole discretion, amend and/or discontinue the Employee’s participation in the Program at any time and
without any liability. The value of the Units is an extraordinary item of compensation outside the scope of the Employee’s
employment contract, if any. The Units are not part of the Employee’s regular or expected compensation for purposes of
calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or
retirement benefits, or any similar payments, which are the exclusive obligations of the Company’s Subsidiary in Mexico
that employs the Employee.
MOROCCO
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
NETHERLANDS
Waiver of Termination Rights. The Employee waives any and all rights to compensation or damages as a result of a
Termination, insofar as those rights result or may result from: (a) the loss or diminution in value of such rights or
entitlements under the Program; or (b) the Employee ceasing to have rights, or ceasing to be entitled to any Awards under
the Program as a result of such Termination.

-- 205 of 409 --

22
NEW ZEALAND
Securities Law Notice.
Warning
This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Program and the Agreement,
will be converted into Shares. Shares give you a stake in the ownership of Abbott Laboratories. You may receive a return if
dividends are paid.
If Abbott Laboratories runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of
preference shares have been paid. You may lose some or all of your investment.
New Zealand law normally requires people who offer financial products to give information to investors before they invest.
This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer
because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually
required. You will also have fewer other legal protections for this investment.
Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting rights) with respect to
the underlying Shares.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The Shares are quoted on the New York Stock Exchange. This means that if you acquire Shares under the Program, you
may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you
invested. The price will depend on the demand for the Shares.
You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed
below:
1. Abbott Laboratories’ most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?
CIK=abt&owner=exclude&action=getcompany&Find=Search
2. Abbott Laboratories’ most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on
those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?
CIK=abt&owner=exclude&action=getcompany&Find=Search
3. The Abbott Laboratories 2017 Incentive Stock Program: This document can be accessed in the library section of
the UBS website at www.ubs.com/onesource/abt.
4. Abbott Laboratories 2017 Incentive Stock Program Prospectus: This document can be accessed in the library
section of the UBS website at www.ubs.com/onesource/abt.
A copy of the above documents will be sent to you free of charge on written request being mailed to: Senior Manager,
Equity Programs, Abbott Laboratories, D058G, AP6B-2, Abbott Park, IL 60064, USA.
PAKISTAN
1. 	Repatriation Requirements. As a condition of this Award, the Employee agrees to repatriate all Dividend
Equivalents and all sales proceeds and dividends attributable to Shares acquired under the Program in accordance with local
foreign exchange rules and regulations. Neither the Company nor any

-- 206 of 409 --

23
of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to comply with applicable
laws.
2. 	Exchange Control Obligations. To the extent applicable, the Employee is required to comply with certain consent
and reporting requirements to the State Bank of Pakistan (Pakistan’s central bank) under the exchange control laws of
Pakistan. As the exchange control regulations can change frequently and at times, without notice, the Employee should
consult his or her legal advisor prior to acquiring or selling Shares under the Program to ensure compliance with current
regulations. Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the
Employee’s failure to comply with applicable laws.
PHILIPPINES
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
ROMANIA
1. 	Termination. A Termination shall include the situation where the Employee’s employment contract is terminated by
operation of law on the date the Employee reaches the standard retirement age and has completed the minimum contribution
record for receipt of state retirement pension or the relevant authorities award the Employee an early-retirement pension of
any type.
2. 	English Language. The Employee hereby expressly agrees that this Agreement, the Program as well as all
documents, notices and proceedings entered into, relating directly or indirectly hereto, be drawn up or communicated only in
the English language. Angajatul consimte în mod expres prin prezentul ca acest Contract, Programul precum şi orice alte
documente, notificări, înştiinţări legate direct sau indirect de acest Contract să fie redactate sau efectuate doar în limba
engleză.
RUSSIA
1. 	Sale or Transfer of Shares. Notwithstanding anything to the contrary in the Program or the Agreement, the
Employee shall not be permitted to sell or otherwise dispose of the Shares acquired pursuant to the Award in Russia. The
Employee may sell the Shares only through a broker established and operating outside Russia.
2. 	Cash Payments to a Russian Bank Account. The Employee agrees to promptly repatriate proceeds resulting from
the sale of Shares acquired under the Program to a foreign currency account at an authorized bank in Russia if legally
required at the time Shares are sold and to comply with all applicable local foreign exchange rules and regulations. Neither
the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to
comply with applicable laws.
SINGAPORE
Qualifying Person Exemption. The grant of the Award under the Program is being made pursuant to the “Qualifying
Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the “SFA”). The
Program has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is
not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability
under the SFA in relation to the content of prospectuses would not apply. The Employee should note that, as a result,
the Award is subject

-- 207 of 409 --

24
to section 257 of the SFA and the Employee will not be able to make: (a) any subsequent sale of the Shares underlying the
Award in Singapore; or (b) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such
sale or offer is made pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the
SFA.
SOUTH AFRICA
1. 	Exchange Control Obligations. The Employee is solely responsible for complying with applicable exchange control
regulations and rulings (the “Exchange Control Regulations”) in South Africa. As the Exchange Control Regulations change
frequently and without notice, the Employee should consult the Employee’s legal advisor prior to the acquisition or sale of
Shares under the Program to ensure compliance with current Exchange Control Regulations. Neither the Company nor any
of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to comply with applicable
laws.
2. 	Securities Law Information and Deemed Acceptance of Units. Neither the Units nor the underlying Shares shall be
publicly offered or listed on any stock exchange in South Africa. The offer is intended to be private pursuant to Section
96(1)(g)(ii) of the Companies Act, 71 of 2008 (the “Companies Act”) and is not subject to the supervision of any South
African governmental authority.
Pursuant to Section 96(1)(g)(ii) of the Companies Act, the Units offer must be finalized within six (6) months following the
date the offer is communicated to the Employee. If the Employee does not want to accept the Units, the Employee is
required to decline the Units no later than the six (6) months following the date the offer is communicated to the Employee.
If the Employee does not reject the Units within six (6) months following the date the offer is communicated to the
Employee, the Employee will be deemed to accept the Units.
SPAIN
1. 	Acknowledgement of Discretionary Nature of the Program; No Vested Rights
By accepting the Award, the Employee consents to participation in the Program and acknowledges receipt of a copy of the
Program.
The Employee understands that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the
Program to individuals who may be employees of the Company or its Subsidiaries throughout the world. The decision is a
limited decision that is entered into upon the express assumption and condition that any grant will not economically or
otherwise bind the Company or any of its Subsidiaries on an ongoing basis. Consequently, the Employee understands that
the Units are granted on the assumption and condition that the Units and the Shares acquired upon settlement of the Units
shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be
considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.
In addition, the Employee understands that this grant would not be made to the Employee but for the assumptions and
conditions referenced above; thus, the Employee acknowledges and freely accepts that should any or all of the assumptions
be mistaken or should any of the conditions not be met for any reason the Award shall be null and void.
The Employee understands and agrees that, as a condition of the Award, unless otherwise provided in Sections 4 or 5 of the
Agreement, any unvested Units as of the date the Employee ceases active employment will be forfeited without entitlement
to the underlying Shares or to any amount of indemnification in the event of Termination. The Employee acknowledges that
the Employee has read

-- 208 of 409 --

25
and specifically accepts the conditions referred to in the Agreement regarding the impact of a Termination on the Units.
2. 	Termination for Cause. Notwithstanding anything to the contrary in the Program or the Agreement, “Cause” shall be
as defined as set forth in the Agreement, regardless of whether the Termination is considered a fair termination (i.e.,
“despido procedente”) under Spanish legislation.
TUNISIA
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
UKRAINE
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
UNITED KINGDOM
1. 	Withholding Taxes. The following provision supplements Section 8 of the Agreement.
The Employee agrees that he or she is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related
Items as and when requested by the Company or the Subsidiary in the United Kingdom that employs the Employee (the
“Employer”) or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant
authority). The Employee also agrees to indemnify and keep indemnified the Company and the Employer against any Tax-
Related Items that they are required to pay or withhold or have paid or will pay on the Employee’s behalf to HMRC (or any
other tax authority or any other relevant authority).
Notwithstanding the foregoing, if the Employee is a director or executive officer of the Company (within the meaning of
Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), he or she would not be eligible to have the
Company or the Employer cover any income tax liability on his or her behalf. In this case, any income tax not collected
from or paid by the Employee within 90 days after the end of the U.K. tax year in which the event giving rise to the income
tax liability occurred (or such other period specified in U.K. law) will constitute a benefit to the Employee on which
additional income tax and national insurance contributions (“NICs”) will be payable. The Employee will be responsible for
paying and reporting any income tax due on this additional benefit directly to HMRC under the self-assessment regime and
for reimbursing the Company or the Employer (as applicable) the value of any employee NICs due on this additional benefit,
which the Company or the Employer may recover from the Employee by any of the means referred to in Section 8 of the
Agreement.
2. 	Exclusion of Claim. The Employee acknowledges and agrees that the Employee will have no entitlement to
compensation or damages insofar as such entitlement arises or may arise from the Employee’s ceasing to have rights under
or to be entitled to the Units, whether or not as a result of Termination (whether the Termination is in breach of contract or
otherwise), or from the loss or diminution in value of the Units. Upon the grant of the Award, the Employee shall be deemed
to have waived irrevocably any such entitlement.

-- 209 of 409 --

26
UZBEKISTAN
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
VIETNAM
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.

-- 210 of 409 --

Exhibit 10.61
ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT
On «Grant_Date» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the
“Employee”) a Performance Restricted Stock Unit Award (the “Award”) of «NoShares12345» restricted stock units (the
“Units”).
The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the
Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement. In the
event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus,
and the Program administrative rules, the Program shall control. This Award is intended to conform with the qualified
performance-based compensation requirements of Section 162(m) of the Code and the regulations thereunder, to the extent
applicable, and shall be construed accordingly.
The terms and conditions of the Award are as follows:
1. 	Definitions. To the extent not defined herein, capitalized terms shall have the same meaning as in the
Program.
(a) 	Agreement: This Performance Restricted Stock Unit Agreement.
(b) 	Cause: Cause shall mean the following, as determined by the Company in its sole discretion:
(i) 	material breach by the Employee of the terms and conditions of the Employee’s
employment, including, but not limited to:
(A) 	material breach by the Employee of the Code of Business Conduct;
(B) 	material breach by the Employee of the Employee’s employment contract,
if any;
(C) 	commission by the Employee of an act of fraud, embezzlement or theft in
connection with the Employee’s duties or in the course of the Employee’s
employment;
(D) 	wrongful disclosure by the Employee of secret processes or confidential
information of the Company or any of its Subsidiaries; or
(E) 	failure by the Employee to substantially perform the duties of the
Employee’s employment (other than any such failure resulting from the
Employee’s Disability); or
(ii) 	to the extent permitted by applicable law, engagement by the Employee, directly or
indirectly, for the benefit of the Employee or others, in any

-- 211 of 409 --

2
activity, employment or business which is competitive with the Company or any of its
Subsidiaries.
(c) 	Change in Control Agreement: An Agreement Regarding Change in Control in effect between the
Company (or the Surviving Entity) and the Employee, if any.
(d) 	Change in Control Cause: shall mean the occurrence of any of the following circumstances during
the period that begins six (6) months immediately before a Change in Control and ends two (2)
years immediately following such Change in Control: the willful engaging by the Employee in
illegal conduct or gross misconduct which is demonstrably and materially injurious to the Company.
For purposes of this definition, no act, or failure to act, on the Employee’s part shall be deemed
“willful” unless done, or omitted to be done, by the Employee not in good faith and without
reasonable belief that the Employee’s action or omission was in the best interest of the Company.
Notwithstanding the foregoing, the Employee shall not be deemed to have been terminated for
Change in Control Cause unless and until the Company delivers to the Employee a copy of a
resolution duly adopted by the affirmative vote of not less than three-quarters of the entire
membership of the Board at a meeting of the Board called and held for such purpose (after
reasonable notice to the Employee and an opportunity for the Employee, together with counsel, to
be heard before the Board) finding that, in the good faith opinion of the Board, the Employee was
guilty of conduct set forth above and specifying the particulars thereof in detail.
(e) 	Change in Control Good Reason: shall mean the occurrence of any of the following circumstances
without the Employee’s express written consent during the period that begins six (6) months
immediately before a Change in Control and ends two (2) years immediately following such Change
in Control:
(i) 	a significant adverse change in the nature, scope or status of the Employee’s position,
authorities or duties from those in effect immediately prior to the Change in Control,
including, without limitation, if the Employee was, immediately prior to the Change in
Control, an Employee officer of a public company, the Employee ceasing to be an
Employee officer of a public company;
(ii) 	the failure by the Company to pay the Employee any portion of the Employee’s current
compensation, or to pay the Employee any portion of any installment of deferred
compensation under any deferred compensation program of the Company, within seven
(7) days of the date such compensation is due;
(iii) 	a reduction in the Employee’s annual base salary (or a material change in the frequency of
payment) as in effect immediately prior to the Change in Control as the same may be
increased from time to time;
(iv) 	the failure by the Company to award the Employee an annual bonus in any year which is at
least equal to the annual bonus, awarded to the Employee under the annual bonus plan of
the Company for the year immediately preceding the year of the Change in Control;

-- 212 of 409 --

3
(v) 	the failure by the Company to award the Employee equity-based incentive compensation
(such as stock options, shares of restricted stock, restricted stock units, or other equity-based
compensation) on a periodic basis consistent with the Company’s practices with respect to
timing, value and terms prior to the Change in Control;
(vi) 	the failure by the Company to continue to provide the Employee with the welfare benefits,
fringe benefits and perquisites enjoyed by the Employee immediately prior to the Change in
Control under any of the Company’s plans or policies, including, but not limited to, those
plans and policies providing pension, life insurance, medical, health and accident, disability,
vacation, Employee automobile, Employee tax or financial advice benefits or club dues;
(vii) 	the relocation of the Company’s principal Employee offices to a location more than 35
miles from the location of such offices immediately prior to the Change in Control or the
Company requiring the Employee to be based anywhere other than the location where the
Employee primarily performs services for the Company immediately prior to the Change in
Control except for required travel for the Company’s business to an extent substantially
consistent with the Employee’s business travel obligations immediately prior to the Change
in Control; or
(viii) the failure of the Company to obtain a satisfactory agreement from any successor to the
Company to assume and agree to perform any Change in Control Agreement.
For purposes of any determination regarding the existence of Change in Control Good Reason, any
good faith determination by the Employee that Change in Control Good Reason exists shall be
conclusive.
(f) 	Code of Business Conduct: The Company’s Code of Business Conduct, as amended from time to
time.
(g) 	Controlled Group:
(i) 	Abbott and any corporation, partnership and proprietorship under common control (as
defined under the aggregation rules of subsections 414 (b), (c), or (m) of the Code) with
Abbott; and
(ii) 	during the period of the TAP Pharmaceutical Products Inc. (“TAP”) joint venture between
Takeda Pharmaceutical Company Limited and Abbott ending April 30, 2008, TAP and any
corporation, partnership and proprietorship under common control (as defined above) with
TAP.
(h) 	Data: Certain personal information about the Employee held by the Company and the Subsidiary
that employs the Employee (if applicable), including (but not limited to) the Employee’s name,
home address and telephone number, date of birth, social security number or other employee
identification number, salary, nationality, job title, any Shares held in the Company, details of all
Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested

-- 213 of 409 --

4
or outstanding in the Employee’s favor, for the purpose of managing and administering the Program.
(i) 	Disability: As of a particular date, the Employee is, by reason of any medically determinable
physical or mental impairment that can be expected to result in death or can be expected to last for a
continuous period of not less than 12 months, receiving income replacement benefits for a period of
at least six (6) months under (i) the terms of the Abbott Laboratories Long-Term Disability Plan
(formerly known as the Extended Disability Plan) (the “LTD Plan”), or (ii) if the Employee’s
employer does not participate in the LTD Plan, such similar accident and health plan providing
replacement benefits in which the Employee’s employer participates.
(j) 	Employee’s Representative: The Employee’s legal guardian or other legal representative.
(k) 	Program: The Abbott Laboratories 2017 Incentive Stock Program.
(l) 	Retirement:
(i) 	Except as provided under (iii) below, for employees hired by the Controlled Group prior to
January 1, 2004, Retirement means any of the following:
· 	age 50 with 10 years of service;
· 	age 65 with at least three (3) years of service; or
· 	age 55 with an age and service combination of 70 points, where each year of age is
one (1) point and each year of service is one (1) point.
(ii) 	Except as provided under (iii) below, for employees hired by the Controlled Group after
December 31, 2003, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iii) 	For participants in the Abbott Laboratories Pension Plan for Former BASF and Former
Solvay Employees, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iv) 	For purposes of calculating service under this Section 1(l), except as otherwise provided by
the Committee or its delegate, service is earned only if performed for a member of the
Controlled Group while that

-- 214 of 409 --

5
Controlled Group member is a part of the Controlled Group. Program administrative rules
apply in determining Retirement eligibility and credited service.
(v) 	If an Employee has a Termination and (A) as of the date of that Termination met the
definition of Retirement, and (B) is subsequently rehired by a member of the Controlled
Group, then for purposes of this Agreement that Employee will continue to be treated as
meeting the definition of Retirement.
(m) 	Termination: A severance of employment for any reason (including Retirement) from the Company
and all Subsidiaries. Any Termination shall be effective on the last day the Employee performs
services for or on behalf of the Company or its Subsidiary, and employment shall not be extended
by any statutory or common law notice of termination period.
2. 	Delivery Dates and Shareholder Rights. The Delivery Dates for Shares underlying the Units are the
respective dates on which the Shares are payable to the Employee pursuant to Section 4 below. Prior to the
Delivery Date(s):
(a) 	the Employee shall not be treated as a shareholder as to those Shares underlying the Units, and shall
have only a contractual right to receive Shares, unsecured by any assets of the Company or its
Subsidiaries;
(b) 	the Employee shall not be permitted to vote the Shares underlying the Units; and
(c) 	the Employee’s right to receive such Shares will be subject to the adjustment provisions relating to
mergers, reorganizations, and similar events set forth in the Program.
Subject to the requirements of local law, the Employee shall receive cash payments equal to the dividends
and distributions paid on Shares underlying the Units (the “Dividend Equivalents”) (other than dividends or
distributions of securities of the Company which may be issued with respect to its Shares by virtue of any
stock split, combination, stock dividend or recapitalization) to the same extent and on the same date (or as
soon as practicable thereafter) as if each Unit were a Share; provided, however, that no Dividend
Equivalents shall be payable to or for the benefit of the Employee with respect to dividends or distributions
the record date for which occurs on or after the date the Employee has forfeited the Units, or the date the
Units are settled. For purposes of compliance with the requirements of Code Section 409A, to the extent
applicable, the specified date for payment of any Dividend Equivalents to which the Employee is entitled
under this Section 2 is the calendar year during the term of this Agreement in which the associated dividends
or distributions are paid on Shares underlying the Units. The Employee shall have no right to determine the
year in which Dividend Equivalents will be paid.
3. 	Restrictions. The Units are subject to the forfeiture provisions in Sections 6 and 7 below. The Units are not
earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of
(collectively, the “Restrictions”) until the Units are settled.

-- 215 of 409 --

6
4. 	Lapse of Restrictions. Subject to Sections 5, 6 and 7 below:
(a) 	During Employment. While the Employee is employed with the Company or its Subsidiaries:
(i) 	the Restrictions on one-third of the total number of Units will lapse on «M_1st_yr_vest»,
provided the Company’s prior year return on equity is a minimum of [•] percent;
(ii) 	the Restrictions on an additional one-third of the total number of Units will lapse on
«M_2nd_yr_vest», provided the Company’s prior year return on equity is a minimum of [•]
percent; and
(iii) 	the Restrictions on an additional one-third of the total number of Units will lapse on
«M_3rd_yr_vest», provided the Company’s prior year return on equity is a minimum of
[•] percent.
If the Restrictions do not lapse on the respective date set forth in subsection 4(a)(i), (ii), and (iii)
above, such Restrictions shall not lapse at a later date.
Units for which Restrictions have lapsed, as described in this subsection 4(a), shall be settled in the
form of Shares on the date(s) on which such Restrictions lapse (each, a “Delivery Date”). Unless
indicated otherwise, Shares shall be delivered in an equal number (subject to rounding) as of each
Delivery Date.
(b) 	Retirement. The Restrictions shall continue to apply in the event of the Employee’s Termination
due to Retirement, but may lapse thereafter in accordance with the provisions of subsection 4(a), in
which case any Units not previously settled shall be settled in the form of Shares on the Delivery
Date(s) set forth in subsection 4(a) above occurring after the date of such Retirement as if the
Employee had remained employed. Notwithstanding the foregoing, in the event of the Employee’s
death after his or her Termination due to Retirement, for any Units not previously settled on a
Delivery Date, the restrictions shall lapse on the Employee’s date of death and the Units will be
settled in the form of Shares as soon as administratively possible after, and effective as of, the date
of death.
(c) 	Death. The Restrictions shall lapse on the date of the Employee’s Termination due to death, and
any Units not previously settled on a Delivery Date shall be settled (for the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution) in the form
of Shares as soon as administratively possible after, and effective as of, the date of death.
(d) 	Disability. The Restrictions shall lapse on the date of the Employee’s Disability, and any Units not
previously settled on a Delivery Date shall be settled in the form of Shares as soon as
administratively possible after, and effective as of, the date of Disability.
5. 	Change in Control. In the event of a Change in Control, the entity surviving such Change in Control or the
ultimate parent thereof (referred to herein as the “Surviving Entity”) may assume, convert or replace this
Award with an award of at least equal value (determined using the same value for purchasing Company
shares as used for purchasing

-- 216 of 409 --

7
Company shares not subject to this Agreement on the date of the Change in Control) with terms and
conditions not less favorable than the terms and conditions provided in this Agreement, in which case the
new award will vest according to the terms of the applicable award agreement. If the Surviving Entity does
not assume, convert or replace this Award, the Restrictions shall lapse on the date of the Change in Control.
If the Surviving Entity does assume, convert or replace this Award, then in the event the Employee’s
Termination (i) occurs within the time period beginning six (6) months immediately before a Change in
Control and ending two (2) years immediately following such Change in Control, and (ii) was initiated by
the Company (or the Surviving Entity) for a reason other than Change in Control Cause or was initiated by
the Employee for Change in Control Good Reason, the Restrictions shall lapse on the later of the date of the
Change in Control and the date of the Employee’s Termination. The provisions of this Section 5 shall
supersede Section 13(a)(iv) and (v) of the Program.
6. 	Effect of Certain Bad Acts. If Section 5 does not apply, any Units not previously settled shall be cancelled
and forfeited immediately if, in the sole opinion and discretion of the Committee or its delegate, the
Employee engages in activity that constitutes Cause, whether or not the Employee experiences a
Termination or remains employed with the Company or a Subsidiary. If Section 5 does apply, any Units not
previously settled shall be cancelled and forfeited immediately if, in the sole opinion and discretion of the
Board, the Employee engages in an activity that constitutes Change in Control Cause.
7. 	Forfeiture of Units. In the event of the Employee’s Termination for any reason other than those set forth in
subsections 4 (b), (c), (d) or Section 5, any Units with respect to which Restrictions have not lapsed as of the
date of Termination shall be forfeited without consideration to the Employee or the Employee’s
Representative. If the Company terminates the Employee other than for Cause and such termination is not
covered by Section 5, the Company may, in its sole discretion, cause some or all of the Units not previously
settled on a Delivery Date to continue to be subject to the Restrictions, provided such Restrictions may lapse
thereafter in accordance with the provisions of subsection 4(a), in which case such Units shall be settled in
the form of Shares on the Delivery Date(s) set forth in subsection 4(a) above occurring after the date of such
Termination. In accepting this Award, the Employee acknowledges that in the event of Termination
(whether or not in breach of local labor laws), the Employee’s right to vest in the Units, if any, will
terminate effective as of the date that the Employee is no longer actively employed and will not be extended
by any notice period mandated under local law (e.g., active employment would not include a period of
“garden leave” or similar period pursuant to local law) and that the Committee shall have the exclusive
discretion to determine when the Employee is no longer actively employed for purposes of this Award.
8. 	Withholding Taxes. The Company shall be entitled to withhold, or require the Employee to remit, any
federal, state, local, and other applicable taxes (in U.S. or non-U.S. jurisdictions), including income, social
security and Medicare withholding taxes arising from the grant of the Award, the lapse of Restrictions or the
delivery of Shares pursuant to this Agreement by, without limitation:
(a) 	having the Company withhold Shares;
(b) 	tendering Shares received in connection with the Units back to the Company;

-- 217 of 409 --

8
(c) 	delivering other previously acquired Shares having a Fair Market Value approximately equal to the
amount to be withheld;
(d) 	selling Shares issued pursuant to the Units and having the Company withhold from proceeds of the
sale of such Shares;
(e) 	having the Company or a Subsidiary, as applicable, withhold from any cash compensation payable
to the Employee; or
(f) 	requiring the Employee to repay the Company or Subsidiary, in cash or in Shares, for taxes paid on
the Employee’s behalf.
Notwithstanding the foregoing, if the Employee is subject to Section 16 of the Exchange Act pursuant to
Rule 16a-2 promulgated thereunder, any tax withholding obligations shall be satisfied by having the
Company withhold a number of Shares otherwise issuable upon settlement of the Units that is sufficient to
satisfy such obligations consistent with the Company’s withholding practices.
If, to satisfy tax withholding obligations, the Company withholds Shares otherwise issuable to the
Employee, the Employee shall be deemed to have been issued the full number of Shares underlying the
Units, subject to the Restrictions set forth in this Agreement.
9. 	No Right to Continued Employment. This Agreement and the Employee’s participation in the Program is
not and shall not be interpreted to:
(a) 	form an employment contract or relationship with the Company or its Subsidiaries;
(b) 	confer upon the Employee any right to continue in the employ of the Company or any of its
Subsidiaries; or
(c) 	interfere with the ability of the Company or its Subsidiaries to terminate the Employee’s
employment at any time.
10. 	Nature of Grant. In accepting this grant of Units, the Employee acknowledges that:
(a) 	The Program is established voluntarily by the Company, it is discretionary in nature and it may be
modified, amended, suspended or terminated by the Company at any time;
(b) 	This Award is a one-time benefit and does not create any contractual or other right to receive future
grants of Units, benefits in lieu of Units, or other Program Benefits in the future, even if Units have
been granted repeatedly in the past;
(c) 	All decisions with respect to future Unit grants, if any, and their terms and conditions, will be made
by the Committee, in its sole discretion;
(d) 	Nothing contained in this Agreement is intended to create or enlarge any other contractual
obligations between the Company and the Employee;

-- 218 of 409 --

9
(e) 	The Employee is voluntarily participating in the Program;
(f) 	The Units and Shares subject to the Units are:
(i) 	extraordinary items that do not constitute compensation of any kind for services of any kind
rendered to the Company or its Subsidiaries, and are outside the scope of the Employee’s
employment contract, if any;
(ii) 	not intended to replace any pension rights or compensation;
(iii) 	not part of the Employee’s normal or expected compensation or salary for any purposes,
including, but not limited to, calculating any severance, resignation, termination,
redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or
retirement or welfare benefits, or similar payments and in no event should be considered as
compensation for, or relating in any way to, past services for the Company or its
Subsidiaries;
(g) 	The future value of the Shares underlying the Units is unknown and cannot be predicted with
certainty;
(h) 	In consideration of the Award, no claim or entitlement to compensation or damages shall arise from
the Units resulting from Termination (for any reason whatsoever) and the Employee irrevocably
releases the Company and its Subsidiaries from any such claim that may arise; if any such claim is
found by a court of competent jurisdiction to have arisen, then, by signing or electronically
accepting this Agreement, the Employee shall be deemed irrevocably to have waived the
Employee’s entitlement to pursue such claim;
(i) 	The Units and the Benefits under the Program, if any, will not automatically transfer to another
company in the case of a merger, take-over or transfer of liability; and
(j) 	Neither the Company nor any of its Subsidiaries shall be liable for any change in value of the Units,
the amount realized upon settlement of the Units or the amount realized upon a subsequent sale of
any Shares acquired upon settlement of the Units, resulting from any fluctuation of the United States
Dollar/local currency foreign exchange rate.
11. 	Data Privacy.
(a) 	Pursuant to applicable personal data protection laws, the collection, processing and transfer of the
Employee’s personal Data is necessary for the Company’s administration of the Program and the
Employee’s participation in the Program. The Employee’s denial and/or objection to the collection,
processing and transfer of personal Data may affect his or her ability to participate in the Program.
As such (where required under applicable law), the Employee:
(i) 	voluntarily acknowledges, consents and agrees to the collection, use, processing and
transfer of personal Data as described herein; and

-- 219 of 409 --

10
(ii) 	authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic
or other form, for purposes of implementing, administering and managing the Employee’s
participation in the Program, including any requisite transfer of such Data as may be
required for the administration of the Program and/or the subsequent holding of Shares on
the Employee’s behalf to a broker or other third party with whom the Employee may elect
to deposit any Shares acquired pursuant to the Program.
(b) 	Data may be provided by the Employee or collected, where lawful, from third parties, and the
Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the
exclusive purpose of implementing, administering and managing the Employee’s participation in the
Program. Data processing will take place through electronic and non-electronic means according to
logics and procedures strictly correlated to the purposes for which the Data is collected and with
confidentiality and security provisions as set forth by applicable laws and regulations in the
Employee’s country of residence. Data processing operations will be performed minimizing the use
of personal and identification data when such operations are unnecessary for the processing
purposes sought. The Data will be accessible within the Company’s organization only by those
persons requiring access for purposes of the implementation, administration and operation of the
Program and for the Employee’s participation in the Program.
(c) 	The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as
necessary for the purpose of implementation, administration and management of the Employee’s
participation in the Program, and the Company and the Subsidiary that employs the Employee (if
applicable) may further transfer Data to any third parties assisting the Company in the
implementation, administration and management of the Program. These recipients may be located
throughout the world.
(d) 	The Employee may, at any time, exercise his or her rights provided under applicable personal data
protection laws, which may include the right to:
(i) 	obtain confirmation as to the existence of the Data;
(ii) 	verify the content, origin and accuracy of the Data;
(iii) 	request the integration, update, amendment, deletion or blockage (for breach of applicable
laws) of the Data; and
(iv) 	oppose, for legal reasons, the collection, processing or transfer of the Data which is not
necessary or required for the implementation, administration and/or operation of the
Program and the Employee’s participation in the Program.
The Employee may seek to exercise these rights by contacting his or her local human resources
manager.

-- 220 of 409 --

11
(e) 	Upon request of the Company or the Subsidiary that employs the Employee (if applicable), the
Employee agrees to provide an executed data privacy consent form (or any other agreements or
consents that may be required), as deemed necessary by the Company or the Subsidiary that
employs the Employee (if applicable) for the purpose of administering the Employee’s participation
in the Program in compliance with the data privacy laws in the Employee’s country, either now or in
the future. If the Employee fails to provide any such consent or agreement requested by the
Company and/or the Subsidiary that employs the Employee (if applicable) and the Committee or its
delegate determines that the collection, processing and/or transfer of Data without such consent or
agreement would violate the laws in the Employee’s country, the Employee understands and agrees
that the Employee will not be able to participate in the Program and the Award will be null and void.
12. 	Form of Payment. The Company may, in its sole discretion, settle the Employee’s Units in the form of a
cash payment to the extent settlement in Shares: (i) is prohibited under local law; (ii) would require the
Employee, the Company and/or its Subsidiaries to obtain the approval of any governmental and/or
regulatory body in the Employee’s country; (iii) would result in adverse tax consequences for the Employee
or the Company; or (iv) is administratively burdensome. Alternatively, the Company may, in its sole
discretion, settle the Employee’s Units in the form of Shares but require the Employee to sell such Shares
immediately or within a specified period of time following the Employee’s Termination (in which case, this
Agreement shall give the Company the authority to issue sales instructions on the Employee’s behalf).
13. 	Private Placement. The grant of this Unit is not intended to be a public offering of securities in the
Employee’s country. The Company has not submitted any registration statement, prospectus or other filings
with the local securities authorities (unless otherwise required under local law), and this grant of Units is not
subject to the supervision of the local securities authorities.
14. 	Exchange Controls. As a condition to this grant of Units, the Employee agrees to comply with any
applicable foreign exchange rules and regulations.
15. 	Compliance with Applicable Laws and Regulations.
(a) 	The Company shall not be required to issue or deliver any Shares pursuant to this Agreement
pending compliance with all applicable federal and state securities and other laws (including any
registration requirements or tax withholding requirements) and compliance with the rules and
practices of any stock exchange upon which the Company’s Shares are listed.
(b) 	Regardless of any action the Company or its Subsidiaries take with respect to any or all income tax,
social insurance, payroll tax, payment on account or other tax-related items related to the
Employee’s participation in the Program and legally applicable to the Employee or deemed by the
Company or its Subsidiaries to be an appropriate charge to the Employee even if technically due by
the Company or its Subsidiaries (“Tax-Related Items”), the Employee acknowledges that the
ultimate liability for all Tax-Related Items is and remains the Employee’s responsibility and may
exceed the amount actually withheld by the Company or its Subsidiaries. The Employee further
acknowledges that the Company and/or

-- 221 of 409 --

12
its Subsidiaries: (i) make no representations or undertakings regarding the treatment of any Tax-
Related Items in connection with any aspect of the Units, including, but not limited to, the grant,
lapse of Restrictions or settlement of the Units, the issuance of Shares upon payment of the Units,
the subsequent sale of Shares acquired pursuant to such issuance and the receipt of any dividends
and/or any Dividend Equivalents; and (ii) do not commit to and are under no obligation to structure
the terms of the grant or any aspect of the Units to reduce or eliminate the Employee’s liability for
Tax-Related Items or achieve any particular tax result. Further, if the Employee has become subject
to tax in more than one (1) jurisdiction between the date of grant and the date of any relevant
taxable event, the Employee acknowledges that the Company and/or its Subsidiaries may be
required to withhold or account for Tax-Related Items in more than one (1) jurisdiction.
16. 	Code Section 409A. Payments made pursuant to this Agreement are intended to be exempt from or to
otherwise comply with the provisions of Code Section 409A to the extent applicable. The Program and this
Agreement shall be administered and interpreted in a manner consistent with this intent. If the Company
determines that any payments under this Agreement are subject to Code Section 409A and this Agreement
fails to comply with that section’s requirements, the Company may, at the Company’s sole discretion, and
without the Employee’s consent, amend this Agreement to cause it to comply with Code Section 409A or
otherwise be exempt from Code Section 409A.
To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A and
applicable guidance issued thereunder, the Employee shall not be deemed to have had a Termination unless
the Employee has incurred a “separation from service” as defined in Treasury Regulation §1.409A-1(h), and
amounts that would otherwise be payable pursuant to this Agreement during the six-month period
immediately following the Employee’s Termination (including Retirement) shall instead be paid on the first
business day after the date that is six (6) months following the Employee’s Termination (or upon the
Employee’s death, if earlier). For purposes of Code Section 409A, to the extent applicable: (i) all payments
provided hereunder shall be treated as a right to a series of separate payments and each separately identified
amount to which the Employee is entitled under this Agreement shall be treated as a separate payment; (ii)
except as otherwise provided in Section 13(a) of the Program, upon the lapse of Restrictions pursuant to
Section 5 of this Agreement, any Units not previously settled on a Delivery Date shall be settled as soon as
administratively possible after, and effective as of, the date of the Change in Control or the date of the
Employee’s Termination (as applicable); (iii) the term “as soon as administratively possible” means a period
of time that is within 60 days after the Termination, Disability or Change in Control (as applicable); and (iv)
the date of the Employee’s Disability shall be determined by the Company in its sole discretion.
Although this Agreement and the payments provided hereunder are intended to be exempt from or to
otherwise comply with the requirements of Code Section 409A, the Company does not represent or warrant
that this Agreement or the payments provided hereunder will comply with Code Section 409A or any other
provision of federal, state, local, or non-United States law. None of the Company, its Subsidiaries, or their
respective directors, officers, employees or advisers shall be liable to the Employee (or any other individual
claiming a benefit through the Employee) for any tax, interest, or penalties the Employee may owe as a
result of compensation paid under this Agreement,

-- 222 of 409 --

13
and the Company and its Subsidiaries shall have no obligation to indemnify or otherwise protect the
Employee from the obligation to pay any taxes pursuant to Code Section 409A.
17. 	No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the
Company making any recommendations regarding the Units, the Employee’s participation in the Program or
the Employee’s acquisition or sale of the underlying Shares. The Employee is hereby advised to consult
with the Employee’s own personal tax, legal and financial advisors regarding participation in the Program
before taking any action related to the Program.
18. 	Imposition of Other Requirements. The Company reserves the right to impose other requirements on the
Employee’s participation in the Program, on the Units and on any Shares acquired under the Program, to the
extent the Company or its Subsidiaries determines it is necessary or advisable in order to comply with local
law or facilitate the administration of the Program, and to require the Employee to sign any additional
agreements or undertakings that may be necessary to accomplish the foregoing. The Employee agrees to
take any and all actions, and consents to any and all actions taken by the Company and its Subsidiaries, as
may be required to allow the Company and its Subsidiaries to comply with local laws, rules and regulations
in the Employee’s country. In addition, the Employee agrees to take any and all actions as may be required
to comply with the Employee’s personal obligations under local laws, rules and regulations in the
Employee’s country.
19. 	Determinations. Each decision, determination, interpretation or other action made or taken pursuant to the
provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be
final, conclusive and binding for all purposes and upon all persons, including, without limitation, the
Company, the Employee, the Employee’s Representative, and the person or persons to whom rights under
the Award have passed by will or the laws of descent or distribution.
20. 	Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to
current or future participation in the Program by electronic means. The Employee hereby consents to
receive such documents by electronic delivery and agrees to participate in the Program through an on-line or
electronic system established and maintained by the Company or a third party designated by the Company.
21. 	Addendum. This grant of Units shall be subject to any special terms and conditions set forth in any
Addendum to this Agreement for the Employee’s country. Moreover, if the Employee relocates to one of
the countries included in the Addendum, the special terms and conditions for such country will apply to the
Employee, to the extent the Company determines that the application of such terms and conditions is
necessary or advisable in order to comply with local law or facilitate the administration of the Program (or
the Company may establish alternative terms and conditions as may be necessary or advisable to
accommodate the Employee’s relocation). The Addendum constitutes part of this Agreement.
22. 	Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, and each other provision of this
Agreement shall be severable and enforceable to the extent permitted by law. To the extent a court or
tribunal of competent jurisdiction determines

-- 223 of 409 --

14
that any provision of this Agreement is invalid or unenforceable, in whole or in part, the Company, in its
sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent
necessary to make it valid and enforceable to the full extent permitted under local law.
23. 	Entire Agreement. This Agreement, the Program, the Program prospectus, the Program administrative
rules and any applicable Company policies constitute the entire agreement between the Employee and the
Company regarding the Award and supersede all prior and contemporaneous agreements and
understandings, oral or written, between the parties regarding the Award. Except as expressly set forth
herein, this Agreement (and any provision of this Agreement) may not be modified, changed, clarified, or
interpreted by the parties, except in a writing specifying the modification, change, clarification, or
interpretation, and signed by a duly authorized Company officer.
24. 	Succession. This Agreement shall be binding upon and operate for the benefit of the Company and its
successors and assigns, and the Employee, the Employee’s Representative, and the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution.
25. 	Language. If the Employee has received this Agreement or any other document related to the Program
translated into a language other than English and if the meaning of the translated version is different than the
English version, the English version will control.
26. 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
U.S. State of Illinois without giving effect to any state’s conflict of laws principles.
27. 	Venue. For any legal action relating to this Agreement, the parties to this Agreement consent to the
exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there
is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County,
Illinois, USA.
* 	* 	*
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer as of the
grant date above set forth.
ABBOTT LABORATORIES
By
Robert B. Ford
President and Chief Executive Officer

-- 224 of 409 --

15
ADDENDUM TO THE ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK UNIT AGREEMENT
In addition to the terms and conditions set forth in the Agreement, the Award is subject to the following terms and
conditions. All defined terms contained in this Addendum shall have the same meaning as set forth in the Program. If the
Employee is employed in a country identified in the Addendum, the additional terms and conditions for such country shall
apply. If the Employee transfers residence and/or employment to a country identified in the Addendum, the additional terms
and conditions for such country shall apply to the extent the Company determines, in its sole discretion, that the application
of such terms and conditions is necessary or advisable to comply with local law or to facilitate administration of the Program
(or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the
Employee’s transfer).
EUROPEAN UNION / EUROPEAN ECONOMIC AREA, SWITZERLAND AND THE UNITED KINGDOM
Data Privacy. The following provision replaces Section 11 of the Agreement in its entirety:
Pursuant to applicable personal data protection laws, Abbott and the Subsidiary that employs the Employee (the
“Employer”) hereby notifies the Employee of the following in relation to the Employee’s Personal Data (defined below) and
the collection, processing and transfer in electronic or other form of such Personal Data in relation to the administration of
the Units and the Employee’s participation in the Program. The collection, processing and transfer of the Employee’s
Personal Data is necessary for the legitimate purpose of Abbott and the Employer’s administration of the Units and the
Employee’s participation in the Program, and the Employee’s denial and/or objection to the collection, processing and
transfer of Personal Data may affect the Employee’s participation in the Program. As such, by accepting the Units, the
Employee acknowledges the collection, use, processing and transfer of Personal Data as described herein.
Abbott and the Employer hold certain personally identifiable information about the Employee, specifically, the Employee’s
name, home address and telephone number, date of birth, social security number or other employee identification number,
salary, nationality, job title, any Shares or directorships held in Abbott, details of all Units or any other entitlement to Shares
awarded, canceled, purchased, vested, unvested or outstanding in the Employee’s favor, for the purpose of managing and
administering the Program (“Personal Data”). The Personal Data may be provided by the Employee or collected, where
lawful, from third parties. Abbott or the Employer each act as controllers of the Personal Data and will process the Personal
Data in this context for the exclusive legitimate purpose of implementing, administering and managing the Employee’s
participation in the Program and meeting related legal obligations associated with these actions.
The processing will take place through electronic and non-electronic means according to logics and procedures correlated to
the purposes for which the Personal Data was collected and with confidentiality and security provisions as set forth by
applicable laws and regulations. Personal Data will be accessible within Abbott’s organization only by those persons
requiring access for purposes of the implementation, administration and operation of the Program and other aspects of the
employment relationship and for the Employee’s participation in the Program.
Abbott and the Employer will transfer Personal Data amongst themselves as necessary for the purpose of implementation,
administration and management of the Employee’s participation in the Program, and Abbott and the Employer may each
further transfer Personal Data to third parties assisting Abbott or the Employer in the implementation, administration and
management of the Program, including UBS

-- 225 of 409 --

16
Financial Services Inc. or any successor or other third party that Abbott, the Employer or UBS Financial Services Inc. (or its
successor) may engage to assist with the administration of the Program from time to time. These recipients may be located in
the European Economic Area, Switzerland, the United Kingdom, or elsewhere throughout the world, such as the United
States. By participating in the Program, the Employee understands that these recipients may receive, possess, use, retain and
transfer the Personal Data, in electronic or other form, for purposes of implementing, administering and managing the
Employee’s participation in the Program, including any requisite transfer of such Personal Data as may be required for the
administration of the Program and/or the subsequent holding of Shares on the Employee’s behalf to a broker or other third
party with whom the Employee may elect to deposit any Shares acquired pursuant to the Program. The Employee further
understands that he or she may request a list with the names and addresses of any potential recipients of the Employee’s
Personal Data by contacting the Employee’s local human resources manager or Abbott's human resources Department.
When transferring Personal Data to these potential recipients, Abbott and the Employer provide appropriate safeguards in
accordance with EU Standard Contractual Clauses, the EU-U.S. Privacy Shield Framework, or other legally binding and
permissible arrangements. The Employee may request a copy of such safeguards from the Employee’s local human
resources manager or Abbott's human resources department.
To the extent provided by law, the Employee may, at any time, have the right to request: access to Personal Data,
rectification of Personal Data, erasure of Personal Data, restriction of processing of Personal Data, and portability of
Personal Data. The Employee may also have the right to object, on grounds related to a particular situation, to the processing
of Personal Data, as well as opt-out of the Program herein, in any case without cost, by contacting in writing the Employee’s
human resources manager. The Employee’s provision of Personal Data is a contractual requirement. The Employee
understands, however, that the only consequence of refusing to provide Personal Data is that Abbott and the Employer may
not be able to let the Employee participate in the Program, or grant other equity awards or administer or maintain such
awards. For more information on the consequences of the Employee’s refusal to provide Personal Data, the Employee
understands that the Employee may contact his or her local human resources manager or Abbott's human resources
department.
When Abbott and the Employer no longer need to use Personal Data for the purposes above or do not need to retain it for
compliance with any legal or regulatory purpose, each will take reasonable steps to remove Personal Data from their systems
and/or records containing the Personal Data and/or take steps to properly anonymize it so that the Employee can no longer
be identified from it.
ALGERIA
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
AUSTRALIA
1. 	Breach of Law. Notwithstanding anything to the contrary in the Agreement or the Program, the Employee will not
be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Program if the provision
of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act,
or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.
2. 	Australian Offer Document. In addition to the Agreement and the Program, the Employee must review the
Australian Offer Document and the Australian Addendum to the Program for additional important information pertaining to
the Award. Both of these documents can be accessed in the library

-- 226 of 409 --

17
section of the UBS website at www.ubs.com/onesource/abt. By accepting the Award, the Employee acknowledges and
confirms that the Employee has reviewed these documents.
BRAZIL
Labor Law Acknowledgment. The Employee agrees, for all legal purposes, (i) the benefits provided under the Agreement
and the Program are the result of commercial transactions unrelated to the Employee’s employment; (ii) the Agreement and
the Program are not a part of the terms and conditions of the Employee’s employment; and (iii) the income from the Units, if
any, is not part of the Employee’s remuneration from employment.
CANADA
1. 	Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the
Award shall be settled only in Shares (and may not be settled in cash).
2. 	Resale Restriction. The Employee understands that the Employee is permitted to sell Shares acquired under the
Program through the designated broker appointed under the Program, provided the resale of Shares takes place outside of
Canada through the facilities of the stock exchange on which the Shares are traded. The principal market for the Shares is the
New York Stock Exchange under the symbol "ABT". Shares are also listed on the Chicago Stock Exchange and traded on
various regional and electronic exchanges. Outside the United States, the Shares are listed on the SIX Swiss Exchange.
3. 	English Language. The parties to the Agreement acknowledge that it is their express wish that the Agreement, as
well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or
indirectly hereto, be drawn up in English. Les parties reconnaissent avoir exigé la rédaction en anglais de la présente
convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou
indirectement, relativement à ou suite à la présente convention.
4. 	Data Privacy. The following provision supplements Section 11 of the Agreement:
The Employee hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant
information from all personnel involved in the administration and operation of the Program. The Employee further
authorizes the Company and any of its Subsidiaries to disclose and discuss the Program with their advisors. The Employee
further authorizes the Company and any of its Subsidiaries to record such information and to keep such information in the
Employee’s employee file.
CHILE
Private Placement. The following provision shall replace Section 13 of the Agreement:
The grant of the Units hereunder is not intended to be a public offering of securities in Chile but instead is intended to be
a private placement.
a) The starting date of the offer will be the Grant Date (as defined in the Agreement), and this offer conforms to
General Ruling no. 336 of the Chilean Commission for the Financial Market;
b) The offer deals with securities not registered in the registry of securities or in the registry of foreign securities of the
Chilean Commission for the Financial Market, and therefore such securities are not subject to its oversight;

-- 227 of 409 --

18
c) The issuer is not obligated to provide public information in Chile regarding the foreign securities, as such securities
are not registered with the Chilean Commission for the Financial Market; and
d) The foreign securities shall not be subject to public offering as long as they are not registered with the
corresponding registry of securities in Chile.
a) La fecha de inicio de la oferta será el de la fecha de otorgamiento (o “Grant Date”, según este término se define en
el documento denominado “Agreement”) y esta oferta se acoge a la norma de Carácter General n° 336 de la
Comisión para el Mercado Financiero de Chile;
b) La oferta versa sobre valores no inscritos en el registro de valores o en el registro de valores extranjeros que lleva
la Comisión para el Mercado Financiero de Chile, por lo que tales valores no están sujetos a la fiscalización de
ésta;
c) Por tratar de valores no inscritos no existe la obligación por parte del emisor de entregar en chile información
pública respecto de esos valores; y
d) Esos valores no podrán ser objeto de oferta pública mientras no sean inscritos en el registro de valores
correspondiente.
CHINA
The following provisions shall apply to individuals who are subject to the People’s Republic of China (“China”) exchange
control requirements, as determined by the Company in its sole discretion:
1. 	Treatment of Units upon Retirement. Provided that the Employee is not subject to Section 16 of the Exchange Act
pursuant to Rule 16a-2 promulgated thereunder, if the Employee experiences a Termination due to Retirement, Restrictions
on the Units shall lapse on the date of the Termination, and any Units not previously settled on a Delivery Date shall be
settled in the form of Shares as soon as administratively possible after, and effective as of, the date of Termination.
2. 	Foreign Exchange Control Laws. The Employee agrees to hold the Shares received upon settlement of the Units
with the Company’s designated broker. Upon a Termination, the Employee shall be required to sell all Shares issued
pursuant to the Units within 90 days (or such shorter period as may be required by the State Administration of Foreign
Exchange) of the Termination date and repatriate the sales proceeds to China in the manner designated by the Company. For
purposes of the foregoing, the Company shall establish procedures for effectuating the forced sale of the Shares (including
procedures whereby the Company may issue sell instructions on behalf of the Employee), and the Employee hereby agrees
to comply with such procedures and take any and all actions as the Company determines, in its sole discretion, are necessary
or advisable for purposes of complying with local laws, rules and regulations in China.
The Employee understands and agrees that the repatriation of dividends and sales proceeds may need to be effected through
a special exchange control account established by the Company or its Subsidiaries, and the Employee hereby consents and
agrees that sales proceeds from the sale of Shares acquired under the Program may be transferred to such account by the
Company on the Employee’s behalf prior to being delivered to the Employee. The sales proceeds may be paid to the
Employee in U.S. dollars or local currency at the Company’s discretion. If the sales proceeds are paid to the Employee in
U.S. dollars, the Employee understands that the Employee will be required to set up a U.S. dollar bank account in China so
that the proceeds may be deposited into this account. If the sales proceeds are paid to the Employee in local currency, the
Employee acknowledges that the Company is under no obligation to secure any

-- 228 of 409 --

19
particular exchange conversion rate and that the Company may face delays in converting the dividends and proceeds to local
currency due to exchange control restrictions. The Employee agrees to bear any currency fluctuation risk between the time
the Shares are sold and the net proceeds are converted into local currency and distributed to the Employee. The Employee
further agrees to comply with any other requirements that may be imposed by the Company or its Subsidiaries in China in
the future in order to facilitate compliance with exchange control requirements in China. The Employee agrees to be subject
to these restrictions even after Termination.
Neither the Company nor any of its Subsidiaries shall be liable for any costs, fees, lost interest or dividends or other losses
the Employee may incur or suffer resulting from the enforcement of the terms of this Addendum or otherwise from the
Company’s operation and enforcement of the Program, the Agreement and the Units in accordance with Chinese law
including, without limitation, any applicable State Administration of Foreign Exchange rules, regulations and requirements.
CROATIA
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
DENMARK
Treatment of Units upon Termination. Notwithstanding any provisions in the Agreement to the contrary, if the Employee is
determined to be an “Employee,” as defined in Section 2 of the Danish Act on the Use of Rights to Purchase or Subscribe
for Shares etc. in Employment Relationships, as in effect prior to January 1, 2019 (the “Stock Option Act”), the treatment of
the Units upon a Termination shall be governed by Sections 4 and 5 of the Stock Option Act. However, if the provisions in
the Agreement or the Program governing the treatment of the Units upon a Termination are more favorable, the provisions of
the Agreement or the Program will govern.
FINLAND
Withholding of Tax-Related Items. Notwithstanding Section 8 of the Agreement, if the Employee is a local national of
Finland, any Tax-Related Items shall be withheld only in cash from the Employee’s regular salary/wages or other amounts
payable to the Employee in cash, or such other withholding methods as may be permitted under the Program and allowed
under local law.
FRANCE
1. 	Nature of the Award. The Units are not granted under the French specific regime provided by Articles L225-197-1
and seq. of the French commercial code.
2. 	English Language. The parties to the Agreement acknowledge that it is their express wish that the Agreement, as
well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or
indirectly hereto, be drawn up in English. Les parties reconnaissent avoir exigé la rédaction en anglais de la présente
convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaires intentées, directement ou
indirectement, relativement à ou suite à la présente convention.

-- 229 of 409 --

20
HONG KONG
1. 	Settlement in Shares. Notwithstanding anything to the contrary in the Agreement, Addendum or the Program, the
Award shall be settled only in Shares (and may not be settled in cash).
2. 	Lapse of Restrictions. If, for any reason, Shares are issued to the Employee within six (6) months of the Grant Date,
the Employee agrees that he or she will not sell or otherwise dispose of any such Shares prior to the six-month anniversary
of the Grant Date.
3. 	IMPORTANT NOTICE. WARNING: The contents of the Agreement, the Addendum, the Program, and all other
materials pertaining to the Units and/or the Program have not been reviewed by any regulatory authority in Hong Kong. The
Employee is hereby advised to exercise caution in relation to the offer thereunder. If the Employee has any doubts about any
of the contents of the aforesaid materials, the Employee should obtain independent professional advice.
4. 	Wages. The Units and Shares subject to the Units do not form part of the Employee’s wages for the purposes of
calculating any statutory or contractual payments under Hong Kong law.
5. 	Nature of the Program. The Company specifically intends that the Program will not be treated as an occupational
retirement scheme for purposes of the Occupational Retirement Schemes Ordinance (“ORSO”). To the extent any court,
tribunal or legal/regulatory body in Hong Kong determines that the Program constitutes an occupational retirement scheme
for the purposes of ORSO, the grant of the Units shall be null and void.
INDIA
Repatriation Requirements. As a condition of this Award, the Employee agrees to repatriate all sales proceeds and dividends
attributable to Shares acquired under the Program in accordance with local foreign exchange rules and regulations. Neither
the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to
comply with applicable laws.
ISRAEL
1. 	Securities Law Notice. The Israeli Securities Authority granted to the Company an exemption from the requirement
to file a prospectus with respect to the Program. A copy of the Program and the Form S-8 registration statement for the
Program filed with the United States Securities and Exchange Commission can be accessed in the library section of the UBS
website at www.ubs.com/onesource/abt or are available free of charge upon request from the Employee’s local human
resources department.
2. 	Holding and Sale of Shares. In consideration for the grant of the Award, the Employee agrees to hold the Shares
received upon settlement of the Units subject to the Award and any and all previously granted restricted stock units with the
Company’s designated broker. The Employee understands and agrees that upon the Employee’s sale of Shares, unless
otherwise determined by the Company, (a) the repatriation of sales proceeds shall be effected through the Subsidiary that
employs the Employee, (b) the Subsidiary that employs the Employee will withhold the requisite tax and other mandatory
withholding (e.g., National Insurance payments) from the sales proceeds and (c) the Subsidiary that employs the Employee
will transfer the remaining sale proceeds (net of the requisite tax and other mandatory withholding) to the Employee. The
Employee acknowledges and agrees that the process and requirements set forth herein shall continue to apply following the
Employee’s Termination.

-- 230 of 409 --

21
3. 	Indemnification for Tax Liabilities. As a condition of the grant of Units, the Employee expressly consents and
agrees to indemnify the Company and/or its Subsidiaries and hold them harmless from any and all liability attributable to
taxes, interest or penalties thereon, including without limitation, liabilities relating to the necessity to withhold any taxes.
MEXICO
1. 	Commercial Relationship. The Employee expressly acknowledges that the Employee’s participation in the Program
and the Company’s grant of the Award does not constitute an employment relationship between the Employee and the
Company. The Employee has been granted the Award as a consequence of the commercial relationship between the
Company and the Company’s Subsidiary in Mexico that employs the Employee, and the Company’s Subsidiary in Mexico is
the Employee’s sole employer. Based on the foregoing: (a) the Employee expressly acknowledges that the Program and the
benefits derived from participation in the Program do not establish any rights between the Employee and the Subsidiary in
Mexico that employs the Employee; (b) the Program and the benefits derived from participation in the Program are not part
of the employment conditions and/or benefits provided by the Subsidiary in Mexico that employs the Employee; and (c) any
modifications or amendments of the Program or benefits granted thereunder by the Company, or a termination of the
Program by the Company, shall not constitute a change or impairment of the terms and conditions of the Employee’s
employment with the Subsidiary in Mexico.
2. 	Extraordinary Item of Compensation. The Employee expressly recognizes and acknowledges that the Employee’s
participation in the Program is a result of the discretionary and unilateral decision of the Company, as well as the
Employee’s free and voluntary decision to participate in the Program in accord with the terms and conditions of the
Program, the Employee’s Agreement and this Addendum. As such, the Employee acknowledges and agrees that the
Company may, in its sole discretion, amend and/or discontinue the Employee’s participation in the Program at any time and
without any liability. The value of the Units is an extraordinary item of compensation outside the scope of the Employee’s
employment contract, if any. The Units are not part of the Employee’s regular or expected compensation for purposes of
calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or
retirement benefits, or any similar payments, which are the exclusive obligations of the Company’s Subsidiary in Mexico
that employs the Employee.
MOROCCO
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
NETHERLANDS
Waiver of Termination Rights. The Employee waives any and all rights to compensation or damages as a result of a
Termination, insofar as those rights result or may result from: (a) the loss or diminution in value of such rights or
entitlements under the Program; or (b) the Employee ceasing to have rights, or ceasing to be entitled to any Awards under
the Program as a result of such Termination.

-- 231 of 409 --

22
NEW ZEALAND
Securities Law Notice.
Warning
This is an offer of Units which, upon vesting and settlement in accordance with the terms of the Program and the Agreement,
will be converted into Shares. Shares give you a stake in the ownership of Abbott Laboratories. You may receive a return if
dividends are paid.
If Abbott Laboratories runs into financial difficulties and is wound up, you will be paid only after all creditors and holders of
preference shares have been paid. You may lose some or all of your investment.
New Zealand law normally requires people who offer financial products to give information to investors before they invest.
This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer
because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually
required. You will also have fewer other legal protections for this investment.
Ask questions, read all documents carefully, and seek independent financial advice before committing.
Prior to the vesting and settlement of the Units, you will not have any rights of ownership (e.g., voting rights) with respect to
the underlying Shares.
No interest in any Units may be transferred (legally or beneficially), assigned, mortgaged, charged or encumbered.
The Shares are quoted on the New York Stock Exchange. This means that if you acquire Shares under the Program, you
may be able to sell them on the New York Stock Exchange if there are interested buyers. You may get less than you
invested. The price will depend on the demand for the Shares.
You also are hereby notified that the documents listed below are available for review on sites at the web addresses listed
below:
1. Abbott Laboratories’ most recent Annual Report (Form 10-K): https://www.sec.gov/cgi-bin/browse-edgar?
CIK=abt&owner=exclude&action=getcompany&Find=Search
2. Abbott Laboratories’ most recent published financial statements (Form 10-Q or 10-K) and the auditor’s report on
those financial statements: https://www.sec.gov/cgi-bin/browse-edgar?
CIK=abt&owner=exclude&action=getcompany&Find=Search
3. The Abbott Laboratories 2017 Incentive Stock Program: This document can be accessed in the library section of
the UBS website at www.ubs.com/onesource/abt.
4. Abbott Laboratories 2017 Incentive Stock Program Prospectus: This document can be accessed in the library
section of the UBS website at www.ubs.com/onesource/abt.
A copy of the above documents will be sent to you free of charge on written request being mailed to: Senior Manager,
Equity Programs, Abbott Laboratories, D058G, AP6B-2, Abbott Park, IL 60064, USA.
PAKISTAN
1. 	Repatriation Requirements. As a condition of this Award, the Employee agrees to repatriate all Dividend
Equivalents and all sales proceeds and dividends attributable to Shares acquired under the Program in accordance with local
foreign exchange rules and regulations. Neither the Company nor any

-- 232 of 409 --

23
of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to comply with applicable
laws.
2. 	Exchange Control Obligations. To the extent applicable, the Employee is required to comply with certain consent
and reporting requirements to the State Bank of Pakistan (Pakistan’s central bank) under the exchange control laws of
Pakistan. As the exchange control regulations can change frequently and at times, without notice, the Employee should
consult his or her legal advisor prior to acquiring or selling Shares under the Program to ensure compliance with current
regulations. Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the
Employee’s failure to comply with applicable laws.
PHILIPPINES
Settlement in Cash. Notwithstanding Section 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
ROMANIA
1. 	Termination. A Termination shall include the situation where the Employee’s employment contract is terminated by
operation of law on the date the Employee reaches the standard retirement age and has completed the minimum contribution
record for receipt of state retirement pension or the relevant authorities award the Employee an early-retirement pension of
any type.
2. 	English Language. The Employee hereby expressly agrees that this Agreement, the Program as well as all
documents, notices and proceedings entered into, relating directly or indirectly hereto, be drawn up or communicated only in
the English language. Angajatul consimte în mod expres prin prezentul ca acest Contract, Programul precum şi orice alte
documente, notificări, înştiinţări legate direct sau indirect de acest Contract să fie redactate sau efectuate doar în limba
engleză.
RUSSIA
1. 	Sale or Transfer of Shares. Notwithstanding anything to the contrary in the Program or the Agreement, the
Employee shall not be permitted to sell or otherwise dispose of the Shares acquired pursuant to the Award in Russia. The
Employee may sell the Shares only through a broker established and operating outside Russia.
2. 	Cash Payments to a Russian Bank Account. The Employee agrees to promptly repatriate proceeds resulting from
the sale of Shares acquired under the Program to a foreign currency account at an authorized bank in Russia if legally
required at the time Shares are sold and to comply with all applicable local foreign exchange rules and regulations. Neither
the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to
comply with applicable laws.
SINGAPORE
Qualifying Person Exemption. The grant of the Award under the Program is being made pursuant to the “Qualifying
Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (the “SFA”). The
Program has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore and is
not regulated by any financial supervisory authority pursuant to any legislation in Singapore. Accordingly, statutory liability
under the SFA in relation to the content of prospectuses would not apply. The Employee should note that, as a result,
the Award is subject

-- 233 of 409 --

24
to section 257 of the SFA and the Employee will not be able to make: (a) any subsequent sale of the Shares underlying the
Award in Singapore; or (b) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such
sale or offer is made pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the
SFA.
SOUTH AFRICA
1. 	Exchange Control Obligations. The Employee is solely responsible for complying with applicable exchange control
regulations and rulings (the “Exchange Control Regulations”) in South Africa. As the Exchange Control Regulations change
frequently and without notice, the Employee should consult the Employee’s legal advisor prior to the acquisition or sale of
Shares under the Program to ensure compliance with current Exchange Control Regulations. Neither the Company nor any
of its Subsidiaries shall be liable for any fines or penalties resulting from the Employee’s failure to comply with applicable
laws.
2. 	Securities Law Information and Deemed Acceptance of Units. Neither the Units nor the underlying Shares shall be
publicly offered or listed on any stock exchange in South Africa. The offer is intended to be private pursuant to Section
96(1)(g)(ii) of the Companies Act, 71 of 2008 (the “Companies Act”) and is not subject to the supervision of any South
African governmental authority.
Pursuant to Section 96(1)(g)(ii) of the Companies Act, the Units offer must be finalized within six (6) months following the
date the offer is communicated to the Employee. If the Employee does not want to accept the Units, the Employee is
required to decline the Units no later than the six (6) months following the date the offer is communicated to you. If the
Employee does not reject the Units within six (6) months following the date the offer is communicated to the Employee, the
Employee will be deemed to accept the Units.
SPAIN
1. 	Acknowledgement of Discretionary Nature of the Program; No Vested Rights
By accepting the Award, the Employee consents to participation in the Program and acknowledges receipt of a copy of the
Program.
The Employee understands that the Company has unilaterally, gratuitously and in its sole discretion granted Units under the
Program to individuals who may be employees of the Company or its Subsidiaries throughout the world. The decision is a
limited decision that is entered into upon the express assumption and condition that any grant will not economically or
otherwise bind the Company or any of its Subsidiaries on an ongoing basis. Consequently, the Employee understands that
the Units are granted on the assumption and condition that the Units and the Shares acquired upon settlement of the Units
shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be
considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.
In addition, the Employee understands that this grant would not be made to the Employee but for the assumptions and
conditions referenced above; thus, the Employee acknowledges and freely accepts that should any or all of the assumptions
be mistaken or should any of the conditions not be met for any reason the Award shall be null and void.
The Employee understands and agrees that, as a condition of the Award, unless otherwise provided in Sections 4 or 5 of the
Agreement, any unvested Units as of the date the Employee ceases active employment will be forfeited without entitlement
to the underlying Shares or to any amount of indemnification in the event of Termination. The Employee acknowledges that
the Employee has read

-- 234 of 409 --

25
and specifically accepts the conditions referred to in the Agreement regarding the impact of a Termination on the Units.
2. 	Termination for Cause. Notwithstanding anything to the contrary in the Program or the Agreement, “Cause” shall be
as defined as set forth in the Agreement, regardless of whether the Termination is considered a fair termination (i.e.,
“despido procedente”) under Spanish legislation.
TUNISIA
Settlement in Cash. Notwithstanding Section 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
UKRAINE
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
UNITED KINGDOM
1. 	Withholding Taxes. The following provision supplements Section 8 of the Agreement.
The Employee agrees that he or she is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related
Items as and when requested by the Company or the Subsidiary in the United Kingdom that employs the Employee (the
“Employer”) or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant
authority). The Employee also agrees to indemnify and keep indemnified the Company and the Employer against any Tax-
Related Items that they are required to pay or withhold or have paid or will pay on the Employee’s behalf to HMRC (or any
other tax authority or any other relevant authority).
Notwithstanding the foregoing, if the Employee is a director or executive officer of the Company (within the meaning of
Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), he or she would not be eligible to have the
Company or the Employer cover any income tax liability on his or her behalf. In this case, any income tax not collected
from or paid by the Employee within 90 days after the end of the U.K. tax year in which the event giving rise to the income
tax liability occurred (or such other period specified in U.K. law) will constitute a benefit to the Employee on which
additional income tax and national insurance contributions (“NICs”) will be payable. The Employee will be responsible for
paying and reporting any income tax due on this additional benefit directly to HMRC under the self-assessment regime and
for reimbursing the Company or the Employer (as applicable) the value of any employee NICs due on this additional benefit,
which the Company or the Employer may recover from the Employee by any of the means referred to in Section 8 of the
Agreement.
2. 	Exclusion of Claim. The Employee acknowledges and agrees that the Employee will have no entitlement to
compensation or damages insofar as such entitlement arises or may arise from the Employee’s ceasing to have rights under
or to be entitled to the Units, whether or not as a result of Termination (whether the Termination is in breach of contract or
otherwise), or from the loss or diminution in value of the Units. Upon the grant of the Award, the Employee shall be deemed
to have waived irrevocably any such entitlement.

-- 235 of 409 --

26
UZBEKISTAN
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.
VIETNAM
Settlement in Cash. Notwithstanding Sections 4 or 5 of the Agreement or any other provision in the Agreement to the
contrary, pursuant to Section 12 of the Agreement, the Units will be settled in the form of a cash payment, except as
otherwise determined by the Company.

-- 236 of 409 --

Exhibit 10.62
ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK AGREEMENT
On «Grant_Date» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the
“Employee”) a Performance Restricted Stock Award (the “Award”) of «NoShares12345» Shares.
The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the
Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement. In the
event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus,
and the Program administrative rules, the Program shall control. This Award is intended to conform with the qualified
performance-based compensation requirements of Section 162(m) of the Code and the regulations thereunder, to the extent
applicable, and shall be construed accordingly.
The terms and conditions of the Award are as follows:
1. 	Definitions. To the extent not defined herein, capitalized terms shall have the same meaning as in the Program.
(a) 	Agreement: This Performance Restricted Stock Agreement.
(b) 	Cause: Cause shall mean the following, as determined by the Company in its sole discretion:
(i) 	material breach by the Employee of the terms and conditions of the Employee’s employment,
including, but not limited to:
(A) 	material breach by the Employee of the Code of Business Conduct;
(B) 	material breach by the Employee of the Employee’s Employee Agreement;
(C) 	commission by the Employee of an act of fraud, embezzlement or theft in connection with
the Employee’s duties or in the course of the Employee’s employment;
(D) 	wrongful disclosure by the Employee of secret processes or confidential information of the
Company or any of its Subsidiaries; or
(E) 	failure by the Employee to substantially perform the duties of the Employee’s employment
(other than any such failure resulting from the Employee’s Disability); or
(ii) 	to the extent permitted by applicable law, engagement by the Employee, directly or indirectly, for
the benefit of the Employee or others, in any activity, employment or business which is competitive
with the Company or any of its Subsidiaries.
(c) 	Change in Control Agreement: An Agreement Regarding Change in Control in effect between the
Company (or the Surviving Entity) and the Employee, if any.

-- 237 of 409 --

2
(d) 	Change in Control Cause: shall mean the occurrence of any of the following circumstances during the
period that begins six (6) months immediately before a Change in Control and ends two (2) years
immediately following such Change in Control: the willful engaging by the Employee in illegal conduct or
gross misconduct which is demonstrably and materially injurious to the Company. For purposes of this
definition, no act, or failure to act, on the Employee’s part shall be deemed “willful” unless done, or omitted
to be done, by the Employee not in good faith and without reasonable belief that the Employee’s action or
omission was in the best interest of the Company. Notwithstanding the foregoing, the Employee shall not be
deemed to have been terminated for Change in Control Cause unless and until the Company delivers to the
Employee a copy of a resolution duly adopted by the affirmative vote of not less than three-quarters of the
entire membership of the Board at a meeting of the Board called and held for such purpose (after reasonable
notice to the Employee and an opportunity for the Employee, together with counsel, to be heard before the
Board) finding that, in the good faith opinion of the Board, the Employee was guilty of conduct set forth
above and specifying the particulars thereof in detail.
(e) 	Change in Control Good Reason: shall mean the occurrence of any of the following circumstances without
the Employee’s express written consent during the period that begins six (6) months immediately before a
Change in Control and ends two (2) years immediately following such Change in Control:
(i) 	a significant adverse change in the nature, scope or status of the Employee’s position, authorities or
duties from those in effect immediately prior to the Change in Control, including, without
limitation, if the Employee was, immediately prior to the Change in Control, an Employee officer of
a public company, the Employee ceasing to be an Employee officer of a public company;
(ii) 	the failure by the Company to pay the Employee any portion of the Employee’s current
compensation, or to pay the Employee any portion of any installment of deferred compensation
under any deferred compensation program of the Company, within seven (7) days of the date such
compensation is due;
(iii) 	a reduction in the Employee’s annual base salary (or a material change in the frequency of payment)
as in effect immediately prior to the Change in Control as the same may be increased from time to
time;
(iv) 	the failure by the Company to award the Employee an annual bonus in any year which is at least
equal to the annual bonus, awarded to the Employee under the annual bonus plan of the Company
for the year immediately preceding the year of the Change in Control;
(v) 	the failure by the Company to award the Employee equity-based incentive compensation (such as
stock options, shares of restricted stock, restricted stock units, or other equity-based compensation)
on a periodic basis consistent with the Company’s practices with respect to timing, value and terms
prior to the Change in Control;
(vi) 	the failure by the Company to continue to provide the Employee with the welfare benefits, fringe
benefits and perquisites enjoyed by the Employee immediately prior to the Change in Control under
any of the Company’s plans or policies,

-- 238 of 409 --

3
including, but not limited to, those plans and policies providing pension, life insurance, medical,
health and accident, disability, vacation, Employee automobile, Employee tax or financial advice
benefits or club dues;
(vii) 	the relocation of the Company’s principal Employee offices to a location more than 35 miles from
the location of such offices immediately prior to the Change in Control or the Company requiring
the Employee to be based anywhere other than the location where the Employee primarily performs
services for the Company immediately prior to the Change in Control except for required travel for
the Company’s business to an extent substantially consistent with the Employee’s business travel
obligations immediately prior to the Change in Control; or
(viii) the failure of the Company to obtain a satisfactory agreement from any successor to the Company to
assume and agree to perform any Change in Control Agreement.
For purposes of any determination regarding the existence of Change in Control Good Reason, any good
faith determination by the Employee that Change and Control Good Reason exists shall be conclusive.
(f) 	Code of Business Conduct: The Company’s Code of Business Conduct, as amended from time to time.
(g) 	Controlled Group:
(i) 	Abbott and any corporation, partnership and proprietorship under common control (as defined
under the aggregation rules of subsections 414 (b), (c), or (m) of the Code) with Abbott; and
(ii) 	during the period of the TAP Pharmaceutical Products Inc. (“TAP”) joint venture between Takeda
Pharmaceutical Company Limited and Abbott ending April 30, 2008, TAP and any corporation,
partnership and proprietorship under common control (as defined above) with TAP.
(h) 	Data: Certain personal information about the Employee held by the Company and the Subsidiary that
employs the Employee (if applicable), including (but not limited to) the Employee’s name, home address
and telephone number, date of birth, social security number or other employee identification number, salary,
nationality, job title, any Shares held in the Company, details of all Awards or any other entitlement to
Shares awarded, canceled, purchased, vested, unvested or outstanding in the Employee’s favor, for the
purpose of managing and administering the Program.
(i) 	Disability: Sickness or accidental bodily injury, directly and independently of all other causes, that disables
the Employee so that the Employee is completely prevented from performing all the duties of his or her
occupation or employment.
(j) 	Employee Agreement: The Employee Agreement entered into by and between the Company and the
Employee as it may be amended from time to time.
(k) 	Employee’s Representative: The Employee’s legal guardian or other legal representative.

-- 239 of 409 --

4
(l) 	Program: The Abbott Laboratories 2017 Incentive Stock Program.
(m) 	Retirement:
(i) 	Except as provided under (iii) below, for employees hired by the Controlled Group prior to January
1, 2004, Retirement means any of the following:
· 	age 50 with 10 years of service;
· 	age 65 with at least three (3) years of service; or
· 	age 55 with an age and service combination of 70 points, where each year of age is one (1)
point and each year of service is one (1) point.
(ii) 	Except as provided under (iii) below, for employees hired by the Controlled Group after December
31, 2003, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iii) 	For participants in the Abbott Laboratories Pension Plan for Former BASF and Former Solvay
Employees, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iv) 	For purposes of calculating service under this Section 1(m), except as otherwise provided by the
Committee or its delegate, service is earned only if performed for a member of the Controlled
Group while that Controlled Group member is a part of the Controlled Group. Program
administrative rules apply in determining Retirement eligibility and credited service.
(v) 	If an Employee has a Termination and (A) as of the date of that Termination met the definition of
Retirement, and (B) is subsequently rehired by a member of the Controlled Group, then for purposes
of this Agreement that Employee will continue to be treated as meeting the definition of Retirement.
(n) 	Termination: A severance of employment for any reason (including Retirement) from the Company and all
Subsidiaries.
2. 	Shareholder Rights. Subject to the conditions below, the Employee shall have all the rights of a shareholder with
respect to the Shares (and any securities of the Company which may be issued with respect to the Shares by virtue of
any stock split, combination, stock dividend or recapitalization, which securities shall be deemed to be “Shares”
hereunder) including the right to vote and to receive all cash dividends or other cash distributions paid or made with
respect to the Shares regardless of whether the Restrictions described below are in effect.
3. 	Restrictions. The Shares are subject to the forfeiture provisions in Sections 6 and 7 below. The Shares are not
earned and may not be sold, exchanged, assigned, transferred, pledged or

-- 240 of 409 --

5
otherwise disposed of (collectively, the “Restrictions”) until an event or combination of events described in
subsections 4(a), (b), (c), (d) or Section 5 occurs.
4. 	Lapse of Restrictions. Subject to the provisions of Sections 5, 6 and 7 below:
(a) 	During Employment. While the Employee is employed with the Company or its Subsidiaries:
(i) 	the Restrictions on one-third of the Shares will lapse on the last business day of February 202_,
provided the Company’s prior year return on equity is a minimum of [•] percent;
(ii) 	the Restrictions on an additional one-third of the total number of Shares will lapse on the last
business day of February 202_, provided the Company’s prior year return on equity is a minimum of
[•] percent; and
(iii) 	the Restrictions on an additional one-third of the total number of Shares will lapse on the last
business day of February 202_, provided the Company’s prior year return on equity is a minimum of
[•] percent.
If the Restrictions do not lapse on the respective date set forth in subsection 4(a)(i), (ii), and (iii) above, such
Restrictions shall not lapse at a later date.
(b) 	Retirement. The Restrictions shall continue to apply in the event of the Employee’s Termination due to
Retirement, but may lapse thereafter in accordance with the provisions of subsection 4(a) above as if the
Employee had remained employed. Notwithstanding the foregoing, in the event of the Employee’s death
after his or her Termination due to Retirement, the restrictions shall lapse on the date of the Employee’s
death.
(c) 	Death. The Restrictions shall lapse on the date of the Employee’s Termination due to death.
(d) 	Disability. The Restrictions shall lapse on the date the Employee incurs 12 consecutive months of
Disability.
5. 	Change in Control. In the event of a Change in Control, the entity surviving such Change in Control or the
ultimate parent thereof (referred to herein as the “Surviving Entity”) may assume, convert or replace this Award with
an award of at least equal value (determined using the same value for purchasing Company shares as used for
purchasing Company shares not subject to this Agreement on the date of the Change in Control) with terms and
conditions not less favorable than the terms and conditions provided in this Agreement, in which case the new award
will vest according to the terms of the applicable award agreement. If the Surviving Entity does not assume, convert
or replace this Award, the Restrictions shall lapse on the date of the Change in Control. If the Surviving Entity does
assume, convert or replace this Award, then in the event the Employee’s Termination (i) occurs within the time
period beginning six (6) months immediately before a Change in Control and ending two (2) years immediately
following such Change in Control, and (ii) was initiated by the Company (or the Surviving Entity) for a reason other
than Change in Control Cause or was initiated by the Employee for Change in Control Good Reason, the
Restrictions shall lapse on the later of the date of the Change in Control and the date of the

-- 241 of 409 --

6
Employee’s Termination. The provisions of this Section 5 shall supersede Section 13(a)(iii) and (v) of the Program.
6. 	Effect of Certain Bad Acts. If Section 5 does not apply, any Shares with respect to which Restrictions have not
lapsed shall be cancelled and forfeited immediately if, in the sole opinion and discretion of the Committee or its
delegate, the Employee engages in activity that constitutes Cause, whether or not the Employee experiences a
Termination or remains employed with the Company or a Subsidiary. If Section 5 does apply, any Shares with
respect to which Restrictions have not lapsed shall be cancelled and forfeited immediately if, in the sole opinion and
discretion of the Board, the Employee engages in an activity that constitutes Change in Control Cause.
7. 	Forfeiture of Shares. In the event of the Employee’s Termination for any reason other than those set forth in
subsections 4 (b), (c), (d) or Section 5, any Shares with respect to which Restrictions have not lapsed as of the date
of Termination shall be forfeited without consideration to the Employee or the Employee’s Representative. If the
Company terminates the Employee for any reason other than for Cause and such termination is not covered by
Section 5, the Company may, in its sole discretion, cause Restrictions on some or all of the Shares to lapse on the
dates set forth in subsection 4(a) above as if the Employee had remained employed on such dates.
8. 	Withholding Taxes. The Company shall be entitled to withhold, or require the Employee to remit, any federal,
state, local, and other applicable taxes (in U.S. or non-U.S. jurisdictions), including income, social security and
Medicare withholding taxes arising from the grant of the Award, the lapse of Restrictions or the delivery of Shares
pursuant to this Agreement by, without limitation:
(a) 	having the Company withhold Shares;
(b) 	tendering Shares received in connection with the Award back to the Company;
(c) 	delivering other previously acquired Shares having a Fair Market Value approximately equal to the amount
to be withheld;
(d) 	selling Shares issued pursuant to the Award and having the Company withhold from proceeds of the sale of
such Shares;
(e) 	having the Company or a Subsidiary, as applicable, withhold from any cash compensation payable to the
Employee; or
(f) 	requiring the Employee to repay the Company or Subsidiary, in cash or in Shares, for taxes paid on the
Employee’s behalf.
Notwithstanding the foregoing, if the Employee is subject to Section 16 of the Exchange Act pursuant to Rule 16a-2
promulgated thereunder, any tax withholding obligations shall be satisfied by having the Company withhold a
number of Shares otherwise issuable pursuant to the Award that is sufficient to satisfy such obligations consistent
with the Company’s withholding practices.
If, to satisfy tax withholding obligations, the Company withholds Shares otherwise issuable to the Employee, the
Employee shall be deemed to have been issued the full number of Shares underlying the Award, subject to the
Restrictions set forth in this Agreement.

-- 242 of 409 --

7
9. 	No Right to Continued Employment. This Agreement and the Employee’s participation in the Program is not and
shall not be interpreted to:
(a) 	form an employment contract or relationship with the Company or its Subsidiaries;
(b) 	confer upon the Employee any right to continue in the employ of the Company or any of its Subsidiaries; or
(c) 	interfere with the ability of the Company or its Subsidiaries to terminate the Employee’s employment at any
time.
10. 	No Contract as of Right. The Award does not create any contractual or other right to receive additional Awards or
other Program Benefits. Nothing contained in this Agreement is intended to create or enlarge any other contractual
obligations between the Company and the Employee. Future Awards, if any, and their terms and conditions, will be
at the sole discretion of the Committee.
11. 	No Right to Compensation. Unless expressly provided by the Company in writing, any value associated with the
Award is an item of compensation outside the scope of the Employee’s employment contract, if any, and shall not be
deemed part of the Employee’s normal or expected compensation for purposes of calculating any severance,
resignation, redundancy, or end-of-service payments, bonuses, long-service awards, insurance plan, investment or
stock purchase plan, pension, retirement, or any other employee benefits, or similar payments under plans of the
Company or any of its Subsidiaries.
12. 	Data Privacy.
(a) 	Pursuant to applicable personal data protection laws, the collection, processing and transfer of the
Employee’s personal Data is necessary for the Company’s administration of the Program and the
Employee’s participation in the Program. The Employee’s denial and/or objection to the collection,
processing and transfer of personal Data may affect his or her ability to participate in the Program. As such
(where required under applicable law), the Employee:
(i) 	voluntarily acknowledges, consents and agrees to the collection, use, processing and transfer of
personal Data as described herein; and
(ii) 	authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic or
other form, for purposes of implementing, administering and managing the Employee’s participation
in the Program, including any requisite transfer of such Data as may be required for the
administration of the Program and/or the subsequent holding of Shares on the Employee’s behalf to
a broker or other third party with whom the Employee may elect to deposit any Shares acquired
pursuant to the Program.
(b) 	Data may be provided by the Employee or collected, where lawful, from third parties, and the Company and
the Subsidiary that employs the Employee (if applicable) will process the Data for the exclusive purpose of
implementing, administering and managing the Employee’s participation in the Program. Data processing
will take place through electronic and non-electronic means according to logics and procedures strictly
correlated to the purposes for which the Data is collected and with confidentiality and security

-- 243 of 409 --

8
provisions as set forth by applicable laws and regulations in the Employee’s country of residence. Data
processing operations will be performed minimizing the use of personal and identification data when such
operations are unnecessary for the processing purposes sought. The Data will be accessible within the
Company’s organization only by those persons requiring access for purposes of the implementation,
administration and operation of the Program and for the Employee’s participation in the Program.
(c) 	The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as necessary
for the purpose of implementation, administration and management of the Employee’s participation in the
Program, and the Company and the Subsidiary that employs the Employee (if applicable) may further
transfer Data to any third parties assisting the Company in the implementation, administration and
management of the Program. These recipients may be located throughout the world.
(d) 	The Employee may, at any time, exercise his or her rights provided under applicable personal data
protection laws, which may include the right to:
(i) 	obtain confirmation as to the existence of the Data;
(ii) 	verify the content, origin and accuracy of the Data;
(iii) 	request the integration, update, amendment, deletion or blockage (for breach of applicable laws) of
the Data; and
(iv) 	oppose, for legal reasons, the collection, processing or transfer of the Data which is not necessary
or required for the implementation, administration and/or operation of the Program and the
Employee’s participation in the Program.
The Employee may seek to exercise these rights by contacting his or her local human resources manager.
13. 	No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the Company
making any recommendations regarding the Award, the Employee’s participation in the Program or the Employee’s
acquisition or sale of the underlying Shares. The Employee is hereby advised to consult with the Employee’s own
personal tax, legal and financial advisors regarding participation in the Program before taking any action related to
the Program.
14. 	Entire Agreement. This Agreement, the Program, the Program prospectus, the Program administrative rules, and
any applicable Company policies constitute the entire agreement between the Employee and the Company regarding
the Award and supersede all prior and contemporaneous agreements and understandings, oral or written, between the
parties regarding the Award. Except as expressly set forth herein, this Agreement (and any provision of this
Agreement) may not be modified, changed, clarified, or interpreted by the parties, except in a writing specifying the
modification, change, clarification, or interpretation, and signed by a duly authorized Company officer.
15. 	Succession. This Agreement shall be binding upon and operate for the benefit of the Company and its successors
and assigns, and the Employee, the Employee’s Representative, and the person or persons to whom rights under the
Award have passed by will or the laws of descent or distribution.

-- 244 of 409 --

9
16. 	Compliance with Applicable Laws and Regulations. The Company shall not be required to issue or deliver any
Shares pursuant to this Agreement pending compliance with all applicable federal and state securities and other laws
(including any registration requirements or tax withholding requirements) and compliance with the rules and
practices of any stock exchange upon which the Company’s Shares are listed. Furthermore, if the Employee
relocates to another country, the Company may establish special or alternative terms and conditions as necessary or
advisable to comply with local law, facilitate the administration of the Program, and/or accommodate the
Employee’s relocation.
17. 	Code Section 409A. The Award is intended to be exempt from the requirements of Code Section 409A. The
Program and this Agreement shall be administered and interpreted in a manner consistent with this intent. If the
Company determines that the Award is subject to Code Section 409A and this Agreement fails to comply with that
section’s requirements, the Company may, at the Company’s sole discretion, and without the Employee’s consent,
amend this Agreement to cause it to comply with Code Section 409A or otherwise be exempt from Code Section
409A.
Although this Agreement and the Benefits provided hereunder are intended to be exempt from the requirements of
Code Section 409A, the Company does not represent or warrant that this Agreement or the Benefits provided
hereunder will comply with Code Section 409A or any other provision of federal, state, local, or non-United States
law. None of the Company, its Subsidiaries, or their respective directors, officers, employees or advisers shall be
liable to the Employee (or any other individual claiming a benefit through the Employee) for any tax, interest, or
penalties the Employee may owe as a result of compensation paid under this Agreement, and the Company and its
Subsidiaries shall have no obligation to indemnify or otherwise protect the Employee from the obligation to pay any
taxes pursuant to Code Section 409A.
18. 	Determinations. Each decision, determination, interpretation or other action made or taken pursuant to the
provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be final,
conclusive and binding for all purposes and upon all persons, including, without limitation, the Company, the
Employee, the Employee’s Representative, and the person or persons to whom rights under the Award have passed
by will or the laws of descent or distribution.
19. 	Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or
enforceability of any other provision of this Agreement, and each other provision of this Agreement shall be
severable and enforceable to the extent permitted by law. To the extent a court or tribunal of competent jurisdiction
determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, the Company, in its
sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent
necessary to make it valid and enforceable to the full extent permitted under local law.
20. 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the U.S. State
of Illinois without giving effect to any state’s conflict of laws principles.
21. 	Venue. For any legal action relating to this Agreement, the parties to this Agreement consent to the exclusive
jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there is no jurisdiction in
federal court, to the exclusive jurisdiction and venue of the state courts in Lake County, Illinois, USA.
* 	* 	*

-- 245 of 409 --

10
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer as of the
grant date above set forth.
ABBOTT LABORATORIES
By
[Name]
[Title]

-- 246 of 409 --

Exhibit 10.63
ABBOTT LABORATORIES
PERFORMANCE RESTRICTED STOCK AGREEMENT
On «Grant_Date» (the “Grant Date”), Abbott Laboratories hereby grants to «First Name» «MI» «Last Name» (the
“Employee”) a Performance Restricted Stock Award (the “Award”) of «NoShares12345» Shares.
The Award is granted under the Program and is subject to the provisions of the Program, the Program prospectus, the
Program administrative rules, applicable Company policies, and the terms and conditions set forth in this Agreement. In the
event of any inconsistency among the provisions of this Agreement, the provisions of the Program, the Program prospectus,
and the Program administrative rules, the Program shall control. This Award is intended to conform with the qualified
performance-based compensation requirements of Section 162(m) of the Code and the regulations thereunder, to the extent
applicable, and shall be construed accordingly.
The terms and conditions of the Award are as follows:
1. 	Definitions. To the extent not defined herein, capitalized terms shall have the same meaning as in the
Program.
(a) 	Agreement: This Performance Restricted Stock Agreement.
(b) 	Cause: Cause shall mean the following, as determined by the Company in its sole discretion:
(i) 	material breach by the Employee of the terms and conditions of the Employee’s
employment, including, but not limited to:
(A) 	material breach by the Employee of the Code of Business Conduct;
(B) 	material breach by the Employee of the Employee’s Employee Agreement;
(C) 	commission by the Employee of an act of fraud, embezzlement or theft in
connection with the Employee’s duties or in the course of the Employee’s
employment;
(D) 	wrongful disclosure by the Employee of secret processes or confidential
information of the Company or any of its Subsidiaries; or
(E) 	failure by the Employee to substantially perform the duties of the Employee’s
employment (other than any such failure resulting from the Employee’s Disability);
or
(ii) 	to the extent permitted by applicable law, engagement by the Employee, directly or
indirectly, for the benefit of the Employee or others, in any activity, employment or business
which is competitive with the Company or any of its Subsidiaries.

-- 247 of 409 --

2
(c) 	Change in Control Agreement: An Agreement Regarding Change in Control in effect between the
Company (or the Surviving Entity) and the Employee, if any.
(d) 	Change in Control Cause: shall mean the occurrence of any of the following circumstances during
the period that begins six (6) months immediately before a Change in Control and ends two (2)
years immediately following such Change in Control: the willful engaging by the Employee in
illegal conduct or gross misconduct which is demonstrably and materially injurious to the Company.
For purposes of this definition, no act, or failure to act, on the Employee’s part shall be deemed
“willful” unless done, or omitted to be done, by the Employee not in good faith and without
reasonable belief that the Employee’s action or omission was in the best interest of the Company.
Notwithstanding the foregoing, the Employee shall not be deemed to have been terminated for
Change in Control Cause unless and until the Company delivers to the Employee a copy of a
resolution duly adopted by the affirmative vote of not less than three-quarters of the entire
membership of the Board at a meeting of the Board called and held for such purpose (after
reasonable notice to the Employee and an opportunity for the Employee, together with counsel, to
be heard before the Board) finding that, in the good faith opinion of the Board, the Employee was
guilty of conduct set forth above and specifying the particulars thereof in detail.
(e) 	Change in Control Good Reason: shall mean the occurrence of any of the following circumstances
without the Employee’s express written consent during the period that begins six (6) months
immediately before a Change in Control and ends two (2) years immediately following such Change
in Control:
(i) 	a significant adverse change in the nature, scope or status of the Employee’s position,
authorities or duties from those in effect immediately prior to the Change in Control,
including, without limitation, if the Employee was, immediately prior to the Change in
Control, an Employee officer of a public company, the Employee ceasing to be an
Employee officer of a public company;
(ii) 	the failure by the Company to pay the Employee any portion of the Employee’s current
compensation, or to pay the Employee any portion of any installment of deferred
compensation under any deferred compensation program of the Company, within seven
(7) days of the date such compensation is due;
(iii) 	a reduction in the Employee’s annual base salary (or a material change in the frequency of
payment) as in effect immediately prior to the Change in Control as the same may be
increased from time to time;
(iv) 	the failure by the Company to award the Employee an annual bonus in any year which is at
least equal to the annual bonus, awarded to the Employee under the annual bonus plan of
the Company for the year immediately preceding the year of the Change in Control;
(v) 	the failure by the Company to award the Employee equity-based incentive compensation
(such as stock options, shares of restricted stock, restricted stock units, or other equity-based
compensation) on a periodic

-- 248 of 409 --

3
basis consistent with the Company’s practices with respect to timing, value and terms prior
to the Change in Control;
(vi) 	the failure by the Company to continue to provide the Employee with the welfare benefits,
fringe benefits and perquisites enjoyed by the Employee immediately prior to the Change in
Control under any of the Company’s plans or policies, including, but not limited to, those
plans and policies providing pension, life insurance, medical, health and accident, disability,
vacation, Employee automobile, Employee tax or financial advice benefits or club dues;
(vii) 	the relocation of the Company’s principal Employee offices to a location more than 35
miles from the location of such offices immediately prior to the Change in Control or the
Company requiring the Employee to be based anywhere other than the location where the
Employee primarily performs services for the Company immediately prior to the Change in
Control except for required travel for the Company’s business to an extent substantially
consistent with the Employee’s business travel obligations immediately prior to the Change
in Control; or
(viii) the failure of the Company to obtain a satisfactory agreement from any successor to the
Company to assume and agree to perform any Change in Control Agreement.
For purposes of any determination regarding the existence of Change in Control Good Reason, any
good faith determination by the Employee that Change in Control Good Reason exists shall be
conclusive.
(f) 	Code of Business Conduct: The Company’s Code of Business Conduct, as amended from time to
time.
(g) 	Controlled Group:
(i) 	Abbott and any corporation, partnership and proprietorship under common control (as
defined under the aggregation rules of subsections 414 (b), (c), or (m) of the Code) with
Abbott; and
(ii) 	during the period of the TAP Pharmaceutical Products Inc. (“TAP”) joint venture between
Takeda Pharmaceutical Company Limited and Abbott ending April 30, 2008, TAP and any
corporation, partnership and proprietorship under common control (as defined above) with
TAP.
(h) 	Data: Certain personal information about the Employee held by the Company and the Subsidiary
that employs the Employee (if applicable), including (but not limited to) the Employee’s name,
home address and telephone number, date of birth, social security number or other employee
identification number, salary, nationality, job title, any Shares held in the Company, details of all
Awards or any other entitlement to Shares awarded, canceled, purchased, vested, unvested or
outstanding in the Employee’s favor, for the purpose of managing and administering the Program.

-- 249 of 409 --

4
(i) 	Disability: Sickness or accidental bodily injury, directly and independently of all other causes, that
disables the Employee so that the Employee is completely prevented from performing all the duties
of his or her occupation or employment.
(j) 	Employee Agreement: The Employee Agreement entered into by and between the Company and
the Employee as it may be amended from time to time.
(k) 	Employee’s Representative: The Employee’s legal guardian or other legal representative.
(l) 	Program: The Abbott Laboratories 2017 Incentive Stock Program.
(m) 	Retirement:
(i) 	Except as provided under (iii) below, for employees hired by the Controlled Group prior to
January 1, 2004, Retirement means any of the following:
· 	age 50 with 10 years of service;
· 	age 65 with at least three (3) years of service; or
· 	age 55 with an age and service combination of 70 points, where each year of age is
one (1) point and each year of service is one (1) point.
(ii) 	Except as provided under (iii) below, for employees hired by the Controlled Group after
December 31, 2003, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iii) 	For participants in the Abbott Laboratories Pension Plan for Former BASF and Former
Solvay Employees, Retirement means any of the following:
· 	age 55 with 10 years of service; or
· 	age 65 with at least three (3) years of service.
(iv) 	For purposes of calculating service under this Section 1(m), except as otherwise provided
by the Committee or its delegate, service is earned only if performed for a member of the
Controlled Group while that Controlled Group member is a part of the Controlled Group.
Program administrative rules apply in determining Retirement eligibility and credited
service.
(v) 	If an Employee has a Termination and (A) as of the date of that Termination met the
definition of Retirement, and (B) is subsequently

-- 250 of 409 --

5
rehired by a member of the Controlled Group, then for purposes of this Agreement that
Employee will continue to be treated as meeting the definition of Retirement.
(n) 	Termination: A severance of employment for any reason (including Retirement) from the Company
and all Subsidiaries.
2. 	Shareholder Rights. Subject to the conditions below, the Employee shall have all the rights of a
shareholder with respect to the Shares (and any securities of the Company which may be issued with respect
to the Shares by virtue of any stock split, combination, stock dividend or recapitalization, which securities
shall be deemed to be “Shares” hereunder) including the right to vote and to receive all cash dividends or
other cash distributions paid or made with respect to the Shares regardless of whether the Restrictions
described below are in effect.
3. 	Restrictions. The Shares are subject to the forfeiture provisions in Sections 6 and 7 below. The Shares are
not earned and may not be sold, exchanged, assigned, transferred, pledged or otherwise disposed of
(collectively, the “Restrictions”) until an event or combination of events described in subsections 4(a), (b),
(c), (d) or Section 5 occurs.
4. 	Lapse of Restrictions. Subject to the provisions of Sections 5, 6 and 7 below:
(a) 	During Employment. While the Employee is employed with the Company or its Subsidiaries:
(i) 	the Restrictions on one-third of the Shares will lapse on «M_1st_yr_vest», provided the
Company’s prior year return on equity is a minimum of [•] percent;
(ii) 	the Restrictions on an additional one-third of the total number of Shares will lapse on
«M_2nd_yr_vest», provided the Company’s prior year return on equity is a minimum of [•]
percent; and
(iii) 	the Restrictions on an additional one-third of the total number of Shares will lapse on
«M_3rd_yr_vest», provided the Company’s prior year return on equity is a minimum of [•]
percent.
If the Restrictions do not lapse on the respective date set forth in subsection 4(a)(i), (ii), and (iii)
above, such Restrictions shall not lapse at a later date.
(b) 	Retirement. The Restrictions shall continue to apply in the event of the Employee’s Termination
due to Retirement, but may lapse thereafter in accordance with the provisions of subsection 4(a)
above as if the Employee had remained employed. Notwithstanding the foregoing, in the event of
the Employee’s death after his or her Termination due to Retirement, the restrictions shall lapse on
the date of the Employee’s death.
(c) 	Death. The Restrictions shall lapse on the date of the Employee’s Termination due to death.

-- 251 of 409 --

6
(d) 	Disability. The Restrictions shall lapse on the date the Employee incurs 12 consecutive months of
Disability.
5. 	Change in Control. In the event of a Change in Control, the entity surviving such Change in Control or the
ultimate parent thereof (referred to herein as the “Surviving Entity”) may assume, convert or replace this
Award with an award of at least equal value (determined using the same value for purchasing Company
shares as used for purchasing Company shares not subject to this Agreement on the date of the Change in
Control) with terms and conditions not less favorable than the terms and conditions provided in this
Agreement, in which case the new award will vest according to the terms of the applicable award
agreement. If the Surviving Entity does not assume, convert or replace this Award, the Restrictions shall
lapse on the date of the Change in Control. If the Surviving Entity does assume, convert or replace this
Award, then in the event the Employee’s Termination (i) occurs within the time period beginning six (6)
months immediately before a Change in Control and ending two (2) years immediately following such
Change in Control, and (ii) was initiated by the Company (or the Surviving Entity) for a reason other than
Change in Control Cause or was initiated by the Employee for Change in Control Good Reason, the
Restrictions shall lapse on the later of the date of the Change in Control and the date of the Employee’s
Termination. The provisions of this Section 5 shall supersede Section 13(a)(iii) and (v) of the Program.
6. 	Effect of Certain Bad Acts. If Section 5 does not apply, any Shares with respect to which Restrictions have
not lapsed shall be cancelled and forfeited immediately if, in the sole opinion and discretion of the
Committee or its delegate, the Employee engages in activity that constitutes Cause, whether or not the
Employee experiences a Termination or remains employed with the Company or a Subsidiary. If Section 5
does apply, any Shares with respect to which Restrictions have not lapsed shall be cancelled and forfeited
immediately if, in the sole opinion and discretion of the Board, the Employee engages in an activity that
constitutes Change in Control Cause.
7. 	Forfeiture of Shares. In the event of the Employee’s Termination for any reason other than those set forth
in subsections 4(b), (c), (d) or Section 5, any Shares with respect to which Restrictions have not lapsed as of
the date of Termination shall be forfeited without consideration to the Employee or the Employee’s
Representative. If the Company terminates the Employee other than for Cause and such termination is not
covered by Section 5, the Company may, in its sole discretion, cause Restrictions on some or all of the
Shares to lapse on the dates set forth in subsection 4(a) above as if the Employee had remained employed on
such dates.
8. 	Withholding Taxes. The Company shall be entitled to withhold, or require the Employee to remit, any
federal, state, local, and other applicable taxes (in U.S. or non-U.S. jurisdictions), including income, social
security and Medicare withholding taxes arising from the grant of the Award, the lapse of Restrictions or the
delivery of Shares pursuant to this Agreement by, without limitation:
(a) 	having the Company withhold Shares;
(b) 	tendering Shares received in connection with the Award back to the Company;
(c) 	delivering other previously acquired Shares having a Fair Market Value approximately equal to the
amount to be withheld;

-- 252 of 409 --

7
(d) 	selling Shares issued pursuant to the Award and having the Company withhold from proceeds of the
sale of such Shares;
(e) 	having the Company or a Subsidiary, as applicable, withhold from any cash compensation payable
to the Employee; or
(f) 	requiring the Employee to repay the Company or Subsidiary, in cash or in Shares, for taxes paid on
the Employee’s behalf.
Notwithstanding the foregoing, if the Employee is subject to Section 16 of the Exchange Act pursuant to
Rule 16a-2 promulgated thereunder, any tax withholding obligations shall be satisfied by having the
Company withhold a number of Shares otherwise issuable pursuant to the Award that is sufficient to satisfy
such obligations consistent with the Company’s withholding practices.
If, to satisfy tax withholding obligations, the Company withholds Shares otherwise issuable to the
Employee, the Employee shall be deemed to have been issued the full number of Shares underlying the
Award, subject to the Restrictions set forth in this Agreement.
9. 	No Right to Continued Employment. This Agreement and the Employee’s participation in the Program is
not and shall not be interpreted to:
(a) 	form an employment contract or relationship with the Company or its Subsidiaries;
(b) 	confer upon the Employee any right to continue in the employ of the Company or any of its
Subsidiaries; or
(c) 	interfere with the ability of the Company or its Subsidiaries to terminate the Employee’s
employment at any time.
10. 	No Contract as of Right. The Award does not create any contractual or other right to receive additional
Awards or other Program Benefits. Nothing contained in this Agreement is intended to create or enlarge any
other contractual obligations between the Company and the Employee. Future Awards, if any, and their
terms and conditions, will be at the sole discretion of the Committee.
11. 	No Right to Compensation. Unless expressly provided by the Company in writing, any value associated
with the Award is an item of compensation outside the scope of the Employee’s employment contract, if any,
and shall not be deemed part of the Employee’s normal or expected compensation for purposes of
calculating any severance, resignation, redundancy, or end-of-service payments, bonuses, long-service
awards, insurance plan, investment or stock purchase plan, pension, retirement, or any other employee
benefits, or similar payments under plans of the Company or any of its Subsidiaries.
12. 	Data Privacy.
(a) 	Pursuant to applicable personal data protection laws, the collection, processing and transfer of the
Employee’s personal Data is necessary for the Company’s administration of the Program and the
Employee’s participation in the Program.

-- 253 of 409 --

8
The Employee’s denial and/or objection to the collection, processing and transfer of personal Data
may affect his or her ability to participate in the Program. As such (where required under applicable
law), the Employee:
(i) 	voluntarily acknowledges, consents and agrees to the collection, use, processing and
transfer of personal Data as described herein; and
(ii) 	authorizes Data recipients to receive, possess, use, retain and transfer the Data, in electronic
or other form, for purposes of implementing, administering and managing the Employee’s
participation in the Program, including any requisite transfer of such Data as may be
required for the administration of the Program and/or the subsequent holding of Shares on
the Employee’s behalf to a broker or other third party with whom the Employee may elect
to deposit any Shares acquired pursuant to the Program.
(b) 	Data may be provided by the Employee or collected, where lawful, from third parties, and the
Company and the Subsidiary that employs the Employee (if applicable) will process the Data for the
exclusive purpose of implementing, administering and managing the Employee’s participation in the
Program. Data processing will take place through electronic and non-electronic means according to
logics and procedures strictly correlated to the purposes for which the Data is collected and with
confidentiality and security provisions as set forth by applicable laws and regulations in the
Employee’s country of residence. Data processing operations will be performed minimizing the use
of personal and identification data when such operations are unnecessary for the processing
purposes sought. The Data will be accessible within the Company’s organization only by those
persons requiring access for purposes of the implementation, administration and operation of the
Program and for the Employee’s participation in the Program.
(c) 	The Company and the Subsidiary that employs the Employee (if applicable) will transfer Data as
necessary for the purpose of implementation, administration and management of the Employee’s
participation in the Program, and the Company and the Subsidiary that employs the Employee (if
applicable) may further transfer Data to any third parties assisting the Company in the
implementation, administration and management of the Program. These recipients may be located
throughout the world.
(d) 	The Employee may, at any time, exercise his or her rights provided under applicable personal data
protection laws, which may include the right to:
(i) 	obtain confirmation as to the existence of the Data;
(ii) 	verify the content, origin and accuracy of the Data;
(iii) 	request the integration, update, amendment, deletion or blockage (for breach of applicable
laws) of the Data; and
(iv) 	oppose, for legal reasons, the collection, processing or transfer of the Data which is not
necessary or required for the implementation,

-- 254 of 409 --

9
administration and/or operation of the Program and the Employee’s participation in the
Program.
The Employee may seek to exercise these rights by contacting his or her local human resources
manager.
13. 	No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the
Company making any recommendations regarding the Award, the Employee’s participation in the Program
or the Employee’s acquisition or sale of the underlying Shares. The Employee is hereby advised to consult
with the Employee’s own personal tax, legal and financial advisors regarding participation in the Program
before taking any action related to the Program.
14. 	Entire Agreement. This Agreement, the Program, the Program prospectus, the Program administrative
rules, and any applicable Company policies constitute the entire agreement between the Employee and the
Company regarding the Award and supersede all prior and contemporaneous agreements and
understandings, oral or written, between the parties regarding the Award. Except as expressly set forth
herein, this Agreement (and any provision of this Agreement) may not be modified, changed, clarified, or
interpreted by the parties, except in a writing specifying the modification, change, clarification, or
interpretation, and signed by a duly authorized Company officer.
15. 	Succession. This Agreement shall be binding upon and operate for the benefit of the Company and its
successors and assigns, and the Employee, the Employee’s Representative, and the person or persons to
whom rights under the Award have passed by will or the laws of descent or distribution.
16. 	Compliance with Applicable Laws and Regulations. The Company shall not be required to issue or
deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state
securities and other laws (including any registration requirements or tax withholding requirements) and
compliance with the rules and practices of any stock exchange upon which the Company’s Shares are listed.
Furthermore, if the Employee relocates to another country, the Company may establish special or alternative
terms and conditions as necessary or advisable to comply with local law, facilitate the administration of the
Program and/or accommodate the Employee’s relocation.
17. 	Code Section 409A. The Award is intended to be exempt from the requirements of Code Section 409A.
The Program and this Agreement shall be administered and interpreted in a manner consistent with this
intent. If the Company determines that the Award is subject to Code Section 409A and this Agreement fails
to comply with that section’s requirements, the Company may, at the Company’s sole discretion, and
without the Employee’s consent, amend this Agreement to cause it to comply with Code Section 409A or
otherwise be exempt from Code Section 409A.
Although this Agreement and the Benefits provided hereunder are intended to be exempt from the
requirements of Code Section 409A, the Company does not represent or warrant that this Agreement or the
Benefits provided hereunder will comply with Code Section 409A or any other provision of federal, state,
local, or non-United States law. None of the Company, its Subsidiaries, or their respective directors,
officers, employees or advisers shall be liable to the Employee (or any other individual claiming a benefit

-- 255 of 409 --

10
through the Employee) for any tax, interest, or penalties the Employee may owe as a result of compensation
paid under this Agreement, and the Company and its Subsidiaries shall have no obligation to indemnify or
otherwise protect the Employee from the obligation to pay any taxes pursuant to Code Section 409A.
18. 	Determinations. Each decision, determination, interpretation or other action made or taken pursuant to the
provisions of this Agreement by the Company, the Committee or any delegate of the Committee shall be
final, conclusive and binding for all purposes and upon all persons, including, without limitation, the
Company, the Employee, the Employee’s Representative, and the person or persons to whom rights under
the Award have passed by will or the laws of descent or distribution.
19. 	Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, and each other provision of this
Agreement shall be severable and enforceable to the extent permitted by law. To the extent a court or
tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or
unenforceable, in whole or in part, the Company, in its sole discretion, shall have the power and authority to
revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full
extent permitted under local law.
20. 	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
U.S. State of Illinois without giving effect to any state’s conflict of laws principles.
21. 	Venue. For any legal action relating to this Agreement, the parties to this Agreement consent to the
exclusive jurisdiction and venue of the federal courts of the Northern District of Illinois, USA, and, if there
is no jurisdiction in federal court, to the exclusive jurisdiction and venue of the state courts in Lake County,
Illinois, USA.
* 	* 	*
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer as of the
grant date above set forth.
ABBOTT LABORATORIES
By
Robert B. Ford
President and Chief Executive Officer

-- 256 of 409 --

Exhibit 10.66
[Date]
To: 	[Executive]
Re: 	CIC Agreement Extension
Abbott’s Board of Directors recently extended your Change in Control (CIC) agreement. Its term now continues through
December 31, 2022. The CIC agreement provides you with financial, health and welfare benefits in the event of a Change in
Control. No action is required on your part to continue participation in the CIC agreement.
You are hereby notified that your current Change in Control Agreement, which was set to expire on December 31, 2020, has
been extended to December 31, 2022.
Please retain a copy of this Notification of Extension with your important records.

-- 257 of 409 --

Exhibit 10.68
TIME SHARING AGREEMENT
This Time Sharing Agreement ("Agreement") is dated as of _______________, 2020 by and between Abbott
Laboratories Inc. ("Company") and ________________ ("Executive").
RECITALS
WHEREAS, Company owns or rightfully possesses and operates the aircraft set forth in Exhibit A attached
hereto (individually and collectively, as the context requires, the "Aircraft"); and
WHEREAS, Company employs a fully qualified flight crew to operate the Aircraft; and
WHEREAS, Executive is ____________ of Abbott Laboratories, an Illinois corporation ("Abbott") and the parent
corporation of Company; and
WHEREAS, in order to protect the safety and security of Executive and maximize his/her availability to carry out
his/her responsibilities, Abbott's Board of Directors (the "Board") has adopted a policy that generally requires
Executive to travel on the Aircraft for all his/her air travel, whether on Abbott business or personal travel; and
WHEREAS, Executive desires to use, and the Company desires to make available to Executive, the Aircraft from
time to time on a time sharing basis permitted by the Federal Aviation Regulations ("FARs") when he/she is
required under the Board's policy to fly on the Aircraft for personal travel.
NOW, THEREFORE, in consideration of the foregoing, and the other promises contained herein, the parties,
intending to be legally bound hereby, agree as follows:
1. Provision of Aircraft. Company agrees to provide the Aircraft to Executive on a non-exclusive, time sharing
basis from time to time as mutually agreed between the parties pursuant to the provisions of FAR
Sections 91.501(b)(6), 91.501(c)(1) and 91.501(d) and to provide a fully qualified flight crew for all operations
conducted under this Agreement.
2. Term. This Agreement shall remain in effect until terminated by either party upon ten (10) days’ prior written
notice to the other or as otherwise set forth in Section 17.
3. Reimbursement of Expenses. For each flight conducted under this Agreement, Executive shall pay to
Company an amount equal to the lesser of:
(a) the actual expenses of each flight up to the amount authorized by FAR Part 91.501(d) as set forth
below:
(i) Fuel, oil, lubricants, and other additives;
(ii) Travel expenses of the crew, including food, lodging and ground transportation;
(iii) Hangar and tie-down costs away from the Aircraft's base of operation;
(iv) Insurance obtained for the specific flight;
(v) Landing fees, airport taxes and similar assessments;
(vi) Customs, foreign permits, and similar fees directly related to the flight;
(vii) In-flight food and beverages;
(viii) Passenger ground transportation; and
(ix) Flight planning and weather contract services.
(collectively, the "501(d) Amount"); and

-- 258 of 409 --

2
(b) the greater of (x) or (y) below, where:
(x) equals the applicable subsection (i) or (ii) below:
(i) For travel between cities served by regularly scheduled first class commercial airline
service, an amount equal to the lowest published cost of the first class airfare available to the
general public for the dates traveled, which will be solicited within one business day of the date the
Executive requests the specific flight, multiplied by the number of persons in Executive's party for
the flight; or
(ii) For travel between cities served by regularly scheduled coach or business class, but
not first class commercial airline service, an amount equal to the lowest published cost of the
unrestricted coach (or, if available, business class) airfare available to the general public for the
dates traveled, which will be solicited within one business day of the date the Executive requests
the specific flight, multiplied by the number of persons in Executive's party for the flight.
For purposes of the computation in subsection (x)(i) and (x)(ii) above, if a city is not served by
regularly scheduled commercial airline service, the foregoing provisions shall be applied utilizing a
city selected by Company as close as reasonably practicable to the city without such service.
The amount calculated under this Section 3(b)(x) shall be referred to as the "Commercial Fare
Amount"
(y) equals the amount of income that would be imputed to Executive for the flight under the
applicable Standard Industry Fare Levels as set forth in 26 C.F.R. §1.61-21(g), assuming that Executive
did not pay the Time Sharing Fee ("SIFL Amount").
The amount to be paid by Executive under this Section 3 shall be referred to as the "Time Sharing Fee"
regardless of the provision under which it was calculated. The Time Sharing Fee shall never exceed the amount
permitted under FAR Section 91.501(d).
(c) Prior to any proposed flight, Company shall provide Executive with an estimate of the Time Sharing
Fee that will be due for such flight. If Executive proceeds with the proposed flight, he/she shall be obligated to
pay the Time Sharing Fee. Notwithstanding anything to the contrary herein, upon receipt of all invoices related to
the flight(s), Company shall calculate the actual expenses for which reimbursement is permitted under FAR
Section 91.501(d) and shall reconcile it with the payments received from Executive for such flight(s). In the event
Executive has paid more than the amount permitted under FAR Section 91.501(d), Company shall credit such
excess amount to Executive. Company's calculation of the 501(d) Amount, the Commercial Fare Amount, and
the SIFL Amount, as well as its determination of which calculation will be used for the Time Sharing Fee, shall be
conclusive subject only to the limitation on the permissible reimbursements as set forth in FAR Section 91.501(d).
If Executive declines the proposed flight(s), neither Executive nor Company shall have any further obligation with
respect to the proposed flight(s).
4. Invoicing and Payment.
(a) Company will pay all expenses related to the operation of the Aircraft when incurred and, within thirty
(30) days after the end of each calendar month, provide an invoice to Executive for the total Time Sharing Fee
due for the personal flights operated for Executive during the preceding calendar month (plus associated taxes,
charges and fees, including but not limited to federal air transportation excise taxes, international
departure/arrival fees, and state taxes, that are required to be collected from passengers and remitted by the
aircraft operator ("Taxes")). Executive shall pay

-- 259 of 409 --

3
Company the amount set forth therein within thirty (30) days after the date of such invoice. In the event that
flights that are part of a single trip occur in more than one (1) calendar month, Company shall have the option
each such time, exercisable in its sole discretion, to invoice the flights based on the months in which they occur
or based on the month in which the final flight of the trip was operated.
(b) In the event that Company has not received supplier invoices for reimbursable charges listed in
Section 3(a) above relating to flight(s) prior to the issuance of its invoice, Company shall have the right, following
receipt of such supplier invoices, if any, to issue supplemental invoice(s) for such charge(s) to Executive or to
include such charges on the next subsequent invoice and the amount set forth therein shall be paid in the same
manner as set forth in Section 4(a).
(c) Executive shall have the right to advance to Company an amount to be held by Company to be
credited to such future flights under this Agreement as designated by Executive. Company acknowledges and
agrees that such advance payment is held on behalf of Executive and is not the property of Company until it has
operated the flight(s) to which the payments will be applied and that if any such advanced funds remain at the
termination of this Agreement, the balance shall be refunded to Executive, less any outstanding amounts due to
Company for flights performed prior to such termination.
5. Flight Requests. Executive will provide Company with requests for flight time and proposed flight schedules
as far in advance of any given flight as possible, and in any case, at least two (2) business days in advance of
Executive's planned departure (unless Company agrees to a shorter notice in a particular case in its discretion).
Requests for flight time shall be in a form, whether written or oral, mutually convenient to, and agreed upon, by
the parties. In addition to the proposed schedules and flight times, Executive shall provide at least the following
information for each proposed flight prior to scheduled departure as required by the Company or Company's
flight crew:
(a) proposed departure point;
(b) destination;
(c) date and time of flight;
(d) the number, name, and relationship to the Executive of anticipated passengers;
(e) the nature and extent of luggage and/or cargo to be carried;
(f) the date and time of return flight, if any; and
(g) any other information concerning the proposed flight that may be pertinent or required by Company or
Company's flight crew.
6. Aircraft Schedule. Company shall have final authority over the scheduling of the Aircraft; provided, however,
that Company will use reasonable efforts to accommodate Executive's requests and to avoid conflicts in
scheduling. It is understood that Company shall not be obligated to retain or contract for additional flight crew or
maintenance personnel or equipment in order to accommodate Executive's schedule requests or provide a
specific Aircraft.
7. Maintenance. Company shall be solely responsible for securing maintenance, preventive maintenance, and
required or otherwise necessary inspections on the Aircraft, and shall take such requirements into account in
scheduling the Aircraft. No period of maintenance, preventative maintenance, or inspection shall be delayed or
postponed for the purpose of scheduling the Aircraft, unless said maintenance or inspection can be safely
conducted at a later time in compliance with all applicable laws and regulations, and within the sound discretion
of the pilot in command. The pilot in command shall have final and complete authority to cancel any flight for any
reason or condition that in his or her judgment would compromise the safety of the flight.

-- 260 of 409 --

4
8. [Intentionally Left Blank]
9. Operational Control and Authority.
(a) Company shall ensure that each flight conducted for Executive under this Agreement shall be
conducted under Part 91 of the FARs. The Company shall have and exercise exclusive operational control of the
Aircraft during all phases of all flights under this Agreement, including, without limitation, all flights during which
Executive and/or his/her guests, designees, or property are on-board the Aircraft, and during all pre- and post-
flight checks.
(b) In accordance with applicable FARs, the qualified flight crew provided by Company will exercise all of
its duties and responsibilities in regard to the safety of each flight conducted hereunder. Executive specifically
agrees that the flight crew, in its sole discretion, may terminate any flight, refuse to commence any flight, or take
other action that, in the considered judgment of the pilot in command, is necessitated by considerations of safety.
No such action of the pilot in command shall create or support any liability for loss, injury, damage or delay to
Executive or any other person. The parties further agree that Company shall not be liable for delay or failure to
furnish the Aircraft and crew pursuant to this Agreement for any reason whatsoever.
10. Insurance; Limitation of Liability; Indemnification.
(a) Company will maintain or cause to be maintained in full force and effect throughout the term of this
Agreement aircraft liability insurance in respect of the Aircraft. Such insurance shall (i) name Executive as an
additional insured; (ii) contain a waiver of subrogation against Executive; and (iii) shall contain an agreement by
the insurer that, notwithstanding the deletion, cancellation or material change in coverage, lapse of any such
policy for any reason or any right of cancellation by the insurer or Company, as applicable, such policy shall
continue in force for the benefit of Executive for at least thirty (30) days (ten (10) days in the case of non-payment
of premium and seven (7) days in the case of war risk) after written notice of deletion, cancellation, or material
change in coverage, lapse of coverage or cancellation, shall have been given to Executive.
(b) Company will use reasonable commercial efforts to procure such additional insurance coverage as
Executive shall request; provided, however, that the cost of such additional insurance shall be borne by
Executive as set forth in Section 3(a)(iv).
(c) Company assumes and shall bear the entire risk of loss, theft, confiscation, damage to, or destruction
of the Aircraft. Company shall release, indemnify, defend, and hold harmless Executive and his/her heirs,
executors and personal representatives from and against any and all losses, liabilities, claims, judgments,
damages, fines, penalties, deficiencies, and expenses (including, without limitation, reasonable attorneys' fees
and expenses) incurred or suffered by Executive on account of a claim or action made or instituted by a third
person arising out of or resulting from operations of the Aircraft hereunder and/or any services provided by
Company to Executive hereunder, except to the extent attributable to the gross negligence or willful misconduct
of Executive or his/her guests on the Aircraft.
11. Representations and Warranties. Executive warrants that:
(a) He/she will use the Aircraft for and on account of his/her own business or personal use only, and will
not use the Aircraft for the purpose of providing transportation of passengers or cargo in air commerce for
compensation or hire;
(b) He/she will not permit, and will refrain from incurring, any lien, security interest or other charge or
encumbrance on the Aircraft as a result of Executive's (or his/her invitees' or guests') acts

-- 261 of 409 --

5
or omissions, whether permissible or impermissible under this Agreement, and shall not attempt or take (or
permit to be attempted or taken) any action that could be deemed to convey, mortgage, assign, lease, or any way
alienate the Aircraft or Company's rights hereunder or that might mature into any such prohibition; and
(c) During the term of this Agreement, he/she will, and will cause his/her invitees and guests to abide by
and conform to all such laws, governmental and airport orders, rules, and regulations as shall from time to time
be in effect relating in any way to the operation and use of the Aircraft under Part 91 of the FARs.
12. Aircraft Base. For purposes of this Agreement, the permanent base of operation of the Aircraft shall be
Waukegan, Illinois; provided, however, such base may be changed upon notice from Company to Executive.
13. Notices and Communications. All notices, reports, and other communications under this Agreement shall
be in writing (except as permitted in Section 5) and shall be deemed to have been duly given upon receipt or
refusal to accept receipt when given by personal delivery, the next business day when given by reputable
overnight courier service, addressed as follows:
If to Company: 	Abbott Laboratories Inc.
Attn:
Phone:
Fax:
email:
If to Executive:
Phone:
Fax:
email:
or to such other person or address as either party shall from time to time designate in writing to the other party.
14. Assignments. Neither this Agreement nor any party's interest herein shall be assignable to any other party
whatsoever without the other party's prior written consent. Without limiting the generality of the preceding
sentence, this Agreement shall inure to the benefit of and be binding upon the parties hereto, in the case of
Company, to its successors and permitted assignees and in the case of Executive, to Executive's, his/her heir(s).
15. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the
State of Illinois.
16. Further Acts. Company and Executive shall from time to time perform such other and further acts and
execute such other and further instruments as may be required by law or may be reasonably necessary (i) to
carry out the intent and purpose of this Agreement and (ii) to establish, maintain, and protect the respective rights
and remedies of the other party.

-- 262 of 409 --

6
17. Termination. This Agreement shall automatically terminate when Executive is no longer an officer of
Company or upon death of Executive. This Agreement may be terminated as a result of a breach by either party
of its obligations under this Agreement on ten (10) days' prior written notice by the non-breaching party to the
breaching party or such other period as may be required to comply with applicable laws, regulations, or insurance
requirements, or in the event that the insurance required hereunder is not in full force and effect.
18. Severability. If any provision of this Agreement is held to be illegal, invalid, or unenforceable in any
jurisdiction, such provision shall, as to such jurisdiction, be ineffective to the extent of such prohibition or
unenforceability without invalidating the remaining provisions hereof. To the extent permitted by applicable law,
each party waives any provision of law that renders any provision hereof prohibited or unenforceable in any
respect.
19. Amendment or Modification. This Agreement constitutes the entire agreement between the parties with
respect to the subject matter hereof and is not intended to confer upon any person or entity any rights or
remedies hereunder which are not expressly granted herein. This Agreement may be amended or modified only
in writing duly executed by the parties hereto.
20. Waivers. The failure or delay on the part of any party hereto to insist upon or enforce strict performance of
any provision of this Agreement by any other party hereto, or to exercise any right, power or remedy under this
Agreement, shall not be deemed or construed as a waiver thereof, nor shall it be deemed or construed as a
general waiver thereof or of any other provision or rights thereunder.
21. Force Majeure. Company shall not be liable for delay or failure to furnish the Aircraft and crew pursuant to
this Agreement when scheduled when such failure is caused by government regulation or authority, mechanical
difficulty, or breakdown, war, civil commotion, strikes or labor disputes, weather conditions, acts of God, or other
circumstances beyond Company’s reasonable control.
22. Counterparts. This Agreement may be executed by the parties hereto on any number of separate
counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall
together constitute but one and the same instrument.
23. Survival. The provisions set forth in Sections 3, 4, 9, 10, 11 and 13-24 shall survive termination of this
Agreement.
[REMAINDER OF PAGE INTENTIONALLY BLANK]

-- 263 of 409 --

Signature Page
24. TRUTH IN LEASING STATEMENT
TRUTH IN LEASING STATEMENT UNDER SECTION 91.23 OF THE FEDERAL AVIATION REGULATIONS.
COMPANY HEREBY CERTIFIES THAT THE AIRCRAFT HAS BEEN INSPECTED AND MAINTAINED WITHIN
THE TWELVE (12) MONTH PERIOD PRECEDING THE DATE OF THIS AGREEMENT, OR SUCH SHORTER
PERIOD AS COMPANY SHALL HAVE HAD POSSESSION OF THE AIRCRAFT, IN ACCORDANCE WITH THE
PROVISIONS OF FAR PART 91 AND ALL APPLICABLE REQUIREMENTS FOR MAINTENANCE AND
INSPECTION THEREUNDER HAVE BEEN MET.
COMPANY AGREES, CERTIFIES, AND KNOWINGLY ACKNOWLEDGES THAT WHEN THE AIRCRAFT IS
OPERATED UNDER THIS AGREEMENT, COMPANY SHALL BE KNOWN AS, CONSIDERED, AND SHALL IN
FACT BE THE OPERATOR OF THE AIRCRAFT AND THAT THE AIRCRAFT WILL BE MAINTAINED AND
INSPECTED UNDER PART 91 OF THE FARS.
Abbott Laboratories Inc.
By:
Name:
Title:
THE PARTIES UNDERSTAND THAT AN EXPLANATION OF FACTORS AND PERTINENT FEDERAL AVIATION
REGULATIONS BEARING ON OPERATIONAL CONTROL CAN BE OBTAINED FROM THE RESPONSIBLE
FAA FLIGHT STANDARDS OFFICE. OPERATOR AGREES TO SEND AN EXECUTED COPY OF THIS
EXECUTED AGREEMENT FOR AND ON BEHALF OF BOTH PARTIES TO: AIRCRAFT REGISTRATION
BRANCH (AFS-750), ATTN: TECHNICAL SECTION, P.O. BOX 25724, OKLAHOMA CITY, OKLAHOMA 73125,
WITHIN TWENTY-FOUR (24) HOURS OF ITS EXECUTION, AS PROVIDED BY FAR §91.23(c)(1).
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.
COMPANY: 	EXECUTIVE:
ABBOTT LABORATORIES INC.
By: 	By:
Name: 	Name:
Title:

-- 264 of 409 --

Exhibit A
Exhibit A
List of Aircraft

-- 265 of 409 --

Exhibit 10.74
ABBOTT OVERSEAS
MANAGERS PENSION PLAN
ARTICLE 1
INTRODUCTION
1.1 	Purpose. The Abbott Overseas Managers Pension Plan provides retirement income to Participants, none of
whom are United States citizens (other than designated Overseas Managers who are United States citizens and for whom the
Company or an Affiliate provides tax equalization based on Puerto Rico tax law) or Residents.
1.2 	History, Effective Date. The Plan was established on June 1, 1965, amended and restated in its entirety,
effective as of January 1, 1976, revised at various times thereafter, amended and restated, effective as of January 1, 2010,
and hereby amended and restated in its entirety, effective as of January 1, 2020 (the “Effective Date”).
1.3 	ERISA. The Plan is intended to be exempt from Parts 2, 3, and 4 of Title I of ERISA and, therefore,
participation in the Plan is limited to a select group of management or highly compensated employees, within the meaning of
Sections 201(2), 301(a)(3) and 401(a)(1) of ERISA.

-- 266 of 409 --

ARTICLE 2
DEFINITIONS
When used in this Plan, including its appendices, the following words and terms shall have the meanings set forth
below, unless a different meaning clearly is required by the context. Whenever appropriate, words in the singular shall be
deemed to include the plural, and vice versa, and the masculine gender shall be deemed to include the feminine gender,
unless a different meaning is clearly required by the context.
2.1 	Administrator. “Administrator” means the Company’s Divisional Vice President, Compensation and
Benefits. If the office of Divisional Vice President, Compensation and Benefits is vacant or ceases to exist, then the person
performing the duties previously performed by the Company’s Divisional Vice President, Compensation and Benefits shall
be the Administrator.
2.2 	Affiliate. “Affiliate” means any corporation, partnership, joint venture, business trust or other entity 50
percent or more of the voting stock or control of which is owned, directly or indirectly, by the Company.
2.3 	Annuity Retirement Plan. “Annuity Retirement Plan” means the Abbott Laboratories Annuity Retirement
Plan, as amended from time to time.
2.4 	Beneficiary. “Beneficiary” means the person, persons or entity designated under the Plan pursuant to
Section 6.1 or Section 6.2.
2.5 	Code. “Code” means the Internal Revenue Code of 1986, as amended, and any regulations promulgated
thereunder. Any reference to any section or subsection of the Code also refers to any comparable or succeeding provisions of
any legislation which amends, supplements, or replaces such section or subsection.
2.6 	Company. “Company” means Abbott Laboratories, its successors, any organization into which or with
which Abbott Laboratories may merge or consolidate.
2.7 	Effective Date. The term “Effective Date” shall have the meaning ascribed to it in Section 1.2.
2.8 	ERISA. “ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and any
regulations promulgated thereunder. Any reference to any section or subsection of ERISA also refers to any comparable or
succeeding provisions of any legislation which amends, supplements, or replaces such section or subsection.
2.9 	Overseas Manager. “Overseas Manager” means an employee of the Company or an Affiliate, provided such
employee is not a United States citizen (other than a designated employee who is a United States citizen and for whom the
Company or an Affiliate provides tax equalization based on Puerto Rico tax law) or a Resident.
2.10 	Participant. “Participant” means an Overseas Manager who is participating in the Plan pursuant to Article
3.
2.11 	Plan. “Plan” means the Abbott Overseas Managers Pension Plan, as amended from time to time.

-- 267 of 409 --

2.12 	Resident. “Resident” means any individual who is considered to be a resident under Code Section 7701(b).
2.13 	Retirement Date. “Retirement Date” shall have the meaning ascribed to it in Section 3.6 of the Annuity
Retirement Plan, unless otherwise required under Appendix B “Code Sections 409A and 457A.”
2.14 	Retirement Benefit. The term “Retirement Benefit” shall have the meaning ascribed to it in Section 4.1(a)
or Section 4.1(h), as applicable, unless otherwise required under Appendix B “Code Sections 409A and 457A.”
2.15 	Social Insurance Benefits. The term “Social Insurance Benefits” shall have the meaning ascribed to it in
Section 4.1(c).
2.16 	Termination Date. “Termination Date” means the last day on which the Participant is an employee of the
Company and all its Affiliates, as determined in each case without including any required advance notice period and
irrespective of the status of the termination under local law. A transfer from one Affiliate to another, or from the Company
to an Affiliate or from an Affiliate to the Company, will not be considered a termination of employment for purposes of the
Plan.
2.17 	U.S. Dollars. “U.S. Dollars” means lawful currency of the United States.

-- 268 of 409 --

ARTICLE 3
ELIGIBILITY AND PARTICIPATION
3.1 	Eligibility and Participation. Participation in the Plan shall be limited to Overseas Managers designated, in
writing, by the Administrator, in its sole discretion.
3.2 	Commencement and Duration of Participation.
(a) 	Commencement. The Administrator, in its sole discretion, shall determine the date on which a
Participant’s participation commences.
(b) 	Duration. A Participant will remain a Participant until the earliest of:
(i) 	The date the Participant first becomes a United States citizen (unless the Participant is a
United States citizen for whom the Company or an Affiliate provides tax equalization based on Puerto Rico
tax law) or Resident;
(ii) 	The date the Participant’s contributions are withdrawn pursuant to Section 4.2; or
(iii) 	The date determined by the Administrator, in the Administrator’s sole discretion.

-- 269 of 409 --

ARTICLE 4
BENEFITS
4.1 	Amount, Timing, and Form of Retirement Benefit.
(a) 	Amount. Subject to the provisions of this Section 4.1, commencing on the Participant’s Retirement
Date, a Participant will receive a defined benefit pension in an amount equal to the defined benefit pension the
Participant would have received under the Annuity Retirement Plan had the Participant terminated employment as
an Annuity Retirement Plan participant instead of as a Plan Participant; provided, however, that the benefit received
under the Plan shall be calculated without considering eligibility for payments under the Social Security laws of the
United States, shall be calculated without regard to applicable limitations and restrictions imposed under Code
Sections 415 and 401(a)(17) on pensionable earnings and benefits, and shall be reduced by both:
(i) 	the value of any Social Insurance Benefits (as defined below) to which the Participant is
entitled at the Participant’s Retirement Date, or will subsequently be entitled; and
(ii) 	the value of any other retirement benefits payable financed by the Company or any
Affiliate or other source to which one or more of the Company and Affiliates may have contributed.
The Administrator in its sole discretion shall determine the value of any retirement benefits payable, as described in
this Section 4.1(a), and that determination will be final and binding on all Participants and Beneficiaries. The
Administrator shall make any adjustments the Administrator considers necessary, in its sole discretion, to prevent
duplication of benefits.
The benefit determined under this Section 4.1(a) (the “Retirement Benefit”) will be calculated as of the
Participant’s Retirement Date and the amount payable will not be adjusted thereafter for changes in the value of
benefits or offsets.
(b) 	Determination of Final Earnings. For purposes of determining a Participant’s Retirement Benefit,
the Participant’s “final earnings” will be the average of the Participant’s monthly earnings for the 60 consecutive
calendar months during which the Participant received monthly earnings and for which the Participant’s monthly
earnings were highest (or the average of the Participant’s monthly earnings for the entire consecutive month period
during which the Participant received monthly earnings if such period is less than 60 calendar months), as reflected
in the records of the Company and Affiliates. Such average shall be computed by dividing the total of the
Participant’s monthly earnings for such 60-calendar-month period (or shorter total period if applicable) by 60 (or by
the number of consecutive months within that shorter period for which the Participant had monthly earnings). Such
monthly earnings will be computed in U.S. Dollars unless the Administrator, in the Administrator’s sole discretion,
determines that a different currency is more appropriate. For this purpose, “monthly earnings” will be exclusive of
any allowances, 13th month salary, holiday pay, vacation pay, garden leave payments, redundancy payments,
severance or termination payments or indemnity, or disability payments, unless the Administrator in its sole
discretion otherwise specifically agrees.
(c) 	Definition of “Social Insurance Benefits.” For purposes of Section 4.1(a)(i) and (h)(i), the term
“Social Insurance Benefits” shall mean benefits, whether payable periodically or

-- 270 of 409 --

in one lump sum, and shall include, but not be limited to, the following: severance payments on retirement;
provident fund payments, retirement or long-service benefits payable under any national or other government
sponsored public social security systems or program; any severance payments to which an employer contributed
upon transfer of the employee from one Affiliate to another or from the Company to an Affiliate or from an Affiliate
to the Company, plus interest from the date of payment; and any benefits of a similar type as determined by the
Administrator, in the Administrator’s discretion. The Administrator in its sole discretion shall determine the value
of any Social Insurance Benefit and that determination will be final and binding on all Participants and
Beneficiaries.
(d) 	Return of Employee Contributions upon Retirement Date. If the Participant’s benefit is reduced as
specified in Section 4.1(a), then the Participant will be returned a percentage of the Participant’s total Plan
contributions, if any, equal to the percentage by which the Participant’s benefit is reduced plus 50 percent of this
amount. If no Retirement Benefit is payable, then an amount equal to 150 percent of the Participant’s total
contributions, if any, will be returned to the Participant.
(e) 	Vesting of Benefits. The Administrator, in its sole discretion, shall determine each Participant’s
vested interest in the Retirement Benefit.
(f) 	Form of Benefit Payment. The form in which a Participant’s Retirement Benefits are paid shall be
determined as if the Participant was a participant in the Annuity Retirement Plan (unless otherwise required under
Appendix B “Code Sections 409A and 457A”); provided, however, that neither a 75 percent joint and survivor
annuity option nor a level income option shall be available under the Plan. Notwithstanding the foregoing, the
Administrator, in the Administrator’s sole discretion, may vary the form in which a Participant’s Retirement Benefits
may be paid.
(g) 	No Post-Retirement Medical Benefits. Notwithstanding anything to the contrary in the Plan or the
Annuity Retirement Plan, a Participant shall not be entitled to any post-retirement medical benefits under the Plan.
(h) 	Designated Executive Benefits. Notwithstanding any provision to the contrary in the Plan, the
Annuity Retirement Plan or the Abbott Laboratories Supplemental Pension Plan (the “SERP”), an Overseas
Manager who is a corporate officer of the Company (as described in Section 6-1 of the SERP) and who is designated
as a Participant pursuant to Section 3.1 (“Designated Executive“) shall be entitled to receive a Retirement Benefit
calculated under this Section 4.1(h) in lieu of the Retirement Benefit calculated under Section 4.1(a) above.
Subject to the other provisions of this Section 4.1, commencing on the Designated Executive’s Retirement Date, a
Designated Executive will receive a defined benefit pension in an amount equal to the total defined benefit pension
the Designated Executive would have received under both the Annuity Retirement Plan and the SERP (including a
determination of “final earnings” pursuant to the rules set forth in the SERP) had the Designated Executive
terminated employment as a participant under such plans instead of as a Plan Participant; provided, however, that the
Designated Executive shall not be entitled to elect to receive current payment of the present value of the
supplemental pension (as described in Section 9 of the SERP); and provided, further, that the benefit received under
the Plan shall be calculated without considering eligibility for payments under the Social Security laws of the United
States, and shall be reduced by both:

-- 271 of 409 --

(i) 	the value of any Social Insurance Benefits (as defined in Section 4.1(c)) to which the
Designated Executive is entitled at the Designated Executive’s Retirement Date, or will subsequently be
entitled; and
(ii) 	the value of any other retirement benefits payable financed by the Company or any Affiliate
or other source to which one or more of the Company and Affiliates may have contributed.
Monthly earnings will be computed in U.S. Dollars (unless the Administrator, in the Administrator’s sole
discretion, determines that a different currency is more appropriate), and will be exclusive of any allowances, 13th
month salary, holiday pay, vacation pay, garden leave payments, redundancy payments, severance or termination
payments or indemnity, or disability payments, unless the Administrator in its sole discretion otherwise specifically
agrees.
The Administrator in its sole discretion shall determine the value of any retirement benefits payable, as
described in this Section 4.1(h), and that determination will be final and binding on all Participants and
Beneficiaries. The Administrator shall make any adjustments the Administrator considers necessary, in its sole
discretion, to prevent duplication of benefits.
The Retirement Benefit described in this Section 4.1(h) will be calculated as of the Designated Executive’s
Retirement Date and the amount payable will not be adjusted thereafter for changes in the value of benefits or
offsets.
4.2 	Repayment of Contributions upon Withdrawal or Termination of Employment. At any time prior to the
Participant’s Retirement Date, upon written notice to the Administrator, a Participant may withdraw an amount equal to all
of the Participant’s contributions, if any, without interest; provided, however, that upon such withdrawal of contributions, the
Participant will no longer be eligible to participate in the Plan, except upon such terms and conditions as the Administrator
in its sole discretion may approve. In the event of voluntary or involuntary termination of employment, or death, before the
Participant’s Retirement Date, the Participant or the Participant’s Beneficiary, as the case may be, shall be entitled to receive,
in lieu of all other benefits, an amount equal to 150 percent of all contributions, if any, made by the Participant. A transfer
from one Affiliate to another, or from the Company to an Affiliate or from an Affiliate to the Company, will not be
considered a termination of employment for purposes of the Plan.
4.3 	Tax Withholding. The Company or an Affiliate, as applicable, may deduct from any Retirement Benefit an
amount equal to any tax or duty of whatever nature for which it or the Participant may be accountable in consequence of
such Retirement Benefit.
4.4. 	Sanctioned Countries. Notwithstanding any provision in the Plan, no payment shall be made to any
Participant or Beneficiary, if such payment would be considered a payment to a sanctioned country pursuant to the United
States Department of Treasury Office of Foreign Asset Control boycott list, or a similar boycott list published by the United
States or other countries, as determined by the Administrator in its sole discretion.

-- 272 of 409 --

ARTICLE 5
SOURCE OF BENEFIT PAYMENTS
5.1 	Prior Participant Contributions. Prior to October 1, 1989, certain Participants were required to make
contributions to the Plan. Effective on and after October 1, 1989, Participant contributions are neither required nor permitted.
5.2 	Unfunded Plan. The Plan is unfunded. All Retirement Benefits and other payments hereunder shall be
made from the general funds of the Company and no special or separate fund shall be established or other segregation of
assets made to assure payment. No Participant, Beneficiary, or other person shall have under any circumstances any interest
in any particular property or assets of the Company or any Affiliate as a result of participating in the Plan.

-- 273 of 409 --

ARTICLE 6
BENEFICIARY DESIGNATIONS
6.1 	Beneficiary Designation. Each Participant shall have the right, at any time, to designate any person, persons
or entity as such Participant’s Beneficiary or Beneficiaries. A Beneficiary designation shall be made, and may be amended,
by the Participant by filing a designation with the Administrator, on such form and in accordance with such procedures as
the Administrator in its sole discretion may establish from time to time.
6.2 	Failure to Designate a Beneficiary. If a Participant fails to designate a Beneficiary as provided in Section
6.1, or if all designated Beneficiaries predecease the Participant, then the Participant’s Beneficiary shall be deemed to be, in
the following order:
(a) 	the surviving spouse of such person, if any; or
(b) 	the Participant’s estate.
6.3 	Facility of Payment. When, in the Administrator’s opinion, a Participant or Beneficiary is under a legal
disability or is incapacitated in any way so as to be unable to manage such Participant’s or Beneficiary’s financial affairs, the
Administrator may make any benefit payments to the Participant or Beneficiary’s legal representative, or spouse, or the
Administrator may apply the payment for the benefit of the Participant or Beneficiary in any way the Administrator, in its
sole discretion, considers advisable.

-- 274 of 409 --

ARTICLE 7
PLAN ADMINISTRATION
7.1. 	Administrator’s Powers. The Administrator shall have full discretionary power to administer the Plan in all
of its details. Benefits under the Plan shall be paid only if the Administrator determines, in the sole discretion of the
Administrator, that the applicant is entitled to them.
7.2 	Administrator’s Discretion. For purposes of exercising the powers and responsibilities granted to the
Administrator under the Plan, the Administrator’s powers shall include, but shall not be limited to, the following
discretionary authority:
(a) 	to make and enforce such rules and regulations (which shall be binding on employees, Overseas
Managers, Participants, Beneficiaries and other persons) as the Administrator deems necessary or proper for the
efficient administration of the Plan or as required to comply with applicable law;
(b) 	to interpret and enforce the Plan in accordance with the terms of the Plan (including the rules and
regulations adopted under Section 7.2(a)) and to make factual determinations thereunder, including the discretionary
power to determine the rights and eligibility of Overseas Managers, Participants, Beneficiaries and any other
persons, and the amount, if any, of their benefits under the Plan, and their vested interest, if any, in any benefits
under the Plan, and to construe or interpret disputed, ambiguous, or uncertain terms;
(c) 	to compute benefit amounts under the Plan, to determine vested interests, to determine the person or
persons to whom such amounts are to be distributed, to establish the currency (if other than U.S. Dollars) in which
benefits are payable and the method and basis on which such currency conversion shall be made, and to make
equitable adjustments for mistakes or errors or to prevent duplication of benefits;
(d) 	to authorize the payment of benefits and to compromise and settle any disputed claims;
(e) 	to keep such records and submit such filings, elections, applications, returns or other documents or
forms as may be required under any applicable laws or regulations;
(f) 	to allocate and delegate the duties and responsibilities of the Administrator and to appoint such
agents, counsel, accountants, consultants, actuaries, insurance companies and other persons as may be required or
desired to assist in administering the Plan;
(g) 	to furnish each employer, tax advisor, or other person with such information and data as may be
required by it for tax and other purposes in connection with the Plan;
(h) 	to vary the terms of the Plan in individual cases; provided, however, that no such variation shall
reduce any Retirement Benefits accrued prior to the date the variation is made; and provided, further, that no such
variation shall violate any applicable nondiscrimination laws; and
(i) 	to take all action in connection with administration of the Plan as deemed necessary or advisable by
the Administrator.
7.3 	Delegation. To the extent permitted under applicable law, the Administrator may delegate the
Administrator’s power, authority and responsibilities under the Plan to one or more officers

-- 275 of 409 --

or employees of the Company or any Affiliate, including a committee of one or more such officers or employees, at any time
in the Administrator’s sole discretion. Any reference to the Administrator in the Plan shall be deemed to include a reference
to the Administrator’s delegate.
7.4 	Effect of Administrator’s Actions. Actions taken in good faith by the Administrator, or by a person to
whom the Administrator’s powers have been duly delegated, shall be binding and conclusive on all parties.
7.5 	Claims and Appeals.
(a) 	Claims for Retirement Benefits. Claims for Retirement Benefits shall be made in accordance with
rules prescribed by the Administrator and shall be adjudicated by a person or persons designated by the
Administrator for the purpose of claims adjudication. The rules governing Claims for Retirement Benefits shall be
as set forth in Appendix A “Claims for Retirement Benefits and Appeals of Benefit Determinations.”
(b) 	Appeals of Benefit Determinations. A Participant, Beneficiary, or other claimant of Retirement
Benefits shall be entitled to appeal a claim decision by submitting an appeal in such form and within such time as the
Administrator may prescribe. Appeals shall be adjudicated by the Administrator, or the Administrator’s delegate,
whose decision shall be binding and conclusive on all parties. The rules governing Claims for Appeals of Benefit
Determinations shall be as set forth in Appendix A “Claims for Retirement Benefits and Appeals of Benefit
Determinations.”

-- 276 of 409 --

ARTICLE 8
AMENDMENT AND TERMINATION
8.1 	Amendment and Termination.
The Company reserves the right and the power (and may and hereby does specifically delegate the power to the
Executive Vice President, Human Resources (or, if no individual holds such title, such individual performing the duties of
such title)) at any time or times to amend the provisions of the Plan, including an amendment to terminate the Plan, to any
extent and in any manner that it may deem advisable.

-- 277 of 409 --

ARTICLE 9
MISCELLANEOUS
9.1 	Employment Rights. The Plan does not constitute a contract of employment, and participation in the Plan
shall not give any employee the right to be retained in the employ of the Company or any Affiliate, or any right or claim to
any benefit under the Plan, unless such right or claim has specifically accrued under the terms of the Plan.
9.2 	Interests Not Transferable. The interests of persons entitled to benefits under the Plan are not subject to
their debts or other obligations and, except as may be required by the provisions of any applicable law (including a qualified
domestic relations order under Code Section 401(a)(13) as amended from time to time), may not be voluntarily or
involuntarily sold, transferred, alienated, assigned or encumbered.
9.3 	Successors. The Plan is binding on all persons entitled to benefits hereunder and their respective heirs and
legal representatives, and on the Company, any Affiliate and their successors and assigns.
9.4 	Governing Law. The validity, interpretation, construction and performance of this Plan shall in all respects
be governed by the laws of the State of Illinois, without reference to principles of conflict of law, except to the extent
preempted by U.S. federal law.
9.5 	Personal Data. The rules governing personal data shall be as set forth in Appendix C “Consent to
Collection, Processing and Transfer of Personal Data.”
9.6 	Electronic Delivery. By participating in the Plan or accepting any rights granted under it, each Participant
consents and agrees (i) to electronic delivery of any documents that the Administrator may elect to deliver (including, but
not limited to, Plan documents, account statements, and all other forms of communication) in connection with any
participation in the Plan; (ii) to any and all procedures the Administrator has established or may establish for an electronic
signature system for delivery and acceptance of any such documents that the Administrator may elect to deliver, and agrees
that the Participant’s electronic signature is the same as, and shall have the same force and effect as, the Participant’s manual
signature; (iii) that any such procedures and delivery may be effected by a third party engaged by the Company, including
the Administrator, to provide administrative services related to the Plan; and (iv) to be informed about the risks associated
with the communication by way of unsecured e-mail, and to being a recipient of such e-mail.
9.7 	Rules for Certain Jurisdictions. Notwithstanding anything in the Plan to the contrary, the Administrator
may, in its sole discretion: (i) amend or vary the terms of the Plan in order to conform such terms with the requirements of
each jurisdiction where the Company and its Affiliates are located; (ii) amend or vary the terms of the Plan in each
jurisdiction where the Company and its Affiliates are located as the Administrator considers necessary or desirable to take
into account or to mitigate or reduce the burden of taxation and social security contributions for Participants and/or the
Company or its Affiliates; and (iii) amend or vary the terms of the Plan in a jurisdiction where the Company or any of its
Affiliates are located as the Administrator considers necessary or desirable to meet the goals and objectives of the Plan. The
Administrator may, in the Administrator’s sole discretion, establish one or more sub-plans for these purposes. Any sub-
plans and modifications to Plan terms and procedures established under this Section 9.7 by the Administrator shall be
attached to the Plan document as Appendices or shall be reflected in the Plan’s rules and regulations. The Administrator
may, in the Administrator’s sole

-- 278 of 409 --

discretion, establish administrative rules, regulations and procedures to facilitate the operation of the Plan in such
jurisdictions.

-- 279 of 409 --

APPENDIX A
CLAIMS FOR RETIREMENT BENEFITS AND APPEALS OF BENEFIT DETERMINATIONS
This Appendix A contains rules governing claims for Retirement Benefits and appeals of Retirement Benefit
determinations. Unless otherwise defined in this Appendix A, all capitalized terms contained in this Appendix A shall have
the same meaning as set forth in the Plan.
A-1 	Claims for Retirement Benefits.
(a) 	Form of Claims. All claims for Retirement Benefits shall be submitted in writing to the Administrator on a
form and in a manner specified by the Administrator in its discretion. To consider a claim for Retirement Benefits, the
Administrator may request additional information.
(b) 	Time to Decide Claim. If a claim is wholly or partially denied, the Administrator shall notify the claimant
of the adverse decision within a reasonable period of time, but not later than 90 days after receiving the claim, unless the
Administrator determines that special circumstances require an extension. In such case, a written extension notice shall be
furnished to the claimant before the end of the initial 90-day period. The extension cannot exceed 90 days from the end of
the initial 90-day period. The extension notice shall indicate the special circumstances requiring an extension of time and
the date by which the Administrator expects to render the decision. The time for making a claim determination shall begin
when a claim is filed, without regard to whether all the information necessary to make a claim determination accompanies
that filing.
(c) 	Notice of Denial of Claim. In the event of a claim denial, the Administrator denial, shall supply the
claimant with the following:
(i) 	An explanation of the specific reason(s) for the denial;
(ii) 	Specific references to the pertinent Plan provisions on which the denial is based;
(iii) 	A description of any additional material or information necessary to establish the claim properly and
an explanation of why such material or information is necessary; and
(iv) 	A description of the Plan’s appeal procedures and time frames, including a statement of the
claimant’s right to bring a civil action under Section 502(a) of ERISA following an adverse decision on appeal.
A-2 	Appeal of Benefit Determinations. A claimant, or a claimant’s authorized representative, may appeal a
denied claim within 60 days after receiving the Administrator’s notice of denial. A claimant may:
(i) 	Submit to the Administrator, for review, written comments, documents, records and other
information relating to the claim;
(ii) 	Request, free of charge, reasonable access to, and copies of, all documents, records and other
information relevant to the claimant’s claim; and
(iii) 	A review on appeal that takes into account all comments, documents, records, and other information
submitted by the claimant, without regard to whether such information was submitted or considered in the initial
claim decision.

-- 280 of 409 --

A-3 	Time to Decide Appeal. The Administrator will make a full and fair review of the appeal and may require
additional documents as it deems necessary in making such a review. A final decision on review shall be made within a
reasonable period of time, but not later than 60 days following receipt of the written request for review, unless the
Administrator determines that special circumstances require an extension. In such case, a written extension notice will be
sent to the claimant before the end of the initial 60-day period. The extension notice shall indicate the special circumstances
and the date by which the Administrator expects to render the appeal decision. The extension cannot exceed a period of 60
days from the end of the initial 60-day period. The appeal time frames begin when an appeal is filed, without regard to
whether all the information necessary to make an appeal decision accompanies the filing. If an extension is necessary
because the claimant failed to submit necessary information, the days from the date the Administrator sends the extension
notice until the claimant responds to the request for additional information shall not be counted as part of the appeal
determination period. The Administrator’s notice of denial on appeal shall include:
(i) 	The specific reason or reasons for denial with reference to those Plan provisions on which the denial
is based;
(ii) 	A statement that the claimant is entitled to receive, upon request and free of charge, reasonable
access to, and copies of all documents, records, and other information relevant to the claimant’s claim; and
(iii) 	A statement describing any voluntary appeal procedures offered by the Plan and the claimant’s right
to obtain the information about such procedures, and a statement of the claimant’s right to bring an action under
Section 502(a) of ERISA.
A-4. 	Limitation on Suits. A Participant must exhaust the administrative remedies under the Plan before bringing
an action for benefits under the Plan. After exhaustion of the Plan’s administrative remedies, a Participant will have the
right to bring a civil action in a U.S. federal court of law under Section 502(a) of ERISA. Any legal action taken against the
Plan, Abbott Laboratories, a participating division, a subsidiary, or any Plan fiduciary (or any of those entities’ directors,
officers, or employees) must be filed in a U.S. federal court no later than the earliest of the following: (a) 90 days after the
Administrator’s final decision regarding the appeal; (b) three years after the date when the Participant submitted an
authorization to commence payment of the Plan benefits at issue in the judicial proceeding; or (c) the statutory deadline for
filing a claim or lawsuit with respect to the benefits at issue in the judicial proceeding as determined by the most analogous
statute of limitations under Illinois law. In no case may a suit or legal action be brought if the claim for benefits was not
made within the time period specified in the claims and appeals procedures. This limitation on suits for benefits applies in
any forum where a claimant initiates a suit or legal action. If a Participant pursues legal action for benefits relating to a
claim under the Plan, the evidence that may be presented will be strictly limited to the documents, information and other
evidence timely presented to the Administrator during the claim and appeal procedures. Unless prohibited by applicable
law, all decisions and communications relating to claims by applications, denials of claims or claims appeals shall be held
strictly confidential by the applicant, the Administrator, and Abbott Laboratories during and at all times after the applicant’s
claim has been submitted.

-- 281 of 409 --

APPENDIX B
CODE SECTIONS 409A AND 457A
This Appendix B contains rules governing Participants who become subject to Code Section 409A or 457A. Unless
otherwise defined in this Appendix B, all capitalized terms contained in this Appendix shall have the same meaning as set
forth in the Plan. Notwithstanding any Plan provision to the contrary, if a Participant is or becomes subject to Code Section
409A or 457A, taking into account any applicable exemptions (the “United States Participant”), then that Participant’s
continued participation and benefits shall be subject to the following rules:
B-1 	Form of Payment. To the extent necessary to comply with Code Section 409A, the form of payment of the
United States Participant’s Retirement Benefit (including the portions accrued both before and after the time the United
States Participant becomes subject to Code Section 409A) shall be as follows:
(a) 	Life Annuity. A United States Participant who is not legally married on such United States
Participant’s Retirement Date (as defined below) shall receive such United States Participant’s Retirement Benefit in
monthly installments payable on a life annuity basis, with the last payment to be made for the month in which such
United States Participant’s death occurs.
(b) 	50% Joint and Survivor Annuity. A United States Participant who is legally married on such
United States Participant’s Retirement Date (as defined below) shall receive a 50% joint and survivor annuity which
is actuarially equivalent to the Retirement Benefit payable to the United States Participant in monthly installments
on a life annuity basis. Such joint and survivor annuity shall consist of reduced monthly installment continuing
during the United States Participant’s lifetime, and if the United States Participant’s spouse is living at the date of
such United States Participant’s death, payment of one-half of such reduced monthly installments to such spouse
until the spouse’s death occurs, with the last payment to be made for the month of the death of the last to die of the
United States Participant and the United States Participant’s spouse.
For purposes of this Appendix B, “Retirement Date” means one of the following dates, as applicable:
(i) 	for a Participant whose employment with the Company and Affiliates terminates after completing
10 years of “seniority service” (as such term is described in the Annuity Retirement Plan) and attaining age 55 (with
respect to Participants hired by the Company or an Affiliate before 2004, age 50), the Participant’s Termination
Date; and otherwise
(ii) 	the date on which the Participant attains age 65.
B-2 	Changing the Form of Payment. In lieu of the form of payment of the Retirement Benefit specified in Rule
B-1 above, a United States Participant may elect, prior to commencement, payment of the Retirement Benefit in an annuity
form permitted by the Administrator which is actuarially equivalent to the form of payment specified in Rule B-1 above,
provided that the scheduled date for the first annuity payment is not changed as a result of such election. For purposes of
this provision, the term “actuarially equivalent” shall have the meaning provided by Treasury Regulation §1.409A-2(b)(2)(ii)
(A), applying reasonable actuarial methods and assumptions, which must be the same for each annuity payment option and
otherwise comply with the rules provided by Treasury Regulation §1.409A-2(b)(2)(ii)(D). An election under this Rule B-2
must be in writing, signed by the United States Participant, and filed with the Administrator at such time and in such manner
as the Administrator shall determine and will be effective only if the United States Participant’s spouse, if any, consents to
the election in writing, and such consent

-- 282 of 409 --

acknowledges the effect of the election and is witnessed by a Plan representative or a notary public. An election under this
Rule B-2 may not be changed after payment of the United States Participant’s Retirement Benefit has commenced.
B-3 	Benefits described in Section 4.1(d), Section 4.1(h) or Section 4.2 of the Plan, if any, shall be paid in
accordance with Rules B-1 and B-2 of this Appendix.
B-4 	Avoidance of Accelerated Taxation and Penalties. To the extent required to avoid accelerated taxation or tax
penalties under Code Section 409A, amounts that would otherwise be payable pursuant to the Plan during the six-month
period immediately following the United States Participant’s termination of employment shall instead be paid on the first
business day after the date that is six months following the United States Participant’s termination of employment (or shall
be paid upon the United States Participant’s death, if earlier), plus interest thereon, at a rate equal to the applicable “Federal
short-term rate” (as defined in Code Section 1274(d)) for the month in which such termination of employment occurs, from
the respective dates on which such amounts would otherwise have been paid until the actual date of payment.
Notwithstanding anything contained herein to the contrary, a United States Participant shall not be considered to have
terminated employment with the Company and Affiliates for purposes of the Plan, and no payments shall be due under the
Plan which are payable upon the United States Participant’s termination of employment, unless the United States Participant
would be considered to have incurred a “separation from service” from the Company and Affiliates within the meaning of
Code Section 409A. The time or schedule of any payment subject to Code Section 409A or amount scheduled to be paid
pursuant to the terms of the Plan may not be accelerated except as otherwise permitted under Code Section 409A. For
purposes of applying the provisions of Code Section 409A, each separately identifiable amount to which a Participant is
entitled under the Plan will be treated as a separate payment, the entitlement to a life annuity will be treated as the
entitlement to a single payment, and, to the extent necessary or advisable, the offsets described in Section 4.1 shall be
limited to the extent required to comply with Code Section 409A.
B-5 	Participants subject to Code Section 457A. If a United States Participant is subject to Code Section 457A in
a calendar year then, to the extent required by Code Section 457A, all allocations made during such calendar year and
earnings credited thereon shall be considered taxable income to the extent vested in such year. Notwithstanding any
provision of the Plan and this Appendix B to the contrary, the Administrator may authorize the payment of amounts in the
year such amounts are included in income under this Rule B-5 unless payment at such time would violate Code Section
409A. Further, to the extent that any prior deferred amounts were attributable to services performed prior to January 1, 2009
and would be required to be distributed prior to January 1, 2018 in order to be exempt from Code Section 457A, such prior
deferred amounts were distributed in 2017.
B-6 	No Guarantee. With respect to any United States Participant, the Plan and the benefits provided hereunder
are intended to comply, to the extent applicable thereto, with Code Sections 409A and 457A, and the provisions of the Plan
shall be interpreted and construed consistent with this intent. Although the Company intends to administer the Plan so that it
will comply with the requirements of Code Sections 409A and 457A, to the extent applicable, neither the Company nor any
Affiliate represents or warrants that the Plan will comply with Code Section 409A or 457A or any other provision of federal,
state, local, or non-United States law. Neither the Company nor its Affiliates, nor any of their respective directors, officers,
employees or advisers, shall be liable to the United States Participant (or any individual claiming a benefit through the
United States Participant) for any tax, interest, or penalties the United States Participant may owe as a result of the Plan, and
the Company and Affiliates shall have no obligation to indemnify or otherwise protect the United States Participant from the
obligation to pay any taxes pursuant to Code Section 409A or 457A.

-- 283 of 409 --

APPENDIX C
CONSENT TO COLLECTION, PROCESSING AND TRANSFER OF PERSONAL DATA
This Appendix C contains rules governing personal data and the collection, processing and transfer of personal
data. Unless otherwise defined in this Appendix C, all capitalized terms contained in this Appendix shall have the same
meaning as set forth in the Plan.
C-1 	Participant Acknowledgment and Consent. The collection, processing and transfer of the Participant’s
personal data are necessary for the administration of the Plan and the Participant’s participation in the Plan. The
Participant’s denial and/or objection to the collection, processing and transfer of personal data may affect the Participant’s
participation in the Plan. As such, the Participant, by participating in the Plan, voluntarily acknowledges and consents
(where required under applicable law) to the collection, use, processing and transfer of personal data as described in this
Appendix C.
C-2 	Collection and Processing of Personal Data. The Company and Affiliates hold certain personal information
about the Participant, including name, home address and telephone number, date of birth, social security number or other
employee identification number, salary, nationality, job title, data about participation in the Plan, details of earnings and
benefits, tax identification number, records relating to working time records, details of any retirement plans or schemes the
Participant participates in, and other appropriate financial and other data, for the purpose of managing and administering the
Plan (“Data”). The Data may be provided by the Participant or collected, where lawful, from third parties, and the Company
and Affiliates will process the Data for the exclusive purpose of implementing, administering and managing the Participant’s
participation in the Plan. The Data processing will take place through electronic and non-electronic means according to
logics and procedures strictly correlated to the purposes for which Data is collected and with confidentiality and security
provisions as set forth by applicable laws and regulations in the Participant’s country of residence. Data processing
operations will be performed minimizing the use of personal and identification data when such operations are unnecessary
for the processing purposes sought. Data will be accessible within the Company’s organization only by those persons
requiring access for purposes of the implementation, administration and operation of the Plan and for the Participant’s
participation in the Plan.
C-3 	Transfer of Personal Data. The Company and Affiliates will transfer Data amongst themselves as necessary
for the purpose of implementation, administration and management of the Participant’s participation in the Plan, and the
Company and Affiliates may each further transfer Data to any third parties assisting in the implementation, administration
and management of the Plan. These recipients may be located in the European Economic Area or elsewhere throughout the
world, such as the United States. By participating in the Plan, the Participant authorizes (where required under applicable
law) the Company and Affiliates and such third parties to receive, possess, use, retain and transfer the Data, in electronic or
other form, for purposes of implementing, administering and managing the Participant’s participation in the Plan.
C-4 	Participant Rights. The Participant may, at any time, exercise the Participant’s rights provided under
applicable personal data protection laws, which may include the right to (a) obtain confirmation as to the existence of the
Data, (b) verify the content, origin and accuracy of the Data, (c) request the integration, update, amendment, deletion, or
blockage (for breach of applicable laws) of the Data, and (d) oppose, for legal reasons, the collection, processing or transfer
of the Data which is not necessary or required for the implementation, administration and/or operation of the Plan and the
Participant’s participation in the Plan. The Participant may seek to exercise these rights by contacting the Participant’s local
human resources manager, the Company’s human resources department or the Administrator.

-- 284 of 409 --

Exhibit 10.75
Execution Version
U.S. $5,000,000,000
FIVE YEAR CREDIT AGREEMENT
Dated as of November 12, 2020
among
ABBOTT LABORATORIES,
as Borrower,
and
VARIOUS FINANCIAL INSTITUTIONS,
as Lenders,
and
JPMORGAN CHASE BANK, N.A.,
as Administrative Agent,
and
BARCLAYS BANK PLC
BANK OF AMERICA, N.A.
and
MORGAN STANLEY SENIOR FUNDING, INC.
as Syndication Agents
JPMORGAN CHASE BANK, N.A.
BARCLAYS BANK PLC
BOFA SECURITIES, INC.
and
MORGAN STANLEY SENIOR FUNDING, INC.
Joint Lead Arrangers and Joint Book Runners

-- 285 of 409 --

i
TABLE OF CONTENTS
Page
ARTICLE I
DEFINITIONS AND ACCOUNTING TERMS
SECTION 1.01 	Certain Defined Terms 	1
SECTION 1.02 	Computation of Time Periods 	24
SECTION 1.03 	Accounting Terms; Interpretative Provisions 	25
SECTION 1.04 	Interest Rates; LIBOR Notification 	25
SECTION 1.05 	Divisions 	26
ARTICLE II
AMOUNTS AND TERMS OF THE ADVANCES
SECTION 2.01 	The Advances 	26
SECTION 2.02 	Making the Advances 	26
SECTION 2.03 	[Reserved] 	28
SECTION 2.04 	Fees 	28
SECTION 2.05
Termination, Reduction or Increase of the Commitments; Extension of the
Commitment Termination Date 	28
SECTION 2.06 	Repayment of Advances 	30
SECTION 2.07 	Interest on Advances 	31
SECTION 2.08 	Interest Rate Determination 	31
SECTION 2.09 	Interest Elections 	32
SECTION 2.10 	Optional Prepayments of Advances 	33
SECTION 2.11 	Increased Costs; Reserves on Eurodollar Rate Loans 	33
SECTION 2.12 	Illegality 	35
SECTION 2.13 	Payments and Computations 	35
SECTION 2.14 	Taxes 	36
SECTION 2.15 	Sharing of Payments, Etc. 	41
SECTION 2.16 	Use of Proceeds 	41
SECTION 2.17 	Evidence of Debt 	41
SECTION 2.18 	Alternate Rate of Interest 	42
SECTION 2.19 	Defaulting Lenders 	43
SECTION 2.20 	Mitigation 	45

-- 286 of 409 --

ii
ARTICLE III
CONDITIONS TO EFFECTIVENESS AND LENDING
SECTION 3.01 	Conditions Precedent to Closing Date 	45
SECTION 3.02 	Conditions Precedent to Each Borrowing 	47
ARTICLE IV
REPRESENTATIONS AND WARRANTIES
SECTION 4.01 	Representations and Warranties of the Borrower 	48
ARTICLE V
COVENANTS OF THE BORROWER
SECTION 5.01 	Affirmative Covenants 	52
SECTION 5.02 	Negative Covenants 	55
SECTION 5.03 	Financial Covenant 	58
ARTICLE VI
EVENTS OF DEFAULT
SECTION 6.01 	Events of Default 	58
ARTICLE VII
THE AGENTS
SECTION 7.01 	Authorization and Action 	61
SECTION 7.02 	Administrative Agent Individually 	61
SECTION 7.03 	Duties of Administrative Agent; Exculpatory Provisions 	61
SECTION 7.04 	Reliance by Administrative Agent 	62
SECTION 7.05 	Delegation of Duties 	63
SECTION 7.06 	Resignation of Administrative Agent 	63
SECTION 7.07 	Non-Reliance on Administrative Agent and Other Lenders 	64
SECTION 7.08 	Indemnification 	64
SECTION 7.09 	Other Agents 	65
SECTION 7.10 	ERISA 	65
ARTICLE VIII
MISCELLANEOUS
SECTION 8.01 	Amendments, Etc. 	66
SECTION 8.02 	Notices, Etc. 	67
SECTION 8.03 	No Waiver; Remedies 	69
SECTION 8.04 	Expenses; Indemnity 	69

-- 287 of 409 --

iii
SECTION 8.05 	Right of Setoff 	72
SECTION 8.06 	Binding Effect 	72
SECTION 8.07 	Assignments and Participations 	72
SECTION 8.08 	Confidentiality 	77
SECTION 8.09 	Governing Law 	78
SECTION 8.10 	Execution in Counterparts 	78
SECTION 8.11 	Electronic Execution of Assignments and Certain Other Documents 	78
SECTION 8.12 	Jurisdiction, Etc. 	78
SECTION 8.13 	Patriot Act Notice 	79
SECTION 8.14 	No Advisory or Fiduciary Responsibility 	79
SECTION 8.15 	Termination of Credit Documents 	80
SECTION 8.16 	Acknowledgment and Consent to Bail-In of Affected Financial Institutions 	80
SECTION 8.17 	Integration 	80
SECTION 8.18 	Waiver of Jury Trial 	81
SCHEDULES
Schedule I 	– 	Commitments
Schedule II 	– 	Administrative Agent’s Office; Certain Addresses for Notices
Schedule 4.01(f) 	– 	Litigation
EXHIBITS
Exhibit A 	– 	Form of Notice of Borrowing
Exhibit B 	– 	Form of Assignment and Acceptance
Exhibits C-1 – C-4 	– 	Forms of U.S. Tax Compliance Certificate

-- 288 of 409 --

FIVE YEAR CREDIT AGREEMENT
Dated as of November 12, 2020
ABBOTT LABORATORIES, a corporation organized and existing under the Laws of the State of
Illinois (the “Borrower”), the Lenders (as defined below) that are parties hereto, and JPMorgan Chase Bank, N.A.
(“JPMorgan”), as administrative agent (together with any successor thereto appointed pursuant to Article VII, the
“Administrative Agent”) for the Lenders, agree as follows:
ARTICLE I
DEFINITIONS AND ACCOUNTING TERMS
SECTION 1.01 	Certain Defined Terms.
As used in this Five Year Credit Agreement (as amended, restated, supplemented or otherwise
modified and in effect from time to time, this “Agreement”), the following terms shall have the following
meanings (such meanings to be equally applicable to both the singular and plural forms of the terms defined):
“2018 Credit Agreement” means the Five Year Credit Agreement, dated as of November 30, 2018,
by and among the Borrower, JPMorgan, as administrative agent, and the lenders party thereto.
“Additional Lender” has the meaning specified in Section 2.05(c).
“Administrative Agent” has the meaning specified in the recital of parties to this Agreement.
“Administrative Agent’s Office” means the Administrative Agent’s address and, as appropriate,
account as set forth on Schedule II, or such other address or account as the Administrative Agent may
from time to time notify the Borrower and the Lenders.
“Administrative Questionnaire” means an administrative questionnaire in the form supplied by the
Administrative Agent.
“Advance” means any advance made by a Lender to the Borrower as part of a Borrowing and
refers to a Base Rate Advance or a Eurodollar Rate Advance (each of which shall be a “Type” of
Advance).
“Affected Financial Institution” means (a) any EEA Financial Institution or (b) any UK Financial
Institution.
“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly, controls,
is controlled by or is under common control with such Person or is a director or officer of such Person.
For purposes of this definition, the term “control”

-- 289 of 409 --

2
(including the terms “controlling”, “controlled by” and “under common control with”) of a Person means
the possession, direct or indirect, of the power to vote 10% or more of the Voting Stock of such Person or
to direct or cause the direction of the management and policies of such Person, whether through the
ownership of Voting Stock, by contract or otherwise.
“Agent Parties” has the meaning specified in Section 8.02(c).
“Agents” means, collectively, the Administrative Agent, the Syndication Agents and the Arrangers.
“Agreement Value” means, with respect to any Hedge Agreement at any date of determination, the
amount, if any, that would be payable to any bank thereunder in respect of the “agreement value” under
such Hedge Agreement if such Hedge Agreement were terminated on such date, calculated as provided in
the International Swap Dealers Association, Inc. Code of Standard Wording, Assumptions and Provisions
for Swaps, 1986 Edition.
“Applicable Lending Office” means, with respect to each Lender, such Lender’s Domestic Lending
Office in the case of a Base Rate Advance and such Lender’s Eurodollar Lending Office in the case of a
Eurodollar Rate Advance.
“Applicable Margin” means, as of any date, a percentage per annum determined by reference to the
Public Debt Rating in effect on such date as set forth below:
Applicable Margin Applicable Margin
for Eurodollar Rate 	for Base Rate
Public Debt Rating S&P/Moody’s 	Advances 	Advances
Level 1: 	AA-/Aa3 or above 	0.625% 	0.000%
Level 2: 	Less than Level 1 but at least A+/A1 	0.750% 	0.000%
Level 3: 	Less than Level 2 but at least A/A2 	0.875% 	0.000%
Level 4: 	Less than Level 3 but at least A-/A3 	1.000% 	0.000%
Level 5: 	Less than Level 4 but at least Baa1/BBB+ 	1.125% 	0.125%
Level 6: 	Less than Level 5 but at least Baa2/BBB 	1.250% 	0.250%
Level 7: 	Less than Level 6 	1.500% 	0.500%
“Applicable Percentage” means, in the case of the commitment fee paid pursuant to
Section 2.04(a), as of any date, a percentage per annum determined by reference to the Public Debt Rating
in effect on such date as set forth below:
Public Debt Rating S&P/Moody’s 	Applicable Percentage
Level 1: 	AA-/Aa3 or above 	0.045%
Level 2: 	Less than Level 1 but at least A+/A1 	0.050%
Level 3: 	Less than Level 2 but at least A/A2 	0.070%
Level 4: 	Less than Level 3 but at least A-/A3 	0.090%
Level 5: 	Less than Level 4 but at least Baa1/BBB+ 	0.100%
Level 6: 	Less than Level 5 but at least Baa2/BBB 	0.125%
Level 7: 	Less than Level 6 	0.175%

-- 290 of 409 --

3
“Arrangers” means JPMorgan, Barclays Bank PLC, BofA Securities, Inc., and Morgan Stanley
Senior Funding, Inc.
“Assignment and Acceptance” means an assignment and acceptance entered into by a Lender and
an Eligible Assignee, and accepted by the Administrative Agent, in substantially the form of Exhibit B
hereto.
“Attributable Debt” means (except as otherwise provided in this paragraph), as to any particular
lease under which any Person is at the time liable for a term of more than 12 months, at any date as of
which the amount thereof is to be determined (the “determination date”), the total net amount of rent
required to be paid by such Person under such lease during the remaining term thereof (excluding any
subsequent renewal or other extension options held by the lessee), discounted from the respective due
dates thereof to the determination date at the rate of 8% per annum, compounded monthly. The net
amount of rent required to be paid under any such lease for any such period shall be the aggregate amount
of the rent payable by the lessee with respect to such period after excluding amounts required to be paid on
account of maintenance and repairs, services, insurance, Taxes, assessments, water rates and similar
charges and contingent rents (such as those based on sales or monetary inflation). If (a) any such lease is
terminable by the lessee upon the payment of a penalty, (b) the terms of such lease provide that the
termination right is not exercisable until after the determination date and (c) the amount of such penalty
discounted to the determination date at the rate of 8% per annum compounded monthly is less than the net
amount of rentals payable after the time as of which such termination could occur (the “termination time”)
discounted to the determination date at the rate of 8% per annum compounded monthly, then such
discounted penalty amount shall be used instead of such discounted amount of net rentals payable after the
termination time in calculating the Attributable Debt for such lease. If (i) any such lease is terminable by
the lessee upon the payment of a penalty, (ii) such termination right is exercisable on the determination
date and (iii) the amount of the net rentals payable under such lease after the determination date discounted
to the determination date at the rate of 8% per annum compounded monthly is greater than the amount of
such penalty, the Attributable Debt for such lease as of such determination date shall be equal to the
amount of such penalty.
“Available Tenor” means, as of any date of determination and with respect to the then-current
Benchmark, as applicable, any tenor for such Benchmark or payment period for interest calculated with
reference to such Benchmark, as applicable, that is or may be used for determining the length of an Interest
Period pursuant to this Agreement as of such date and not including, for the avoidance of doubt, any tenor
for such Benchmark that is then-removed from the definition of “Interest Period” pursuant to clause (e) of
Section 2.18.
“Bail-In Action” means the exercise of any Write-Down and Conversion Powers by the applicable
Resolution Authority in respect of any liability of an Affected Financial Institution.

-- 291 of 409 --

4
“Bail-In Legislation” means, (a) with respect to any EEA Member Country implementing
Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union,
the implementing Law for such EEA Member Country from time to time which is described in the EU
Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the United Kingdom
Banking Act of 2009 (as amended from time to time) and any other law, regulation or rule applicable in
the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other
financial institutions or their affiliates (other than through liquidation, administration or other insolvency
proceedings).
“Base Rate” means, for any day, a fluctuating rate per annum equal to the highest of (a) the Federal
Funds Rate plus 1/2 of 1%, (b) the rate of interest last quoted by The Wall Street Journal as the “Prime
Rate” in the U.S. or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest
rate published by the Federal Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected
Interest Rates) as the “bank prime loan” rate or, if such rate is no longer quoted therein, any similar rate
quoted therein (as reasonably determined by the Administrative Agent) or any similar release by the
Federal Reserve Board (as reasonably determined by the Administrative Agent), and (c) the Eurodollar
Rate for a one month Interest Period (but not less than 0.00%) plus 1.00%; provided that if the Base Rate
as determined pursuant to the foregoing would be less than zero, such rate shall be deemed to be zero for
purposes of this Agreement. If the Base Rate is being used as an alternate rate of interest pursuant to
Section 2.18 (for the avoidance of doubt, only until the Benchmark Replacement has been determined
pursuant to Section 2.18(a)), then the Base Rate shall be the greater of clauses (a) and (b) above and shall
be determined without reference to clause (c) above.
“Base Rate Advance” means an Advance denominated in Dollars that bears interest as provided in
Section 2.07(a)(i).
“Benefit Plan” means any of (a) an “employee benefit plan” (as defined in ERISA) that is subject
to Title I of ERISA, (b) a “plan” as defined in Section 4975 of the Internal Revenue Code or (c) any
Persons whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of
ERISA or Section 4975 of the Internal Revenue Code) the assets of any such “employee benefit plan” or
“plan”.
“Benchmark” means, initially, LIBOR; provided that if a Benchmark Transition Event, a Term
SOFR Transition Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement
Date have occurred with respect to LIBOR or the then-current Benchmark, then “Benchmark” means the
applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such
prior benchmark rate pursuant to clause (a) or clause (b) of Section 2.18.
“Benchmark Replacement” means, for any Available Tenor, the first alternative set forth in the
order below that can be determined by the Administrative Agent for the applicable Benchmark
Replacement Date:

-- 292 of 409 --

5
(1) 	the sum of: (a) Term SOFR and (b) the related Benchmark Replacement
Adjustment;
(2) 	the sum of: (a) Daily Simple SOFR and (b) the related Benchmark Replacement
Adjustment;
(3) 	the sum of: (a) the alternate benchmark rate that has been selected by the
Administrative Agent and the Borrower as the replacement for the then-current Benchmark for the
applicable Corresponding Tenor giving due consideration to (i) any selection or recommendation of
a replacement benchmark rate or the mechanism for determining such a rate by the Relevant
Governmental Body or (ii) any evolving or then-prevailing market convention for determining a
benchmark rate as a replacement for the then-current Benchmark for dollar-denominated
syndicated credit facilities at such time and (b) the related Benchmark Replacement Adjustment;
provided that, in the case of clause (1), such Unadjusted Benchmark Replacement is displayed on a screen
or other information service that publishes such rate from time to time as selected by the Administrative
Agent in its reasonable discretion; provided further that, notwithstanding anything to the contrary in this
Agreement or in any other Loan Document, upon the occurrence of a Term SOFR Transition Event, and
the delivery of a Term SOFR Notice, on the applicable Benchmark Replacement Date the “Benchmark
Replacement” shall revert to and shall be deemed to be the sum of (a) Term SOFR and (b) the related
Benchmark Replacement Adjustment, as set forth in clause (1) of this definition (subject to the first
proviso above).
If the Benchmark Replacement as determined pursuant to clause (1), (2) or (3) above would be less
than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this
Agreement and the other Loan Documents.
“Benchmark Replacement Adjustment” means, with respect to any replacement of the then-current
Benchmark with an Unadjusted Benchmark Replacement for any applicable Interest Period and Available
Tenor for any setting of such Unadjusted Benchmark Replacement:
(1) 	for purposes of clauses (1) and (2) of the definition of “Benchmark Replacement,”
the first alternative set forth in the order below that can be determined by the Administrative
Agent:
(a) the spread adjustment, or method for calculating or determining such spread adjustment,
(which may be a positive or negative value or zero) as of the Reference Time such
Benchmark Replacement is first set for such Interest Period that has been selected or
recommended by the Relevant Governmental Body for the replacement of such Benchmark
with the applicable Unadjusted Benchmark Replacement for the applicable Corresponding
Tenor;

-- 293 of 409 --

6
(b) the spread adjustment (which may be a positive or negative value or zero) as of the
Reference Time such Benchmark Replacement is first set for such Interest Period that
would apply to the fallback rate for a derivative transaction referencing the ISDA
Definitions to be effective upon an index cessation event with respect to such Benchmark
for the applicable Corresponding Tenor; and
(2) 	for purposes of clause (3) of the definition of “Benchmark Replacement,” the
spread adjustment, or method for calculating or determining such spread adjustment, (which may
be a positive or negative value or zero) that has been selected by the Administrative Agent and the
Borrower for the applicable Corresponding Tenor giving due consideration to (i) any selection or
recommendation of a spread adjustment, or method for calculating or determining such spread
adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark
Replacement by the Relevant Governmental Body on the applicable Benchmark Replacement Date
or (ii) any evolving or then-prevailing market convention for determining a spread adjustment, or
method for calculating or determining such spread adjustment, for the replacement of such
Benchmark with the applicable Unadjusted Benchmark Replacement for dollar-denominated
syndicated credit facilities;
provided that, in the case of clause (1) above, such adjustment is displayed on a screen or other
information service that publishes such Benchmark Replacement Adjustment from time to time as selected
by the Administrative Agent in its reasonable discretion.
“Benchmark Replacement Conforming Changes” means, with respect to any Benchmark
Replacement, any technical, administrative or operational changes (including changes to the definition of
“Base Rate,” the definition of “Business Day,” the definition of “Interest Period,” timing and frequency of
determining rates and making payments of interest, timing of borrowing requests or prepayment,
conversion or continuation notices, length of lookback periods, the applicability of breakage provisions,
and other technical, administrative or operational matters) that the Administrative Agent decides in its
reasonable discretion may be appropriate to reflect the adoption and implementation of such Benchmark
Replacement and to permit the administration thereof by the Administrative Agent in a manner
substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any
portion of such market practice is not administratively feasible or if the Administrative Agent determines
that no market practice for the administration of such Benchmark Replacement exists, in such other
manner of administration as the Administrative Agent decides is reasonably necessary in connection with
the administration of this Agreement and the other Loan Documents).
“Benchmark Replacement Date” means the earliest to occur of the following events with respect to
the then-current Benchmark:
(1) 	in the case of clause (1) or (2) of the definition of “Benchmark Transition Event,”
the later of (a) the date of the public statement or publication of information referenced therein and
(b) the date on which the administrator of such

-- 294 of 409 --

7
Benchmark (or the published component used in the calculation thereof) permanently or
indefinitely ceases to provide all Available Tenors of such Benchmark (or such component
thereof);
(2) 	in the case of clause (3) of the definition of “Benchmark Transition Event,” the date
of the public statement or publication of information referenced therein;
(3) 	in the case of a Term SOFR Transition Event, the date that is thirty (30) days after
the date a Term SOFR Notice is provided to the Lenders and the Borrower pursuant to Section
2.18(b); or
(4) 	in the case of an Early Opt-in Election, the sixth (6th) Business Day after the date
notice of such Early Opt-in Election is provided to the Lenders, so long as the Administrative
Agent has not received, by 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the
date notice of such Early Opt-in Election is provided to the Lenders, written notice of objection to
such Early Opt-in Election from Lenders comprising the Required Lenders.
For the avoidance of doubt, (i) if the event giving rise to the Benchmark Replacement Date occurs
on the same day as, but earlier than, the Reference Time in respect of any determination, the Benchmark
Replacement Date will be deemed to have occurred prior to the Reference Time for such determination
and (ii) the “Benchmark Replacement Date” will be deemed to have occurred in the case of clause (1) or
(2) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein
with respect to all then-current Available Tenors of such Benchmark (or the published component used in
the calculation thereof).
“Benchmark Transition Event” means the occurrence of one or more of the following events with
respect to the then-current Benchmark:
(1) 	a public statement or publication of information by or on behalf of the administrator
of such Benchmark (or the published component used in the calculation thereof) announcing that
such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or
such component thereof), permanently or indefinitely, provided that, at the time of such statement
or publication, there is no successor administrator that will continue to provide any Available Tenor
of such Benchmark (or such component thereof);
(2) 	a public statement or publication of information by the regulatory supervisor for the
administrator of such Benchmark (or the published component used in the calculation thereof), the
Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with
jurisdiction over the administrator for such Benchmark (or such component), a resolution authority
with jurisdiction over the administrator for such Benchmark (or such component) or a court or an
entity with similar insolvency or resolution authority over the administrator for such Benchmark
(or such component), which states that the administrator of such

-- 295 of 409 --

8
Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such
Benchmark (or such component thereof) permanently or indefinitely, provided that, at the time of
such statement or publication, there is no successor administrator that will continue to provide any
Available Tenor of such Benchmark (or such component thereof); or
(3) 	a public statement or publication of information by the regulatory supervisor for the
administrator of such Benchmark (or the published component used in the calculation thereof)
announcing that all Available Tenors of such Benchmark (or such component thereof) are no longer
representative.
For the avoidance of doubt, a “Benchmark Transition Event” will be deemed to have occurred with
respect to any Benchmark if a public statement or publication of information set forth above has occurred
with respect to each then-current Available Tenor of such Benchmark (or the published component used in
the calculation thereof).
“Benchmark Unavailability Period” means the period (if any) (x) beginning at the time that a
Benchmark Replacement Date pursuant to clauses (1) or (2) of that definition has occurred if, at such time,
no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and
under any Loan Document in accordance with Section 2.18 and (y) ending at the time that a Benchmark
Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan
Document in accordance with Section 2.18.
“Beneficial Ownership Certification” means a certification regarding beneficial ownership required
by the Beneficial Ownership Regulation.
“Beneficial Ownership Regulation” means 31 C.F.R. § 1010.230.
“Borrowed Debt” means any Debt for money borrowed represented by notes, bonds, debentures or
other similar evidences of Debt for money borrowed.
“Borrower” has the meaning specified in the recital of parties to this Agreement.
“Borrower Materials” has the meaning specified in Section 5.01(i).
“Borrowing” means a borrowing consisting of Advances of the same Type made, Converted or
continued on the same date and, in the case of Eurodollar Rate Advances, as to which a single Interest
Period is in effect.
“Borrowing Minimum” means $10,000,000.
“Borrowing Multiple” means $1,000,000.
“Business Day” means any day other than a Saturday, Sunday or other day on which commercial
banks are authorized to close under the Laws of, or are in fact closed in, New York City or Chicago and, if
such day relates to any Eurodollar Rate Advance, means any

-- 296 of 409 --

9
such day on which dealings in Dollar deposits are conducted by and between banks in the London
interbank Eurodollar market.
“CERCLIS” means the Comprehensive Environmental Response, Compensation and Liability
Information System maintained by the U.S. Environmental Protection Agency.
“Closing Date” means the date on which each of the conditions set forth in Section 3.01 have been
satisfied (or waived in accordance with Section 8.01).
“Commitment” means as to any Lender (a) the Dollar amount set forth opposite such Lender’s
name on Schedule I hereto, or (b) if such Lender has entered into any Assignment and Acceptance or
Lender Joinder Agreement, the Dollar amount set forth for such Lender in the Register maintained by the
Administrative Agent pursuant to Section 8.07(d), in each case as such commitment may be increased or
reduced from time to time pursuant to the terms hereof. The aggregate amount of the Commitments as of
the Closing Date is $5,000,000,000 as such commitment may be reduced thereafter in accordance with
Section 2.05 or 6.01 or increased thereafter in accordance with Section 2.05(d).
“Commitment Termination Date” means the earlier of (i) the date that is the fifth anniversary of the
Closing Date, as such date may be extended with respect to any Consenting Lender pursuant to
Section 2.05(d), and (ii) the date on which the Commitments are terminated. Following such extension,
unless otherwise specified herein, the term “Commitment Termination Date” shall mean the Commitment
Termination Date as so extended.
“Consenting Lender” has the meaning specified in Section 2.05(d).
“Consolidated” refers to the consolidation of accounts in accordance with GAAP.
“Consolidated Group” means the Borrower and its Subsidiaries.
“Consolidated Net Assets” means the aggregate amount of assets (less applicable reserves and
other properly deductible items) after deducting therefrom all current liabilities, as set forth on the
Consolidated balance sheet of the Consolidated Group most recently furnished to the Lenders pursuant to
Section 5.01(i)(ii) prior to the time as of which Consolidated Net Assets shall be determined.
“Consolidated Net Worth” means, at any date of determination, (a) total assets of the Borrower and
its Subsidiaries (including, without limitation, all items that are treated as intangibles in accordance with
GAAP) at such date less (b) total liabilities of the Borrower and its Subsidiaries (including, without
limitation, all deferred Taxes) at such date, in each case determined in accordance with GAAP on a
Consolidated basis.
“Continuing Director” means, for any period, an individual who is a member of the board of
directors of the Borrower on the first day of such period or whose election to the

-- 297 of 409 --

10
board of directors of the Borrower is approved by a majority of the other Continuing Directors.
“Conversion”, “Convert”, or “Converted” each refers to a conversion of Advances of one Type into
Advances of the other Type pursuant to Section 2.08 or 2.09.
“Corresponding Tenor” with respect to any Available Tenor means, as applicable, either a tenor
(including overnight) or an interest payment period having approximately the same length (disregarding
business day adjustment) as such Available Tenor.
“Daily Simple SOFR” means, for any day, SOFR, with the conventions for this rate (which will
include a lookback) being established by the Administrative Agent in accordance with the conventions for
this rate selected or recommended by the Relevant Governmental Body for determining “Daily Simple
SOFR” for business loans; provided, that if the Administrative Agent decides that any such convention is
not administratively feasible for the Administrative Agent, then the Administrative Agent may establish
another convention in its reasonable discretion.
“Debt” of any Person means, without duplication, (a) all indebtedness of such Person for borrowed
money, (b) all obligations of such Person for the deferred purchase price of property or services (other than
trade payables incurred in the ordinary course of such Person’s business), (c) all obligations of such Person
evidenced by notes, bonds, debentures or other similar instruments, (d) all obligations of such Person
created or arising under any conditional sale or other title retention agreement with respect to property
acquired by such Person (even though the rights and remedies of the seller or lender under such agreement
in the event of default are limited to repossession or sale of such property), (e) all obligations of such
Person as lessee under leases that have been or should be, in accordance with GAAP, recorded as finance
leases, (f) all obligations, contingent or otherwise, of such Person in respect of acceptances, letters of
credit or similar extensions of credit, (g) all obligations of such Person in respect of Hedge Agreements,
(h) all Debt of others referred to in clauses (a) through (g) above or clause (i) below directly guaranteed in
any manner by such Person, or the payment of which is otherwise provided for by such Person, and (i) all
Debt referred to in clauses (a) through (h) above secured by (or for which the holder of such Debt has an
existing right, contingent or otherwise, to be secured by) any Lien on property (including, without
limitation, accounts and contract rights) owned by such Person, even though such Person has not assumed
or become liable for the payment of such Debt.
“Debtor Relief Laws” means the Bankruptcy Code of the United States of America, and all other
liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium,
rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States
or other applicable jurisdictions from time to time in effect.
“Declining Lender” has the meaning specified in Section 2.05(d).

-- 298 of 409 --

11
“Default” means any Event of Default or any event that would constitute an Event of Default but
for the requirement that notice be given or time elapse or both.
“Default Interest” has the meaning specified in Section 2.07(b).
“Defaulting Lender” means, subject to Section 2.19(b), any Lender that (a) has failed to (i) fund all
or any portion of its Advances within two Business Days of the date such Advances were required to be
funded hereunder unless such Lender notifies the Administrative Agent and the Borrower in writing that
such failure is the result of such Lender’s determination that one or more conditions precedent to funding
(each of which conditions precedent, together with any applicable default, shall be specifically identified
in such writing) has not been satisfied, or (ii) pay to the Administrative Agent or any other Lender any
other amount required to be paid by it hereunder within two Business Days of the date when due, (b) has
notified the Borrower or the Administrative Agent in writing that it does not intend to comply with its
funding obligations hereunder, or has made a public statement to that effect (unless such writing or public
statement relates to such Lender’s obligation to fund an Advance hereunder and states that such position is
based on such Lender’s determination that a condition precedent to funding (which condition precedent,
together with any applicable default, shall be specifically identified in such writing or public statement)
cannot be satisfied), (c) has failed, within three Business Days after written request by the Administrative
Agent or the Borrower, to confirm in writing to the Administrative Agent and the Borrower that it will
comply with its prospective funding obligations hereunder (provided that such Lender shall cease to be a
Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the
Administrative Agent and the Borrower), or (d) has, or has a direct or indirect parent company that has,
(i) become the subject of a proceeding under any Debtor Relief Law, (ii) had appointed for it a receiver,
custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person
charged with reorganization or liquidation of its business or assets, including the Federal Deposit
Insurance Corporation or any other state or federal regulatory authority acting in such a capacity,
(iii) become an Embargoed Lender or (iv) become the subject of a Bail-In Action; provided that for the
avoidance of doubt, a Lender shall not be a Defaulting Lender solely by virtue of (A) the ownership or
acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a
Governmental Authority or (B) in the case of a solvent Person, the precautionary appointment of an
administrator, guardian or custodian or similar official by a Governmental Authority under or based on the
Law of the country where such Person is organized if the applicable Law of such jurisdiction requires that
such appointment not be publicly disclosed, in any such case, where such ownership or action, as
applicable, does not result in or provide such Lender with immunity from the jurisdiction of courts within
the United States or from the enforcement of judgments or writs of attachment on its assets or permit such
Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or
agreements made with such Lender. Any determination by the Administrative Agent that a Lender is a
Defaulting Lender under any one or more of clauses (a) through (d) above shall be conclusive and binding
as to such Lender absent manifest error, and such Lender shall be deemed to be a Defaulting Lender
(subject to Section 2.19(b)) upon delivery of written notice of such determination to the Borrower and
each Lender.

-- 299 of 409 --

12
“Designated Jurisdiction” means any country, region or territory that is, or has a government that
is, subject to comprehensive country-wide economic or financial sanctions or trade embargoes imposed,
administered or enforced by any Person listed in the definition of “Sanction(s)”.
“Division” means the division of the assets, liabilities and/or obligations of a Person (the “Dividing
Person”) among two or more Persons (whether pursuant to a “plan of division” or similar arrangement),
which may or may not include the Dividing Person and pursuant to which the Dividing Person may or may
not survive.
“Dollars” and the “$” sign each means lawful currency of the United States.
“Domestic Lending Office” means, with respect to any Lender, the office of such Lender specified
as its “Domestic Lending Office” in its Administrative Questionnaire or in the Assignment and
Acceptance, pursuant to which it became a Lender, or such other office of such Lender as such Lender
may from time to time specify to the Borrower and the Administrative Agent.
“Domestic Subsidiary” means any Subsidiary of the Borrower substantially all the property of
which is located, or substantially all of the business of which is carried on, within the United States
(excluding its territories and possessions and Puerto Rico), provided, however, that the term shall not
include any Subsidiary of the Borrower which (a) is engaged principally in the financing of operations
outside of the United States or in leasing personal property or financing inventory, receivables or other
property or (b) does not own a Principal Domestic Property.
“Early Opt-in Election” means, if the then-current Benchmark is LIBOR, the occurrence of:
(1) 	a notification by the Administrative Agent to (or the request by the Borrower to the
Administrative Agent to notify) each of the other parties hereto that at least five currently
outstanding dollar-denominated syndicated credit facilities at such time contain (as a result of
amendment or as originally executed) a SOFR-based rate (including SOFR, a term SOFR or any
other rate based upon SOFR) as a benchmark rate (and such syndicated credit facilities are
identified in such notice and are publicly available for review), and
(2) 	the joint election by the Administrative Agent and the Borrower to trigger a
fallback from LIBOR and the provision by the Administrative Agent of written notice of such
election to the Lenders.
“EEA Financial Institution” means (a) any credit institution or investment firm established in any
EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity
established in an EEA Member Country which is a parent of an institution described in clause (a) of this
definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of
an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision
with its parent.

-- 300 of 409 --

13
“EEA Member Country” means any of the member states of the European Union, Iceland,
Liechtenstein, and Norway.
“EEA Resolution Authority” means any public administrative authority or any Person entrusted
with public administrative authority of any EEA Member Country (including any delegee) having
responsibility for the resolution of any EEA Financial Institution.
“Eligible Assignee” means (a) a Lender; (b) an Affiliate of a Lender; (c) a commercial bank
organized under the Laws of the United States, or any State thereof, and having total assets in excess of
$10,000,000,000; (d) a commercial bank organized under the Laws of any other country that is a member
of the Organization for Economic Cooperation and Development or has concluded special lending
arrangements with the International Monetary Fund associated with its General Arrangements to Borrow,
or a political subdivision of any such country, and having total assets in excess of $10,000,000,000, so
long as such bank is acting through a branch or agency located in the country in which it is organized or
another country that is described in this clause (d); and (e) any other Person approved by the
Administrative Agent and, so long as no Event of Default has occurred and is continuing, by the Borrower,
such approval not to be unreasonably withheld or delayed; provided, however, that no Defaulting Lender
(or Person who would be a Defaulting Lender upon becoming a Lender) nor the Borrower nor any
Affiliate of the Borrower shall qualify as an Eligible Assignee.
“Embargoed Lender” means any Lender (a) that is the subject of any Sanctions or (b) that is
located, organized or resident in any Designated Jurisdiction.
“Environmental Action” means any action, suit, demand, demand letter, claim, notice of
noncompliance or violation, notice of liability or potential liability, investigation, proceeding, consent
order or consent agreement relating in any way to any Environmental Law, Environmental Permit or
Hazardous Materials or arising from alleged injury or threat of injury to health, safety or the environment,
including, without limitation, (a) by any governmental or regulatory authority for enforcement, cleanup,
removal, response, remedial or other actions or damages and (b) by any governmental or regulatory
authority or any third party for damages, contribution, indemnification, cost recovery, compensation or
injunctive relief.
“Environmental Law” means any federal, state, local or foreign statute, Law, ordinance, rule,
regulation, code, order, judgment, decree or judicial or agency interpretation, policy or guidance relating to
pollution or protection of the environment, health, safety or natural resources, including, without
limitation, those relating to the use, handling, transportation, treatment, storage, disposal, release or
discharge of Hazardous Materials.
“Environmental Liability” means any liability, contingent or otherwise (including any liability for
damages, costs of environmental remediation, fines, penalties or indemnities), of the Borrower or any of
its Subsidiaries directly or indirectly resulting from or based upon (a) violation of any Environmental Law,
(b) the generation, use, handling,

-- 301 of 409 --

14
transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous
Materials, (d) the release or threatened release of any Hazardous Materials into the environment or (e) any
contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed
with respect to any of the foregoing.
“Environmental Permit” means any permit, approval, identification number, license or other
authorization required under any Environmental Law.
“ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to
time, and the regulations promulgated and rulings issued thereunder.
“ERISA Affiliate” means any Person that for purposes of Title IV of ERISA is a member of the
Borrower’s controlled group, or under common control with the Borrower, within the meaning of
Section 414 of the Internal Revenue Code.
“ERISA Event” means:
(a) 	(i) the occurrence of a reportable event, within the meaning of Section 4043 of ERISA,
with respect to any Plan unless the 30-day notice requirement with respect to such event has been waived
by the PBGC, or (ii) the requirements of subsection (1) of Section 4043(b) of ERISA (without regard to
subsection (2) of such Section) are being met with a contributing sponsor, as defined in Section 4001(a)
(13) of ERISA, of a Plan, and an event described in paragraph (9), (10), (11), (12) or (13) of
Section 4043(c) of ERISA is reasonably expected to occur with respect to such Plan within the following
30 days;
(b) 	the application for a minimum funding waiver with respect to a Plan;
(c) 	the provision by the administrator of any Plan of a notice of intent to terminate such Plan
pursuant to Section 4041(a)(2) of ERISA (including any such notice with respect to a plan amendment
referred to in Section 4041(e) of ERISA);
(d) 	the cessation of operations at a facility of the Borrower or any ERISA Affiliate in the
circumstances described in Section 4062(e) of ERISA;
(e) 	the withdrawal by the Borrower or any ERISA Affiliate from a Multiple Employer Plan
during a plan year for which it was a substantial employer, as defined in Section 4001(a)(2) of ERISA;
(f) 	the conditions for the imposition of a lien under Section 303(k) of ERISA shall have been
met with respect to any Plan; or
(g) 	the institution by the PBGC of proceedings to terminate a Plan pursuant to Section 4042 of
ERISA, or the occurrence of any event or condition described in Section 4042 of ERISA that could
constitute grounds for the termination of, or the appointment of a trustee to administer, a Plan.

-- 302 of 409 --

15
“EU Bail-In Legislation Schedule” means the EU Bail-In Legislation Schedule published by the
Loan Market Association (or any successor Person), as in effect from time to time.
“Eurocurrency Liabilities” has the meaning specified in Regulation D of the Board of Governors of
the Federal Reserve System, as in effect from time to time.
“Eurodollar Lending Office” means, with respect to any Lender, the office of such Lender specified
as its “Eurodollar Lending Office” in its Administrative Questionnaire or in the Assignment and
Acceptance pursuant to which it became a Lender (or, if no such office is specified, its Domestic Lending
Office), or such other office, branch, subsidiary or affiliate of such Lender as such Lender may from time
to time specify to the Borrower and the Administrative Agent.
“Eurodollar Rate” means,
(a) 	for any Interest Period with respect to a Eurodollar Rate Advance, the rate per annum equal
to the London Interbank Offered Rate (“LIBOR”) as published on the applicable Bloomberg screen page
(or other comparable commercially available source providing quotations of LIBOR as may be designated
by the Administrative Agent from time to time), at approximately 11:00 a.m., London time, two Business
Days prior to the commencement of such Interest Period, for Dollar deposits (for delivery on the first day
of such Interest Period) with a term equivalent to such Interest Period (the “Screen Rate”);
(b) 	for any interest rate calculation with respect to a Base Rate Advance on any date, the rate
per annum equal to LIBOR, at approximately 11:00 a.m., London time determined two Business Days
prior to such date for Dollar deposits being delivered in the London interbank market for a term of one
month commencing that date; and
(c) 	if the Eurodollar Rate shall be less than zero, such rate shall be deemed zero for purposes of
this Agreement.
“Eurodollar Rate Advance” means an Advance denominated in Dollars that bears interest as
provided in Section 2.07(a)(ii).
“Events of Default” has the meaning specified in Section 6.01.
“Excluded Taxes” means any of the following Taxes imposed on or with respect to any Lender or
the Administrative Agent or required to be withheld or deducted from a payment to any Lender or the
Administrative Agent: (a) Taxes imposed on or measured by net income (however denominated), franchise
Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Lender or the Administrative
Agent being organized under the laws of, or having its principal office or, in the case of any Lender, its
Lending Office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii)
that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed on
amounts payable to or for the account of such Lender pursuant to a law in effect on the date such Lender
becomes a party to this Agreement (or designates a new Applicable Lending Office), except to the extent
that such Lender (or its assignor, if any)

-- 303 of 409 --

16
was entitled, on the date of designation of a new Applicable Lending Office (or assignment), to receive
additional amounts from the Borrower with respect to such withholding Tax pursuant to Section 2.14(a)(ii)
or Section 2.14(c), (c) Taxes attributable to a failure by such Lender or the Administrative Agent to
comply with Section 2.14(e) and (d) any U.S. federal withholding Taxes imposed pursuant to FATCA.
“Existing Commitment Termination Date” has the meaning specified in Section 2.05(e).
“Extension Date” has the meaning specified in Section 2.05(d).
“FATCA” means Sections 1471 through 1474 of the Internal Revenue Code, as of the date of this
Agreement (or any amended or successor version that is substantively comparable and not materially more
onerous to comply with), any current or future regulations or official interpretations thereof, any
agreements entered into pursuant to Section 1471(b)(1) of the Internal Revenue Code, any published
intergovernmental agreement entered into in connection with the implementation of such Sections of the
Internal Revenue Code and any fiscal or regulatory legislation adopted pursuant to such published
intergovernmental agreements.
“Federal Funds Effective Rate” means, for any day, the rate calculated by the Federal Reserve
Bank of New York based on such day’s federal funds transactions by depositary institutions, as determined
in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to
time, and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the
effective federal funds rate; provided that if the Federal Funds Effective Rate as so determined would be
less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.
“Federal Funds Rate” means, for any day, the greater of (a) the Federal Funds Effective Rate in
effect on such day and (b) the Overnight Bank Funding Rate in effect on such day (or for any day that is
not a Business Day, for the immediately preceding Business Day); provided that if none of such rates are
published for any day that is a Business Day, the term “Federal Funds Rate” means the rate for a federal
funds transaction quoted at 11:00 a.m. on such day received by the Administrative Agent from a federal
funds broker of recognized standing selected by it; provided, further, that if any of the aforesaid rates as so
determined shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.
“Fee Letter” means the Fee Letter dated as of October 21, 2020 among the Borrower, the Arrangers
and the Administrative Agent.
“Floor” means the benchmark rate floor, if any, provided in this Agreement initially (as of the
execution of this Agreement, the modification, amendment or renewal of this Agreement or otherwise)
with respect to the Eurodollar Rate.
“Foreign Lender” means a Lender that is not a U.S. Person.

-- 304 of 409 --

17
“Funded Debt” means Debt of the Borrower (other than Debt in respect of the Advances or Debt
subordinated in right of payment to the Advances) or Debt of any wholly-owned Domestic Subsidiary, for
money borrowed, having a stated maturity of more than 12 months from the date of application of
sale/leaseback proceeds or which is extendible at the option of the obligor thereon to a date more than 12
months from the date of such application.
“GAAP” has the meaning specified in Section 1.03.
“Governmental Authority” means any nation or government, any state or other political
subdivision thereof, any agency, authority, instrumentality, regulatory body, court, administrative tribunal,
central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative
powers or functions of or pertaining to government (including any supra-national bodies such as the
European Union or the European Central Bank).
“Hazardous Materials” means (a) petroleum and petroleum products, byproducts or breakdown
products, radioactive materials, asbestos-containing materials, polychlorinated biphenyls and radon gas
and (b) any other chemicals, materials or substances designated, classified or regulated as “hazardous” or
“toxic” or as a “pollutant” or “contaminant” under any Environmental Law.
“Hedge Agreements” means interest rate swap, cap or collar agreements, interest rate future or
option contracts, currency swap agreements, currency future or option contracts and other similar
agreements.
“Increase Effective Date” has the meaning specified in Section 2.05(c).
“Increasing Lender” has the meaning specified in Section 2.05(c).
“Indemnified Party” has the meaning specified in Section 8.04(b).
“Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to
any payment made by or on account of any obligation of the Borrower under any Loan Document and (b)
to the extent not otherwise described in clause (a), Other Taxes.
“Information” has the meaning specified in Section 8.08.
“Information Memorandum” means the information memorandum dated October 2020 used by the
Arrangers in connection with the syndication of the Commitments.
“Initial Lenders” has the meaning specified in the definition of “Lenders”.
“Interest Election Request” means a request by the Borrower to Convert or continue a Borrowing
in accordance with Section 2.09.

-- 305 of 409 --

18
“Interest Period” means, for each Eurodollar Rate Advance comprising part of the same
Borrowing, the period commencing on the date of such Eurodollar Rate Advance or the date of the
continuation of, or Conversion of any Base Rate Advance into, such Eurodollar Rate Advance and ending
on the last day of the period selected by the Borrower pursuant to the provisions below. The duration of
each such Interest Period shall be one, two, three or six months, as the Borrower may, upon notice received
by the Administrative Agent not later than 11:00 A.M. (New York City time) on the third Business Day
prior to the first day of such Interest Period (or in any case at such later time as the Administrative Agent,
in its reasonable discretion, may agree to), select; provided, however, that: (a) the Borrower may not select
any Interest Period that ends after the latest then-effective Commitment Termination Date; (b) Interest
Periods commencing on the same date for Eurodollar Rate Advances comprising part of the same
Borrowing shall be of the same duration (it being understood that the Borrower shall be permitted to make
multiple Borrowings consisting of Eurodollar Rate Advances on the same date, each of which may be of
different durations); (c) whenever the last day of any Interest Period would otherwise occur on a day other
than a Business Day, the last day of such Interest Period shall be extended to occur on the next succeeding
Business Day, provided, however, that, if such extension would cause the last day of such Interest Period
to occur in the next succeeding calendar month, the last day of such Interest Period shall occur on the
immediately preceding Business Day; and (d) whenever the first day of any Interest Period occurs on a day
of an initial calendar month for which there is no numerically corresponding day in the calendar month
that succeeds such initial calendar month by the number of months equal to the number of months in such
Interest Period, such Interest Period shall end on the last Business Day of such succeeding calendar month.
“Internal Revenue Code” means the Internal Revenue Code of 1986, as amended from time to
time, and the regulations promulgated and the rulings issued thereunder.
“IRS” means the United States Internal Revenue Service.
“ISDA Definitions” means the 2006 ISDA Definitions published by the International Swaps and
Derivatives Association, Inc. or any successor thereto, as amended or supplemented from time to time, or
any successor definitional booklet for interest rate derivatives published from time to time by the
International Swaps and Derivatives Association, Inc. or such successor thereto.
“Laws” means, collectively, all international, foreign, federal, state and local statutes, treaties,
rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities,
including the interpretation or administration thereof by any Governmental Authority charged with the
enforcement, interpretation or administration thereof, and all applicable administrative orders, directed
duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental
Authority, in each case whether or not having the force of Law.
“Lender Joinder Agreement” means a joinder agreement in a form reasonably satisfactory to the
Administrative Agent delivered in connection with Section 2.05(c).

-- 306 of 409 --

19
“Lenders” means, collectively, (a) each bank, financial institution and other institutional lender
listed on the signature pages hereof (each, an “Initial Lender”) and (b) each Eligible Assignee that shall
become a party hereto pursuant to Section 8.07(a), (b) and (c).
“Lien” means any lien, security interest or other charge or encumbrance of any kind, or any other
type of preferential arrangement, including, without limitation, the lien or retained security title of a
conditional vendor and any easement, right of way or other encumbrance on title to real property.
“Loan Documents” means this Agreement and any Lender Joinder Agreements, notes, security
agreements or other documents entered into in connection herewith, each as amended, restated,
supplemented, waived or otherwise modified from time to time.
“Material Adverse Effect” means a material adverse effect on (a) the financial condition or results
of operations of the Borrower or the Borrower and its Subsidiaries taken as a whole, (b) the rights and
remedies of the Administrative Agent or any Lender under this Agreement, taken as a whole, or (c) the
ability of the Borrower to perform its obligations under this Agreement.
“Moody’s” means Moody’s Investors Service, Inc. (or any successor thereof).
“Multiemployer Plan” means a multiemployer plan, as defined in Section 4001(a)(3) of ERISA, to
which the Borrower or any ERISA Affiliate is making or accruing an obligation to make contributions, or
has within any of the preceding five plan years made or accrued an obligation to make contributions.
“Multiple Employer Plan” means a single employer plan, as defined in Section 4001(a)(15) of
ERISA, that (a) is maintained for employees of the Borrower or any ERISA Affiliate and at least one
Person other than the Borrower and the ERISA Affiliates or (b) was so maintained and in respect of which
the Borrower or any ERISA Affiliate could have liability under Section 4064 or 4069 of ERISA in the
event such plan has been or were to be terminated.
“Non-Defaulting Lender” means, at any time, a Lender that is not a Defaulting Lender.
“Notice of Borrowing” has the meaning specified in Section 2.02(a).
“NPL” means the National Priorities List under the Comprehensive Environmental Response,
Compensation and Liability Act of 1980, as amended from time to time.
“OFAC” means the U.S. Treasury Department’s Office of Foreign Assets Control.
“Other Connection Taxes” means, with respect to any Lender or the Administrative Agent, Taxes
imposed as a result of a present or former connection between such Lender or the Administrative Agent
and the jurisdiction imposing such Tax (other than connections arising from such Lender or the
Administrative Agent having executed, delivered, become

-- 307 of 409 --

20
a party to, performed its obligations under, received payments under, engaged in any other transaction
pursuant to or enforced any Loan Document, or sold or assigned an interest in any Advance or Loan
Document).
“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing
or similar Taxes that arise from any payment made under, from the execution, delivery, performance,
enforcement or registration of, or otherwise with respect to, any Loan Document, except any such Taxes
that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made
pursuant to the first parenthetical clause in Section 8.07(a)).
“Overnight Bank Funding Rate” means, for any day, the rate comprised of both overnight federal
funds and overnight eurodollar borrowings by U.S.-managed banking offices of depository institutions, as
such composite rate shall be determined by the Federal Reserve Bank of New York as set forth on its
public website from time to time, and published on the next succeeding Business Day by the Federal
Reserve Bank of New York as an overnight bank funding rate.
“Participant Register” has the meaning specified in Section 8.07(e).
“Patriot Act” means the Uniting and Strengthening America by Providing Appropriate Tools
Required to Intercept and Obstruct Terrorism Act of 2001, Pub. L. 107-56, signed into law October 26,
2001.
“PBGC” means the Pension Benefit Guaranty Corporation (or any successor thereto).
“Person” means an individual, partnership, corporation (including a business trust), joint stock
company, trust, unincorporated association, joint venture, limited liability company or other entity, or a
government or any political subdivision or agency thereof.
“Plan” means a Single Employer Plan or a Multiple Employer Plan.
“Plan Asset Regulations” means 29 CFR § 2510.3-101 et seq., as modified by Section 3(42) of
ERISA, as amended from time to time.
“Platform” has the meaning specified in Section 5.01(i).
“Principal Domestic Property” means any building, structure or other facility, together with the
land upon which it is erected and fixtures comprising a part thereof, used primarily for manufacturing,
processing, research, warehousing or distribution and located in the United States (excluding its territories
and possessions and Puerto Rico) owned or leased by a member of the Consolidated Group the net book
value of which on the date as of which the determination is being made exceeds 2% of Consolidated Net
Assets, other than any such building structure or other facility or portion of any thereof (a) which is an air
or water pollution control facility financed by obligations issued by a State or local governmental unit or
(b) which the Chief Executive Officer, any President, the Chief Financial Officer, the Controller or the
Treasurer of the Borrower determines in good faith

-- 308 of 409 --

21
is not of material importance to the total business conducted, or assets owned, by the Consolidated Group
taken as a whole.
“Proceeding” has the meaning specified in Section 8.04(b).
“PTE” means a prohibited transaction class exemption issued by the U.S. Department of Labor, as
any such exemption may be amended from time to time.
“Public Debt Rating” means, as of any date of determination, the rating as determined by S&P or
Moody’s of the Borrower’s long-term unsecured senior debt; provided, that (a) if only one of S&P and
Moody’s shall have in effect a Public Debt Rating, the Applicable Percentage and the Applicable Margin,
as applicable, shall be determined by reference to the available Public Debt Rating; (b) if neither S&P nor
Moody’s shall have in effect a Public Debt Rating, the Applicable Percentage and the Applicable Margin,
as applicable, shall be set in accordance with Level VII of the definition of Applicable Percentage or
Applicable Margin, as the case may be, until such time as either S&P or Moody’s shall have in effect a
Public Debt Rating; (c) if the Public Debt Ratings established by S&P and Moody’s shall fall within
different levels, the Applicable Percentage and the Applicable Margin, as applicable, shall be based upon
the higher of such Public Debt Ratings, except that in the event that the lower of such Public Debt Ratings
is more than one level below the higher of such Public Debt Ratings, the Applicable Percentage and the
Applicable Margin, as applicable, shall be based upon the level immediately below the higher of such
Public Debt Ratings; (d) if any Public Debt Rating established by S&P or Moody’s shall be changed, such
change shall be effective as of the date on which such change is first announced publicly by the rating
agency making such change and (e) if S&P or Moody’s shall change the basis on which Public Debt
Ratings are established, each reference to the Public Debt Ratings announced by S&P or Moody’s, as the
case may be, shall refer to the then equivalent rating by S&P or Moody’s, as the case may be.
“Reference Time” with respect to any setting of the then-current Benchmark means (1) if such
Benchmark is Eurodollar Rate, 11:00 a.m. (London time) on the day that is two London banking days
preceding the date of such setting, and (2) if such Benchmark is not Eurodollar Rate, the time determined
by the Administrative Agent in its reasonable discretion.
“Register” has the meaning specified in Section 8.07(d).
“Related Parties” means, with respect to any Person, such Person’s Affiliates, and the partners,
directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of
such Person and of such Person’s Affiliates.
“Related Person” means, as to any Person, (a) any controlling Person, controlled Affiliate or
Subsidiary of such Person, (b) the respective directors, officers or employees of such Person or any of its
Subsidiaries, controlled Affiliates or controlling Persons and (c) the respective agents and advisors of such
Person or any of its Subsidiaries, controlled Affiliates or controlling Persons.

-- 309 of 409 --

22
“Relevant Governmental Body” means the Federal Reserve Board or the Federal Reserve Bank of
New York, or a committee officially endorsed or convened by the Federal Reserve Board or the Federal
Reserve Bank of New York, or any successor thereto.
“Removal Effective Date” has the meaning specified in Section 7.06(b).
“Required Lenders” means, at any time, Lenders holding more than 50% of the Commitments at
such time or, if the Commitments have been terminated at such time pursuant to Section 2.05 or 6.01,
Lenders owed more than 50% of the aggregate unpaid principal amount of the Advances owing to Lenders
at such time; provided that the Commitment of, and the Advances held or deemed held by, any Defaulting
Lender shall be excluded for purposes of making a determination of Required Lenders.
“Resignation Effective Date” has the meaning specified in Section 7.06(a).
“Resolution Authority” means an EEA Resolution Authority or, with respect to any UK Financial
Institution, a UK Resolution Authority.
“Responsible Officer” means the Chief Executive Officer, the Chief Financial Officer, the
Treasurer, the Controller, any Assistant Treasurer, the Director, Capital Markets and Global Treasury
Operations and the General Counsel of the Borrower (or other executive officer of the Borrower
performing similar functions) or any other officer of the Borrower responsible for overseeing or reviewing
compliance with this Agreement.
“Revised Percentage” has the meaning specified in Section 2.05(c).
“S&P” means S&P Global Ratings, a division of S&P Global Inc., or any successor to its rating
agency business.
“Sale and Leaseback Transaction” has the meaning specified in Section 5.02(c).
“Sanction(s)” means any economic or trade sanction enacted, imposed, administered or enforced
by the United States Government (including, without limitation, the U.S. Department of State and OFAC),
the United Nations Security Council, the European Union, Her Majesty’s Treasury or other relevant
sanctions authority in a jurisdiction material to the Borrower and its Subsidiaries taken as a whole.
“Screen Rate” has the meaning set forth in the definition of “Eurodollar Rate”.
“Significant Subsidiary” means any Subsidiary of the Borrower that constitutes a “significant
subsidiary” under Regulation S-X promulgated by the Securities and Exchange Commission, as in effect
from time to time.
“Single Employer Plan” means a single employer plan, as defined in Section 4001(a)(15) of
ERISA, that (a) is maintained for employees of the Borrower or any ERISA Affiliate and no Person other
than the Borrower and the ERISA Affiliates or (b) was so maintained and in respect of which the Borrower
or any ERISA Affiliate could

-- 310 of 409 --

23
have liability under Section 4069 of ERISA in the event such plan has been or were to be terminated.
“SOFR” means, with respect to any Business Day, a rate per annum equal to the secured overnight
financing rate for such Business Day published by the SOFR Administrator on the SOFR Administrator’s
Website on the immediately succeeding Business Day.
“SOFR Administrator” means the Federal Reserve Bank of New York (or a successor administrator
of the secured overnight financing rate).
“SOFR Administrator’s Website” means the Federal Reserve Bank of New York’s Website,
currently at http://www.newyorkfed.org, or any successor source for the secured overnight financing rate
identified as such by the SOFR Administrator from time to time.
“Subsidiary” means, with respect to any Person, any corporation, partnership, joint venture,
limited liability company, trust or estate of which (or in which) more than 50% of (a) the issued and
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such
corporation (irrespective of whether at the time capital stock of any other class or classes of such
corporation shall or might have voting power upon the occurrence of any contingency), (b) the interest in
the capital or profits of such limited liability company, partnership or joint venture or (c) the beneficial
interest in such trust or estate is at the time directly or indirectly owned or controlled by such Person, by
such Person and one or more of its other Subsidiaries or by one or more of such Person’s other
Subsidiaries.
“Syndication Agents” means Barclays Bank PLC, Bank of America, N.A., and Morgan Stanley
Senior Funding, Inc.
“Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings
(including backup withholding), assessments, fees or other like charges imposed by any Governmental
Authority, including any interest, additions to tax or penalties applicable thereto.
“Term SOFR” means, for the applicable Corresponding Tenor as of the applicable Reference Time,
the forward-looking term rate based on SOFR that has been selected or recommended by the Relevant
Governmental Body.
“Term SOFR Notice” means a notification by the Administrative Agent to the Lenders and the
Borrower of the occurrence of a Term SOFR Transition Event.
“Term SOFR Transition Event” means the determination by the Administrative Agent that (a) Term
SOFR has been recommended for use by the Relevant Governmental Body, (b) the administration of Term
SOFR is administratively feasible for the Administrative Agent and (c) a Benchmark Transition Event or
an Early Opt-in Election, as applicable, has previously occurred resulting in a Benchmark Replacement in
accordance with Section 2.18 that is not Term SOFR.

-- 311 of 409 --

24
“Type” has the meaning specified in the definition of “Advance”.
“UK Financial Institution” means any BRRD Undertaking (as such term is defined under the PRA
Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation
Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time)
promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit
institutions and investment firms, and certain affiliates of such credit institutions or investment firms.
“UK Resolution Authority” means the Bank of England or any other public administrative
authority having responsibility for the resolution of any UK Financial Institution.
“Unadjusted Benchmark Replacement” means the applicable Benchmark Replacement excluding
the related Benchmark Replacement Adjustment.
“United States” and “U.S.” each means the United States of America.
“U.S. Person” means any Person that is a “United States person” as defined in Section 7701(a)(30)
of the Internal Revenue Code.
“U.S. Tax Compliance Certificate” has the meaning specified in Section 2.14
“Voting Stock” means shares of capital stock issued by a corporation, or equivalent interests in any
other Person, the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the
election of directors (or persons performing similar functions) of such Person, even if the right so to vote
has been suspended by the happening of such a contingency.
“Withdrawal Liability” has the meaning specified in Part I of Subtitle E of Title IV of ERISA.
“Write-Down and Conversion Powers” means, (a) with respect to any EEA Resolution Authority,
the write-down and conversion powers of such EEA Resolution Authority from time to time under the
Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are
described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers
of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change
the form of a liability of any UK Financial Institution or any contract or instrument under which that
liability arises, to convert all or part of that liability into shares, securities or obligations of that person or
any other person, to provide that any such contract or instrument is to have effect as if a right had been
exercised under it or to suspend any obligation in respect of that liability or any of the powers under that
Bail-In Legislation that are related to or ancillary to any of those powers.
SECTION 1.02 	Computation of Time Periods. In this Agreement, in the computation of periods
of time from a specified date to a later specified date, the word “from”

-- 312 of 409 --

25
means “from and including”, the word “through” means “through and including” and each of the words “to” and
“until” mean “to but excluding”.
SECTION 1.03 	Accounting Terms; Interpretative Provisions. Except as otherwise expressly
provided herein, all accounting terms not specifically defined herein shall be construed in accordance with, and all
financial data (including financial calculations) required to be submitted pursuant to this Agreement shall be
prepared in conformity with, generally accepted accounting principles as in effect in the United States from time
to time (“GAAP”). If at any time any change in GAAP would affect the calculation of any covenant set forth
herein and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders
and the Borrower shall negotiate in good faith to amend such covenant to preserve the original intent thereof in
light of such change in GAAP (subject to the approval of the Required Lenders); provided that, until so amended,
(a) such covenant shall continue to be calculated in accordance with GAAP prior to such change and (b) the
Borrower shall provide to the Administrative Agent and the Lenders, concurrently with the delivery of any
financial statements or reports with respect to such covenant, statements setting forth a reconciliation between
calculations of such covenant made before and after giving effect to such change in GAAP.
SECTION 1.04 	Interest Rates; LIBOR Notification. The interest rate on Eurodollar Rate
Advances is determined by reference to LIBOR, which is derived from the London interbank offered rate. The
London interbank offered rate is intended to represent the rate at which contributing banks may obtain short-term
borrowings from each other in the London interbank market. In July 2017, the U.K. Financial Conduct Authority
announced that, after the end of 2021, it would no longer persuade or compel contributing banks to make rate
submissions to the ICE Benchmark Administration (together with any successor to the ICE Benchmark
Administrator, the “IBA”) for purposes of the IBA setting the London interbank offered rate. As a result, it is
possible that commencing in 2022, the London interbank offered rate may no longer be available or may no longer
be deemed an appropriate reference rate upon which to determine the interest rate on Eurodollar Rate Advances.
In light of this eventuality, public and private sector industry initiatives are currently underway to identify new or
alternative reference rates to be used in place of the London interbank offered rate. Upon the occurrence of a
Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, Section 2.18(a) and (b)
provide the mechanism for determining an alternative rate of interest. The Administrative Agent will promptly
notify the Borrower and the Lenders, pursuant to Section 2.18(d), of any change to the reference rate upon which
the interest rate on Eurodollar Rate Advances is based. However, the Administrative Agent does not warrant or
accept any responsibility for, and shall not have any liability with respect to, the administration, submission or any
other matter related to the London interbank offered rate or other rates in the definition of “Eurodollar Rate” or
with respect to any alternative or successor rate thereto, or replacement rate thereof (including, without limitation,
(i) any such alternative, successor or replacement rate implemented pursuant to Section 2.18(a) or (b), whether
upon the occurrence of a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in
Election, and (ii) the implementation of any Benchmark Replacement Conforming Changes pursuant to Section
2.18(c)), including without limitation, whether the composition or characteristics of any such alternative,
successor or replacement reference rate will be similar to, or produce the same value or economic equivalence of,
the Eurodollar Rate or have the same volume or liquidity as did the London interbank offered rate prior to its
discontinuance or unavailability.

-- 313 of 409 --

26
SECTION 1.05 	Divisions. For all purposes under the Loan Documents, in connection with any
division or plan of division under Delaware law (or any comparable event under a different jurisdiction’s laws), if
any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different
Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person.
ARTICLE II
AMOUNTS AND TERMS OF THE ADVANCES
SECTION 2.01 	The Advances. Each Lender severally agrees, on the terms and conditions
hereinafter set forth, to make Advances to the Borrower from time to time on any Business Day during the period
from the Closing Date until the Commitment Termination Date in an aggregate amount not to exceed at any time
outstanding such Lender’s Commitment. Each Borrowing shall be in an aggregate amount equal to the Borrowing
Minimum or a Borrowing Multiple in excess thereof and shall consist of Advances of the same Type made on the
same day by the Lenders ratably according to their respective Commitments. Within the limits of each Lender’s
Commitment, the Borrower may borrow under this Section 2.01, prepay pursuant to Section 2.10 and reborrow
under this Section 2.01.
SECTION 2.02 	Making the Advances.
(a) 	Each Borrowing shall be made on notice, given not later than (x) 11:00 A.M. (New York
City time) on the third Business Day prior to the date of the proposed Borrowing (or at such later time as the
Administrative Agent, in its reasonable discretion, may agree to) in the case of a Borrowing consisting of
Eurodollar Rate Advances or (y) 11:00 A.M. (New York City time) on the date of the proposed Borrowing in the
case of a Borrowing consisting of Base Rate Advances, by the Borrower to the Administrative Agent, which shall
give to each Lender prompt notice thereof by telecopier or other electronic communication. Each notice of a
Borrowing shall be by notice in substantially the form of Exhibit A hereto or such other form as may be approved
by the Administrative Agent (including any form on an electronic platform or electronic transmission system as
shall be approved by the Administrative Agent) (a “Notice of Borrowing”), specifying therein the requested
(i) date of such Borrowing (which shall be a Business Day), (ii) Type of Advances comprising such Borrowing,
(iii) aggregate amount of such Borrowing, (iv) initial Interest Period for such Advance, if such Borrowing is to
consist of Eurodollar Rate Advances and (v) account or accounts in which the proceeds of the Borrowing should
be credited. Each Lender shall, before 1:00 P.M. (New York City time) on the date of such Borrowing make
available for the account of its Applicable Lending Office to the Administrative Agent at the applicable
Administrative Agent’s Office, in same day funds, such Lender’s ratable portion of such Borrowing. After the
Administrative Agent’s receipt of such funds and upon fulfillment of the applicable conditions set forth in
Article III, the Administrative Agent will make such funds available to the Borrower in immediately available
funds to the account or accounts specified by the Borrower to the Administrative Agent in the Notice of
Borrowing relating to the applicable Borrowing.
(b) 	Anything in Section 2.02(a) to the contrary notwithstanding, (i) the Borrower may not
select Eurodollar Rate Advances for any Borrowing if the obligation of the

-- 314 of 409 --

27
Lenders to make Eurodollar Rate Advances shall then be suspended pursuant to Section 2.08 or 2.12 and (ii) the
Eurodollar Rate Advances may not be outstanding as part of more than ten separate Borrowings.
(c) 	Each Notice of Borrowing shall be irrevocable and binding on the Borrower. In the case of
any Borrowing that the related Notice of Borrowing specifies is to be comprised of Eurodollar Rate Advances, the
Borrower shall indemnify each Lender against any reasonable loss, cost or expense incurred by such Lender as a
result of any failure to fulfill on or before the date specified in such Notice of Borrowing for such Borrowing the
applicable conditions set forth in Article III, including, without limitation, any reasonable loss (excluding loss of
anticipated profits), cost or expense incurred by reason of the liquidation or reemployment of deposits or other
funds acquired by such Lender to fund the Advance to be made by such Lender as part of such Borrowing when
such Advance, as a result of such failure, is not made on such date.
(d) 	Unless the Administrative Agent shall have received notice from a Lender prior to the time
of any Borrowing that such Lender will not make available to the Administrative Agent such Lender’s ratable
portion of such Borrowing, the Administrative Agent may assume that such Lender has made such portion
available to the Administrative Agent on the date of such Borrowing in accordance with Section 2.02(a) and the
Administrative Agent may, in reliance upon such assumption, make available to the Borrower on such date a
corresponding amount. If and to the extent that any Lender shall not have so made such ratable portion available
to the Administrative Agent, such Lender and the Borrower severally agree to pay or to repay to the
Administrative Agent forthwith on demand such corresponding amount and to pay interest thereon, for each day
from the date such amount is made available to the Borrower until the date such amount is paid or repaid to the
Administrative Agent, at (i) in the case of the Borrower, the higher of (A) the interest rate applicable at the time to
Advances comprising such Borrowing and (B) the cost of funds incurred by the Administrative Agent in respect
of such amount and (ii) in the case of such Lender, the Federal Funds Rate. If the Borrower and such Lender shall
pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent
shall promptly remit to the Borrower the amount of such interest paid by the Borrower for such period. If such
Lender shall pay to the Administrative Agent such corresponding amount, such amount so paid shall constitute
such Lender’s Advance as part of such Borrowing for all purposes of this Agreement. Any payment by the
Borrower shall be without prejudice to any claim the Borrower may have against a Lender that shall have failed to
make such payment to the Administrative Agent.
(e) 	The failure of any Lender to make the Advance to be made by it as part of any Borrowing
shall not relieve any other Lender of its obligation, if any, hereunder to make its Advance on the date of such
Borrowing, but no Lender shall be responsible for the failure of any other Lender to make the Advance to be made
by such other Lender on the date of any Borrowing.
(f) 	If any Lender makes available to the Administrative Agent funds for any Advance to be
made by such Lender as provided herein, and such funds are not made available to a Borrower by the
Administrative Agent because the conditions to such Borrowing are not satisfied or waived in accordance with the
terms hereof, the Administrative Agent shall promptly return such funds (in like funds as received from such
Lender) to such Lender, without interest.

-- 315 of 409 --

28
SECTION 2.03 	[Reserved].
SECTION 2.04 	Fees.
(a) 	Commitment Fee. The Borrower agrees to pay to the Administrative Agent, for the
account of each Lender (other than a Defaulting Lender for such time as such Lender is a Defaulting Lender), a
commitment fee on the actual daily amount of such Lender’s unused Commitment at a rate per annum equal to the
Applicable Percentage, payable in arrears quarterly on the last Business Day of each March, June, September and
December, and on the Commitment Termination Date.
(b) 	Additional Fees. The Borrower shall pay to the Administrative Agent for its own account
such fees as may from time to time be agreed between the Borrower and the Administrative Agent.
SECTION 2.05 	Termination, Reduction or Increase of the Commitments; Extension of the
Commitment Termination Date.
(a) 	Ratable Reduction or Termination. The Borrower shall have the right, upon at least three
Business Days’ notice to the Administrative Agent, to terminate in whole or permanently reduce ratably in part
the unused portions of the respective Commitments of the Lenders; provided that each partial reduction shall be in
an aggregate amount of $10,000,000 or an integral multiple of $1,000,000 in excess thereof; provided, further,
that the aggregate amount of the Commitments shall not be reduced to an amount that is less than the aggregate
principal amount of Advances then outstanding; and provided, further, that any such notice may state that such
notice is conditioned upon the effectiveness of other credit facilities or the consummation of a specific transaction,
in which case such notice may be revoked by the Borrower if such condition is not satisfied.
(b) 	Defaulting Lender Commitment Reductions. The Borrower may terminate the unused
amount of the Commitments of any Lender that is a Defaulting Lender upon not less than three Business Days’
prior notice to the Administrative Agent (which shall promptly notify the Lenders thereof), it being understood
that notwithstanding such Commitment termination, the provisions of Section 2.19(c) will continue to apply to all
amounts thereafter paid by the Borrower for the account of such Defaulting Lender under this Agreement
(whether on account of principal, interest, fees, indemnity or other amounts); provided that such termination shall
not be deemed to be a waiver or release of any claim the Borrower, the Administrative Agent or any Lender may
have against such Defaulting Lender.
(c) 	Increase. The Borrower may, from time to time, by means of a notice delivered to the
Administrative Agent, request that the aggregate amount of the Commitments be increased by (i) increasing the
amount of the Commitment of one or more Lenders that have agreed (in their sole and individual discretion) to
such increase (each an “Increasing Lender”) and/or (ii) adding one or more Eligible Assignees as parties hereto
(each an “Additional Lender”) with Commitments in amounts agreed to by such Additional Lenders; provided
that (A) any such increase shall be in an aggregate amount of $50,000,000 or a higher integral multiple of
$5,000,000, (B) no Additional Lender shall be added as a party hereto without the written consent

-- 316 of 409 --

29
of the Administrative Agent to the extent such consent would be required for an assignment to such Additional
Lender pursuant to Section 8.07 (which consent shall not be unreasonably withheld, conditioned or delayed),
(C) the aggregate Commitments after giving effect to any such increase shall not exceed $7,000,000,000, and
(D) as a condition precedent to such increase, the Borrower shall deliver to the Administrative Agent a certificate
dated as of the Increase Effective Date (as defined below) signed by a Responsible Officer of the Borrower
certifying that before and after giving effect to such increase (1) no Default has occurred and is continuing as of
the date of such increase or would result from such increase and (2) each of the representations and warranties set
forth in Section 4.01 are true and correct in all material respects (except to the extent such representations and
warranties are qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such
representations and warranties shall be true and correct in all respects) as of the date of such increase, except to
the extent any such representation or warranty is stated to relate solely to an earlier date, in which case such
representation or warranty shall have been true and correct in all material respects (except to the extent such
representations and warranties are qualified with “materiality” or “Material Adverse Effect” or similar terms, in
which case such representations and warranties shall be true and correct in all respects) on and as of such earlier
date; provided, that for purposes of this Section 2.05(c), the representations and warranties contained in
Section 4.01(e) shall be deemed to refer to the most recent statements furnished pursuant to Section 5.01(i)(i) and
5.01(i)(ii). Any such increase in Commitments shall be effected pursuant to one or more Lender Joinder
Agreements executed and delivered by the Borrower, the Administrative Agent and the Increasing Lenders and/or
Additional Lenders, as applicable (the date on which such Lender Joinder Agreement(s) are delivered, the
“Increase Effective Date”). The Lender Joinder Agreement(s) may, without the consent of any other Lenders,
effect such amendments to this Agreement and the other Loan Documents as may be necessary or appropriate in
the opinion of the Administrative Agent, to effect the provisions of this Section 2.05(c). On the Increase Effective
Date, (x) each Lender shall advance funds required (if any) to cause all outstanding Advances and unused
Commitments to be held on a pro rata basis in accordance with the respective Commitments of each Lender after
giving effect to such increase (for each Lender, its “Revised Percentage”) and (y) the Administrative Agent shall
use any funds so received to repay the Advances of each Lender to the extent required so that such Lender has its
Revised Percentage of all outstanding Advances (it being understood that the Borrower shall be responsible for
any break funding payments owing pursuant to Section 8.04(c) resulting from such repayments). The
Administrative Agent shall promptly notify the Borrower and the Lenders of any increase in the amount of the
Commitments pursuant to this Section 2.05(c) and of the amount of the Commitment of each Lender after giving
effect thereto.
(d) 	Extension of the Facility. The Borrower may, by written notice to the Administrative
Agent (which shall promptly deliver a copy to each Lender) not more than 60 days and not less than 30 days prior
to the proposed date of effectiveness of an extension (an “Extension Date”), request that the Lenders extend the
Commitment Termination Date for an additional period of one year from the applicable Commitment Termination
Date then in effect hereunder (the then “Existing Commitment Termination Date”), provided that in no event shall
the Commitment Termination Date be extended beyond (i) the fifth anniversary of the effective date of the
Extension Date and (ii) the seventh anniversary of the Closing Date. Each Lender shall, by notice to the Borrower
and the Administrative Agent given not more than 15 days (or such other date specified by the Borrower in such
written notice or any supplement thereto) after such written notice is delivered to the Administrative Agent, advise
the Borrower whether or not it agrees to

-- 317 of 409 --

30
the requested extension (each Lender agreeing to a requested extension being called a “Consenting Lender” and
each Lender declining to agree to a requested extension being called a “Declining Lender”). Any Lender that has
not so advised the Borrower and the Administrative Agent by such day shall be deemed to have declined to agree
to such extension and shall be a Declining Lender (unless such Lender subsequently agrees to such requested
extension and the Borrower elects in its sole discretion to treat such Lender as a Consenting Lender). If Lenders
constituting the Required Lenders shall have agreed to a Commitment Termination Date extension request, then
the Commitment Termination Date shall, as to the Consenting Lenders and any Lender replacing a Declining
Lender, be extended effective as of the Extension Date to the date that is one year after the then Existing
Commitment Termination Date. The decision to agree or withhold agreement to any Commitment Termination
Date extension request shall be at the sole discretion of each Lender. The Commitment of each Declining Lender
shall terminate on the Existing Commitment Termination Date applicable to such Declining Lender. The principal
amount of any outstanding Advances made by Declining Lenders, together with any accrued interest thereon and
any accrued fees and other amounts payable to or for the account of such Declining Lenders hereunder, shall be
due and payable on the Existing Commitment Termination Date applicable to such Declining Lender.
Notwithstanding the foregoing provisions of this subsection, the Borrower shall have the right, at any time prior
to any Existing Commitment Termination Date applicable to any Declining Lender, to require such Declining
Lender to assign and delegate its interests, rights and obligations under this Agreement pursuant to Section 8.07 to
a Lender or (solely to the extent such consent would be required for an assignment pursuant to Section 8.07,
subject to the consent of the Administrative Agent (such consent not to be unreasonably withheld, conditioned or
delayed)) other Eligible Assignee, that agrees to a Commitment Termination Date extension with respect to such
Existing Commitment Termination Date and executes and delivers to the Administrative Agent an appropriate
Assignment and Acceptance. Any such assignee shall for all purposes hereunder constitute a Consenting Lender
with respect to the applicable Commitment Termination Date extension request. Notwithstanding the foregoing,
no extension of the Commitment Termination Date pursuant to this subsection shall become effective unless the
Borrower shall have delivered to the Administrative Agent a certificate dated as of the Extension Date signed by a
Responsible Officer of the Borrower certifying that before and after giving effect to such extension (A) no Default
has occurred and is continuing as of the Extension Date or would result from such extension and (B) each of the
representations and warranties set forth in Section 4.01 are true and correct in all material respects (except to the
extent such representations and warranties are qualified with “materiality” or “Material Adverse Effect” or similar
terms, in which case such representations and warranties shall be true and correct in all respects) as of the
Extension Date, except to the extent any such representation or warranty is stated to relate solely to an earlier date,
in which case such representation or warranty shall have been true and correct in all material respects (except to
the extent such representations and warranties are qualified with “materiality” or “Material Adverse Effect” or
similar terms, in which case such representations and warranties shall be true and correct in all respects) on and as
of such earlier date; provided, that for purposes of this Section 2.05(d), the representations and warranties
contained in Section 4.01(e) shall be deemed to refer to the most recent statements furnished pursuant to
Section 5.01(i)(i) and 5.01(i)(ii). The Borrower may extend the Commitment Termination Date up to two times
under this Section 2.05(d).
SECTION 2.06 	Repayment of Advances. The Borrower shall repay to the Administrative
Agent, for the account of each Lender on the Commitment Termination Date

-- 318 of 409 --

31
applicable to such Lender, the aggregate principal amount of all Advances owing to such Lender outstanding on
such date.
SECTION 2.07 	Interest on Advances.
(a) 	Scheduled Interest. The Borrower shall pay interest on the unpaid principal amount of each
Advance made to it from the date of such Advance until such principal amount shall be paid in full, at the
following rates per annum:
(i) 	Base Rate Advances. During such periods as such Advance is a Base Rate
Advance, a rate per annum equal at all times to the sum of (A) the Base Rate in effect from time to time
and (B) the Applicable Margin, payable in arrears quarterly on the last Business Day of each March, June,
September and December, during such periods and on the Commitment Termination Date applicable to
any Lender.
(ii) 	Eurodollar Rate Advances. During such periods as such Advance is a Eurodollar
Rate Advance, a rate per annum equal at all times during each Interest Period for such Advance to the sum
of (A) the Eurodollar Rate for such Interest Period for such Advance, and (B) the Applicable Margin,
payable in arrears on the last day of such Interest Period and, if such Interest Period has a duration of more
than three months, on each day that occurs during such Interest Period every three months from the first
day of such Interest Period and on the date such Eurodollar Rate Advance shall be Converted, continued or
paid in full.
(b) 	Default Interest. Upon the occurrence and during the continuance of an Event of Default,
the Administrative Agent shall, upon the request of the Required Lenders, require the Borrower to pay interest
(“Default Interest”), which amount shall accrue as of the date of occurrence of the Event of Default, on (i) the
unpaid principal amount of each Advance owing to each Lender, payable in arrears on the dates referred to in
Section 2.07(a)(i) or 2.07(a)(ii), at a rate per annum equal at all times to 2% per annum above the rate per annum
required to be paid on such Advance pursuant to Section 2.07(a)(i) or 2.07(a)(ii) and (ii) to the fullest extent
permitted by Law, the amount of any interest, fee or other amount payable hereunder that is not paid when due,
from the date such amount shall be due until such amount shall be paid in full, payable in arrears on the date such
amount shall be paid in full and on demand, at a rate per annum equal at all times to 2% per annum above the rate
per annum required to be paid on Base Rate Advances pursuant to Section 2.07(a)(i), provided, however, that
following acceleration of the Advances pursuant to Section 6.01, Default Interest shall accrue and be payable
hereunder whether or not previously required by the Administrative Agent.
SECTION 2.08 	Interest Rate Determination.
(a) 	The Administrative Agent shall give prompt notice to the Borrower and the Lenders of the
applicable interest rate determined by the Administrative Agent for purposes of Section 2.07(a)(i) or 2.07(a)(ii).
(b) 	If, with respect to any Eurodollar Rate Advances, the Required Lenders notify the
Administrative Agent that (i) they are unable to obtain matching deposits in the London inter-bank market at or
about 11:00 A.M. (London time) on the second Business Day before the

-- 319 of 409 --

32
making of a Borrowing in sufficient amounts to fund their respective Advances as a part of such Borrowing
during its Interest Period or (ii) the Eurodollar Rate for any Interest Period for such Advances will not adequately
and fairly reflect the cost to the Required Lenders of making, funding or maintaining their respective Eurodollar
Rate Advances for such Interest Period, the Administrative Agent shall forthwith so notify the Borrower and the
Lenders, whereupon (A) the Borrower will, on the last day of the then existing Interest Period therefor, either
(1) prepay such Advances or (2) Convert such Advances into Base Rate Advances and (B) the obligation of the
Lenders to make, continue Eurodollar Rate Advances as, or to Convert Advances into, Eurodollar Rate Advances
shall be suspended until the Administrative Agent shall notify the Borrower and the Lenders that the
circumstances causing such suspension no longer exist.
(c) 	On the date on which the aggregate unpaid principal amount of Eurodollar Rate Advances
comprising any Borrowing shall be reduced, by payment or prepayment or otherwise, to less than $5,000,000,
such Advances shall automatically Convert into Base Rate Advances.
(d) 	Upon the occurrence and during the continuance of any Event of Default, (i) each
Eurodollar Rate Advance will automatically, on the last day of the then existing Interest Period therefor, be
Converted into a Base Rate Advance (unless the Required Lenders otherwise consent) and (ii) the obligation of
the Lenders to make, continue Eurodollar Rate Advances as, or to Convert Advances into, Eurodollar Rate
Advances shall be suspended.
SECTION 2.09 	Interest Elections.
(a) 	Each Borrowing initially shall be of the Type specified in the applicable Notice of
Borrowing and, in the case of a Eurodollar Rate Advance, shall have an initial Interest Period as specified in such
Notice of Borrowing. Thereafter, the Borrower may elect to Convert such Borrowing to a different Type or to
continue such Borrowing and, in the case of a Eurodollar Rate Advance, may elect Interest Periods therefor, all as
provided in this Section. The Borrower may elect different options with respect to different portions of the
affected Borrowing, in which case each such portion shall be allocated ratably among the Lenders holding the
Advances comprising such Borrowing, and the Advances comprising each such portion shall be considered a
separate Borrowing.
(b) 	To make an election pursuant to this Section, the Borrower shall notify the Administrative
Agent of such election by delivering to the Administrative Agent an Interest Election Request by the time that a
Notice of Borrowing would be required under Section 2.02 if the Borrower were requesting a Borrowing of the
Type resulting from such election to be made on the effective date of such election.
(c) 	Each Interest Election Request shall specify the following information:
(i) 	the Borrowing to which such Interest Election Request applies and, if different
options are being elected with respect to different portions thereof, the portions thereof to be allocated to
each resulting Borrowing (in which case the information to be specified pursuant to clauses (iii) and
(iv) below shall be specified for each resulting Borrowing);

-- 320 of 409 --

33
(ii) 	the effective date of the election made pursuant to such Interest Election Request,
which shall be a Business Day;
(iii) 	whether the resulting Borrowing is to consist of Base Rate Advances or Eurodollar
Rate Advances; and
(iv) 	if the resulting Borrowing is to consist of Eurodollar Rate Advances, the Interest
Period to be applicable thereto (which Interest Period shall be a period contemplated by the definition of
the term “Interest Period”).
(d) 	Promptly following receipt of an Interest Election Request, the Administrative Agent shall
advise each Lender of the details thereof and of such Lender’s portion of each resulting Borrowing.
If the Borrower requests a Borrowing of Eurodollar Rate Advances but does not specify an Interest
Period or fails to deliver a timely Interest Election Request with respect to a Borrowing consisting of Eurodollar
Rate Advances prior to the end of the Interest Period applicable thereto, then, unless such Borrowing is repaid as
provided herein or Section 2.08(d) is applicable thereto, at the end of such Interest Period, such Borrowing shall
automatically continue as a Borrowing consisting of Eurodollar Rate Advances with an Interest Period of one
month unless such Borrowing is or was repaid in accordance with Section 2.10.
SECTION 2.10 	Optional Prepayments of Advances. The Borrower may, upon notice to the
Administrative Agent stating the proposed date and aggregate principal amount of the proposed prepayment,
given not later than 11:00 A.M. (New York City time) on the date (which date shall be a Business Day) of such
proposed prepayment, in the case of a Borrowing consisting of Base Rate Advances, and not later than 11:00
A.M. (New York City time) at least two Business Days prior to the date of such proposed prepayment, in the case
of a Borrowing consisting of Eurodollar Rate Advances, and if such notice is given, the Borrower shall, prepay
the outstanding principal amount of the Advances comprising part of the same Borrowing in whole or ratably in
part, and in the case of any Borrowing consisting of Eurodollar Rate Advances, together with accrued interest to
the date of such prepayment on the principal amount prepaid; provided, however, that (a) each partial prepayment
shall be in an aggregate principal amount of the Borrowing Minimum or a Borrowing Multiple in excess thereof
and (b) if any prepayment of a Eurodollar Rate Advance is made on a date other than the last day of an Interest
Period for such Eurodollar Rate Advance, the Borrower shall also pay any amount owing pursuant to
Section 8.04(c); and provided, further, that, subject to clause (b) of the immediately preceding proviso, any such
notice may state that such notice is conditioned upon the effectiveness of other credit facilities or the
consummation of a specific transaction, in which case such notice may be revoked by the Borrower if such
condition is not satisfied.
SECTION 2.11 	Increased Costs; Reserves on Eurodollar Rate Loans.
(a) 	If, due to either (i) the introduction of or any change in or in the interpretation of any Law
or regulation or (ii) the compliance with any directive, guideline or request from any central bank or other
Governmental Authority including, without limitation, any agency of the European Union or similar monetary or
multinational authority (whether or not

-- 321 of 409 --

34
having the force of Law), in each case after the date hereof (or with respect to any Lender, if later, the date on
which such Lender becomes a Lender), there shall be any increase in the cost to any Lender of agreeing to make
or making, funding or maintaining Eurodollar Rate Advances (excluding for purposes of this Section 2.11 any
such increased costs resulting from (A) Taxes as to which such Lender is indemnified under Section 2.14,
(B) Excluded Taxes and (C) Other Taxes), and such Lender is generally charging, or intends to generally charge,
such amounts to its customers that are similarly situated to the Borrower and with similar credit facilities, to the
extent such Lender has the right under such similar credit facilities to do so (but such Lender shall not be required
to disclose any confidential or proprietary information), then the Borrower shall from time to time, upon demand
by such Lender (with a copy of such demand to the Administrative Agent), pay to the Administrative Agent for
the account of such Lender additional amounts sufficient to compensate such Lender for such increased cost. A
certificate as to such increased cost submitted to the Borrower and the Administrative Agent by such Lender shall
be conclusive and binding for all purposes, absent demonstrable error.
(b) 	If any Lender determines that compliance with any Law or regulation or any directive,
guideline or request from any central bank or other Governmental Authority including, without limitation, any
agency of the European Union or similar monetary or multinational authority (whether or not having the force of
Law), in each case promulgated or given after the date hereof (or with respect to any Lender, if later, the date on
which such Lender becomes a Lender), affects or would affect the amount of capital or liquidity required or
expected to be maintained by such Lender or any corporation controlling such Lender and that the amount of such
capital or liquidity is increased by or based upon the existence of such Lender’s commitment to lend hereunder
and other commitments of this type, and such Lender is generally charging, or intends to generally charge, such
amounts to its customers that are similarly situated to the Borrower and with similar credit facilities, to the extent
such Lender has the right under such similar credit facilities to do so (but such Lender shall not be required to
disclose any confidential or proprietary information), the Borrower shall, from time to time upon demand by such
Lender (with a copy of such demand to the Administrative Agent), pay to the Administrative Agent for the
account of such Lender, additional amounts sufficient to compensate such Lender or such corporation in the light
of such circumstances, to the extent that such Lender reasonably determines such increase in capital or liquidity to
be allocable to the existence of such Lender’s commitment to lend hereunder. A certificate as to such amounts
submitted to the Borrower and the Administrative Agent by such Lender shall be conclusive and binding for all
purposes, absent demonstrable error.
(c) 	Notwithstanding anything in this Section 2.11 to the contrary, for purposes of this
Section 2.11, (i) the Dodd Frank Wall Street Reform and Consumer Protection Act and the rules and regulations
issued thereunder or in connection therewith or in implementation thereof, and (ii) all requests, rules, guidelines
and directions promulgated by the Bank for International Settlements, the Basel Committee on Banking
Supervision (or any similar or successor agency, or the United States or foreign regulatory authorities, in each
case, pursuant to Basel III) shall be deemed to have been enacted following the date hereof (or with respect to any
Lender, if later, the date on which such Lender becomes a Lender).
(d) 	The Borrower shall pay to each Lender, as long as such Lender shall be required to
maintain reserves with respect to liabilities or assets consisting of or including

-- 322 of 409 --

35
Eurocurrency funds or deposits (currently known as Eurocurrency Liabilities), additional interest on the unpaid
principal amount of each Eurodollar Rate Advance equal to the actual costs of such reserves allocated to such
Advance by such Lender (as determined by such Lender in good faith, which determination shall be conclusive
and binding absent demonstrable error), which shall be due and payable on each date on which interest is payable
on such Advance, provided the Borrower shall have received at least 10 days’ prior notice (with a copy to the
Administrative Agent) of such additional interest from such Lender. If a Lender fails to give notice 10 days prior
to the relevant interest payment date, but such Lender gives notice within 30 days after such interest payment date,
such additional interest shall be due and payable 10 days from receipt of such notice.
SECTION 2.12 	Illegality. Notwithstanding any other provision of this Agreement, (a) if any
Lender shall notify the Administrative Agent that the introduction of or any change in or in the interpretation of
any Law or regulation makes it unlawful, or any central bank or other Governmental Authority, including without
limitation, any agency of the European Union or similar monetary or multinational authority, asserts that it is
unlawful, for such Lender or its Eurodollar Lending Office to perform its obligations hereunder to make
Eurodollar Rate Advances or to fund or maintain Eurodollar Rate Advances hereunder, (i) each Eurodollar Rate
Advance of such Lender will automatically, upon such notification, be Converted into a Base Rate Advance,
(ii) the obligation of such Lender to make Eurodollar Rate Advances or to Convert Advances into Eurodollar Rate
Advances shall be suspended until the Administrative Agent shall notify the Borrower and such Lender that the
circumstances causing such suspension no longer exist and (iii) the Administrative Agent shall during the period
of such suspension compute the Base Rate applicable to such Lender without reference to the Eurodollar Rate
component thereof and (b) if Lenders constituting the Required Lenders so notify the Administrative Agent,
(i) each Eurodollar Rate Advance of each Lender will automatically, upon such notification, Convert into a Base
Rate Advance, (ii) the obligation of each Lender to make Eurodollar Rate Advances or to Convert Advances into,
or to continue Eurodollar Rate Advances as, Eurodollar Rate Advances shall be suspended until the
Administrative Agent shall notify the Borrower and each Lender that the circumstances causing such suspension
no longer exist and (iii) the Administrative Agent shall during the period of such suspension compute the Base
Rate applicable to each Lender without reference to the Eurodollar Rate component thereof.
SECTION 2.13 	Payments and Computations.
(a) 	The Borrower shall make each payment required to be made by it under this Agreement not
later than 11:00 A.M. (New York City time) on the day when due in Dollars to the Administrative Agent at the
applicable Administrative Agent’s Office in same day funds. The Administrative Agent will promptly thereafter
cause to be distributed like funds relating to the payment of principal or interest or commitment fees ratably (other
than amounts payable pursuant to Section 2.02(c), 2.11, 2.12(a), 2.14, 2.15 or 8.04(c)) to the Lenders for the
account of their respective Applicable Lending Offices, and like funds relating to the payment of any other
amount payable to any Lender to such Lender for the account of its Applicable Lending Office, in each case to be
applied in accordance with the terms of this Agreement. Upon its acceptance of an Assignment and Acceptance
and recording of the information contained therein in the Register pursuant to Section 8.07(c), from and after the
effective date specified in such Assignment and Acceptance, the Administrative Agent shall make all payments
hereunder in respect of the interest assigned thereby to the assignor for amounts which have accrued to but
excluding the effective

-- 323 of 409 --

36
date of such assignment and to the assignee for amounts which have accrued from and after the effective date of
such assignment. All payments to be made by the Borrower shall be made without condition or deduction for any
counterclaim, defense, recoupment or setoff.
(b) 	The Borrower hereby authorizes each Lender, if and to the extent payment owed to such
Lender is not made when due hereunder, to charge from time to time against any or all of the Borrower’s accounts
with such Lender any amount so due.
(c) 	All computations of interest based on the Base Rate shall be made by the Administrative
Agent on the basis of a year of 365 or 366 days, as the case may be, and all computations of interest based on the
Eurodollar Rate or the Federal Funds Rate (other than determinations of the Base Rate made at any time by
reference to the Federal Funds Rate) and of commitment fees shall be made by the Administrative Agent on the
basis of a year of 360 days, in each case for the actual number of days (including the first day but excluding the
last day) occurring in the period for which such interest or such fees are payable. Each determination by the
Administrative Agent of an interest rate hereunder shall be conclusive and binding for all purposes, absent
demonstrable error.
(d) 	Whenever any payment hereunder shall be stated to be due on a day other than a Business
Day, such payment shall be made on the next succeeding Business Day, and such extension of time shall in such
case be included in the computation of payment of interest or commitment fee, as the case may be; provided,
however, that, if such extension would cause payment of interest on or principal of Eurodollar Rate Advances to
be made in the next following calendar month, such payment shall be made on the immediately preceding
Business Day.
(e) 	Unless the Administrative Agent shall have received notice from the Borrower prior to the
date on which any payment is due to the Lenders hereunder that the Borrower will not make such payment in full,
the Administrative Agent may assume that the Borrower has made such payment in full to the Administrative
Agent on such date and the Administrative Agent may, in reliance upon such assumption, cause to be distributed
to each Lender on such due date an amount equal to the amount then due such Lender. If and to the extent the
Borrower shall not have so made such payment in full to the Administrative Agent, each Lender shall repay to the
Administrative Agent, following prompt notice thereof, forthwith on demand such amount distributed to such
Lender, together with interest thereon, for each day from the date such amount is distributed to such Lender until
the date such Lender repays such amount to the Administrative Agent, at the Federal Funds Rate.
SECTION 2.14 	Taxes.
(a) 	Obligation to Withhold; Payments on Account of Taxes.
(i) 	Any and all payments by or on account of any obligation of the Borrower under any Loan
Document shall be made without deduction or withholding for any Taxes, except as required by applicable
Laws. If any applicable Laws require the deduction or withholding of any Tax from any such payment by
the Administrative Agent or the Borrower, then the Administrative Agent or the Borrower shall be entitled
to make such

-- 324 of 409 --

37
deduction or withholding, upon the basis of the information and documentation to be delivered pursuant to
subsection (e) below.
(ii) 	If the Borrower or the Administrative Agent shall be required by any applicable Laws to
withhold or deduct any Taxes from any payment, then (A) the Borrower or the Administrative Agent, as
required by such Laws, shall withhold or make such deductions as required based upon the information
and documentation it has received pursuant to subsection (e) below, (B) the Borrower or the
Administrative Agent, to the extent required by such Laws, shall timely pay the full amount withheld or
deducted to the relevant Governmental Authority in accordance with such Laws, and (C) to the extent that
the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the Borrower
shall be increased as necessary so that after any required withholding or the making of all required
deductions (including deductions applicable to additional sums payable under this Section 2.14) the
Lender (or, as applicable, the Administrative Agent) receives an amount equal to the sum it would have
received had no such withholding or deduction been made.
(b) 	Payment of Other Taxes. Without limiting the provisions of subsection (a) above, the Borrower
shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the
Administrative Agent timely reimburse it for the payment of, any Other Taxes.
(c) 	Tax Indemnifications. (i) The Borrower shall, and does hereby, indemnify each Lender and the
Administrative Agent, and shall make payment in respect thereof within 30 days after demand therefor, for the full
amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts
payable under this Section 2.14) payable or paid by such Lender or the Administrative Agent or required to be
withheld or deducted from a payment to such Lender and the Administrative Agent, and reasonable expenses
arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally
imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or
liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the
Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.
(ii) 	Each Lender shall, and does hereby, severally indemnify, and shall make payment in
respect thereof within 10 days after demand therefor, (x) the Administrative Agent against any Indemnified
Taxes attributable to such Lender (but only to the extent that the Borrower have not already indemnified
the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower
to do so), (y) the Administrative Agent against any Taxes attributable to such Lender’s failure to comply
with the provisions of Section 8.07(e) relating to the maintenance of a Participant Register and (z) the
Administrative Agent against any Excluded Taxes attributable to such Lender that are payable or paid by
the Administrative Agent or the Borrower in connection with any Loan Document, and any reasonable
expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally
imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such
payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent

-- 325 of 409 --

38
manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all
amounts at any time owing to such Lender under this Agreement or any other Loan Document against any
amount due to the Administrative Agent under this clause (ii).
(d) 	Evidence of Payments. Upon request by the Borrower or the Administrative Agent, as the case
may be, after any payment of Taxes by the Borrower or by the Administrative Agent to a Governmental Authority
as provided in this Section 2.14, the Borrower shall deliver to the Administrative Agent or the Administrative
Agent shall deliver to the Borrower, as the case may be, the original or a certified copy of a receipt issued by such
Governmental Authority evidencing such payment, a copy of any return required by Laws to report such payment
or other evidence of such payment reasonably satisfactory to the Borrower or the Administrative Agent, as the
case may be.
(e) 	Status of Lenders; Tax Documentation.
(i) 	Any Lender that is entitled to an exemption from or reduction of withholding Tax with
respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative
Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such
properly completed and executed documentation reasonably requested by the Borrower or the
Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of
withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative
Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the
Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to
determine whether or not such Lender is subject to backup withholding or information reporting
requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion,
execution and submission of such documentation (other than such documentation set forth in Sections
2.14(e)(ii)(A), 2.14(e)(ii)(B) and 2.14(e)(ii)(D) below) shall not be required if in the Lender’s reasonable
judgment such completion, execution or submission would subject such Lender to any material
unreimbursed cost or expense or would materially prejudice the legal or commercial position of such
Lender.
(ii) 	Without limiting the generality of the foregoing,
(A) 	any Lender that is a U.S. Person shall deliver to the Borrower and the
Administrative Agent on or prior to the date on which such Lender becomes a Lender under this
Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the
Administrative Agent), executed originals of IRS Form W-9 certifying that such Lender is exempt
from U.S. federal backup withholding tax;
(B) 	any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the
Borrower and the Administrative Agent (in such number of copies as shall be requested by the
recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this
Agreement (and from time to time thereafter

-- 326 of 409 --

39
upon the reasonable request of the Borrower or the Administrative Agent), whichever of the
following is applicable:
(I) 	in the case of a Foreign Lender claiming the benefits of an income tax treaty
to which the United States is a party (x) with respect to payments of interest under
any Loan Document, executed originals of IRS Form W-8BEN-E (or W-8BEN, as
applicable) establishing an exemption from, or reduction of, U.S. federal
withholding Tax pursuant to the “interest” article of such tax treaty and (y) with
respect to any other applicable payments under any Loan Document, IRS Form W-
8BEN-E (or W-8BEN, as applicable) establishing an exemption from, or reduction
of, U.S. federal withholding Tax pursuant to the “business profits” or “other
income” article of such tax treaty;
(II) 	executed originals of IRS Form W-8ECI;
(III) 	in the case of a Foreign Lender claiming the benefits of the exemption for
portfolio interest under Section 881(c) of the Internal Revenue Code, (x) a
certificate substantially in the form of Exhibit C-1 to the effect that such Foreign
Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Internal
Revenue Code, a “10 percent shareholder” of any of the Borrower within the
meaning of Section 881(c)(3)(B) of the Internal Revenue Code, or a “controlled
foreign corporation” described in Section 881(c)(3)(C) of the Internal Revenue
Code (a “U.S. Tax Compliance Certificate”) and (y) executed originals of IRS Form
W-8BEN-E (or W-8BEN, as applicable); or
(IV) to the extent a Foreign Lender is not the beneficial owner, executed originals
of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN-E
(or W-8BEN, as applicable), a U.S. Tax Compliance Certificate substantially in the
form of Exhibit C-2 or Exhibit C-3, IRS Form W-9, and/or other certification
documents from each beneficial owner, as applicable; provided that if the Foreign
Lender is a partnership and one or more direct or indirect partners of such Foreign
Lender are claiming the portfolio interest exemption, such Foreign Lender may
provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit C-4
on behalf of each such direct and indirect partner;
(C) 	any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the
Borrower and the Administrative Agent (in such number of copies as shall be requested by the
recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this
Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the
Administrative Agent), executed originals of any other form prescribed by applicable law as a basis
for claiming

-- 327 of 409 --

40
exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such
supplementary documentation as may be prescribed by applicable law to permit the Borrower or
the Administrative Agent to determine the withholding or deduction required to be made; and
(D) 	if a payment made to a Lender under any Loan Document would be subject to U.S.
federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the
applicable reporting requirements of FATCA (including those contained in Section 1471(b) or
1472(b) of the Internal Revenue Code, as applicable), such Lender shall deliver to the Borrower
and the Administrative Agent at the time or times prescribed by law and at such time or times
reasonably requested by the Borrower or the Administrative Agent such documentation prescribed
by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Internal Revenue
Code) and such additional documentation reasonably requested by the Borrower or the
Administrative Agent as may be necessary for the Borrower and the Administrative Agent to
comply with their obligations under FATCA and to determine that such Lender has complied with
such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from
such payment. Solely for purposes of this clause (D), “FATCA” shall include any amendments
made to FATCA after the date of this Agreement.
(iii) 	Each Lender agrees that if any form or certification it previously delivered pursuant to this
Section 2.14 expires or becomes obsolete or inaccurate in any respect, it shall update such form or
certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability
to do so.
(f) 	Treatment of Certain Refunds. Unless required by applicable Laws, at no time shall the
Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender any refund of
Taxes withheld or deducted from funds paid for the account of such Lender. If any Lender or the Administrative
Agent determines, in its sole discretion, that it has received a refund of any Taxes as to which it has been
indemnified by the Borrower or with respect to which the Borrower has paid additional amounts pursuant to this
Section 2.14, it shall pay to the Borrower an amount equal to such refund (but only to the extent of indemnity
payments made, or additional amounts paid, by the Borrower under this Section 2.14 with respect to the Taxes
giving rise to such refund), net of all out-of-pocket expenses (including Taxes) incurred by such Lender or the
Administrative Agent, and without interest (other than any interest paid by the relevant Governmental Authority
with respect to such refund), provided that the Borrower, upon the request of such Lender or the Administrative
Agent, agrees to repay the amount paid over to the Borrower (plus any penalties, interest or other charges imposed
by the relevant Governmental Authority) to such Lender or the Administrative Agent in the event such Lender or
the Administrative Agent is required to repay such refund to such Governmental Authority. Notwithstanding
anything to the contrary in this subsection, in no event will the applicable Lender or the Administrative Agent be
required to pay any amount to the Borrower pursuant to this subsection the payment of which would place such
Lender or the Administrative Agent in a less favorable net after-Tax position than it would have been in if the Tax
subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed
and the indemnification payments or additional amounts with respect to such Tax had never been paid. This
subsection shall not be construed to

-- 328 of 409 --

41
require any Lender or the Administrative Agent to make available its Tax returns to the Borrower or any other
Person.
SECTION 2.15 	Sharing of Payments, Etc. Subject to Section 2.19 in the case of a Defaulting
Lender, if any Lender shall obtain any payment (whether voluntary, involuntary, through the exercise of any right
of setoff, or otherwise) on account of the Advances owing to it (other than pursuant to Section 2.02(c), 2.11,
2.12(a), 2.14 or 8.04(c)) in excess of its ratable share of payments on account of the Advances obtained by all the
Lenders, such Lender shall forthwith purchase from the other Lenders such participations in the Advances owing
to them as shall be necessary to cause such purchasing Lender to share the excess payment ratably with each of
them; provided, however, that if all or any portion of such excess payment is thereafter recovered from such
purchasing Lender, such purchase from each Lender shall be rescinded and such Lender shall repay to the
purchasing Lender the purchase price to the extent of such recovery together with an amount equal to such
Lender’s ratable share (according to the proportion of (a) the amount of such Lender’s required repayment to
(b) the total amount so recovered from the purchasing Lender) of any interest or other amount paid or payable by
the purchasing Lender in respect of the total amount so recovered. The Borrower agrees that any Lender so
purchasing a participation from another Lender pursuant to this Section 2.15 may, to the fullest extent permitted
by Law, exercise all its rights of payment (including the right of setoff) with respect to such participation as fully
as if such Lender were the direct creditor of the Borrower in the amount of such participation.
SECTION 2.16 	Use of Proceeds. The proceeds of the Advances shall be available, and the
Borrower agrees that it shall use such proceeds, solely for general corporate purposes of the Borrower and its
Subsidiaries.
SECTION 2.17 	Evidence of Debt.
(a) 	Each Lender shall maintain in accordance with its usual practice an account or accounts
evidencing the indebtedness of the Borrower to such Lender resulting from each Advance owing to such Lender
from time to time, including the amounts of principal and interest payable and paid to such Lender from time to
time hereunder in respect of Advances.
(b) 	The Register maintained by the Administrative Agent pursuant to Section 8.07(d) shall
include a control account, and a subsidiary account for each Lender, in which accounts (taken together) shall be
recorded (i) the date and amount of each Borrowing made hereunder, the Type of Advances comprising such
Borrowing and, if appropriate, the Interest Period applicable thereto, (ii) the terms of each Assignment and
Acceptance delivered to and accepted by it, (iii) the amount of any principal or interest due and payable or to
become due and payable from the Borrower to each Lender hereunder and (iv) the amount of any sum received by
the Administrative Agent from the Borrower hereunder and each Lender’s share thereof.
(c) 	Entries made reasonably and in good faith by the Administrative Agent in the Register
pursuant to subsection 2.17(b) above, and by each Lender in its account or accounts pursuant to subsection 2.17(a)
above, shall be prima facie evidence of the amount of principal and interest due and payable or to become due and
payable from the Borrower to, in the case of the Register, each Lender and, in the case of such account or
accounts, such Lender, under this Agreement, absent manifest error; provided, however, that the failure of the
Administrative Agent

-- 329 of 409 --

42
or such Lender to make an entry, or any finding that an entry is incorrect, in the Register or such account or
accounts shall not limit, expand or otherwise affect the obligations of the Borrower under this Agreement.
(d) 	Upon the request of any Lender made through the Administrative Agent, the Borrower
shall prepare, execute and deliver to such Lender a promissory note of the Borrower payable to such Lender,
substantially in the form of any promissory note delivered to any Lender on the Closing Date pursuant to Section
3.01(j) (or such other form reasonably approved by the Administrative Agent), which promissory note shall, in
addition to the Register, evidence such Lender’s Advances.
SECTION 2.18 	Alternate Rate of Interest(a) 	.
(a) 	Notwithstanding anything to the contrary herein or in any other Loan Document, if a
Benchmark Transition Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement
Date have occurred prior to the Reference Time in respect of any setting of the then-current Benchmark, then (x)
if a Benchmark Replacement is determined in accordance with clause (1) or (2) of the definition of “Benchmark
Replacement” for such Benchmark Replacement Date, such Benchmark Replacement will replace such
Benchmark for all purposes hereunder and under any Loan Document in respect of such Benchmark setting and
subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this
Agreement or any other Loan Document and (y) if a Benchmark Replacement is determined in accordance with
clause (3) of the definition of “Benchmark Replacement” for such Benchmark Replacement Date, such
Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document
in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5th) Business Day
after the date notice of such Benchmark Replacement is provided to the Lenders without any amendment to, or
further action or consent of any other party to, this Agreement or any other Loan Document so long as the
Administrative Agent has not received, by such time, written notice of objection to such Benchmark Replacement
from Lenders comprising the Required Lenders.
(b) 	Notwithstanding anything to the contrary herein or in any other Loan Document and
subject to the proviso below in this paragraph, if a Term SOFR Transition Event and its related Benchmark
Replacement Date have occurred prior to the Reference Time in respect of any setting of the then-current
Benchmark, then the applicable Benchmark Replacement will replace the then-current Benchmark for all purposes
hereunder or under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings,
without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan
Document; provided that, this clause (b) shall not be effective unless the Administrative Agent has delivered to
the Lenders and the Borrower a Term SOFR Notice. For the avoidance of doubt, the Administrative Agent shall
not be required to deliver a Term SOFR Notice after a Term SOFR Transition Event and may do so in its sole
discretion.
(c) 	In connection with the implementation of a Benchmark Replacement, the Administrative
Agent will have the right to make Benchmark Replacement Conforming Changes from time to time and,
notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing
such Benchmark Replacement Conforming Changes

-- 330 of 409 --

43
will become effective without any further action or consent of any other party to this Agreement or any other Loan
Document.
(d) 	The Administrative Agent will promptly notify the Borrower and the Lenders of (i) any
occurrence of a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, as
applicable, and its related Benchmark Replacement Date, (ii) the implementation of any Benchmark Replacement,
(iii) the effectiveness of any Benchmark Replacement Conforming Changes, (iv) the removal or reinstatement of
any tenor of a Benchmark pursuant to clause (e) below and (v) the commencement or conclusion of any
Benchmark Unavailability Period. Any determination, decision or election that may be made by the
Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this Section 2.18, including
any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event,
circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive
and binding absent manifest error and may be made in its or their sole discretion and without consent from any
other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to
this Section 2.18.
(e) 	Notwithstanding anything to the contrary herein or in any other Loan Document, at any
time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current
Benchmark is a term rate (including Term SOFR or LIBOR) and either (A) any tenor for such Benchmark is not
displayed on a screen or other information service that publishes such rate from time to time as selected by the
Administrative Agent in its reasonable discretion or (B) the regulatory supervisor for the administrator of such
Benchmark has provided a public statement or publication of information announcing that any tenor for such
Benchmark is or will be no longer representative, then the Administrative Agent may modify the definition of
“Interest Period” for any Benchmark settings at or after such time to remove such unavailable or non-
representative tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently
displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not,
or is no longer, subject to an announcement that it is or will no longer be representative for a Benchmark
(including a Benchmark Replacement), then the Administrative Agent may modify the definition of “Interest
Period” for all Benchmark settings at or after such time to reinstate such previously removed tenor.
(f) 	Upon the Borrower’s receipt of notice of the commencement of a Benchmark
Unavailability Period, the Borrower may revoke any request for a borrowing of, conversion to or continuation of
Eurodollar Rate Advances to be made, converted or continued during any Benchmark Unavailability Period and,
failing that, the Borrower will be deemed to have converted any such request into a request for a Borrowing of or
conversion to Base Rate Advances. During any Benchmark Unavailability Period or at any time that a tenor for
the then-current Benchmark is not an Available Tenor, the component of Base Rate based upon the then-current
Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of Base Rate.
SECTION 2.19 	Defaulting Lenders.
(a) 	Notwithstanding any provision of this Agreement to the contrary, if any Lender becomes a
Defaulting Lender, then the following provisions shall apply for so long as such

-- 331 of 409 --

44
Lender is a Defaulting Lender (it being understood that the determination of whether a Lender is no longer a
Defaulting Lender shall be made as described in Section 2.19(b)):
(i) 	such Defaulting Lender will not be entitled to any fees accruing during such period
pursuant to Section 2.04(a);
(ii) 	to the fullest extent permitted by applicable Law, such Lender will not be entitled to
vote in respect of amendments and waivers hereunder, and the Commitment and the outstanding Advances
of such Lender hereunder will not be taken into account in determining whether the Required Lenders or
all of the Lenders, as required, have approved any such amendment or waiver (and the definition of
“Required Lenders” will automatically be deemed modified accordingly for the duration of such period);
provided that any such amendment or waiver that would increase or extend the term of the Commitment of
such Defaulting Lender, extend the date fixed for the payment of principal or interest owing to such
Defaulting Lender hereunder, reduce the principal amount of any obligation owing to such Defaulting
Lender, reduce the amount of or the rate or amount of interest on any amount owing to such Defaulting
Lender or of any fee payable to such Defaulting Lender hereunder, or alter the terms of this proviso, will
require the consent of such Defaulting Lender; and
(iii) 	the Borrower may, at its sole expense and effort, require such Defaulting Lender to
assign and delegate its interests, rights and obligations under this Agreement pursuant to Section 8.07.
(b) 	If the Borrower and the Administrative Agent agree in writing in their sole discretion that a
Lender is no longer a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as
of the effective date specified in such notice and subject to any conditions set forth therein, such Lender will, to
the extent applicable, purchase at par such portion of outstanding Advances of the other Lenders and/or make such
other adjustments as the Administrative Agent may determine to be necessary to cause the Advances and unused
Commitments to be on a pro rata basis in accordance with their respective Commitments, whereupon such Lender
will cease to be a Defaulting Lender and will be a Non-Defaulting Lender; provided, that no adjustments will be
made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while such
Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the
affected parties, no change hereunder from Defaulting Lender to Non-Defaulting Lender will constitute a waiver
or release of any claim of any party hereunder arising from such Lender’s having been a Defaulting Lender.
(c) 	Any payment of principal, interest, fees or other amounts received by the Administrative
Agent hereunder for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant
to Section 6.01 or otherwise) or received by the Administrative Agent from a Defaulting Lender pursuant to
Section 8.05 shall be applied at such time or times as follows: first, to the payment of any amounts owing by such
Defaulting Lender to the Administrative Agent hereunder; second as the Borrower may request (so long as no
Default or Event of Default exists), to the funding of any Advance in respect of which such Defaulting Lender has
failed to fund its portion thereof as required by this Agreement, as reasonably determined by the Administrative
Agent; third, as the Borrower may request, to be held in a deposit account and

-- 332 of 409 --

45
released pro rata in order to satisfy such Defaulting Lender’s potential future funding obligations with respect to
Advances under this Agreement; fourth, to the payment of any amounts owing to the Lenders as a result of any
judgment of a court of competent jurisdiction obtained by any Lender against such Defaulting Lender as a result
of such Defaulting Lender’s breach of its obligations under this Agreement; fifth, to the payment of any amounts
owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower
against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this
Agreement; and sixth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction.
Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to
pay amounts owed by a Defaulting Lender or otherwise pursuant to this Section 2.19(c) shall be deemed paid to
and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto.
SECTION 2.20 	Mitigation.
(a) 	Each Lender shall promptly notify the Borrower and the Administrative Agent of any event
of which it has knowledge that will result in, and will use reasonable commercial efforts available to it (and not, in
such Lender’s good faith judgment, otherwise disadvantageous to such Lender) to mitigate or avoid, (i) any
obligation by the Borrower to pay any amount pursuant to Sections 2.11 or 2.14 or (ii) the occurrence of any
circumstance described in Section 2.12 (and, if any Lender has given notice of any such event described in clause
(i) or (ii) above and thereafter such event ceases to exist, such Lender shall promptly so notify the Borrower and
the Administrative Agent). In furtherance of the foregoing, each Lender will designate a different Applicable
Lending Office if such designation will avoid (or reduce the cost to the Borrower of) any event described in clause
(i) or (ii) of the preceding sentence and such designation will not, in such Lender’s good faith judgment, be
otherwise disadvantageous to such Lender.
(b) 	Failure or delay on the part of any Lender to demand compensation pursuant to Sections
2.11 or 2.14 shall not constitute a waiver of such Lender’s right to demand such compensation; provided that,
notwithstanding any other provision of this Agreement, if any Lender fails to notify the Borrower of any event or
circumstance which will entitle such Lender to compensation pursuant to Sections 2.11 or 2.14 within 180 days
after such Lender obtains knowledge of such event or circumstance, then such Lender shall not be entitled to
compensation from the Borrower for any amount arising prior to the date which is 180 days before the date on
which such Lender notifies the Borrower of such event or circumstance (except that, if the event or circumstance
giving rise to such entitlement for compensation is retroactive, then the 180-day period referred to above shall be
extended to include the period of retroactive effect thereof).
ARTICLE III
CONDITIONS TO EFFECTIVENESS AND LENDING
SECTION 3.01 	Conditions Precedent to Closing Date. This Agreement shall become effective
on and as of the first date on which the following conditions precedent have been satisfied (or waived in
accordance with Section 8.01):

-- 333 of 409 --

46
(a) 	The Administrative Agent (or its counsel) shall have received from each party hereto either
(i) a counterpart of this Agreement and the other Loan Documents signed on behalf of such party or
(ii) written evidence reasonably satisfactory to the Administrative Agent (which may include facsimile
transmission of a signed signature page of this Agreement) that such party has signed a counterpart of this
Agreement.
(b) 	Since December 31, 2019, there shall not have occurred any event or condition that has had
or would be reasonably expected to have, either individually or in the aggregate, a Material Adverse
Effect.
(c) 	All fees due to the Administrative Agent, the Arrangers and the Lenders shall have been
paid, and all expenses of the Administrative Agent and the Arrangers that are required to be paid or
reimbursed by the Borrower and that have been invoiced at least three Business Days prior to the Closing
Date shall have been so paid or reimbursed.
(d) 	On the Closing Date, the following statements shall be true and the Administrative Agent
shall have received a certificate of the Borrower, dated the Closing Date, stating that:
(i) 	Each of the representations and warranties set forth in Section 4.01 are true and
correct in all material respects (except to the extent such representations and warranties are
qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such
representations and warranties shall be true and correct in all respects), on and as of the Closing
Date, except to the extent any such representation or warranty is stated to relate solely to an earlier
date, in which case such representation or warranty shall have been true and correct in all material
respects (except to the extent such representations and warranties are qualified with “materiality”
or “Material Adverse Effect” or similar terms, in which case such representations and warranties
shall be true and correct in all respects) on and as of such earlier date; and
(ii) 	No event has occurred and is continuing, or shall occur as a result of the occurrence
of the Closing Date, that constitutes a Default.
(e) 	The Administrative Agent shall have received on or before the Closing Date, each dated on
or about such date:
(i) 	Certified copies of the resolutions or similar authorizing documentation of the
governing body of the Borrower, and of all documents evidencing other necessary corporate action
and governmental approvals, if any, with respect to this Agreement;
(ii) 	A certificate of the Secretary or an Assistant Secretary of the Borrower certifying
the names and true signatures of the officers of the Borrower authorized to sign this Agreement and
the other documents to be delivered by it hereunder; and

-- 334 of 409 --

47
(iii) 	A favorable opinion letter from Latham & Watkins LLP, as counsel to the Borrower,
in the form agreed on or prior to the Closing Date.
(f) 	The 2018 Credit Agreement shall have been terminated in accordance with Section 8.15.
(g) 	To the extent requested by a Lender, delivery of executed promissory notes.
(h) 	To the extent requested by any Lender through the Administrative Agent in writing at least
10 Business Days prior to the Closing Date, the Borrower shall have provided the documentation and other
information to the Administrative Agent that is required by regulatory authorities under applicable “know-
your-customer” rules and regulations, including the Patriot Act and the Beneficial Ownership Regulation,
at least three Business Days prior to the Closing Date.
The Administrative Agent shall notify the Borrower and the Lenders of the Closing Date in writing
promptly upon such conditions precedent being satisfied (or waived in accordance with Section 8.01), and such
notice shall be conclusive and binding evidence of the occurrence thereof.
SECTION 3.02 	Conditions Precedent to Each Borrowing. The obligation of each Lender to
make an Advance on the occasion of each Borrowing (other than a Borrowing consisting only of a Conversion of
Advances to the other Type, or a continuation of Eurodollar Rate Advances) shall be subject to the conditions
precedent that the Closing Date shall have occurred and on the date of such Borrowing the following statements
shall be true (and each of the giving of the applicable Notice of Borrowing and the acceptance by the Borrower of
the proceeds of such Borrowing shall constitute a representation and warranty by the Borrower that on the date of
such Borrowing such statements are true):
(a) 	Each of the representations and warranties set forth in Section 4.01 (other than the
representations and warranties set forth in Section 4.01(f)(i)) are true and correct in all material respects
(except to the extent such representations and warranties are qualified with “materiality” or “Material
Adverse Effect” or similar terms, in which case such representations and warranties shall be true and
correct in all respects) as of such date, before and after giving effect to such Borrowing and the application
of proceeds therefrom, as though made on and as of such date, except to the extent any such representation
or warranty is stated to relate solely to an earlier date, in which case such representation or warranty shall
have been true and correct in all material respects (except to the extent such representations and warranties
are qualified with “materiality” or “Material Adverse Effect” or similar terms, in which case such
representations and warranties shall be true and correct in all respects) on and as of such earlier date, and
(b) 	no event has occurred and is continuing, or would result from such Borrowing or from the
application of the proceeds therefrom, that constitutes a Default.

-- 335 of 409 --

48
ARTICLE IV
REPRESENTATIONS AND WARRANTIES
SECTION 4.01 	Representations and Warranties of the Borrower. The Borrower represents and
warrants on the Closing Date, on the date of the making of each Advance, on any Increase Effective Date and on
any Extension Date as follows (but with respect to the representations and warranties set forth in Section 4.01(f)
(i), only on the Closing Date, any Increase Effective Date and any Extension Date):
(a) 	The Borrower is a corporation duly organized, validly existing and in good standing under
the Laws of the jurisdiction of organization.
(b) 	The execution, delivery and performance by the Borrower of this Agreement and the other
Loan Documents to which it is a party, and the consummation of the transactions contemplated hereby and
thereby, (i) are within the Borrower’s corporate powers, (ii) have been duly authorized by all necessary
corporate action, (iii) do not contravene (A) the Borrower’s charter or by-laws or other organizational
documents or (B) any Law, regulation or contractual restriction binding on or affecting the Borrower and
(iv) will not result in or require the creation or imposition of any Lien upon or with respect to any of the
properties of the Consolidated Group (other than Liens created or required to be created pursuant to the
terms hereof), except, in the case of clause (iii)(B) and (iv), as would not be reasonably expected to have a
Material Adverse Effect.
(c) 	No authorization or approval or other action by, and no notice to or filing with, any
Governmental Authority or regulatory body or, except as would not be reasonably expected to have a
Material Adverse Effect, any other third party is required for the due execution, delivery and performance
by the Borrower of this Agreement.
(d) 	This Agreement has been duly executed and delivered by the Borrower. This Agreement is
the legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance
with its terms, except as affected by applicable bankruptcy, insolvency, reorganization, moratorium or
similar Laws affecting creditors’ rights generally and general principles of equity (whether considered in a
proceeding in equity or at Law) and an implied covenant of good faith and fair dealing.
(e) 	The Consolidated balance sheet of the Borrower and its Subsidiaries as at December 31,
2019, and the related Consolidated statements of earnings and cash flows of the Borrower and its
Subsidiaries for the fiscal year then ended, accompanied by an opinion of Ernst & Young LLP or other
independent public accountants of recognized national standing, and the Consolidated balance sheet of the
Borrower and its Subsidiaries as at September 30, 2020, and the related Consolidated statements of
earnings and cash flows of the Borrower and its Subsidiaries for the nine months then ended, duly certified
by the Executive Vice President, Finance and Chief Financial Officer of the Borrower, copies of which
have been furnished to each Lender, fairly present, in all material respects, the Consolidated financial
condition of the Borrower and its Subsidiaries as at such dates and the Consolidated results of the
operations of the Borrower and its Subsidiaries for the

-- 336 of 409 --

49
periods ended on such dates, all in accordance with GAAP (subject, in the case of the Consolidated
balance sheet as at September 30, 2020 and the related statements of earnings and cash flows, to the
absence of footnotes and year-end audit adjustments); provided that information referenced in this Section
4.01(e) shall be deemed to have been furnished if such information, or one or more annual or quarterly or
other reports or proxy statements containing such information, shall have been posted and be available on
the website of the Securities and Exchange Commission at http://www.sec.gov.
(f) 	As of the Closing Date (or, in the case that this representation and warranty is made on any
Increase Effective Date or any Extension Date, as of such Increase Effective Date or Extension Date, as
applicable), there is no action, suit, investigation, litigation or proceeding (including, without limitation,
any Environmental Action), affecting the Consolidated Group pending or, to the knowledge of the
Borrower, threatened before any court, governmental agency or arbitrator that would reasonably be
expected to be adversely determined, and if so determined, (i) would reasonably be expected to have a
material adverse effect on the financial condition or results of operations of the Consolidated Group taken
as a whole (other than the litigation set forth on Schedule 4.01(f) attached hereto (or, in the case that this
representation and warranty is made on any date after the date hereof, as set forth on a schedule delivered
to the Administrative Agent on or prior to such date, as applicable)) or (ii) would adversely affect the
legality, validity and enforceability of any material provision of this Agreement in any material respect.
(g) 	Following application of the proceeds of each Advance, not more than 25 percent of the
value of the assets of the Borrower and of the Consolidated Group, on a Consolidated basis, subject to the
provisions of Section 5.02(a) will be margin stock (within the meaning of Regulation U issued by the
Board of Governors of the Federal Reserve System).
(h) 	All written information (other than the projections, any forward-looking statements and
information of a general economic or industry nature) concerning the Borrower, its Subsidiaries and the
transactions contemplated hereby included in the Information Memorandum or otherwise prepared by the
Borrower and its Subsidiaries and furnished to the Agents or the Lenders in connection with the
negotiation of, or pursuant to the terms of, this Agreement when taken as a whole, was true and correct in
all material respects as of the date when furnished by the Borrower and its subsidiaries to the Agents or the
Lenders and did not, taken as a whole, when so furnished contain any untrue statement of a material fact as
of any such date or omit to state a material fact necessary in order to make the statements contained
therein, taken as a whole, not misleading in light of the circumstances under which such statements were
made.
(i) 	No ERISA Event has occurred or is reasonably expected to occur with respect to any Plan
which would reasonably be expected to have a Material Adverse Effect.
(j) 	As of the last annual actuarial valuation date prior to the Closing Date, the Abbott
Laboratories Annuity Retirement Plan was not in at-risk status (as defined in Section 430(i)(4) of the
Internal Revenue Code) and no other Plan subject to ERISA was in at-risk status (as defined in
Section 430(i)(4) of the Internal Revenue Code), and since

-- 337 of 409 --

50
such annual actuarial valuation date there has been no material adverse change in the funding status of any
Plan subject to ERISA that would reasonably be expected to cause such Plan to be in at-risk status (as
defined in Section 430(i)(4) of the Internal Revenue Code).
(k) 	Neither the Borrower nor any ERISA Affiliate (i) is reasonably expected to incur any
Withdrawal Liability to any Multiemployer Plan or has incurred any such Withdrawal Liability that has not
been satisfied in full or (ii) has been notified by the sponsor of a Multiemployer Plan that such
Multiemployer Plan is in reorganization (within the meaning of Section 4241 of ERISA), insolvent (within
the meaning of Section 4245 of ERISA) or has been determined to be in “endangered” or “critical” status
(within the meaning of Section 432 of the Internal Revenue Code or Section 305 of ERISA), and no such
Multiemployer Plan is reasonably expected to be in reorganization, insolvent or in “endangered” or
“critical” status.
(l) 	(i) The operations and properties of the Consolidated Group comply in all respects with all
applicable Environmental Laws and Environmental Permits except to the extent that the failure to so
comply, either individually or in the aggregate, would not reasonably be expected to have a Material
Adverse Effect; (ii) all past non-compliance with such Environmental Laws and Environmental Permits
has been resolved without any ongoing obligations or costs except to the extent that such non-compliance,
individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect; and
(iii) no circumstances exist that would be reasonably expected to (A) form the basis of an Environmental
Action against a member of the Consolidated Group or any of its properties that, either individually or in
the aggregate, would have a Material Adverse Effect or (B) cause any such property to be subject to any
restrictions on ownership, occupancy, use or transferability under any Environmental Law that, either
individually or in the aggregate, would have a Material Adverse Effect.
(m) 	(i) None of the properties currently or formerly owned or operated by a member of the
Consolidated Group is listed or proposed for listing on the NPL or on the CERCLIS or any analogous
foreign, state or local list or, to the best knowledge of the Borrower, is adjacent to any such property other
than such properties of a member of the Consolidated Group that, individually or in the aggregate, would
not reasonably be expected to have a Material Adverse Effect; (ii) there are no, and never have been any,
underground or aboveground storage tanks or any surface impoundments, septic tanks, pits, sumps or
lagoons in which Hazardous Materials are being or have been treated, stored or disposed of on any
property currently owned or operated by any member of the Consolidated Group or, to the best knowledge
of the Borrower, on any property formerly owned or operated by a member of the Consolidated Group
that, either individually or in the aggregate, would reasonably be expected to have a Material Adverse
Effect; (iii) there is no asbestos or asbestos-containing material on any property currently owned or
operated by a member of the Consolidated Group that, either individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect; and (iv) Hazardous Materials have not been
released, discharged or disposed of on any property currently or formerly owned or operated by a member
of the Consolidated Group or, to the best knowledge of

-- 338 of 409 --

51
the Borrower, on any adjoining property that, either individually or in the aggregate, would reasonably be
expected to have a Material Adverse Effect.
(n) 	No member of the Consolidated Group is undertaking, and no member of the Consolidated
Group has completed, either individually or together with other potentially responsible parties, any
investigation or assessment or remedial or response action relating to any actual or threatened release,
discharge or disposal of Hazardous Materials at any site, location or operation, either voluntarily or
pursuant to the order of any governmental or regulatory authority or the requirements of any
Environmental Law that, either individually or in the aggregate, would reasonably be expected to have a
Material Adverse Effect; and all Hazardous Materials generated, used, treated, handled or stored at, or
transported to or from, any property currently or formerly owned or operated by a member of the
Consolidated Group have been disposed of in a manner that, either individually or in the aggregate, would
not reasonably be expected to have a Material Adverse Effect.
(o) 	No member of the Consolidated Group is an “investment company”, or an “affiliated
person” of, or “promoter” or “principal underwriter” for, an “investment company” (each as defined in the
Investment Company Act of 1940, as amended). Neither the making of any Advances nor the application
of the proceeds or repayment thereof by the Borrower, nor the consummation of the other transactions
contemplated hereby, will violate any provision of such Act or any rule, regulation or order of the
Securities and Exchange Commission thereunder.
(p) 	The Advances and all related obligations of the Borrower under this Agreement rank pari
passu with all other unsecured obligations of the Borrower that are not, by their terms, expressly
subordinate to the obligations of the Borrower hereunder.
(q) 	The proceeds of the Advances will be used in accordance with Section 2.16.
(r) 	Neither the Borrower nor any of its Subsidiaries or, to the knowledge of senior management
of the Borrower, any director, officer, employee or agent of the Borrower or any of its Subsidiaries is an
individual or entity currently the subject of any Sanctions, and neither the Borrower nor any of its
Subsidiaries is located, organized or resident in a Designated Jurisdiction in violation of any Sanctions;
provided that if the Borrower or any Subsidiary is located, organized or resident in a jurisdiction that
becomes a Designated Jurisdiction after the Closing Date, such Person shall not be included in this
representation so long as (i) the Borrower is taking reasonable steps to either obtain appropriate licenses
for transacting business in such country or territory or to cause such Person to no longer be located, be
organized or be resident in such country or territory and (ii) such Person’s being located, organized or
resident in such country or territory (A) will not result in any violation of Sanctions by any Lender, any
Arranger or the Administrative Agent and (B) would not be reasonably expected to have Material Adverse
Effect.
(s) 	The Borrower and its Subsidiaries (i) have conducted their businesses in compliance with
applicable anti-corruption Laws, except to the extent that failure to so comply would not be reasonably
expected to have Material Adverse Effect; and (ii) have

-- 339 of 409 --

52
instituted and maintained policies and procedures reasonably designed to promote and achieve compliance
with such Laws.
(t) 	As of the Closing Date, the information included in any Beneficial Ownership Certification
(to the extent required to be provided) is true and correct in all respects.
ARTICLE V
COVENANTS OF THE BORROWER
SECTION 5.01 	Affirmative Covenants. So long as any Advance shall remain unpaid or any
Lender shall have any Commitment hereunder, the Borrower will:
(a) 	Compliance with Laws, Etc. Comply, and cause each of its Subsidiaries to comply, with all
applicable Laws, rules, regulations and orders (such compliance to include, without limitation, compliance
with ERISA and Environmental Laws), except to the extent that the failure to so comply, either
individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
(b) 	Payment of Taxes, Etc. Pay and discharge, or cause to be paid and discharged, before the
same shall become delinquent, all Taxes imposed upon any member of the Consolidated Group except to
the extent that (i) the amount, applicability or validity thereof is being contested in good faith and by
proper proceedings or (ii) the failure to pay such Taxes, either individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect.
(c) 	Maintenance of Insurance. Maintain, and cause each of its Subsidiaries to maintain,
insurance with responsible and reputable insurance companies or associations (or pursuant to self-
insurance arrangements) in such amounts and covering such risks as is usually carried by companies
engaged in similar businesses and owning similar properties in the same general areas in which any
member of the Consolidated Group operates.
(d) 	Preservation of Existence, Etc. Do, or cause to be done, all things necessary to preserve
and keep in full force and effect its (i) existence and (ii) rights (charter and statutory) and franchises;
provided, however, that the Borrower may consummate any merger or consolidation permitted under
Section 5.02(b); and provided, further, that the Borrower shall not be required to preserve any such right or
franchise if the management of the Borrower shall determine that the preservation thereof is no longer
desirable in the conduct of the business of the Borrower and that the loss thereof is not disadvantageous in
any material respect to the Lenders.
(e) 	Visitation Rights. At any reasonable time and from time to time during normal business
hours, upon reasonable notice to the Borrower, permit the Administrative Agent or any of the Lenders, or
any agents or representatives thereof, to examine and make copies of and abstracts from the records and
books of account, and visit the properties, of

-- 340 of 409 --

53
the Borrower, and to discuss the affairs, finances and accounts of the Borrower and/or any of its
Subsidiaries with any of the members of the senior treasury staff of the Borrower.
(f) 	Keeping of Books. Keep, and cause each of its Subsidiaries to keep, proper books of record
and account, in which full and correct entries shall be made of all financial transactions and the assets and
business of the Borrower and each such Subsidiary sufficient to permit the preparation of financial
statements in accordance with GAAP.
(g) 	Maintenance of Properties, Etc. Cause all of its properties that are used or useful in the
conduct of its business or the business of any of its Subsidiaries to be maintained and kept in good
condition, repair and working order and supplied with all necessary equipment, and cause to be made all
necessary repairs, renewals, replacements, betterments and improvements thereof, all as in the judgment of
the Borrower may be necessary so that the business carried on in connection therewith may be properly
and advantageously conducted at all times, except, in each case, where the failure to do so would not
reasonably be expected to result in a Material Adverse Effect.
(h) 	Transactions with Affiliates. Conduct, and cause each of its Subsidiaries to conduct, all
material transactions otherwise permitted under this Agreement with any of their Affiliates (excluding the
members of the Consolidated Group) on terms that are fair and reasonable and no less favorable to the
Borrower or such Subsidiary than it would obtain in a comparable arm’s-length transaction with a Person
not an Affiliate; provided that the provisions of this Section 5.01(h) shall not apply to the following:
(i) 	the payment of dividends or other distributions (whether in cash, securities or other
property) with respect to any equity interests in a member of the Consolidated Group, or any
payment (whether in cash, securities or other property), including any sinking fund or similar
deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or
termination of any such equity interests in such Person or any option, warrant or other right to
acquire any such equity interests in such Person;
(ii) 	payment of, or other consideration in respect of, compensation to, the making of
loans to and payment of fees and expenses of and indemnities to officers, directors, employees or
consultants of a member of the Consolidated Group and payment, or other consideration in respect
of, directors’ and officers’ indemnities;
(iii) 	transactions pursuant to any agreement to which a member of the Consolidated
Group is a party on the date hereof; or
(iv) 	transactions with joint ventures for the purchase or sale of property or other assets
and services entered into in the ordinary course of business and in a manner consistent with past
practices.
(i) 	Reporting Requirements. Furnish to the Administrative Agent for further distribution to
the Lenders:

-- 341 of 409 --

54
(i) 	as soon as available and in any event within 50 days after the end of each of the
first three quarters of each fiscal year of the Borrower, a Consolidated balance sheet of the
Consolidated Group as of the end of such quarter and Consolidated statements of earnings and cash
flows of the Consolidated Group for the period commencing at the end of the previous fiscal year
and ending with the end of such quarter, duly certified by the Chief Financial Officer, the
Controller or the Treasurer of the Borrower as having been prepared in accordance with GAAP
(subject to the absence of footnotes and year end audit adjustments);
(ii) 	as soon as available and in any event within 100 days after the end of each fiscal
year of the Borrower, a copy of the annual audit report for such year for the Consolidated Group,
containing a Consolidated balance sheet of the Consolidated Group as of the end of such fiscal year
and Consolidated statements of earnings and cash flows of the Consolidated Group for such fiscal
year, in each case accompanied by an unqualified opinion or an opinion reasonably acceptable to
the Required Lenders by Ernst & Young LLP or other independent public accountants of
recognized national standing;
(iii) 	simultaneously with each delivery of the financial statements referred to in
subclauses (i)(i) and (i)(ii) of this Section 5.01, a certificate of the Chief Financial Officer, the
Controller or the Treasurer of the Borrower as to compliance with the terms of this Agreement and
setting forth in reasonable detail the calculations necessary to demonstrate compliance with
Section 5.03;
(iv) 	as soon as possible and in any event within five days after any Responsible Officer
shall have obtained knowledge of the occurrence of each Default continuing on the date of such
statement, a statement of the Chief Financial Officer, the Controller or the Treasurer of the
Borrower setting forth details of such Default and the action that the Borrower has taken and
proposes to take with respect thereto;
(v) 	promptly after the sending or filing thereof, copies of all reports that the Borrower
sends to any of its securityholders, and copies of all reports and registration statements that
members of the Consolidated Group file with the Securities and Exchange Commission or any
national securities exchange;
(vi) 	promptly after a Responsible Officer obtains knowledge of the commencement
thereof, notice of all actions, suits, investigations, litigations and proceedings before any court,
governmental agency or arbitrator affecting the Consolidated Group of the type described in
Section 4.01(f)(ii); and
(vii) 	such other information respecting the Consolidated Group as any Lender through
the Administrative Agent may from time to time reasonably request.
Information required to be delivered pursuant to subsections (i), (ii) and (v) of this Section 5.01(i)
shall be deemed to have been delivered if such information, or one

-- 342 of 409 --

55
or more annual or quarterly or other reports or proxy statements containing such information, shall
have been posted and be available on the website of the Securities and Exchange Commission at
http://www.sec.gov (and a confirming electronic correspondence is delivered or caused to be
delivered by the Borrower to the Administrative Agent providing notice of such availability). The
Borrower hereby acknowledges that the Administrative Agent and/or the Arrangers will make
available to the Lenders materials and/or information provided by or on behalf of the Borrower
hereunder (collectively, “Borrower Materials”) by posting the Borrower Materials on IntraLinks or
another similar secure electronic system (the “Platform”).
(j) 	Anti-Corruption Laws. Maintain policies and procedures with respect to itself and its
Subsidiaries reasonably designed to promote and achieve compliance with applicable anti-corruption
Laws.
SECTION 5.02 	Negative Covenants. So long as any Advance shall remain unpaid or any
Lender shall have any Commitment hereunder, the Borrower will not:
(a) 	Liens, Etc. Incur, issue, assume or guarantee, or permit any Domestic Subsidiary to incur,
issue, assume or guaranty, at any time, any Borrowed Debt secured by a Lien on any Principal Domestic
Property of the Borrower or any Domestic Subsidiary, or any shares of stock or Borrowed Debt of any
Domestic Subsidiary, without effectively providing that the Advances outstanding at such time (together
with, if the Borrower shall so determine, any other Borrowed Debt of the Borrower or such Domestic
Subsidiary existing at such time or thereafter created that is not subordinate to the Advances) shall be
secured equally and ratably with (or prior to) such secured Borrowed Debt, so long as such secured
Borrowed Debt shall be so secured, unless, after giving effect thereto, the aggregate amount of all such
secured Borrowed Debt plus the aggregate amount of all Attributable Debt of the Borrower and the
Domestic Subsidiaries in respect of Sale and Leaseback Transactions would not exceed 15% of
Consolidated Net Assets; provided, however, that this Section 5.02(a) shall not apply to, and there shall be
excluded from secured Borrowed Debt in any computation under this Section 5.02(a), Borrowed Debt
secured by:
(i) 	Liens on property of, or on any shares of stock or Borrowed Debt of, any Person
existing at the time such Person becomes a Domestic Subsidiary;
(ii) 	Liens in favor of the Borrower or any Domestic Subsidiary;
(iii) 	Liens on property of the Borrower or a Domestic Subsidiary in favor of the United
States or any State thereof, or any department, agency or instrumentality or political subdivision of
the United States or any State thereof, or in favor of any other country, or any political subdivision
thereof, to secure partial, progress, advance or other payments pursuant to any contract or statute;
(iv) 	Liens on property, shares of stock or Borrowed Debt existing at the time of
acquisition thereof (including acquisition through merger or consolidation)

-- 343 of 409 --

56
or to secure the payment of all or any part of the purchase price or construction or improvement
cost thereof or to secure any Debt incurred prior to, at the time of, or within 120 days after, the
acquisition of such property or shares or Borrowed Debt or the completion of any such
construction or improvement for the purpose of financing all or any part of the purchase price or
construction or improvement cost thereof;
(v) 	Liens existing on the Closing Date;
(vi) 	Liens incurred in connection with pollution control, industrial revenue or similar
financing; and
(vii) 	Any extension, renewal or replacement (or successive extensions, renewals or
replacements), as a whole or in part, of any Borrowed Debt secured by any Lien referred to in
subclauses (i) through (vi) of this Section 5.02(a); provided, that (A) such extension renewal or
replacement Lien shall be limited to all or a part of the same property, shares of stock or Debt that
secured the Lien extended, renewed or replaced (plus improvements on such property) and (B) the
Borrowed Debt secured by such Lien at such time is not increased.
(b) 	Mergers, Etc. Merge or consolidate with or into, or convey, transfer, lease or otherwise
dispose (including by means of a Division) of (whether in one transaction or in a series of transactions) all
or substantially all of its assets (whether now owned or hereafter acquired) to, any Person, or permit any of
its Subsidiaries to do so, except that:
(i) 	any Subsidiary of the Borrower may merge or consolidate with or into, or dispose
(including by means of a Division) of assets to, any other Subsidiary of the Borrower or the
Borrower;
(ii) 	the Borrower may merge or consolidate with or into any other Person so long as
(A) the Borrower is the surviving Person or (B) if the Borrower is not the surviving Person, (1) the
surviving Person shall assume, by agreement reasonably satisfactory in form and substance to the
Required Lenders, all of the rights and obligations of the Borrower under this Agreement and the
other Loan Documents, (2) such surviving Person shall have delivered to the Administrative Agent
(x) an officer’s certificate stating that such surviving Person’s obligations under this Agreement are
enforceable and (y) if requested by the Administrative Agent, an opinion of counsel to the effect
that such merger or consolidation does not violate this Agreement or any other Loan Document and
that such surviving Person’s obligations under this Agreement are enforceable and (3) the
Administrative Agent shall have received the information and documentation reasonably requested
by the Administrative Agent or any Lender, in each case with respect to such surviving Person, for
purposes of compliance with applicable “know your customer” and anti-money laundering rules
and regulations, including, without limitation, the Patriot Act and the Beneficial Ownership
Regulation (it being understood that, if the foregoing are satisfied, such surviving Person will
succeed to, and be substituted for, the Borrower under this Agreement);

-- 344 of 409 --

57
(iii) 	any Subsidiary of the Borrower may merge or consolidate with or into another
Person, or convey, transfer, lease or otherwise dispose (including by means of a Division) of all or
any portion of its assets so long as (A) the consideration received in respect of such merger,
consolidation, conveyance, transfer, lease or other disposition is at least equal to the fair market
value of such assets and (B) no Material Adverse Effect would reasonably be expected to result
from such merger, consolidation, conveyance, transfer, lease or other disposition;
provided, in the cases of clause (ii) hereof, that no Default shall have occurred and be continuing at the
time of such proposed transaction or would result therefrom.
(c) 	Sales and Leaseback. Enter into, or permit any Domestic Subsidiary to enter into, any
arrangement with any bank, insurance company or other lender or investor (not including any member of
the Consolidated Group) or to which any such lender or investor is a party, providing for the leasing by the
Borrower or any Domestic Subsidiary for a period, including renewals, in excess of three years of any
Principal Domestic Property which has been or is to be sold or transferred, more than 120 days after the
acquisition thereof or the completion of construction and commencement of full operation thereof, by the
Borrower or any Domestic Subsidiary to such lender or investor or to any Person to whom funds have
been or are to be advanced by such lender or investor on the security of such Principal Domestic Property
(any such arrangement being referred to herein as a “Sale and Leaseback Transaction”) unless either:
(i) 	the Borrower or such Domestic Subsidiary could create Borrowed Debt secured by
a Lien pursuant to Section 5.02(a) on the Principal Domestic Property to be leased back in an
amount equal to the Attributable Debt with respect to such Sale and Leaseback Transaction without
equally and ratably securing Advances outstanding at the time the Borrower or such Domestic
Subsidiary enters into such Sale and Leaseback Transaction, or
(ii) 	the Borrower, within 120 days after the sale or transfer shall have been made by the
Borrower or by such Domestic Subsidiary, applies an amount equal to the greater of (A) the net
proceeds of the sale of the Principal Domestic Property sold and leased back pursuant to such Sale
and Leaseback Transaction or (B) the fair market value of the Principal Domestic Property so sold
and leased back at the time of entering into such Sale and Leaseback Transaction (as determined by
any two of the following: the Chief Executive Officer, any President, the Chief Financial Officer,
the Controller or the Treasurer of the Borrower) to the retirement of Funded Debt; provided that the
amount to be applied to the retirement of Funded Debt shall be reduced by (1) the principal amount
of any Advances paid or prepaid within 120 days after such sale or transfer and (2) the principal
amount of such Funded Debt voluntarily retired by the Borrower within 120 days after such sale or
transfer. Notwithstanding the foregoing, no retirement referred to in this Section 5.02(c)(ii) may be
effected by payment at maturity or pursuant to any mandatory sinking fund payment or any
mandatory prepayment provision.

-- 345 of 409 --

58
(d) 	Accounting Changes. Change its fiscal year-end from December 31 of each calendar year.
(e) 	Change in Nature of Business. Make any material change in the nature of the business of
the Consolidated Group, taken as a whole, from that carried out at the Closing Date; it being understood
that this Section 5.02(e) shall not prohibit members of the Consolidated Group from conducting any
business or business activities incidental or related to the business of the Borrower and its Subsidiaries as
carried on as of the Closing Date or any business or activity that is reasonably similar or complementary
thereto or a reasonable extension, development or expansion thereof or ancillary thereto.
(f) 	Use of Proceeds. Directly or, to the knowledge of the Borrower, indirectly (i) use the
proceeds of any Borrowing for any purpose that would breach the United States Foreign Corrupt Practices
Act of 1977, the UK Bribery Act of 2010, or other similar applicable legislation in other jurisdictions or
(ii) use the proceeds of any Borrowing, or lend, contribute or otherwise make available such proceeds to
any Subsidiary, joint venture partner or other individual or entity, to fund any activities of or business with
any individual or entity that, at the time of such funding, is (A) the subject of Sanctions or (B) in any
Designated Jurisdiction, in each case in violation of Sanctions.
SECTION 5.03 	Financial Covenant. So long as any Advance shall remain unpaid or any
Lender shall have any Commitment hereunder, as of the last day of each fiscal quarter of the Borrower,
commencing with the first fiscal quarter-end date occurring after the Closing Date, the Borrower shall not permit
Consolidated Net Worth to be less than $10,000,000,000; provided that, notwithstanding the foregoing, if the
Borrower has Public Debt Ratings of (a) A2 or higher from Moody’s and (b) A or higher from S&P, in each case
as of the last day of any fiscal quarter, this Section 5.03 shall cease to apply to the Borrower for such fiscal quarter
and thereafter, until (x) the Public Debt Rating from Moody’s shall be lower than A2, (y) the Public Debt Rating
from S&P shall be lower than A or (z) either Moody’s or S&P shall not have in effect a Public Debt Rating, in
each case as of the last day of any fiscal quarter, in which case this Section 5.03 shall once again apply to the
Borrower as of such fiscal quarter and thereafter.
ARTICLE VI
EVENTS OF DEFAULT
SECTION 6.01 	Events of Default. If any of the following events (“Events of Default”) shall
occur and be continuing:
(a) 	The Borrower shall fail (i) to pay any principal of any Advance when the same becomes
due and payable or (ii) to pay any interest on any Advance or make any payment of fees or other amounts
payable under this Agreement within five Business Days after the same becomes due and payable; or

-- 346 of 409 --

59
(b) 	Any representation or warranty made by the Borrower herein or by the Borrower (or any of
its officers) in connection with this Agreement shall prove to have been incorrect in any material respect
when made; or
(c) 	(i) The Borrower shall fail to perform or observe any term, covenant or agreement
contained in Section 5.01(d)(i), 5.01(i)(iv), 5.02(a), 5.02(b), 5.02(c), 5.02(e), 5.02(f)(ii) (to the extent the
use of proceeds would result in a violation of Sanctions by a Lender, an Arranger or the Administrative
Agent) or 5.03 or (ii) the Borrower shall fail to perform or observe any term, covenant or agreement
contained in Section 5.01(e) or clauses (i)-(iii) or (v)-(vii) of Section 5.01(i) if such failure shall remain
unremedied for 10 Business Days after written notice thereof shall have been given to the Borrower by the
Administrative Agent or any Lender, or (iii) the Borrower shall fail to perform or observe any other term,
covenant or agreement contained in this Agreement on its part to be performed or observed if such failure
shall remain unremedied for 30 days after written notice thereof shall have been given to the Borrower by
the Administrative Agent or any Lender; or
(d) 	The Borrower or a Significant Subsidiary shall fail to pay any principal of or premium or
interest on any Debt that is outstanding in a principal amount, or, in the case of any Hedge Agreement,
having a maximum Agreement Value, of at least $250,000,000 in the aggregate (but excluding Debt
outstanding hereunder) of the Borrower or such Significant Subsidiary, when the same becomes due and
payable (whether by scheduled maturity, required prepayment, acceleration, demand or otherwise), and
such failure shall continue after the applicable grace period, if any, specified in the agreement or
instrument relating to such Debt; or the Borrower or a Significant Subsidiary shall default in its obligations
under any agreement or instrument relating to any such Debt, which default shall continue after the
applicable grace period, if any, specified in such agreement or instrument if the effect of such default is to
accelerate the maturity of such Debt; or any such Debt shall be declared to be due and payable, or required
to be prepaid or redeemed, purchased or defeased, or an offer to prepay, redeem, purchase or defease such
Debt shall be required to be made, in each case prior to the stated maturity thereof (other than due to any
(i) regularly scheduled required prepayment or redemption or (ii) prepayment of Debt which is mandatory
under the terms of the documentation governing such Debt by reason of the receipt of net cash proceeds of
other Debt or dispositions (including, without limitation, as the result of casualty events and governmental
takings); or
(e) 	The Borrower or any Significant Subsidiary shall generally not pay its debts as such debts
become due, or shall admit in writing its inability to pay its debts generally, or shall make a general
assignment for the benefit of creditors; or any proceeding shall be instituted by or against the Borrower or
any Significant Subsidiary seeking to adjudicate it as bankrupt or insolvent, or seeking liquidation,
winding up, reorganization, arrangement, adjustment, protection, relief, or composition of it or its debts
under any Law relating to bankruptcy, insolvency or reorganization or relief of debtors, or seeking the
entry of an order for relief or the appointment of a receiver, trustee, custodian or other similar official for it
or for any substantial part of its property and, in the case of any such proceeding instituted against it (but
not instituted by it), such proceeding shall remain undismissed or unstayed for a period of 60 days; or the
Borrower or any Significant Subsidiary shall take

-- 347 of 409 --

60
any corporate action to authorize any of the actions set forth above in this Section 6.01(e); or
(f) 	Any one or more judgments or orders for the payment of money in excess of $250,000,000
shall be rendered against the Borrower or a Significant Subsidiary and either (i) enforcement proceedings
shall have been commenced by any creditor upon such judgment or order or (ii) there shall be any period
of 60 consecutive days during which a stay of enforcement of such judgment or order, by reason of a
pending appeal or otherwise, shall not be in effect; provided, however, that, for purposes of determining
whether an Event of Default has occurred under this Section 6.01(f), the amount of any such judgment or
order shall be reduced to the extent that (A) such judgment or order is covered by a valid and binding
policy of insurance between the defendant and the insurer covering payment thereof and (B) such insurer,
which shall be rated at least “A” by A.M. Best Company, has been notified of, and has not disputed the
claim made for payment of, such judgment or order; or
(g) 	(i) Any Person or two or more Persons acting in concert shall have acquired beneficial
ownership (within the meaning of Rule 13d-3 of the Securities and Exchange Commission under the
Securities Exchange Act of 1934, as amended), directly or indirectly, of Voting Stock of the Borrower (or
other securities convertible into or exchangeable for such Voting Stock) representing more than 50% of the
combined voting power of all Voting Stock of the Borrower (on a fully diluted basis) or (ii) during any
period of up to 24 consecutive months, commencing before or after the date of this Agreement, a majority
of the members of the board of directors of the Borrower shall not be Continuing Directors; or
(h) 	The Borrower or any of its ERISA Affiliates shall incur, or shall be reasonably likely to
incur, liability in excess of $250,000,000 in the aggregate as a result of one or more of the following:
(i) the occurrence of any ERISA Event; (ii) the partial or complete withdrawal of the Borrower or any
ERISA Affiliate from a Multiemployer Plan; or (iii) the reorganization or termination of a Multiemployer
Plan;
then, and in any such event, (i) the Administrative Agent shall at the request, or may with the consent, of the
Required Lenders, by notice to the Borrower, declare the Commitments of each Lender to be terminated,
whereupon the same shall forthwith terminate, and (ii) shall at the request, or may with the consent, of the
Required Lenders, by notice to the Borrower, declare the Advances, all interest thereon and all other amounts
payable under this Agreement to be forthwith due and payable, whereupon the Advances, all such interest and all
such amounts shall become and be forthwith due and payable, without presentment, demand, protest or further
notice of any kind, all of which are hereby expressly waived by the Borrower; provided, however, that in the event
of an actual or deemed entry of an order for relief with respect to the Borrower under the Federal Bankruptcy
Code, (A) the Commitment of each Lender shall automatically be terminated and (B) the Advances, all such
interest and all such amounts shall automatically become and be due and payable, without presentment, demand,
protest or any notice of any kind, all of which are hereby expressly waived by the Borrower.

-- 348 of 409 --

61
ARTICLE VII
THE AGENTS
SECTION 7.01 	Authorization and Action. Each Lender hereby irrevocably appoints JPMorgan
to act on its behalf as the Administrative Agent hereunder and authorizes the Administrative Agent to take such
actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof,
together with such actions and powers as are reasonably incidental thereto. The provisions of this Article VII
(other than the third sentence of Section 7.04 and Section 7.06) are solely for the benefit of the Administrative
Agent and the Lenders, and the Borrower shall not have rights as a third-party beneficiary of any of such
provisions (other than the third sentence of Section 7.04 and Section 7.06). It is understood and agreed that the
use of the term “agent” herein (or any other similar term) with reference to the Administrative Agent is not
intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any
applicable Law. Instead such term is used as a matter of market custom, and is intended to create or reflect only
an administrative relationship between contracting parties.
SECTION 7.02 	Administrative Agent Individually. The Person serving as the Administrative
Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may
exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall,
unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the
Administrative Agent hereunder in its individual capacity as a Lender. Such Person and its Affiliates may accept
deposits from, own securities of, lend money to, act as the financial advisor or in any other advisory capacity for
and generally engage in any kind of business with any member of the Consolidated Group or other Affiliate
thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to
the Lenders.
SECTION 7.03 	Duties of Administrative Agent; Exculpatory Provisions.
(a) 	The Administrative Agent’s duties hereunder and under the other Loan Documents are
solely ministerial and administrative in nature, and the Administrative Agent shall not have any duties or
obligations except those expressly set forth herein or in any other Loan Document. Without limiting the
generality of the foregoing, the Administrative Agent (i) shall not be subject to any fiduciary or other implied
duties, regardless of whether a Default has occurred and is continuing, (ii) shall not have any duty to take any
discretionary action or exercise any discretionary powers but shall be required to act or refrain from acting (and
shall be fully protected in so acting or refraining from acting) upon the written direction of the Required Lenders
(or such other number or percentage of the Lenders as shall be expressly provided for herein or in any other Loan
Document); provided that the Administrative Agent shall not be required to take any action that, in its opinion or
the opinion of its counsel, may expose the Administrative Agent or any of its Affiliates to liability or that is
contrary to any Loan Document or applicable Law, including for the avoidance of doubt, any action that may be in
violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or
termination of property of a Defaulting Lender in violation of any Debtor Relief Law and (iii) shall not, except as
expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for
the failure

-- 349 of 409 --

62
to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained
by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.
(b) 	The Administrative Agent shall not be liable for any action taken or not taken by it (i) with
the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall
be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the
circumstances as provided in Section 8.01 or 6.01) or (ii) in the absence of its own gross negligence or willful
misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The
Administrative Agent shall be deemed not to have knowledge of any Default or Event of Default unless and until
the Borrower or any Lender shall have given notice to the Administrative Agent describing such Default or Event
of Default.
(c) 	Neither the Administrative Agent nor any other Agent shall be responsible for or have any
duty to ascertain or inquire into (i) any statement, warranty, representation or other information made or supplied
in or in connection with this Agreement, any other Loan Document or the Information Memorandum, (ii) the
contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith
or therewith or the adequacy, accuracy and/or completeness of the information contained therein, (iii) the
performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or
therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this
Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of
any condition set forth in Article III or elsewhere herein, other than (but subject to the foregoing clause (ii)) to
confirm receipt of items expressly required to be delivered to the Administrative Agent.
(d) 	Nothing in this Agreement or any other Loan Document shall require the Administrative
Agent or any of its Related Parties to carry out any “know your customer” or other checks in relation to any
Person on behalf of any Lender, and each Lender confirms to the Administrative Agent that it is solely responsible
for any such checks it is required to carry out and that it may not rely on any statement in relation to such checks
made by the Administrative Agent or any of its Related Parties.
SECTION 7.04 	Reliance by Administrative Agent. The Administrative Agent shall be entitled
to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement,
instrument, document or other writing (including any electronic message, Internet or intranet website posting or
other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the
proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and
believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In
determining compliance with any condition hereunder to the Closing Date or the making of any Advance that by
its terms must be fulfilled to the satisfaction of a Lender, each Lender shall be deemed to have consented to,
approved or accepted such condition unless (a) an officer of the Administrative Agent responsible for the
transactions contemplated hereby shall have received notice to the contrary from such Lender prior to the Closing
Date or the making of such Advance, as applicable, and (b) in the case of a condition to the making of an
Advance, such Lender shall

-- 350 of 409 --

63
not have made available to the Administrative Agent such Lender’s ratable portion of such Borrowing. The
Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent
accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in
accordance with the advice of any such counsel, accountants or experts.
SECTION 7.05 	Delegation of Duties. The Administrative Agent may perform any and all of its
duties and exercise its rights and powers hereunder by or through any one or more sub-agents appointed by the
Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties
and exercise its rights and powers by or through their respective Related Parties. Each such sub-agent and the
Related Parties of the Administrative Agent and each such sub-agent shall be entitled to the benefits of all
provisions of this Article VII and Section 8.04 (as though such sub-agents were the “Administrative Agent” under
this Agreement) as if set forth in full herein with respect thereto. The Administrative Agent shall not be
responsible to any Lender for the negligence or misconduct of any sub-agents except to the extent that a court of
competent jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with
gross negligence or willful misconduct in the selection of such sub-agents.
SECTION 7.06 	Resignation of Administrative Agent.
(a) 	The Administrative Agent may at any time give notice of its resignation to the Lenders and
the Borrower. Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in
consultation with the Borrower, to appoint a successor, which shall be a bank with an office in the United States,
or an Affiliate of any such bank with an office in the United States. If no such successor shall have been so
appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring
Administrative Agent gives notice of its resignation (or such earlier day as shall be agreed by the Required
Lenders) (the “Resignation Effective Date”), then the retiring Administrative Agent may (but shall not be
obligated to), on behalf of the Lenders and in consultation with the Borrower, appoint a successor Administrative
Agent meeting the qualifications set forth above. Whether or not a successor has been appointed, such resignation
shall become effective in accordance with such notice on the Resignation Effective Date.
(b) 	If the Person serving as Administrative Agent is a Defaulting Lender pursuant to clause (d)
of the definition thereof, such Person shall automatically and without the taking of any action by any Person, be
removed as Administrative Agent on the date that is 30 days following the date such Person became a Defaulting
Lender (or such earlier day as shall be agreed by the Required Lenders) (the “Removal Effective Date”). In
connection therewith, the Required Lenders, in consultation with the Borrower, shall appoint a successor. If no
such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment
on or prior to the Removal Effective Date, then such removal shall nonetheless become effective in accordance
with such notice on the Removal Effective Date.
(c) 	With effect from the Resignation Effective Date or the Removal Effective Date (as
applicable) (i) the retiring or removed Administrative Agent shall be discharged from its duties and obligations
hereunder and under the other Loan Documents and (ii) except for any

-- 351 of 409 --

64
indemnity payments owed to the retiring or removed Administrative Agent, all payments, communications and
determinations to be made by, to or through the Administrative Agent shall instead be made by or to each Lender
directly, until such time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for
above. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor
shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring or removed
Administrative Agent (other than any rights to indemnity payments or other amounts owed to the retiring or
removed Administrative Agent), and the retiring or removed Administrative Agent shall be discharged from all of
its duties and obligations hereunder and under the other Loan Documents (if not already discharged therefrom as
provided above in this Section 7.06). The fees payable by the Borrower to a successor Administrative Agent shall
be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor.
After the retiring or removed Administrative Agent’s resignation or removal hereunder and under the other Loan
Documents, the provisions of this Article VII and Section 8.04 shall continue in effect for the benefit of such
retiring or removed Administrative Agent, its sub-agents and their respective Related Parties in respect of any
actions taken or omitted to be taken by any of them while the retiring or removed Administrative Agent was
acting as Administrative Agent.
SECTION 7.07 	Non-Reliance on Administrative Agent and Other Lenders. Each Lender
acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender
or any of their Related Parties and based on such documents and information as it has deemed appropriate, made
its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will,
independently and without reliance upon the Administrative Agent or any other Lender or any of their Related
Parties and based on such documents and information as it shall from time to time deem appropriate, continue to
make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan
Document or any related agreement or any document furnished hereunder or thereunder.
SECTION 7.08 	Indemnification. The Lenders agree to indemnify the Administrative Agent (to
the extent not reimbursed by the Borrower), ratably according to the respective principal amounts of the Advances
made by each of them (or, if no Advances are at the time outstanding, ratably according to the respective amounts
of their Commitments), from and against any and all liabilities, obligations, losses, damages, penalties, actions,
judgments, suits, costs, expenses and disbursements of any kind or nature whatsoever that may be imposed on,
incurred by, or asserted against the Administrative Agent in any way relating to or arising out of this Agreement
or any action taken or omitted by the Administrative Agent under this Agreement, in each case, acting in the
capacity of Administrative Agent; provided that no Lender shall be liable for any portion of such liabilities,
obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements resulting from
the Administrative Agent’s gross negligence or willful misconduct. Without limitation of the foregoing, each
Lender agrees to reimburse the Administrative Agent promptly upon demand for its ratable share of any out-of-
pocket expenses (including reasonable counsel fees) incurred by the Administrative Agent in connection with the
preparation, execution, delivery, administration, modification, amendment or enforcement (whether through
negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or responsibilities under, this
Agreement, to the extent that the Administrative Agent is not promptly reimbursed for such expenses by the
Borrower.

-- 352 of 409 --

65
SECTION 7.09 	Other Agents. None of the Lenders identified on the facing page or signature
pages of this Agreement as a “joint lead arranger”, “joint bookrunner”, or “syndication agent” shall have any
right, power, obligation, liability, responsibility or duty under this Agreement other than those applicable to all
Lenders as such. Without limiting the foregoing, none of the Lenders so identified shall have or be deemed to
have any fiduciary relationship with any Lender. Each Lender acknowledges that it has not relied, and will not
rely, on any of the Lenders so identified in deciding to enter into this Agreement or in taking or not taking action
hereunder.
SECTION 7.10 	ERISA.
(a) 	Each Lender (x) represents and warrants, as of the date such Person became a Lender party
hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person
ceases being a Lender party hereto, for the benefit of, the Agents and their respective Affiliates, and not, for the
avoidance of doubt, to or for the benefit of the Borrower, that at least one of the following is and will be true:
(i) 	such Lender is not using “plan assets” (within the meaning of the Plan Asset
Regulations) of one or more Benefit Plans in connection with the Advances or the Commitments,
(ii) 	the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class
exemption for certain transactions determined by independent qualified professional asset
managers), PTE 95-60 (a class exemption for certain transactions involving insurance company
general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance
company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions
involving bank collective investment funds) or PTE 96-23 (a class exemption for certain
transactions determined by in-house asset managers), is applicable with respect to such Lender’s
entrance into, participation in, administration of and performance of the Advances, the
Commitments and this Agreement, and the conditions for exemptive relief thereunder are and will
continue to be satisfied in connection therewith,
(iii) 	(A) such Lender is an investment fund managed by a “Qualified Professional Asset
Manager” (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset
Manager made the investment decision on behalf of such Lender to enter into, participate in,
administer and perform the Advances, the Commitments and this Agreement, (C) the entrance into,
participation in, administration of and performance of the Advances, the Commitments and this
Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and
(D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-
14 are satisfied with respect to such Lender’s entrance into, participation in, administration of and
performance of the Advances, the Commitments and this Agreement, or such other representation,
warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole
discretion, and such Lender.

-- 353 of 409 --

66
(b) 	In addition, unless either (1) sub-clause (i) in the immediately preceding clause (a) is true
with respect to a Lender or (2) such Lender has not provided another representation, warranty and covenant as
provided in sub-clause (iii) in the immediately preceding clause (a), such Lender further (x) represents and
warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such
Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit
of, each Agent and its respective Affiliates, and not, for the avoidance of doubt, to or for the benefit of the
Borrower, that none of the Agents or any of their respective Affiliates is a fiduciary with respect to the assets of
such Lender involved in such Lender’s entrance into, participation in, administration of and performance of the
Advances, the Commitments and this Agreement (including in connection with the reservation or exercise of any
rights by the Administrative Agent under this Agreement, any Loan Document or any documents related to hereto
or thereto).
(c) 	The Agents and the Arrangers hereby inform the Lenders that each such Person is not
undertaking to provide impartial investment advice, or to give advice in a fiduciary capacity, in connection with
the transactions contemplated hereby, and that such Person has a financial interest in the transactions
contemplated hereby in that such Person or an Affiliate thereof (i) may receive interest or other payments with
respect to the Advances, the Commitments and this Agreement, (ii) may recognize a gain if it extended the
Advances or the Commitments for an amount less than the amount being paid for an interest in the Advances or
the Commitments by such Lender or (iii) may receive fees or other payments in connection with the transactions
contemplated hereby, the Loan Documents or otherwise, including structuring fees, commitment fees,
arrangement fees, facility fees, upfront fees, underwriting fees, ticking fees, agency fees, administrative agent or
collateral agent fees, utilization fees, minimum usage fees, letter of credit fees, fronting fees, deal-away or
alternate transaction fees, amendment fees, processing fees, term out premiums, banker’s acceptance fees,
breakage or other early termination fees or fees similar to the foregoing.
ARTICLE VIII
MISCELLANEOUS
SECTION 8.01 	Amendments, Etc. Subject to Section 2.05(c) and 2.18, no amendment or
waiver of any provision of this Agreement, nor consent to any departure by the Borrower therefrom, shall in any
event be effective unless the same shall be in writing and signed by the Required Lenders and the Borrower and
acknowledged by the Administrative Agent, and then such waiver or consent shall be effective only in the specific
instance and for the specific purpose for which given; provided, however, that no amendment, waiver or consent
shall, unless in writing, do any of the following:
(a) 	waive any of the conditions specified in Section 3.01, unless signed by each Lender directly
and adversely affected thereby:
(b) 	increase or extend the Commitments of a Lender or subject a Lender to any additional
obligations, unless signed by such Lender;

-- 354 of 409 --

67
(c) 	reduce the principal of, or stated rate of interest on, the Advances, the stated rate at which
any fees hereunder are calculated or any other amounts payable hereunder, unless signed by each Lender
directly and adversely affected thereby;
(d) 	postpone any date fixed for any payment of principal of, or interest on, the Advances or
any fees or other amounts payable hereunder, unless signed by each Lender directly and adversely affected
thereby;
(e) 	change the percentage of the Commitments or of the aggregate unpaid principal amount of
the Advances, or the number of Lenders, that shall be required for the Lenders or any of them to take any
action hereunder (including the definition of “Required Lenders”), unless signed by all Lenders;
(f) 	amend this Section 8.01, unless signed by all Lenders; and
(g) 	amend or waive any of the provisions of Section 2.15 or 2.19(c), unless signed by each
Lender directly and adversely affected thereby.
and provided, further, that (i) no amendment, waiver or consent shall, unless in writing and signed by the
Administrative Agent in addition to the Lenders required above to take such action, affect the rights or duties of
the Administrative Agent under this Agreement or any other Loan Document; (ii) the Fee Letter may be amended,
or rights or privileges thereunder waived, in a writing executed only by the parties thereto; and (iii) any
amendment or waiver with respect to Section 8.16 shall require the consent of any Lender that is an Affected
Financial Institution. Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right
to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent
which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of
the applicable Lenders other than Defaulting Lenders), except (x) to the extent set forth in Section 2.19(a)(ii) and
(y) that any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that
by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of
such Defaulting Lender.
SECTION 8.02 	Notices, Etc.
(a) 	Except in the case of notices and other communications expressly permitted to be given by
telephone (and except as provided in Section 8.02(b) below), all notices and other communications provided for
hereunder shall be in writing (including telecopier) and mailed, telecopied or delivered, if to the Borrower or the
Administrative Agent, to the address, telecopier number, electronic mail address or telephone number specified
for such Person on Schedule II; or, as to the Borrower or the Administrative Agent, at such other address as shall
be designated by such party in a written notice to the other parties and, as to each other party, at such other address
as shall be designated by such party in a written notice to the Borrower and the Administrative Agent. Notices
and other communications sent by hand or overnight courier service, or mailed by certified or registered mail,
shall be deemed to have been given when received; notices and other communications sent by facsimile shall be
deemed to have been given when sent (except that, if not given during normal business hours for the recipient,
shall be deemed to have been given at

-- 355 of 409 --

68
the opening of business on the next Business Day for the recipient). Notices and other communications delivered
through electronic communications to the extent provided in Section 8.02(b) below, shall be effective as provided
in such Section 8.02(b).
(b) 	Electronic Communications. Notices and other communications to the Lenders hereunder
may be delivered or furnished by electronic communication (including e-mail, FpML messaging and Internet or
intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing shall
not apply to notices to any Lender pursuant to Article II if such Lender has notified the Administrative Agent that
it is incapable of receiving notices under such Article by electronic communication. The Administrative Agent or
the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic
communications pursuant to procedures approved by it, provided that approval of such procedures may be limited
to particular notices or communications.
Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to
an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended
recipient (such as by the “return receipt requested” function, as available, return e-mail or other written
acknowledgement), provided that if such notice or other communication is not sent during the normal business
hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business
on the next business day for the recipient, and (ii) notices or communications posted to an Internet or intranet
website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as
described in the foregoing clause (i) of notification that such notice or communication is available and identifying
the website address therefor.
(c) 	THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.” THE AGENT
PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE
BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM
LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS. NO WARRANTY
OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD-
PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY
AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no
event shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any
liability to the Borrower, any Lender or any other Person for losses, claims, damages, liabilities or expenses of any
kind (whether in tort, contract or otherwise) arising out of the Borrower’s or the Administrative Agent’s
transmission of Borrower Materials or notices through the platform, any other electronic platform or electronic
messaging service, or through the Internet, except to the extent that such losses, claims, damages, liabilities or
expenses are determined by a court of competent jurisdiction by a final and nonappealable judgment to have
resulted from the gross negligence or willful misconduct of such Agent Party; provided, however, that in no event
shall any Agent Party have any liability to the Borrower, any Lender or any other Person for indirect, special,
incidental, consequential or punitive damages (as opposed to direct or actual damages).

-- 356 of 409 --

69
(d) 	Each of the Borrower and the Administrative Agent may change its address, facsimile or
telephone number for notices and other communications hereunder by notice to the other parties hereto. Each
Lender may change its address, facsimile or telephone number for notices and other communications hereunder by
notice to the Borrower and the Administrative Agent. In addition, each Lender agrees to notify the Administrative
Agent from time to time to ensure that the Administrative Agent has on record (i) an effective address, contact
name, telephone number, facsimile number and electronic mail address to which notices and other
communications may be sent and (ii) accurate wire instructions for such Lender.
(e) 	The Administrative Agent and the Lenders shall be entitled to rely and act upon any notices
(including telephonic notices and Notices of Borrowing) reasonably believed to have been given by or on behalf
of the Borrower even if (i) such notices were not made in a manner specified herein, were incomplete or were not
preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the
recipient, varied from any confirmation thereof. The Borrower shall indemnify the Administrative Agent, each
Lender and the Related Parties of each of them from all losses, costs, expenses and liabilities resulting from the
reasonable reliance by such Person on each notice reasonably believed to have been given by or on behalf of the
Borrower. All telephonic notices to and other telephonic communications with the Administrative Agent may be
recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording. With
respect to notices and other communications hereunder from the Borrower to any Lender, the Borrower shall
provide such notices and other communications to the Administrative Agent, and the Administrative Agent shall
promptly deliver such notices and other communications to any such Lender in accordance with Section 8.02(b)
above or otherwise.
SECTION 8.03 	No Waiver; Remedies. No failure on the part of any Lender or the
Administrative Agent to exercise, and no delay in exercising, any right hereunder shall operate as a waiver
thereof; nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or
the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies
provided by applicable Law.
SECTION 8.04 	Expenses; Indemnity.
(a) 	Costs and Expenses. The Borrower shall pay upon demand (i) all reasonable and
documented or invoiced out-of-pocket fees and expenses incurred by the Administrative Agent and its respective
Affiliates (including, but not limited to, the reasonable and documented or invoiced fees, charges and
disbursements of counsel which shall be limited to the reasonable and documented or invoiced out-of-pocket fees
and other charges of one counsel to the Administrative Agent and its respective Affiliates (which as of the date
hereof is Shearman & Sterling LLP), and, if necessary, of one local counsel to the Administrative Agent and its
respective Affiliates in each relevant jurisdiction, and due diligence expenses), in connection with the syndication
of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of
this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions
hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated) and
(ii) all out of pocket expenses incurred by the Administrative Agent or any Lender (including, but not limited to,
the reasonable and documented or invoiced fees, charges and disbursements of counsel which shall be limited to
the

-- 357 of 409 --

70
reasonable and documented or invoiced out-of-pocket fees and other charges of one counsel to the Lenders and
the Administrative Agent, and, if necessary, of one local counsel to the Lenders, retained by the Administrative
Agent in each relevant jurisdiction (and, solely in the case of an actual or potential conflict of interest, of one
additional counsel (and, if reasonably necessary, one additional local counsel in any relevant jurisdiction) for all
such affected Lenders), and due diligence expenses), in connection with the enforcement or protection of its rights
(A) in connection with this Agreement and the other Loan Documents, including its rights under this Section 8.04,
or (B) in connection with the Advances made hereunder, including all such out of pocket expenses incurred during
any workout, restructuring or negotiations in respect of such Advances.
(b) 	Indemnification by the Borrower. The Borrower shall indemnify the Administrative Agent
(and any sub-agent thereof) and each Lender, and each Related Party of any of the foregoing Persons and any
successors or assigns (each such Person being called an “Indemnified Party”) against, and hold each Indemnified
Party harmless from, all losses, claims, damages, liabilities and related expenses to which any Indemnified Party
may become subject resulting from or in connection with this Agreement, the other Loan Documents, the use of
the proceeds under this Agreement or any related transaction, any actual or alleged presence of Hazardous
Materials on any property of the Consolidated Group or any Environmental Liability related in any way to the
Borrower or any of its Subsidiaries or any claim, litigation, investigation or proceeding relating to any of the
foregoing, regardless of whether any Indemnified Party is a party thereto and regardless of whether brought by a
third party or by the Borrower or any of its Affiliates (any of the foregoing, a “Proceeding”), and shall reimburse
each Indemnified Party upon demand for any legal or other expenses incurred in connection with investigating,
defending, preparing to defend or participating in any such Proceeding, provided that (i) the foregoing indemnity
will not, as to any Indemnified Party, apply to losses, claims, damages, liabilities or related expenses (A) to the
extent they are found by a final, non-appealable judgment of a court of competent jurisdiction to result from the
bad faith, willful misconduct or gross negligence of such Indemnified Party or any of its Related Persons, (B) to
the extent resulting from any Proceeding that does not involve an act or omission of the Borrower or any of its
Affiliates and that is brought by an Indemnified Party solely against another Indemnified Party, other than claims
against any the Administrative Agent or the Arrangers in its capacity in fulfilling its role as an administrative
agent or lead arranger under this Agreement or (C) to the extent resulting from a material breach by such
Indemnified Party or any Related Person thereof of its obligations hereunder as found by a final, non-appealable
judgment by a court of competent jurisdiction and (ii) the Borrower’s obligation to reimburse legal expenses
pursuant to this Section 8.04(b) shall be limited to the fees, charges and disbursements of one counsel to all
Indemnified Parties (and, if reasonably necessary, one local counsel in any relevant jurisdiction) and, solely in the
case of an actual or potential conflict of interest, of one additional counsel (and, if reasonably necessary,
one additional local counsel in any relevant jurisdiction). This Section 8.04(b) shall not apply with respect to
Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.
(c) 	Compensation for Losses. If any payment of principal of, or Conversion of, any Eurodollar
Rate Advance is made by the Borrower to or for the account of a Lender other than on the last day of the Interest
Period for such Advance, as a result of (i) a payment or Conversion pursuant to Section 2.06, 2.08(c), 2.08(d),
2.10 or 2.12, (ii) acceleration of the maturity of the Advances pursuant to Section 6.01, (iii) a payment by an
Eligible Assignee to any Lender other

-- 358 of 409 --

71
than on the last day of the Interest Period for such Advance upon an assignment of the rights and obligations of
such Lender under this Agreement pursuant to Section 8.07 as a result of a demand by the Borrower pursuant to
Section 8.07(a) or (iv) for any other reason (other than, subject to the foregoing clause (iii), a payment by an
Eligible Assignee to any Lender), the Borrower shall, upon demand by such Lender (with a copy of such demand
to the Administrative Agent), pay to the Administrative Agent for the account of such Lender any amounts
required to compensate such Lender for any additional reasonable losses, costs or expenses that it may reasonably
incur as a result of such payment or Conversion or as a result of any inability to Convert or exchange in the case
of Section 2.08 or 2.12, including, without limitation, any reasonable loss (excluding loss of anticipated profits),
cost or expense incurred by reason of the liquidation or reemployment of deposits or other funds acquired by any
Lender to fund or maintain such Advance.
(d) 	Reimbursement by Lenders. Without duplication with respect to Section 7.08, to the extent
that the Borrower for any reason fails to indefeasibly pay any amount required under subsection (a) or (b) of this
Section 8.04 to be paid by it to the Administrative Agent (or any sub-agent thereof) or any Related Party of any of
the foregoing, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent) or such
Related Party, as the case may be, such Lender’s pro rata share (determined as of the time that the applicable
unreimbursed expense or indemnity payment is sought) of such unpaid amount (including any such unpaid
amount in respect of a claim asserted by such Lender), such payment to be made severally among them based on
such Lenders’ pro rata share (determined as of the time that the applicable unreimbursed expense or indemnity
payment is sought based on each Lender’s pro rata share at such time), provided, further that, the unreimbursed
expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or
asserted against the Administrative Agent (or any such sub-agent) in its capacity as such, or against any Related
Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent) in connection with such
capacity.
(e) 	Waiver of Consequential Damages, Etc. To the fullest extent permitted by applicable law,
the Borrower shall not assert, and hereby waives, and acknowledges that no other Person shall have, any claim
against the Administrative Agent (and any sub-agent thereof) and each Lender, and each Related Party of any of
the foregoing Persons and any successors or assigns (each such Person being called a “Lender-Related Person”),
on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual
damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any
agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Advance or
the use of the proceeds thereof. No Lender-Related Person shall be liable for any damages arising from the use by
unintended recipients of any information or other materials distributed to such unintended recipients by such
Lender-Related Person through telecommunications, electronic or other information transmission systems in
connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby
other than for direct or actual damages resulting from the gross negligence, bad faith or willful misconduct of such
Lender-Related Person as determined by a final and nonappealable judgment of a court of competent jurisdiction.
Nothing in this Section 8.04(e) shall relieve the Borrower of any obligation it may have to indemnify an
Indemnified Party against special, indirect, consequential or punitive damages to the extent required under Section
8.04(b).

-- 359 of 409 --

72
(f) 	Survival. Without prejudice to the survival of any other agreement of the Borrower
hereunder, the agreements and obligations of the Borrower contained in Section 2.11, Section 2.14 and this
Section 8.04 shall survive the payment in full of principal, interest and all other amounts payable hereunder.
SECTION 8.05 	Right of Setoff. Upon (a) the occurrence and during the continuance of any
Event of Default and (b) the making of the request or the granting of the consent specified by Section 6.01 to
authorize the Administrative Agent to declare the Advances due and payable pursuant to the provisions of
Section 6.01, each Lender and each of its Affiliates is hereby authorized at any time and from time to time, to the
fullest extent permitted by applicable Law, to set off and apply any and all deposits (general or special, time or
demand, provisional or final) at any time held and other indebtedness at any time owing by such Lender or such
Affiliate to or for the credit or the account of the Borrower against any and all of the obligations of the Borrower
now or hereafter existing under this Agreement, whether or not such Lender shall have made any demand under
this Agreement and although such obligations may be unmatured. Each Lender agrees promptly to notify the
Administrative Agent and the Borrower after any such setoff and application is made by such Lender; provided
that the failure to give such notice shall not affect the validity of such setoff and application. The rights of each
Lender and its Affiliates under this Section 8.05 are in addition to other rights and remedies (including, without
limitation, other rights of setoff) that such Lender and its Affiliates may have.
SECTION 8.06 	Binding Effect. This Agreement shall become effective (other than
Section 2.01, which shall only become effective upon satisfaction of the applicable conditions precedent set forth
in Section 3.01) when it shall have been executed by the Borrower and the Administrative Agent and when the
Administrative Agent shall have been notified by each Initial Lender that such Initial Lender has executed it and,
thereafter, shall be binding upon and inure to the benefit of, and be enforceable by, the Borrower, the
Administrative Agent and each Lender and their respective successors and permitted assigns, except that, subject
to Section 8.07, the Borrower shall have no right to assign their rights hereunder or any interest herein without the
prior written consent of each of the Lenders, and any purported assignment without such consent shall be null and
void.
SECTION 8.07 	Assignments and Participations.
(a) 	Each Lender may, with the consent of the Borrower and the Administrative Agent, which
consents shall not be unreasonably withheld, conditioned or delayed and, in the case of the Borrower, (i) shall not
be required while an Event of Default has occurred and is continuing and (ii) shall be deemed given if the
Borrower shall not have objected within 10 Business Days following its receipt of notice of such assignment (and,
within five days after demand by the Borrower (with a copy of such demand to the Administrative Agent) to
(A) any Defaulting Lender, (B) any Lender that has made a demand for payment pursuant to Section 2.11 or 2.14,
(C) any Lender that has asserted pursuant to Section 2.08(b) or 2.12 that it is impracticable or unlawful for such
Lender to make Eurodollar Rate Advances or (D) any Lender that fails to consent to an amendment or waiver
hereunder for which consent of all Lenders (or all affected Lenders) is required and as to which the Required
Lenders have given their consent, such Lender will), assign to one or more Persons all or a portion of its rights
and obligations under this Agreement

-- 360 of 409 --

73
(including, without limitation, all or a portion of its Commitment and the Advances owing to it); provided,
however, that:
(1) 	such consent shall not be required in the case of an assignment to any other Lender
or an Affiliate of any Lender, provided that notice thereof shall have been given to the Borrower
and the Administrative Agent;
(2) 	each such assignment shall be of a constant, and not a varying, percentage of all
rights and obligations under this Agreement;
(3) 	except in the case of an assignment to a Person that, immediately prior to such
assignment, was a Lender or an assignment of all of a Lender’s rights and obligations under this
Agreement, the amount of the Commitment of the assigning Lender being assigned pursuant to
each such assignment (determined as of the date of the Assignment and Acceptance with respect to
such assignment) shall in no event be less than $10,000,000 or an integral multiple of $1,000,000
in excess thereof;
(4) 	each such assignment shall be to an Eligible Assignee;
(5) 	each such assignment made as a result of a demand by the Borrower pursuant to
this Section 8.07(a) shall be arranged by the Borrower with the approval of the Administrative
Agent (which approval shall not be unreasonably withheld, conditioned or delayed) and shall be
either an assignment of all of the rights and obligations of the assigning Lender under this
Agreement or an assignment of a portion of such rights and obligations made concurrently with
another such assignment or other such assignments that, in the aggregate, cover all of the rights and
obligations of the assigning Lender under this Agreement;
(6) 	no Lender shall be obligated to make any such assignment as a result of a demand
by the Borrower pursuant to this Section 8.07(a), (I) (except in the case of an assignment of the
type described in clause (D) of the first parenthetical clause in this Section 8.07(a) to the extent
such Default would no longer be continuing after giving effect to the relevant amendment or
waiver) so long as a Default shall have occurred and be continuing and (II) unless and until such
Lender shall have received one or more payments from one or more Eligible Assignees in an
aggregate amount at least equal to the aggregate outstanding principal amount of the Advances
owing to such Lender, together with accrued interest thereon to the date of payment of such
principal amount, and from the Borrower or one or more Eligible Assignees in an aggregate
amount equal to all other amounts accrued to such Lender under this Agreement (including,
without limitation, any amounts owing under Sections 2.11, 2.14 or 8.04(c)) and (III) if any such
Eligible Assignee is not an existing Lender, unless and until the Borrower shall have paid (or
caused to be paid) to the Administrative Agent a processing and recordation fee of $3,500;
provided, however, that the Administrative Agent may, in its sole discretion, elect to waive such
processing and recordation fee in the case of any assignment. The

-- 361 of 409 --

74
assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative
Questionnaire; and
(7) 	the parties to each such assignment (other than, except in the case of a demand by
the Borrower pursuant to this Section 8.07(a), the Borrower) shall execute and deliver to the
Administrative Agent, for its acceptance and recording in the Register, an Assignment and
Acceptance and, if such assignment does not occur as a result of a demand by the Borrower
pursuant to this Section 8.07(a) (in which case the Borrower shall pay the fee required by
subclause (6)(III) of this Section 8.07(a)), a processing and recordation fee of $3,500; provided,
however, that the Administrative Agent may, in its sole discretion, elect to waive such processing
and recordation fee in the case of any assignment; provided, further, that in the event that, in
connection with a demand by the Borrower pursuant to this Section 8.07(a), the assignor shall not
execute and deliver the relevant Assignment and Acceptance within one Business Day of the
Borrower’s request, such assignor shall be deemed to have executed and delivered such
Assignment and Acceptance. The assignee, if it is not a Lender, shall deliver to the Administrative
Agent an Administrative Questionnaire.
Upon such execution, delivery, acceptance and recording, from and after the effective date specified in each
Assignment and Acceptance, (x) the assignee thereunder shall be a party hereto and, to the extent that rights and
obligations hereunder have been assigned to it pursuant to such Assignment and Acceptance, have the rights and
obligations of a Lender hereunder and (y) the Lender assignor thereunder shall, to the extent that rights and
obligations hereunder have been assigned by it pursuant to such Assignment and Acceptance, relinquish its rights
and be released from its obligations under this Agreement, except that such assigning Lender shall continue to be
entitled to the benefit of Section 8.04(a) and (b) with respect to matters arising out of the prior involvement of
such assigning Lender as a Lender hereunder (and, in the case of an Assignment and Acceptance covering all or
the remaining portion of an assigning Lender’s rights and obligations under this Agreement, such Lender shall
cease to be a party hereto).
(b) 	By executing and delivering an Assignment and Acceptance, the Lender assignor
thereunder and the assignee thereunder confirm to and agree with each other and the other parties hereto as
follows:
(i) 	other than as provided in such Assignment and Acceptance, such assigning Lender
makes no representation or warranty and assumes no responsibility with respect to any statements,
warranties or representations made in or in connection with this Agreement or the execution, legality,
validity, enforceability, genuineness, sufficiency or value of this Agreement or any other instrument or
document furnished pursuant hereto;
(ii) 	such assigning Lender makes no representation or warranty and assumes no
responsibility with respect to the financial condition of the Borrower or the performance or observance by
the Borrower of any of its obligations under this Agreement or any other instrument or document furnished
pursuant hereto;

-- 362 of 409 --

75
(iii) 	such assignee confirms that it has received a copy of this Agreement, together with
copies of the financial statements referred to in Section 4.01(e) and such other documents and information
as it has deemed appropriate to make its own credit analysis and decision to enter into such Assignment
and Acceptance;
(iv) 	such assignee will, independently and without reliance upon any Agent, such
assigning Lender or any other Lender and based on such documents and information as it shall deem
appropriate at the time, continue to make its own credit decisions in taking or not taking action under this
Agreement;
(v) 	such assignee confirms that it is an Eligible Assignee;
(vi) 	such assignee appoints and authorizes the Administrative Agent to take such action
as agent on its behalf and to exercise such powers and discretion under this Agreement as are delegated to
the Administrative Agent by the terms hereof, together with such powers and discretion as are reasonably
incidental thereto; and
(vii) 	such assignee agrees that it will perform in accordance with their terms all of the
obligations that by the terms of this Agreement are required to be performed by it as a Lender.
(c) 	Upon its receipt of an Assignment and Acceptance executed by an assigning Lender and an
assignee representing that it is an Eligible Assignee, the Administrative Agent shall, if such Assignment and
Acceptance has been completed and is in substantially the form of Exhibit B hereto, (i) accept such Assignment
and Acceptance, (ii) record the information contained therein in the Register and (iii) give prompt notice thereof
to the Borrower.
(d) 	The Administrative Agent, acting solely for this purpose as the agent of the Borrower, shall
maintain at its address referred to in Section 8.02(a) a copy of each Assignment and Acceptance delivered to and
accepted by it and a register for the recordation of the names and addresses of the Lenders and the Commitment
of, and principal amount (and stated interest) of the Advances owing to, each Lender from time to time (the
“Register”). The entries in the Register shall be conclusive and binding for all purposes, absent demonstrable
error, and the Borrower, the Agents and the Lenders may treat each Person whose name is recorded in the Register
as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by the
Borrower or any Lender at any reasonable time and from time to time upon reasonable prior notice.
(e) 	Each Lender may sell participations to one or more banks or other entities (other than a
natural person, the Borrower or any of its Affiliates) in or to all or a portion of its rights and obligations under this
Agreement (including, without limitation, all or a portion of its Commitment and the Advances owing to it)
without the prior consent of, or notice to, the Administrative Agent or the Borrower; provided, however, that:
(i) 	such Lender’s obligations under this Agreement (including, without limitation, its
Commitment) shall remain unchanged;

-- 363 of 409 --

76
(ii) 	such Lender shall remain solely responsible to the other parties hereto for the
performance of such obligations;
(iii) 	such Lender shall remain the Lender of any such Advance for all purposes of this
Agreement;
(iv) 	the Borrower, the Agents and the other Lenders shall continue to deal solely and
directly with such Lender in connection with such Lender’s rights and obligations under this Agreement;
and
(v) 	no participant under any such participation shall have any right to approve any
amendment or waiver of any provision of this Agreement, or any consent to any departure by the Borrower
herefrom or therefrom, except to the extent that such amendment, waiver or consent would reduce the
principal of, or stated rate of interest on, the Advances or the stated rate at which any fees or any other
amounts payable hereunder are calculated, in each case to the extent subject to such participation, or
postpone any date fixed for any payment of principal of, or interest on, the Advances or any fees or any
other amounts payable hereunder, in each case to the extent subject to such participation.
Subject to the immediately succeeding paragraph, the Borrower agrees that such participant shall be entitled to the
benefits of Sections 2.11 and 2.14 to the same extent as if it were a Lender and had acquired its interest by
assignment pursuant to subsection (a) of this Section 8.07 (it being understood that the documentation required
under Section 2.14(e) shall be delivered to the Lender who sells the participation); provided that such participant
(A) agrees to be subject to the provisions of Sections 2.15, 2.20 and 8.05 as if it were an assignee under subsection
(a) of this Section 8.07 and (B) shall not be entitled to receive any greater payment under Sections 2.11 or 2.14,
with respect to any participation, than the Lender from whom it acquired the applicable participation would have
been entitled to receive, unless the sale of such participation is made with the prior written consent of the
Borrower and the Borrower expressly waives the benefit of this provision at the time of such participation. Each
Lender that sells a participation agrees, at the Borrower’s request and expense, to use reasonable efforts to
cooperate with the Borrower to effectuate the provisions of Sections 2.15, 2.20 and 8.05 with respect to any
participant.
A participant shall not be entitled to the benefits of Section 2.14 unless the Borrower is notified of the
participation sold to such participant and such participant agrees, for the benefit of the Borrower, to comply with
Sections 2.14(e) as though it were a Lender (it being understood that the documentation required under Section
2.14(e) shall be delivered by each participant to the participating Lender).
Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower,
maintain a register on which it enters the name and address of each participant and the principal amounts (and
stated interest) of each participant’s interest in the Advances or other obligations under the Loan Documents (the
“Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the
Participant Register (including the identity of any participant or any information relating to a participant’s interest
in any Commitments, Advances or its other obligations under any Loan Document) to any Person except to the
extent that such disclosure is necessary to establish that such Commitment, Advance or other

-- 364 of 409 --

77
obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries
in the Participant Register shall be conclusive absent demonstrable error, and such Lender shall treat each Person
whose name is recorded in the Participant Register as the owner of such participation for all purposes of this
Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in
its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.
(f) 	Any Lender may, in connection with any assignment or participation or proposed
assignment or participation pursuant to this Section 8.07, disclose to the assignee or participant or proposed
assignee or participant, any information relating to the Borrower furnished to such Lender by or on behalf of the
Borrower; provided that, prior to any such disclosure, the assignee or participant or proposed assignee or
participant shall agree to preserve the confidentiality of any Information relating to the Borrower received by it
from such Lender as more fully set forth in Section 8.08.
(g) 	Notwithstanding any other provision set forth in this Agreement, any Lender may at any
time create a security interest in all or any portion of its rights under this Agreement (including, without limitation
and the Advances owing to it) to secure obligations of such Lender, including, without limitation, any pledge or
assignment to secure obligations in favor of any Federal Reserve Bank in accordance with Regulation A of the
Board of Governors of the Federal Reserve System or any central bank having jurisdiction over such Lender.
SECTION 8.08 	Confidentiality. Each of the Administrative Agent and the Lenders agrees to
maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to
its Affiliates and to its and its Affiliates’ respective managers, administrators, trustees, partners, directors, officers,
employees, agents, advisors and other representatives (it being understood that the Persons to whom such
disclosure is made will be informed of the confidential nature of such Information and instructed to keep such
Information confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction
over it or its Affiliates (including any self-regulatory authority, such as the National Association of Insurance
Commissioners), (c) to the extent required by applicable Laws or regulations or by any subpoena or similar legal
process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder or any action
or proceeding relating to this Agreement or the enforcement of rights hereunder or thereunder, (f) subject to an
agreement containing provisions substantially the same as those of this Section 8.08, to (i) any assignee of or
participant in, or any prospective assignee of or participant in, any of its rights or obligations under this
Agreement or (ii) any actual or prospective party (or its managers, administrators, trustees, partners, directors,
officers, employees, agents, advisors and other representatives) to any swap or derivative or similar transaction
under which payments are to be made by reference to the Borrower and its obligations, this Agreement or
payments hereunder, (iii) any rating agency, or (iv) the CUSIP Service Bureau or any similar organization,
(g) with the consent of the Borrower or (h) to the extent such Information (i) becomes publicly available other
than as a result of a breach of this Section or (ii) becomes available to the Administrative Agent, any Lender or
any of their respective Affiliates on a non-confidential basis from a source other than the Borrower, which it has
no reason, after due inquiry, to believe has any confidentiality or fiduciary obligation to the Borrower with respect
to such Information.

-- 365 of 409 --

78
For purposes of this Section 8.08, “Information” means all information received from the Borrower
or any of its Subsidiaries relating to the Borrower or any of its Subsidiaries or any of their respective businesses,
other than any such information that is available to the Administrative Agent or any Lender on a non-confidential
basis prior to disclosure by the Borrower or any of its Subsidiaries, provided that, in the case of information
received from the Borrower or any of its Subsidiaries after the date hereof, such information is clearly identified at
the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as
provided in this Section 8.08 shall be considered to have complied with its obligation to do so if such Person has
exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord
to its own confidential information.
SECTION 8.09 	Governing Law. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of New York.
SECTION 8.10 	Execution in Counterparts. This Agreement may be executed in any number of
counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be
deemed to be an original and all of which taken together shall constitute one and the same agreement.
SECTION 8.11 	Electronic Execution of Assignments and Certain Other Documents. The words
“execute,” “execution,” “signed,” “signature,” and words of like import in or related to this Agreement, any other
document to be signed in connection with this Agreement and the transactions contemplated hereby (including
without limitation Assignment and Acceptances, Notices of Borrowing, amendments or other modifications,
waivers and consents) shall be deemed to include Electronic Signatures (as defined below), deliveries or the
keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as
a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent
and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National
Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state Laws based
on the Uniform Electronic Transactions Act; provided that notwithstanding anything contained herein to the
contrary the Administrative Agent is under no obligation to agree to accept Electronic Signatures in any form or in
any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it.
“Electronic Signatures” means any electronic symbol or process attached to, or associated with, any contract or
other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record.
SECTION 8.12 	Jurisdiction, Etc.
(a) 	The Borrower and the other parties hereto irrevocably and unconditionally agrees that it
will not commence any action, litigation or proceeding of any kind or description, whether in Law or equity,
whether in contract or in tort or otherwise, against any party hereto or any Related Party of the foregoing in any
way relating to this Agreement or any other Loan Document or the transactions relating hereto or thereto, in any
forum other than the federal courts located in the County of New York County (or if such courts lack subject
matter jurisdiction, the Supreme Court of the State of New York sitting in the Borough of Manhattan), and each of
the

-- 366 of 409 --

79
Borrower and the other parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts
and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in
such federal court (or if such courts lack subject matter jurisdiction, the Supreme Court of the State of New York
sitting in the Borough of Manhattan) to the fullest extent permitted by applicable Law. The Borrower and the
other parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be
enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.
(b) 	The Borrower and the other parties hereto irrevocably and unconditionally waives, to the
fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of
venue of any suit, action or proceeding arising out of or relating to this Agreement in any federal court located in
the County of New York County (or if such courts lack subject matter jurisdiction, the Supreme Court of the State
of New York sitting in the Borough of Manhattan). The Borrower and the other parties hereto hereby irrevocably
waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the maintenance of such
action or proceeding in any such court.
(c) 	The Borrower and the other parties hereto irrevocably consents to service of process in the
manner provided for notices in Section 8.02(a). Nothing in this Agreement will affect the right of any party hereto
to serve process in any other manner permitted by applicable Law.
SECTION 8.13 	Patriot Act Notice; Beneficial Ownership Regulation. Each Lender and the
Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower that pursuant to the
requirements of the Patriot Act and the Beneficial Ownership Regulation, it is required to obtain, verify and
record information that identifies the Borrower, which information includes the name and address of the Borrower
and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the
Borrower in accordance with the Patriot Act and the Beneficial Ownership Regulation. The Borrower shall
provide, to the extent commercially reasonable, such information and take such actions as are reasonably
requested by the Administrative Agent or any Lenders in order to assist the Administrative Agent and the Lenders
in maintaining compliance with the Patriot Act and the Beneficial Ownership Regulation.
SECTION 8.14 	No Advisory or Fiduciary Responsibility. In its capacity as an Agent or a
Lender, (a) no Agent or Lender has any responsibility except as set forth herein and (b) no Agent or Lender shall
be subject to any fiduciary duties or other implied duties (to the extent permitted by Law to be waived). The
Borrower agrees that it will not take any position or bring any claim against any Agent or any Lender that is
contrary to the preceding sentence.
In connection with all aspects of each transaction contemplated hereby (including in connection
with any amendment, waiver or other modification hereof), the Borrower acknowledges and agrees that: (i) the
arranging and other services regarding this Agreement provided by the Agents and the Lenders are arm’s-length
commercial transactions between the Borrower and its Affiliates, on the one hand, and the Agents and the
Lenders, on the other hand; (ii) each Agent and each Lender is and has been acting solely as a principal and,
except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an
advisor

-- 367 of 409 --

80
or agent for the Borrower or any of its Affiliates, or any other Person; and (iii) the Agents, the Lenders and each
of their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from
those of the Borrower and its Affiliates, and no Agent or Lender has any obligation to disclose any of such
interests to the Borrower or its Affiliates.
SECTION 8.15 	Termination of Credit Documents. The Borrower and each applicable Lender
agree that concurrently with the effectiveness of this Agreement, the commitment amounts under the 2018 Credit
Agreement shall automatically reduce to zero and the 2018 Credit Agreement shall terminate, without any notice
or other action of any kind and notwithstanding any notice or other requirement contained therein; provided that
(a) the Borrower shall have paid all amounts then payable under the 2018 Credit Agreement; and (b) any
provision of the 2018 Credit Agreement that by its terms survives termination thereof shall continue in full force
and effect. Each Lender that is a party to the 2018 Credit Agreement hereby waives any requirement of prior
notice thereunder in respect of any prepayment or termination of the commitments under such agreement.
SECTION 8.16 	Acknowledgment and Consent to Bail-In of Affected Financial Institutions.
Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or
understanding among any such parties, each party hereto acknowledges that any liability of any Affected
Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to
the Write-Down and Conversion Powers of the applicable EEA Resolution Authority and agrees and consents to,
and acknowledges and agrees to be bound by:
(a) 	the application of any Write-Down and Conversion Powers by the applicable Resolution
Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an
Affected Financial Institution; and
(b) 	the effects of any Bail-In Action on any such liability, including, if applicable: (i) a
reduction in full or in part or cancellation of any such liability; (ii) a conversion of all, or a portion of, such
liability into shares or other instruments of ownership in such Affected Financial Institution, its parent
entity, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or
other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability
under this Agreement or any other Loan Document; or (iii) the variation of the terms of such liability in
connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution
Authority.
SECTION 8.17 	Integration(a) 	. This Agreement, together with the other Loan Documents,
comprises the complete and integrated agreement of the parties on the subject matter hereof and thereof and
supersedes all prior agreements, written or oral, on such subject matter. In the event of any conflict between the
provisions of this Agreement and those of any other Loan Document, the provisions of this Agreement shall
control; provided that the inclusion of supplemental rights or remedies in favor of the Administrative Agent or the
Lenders in any other Loan Document shall not be deemed a conflict with this Agreement. Each Loan Document
was drafted with the joint participation of the respective parties thereto and shall be construed neither against nor
in favor of any party, but rather in accordance with the fair meaning thereof.

-- 368 of 409 --

81
SECTION 8.18 	Waiver of Jury Trial. Each of the Borrower, the Administrative
Agent and the Lenders hereby irrevocably waives all right to trial by jury in any action, proceeding or
counterclaim (whether based on contract, tort or otherwise) arising out of or relating to this Agreement or the
actions of the Administrative Agent or any Lender in the negotiation, administration, performance or enforcement
thereof.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

-- 369 of 409 --

[Abbott – Signature Page to 2020 Revolver]
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
respective officers thereunto duly authorized, as of the date first above written.
ABBOTT LABORATORIES
By: /s/ Karen M. Peterson
Name: Karen M. Peterson
Title: Vice President, Treasurer

-- 370 of 409 --

[Abbott – Signature Page to 2020 Revolver]
JPMORGAN CHASE BANK, N.A., as
Administrative Agent and as a Lender
By: /s/ Stacey Zoland
Name: Stacey Zoland
Title: Executive Director

-- 371 of 409 --

[Abbott – Signature Page to 2020 Revolver]
BANK OF AMERICA, N.A., as a Lender
By: /s/ Darren Merten
Name: Darren Merten
Title: Director

-- 372 of 409 --

[Abbott – Signature Page to 2020 Revolver]
BARCLAYS BANK PLC, as a Lender
By: /s/ Ronnie Glen
Name: Ronnie Glenn
Title: Director

-- 373 of 409 --

[Abbott – Signature Page to 2020 Revolver]
MORGAN STANLEY BANK, N.A., as a Lender
By: /s/ Julie Lilienfeld
Name: Julie Lilienfeld
Title: Authorized Signatory

-- 374 of 409 --

[Abbott – Signature Page to 2020 Revolver]
BNP Paribas, as a Lender
By: /s/ Michael Pearce
Name: Michael Pearce
Title: Managing Director
By: /s/ Emma Petersen
Name: Emma Petersen
Title: Director

-- 375 of 409 --

[Abbott – Signature Page to 2020 Revolver]
CITIBANK, N.A., as a Lender
By: /s/ Patricia A. Guerra
Name: Patricia A. Guerra
Title: Vice President

-- 376 of 409 --

[Abbott – Signature Page to 2020 Revolver]
DEUTSCHE BANK AG NEW YORK BRANCH,
as a Lender
By: /s/ Ming K. Chu
Name: Ming K. Chu
Title: Director
By: /s/ Annie Chung
Name: Annie Chung
Title: Director

-- 377 of 409 --

[Abbott – Signature Page to 2020 Revolver]
MUFG Bank, Ltd., as a Lender
By: /s/ Jack Lonker
Name: Jack Lonker
Title: Director

-- 378 of 409 --

[Abbott – Signature Page to 2020 Revolver]
SOCIETE GENERALE, as a Lender
By: /s/ Kimberly Metzger
Name: Kimberly Metzger
Title: Director

-- 379 of 409 --

[Abbott – Signature Page to 2020 Revolver]
Banco Santander, S.A., New York Branch, as a
Lender
By: /s/ Pablo Urgoiti
Name: Pablo Urgoiti
Title: Managing Director
By: /s/ Rita Walz-Cuccioli
Name: Rita Walz-Cuccioli
Title: Executive Director

-- 380 of 409 --

[Abbott – Signature Page to 2020 Revolver]
HSBC Bank USA, N.A., as a Lender
By: /s/ James Smith
Name: James Smith
Title: Vice President & Relationship Manager

-- 381 of 409 --

[Abbott – Signature Page to 2020 Revolver]
STANDARD CHARTERED BANK, as a Lender
By: /s/ James Beck
Name: James Beck
Title: Associate Director

-- 382 of 409 --

[Abbott – Signature Page to 2020 Revolver]
GOLDMAN SACHS BANK USA, as a Lender
By: /s/ Rebecca Kratz
Name: Rebecca Kratz
Title: Authorized Signatory

-- 383 of 409 --

[Abbott – Signature Page to 2020 Revolver]
The Northern Trust Company, as a Lender
By: /s/ Lisa DeCristofaro
Name: Lisa DeCristofaro
Title: SVP

-- 384 of 409 --

[Abbott – Signature Page to 2020 Revolver]
BANCO BILBAO VIZCAYA ARGENTARIA,
S.A. NEW YORK BRANCH, as a Lender
By: /s/ Cara Younger
Name: Cara Younger
Title: Executive Director
By: /s/ Miriam Trautmann
Name: Miriam Trautmann
Title: Senior Vice President

-- 385 of 409 --

[Abbott – Signature Page to 2020 Revolver]
ING Bank N.V., Dublin Branch as a Lender
By: /s/ Sean Hassett
Name: Sean Hassett
Title: Director
By: /s/ Barry Fehily
Name: Barry Fehily
Title: Managing Director

-- 386 of 409 --

[Abbott – Signature Page to 2020 Revolver]
Intesa Sanpaolo SpA – New York Branch, as a Lender
By: /s/ Alessandro Toigo
Name: Alessandro Toigo
Title: Head of Corporate Desk
By: /s/ Neil Derfler
Name: Neil Derfler
Title: Global Relationship Manager

-- 387 of 409 --

[Abbott – Signature Page to 2020 Revolver]
MIZUHO BANK, LTD., as a Lender
By: /s/ Tracy Rahn
Name: Tracy Rahn
Title: Executive Director

-- 388 of 409 --

[Abbott – Signature Page to 2020 Revolver]
Royal Bank of Canada, as a Lender
By: /s/ Scott Mac Vicar
Scott Mac Vicar
Authorized Signatory

-- 389 of 409 --

[Abbott – Signature Page to 2020 Revolver]
Svenska Handelsbanken AB (publ),
New York Branch as a Lender
By: /s/ Anna Gustafsson
Name: Anna Gustafsson
Title: Vice President
By: /s/ Mark Emmett
Name: Mark Emmett
Title: Vice President

-- 390 of 409 --

[Abbott – Signature Page to 2020 Revolver]
U.S. Bank National Association, as a Lender
By:/s/ Maria Massimino
Name: Maria Massimino
Title: SVP

-- 391 of 409 --

Exhibit 21
SUBSIDIARIES OF ABBOTT LABORATORIES
The following is a list of subsidiaries of Abbott Laboratories as of January 31, 2021. Abbott Laboratories is not a subsidiary of any
other corporation. Where ownership of a subsidiary is less than 100% by Abbott Laboratories or an Abbott Laboratories' subsidiary,
such has been noted by an asterisk (*).
Domestic Subsidiaries 	Incorporation
Abbott Biologicals, LLC 	Delaware
Abbott Cardiovascular Inc. 	Delaware
Abbott Cardiovascular Systems Inc. 	California
Abbott Delaware LLC 	Delaware
Abbott Diabetes Care Inc. 	Delaware
Abbott Diabetes Care Sales Corporation 	Delaware
Abbott Diagnostics Scarborough, Inc. 	Delaware
Abbott Equity Investments LLC 	Delaware
Abbott Finance LLC 	Delaware
Abbott Global LLC 	Delaware
Abbott Health Products, LLC 	Delaware
Abbott Informatics Corporation 	Florida
Abbott International LLC 	Delaware
Abbott Laboratories Inc. 	Delaware
Abbott Laboratories International LLC 	Illinois
Abbott Laboratories Pacific Ltd. 	Illinois
Abbott Laboratories Residential Development Fund, Inc. 	Illinois
Abbott Laboratories Services LLC 	Illinois
Abbott Management LLC 	Delaware
Abbott Molecular Inc. 	Delaware
Abbott Nutrition Manufacturing Inc. 	Delaware
Abbott Point of Care Inc. 	Delaware
Abbott Procurement LLC 	Delaware
Abbott Products Operations, LLC 	Delaware
Abbott Rapid Diagnostics Informatics, Inc. 	Virginia
Abbott Rapid Dx North America, LLC 	Delaware
Abbott Resources Inc. 	Delaware
Abbott Resources International Inc. 	Delaware
Abbott Universal LLC 	Delaware
Abbott Vascular Inc. 	Delaware
Abbott Vascular Solutions Inc. 	Indiana
Abbott Ventures Inc. 	Delaware
Advanced Neuromodulation Systems, Inc. 	Texas
AGA Medical Corporation 	Minnesota
AGA Medical Holdings, Inc. 	Delaware

-- 392 of 409 --

Alere Connect, LLC 	Delaware
Alere Holdco, Inc. 	Delaware
Alere Home Monitoring, Inc. 	Delaware
Alere Inc. 	Delaware
Alere International Holding Corp. 	Delaware
Alere Phoenix ACQ, Inc. 	Delaware
Alere San Diego, Inc. 	Delaware
Alere Toxicology Services, Inc. 	Louisiana
Alere Toxicology, Inc. 	Florida
Alere US Holdings, LLC 	Delaware
Amedica Biotech, Inc. 	California
Ameditech Inc. 	California
American Medical Supplies, Inc. 	Florida
AML Medical, LLC 	Delaware
APK Advanced Medical Technologies LLC 	Georgia
Arriva Medical, LLC 	Florida
Atkinson North Chicago LLC 	Illinois
ATS Laboratories, Inc. 	Delaware
Avee Laboratories Inc. 	Florida
Bioabsorbable Vascular Solutions, Inc. 	Delaware
Biohealth LLC 	Delaware
Biosite Incorporated 	Delaware
Branan Medical Corporation 	Nevada
California Property Holdings III LLC 	California
CardioMEMS LLC 	Delaware
Cephea Valve Technologies, Inc. 	Delaware
Continuum Services LLC 	Delaware
Epocal (US), Inc. 	Delaware
eScreen, Inc. 	Delaware
Evalve International, Inc. 	Delaware
Evalve, Inc. 	Delaware
First Check Diagnostics, LLC 	Delaware
Fournier Pharma Corp. 	Delaware
Global Analytical Development LLC 	Florida
Hi-Tronics Designs, Inc. 	New Jersey
Ibis Biosciences LLC 	Delaware
IDEV Technologies, Inc. 	Delaware
IMTC Technologies, Inc. 	Delaware
Innovacon, Inc. 	Delaware
Instant Tech Subsidiary Acquisition Inc. 	Delaware
Instant Technologies, Inc. 	Virginia
Integrated Vascular Systems, Inc. 	Delaware
Inverness Medical Innovations SK, LLC 	Delaware
Inverness Medical Investments, LLC 	Delaware
Inverness Medical, LLC 	Delaware
Ionian Technologies, LLC 	Delaware
Irvine Biomedical, Inc. 	California

-- 393 of 409 --

Laboratory Specialists of America, Inc. 	Oklahoma
Lake Forest Investments LLC 	Delaware
Lightlab Imaging, Inc. 	Delaware
MediGuide, LLC 	Delaware
Midwest Properties LLC 	Delaware
Murex Diagnostics, Inc. 	Delaware
Natural Supplement Association, LLC 	Colorado
NeuroTherm LLC 	Delaware
Newyu, Inc. 	Delaware
North Shore Properties, Inc. 	Delaware
Pacesetter, Inc. 	Delaware
PBM-Selfcare, LLC 	Delaware
PDD II, LLC 	Delaware
PDD, LLC 	Delaware
Pembrooke Occupational Health, Inc. 	Virginia
Quality Assured Services, Inc. 	Florida
Redwood Toxicology Laboratory, Inc. 	California
RF Medical Holdings LLC 	Delaware
RTL Holdings, Inc. 	Delaware
Sealing Solutions, Inc. 	Georgia
Selfcare Technology, Inc. 	Delaware
SJM International, Inc. 	Delaware
SJM Thunder Holding Company 	Delaware
SPDH, Inc. 	Delaware
Spinal Modulation LLC 	Delaware
St. Jude Medical ATG, Inc. 	Minnesota
St. Jude Medical Business Services, Inc. 	Delaware
St. Jude Medical Europe, Inc. 	Delaware
St. Jude Medical S.C., Inc. 	Minnesota
St. Jude Medical, Atrial Fibrillation Division, Inc. 	Minnesota
St. Jude Medical, Cardiology Division, Inc. 	Delaware
St. Jude Medical, LLC 	Delaware
Standing Stone, LLC 	Delaware
Swan-Myers, Incorporated 	Indiana
TC1 LLC 	Delaware
Tendyne Holdings, Inc. 	Delaware
Tendyne Medical, Inc. 	Delaware
Thoratec Delaware LLC 	Delaware
Thoratec LLC 	California
Tobal Products Incorporated 	Illinois
Topera LLC 	Delaware
US CD LLC 	Delaware
X Technologies Inc. 	Delaware
ZonePerfect Nutrition Company 	Delaware
Foreign Subsidiaries 	Incorporation
Abbott Products Algerie EURL 	Algeria

-- 394 of 409 --

Abbott Laboratories Argentina Sociedad Anónima 	Argentina
Abbott Rapid Diagnostics Argentina S.A. 	Argentina
Atlas Farmacéutica S.A. 	Argentina
Laboratorio Internacional Argentino S.A. 	Argentina
Murex Argentina S.A. 	Argentina*
Polygon Labs S.A. 	Argentina
St. Jude Medical Argentina S.A. 	Argentina
Abbott Australasia Pty Ltd 	Australia
Abbott Medical Australia Pty. Ltd. 	Australia
Abbott Rapid Diagnostics PTY LTD. 	Australia
Alere Holdings Pty Limited 	Australia
Abbott Gesellschaft m.b.H. 	Austria
Abbott Medical Austria Ges.m.b.H. 	Austria
Abbott Rapid Diagnostics Austria GmbH 	Austria
Normann Pharma-Handels GmbH 	Austria
W&R Pharma Handels GmbH 	Austria
Abbott Bahamas Overseas Businesses Corporation 	Bahamas
Abbott Holdings Universal Ltd. 	Bahamas
Abbott Laboratories (Bangladesh) Limited 	Bangladesh*
Alere Bangladesh Limited 	Bangladesh*
Abbott Financial Holdings SRL 	Barbados
Murex Diagnostics International Inc. 	Barbados
Abbott 	Belgium
Abbott Medical Belgium 	Belgium
Abbott Rapid Diagnostics 	Belgium
Abbott Rapid Diagnostics Medical 	Belgium
Abbott Vascular International 	Belgium
AGA Medical Belgium 	Belgium
Endocardial Solutions 	Belgium
St. Jude Medical Coordination Center 	Belgium
Abbott Australia Enterprises Limited 	Bermuda
Abbott Australia Subsidiary Enterprises Limited 	Bermuda
Abbott Diagnostics International, Ltd. 	Bermuda
Abbott Global Enterprises Limited 	Bermuda
Abbott Global Finance Limited 	Bermuda
Abbott Global Holding Finance Limited 	Bermuda
Abbott Global Holdings Limited 	Bermuda
Abbott Healthcare (Puerto Rico) Ltd. 	Bermuda
Abbott Holdings Enterprises, Ltd. 	Bermuda
Abbott International Enterprises, Ltd. 	Bermuda
Abbott International Holdings Limited 	Bermuda
Abbott Ireland 	Bermuda
Abbott Strategic Opportunities Limited 	Bermuda
Alere Holdings Bermuda Limited 	Bermuda
ATS Bermuda Holdings Limited 	Bermuda
Pharmatech Boliviana, S.A. 	Bolivia (Plurinational State of)
Abbott Diagnosticos Rapidos S.A. 	Brazil*

-- 395 of 409 --

Abbott Laboratórios do Brasil Ltda. 	Brazil
Farmacologia Em Aquicultura Veterinária Ltda. 	Brazil
St. Jude Medical Brasil Ltda. 	Brazil
American Pharmacist Inc. 	British Virgin Islands
Rich Horizons International Limited 	British Virgin Islands
Abbott Informatics Canada, Inc 	Canada
Abbott International Corporation 	Canada
Abbott Laboratories Co. 	Canada
Abbott Medical Canada Co./ Medicale Abbott Canada Cie 	Canada
Abbott Point of Care Canada Limited 	Canada
Abbott Rapid Diagnostics ULC 	Canada
eScreen Canada ULC 	Canada
Inverness Canadian Acquisition Corporation 	Canada
Abbott Laboratories (Chile) Holdco (Dos) SpA 	Chile
Abbott Laboratories (Chile) Holdco SpA 	Chile
Abbott Laboratories de Chile Limitada 	Chile
Antares S.A. 	Chile*
Aquagestion Capacitación S.A. 	Chile
Aquagestion S.A. 	Chile
Banco de Vida S.A. 	Chile
Bioalgae S.A. 	Chile*
CFR Chile S.A. 	Chile
Consorcio Tecnológico en Biomedicina Clinico-Molecular S.A. 	Chile*
Dextech S.A. 	Chile*
Esprit de Vie S.A. 	Chile
Farmacología en Aquacultura Veterinaria FAV S.A. 	Chile
Igloo Zone Chile S.A. 	Chile
Instituto de Criopreservación de Chile S.A. 	Chile
Inversiones K2 SpA 	Chile
Laboratorios Lafi Limitada 	Chile
Laboratorios Recalcine S.A. 	Chile
Novasalud.com S.A. 	Chile
Recben Xenerics Farmaceutica Limitada 	Chile
Vida Cell Inversiones S.A. 	Chile
Vida Cell S.A. 	Chile*
Abbott (Jiaxing) Nutrition Co., Ltd. 	China
Abbott (Shanghai) Diagnostics Sales Co., Ltd. 	China
Abbott Diagnostics (Shanghai) Co., Ltd. 	China*
Abbott Laboratories Trading (Shanghai) Co., Ltd. 	China
Abbott Medical (Shanghai) Co., Ltd. 	China
Abbott Medical Devices Trading (Shanghai) Co., Ltd. 	China
Abbott Medical Diagnostics Products Co., Ltd. 	China
ABON Biopharm (Hangzhou) Co., Ltd. 	China
Alere (Shanghai) Healthcare Management Co., Ltd. 	China
Alere (Shanghai) Technology Co., Ltd. 	China
Inverness Medical (Beijing) Co., Ltd. 	China
Shandong Abbott Dairy Product Co., Ltd. 	China

-- 396 of 409 --

Shanghai Abbott Medical Devices Science and Technology Co., Ltd. 	China
Shanghai Abbott Pharmaceutical Co., Ltd. 	China
Shanghai Abbott Pharmaceutical Science and Technology Co., Ltd. 	China
Abbott Laboratories de Colombia SAS 	Colombia
Alere Colombia S.A. 	Colombia
American Generics S.A.S. 	Colombia
Distribuciones Uquifa S.A.S. 	Colombia
Focus Pharmaceutical S.A.S. 	Colombia
Laboratorio Franco Colombiano Lafrancol S.A.S. 	Colombia
Laboratorio Synthesis S.A.S. 	Colombia
Laboratorios Naturmedik S.A.S. 	Colombia
Laboratorios Pauly Pharmaceutical S.A.S. 	Colombia
Lafrancol Internacional S.A.S. 	Colombia
St. Jude Medical Colombia, Ltda. 	Colombia
Abbott Healthcare Costa Rica, S.A. 	Costa Rica
Abbott Medical Costa Rica, Limitada 	Costa Rica
Gynopharm Sociedad Anonima 	Costa Rica
Laboratorio Franco Colombiano De Costa Rica Sociedad Anonima 	Costa Rica
Abbott Laboratories d.o.o. 	Croatia
Abbott Medical Overseas Cyprus Limited 	Cyprus
Abbott Overseas Cyprus Limited 	Cyprus
Arvis Investments Limited 	Cyprus
Abbott Laboratories, s.r.o. 	Czech Republic
Abbott Rapid Diagnostics s.r.o. 	Czech Republic
Abbott Laboratories A/S 	Denmark
Abbott Medical Danmark A/S 	Denmark
Abbott Rapid Diagnostics A/S 	Denmark
Inversiones Komodo, S.R.L. 	Dominican Republic
Lafrancol Dominicana, S.A.S. 	Dominican Republic
Abbott Laboratorios del Ecuador Cia. Ltda. 	Ecuador
Farmacologia en Aquacultura Veterinaria FAV Ecuador S.A. 	Ecuador
Western Pharmaceuticals S.A. 	Ecuador
Abbott Healthcare LLC 	Egypt
Abbott Limited Egypt LLC 	Egypt
Abbott Products Egypt LLC 	Egypt
Abbott Sociedad Anonima de Capital Variable 	El Salvador
CFR Interamericas EL Salvador, Sociedad Anónima de Capital Variable 	El Salvador
Abbott Medical Estonia OÜ 	Estonia
Abbott Medical Finland Oy 	Finland
Abbott Oy 	Finland
Abbott Rapid Diagnostics Oy Ab 	Finland
Abbott France S.A.S. 	France
Abbott Informatics France 	France
Abbott Medical France SAS 	France
Abbott Products Distribution SAS 	France
Abbott Rapid Diagnostics S.A.S. 	France
Laboratoires Fournier S.A.S. 	France

-- 397 of 409 --

Vivalsol 	France
Abbott Automation Solutions GmbH 	Germany
Abbott Diagnostics GmbH 	Germany
Abbott GmbH 	Germany
Abbott Holding GmbH 	Germany
Abbott Informatics Germany GmbH 	Germany
Abbott Laboratories Deutschland GmbH 	Germany
Abbott Laboratories Deutschland Holdings GmbH 	Germany
Abbott Laboratories Deutschland Subsidiary GmbH 	Germany
Abbott Laboratories GmbH 	Germany
Abbott Management GmbH 	Germany
Abbott Medical GmbH 	Germany
Abbott Rapid Diagnostics Germany GmbH 	Germany
Abbott Rapid Diagnostics Jena GmbH 	Germany
Abbott Vascular Instruments Deutschland GmbH 	Germany
Alere Diagnostics GmbH 	Germany
Alere DoA Holding GmbH 	Germany
Alere Holding GmbH 	Germany
Fournier Pharma GmbH 	Germany
Abbott Established Products Holdings (Gibraltar) Limited 	Gibraltar
Abbott Holding (Gibraltar) Limited 	Gibraltar
Abbott Holding Subsidiary (Gibraltar) Limited 	Gibraltar
Abbott Laboratories(Hellas) Societe Anonyme 	Greece
Abbott Medical Hellas Limited Liability Trading Company 	Greece
Abbott Laboratorios, Limitada 	Guatemala
Lafrancol Guatemala S.A. Sociedad Anónima 	Guatemala
Negocios Denia, Sociedad Anónima 	Guatemala
Comercializadora y Distribuidora CFR Interamericas Honduras S.A. 	Honduras
Abbott Hong Kong Holdings Limited 	Hong Kong
Abbott Informatics Asia Pacific Limited 	Hong Kong
Abbott Laboratories Limited 	Hong Kong
Abbott Laboratories Subsidiary Hong Kong Limited 	Hong Kong
Abbott Medical (Hong Kong) Limited 	Hong Kong
Abt Finance HK Holdings Limited 	Hong Kong
Alere HK Holdings Limited 	Hong Kong
Inverness Medical Innovations Hong Kong Limited 	Hong Kong
Abbott Medical Korlátolt Felelősségű Társaság 	Hungary
Abbott Healthcare Private Limited 	India
Abbott India Limited 	India*
Alere Medical Private Limited 	India
Inverness Medical Shimla Private Limited 	India
St. Jude Medical India Private Limited 	India
PT Alere Health 	Indonesia
PT. Abbott Indonesia 	Indonesia*
PT. Abbott Products Indonesia 	Indonesia
Abbott Ireland Financing Designated Activity Company 	Ireland
Abbott Ireland Limited 	Ireland

-- 398 of 409 --

Abbott Laboratories Vascular Enterprises 	Ireland
Abbott Laboratories Vascular Enterprises Limited Partnership 	Ireland
Abbott Laboratories, Ireland, Limited 	Ireland
Abbott Mature Products International Unlimited Company 	Ireland
Abbott Mature Products Management Limited 	Ireland
Abbott Medical Ireland Limited 	Ireland
Abbott Nutrition Limited 	Ireland
Abbott Products Unlimited Company 	Ireland
Abbott Rapid Diagnostics International Holdco Unlimited Company 	Ireland
Abbott Rapid Diagnostics International Investments Unlimited Company 	Ireland
Abbott Rapid Diagnostics International Subsidiary Unlimited Company 	Ireland
Abbott Rapid Diagnostics International Unlimited Company 	Ireland
Abbott Rapid DX International Limited 	Ireland
Alere Technologies Holdings Limited 	Ireland
Apica Cardiovascular Limited 	Ireland
Salviac Limited 	Ireland
Abbott Informatics Technologies Ltd 	Israel
Abbott Medical Laboratories LTD 	Israel
Alere Connected Health LTD 	Israel
MediGuide Ltd. 	Israel
Orgenics Limited 	Israel
Abbott Medical Italia S.R.L. 	Italy
Abbott Rapid Diagnostics S.r.l. 	Italy
Abbott S.r.l. 	Italy
Alere Toxicology S.r.l. in Liquidazione 	Italy
Abbott West Indies Limited 	Jamaica*
Abbott Diagnostics Medical Co., Ltd. 	Japan
Abbott Japan LLC 	Japan
Abbott Medical Japan LLC 	Japan
St. Jude Medical Asia Pacific Holdings GK 	Japan
Abbott Kazakhstan Limited Liability Partnership 	Kazakhstan
Veropharm Limited Liability Partnership 	Kazakhstan
Abbott Kenya Limited 	Kenya
Abbott Diagnostics Korea, Inc. 	Korea (the Republic of)
Abbott Korea Limited 	Korea (the Republic of)
Abbott Medical Korea Limited 	Korea (the Republic of)
Abbott Rapid Diagnostics Inc. 	Korea (the Republic of)
ALR Holdings 	Korea (the Republic of)
"Abbott Laboratories Baltics" 	Latvia
UAB "Abbott Medical Lithuania" 	Lithuania
Abbott Bulgaria Luxembourg S.à r.l. 	Luxembourg
Abbott Healthcare Luxembourg S.à r.l. 	Luxembourg
Abbott Holding Subsidiary (Gibraltar) Limited Luxembourg S.C.S. 	Luxembourg
Abbott International Luxembourg S.àr.l. 	Luxembourg
Abbott Investments Luxembourg S.à r.l. 	Luxembourg
Abbott Luxembourg Finance S.à r.l. 	Luxembourg
Abbott Nederland Luxembourg S.à r.l. 	Luxembourg

-- 399 of 409 --

Abbott Overseas Luxembourg S.à r.l. 	Luxembourg
Abbott Poland Luxembourg S.à r.l. 	Luxembourg
Abbott South Africa Luxembourg S.à r.l. 	Luxembourg
Abbott Volga Luxembourg S.à r.l. 	Luxembourg
St. Jude Medical International Holding 	Luxembourg
St. Jude Medical Luxembourg 	Luxembourg
St. Jude Medical Luxembourg Holdings II 	Luxembourg
St. Jude Medical Luxembourg Holdings NT 	Luxembourg
St. Jude Medical Luxembourg Holdings SMI S.à r.l. 	Luxembourg
St. Jude Medical Luxembourg Holdings TC S.à r.l. 	Luxembourg
Abbott Diagnostics Health Sdn. Bhd. 	Malaysia
Abbott Laboratories (Malaysia) Sdn. Bhd. 	Malaysia
Abbott Medical (Malaysia) Sdn. Bhd. 	Malaysia
St. Jude Medical Operations (Malaysia) Sdn. Bhd. 	Malaysia
Yissum Holding Limited 	Malta
Abbott Laboratories de México, S.A. de C.V. 	Mexico
SJ Medical Mexico, S de R.L. de C.V. 	Mexico
Abbott Morocco SARL 	Morocco
Abbott Affiliate Holdings B.V. 	Netherlands
Abbott B.V. 	Netherlands
Abbott Biologicals B.V. 	Netherlands
Abbott Diagnostics Holding B.V. 	Netherlands
Abbott Diagnostics Investments B.V. 	Netherlands
Abbott Healthcare B.V. 	Netherlands
Abbott Healthcare Products B.V. 	Netherlands
Abbott Holdings B.V. 	Netherlands
Abbott Informatics Netherlands B.V. 	Netherlands
Abbott Laboratories B.V. 	Netherlands
Abbott Laboratories European Holdings B.V. 	Netherlands
Abbott Logistics B.V. 	Netherlands
Abbott Medical Nederland B.V. 	Netherlands
Abbott Nederland C.V. 	Netherlands
Abbott Netherlands Investments B.V. 	Netherlands
Abbott Products B.V. 	Netherlands
Abbott Rapid Diagnostics B.V. 	Netherlands
Abbott Rapid Diagnostics Holding B.V. 	Netherlands
Abbott Vascular Netherlands B.V. 	Netherlands
Alere Health Services B.V. 	Netherlands
Brandex Europe C.V. 	Netherlands
Framed B.V. 	Netherlands
IMTC Finance B.V. 	Netherlands
IMTC Holdings B.V. 	Netherlands
Nether Pharma N.P. C.V. 	Netherlands
Orgenics International Holdings B.V. 	Netherlands
St. Jude Medical Holdings B.V. 	Netherlands
Abbott Laboratories NZ Limited 	New Zealand
Abbott Medical New Zealand Limited 	New Zealand

-- 400 of 409 --

Abbott Rapid Diagnostics Limited 	New Zealand
CFR Interamericas Nicaragua, Sociedad Anónima 	Nicaragua
Alere Healthcare Nigeria Limited 	Nigeria
Abbott Diagnostics Technologies AS 	Norway
Abbott Medical Norway AS 	Norway
Abbott Norge AS 	Norway
Abbott Rapid Diagnostics AS 	Norway
Axis-Shield AS 	Norway
Abbott Laboratories (Pakistan) Limited 	Pakistan*
Alere Medical Pakistan (Private) Limited 	Pakistan
Abbott Laboratories, C.A. 	Panama
Abbott Overseas, S.A. 	Panama
Caripharm Inc. 	Panama
CFR Interamericas Panamá S.A. 	Panama
Forestcreek Overseas S.A. 	Panama
Golnorth Investments S.A. 	Panama
Gynopharm de Centroamérica S.A. 	Panama
Ramses Business Corp. 	Panama
Saboya Enterprises Corporation 	Panama
Fada Pharma Paraguay Sociedad Anonima 	Paraguay
Pharma International Sociedad Anonima 	Paraguay
Abbott Laboratorios S.A. 	Peru
Farmindustria S.A. 	Peru
Lafrancol Perú S.R.L 	Peru
Neosalud S.A.C. 	Peru
Abbott Laboratories (Philippines) 	Philippines
Abbott Products (Philippines), Inc. 	Philippines
Alere Philippines, Inc. 	Philippines
Arriva Medical Philippines, Inc. 	Philippines
Abbott Holdings Poland Spółka z ograniczoną odpowiedzialnością 	Poland
Abbott Laboratories Poland Spółka z ograniczoną odpowiedzialnością 	Poland
Abbott Medical spółka z ograniczoną odpowiedzialnością 	Poland
Abbott Laboratórios, Lda 	Portugal
Abbott Medical (Portugal) Distribuicao de Produtos Medicos Lda 	Portugal
Abbott Rapid Diagnostics LDA 	Portugal
Abbott Laboratories (Puerto Rico) Incorporated 	Puerto Rico
Abbott Medical Puerto Rico LLC 	Puerto Rico
St. Jude Medical Puerto Rico LLC 	Puerto Rico
Abbott Products Romania S.R.L. 	Romania
Garden Hills LLC 	Russian Federation
Limited Liability Company “VEROPHARM” 	Russian Federation
Limited Liability Company Abbott Laboratories 	Russian Federation
OJSC "Voronezhkhimpharm" 	Russian Federation
SC "VEROPHARM" 	Russian Federation
Abbott Saudi Arabia for Trading 	Saudi Arabia
Abbott Medical Balkan d.o.o. Beograd (Novi Beograd) 	Serbia
Abbott Informatics Singapore Pte. Limited 	Singapore

-- 401 of 409 --

Abbott Laboratories (Singapore) Private Limited 	Singapore
ABBOTT LABORATORIES SUBSIDIARY SINGAPORE PRIVATE LTD. 	Singapore
Abbott Manufacturing Singapore Private Limited 	Singapore
Abbott Medical (Singapore) Pte. Ltd. 	Singapore
Abbott Operations Singapore Pte. Ltd. 	Singapore
Abbott Rapid Diagnostics PTE. LTD. 	Singapore
Abbott Laboratories Slovakia s.r.o. 	Slovakia
Abbott Laboratories družba za farmacijo in diagnostiko d.o.o. 	Slovenia
Abbott Laboratories South Africa (Pty) Ltd. 	South Africa
Abbott Rapid Diagnostics (PTY) LTD. 	South Africa
Murex Biotech South Africa 	South Africa
Pantech (RF) (PTY) LTD 	South Africa*
Abbott Doral Investments, S.L. 	Spain
Abbott Informatics Spain, S.A. 	Spain
Abbott Laboratories, S.A. 	Spain
Abbott Medical España, S.A. 	Spain
Abbott Products (Spain), S.L. 	Spain
Abbott Rapid Diagnostics Healthcare, S.L. 	Spain
Alere Spain, S.L. 	Spain
Farmaceutica Mont Blanc, S.L. 	Spain
Igloo Zone, S.L. 	Spain
Abbott Medical Sweden AB 	Sweden
Abbott Rapid Diagnostics AB 	Sweden
Abbott Scandinavia Aktiebolag 	Sweden
European Drug Testing Service EDTS AB 	Sweden
St. Jude Medical AB 	Sweden
St. Jude Medical Systems AB 	Sweden
Abbott AG 	Switzerland
Abbott Finance Company SA 	Switzerland
Abbott Laboratories GmbH 	Switzerland
Abbott Medical (Schweiz) AG 	Switzerland
Abbott Products Operations AG 	Switzerland
Abbott Rapid Diagnostics Schweiz GmbH 	Switzerland
Abbott Switzerland Investments GmbH 	Switzerland
Alere Switzerland GmbH 	Switzerland
SPD Swiss Precision Diagnostics GmbH 	Switzerland
St. Jude Medical GVA Sàrl 	Switzerland
Thoratec Switzerland GmbH 	Switzerland
Abbott Medical Taiwan Co. 	Taiwan (Province of China)
Abbott Rapid Diagnostics Health Corp. 	Taiwan (Province of China)
Abbott Fund Tanzania Limited
Tanzania, the United Republic
of
Abbott Laboratories Limited 	Thailand
Abbott Medical (Thailand) Co., Ltd. 	Thailand
Abbott Products Tunisie S.A.R.L. 	Tunisia
Abbott Laboratuarlari Ithalat Ihracat ve Ticaret Ltd.Sti 	Turkey
St. Jude Medical Turkey Medikal Ürünler Ticaret Limited Sirketi 	Turkey
Limited Liability Company "Abbott Ukraine" 	Ukraine

-- 402 of 409 --

Товариство з обмеженою відповідальністю «Верофарм» (ТОВ «Верофарм») 	Ukraine
St. Jude Medical Middle East DMCC 	United Arab Emirates
Abbott (UK) Finance Limited 	United Kingdom
Abbott (UK) Holdings Limited 	United Kingdom
Abbott Asia Holdings Limited 	United Kingdom
Abbott Asia Investments Limited 	United Kingdom
Abbott Australasia Holdings Limited 	United Kingdom
Abbott Capital India Limited 	United Kingdom
Abbott Diabetes Care Limited 	United Kingdom
Abbott Equity Holdings Unlimited 	United Kingdom
Abbott Healthcare Connections Limited 	United Kingdom
Abbott Healthcare Products Ltd 	United Kingdom
Abbott Informatics Europe Limited 	United Kingdom
Abbott Laboratories Limited 	United Kingdom
Abbott Laboratories Trustee Company Limited 	United Kingdom
Abbott Medical U.K. Limited 	United Kingdom
Abbott Rapid Diagnostics Limited 	United Kingdom
Abbott Toxicology Limited 	United Kingdom
Abbott UK Investments Limited 	United Kingdom
Abbott Vascular Devices (2) Limited 	United Kingdom
Abbott Vascular Devices Limited 	United Kingdom
Alere AS Holdings Limited 	United Kingdom
Alere BBI Holdings Limited 	United Kingdom
Alere Connected Health Limited 	United Kingdom
Alere Technologies Limited 	United Kingdom
Alere UK Holdings Limited 	United Kingdom
Alere UK Subco Limited 	United Kingdom
Alisoc Investment & Co 	United Kingdom
Axis-Shield Diagnostics Limited 	United Kingdom
Axis-Shield Limited 	United Kingdom
BBI Animal Health Limited 	United Kingdom
BBI Diagnostics Group 2 Public Limited Company 	United Kingdom
British Colloids Limited 	United Kingdom
Concateno South Limited 	United Kingdom
Concateno UK Limited 	United Kingdom
Cozart Limited 	United Kingdom
European Chemicals & Co 	United Kingdom
Forensics Limited 	United Kingdom
Fournier Pharmaceuticals Limited 	United Kingdom
Globapharm & CO LP 	United Kingdom
Gynocare Limited 	United Kingdom
IG Innovations Limited 	United Kingdom
Knoll UK Investments Unlimited 	United Kingdom
Mansbridge Pharmaceuticals Limited 	United Kingdom
Medscreen Holdings Limited 	United Kingdom
Murex Biotech Limited 	United Kingdom
Sinensix & Co. 	United Kingdom

-- 403 of 409 --

Thoratec Europe Limited 	United Kingdom
TwistDX Limited 	United Kingdom
Unipath Limited 	United Kingdom
Unipath Management Limited 	United Kingdom
Unipath Pension Trustee Limited 	United Kingdom
Abbott Laboratories Uruguay S.A. 	Uruguay
Abbott Operations Uruguay S.R.L. 	Uruguay
Bosque Bonito S.A. 	Uruguay
European Services S.A. 	Uruguay
Fernwood Investment S.A. 	Uruguay
Kangshenyunga S.A. 	Uruguay
Pharmaceutical Technologies (Pharmatech) S.A. 	Uruguay
Tremora S.A. 	Uruguay
Tuenir S.A. 	Uruguay
Abbott Laboratories, C.A. 	Venezuela
Gynopharm de Venezuela, C.A. 	Venezuela
3A Nutrition (Vietnam) Company Limited 	Viet Nam
Domesco Medical Import-Export Joint-Stock Corporation 	Viet Nam*
Glomed Pharmaceutical Company Limited 	Viet Nam
Abbott Trading Company, Inc. 	Virgin Islands (U.S.)

-- 404 of 409 --

Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
1) 	Registration Statement No. 333-158782 on Form S-8 for the Abbott Laboratories 2009 Incentive Stock Program;
2) 	Registration Statement Nos. 333-74220, 333-102179, 333-124851, 333-153200, 333-169886, 333-204773, 333-227803
and 333-251334 on Form S-8 for the Abbott Laboratories Deferred Compensation Plan;
3) 	Registration Statement Nos. 33-26685, 33-50452, 33-51585, 33-56897, 33-65127, 333-19511, 333-43383, 333-69579,
333-93257, 333-74224, 333-102180, 333-109253, 333-124849, 333-141116, 333-153198, 333-169888, 333-204772,
333-227802 and 333-251335 on Form S-8 for the Abbott Laboratories Stock Retirement Program and Trusts;
4) 	Registration Statement No. 333-239333 on Form S-3;
5) 	Registration Statement Nos. 333-212002 and 333-216141 on Form S-4;
6) 	Post-Effective Amendment on Form S-8 to Registration Statement No. 333-212002 on Form S-4 for the St. Jude
Medical, Inc. 2007 Stock Incentive Plan, as Amended and Restated (2014) and the Thoratec Corporation Amended and
Restated 2006 Incentive Stock Plan;
7) 	Registration Statement Nos. 333-215423 and 333-227804 on Form S-8 for the Management Savings Plan (f/k/a the
St. Jude Medical, Inc. Management Savings Plan), as amended and restated effective January 1, 2016; and
8) 	Registration Statement No. 333-217540 on Form S-8 for the Abbott Laboratories 2017 Incentive Stock Program and
the Abbott Laboratories 2017 Employee Stock Purchase Plan for Non-U.S. Employees
of our reports dated February 19, 2021, with respect to the consolidated financial statements, schedule and the effectiveness of internal
control over financial reporting of Abbott Laboratories and subsidiaries, included in this Annual Report (Form 10-K) of Abbott
Laboratories and subsidiaries for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Chicago, Illinois
February 19, 2021

-- 405 of 409 --

Exhibit 31.1
Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert B. Ford, certify that:
1. 	I have reviewed this annual report on Form 10-K of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods
presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
(a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to Abbott, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period
in which this report is being prepared;
(b) 	Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;
(c) 	Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and
(d) 	Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during
Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect,
Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
(a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process,
summarize and report financial information; and
(b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role
in Abbott’s internal control over financial reporting.
/s/ ROBERT B. FORD
Robert B. Ford,
President and Chief Executive Officer
Date: February 19, 2021

-- 406 of 409 --

Exhibit 31.2
Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert E. Funck, Jr., certify that:
1. 	I have reviewed this annual report on Form 10-K of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods
presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:
(a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to Abbott, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period
in which this report is being prepared;
(b) 	Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;
(c) 	Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and
(d) 	Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during
Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect,
Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:
(a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process,
summarize and report financial information; and
(b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role
in Abbott’s internal control over financial reporting.
/s/ ROBERT E. FUNCK, JR.
Robert E. Funck, Jr.,
Executive Vice President, Finance
and Chief Financial Officer
Date: February 19, 2021

-- 407 of 409 --

Exhibit 32.1
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report of Abbott Laboratories (the “Company”) on Form 10-K for the period ended
December 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, President and Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of
2002, that:
(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
/s/ ROBERT B. FORD
Robert B. Ford,
President and Chief Executive Officer
Date: February 19, 2021
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by
Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

-- 408 of 409 --

Exhibit 32.2
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report of Abbott Laboratories (the “Company”) on Form 10-K for the period ended
December 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Robert E. Funck, Jr., Executive Vice
President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, that:
(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
/s/ ROBERT E. FUNCK, JR.
Robert E. Funck, Jr.,
Executive Vice President, Finance
and Chief Financial Officer
Date: February 19, 2021
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by
Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

-- 409 of 409 --